<html lang="en"><head>
	<!-- Required meta tags -->
	<meta charset="utf-8">
	<meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no">
	<!-- Check Browser, as well as Hostname and set JS, CSS, Favicon path based on that-->

	<!-- Favicon -->
	<!-- cpcommit -->
	<!-- <link rel="shortcut icon" type="image/x-icon" href="https://www.sec.gov/favicon.ico"> -->

	<script>
		(function () {
			var hostName = window.location.hostname;

			var browserAccepted = function () {

				var ua = window.navigator.userAgent;
				var trident = ua.indexOf('Trident/'); //IE 11;
				var msie = ua.indexOf('MSIE '); // IE 10 or older
				if (msie > 0) {
					return false;
				}
				return true;
			}();

			var pathToLibs = './js';
			var pathToError = './';
			// uncomment following lines only when running ix symlink to ix.xhtml on *.sec.gov
			/* commented out for running ix redirector script
			if (hostName === 'www-test.sec.gov' || hostName === 'www.sec.gov') {
				pathToLibs = './ixviewer/js';
				pathToError = '/ixviewer/';
			}
			*/
			if (browserAccepted) {

				// css
				document
					.write('<link rel="stylesheet" href=' + pathToLibs + '/css/custom-bootstrap.css>');
				document
					.write('<link rel="stylesheet" href=' + pathToLibs + '/lib/fontawesome/css/all.min.css>');
				document
					.write('<link rel="stylesheet" href=' + pathToLibs + '/css/app.css>');

				// js
				document
					.write('<script type="text/javascript" src="' + pathToLibs + '/lib/jquery-3.7.1.slim.min.js"><\/script>');
				document
					.write('<script type="text/javascript" src="' + pathToLibs + '/lib/popper.min.js"><\/script>');
				document
					.write('<script type="text/javascript" src="' + pathToLibs + '/lib/bootstrap.min.js"><\/script>');
				document
					.write('<script type="text/javascript" src="' + pathToLibs + '/lib/moment.js"><\/script>');
				document
					.write('<script type="text/javascript" src="' + pathToLibs + '/lib/vanilla-picker.min.js"><\/script>');
				document
					.write('<script type="text/javascript" src="' + pathToLibs + '/lib/he.js"><\/script>');

				var date = new Date();
				var todaysDate = date.getDate() + '-' + (date.getMonth() + 1) + '-'
					+ date.getFullYear();
				document.write('<script type = "text/javascript" defer=true src="'
					+ pathToLibs + '/production.min.js?d=' + todaysDate
					+ '"><\/script>');
			} else {
				// user us on a browser that we do not support
				var currentUrl = window.location.href.split('?')[0];
				var browserError = currentUrl.substring(0, currentUrl
					.lastIndexOf('/'));
				browserError += pathToError + 'browser-error.html?url='
					+ encodeURIComponent(window.location.href);
				window.location.href = browserError;
			}
		})();
	</script><link rel="stylesheet" href="./js/css/custom-bootstrap.css"><link rel="stylesheet" href="./js/lib/fontawesome/css/all.min.css"><link rel="stylesheet" href="./js/css/app.css"><script type="text/javascript" src="./js/lib/jquery-3.7.1.slim.min.js"></script><script type="text/javascript" src="./js/lib/popper.min.js"></script><script type="text/javascript" src="./js/lib/bootstrap.min.js"></script><script type="text/javascript" src="./js/lib/moment.js"></script><script type="text/javascript" src="./js/lib/vanilla-picker.min.js"></script><style>.picker_wrapper.no_alpha .picker_alpha{display:none}.picker_wrapper.no_editor .picker_editor{position:absolute;z-index:-1;opacity:0}.picker_wrapper.no_cancel .picker_cancel{display:none}.layout_default.picker_wrapper{display:-webkit-box;display:flex;-webkit-box-orient:horizontal;-webkit-box-direction:normal;flex-flow:row wrap;-webkit-box-pack:justify;justify-content:space-between;-webkit-box-align:stretch;align-items:stretch;font-size:10px;width:25em;padding:.5em}.layout_default.picker_wrapper input,.layout_default.picker_wrapper button{font-size:1rem}.layout_default.picker_wrapper>*{margin:.5em}.layout_default.picker_wrapper::before{content:'';display:block;width:100%;height:0;-webkit-box-ordinal-group:2;order:1}.layout_default .picker_slider,.layout_default .picker_selector{padding:1em}.layout_default .picker_hue{width:100%}.layout_default .picker_sl{-webkit-box-flex:1;flex:1 1 auto}.layout_default .picker_sl::before{content:'';display:block;padding-bottom:100%}.layout_default .picker_editor{-webkit-box-ordinal-group:2;order:1;width:6.5rem}.layout_default .picker_editor input{width:100%;height:100%}.layout_default .picker_sample{-webkit-box-ordinal-group:2;order:1;-webkit-box-flex:1;flex:1 1 auto}.layout_default .picker_done,.layout_default .picker_cancel{-webkit-box-ordinal-group:2;order:1}.picker_wrapper{box-sizing:border-box;background:#f2f2f2;box-shadow:0 0 0 1px silver;cursor:default;font-family:sans-serif;color:#444;pointer-events:auto}.picker_wrapper:focus{outline:none}.picker_wrapper button,.picker_wrapper input{box-sizing:border-box;border:none;box-shadow:0 0 0 1px silver;outline:none}.picker_wrapper button:focus,.picker_wrapper button:active,.picker_wrapper input:focus,.picker_wrapper input:active{box-shadow:0 0 2px 1px dodgerblue}.picker_wrapper button{padding:.4em .6em;cursor:pointer;background-color:whitesmoke;background-image:-webkit-gradient(linear, left bottom, left top, from(gainsboro), to(transparent));background-image:-webkit-linear-gradient(bottom, gainsboro, transparent);background-image:linear-gradient(0deg, gainsboro, transparent)}.picker_wrapper button:active{background-image:-webkit-gradient(linear, left bottom, left top, from(transparent), to(gainsboro));background-image:-webkit-linear-gradient(bottom, transparent, gainsboro);background-image:linear-gradient(0deg, transparent, gainsboro)}.picker_wrapper button:hover{background-color:white}.picker_selector{position:absolute;z-index:1;display:block;-webkit-transform:translate(-50%, -50%);transform:translate(-50%, -50%);border:2px solid white;border-radius:100%;box-shadow:0 0 3px 1px #67b9ff;background:currentColor;cursor:pointer}.picker_slider .picker_selector{border-radius:2px}.picker_hue{position:relative;background-image:-webkit-gradient(linear, left top, right top, from(red), color-stop(yellow), color-stop(lime), color-stop(cyan), color-stop(blue), color-stop(magenta), to(red));background-image:-webkit-linear-gradient(left, red, yellow, lime, cyan, blue, magenta, red);background-image:linear-gradient(90deg, red, yellow, lime, cyan, blue, magenta, red);box-shadow:0 0 0 1px silver}.picker_sl{position:relative;box-shadow:0 0 0 1px silver;background-image:-webkit-gradient(linear, left top, left bottom, from(white), color-stop(50%, rgba(255,255,255,0))),-webkit-gradient(linear, left bottom, left top, from(black), color-stop(50%, rgba(0,0,0,0))),-webkit-gradient(linear, left top, right top, from(gray), to(rgba(128,128,128,0)));background-image:-webkit-linear-gradient(top, white, rgba(255,255,255,0) 50%),-webkit-linear-gradient(bottom, black, rgba(0,0,0,0) 50%),-webkit-linear-gradient(left, gray, rgba(128,128,128,0));background-image:linear-gradient(180deg, white, rgba(255,255,255,0) 50%),linear-gradient(0deg, black, rgba(0,0,0,0) 50%),linear-gradient(90deg, gray, rgba(128,128,128,0))}.picker_alpha,.picker_sample{position:relative;background:url("data:image/svg+xml,%3Csvg xmlns='http://www.w3.org/2000/svg' width='2' height='2'%3E%3Cpath d='M1,0H0V1H2V2H1' fill='lightgrey'/%3E%3C/svg%3E") left top/contain white;box-shadow:0 0 0 1px silver}.picker_alpha .picker_selector,.picker_sample .picker_selector{background:none}.picker_editor input{font-family:monospace;padding:.2em .4em}.picker_sample::before{content:'';position:absolute;display:block;width:100%;height:100%;background:currentColor}.picker_arrow{position:absolute;z-index:-1}.picker_wrapper.popup{position:absolute;z-index:2;margin:1.5em}.picker_wrapper.popup,.picker_wrapper.popup .picker_arrow::before,.picker_wrapper.popup .picker_arrow::after{background:#f2f2f2;box-shadow:0 0 10px 1px rgba(0,0,0,0.4)}.picker_wrapper.popup .picker_arrow{width:3em;height:3em;margin:0}.picker_wrapper.popup .picker_arrow::before,.picker_wrapper.popup .picker_arrow::after{content:"";display:block;position:absolute;top:0;left:0;z-index:-99}.picker_wrapper.popup .picker_arrow::before{width:100%;height:100%;-webkit-transform:skew(45deg);transform:skew(45deg);-webkit-transform-origin:0 100%;transform-origin:0 100%}.picker_wrapper.popup .picker_arrow::after{width:150%;height:150%;box-shadow:none}.popup.popup_top{bottom:100%;left:0}.popup.popup_top .picker_arrow{bottom:0;left:0;-webkit-transform:rotate(-90deg);transform:rotate(-90deg)}.popup.popup_bottom{top:100%;left:0}.popup.popup_bottom .picker_arrow{top:0;left:0;-webkit-transform:rotate(90deg) scale(1, -1);transform:rotate(90deg) scale(1, -1)}.popup.popup_left{top:0;right:100%}.popup.popup_left .picker_arrow{top:0;right:0;-webkit-transform:scale(-1, 1);transform:scale(-1, 1)}.popup.popup_right{top:0;left:100%}.popup.popup_right .picker_arrow{top:0;left:0}</style><script type="text/javascript" src="./js/lib/he.js"></script><script type="text/javascript" defer="true" src="./js/production.min.js?d=22-4-2024"></script>
	<title>Inline XBRL Viewer</title>
<style type="text/css" id="customized-styles"> #dynamic-xbrl-form [enabled-taxonomy="true"][continued-taxonomy="false"]{border-top:2px solid #FF6600;border-bottom:2px solid #FF6600;display:inline;} #dynamic-xbrl-form [enabled-taxonomy="true"][continued-main-taxonomy="true"]{box-shadow:-2px 0px 0px 0px #FF6600, 2px 0px 0px 0px #FF6600;} #dynamic-xbrl-form [enabled-taxonomy="true"][text-block-taxonomy="true"]{box-shadow:-2px 0px 0px 0px #FF6600, 2px 0px 0px 0px #FF6600;border-top:none;border-bottom:none;} #dynamic-xbrl-form [highlight-taxonomy="true"]{background-color:#FFD700 !important;} #dynamic-xbrl-form [highlight-taxonomy="true"] > *{background-color:#FFD700 !important;} #dynamic-xbrl-form [selected-taxonomy="true"][continued-main-taxonomy="true"]{box-shadow:-2px 0px 0px 0px #003768, 2px 0px 0px 0px #003768;} #dynamic-xbrl-form [selected-taxonomy="true"][text-block-taxonomy="true"]{box-shadow:-2px 0px 0px 0px #003768, 2px 0px 0px 0px #003768;} #dynamic-xbrl-form [selected-taxonomy="true"][continued-taxonomy="false"]{border:3px solid #003768 !important;display:inline;} #dynamic-xbrl-form [hover-taxonomy="true"]{background-color:rgba(255,0,0,0.3);} #dynamic-xbrl-form .text-block-indicator-left{border-left:.75rem solid ##003768;} #dynamic-xbrl-form .text-block-indicator-right{border-right:.75rem solid ##003768;} .tagged-data-example-1{border-top:2px solid #FF6600;border-bottom:2px solid #FF6600;} .search-results-example-1{background-color:#FFD700;} .tag-shading-exmple-1:hover{background-color:rgba(255,0,0,0.3);} .selected-fact-example-1{border:3px solid #003768 !important;}</style></head>

<body>
	<noscript>This application relies heavily on JavaScript, you
		will need to allow JavaScript to use this application.</noscript>
	<nav class="reboot navbar navbar-expand-md navbar-dark navbar-height bg-sec fixed-top w-100 pl-0">
		<button class="reboot navbar-toggler ml-1" type="button" data-test="" data-toggle="collapse" data-target="#main-navbar" aria-controls="main-navbar" aria-expanded="false" aria-label="Toggle navigation">Inline Viewer</button>
		<div class="reboot navbar-height collapse navbar-collapse bg-sec w-100" data-test="main-navbar" id="main-navbar">
			<ul class="reboot navbar-nav mr-auto bg-inherit">
				<li class="reboot nav-item dropdown my-auto ml-1">
					<a id="menu-dropdown-link" data-test="menu-dropdown-link" class="reboot nav-link dropdown-toggle click disabled" role="button" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false" tabindex="1" accesskey="1">
						<i class="reboot nav-loading fas fa-bars" title="Menu"></i>
						<span class="reboot d-md-none d-lg-inline">Menu</span>
						<span class="reboot sr-only sr-only-focusable">Menu</span>
					</a>
					<div class="reboot dropdown-menu">
						<a id="menu-dropdown-information" data-test="menu-dropdown-information" class="reboot dropdown-item click text-body" tabindex="1">Information</a>
						<a id="form-information-instance" data-test="form-information-instance" class="reboot dropdown-item click text-body" target="_blank" tabindex="1">Save XBRL
							Instance</a>
						<a id="form-information-zip" data-test="form-information-zip" class="reboot dropdown-item click text-body" target="_blank" tabindex="1">Save XBRL Zip
							File</a>
						<a id="form-information-html" data-test="form-information-html" class="reboot dropdown-item click text-body" target="_blank" tabindex="1">Open as HTML</a>
						<a id="menu-dropdown-settings" data-test="menu-dropdown-settings" class="reboot dropdown-item click text-body" tabindex="1">Settings</a>
						<a id="form-information-help" data-test="form-information-help" class="reboot dropdown-item click text-body" tabindex="1">Help</a>
						<span id="form-information-version" class="reboot dropdown-item-text text-body" tabindex="1"></span>
					</div>
				</li>
				<li class="reboot nav-item my-auto ml-1">
					<a id="sections-dropdown-link" data-test="sections-dropdown-link" class="reboot nav-link click disabled meta-required" tabindex="2" accesskey="2">
						<i class="reboot fas fa-layer-group" title="Sections"></i>
						<span class="reboot d-md-none d-lg-inline">Sections</span>
						<span class="reboot sr-only sr-only-focusable">Sections</span>
					</a>
				</li>
				<li class="reboot nav-item my-auto ml-1 mr-1">
					<form id="global-search-form" data-test="global-search-form" class="reboot my-2 my-lg-0 input-group disabled" novalidate="">
						<div class="reboot input-group-prepend">
							<button data-name="global-search-options" class="reboot dropdown btn btn-outline-light disabled" type="button" data-toggle="dropdown" tabindex="3">
								<i class="reboot nav-loading fas fa-cog" title="Additional Search Options">
									<span class="reboot sr-only sr-only-focusable">Additional
										Search Options</span>
								</i>
							</button>
							<div class="reboot dropdown-menu px-2">
								<div class="reboot form-check">
									<input disabled="" class="reboot form-check-input meta-required" type="checkbox" name="search-options" value="1" checked="" tabindex="3">
									<label class="reboot form-check-label mb-0">
										<span class="reboot">Include Fact Name</span>
									</label>
								</div>
								<div class="reboot form-check">
									<input disabled="" class="reboot form-check-input meta-required" type="checkbox" name="search-options" value="2" checked="" tabindex="3">
									<label class="reboot form-check-label mb-0">
										<span class="reboot">Include Fact Content</span>
									</label>
								</div>
								<div class="reboot form-check">
									<input disabled="" class="reboot form-check-input meta-required" type="checkbox" name="search-options" value="3" checked="" tabindex="3">
									<label class="reboot form-check-label mb-0">
										<span class="reboot">Include Labels</span>
									</label>
								</div>
								<div class="reboot form-check">
									<input disabled="" class="reboot form-check-input meta-required" type="checkbox" name="search-options" value="4" tabindex="3">
									<label class="reboot form-check-label mb-0">
										<span class="reboot">Include Definitions</span>
									</label>
								</div>
								<div class="reboot form-check">
									<input disabled="" class="reboot form-check-input meta-required" type="checkbox" name="search-options" value="5" tabindex="3">
									<label class="reboot form-check-label mb-0">
										<span class="reboot">Include Dimensions</span>
									</label>
								</div>
								<div class="reboot bg-light border p-1">
									<span class="reboot dropdown-item-text">Reference
										Options</span>
									<div class="reboot form-check">
										<input disabled="" class="reboot form-check-input meta-required" type="checkbox" name="search-options" value="6" tabindex="3">
										<label class="reboot form-check-label mb-0">
											<span class="reboot">Include Topic</span>
										</label>
									</div>
									<div class="reboot form-check">
										<input disabled="" class="reboot form-check-input meta-required" type="checkbox" name="search-options" value="7" tabindex="3">
										<label class="reboot form-check-label mb-0">
											<span class="reboot">Include Sub-Topic</span>
										</label>
									</div>
									<div class="reboot form-check">
										<input disabled="" class="reboot form-check-input meta-required" type="checkbox" name="search-options" value="8" tabindex="3">
										<label class="reboot form-check-label mb-0">
											<span class="reboot">Include Paragraph</span>
										</label>
									</div>
									<div class="reboot form-check">
										<input disabled="" class="reboot form-check-input meta-required" type="checkbox" name="search-options" value="9" tabindex="3">
										<label class="reboot form-check-label mb-0">
											<span class="reboot">Include Publisher</span>
										</label>
									</div>
									<div class="reboot form-check">
										<input disabled="" class="reboot form-check-input meta-required" type="checkbox" name="search-options" value="10" tabindex="3">
										<label class="reboot form-check-label mb-0">
											<span class="disabled">Include Section</span>
										</label>
									</div>
								</div>
								<div class="reboot form-check">
									<input class="reboot form-check-input" type="checkbox" name="search-options" value="11" tabindex="3">
									<label class="reboot form-check-label mb-0">
										<span class="reboot">Match Case</span>
									</label>
								</div>
							</div>
						</div>
						<input type="text" class="reboot form-control disabled" id="global-search" data-test="global-search" placeholder="Search Facts" disabled="" aria-label="Search all Facts and highlight them accordingly." tabindex="4">
						<div class="reboot input-group-append">
							<button id="search-btn-clear" data-name="global-search-clear" class="reboot btn btn-outline-light disabled" type="button" tabindex="5">
								<i class="reboot nav-loading fas fa-times-circle" title="Clear Search"></i>
								<span class="reboot sr-only sr-only-focusable">Clear
									Search</span>
							</button>
							<button class="reboot btn btn-outline-light disabled" type="submit" tabindex="6">
								<i class="reboot nav-loading fas fa-search" title="Submit Search"></i>
								<span class="reboot sr-only sr-only-focusable">Submit
									Search</span>
							</button>
						</div>
					</form>
				</li>
				<li class="reboot nav-item dropdown my-auto ml-1">
					<a href="#" id="nav-filter-data" data-test="nav-filter-data" class="reboot nav-link dropdown-toggle disabled click" role="button" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false" tabindex="7" accesskey="3">
						<i class="reboot nav-loading fas fa-list-alt" title="Data"></i>
						<span class="reboot d-md-none d-lg-inline">Data</span>
						<span class="reboot sr-only sr-only-focusable">Data</span>
					</a>
					<div class="reboot dropdown-menu">
						<form id="nav-filter-dropdown" data-name="data-dropdown" class="reboot px-2">
							<div class="reboot form-check">
								<input class="reboot form-check-input" type="radio" name="data-radios" value="0" checked="" tabindex="7">
								<label class="reboot form-check-label mb-0">All</label>
							</div>
							<div class="reboot form-check">
								<input class="reboot form-check-input" type="radio" name="data-radios" value="1" tabindex="7">
								<label class="reboot form-check-label mb-0">
									<i title="The first time choosing this will take a few moments." class="reboot far fa-clock d-none performance-concern"></i>
									<span class="reboot">Amounts Only</span>
								</label>
							</div>
							<div class="reboot form-check">
								<input class="reboot form-check-input" type="radio" name="data-radios" value="2" tabindex="7">
								<label class="reboot form-check-label mb-0">
									<i title="The first time choosing this will take a few moments." class="reboot far fa-clock d-none performance-concern"></i>
									<span class="reboot">Text Only</span>
								</label>
							</div>
							<div class="reboot form-check">
								<input class="reboot form-check-input meta-required" type="radio" name="data-radios" value="3" disabled="" tabindex="7">
								<label class="reboot form-check-label mb-0">
									<i title="The first time choosing this will take a few moments." class="reboot far fa-clock d-none performance-concern"></i>
									<span class="reboot">Calculations Only</span>
								</label>
							</div>
							<div class="reboot form-check">
								<input class="reboot form-check-input" type="radio" name="data-radios" value="4" tabindex="7">
								<label class="reboot form-check-label mb-0">
									<i title="The first time choosing this will take a few moments." class="reboot far fa-clock d-none performance-concern"></i>
									<span class="reboot">Negatives Only</span>
								</label>
							</div>
							<div class="reboot form-check">
								<input class="reboot form-check-input" type="radio" name="data-radios" value="5" tabindex="7">
								<label class="reboot form-check-label mb-0">
									<i title="The first time choosing this will take a few moments." class="reboot far fa-clock d-none performance-concern"></i>
									<span class="reboot">Additional Items Only</span>
								</label>
							</div>
						</form>
					</div>
				</li>
				<li class="reboot nav-item dropdown my-auto ml-1">
					<a href="#" id="nav-filter-tags" data-test="nav-filter-tags" class="reboot nav-link dropdown-toggle disabled click" role="button" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false" tabindex="8" accesskey="4">
						<i class="reboot nav-loading fas fa-tags" title="Tags"></i>
						<span class="reboot d-md-none d-lg-inline">Tags</span>
						<span class="reboot sr-only sr-only-focusable">Tags</span>
					</a>
					<div class="reboot dropdown-menu">
						<form id="nav-filter-tags-dropdown" data-name="tags-dropdown" class="reboot px-2">
							<div class="reboot form-check">
								<input class="reboot form-check-input" type="radio" name="tags-radios" value="0" aria-label="Radio Button for All Tag Types" checked="" tabindex="8">
								<label class="reboot form-check-label mb-0">All</label>
							</div>
							<div class="reboot form-check">
								<input class="reboot form-check-input" type="radio" name="tags-radios" value="1" aria-label="Radio Button for Standard Only Tag Types" tabindex="8">
								<label class="reboot form-check-label mb-0">
									<i title="The first time choosing this will take a few moments." class="reboot far fa-clock d-none performance-concern"></i>
									<span>Standard Only</span>
								</label>
							</div>
							<div class="reboot form-check">
								<input class="reboot form-check-input meta-required" type="radio" name="tags-radios" value="2" disabled="" aria-label="Radio Button for Custom Only Tag Types" tabindex="8">
								<label class="reboot form-check-label mb-0">
									<i title="Facts whose tags are outside the realm of DEI, US-GAAP, etc." class="reboot far fa-question-circle"></i>
									<i title="The first time choosing this will take a few moments." class="reboot far fa-clock d-none performance-concern"></i>
									<span class="reboot">Custom Only</span>
								</label>
							</div>
						</form>
					</div>
				</li>
				<li class="reboot nav-item dropdown my-auto ml-1">
					<a href="#" id="nav-filter-more" data-test="nav-filter-more" class="reboot nav-link dropdown-toggle disabled click" role="button" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false" tabindex="9" accesskey="5">
						<i id="loading-more-filters" class="reboot nav-loading fas fa-filter" title="More Filters"></i>
						<span class="reboot d-md-none d-lg-inline">More Filters</span>
						<span class="reboot sr-only sr-only-focusable">More Filters</span>
						<span title="Total active filters." class="reboot badge badge-warning"></span>
					</a>
					<div class="reboot dropdown-menu dropdown-menu-width">
						<label class="reboot dropdown-item-text d-none performance-concern">
							Selecting any of the below will take a few moments.</label>
						<div class="reboot accordion" id="more-filters-accordion">
							<form class="reboot" data-test="more-filters-form">
								<div class="reboot mx-1">
									<div class="reboot px-0 py-0">
										<a href="#" data-test="Period" data-target="#user-filters-periods" data-toggle="collapse" class="reboot d-flex justify-content-between align-items-center w-100 click text-primary" tabindex="9">
											<span class="reboot">Periods</span>
											<span data-test="Period-count" id="filters-periods-count" class="reboot badge badge-secondary">
												<i class="reboot fas fa-spinner fa-spin"></i>
											</span>
										</a>
									</div>
									<div id="user-filters-periods" class="reboot collapse height-200 overflow-y-auto" data-parent="#more-filters-accordion">
										<!-- Below is populated dynamically VIA JS -->
										<div class="reboot list-group list-group-flush"></div>
									</div>
								</div>
							</form>
							<form>
								<div class="reboot mx-1">
									<div class="reboot px-0 py-0">
										<a href="#" data-test="Measures" data-target="#user-filters-measures" data-toggle="collapse" class="reboot d-flex justify-content-between align-items-center w-100 click text-primary" tabindex="9">
											<span class="reboot">Measures</span>
											<span data-test="Measures-count" id="filters-measures-count" class="reboot badge badge-secondary">
												<i class="reboot fas fa-spinner fa-spin"></i>
											</span>
										</a>
									</div>
									<div id="user-filters-measures" class="reboot collapse height-200 overflow-y-auto" data-parent="#more-filters-accordion">
										<!-- Below is populated dynamically VIA JS -->
										<div class="reboot list-group list-group-flush"></div>
									</div>
								</div>
							</form>
							<form>
								<div class="reboot mx-1">
									<div class="reboot  px-0 py-0">
										<a href="#" data-test="Axis" data-target="#user-filters-axis" data-toggle="collapse" class="reboot d-flex justify-content-between align-items-center w-100 click text-primary" tabindex="9">
											<span class="reboot">Axis</span>
											<span data-test="Axis-count" id="filters-axis-count" class="reboot badge badge-secondary">
												<i class="fas fa-spinner fa-spin"></i>
											</span>
										</a>
									</div>
									<div id="user-filters-axis" class="reboot collapse height-200 overflow-y-auto" data-parent="#more-filters-accordion">
										<div class="reboot list-group list-group-flush d-none">
											<div class="reboot d-flex justify-content-between align-items-center w-100 px-1">
												<div class="reboot form-check">
													<input id="axes-all-0" title="Select/Deselect all options below." class="reboot form-check-input" type="checkbox" tabindex="9">
													<label class="reboot form-check-label mb-0">
														<a class="reboot" href="#axes-filters-accordion-0" data-toggle="collapse" tabindex="9">Explicit</a>
													</label>
												</div>
												<span class="reboot badge badge-secondary" id="axis-explicit-count"></span>
											</div>
										</div>
										<!-- Below is populated dynamically VIA JS -->
										<div class="reboot list-group list-group-flush d-none">
											<div class="reboot d-flex justify-content-between align-items-center w-100 px-1">
												<div class="reboot form-check">
													<input id="axes-all-1" title="Select/Deselect all options below." class="reboot form-check-input" type="checkbox" tabindex="9">
													<label class="reboot form-check-label mb-0">
														<a class="reboot" href="#axes-filters-accordion-1" data-toggle="collapse" tabindex="9">Typed</a>
													</label>
												</div>
												<span class="reboot badge badge-secondary" id="axis-typed-count"></span>
											</div>
										</div>
									</div>
								</div>
							</form>
							<form>
								<div class="reboot mx-1">
									<div class="reboot px-0 py-0">
										<a href="#" data-test="Members" data-target="#user-filters-members" data-toggle="collapse" class="reboot d-flex justify-content-between align-items-center w-100 click text-primary" tabindex="9">
											<span class="reboot">Members</span>
											<span data-test="Members-count" id="filters-members-count" class="reboot badge badge-secondary">
												<i class="reboot fas fa-spinner fa-spin"></i>
											</span>
										</a>
									</div>
									<div id="user-filters-members" class="reboot collapse height-200 overflow-y-auto" data-parent="#more-filters-accordion">
										<div class="reboot list-group list-group-flush d-none">
											<div class="reboot d-flex justify-content-between align-items-center w-100 px-1">
												<div class="reboot form-check">
													<input id="members-all-0" title="Select/Deselect all options below." class="reboot form-check-input" type="checkbox" tabindex="9">
													<label class="reboot form-check-label mb-0">
														<a class="reboot" href="#members-filters-accordion-0" data-toggle="collapse" tabindex="9">Explicit</a>
													</label>
												</div>
												<span class="reboot badge badge-secondary" id="members-explicit-count"></span>
											</div>
										</div>
										<!-- Below is populated dynamically VIA JS -->
										<div class="reboot list-group list-group-flush d-none">
											<div class="reboot d-flex justify-content-between align-items-center w-100 px-1">
												<div class="reboot form-check">
													<input id="members-all-1" title="Select/Deselect all options below." class="reboot form-check-input" type="checkbox" tabindex="9">
													<label class="reboot form-check-label mb-0">
														<a class="reboot" href="#members-filters-accordion-1" data-toggle="collapse" tabindex="9">Typed</a>
													</label>
												</div>
												<span class="reboot badge badge-secondary" id="members-typed-count"></span>
											</div>
										</div>
									</div>
								</div>
							</form>
							<form>
								<div class="reboot mx-1">
									<div class="reboot px-0 py-0">
										<a href="#" data-test="Scale" data-target="#user-filters-scales" data-toggle="collapse" class="reboot d-flex justify-content-between align-items-center w-100 click text-primary" tabindex="9">
											<span class="reboot">Scale</span>
											<span data-test="Scale-count" id="filters-scales-count" class="reboot badge badge-secondary">
												<i class="reboot fas fa-spinner fa-spin"></i>
											</span>
										</a>
									</div>
									<div id="user-filters-scales" class="reboot collapse height-200 overflow-y-auto" data-parent="#more-filters-accordion">
										<!-- Below is populated dynamically VIA JS -->
										<div class="reboot list-group list-group-flush"></div>
									</div>
								</div>
							</form>
							<form>
								<div class="reboot mx-1">
									<div class="reboot px-0 py-0">
										<a href="#" data-test="Balance" data-target="#user-filters-balances" data-toggle="collapse" class="reboot d-flex justify-content-between align-items-center w-100 click text-primary" tabindex="9">
											<span class="reboot">Balance</span>
											<span data-test="Balance-count" id="filters-balances-count" class="reboot badge badge-secondary">2</span>
										</a>
									</div>
									<div id="user-filters-balances" class="reboot collapse height-200 overflow-y-auto" data-parent="#more-filters-accordion">
										<div class="reboot d-flex justify-content-between align-items-center w-100 px-2">
											<div class="reboot form-check">
												<input id="user-filters-balances-debit" title="Select/Deselect this option." class="reboot form-check-input" type="checkbox" tabindex="9">
												<label class="reboot form-check-label mb-0">Debit</label>
											</div>
										</div>
										<div class="reboot d-flex justify-content-between align-items-center w-100 px-2">
											<div class="reboot form-check">
												<input id="user-filters-balances-credit" title="Select/Deselect this option." class="reboot form-check-input" type="checkbox" tabindex="9">
												<label class="reboot form-check-label mb-0">Credit</label>
											</div>
										</div>
									</div>
								</div>
							</form>
						</div>
					</div>
				</li>
				<li id="current-filters-reset" data-test="current-filters-reset" class="reboot nav-item d-none my-auto ml-1">
					<a href="#" id="current-filters-reset-all" data-name="current-filters-reset" class="reboot nav-link dropdown-toggle text-danger disabled click" tabindex="11" accesskey="7">
						<i class="reboot nav-loading fas fa-redo"></i>
						<span class="reboot d-md-none d-lg-inline">Reset All
							Filters</span>
					</a>
				</li>
				<li id="links-dropdown" data-test="links-dropdown" class="reboot nav-item dropdown d-none my-auto ml-1">
					<a href="#" id="additional-links-dropdown" class="reboot nav-link dropdown-toggle disabled click" role="button" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false" tabindex="12" accesskey="8">
						<i class="reboot nav-loading fas fa-link"></i>
						<span class="reboot d-md-none d-lg-inline">Links</span>
					</a>
					<div id="links-dropdown-content" class="reboot dropdown-menu dropdown-menu-width w-auto"></div>
				</li>
			</ul>
			<ul class="reboot navbar-nav pull-right bg-inherit">
				<li class="reboot nav-item my-auto ml-1">
					<a id="facts-menu" data-test="facts-menu" class="reboot nav-link click" tabindex="13" accesskey="9">
						Facts
						<span class="reboot taxonomy-total-count badge badge-light"><i class="fas fa-spinner fa-spin"></i></span>
					</a>
				</li>
			</ul>
		</div>
	</nav>
	<div class="reboot main-container">
		<div id="error-container" data-test="error-container" class="reboot px-0"></div>
		<div id="xbrl-form-loading" data-test="xbrl-form-loading" class="reboot jumbotron h-100 d-none">
			<h2 class="reboot display-4 text-center">
				<i class="reboot fas fa-spinner fa-spin"></i>
				Loading Inline Form.
			</h2>
		</div>
		<div id="sections-menu" data-test="sections-menu" class="reboot left-sidenav col-sm-3 bg-light overflow-x-auto invisible">
			<div class="reboot mb-2">
				<span class="reboot lead">Tagged Sections</span>
				<a id="sections-menu-toggle" class="reboot float-right click color-inherit" tabindex="2">
					<i class="reboot fas fa-times-circle mt-2 text-dark"></i>
				</a>
			</div>
			<form id="sections-menu-search-submit" data-name="sections-menu-search" class="reboot my-2 my-lg-0 input-group" novalidate="">
				<div id="sections-search-additional" class="reboot input-group-prepend d-none">
					<button class="reboot dropdown btn btn-sec" type="button" data-toggle="dropdown" tabindex="2">
						<i class="reboot nav-loading fas fa-cog"></i>
					</button>
					<div class="reboot dropdown-menu px-2">
						<div class="reboot form-check">
							<input class="reboot form-check-input" type="radio" name="sections-search-options" value="1" checked="" tabindex="2">
							<label class="reboot form-check-label">Search in All.</label>
						</div>
						<div class="reboot form-check">
							<input class="reboot form-check-input" type="radio" name="sections-search-options" value="2" tabindex="2">
							<label class="reboot form-check-label">Search in Internal
								Sections Only.</label>
						</div>
						<div class="reboot form-check">
							<input class="reboot form-check-input" type="radio" name="sections-search-options" value="3" tabindex="2">
							<label class="reboot form-check-label">Search in External
								Sections Only.</label>
						</div>
					</div>
				</div>
				<input type="text" class="reboot form-control" id="sections-search" data-test="sections-search" placeholder="Search Sections" aria-label="Search all Sections by their associated label." name="search-sections" tabindex="2" required="">
				<div class="reboot input-group-append">
					<button id="section-menu-search-btn-clear" data-name="sections-menu-search-clear" class="reboot btn btn-sec" type="button" tabindex="2">
						<i class="nav-loading fas fa-times-circle" title="Clear Sections Search"></i>
						<span class="reboot sr-only sr-only-focusable">Clear
							Sections Search</span>
					</button>
					<button class="reboot btn btn-sec" type="submit" tabindex="2">
						<i class="reboot nav-loading fas fa-search" title="Submit Sections Search"></i>
						<span class="reboot sr-only sr-only-focusable">Submit
							Sections Search</span>
					</button>
				</div>
			</form>
			<hr>

			<div class="reboot accordion" id="tagged-sections">
				<!-- Below is populated dynamically VIA JS -->
			</div>
		</div>



		<div id="help-menu" data-test="help-menu" class="reboot left-sidenav col-sm-3 bg-light overflow-x-auto invisible">

			<div class="reboot mb-2">
				<span class="reboot lead">Help</span> <a id="help-menu-close" data-test="help-menu-close" class="reboot float-right click"> <i class="reboot fas fa-times-circle mt-2"></i>
				</a>
			</div>
			<div class="reboot accordion" id="help-sections">
				<div class="reboot card">
					<div class="reboot card-header px-0 py-0">
						<h5 class="reboot mb-0">
							<button class="reboot btn btn-link d-flex justify-content-between align-items-center w-100" type="button" data-toggle="collapse" data-target="#help-getting-started">
								<span class="reboot font-size-1 ">Getting Started</span>
							</button>
						</h5>
					</div>
					<div id="help-getting-started" class="reboot collapse" data-parent="#help-sections">
						<p class="reboot m-2">The Inline XBRL viewer allows a user
							to quickly and easily review details of the tagged information in
							an Inline document by automatically placing a top and bottom
							highlight border around each tagged numeric fact and left and
							right border for each block tagged fact. Hovering over a tagged
							fact will highlight (shade) all content related to the tagged
							fact, and clicking on a tagged fact will reveal its tagging
							details in the Fact Review Window. Navigation, search and filter
							options are also provided to easily refine and identify specific
							types of tagged information.</p>
					</div>
				</div>
				<div class="reboot card">
					<div class="reboot card-header px-0 py-0">
						<h5 class="reboot mb-0">
							<button class="reboot btn btn-link d-flex justify-content-between align-items-center w-100" type="button" data-toggle="collapse" data-target="#help-fact-review-window">
								<span class="reboot font-size-1">Fact Review Window</span>
							</button>
						</h5>
					</div>
					<div id="help-fact-review-window" class="reboot collapse" data-parent="#help-sections">
						<p class="reboot m-2">The Fact Review Window shows the tagging
							details for the currently selected fact, which is highlighted
							with a solid blue border. There are four categories of fact detail
							which can be viewed; an "N/A" value indicates there is no
							available information for the item within the given category:</p>
						<ul class="reboot">
							<li class="reboot">Attributes - All primary information (as
								applicable) describing the tagged fact including period, sign,
								decimals, dimensional detail (axes and members), scale, measure
								and data type.</li>
							<li class="reboot">Labels - Detailed documentation
								(definition) for the tag used, and other labels.</li>
							<li class="reboot">References - Authoritative reference
								information (as applicable) for the selected tag.</li>
							<li class="reboot">Calculation - Balance and calculation
								hierarchy details (numeric non-dimensioned items only).</li>
						</ul>
					</div>
				</div>
				<div class="reboot card">
					<div class="reboot card-header px-0 py-0">
						<h5 class="reboot mb-0">
							<button class="reboot btn btn-link d-flex justify-content-between align-items-center w-100" type="button" data-toggle="collapse" data-target="#help-search">
								<span class="reboot font-size-1">Searching</span>
							</button>
						</h5>
					</div>
					<div id="help-search" class="reboot collapse" data-parent="#help-sections">
						<p class="reboot m-2">There are two ways to search the
							document: FACTS AND SECTIONS. To search information, enter a
							keyword in a search box and select the magnifying glass icon to
							return matching results. Search operators "and" (via "AND" or
							"&amp;") and "or" (via "OR" or "|") are available to further refine a
							search.</p>
						<p class="reboot m-2">
							<strong>FACTS</strong>
						</p>
						<p class="reboot m-2">The Search Facts box can be used to find
							tagged facts matching entered keywords. By default, tag name, tag
							labels, and tagged content are included in Search. Tagged facts
							matching the search criteria are shown with a yellow-colored
							(default) shading on the page and appear in the Facts List.
							Select the "X" button to the left of the magnifying glass icon to
							clear the search.</p>
						<p class="reboot m-2">The content included in Search can be increased to
							included tag definitions, dimensions, and authoritative
							references by selecting the cog / wheel icon to the left of the
							search box. See Settings for more information.</p>

						<p class="reboot m-2">
							<strong>SECTIONS</strong>
						</p>
						<p class="reboot m-2">The Search Sections box can be used to
							filter the tagged sections of the financial statements.</p>
					</div>
				</div>
				<div class="reboot card">
					<div class="reboot card-header px-0 py-0">
						<h5 class="reboot mb-0">
							<button class="reboot btn btn-link d-flex justify-content-between align-items-center w-100" type="button" data-toggle="collapse" data-target="#help-filter">
								<span class="reboot font-size-1">Filters</span>
							</button>
						</h5>
					</div>
					<div id="help-filter" class="reboot collapse" data-parent="#help-sections">
						<p class="reboot m-2">Filters change the number of highlighted
							facts and items in the fact list by providing several ways to
							review and pinpoint certain tagged information. Multiple filters
							can be used at once.</p>
						<p class="reboot m-2">
							<strong>DATA FILTERS</strong>
						</p>
						<p class="reboot m-2">These filter options allow the user to
							refine the highlighted tagged facts by data type:</p>
						<ul class="reboot">
							<li class="reboot">All - Displays all tagged data (default)</li>
							<li class="reboot">Amounts Only - Numeric facts only</li>
							<li class="reboot">Text Only - Textual facts only</li>
							<li class="reboot">Calculations Only - Numeric facts
								participating in a calculation only</li>
							<li class="reboot">Negatives Only - Negative Numeric amounts
								only</li>
							<li class="reboot">Additional Items Only - Tagged facts
								without a corresponding HTML presentation (i.e., hidden facts)
								only</li>
						</ul>
						<p class="reboot m-2">
							<strong>TAGS FILTER</strong>
						</p>
						<p class="reboot m-2">These filters allow the user to refine
							the highlighted facts by tag type:</p>
						<ul class="reboot">
							<li class="reboot">All - Displays all tagged data (default)</li>
							<li class="reboot">Standard Only- Facts with standard tags
								from a common taxonomy (e.g., US_GAAP, IFRS, DEI).</li>
							<li class="reboot">Custom Only - Facts with extension
								"custom" tags unique to the entity's document.</li>
						</ul>
						<p class="reboot m-2">
							<strong>MORE FILTERS</strong>
						</p>
						<p class="reboot m-2">Additional filters that allow user to
							further refine the highlighted facts:</p>
						<ul class="reboot">
							<li class="reboot">Periods - List of all used context years
								and reporting periods</li>
							<li class="reboot">Measures - List of all used units of
								measure (e.g., US Dollars); as applicable</li>
							<li class="reboot">Axis - List of all used axis
								(dimensions); as applicable (dimensions); as applicable</li>
							<li class="reboot">Scale - List of all used scaled options
								(e.g., thousands, millions); as applicable</li>
							<li class="reboot">Balance - Debit, credit; as applicable</li>
						</ul>
						<p class="reboot m-2">Multiple filters work in conjunction
							with each other. For example, selecting the "Amounts Only" Data
							filter and "Custom Only" Tags filter will highlight only numeric
							tagged facts using custom tags and list them in the fact list.
							Active filters are displayed in the Filter toolbar as they are
							selected. Active filters can be removed individually by
							unchecking or selecting ALL option for each filter, or all at
							once via the "Reset All Filters" option.</p>
					</div>
				</div>
				<div class="reboot card">
					<div class="reboot card-header px-0 py-0">
						<h5 class="reboot mb-0">
							<button class="reboot btn btn-link d-flex justify-content-between align-items-center w-100" type="button" data-toggle="collapse" data-target="#help-facts-results-list">
								<span class="reboot font-size-1">Facts List (Results)</span>
							</button>
						</h5>
					</div>
					<div id="help-facts-results-list" class="reboot collapse" data-parent="#help-sections">
						<p class="reboot m-2">On the toolbar, select the "count" to
							the right of the word Facts (e.g., Facts 234) to reveal the Facts
							List results - a navigable listing of all currently highlighted
							tagged facts. The count represents the current number of facts.</p>
						<p class="reboot m-2">By default, all tagged facts are
							displayed in the Fact List Results. The list content and count
							reflects the currently highlighted facts (i.e., both Filters and
							Search criteria refine the list to match the highlighted tagged
							facts). Navigation controls are available to move through the
							list as well as move the current view to the corresponding
							highlighted fact location automatically. When a fact in the Facts
							Results List is selected, it will reveal the Fact Review Window.</p>
						<p class="reboot m-2">Certain letters may appear to the right
							of an item in the Fact Result list to indicate a certain
							property. If the letter "A" appears for a fact, it indicates the
							fact is additional data (i.e., hidden with potentially no
							corresponding HTML presentation). If the letter "C" appears, the
							fact is tagged with a custom tag. If the letter "D" appears, the
							fact is tagged with dimensional information.</p>
					</div>
				</div>
				<div class="reboot card">
					<div class="reboot card-header px-0 py-0">
						<h5 class="reboot mb-0">
							<button class="reboot btn btn-link d-flex justify-content-between align-items-center w-100" type="button" data-toggle="collapse" data-target="#help-tagged-sections">
								<span class="reboot font-size-1">Sections</span>
							</button>
						</h5>
					</div>
					<div id="help-tagged-sections" class="reboot collapse" data-parent="#help-sections">
						<p class="reboot m-2">The SECTIONS toolbar item provides a
							listing of the tagged sections of the Inline document. Sections
							are divided into three groups:</p>
						<ul class="reboot">
							<li class="reboot">Document &amp; Entity Information</li>
							<li class="reboot">Financial Statements</li>
							<li class="reboot">Notes to the Financial Statements</li>
						</ul>
						<p class="reboot m-2">By expanding a group and selecting a
							section item in the listing, Inline XBRL viewer will navigate to that section.
							When the Tagged Sections feature is open, the Search Sections box
							will additionally filter the list of sections to only those
							sections that match the entered criteria.</p>
					</div>
				</div>

				<div class="reboot card">
					<div class="reboot card-header px-0 py-0">
						<h5 class="reboot mb-0">
							<button class="reboot btn btn-link d-flex justify-content-between align-items-center w-100" type="button" data-toggle="collapse" data-target="#help-tagged-menu">
								<span class="reboot font-size-1">Menu</span>
							</button>
						</h5>
					</div>
					<div id="help-tagged-menu" class="reboot collapse" data-parent="#help-sections">
						<p class="reboot m-2">
							<strong>Information</strong>
						</p>
						<p class="reboot m-2">The Information menu item provides
							additional detail about the current Inline document and
							customizable viewer settings.</p>
						<ul class="reboot">
							<li class="reboot">Company and Document - Basic company and document
								information</li>
							<li class="reboot">Tags - Fact and tag (standard and custom)
								information</li>
							<li class="reboot">Files - Files used</li>
							<li class="reboot">Additional Items - Additional hidden data
								that's been tagged but potentially does not have a corresponding
								location in the HTML</li>
						</ul>
						<p class="reboot m-2">
							<strong>Save XBRL Instance</strong>
						</p>
						<p class="reboot m-2">The Save XBRL Instance menu item allows
							an XBRL instance document (*.xml) that is extracted from the
							Inline document to be saved locally for use by software
							supporting the XBRL format.</p>
						<p class="reboot m-2">
							<strong>Save XBRL Zip</strong>
						</p>
						<p class="reboot m-2">The Save XBRL Zip menu item allows a zip
							file (*.zip) that contains the as-provided XBRL instance document
							and related custom taxonomy files to be saved locally.</p>
						<p class="reboot m-2">
							<strong>Settings</strong>
						</p>
						<p class="reboot m-2">The Settings menu item provides the
							ability to customize Viewer features.</p>
						<p class="reboot m-2">
							<strong>Tagged Fact Hover</strong>
						</p>
						<ul class="reboot">
							<li class="reboot">On - Displays the hover fact review
								window for any tagged fact*</li>
							<li class="reboot">Off - Hides the hover fact review window
								for any tagged fact (default)</li>
						</ul>
						<p class="reboot m-2">* May impact performance with certain
							web browsers.</p>
						<p class="reboot m-2">
							<strong>Auto Scrolling Position </strong>(This setting will have
							no effect on IE 10 or Safari)
						</p>
						<ul class="reboot">
							<li class="reboot">Top - Selecting a fact from the Sections
								Menu or the Fact Menu will automatically scroll that element to
								the Top of the Inline XBRL viewer window (default)</li>
							<li class="reboot">Center - Selecting a fact from the
								Sections Menu or the Fact Menu will automatically scroll that
								element to the middle of the Inline XBRL viewer window</li>
						</ul>
						<p class="reboot m-2">
							<strong>Highlight Colors</strong> (Use the save and reset buttons
							to save the selected setting or reset to default)
						</p>
						<ul class="reboot">
							<li class="reboot">Tagged Data - Change the highlight color
								of the tagged fact border</li>
							<li class="reboot">Search Results - Change the background
								color of tagged items matching the Search results</li>
							<li class="reboot">Selected Fact - Change the color of
								highlight border used to identify the currently selected fact</li>
							<li class="reboot">Tag Shading (hover) - Change the color of
								the shading applied to tagged data on hover</li>
						</ul>
						<p class="reboot m-2">
							<strong>Search Options</strong>
						</p>
						<ul class="reboot">
							<li class="reboot">Match Case - Matches the specific case of
								the entered Search keyword</li>
							<li class="reboot">Include Labels - Extends Search to
								include tag labels</li>
							<li class="reboot">Include Definitions - Extends Search to
								include tag definitions</li>
							<li class="reboot">Include Dimensions - Extends Search to
								include dimensional detail</li>
							<li class="reboot">Include References - Extends Search to
								include authoritative reference information. Optionally specify
								the reference parts to include in the search (e.g., topic,
								subtopic, section)</li>
						</ul>
						<p class="reboot m-2">
							<strong>Help</strong>(this content)
						</p>
						<p class="reboot m-2">
							<strong>Version</strong>
						</p>
						<p class="reboot m-2">Indicates the current build of the Inline XBRL viewer
							application.</p>
					</div>
				</div>

			</div>
		</div>



		<div data-test="taxonomies-menu" id="taxonomies-menu" class="reboot right-sidenav col-sm-3 bg-light invisible">
			<div class="reboot d-flex flex-column flex-fill h-100">
				<div class="reboot mb-2">
					<span class="reboot lead">Facts</span>
					<a id="taxonomy-menu-secondary-toggle" data-test="taxonomy-secondary-toggle" class="reboot float-right click">
						<i class="reboot fas fa-times-circle mt-2"></i>
					</a>
				</div>
				<div id="taxonomies-menu-list-pagination" class="reboot d-flex flex-column flex-fill h-100 w-100">
					<div class="reboot pagination"></div>
					<div class="reboot form-group">
						<select id="taxonomies-menu-page-select" class="reboot form-control" aria-label="Quickly jump to a page in the Fact Menu." tabindex="13">
							<option class="reboot">Select Page</option>
						</select>
					</div>
					<div class="reboot list-group list-group-flush overflow-x-auto w-100"><span class="text-center py-5">Loading.</span></div>
				</div>
			</div>
		</div>
		<div id="back-to-top" class="reboot d-none">
			<button id="back-to-top-btn" type="button" class="btn btn-sm btn-primary">
				<i class="reboot fas fa-arrow-up"></i>
			</button>
		</div>

		<div id="dynamic-xbrl-form" class="position-relative"><!--?xml version="1.0" ?--><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:70c62309-6771-471a-8714-bd6788d518c8,g:cbaadc14-9edf-41c3-b5b2-727f7a2d2243,d:e8dc61f8e15b44db82ba16050d5b7b44--><meta http-equiv="Content-Type" content="text/html">


<title>lly-20220331</title><div style="display:none"><ix:header><ix:hidden><ix:nonnumeric contextref="id879b497a407453985551e83dbee75f8_D20220101-20220331" name="dei:AmendmentFlag" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80L2ZyYWc6MmIxZjZhOGFjNmJlNGZlZGFjOTU1Y2NjN2NlZjQ5NDYvdGFibGU6Nzk3MjM5YTg4YzljNDQxOGFkMWY2MjU5YzcwZTkyMDQvdGFibGVyYW5nZTo3OTcyMzlhODhjOWM0NDE4YWQxZjYyNTljNzBlOTIwNF8zLTEtMS0xLTEwMTE5MA_624c6d1b-12b3-43a9-addc-d2d1feb3d866">FALSE</ix:nonnumeric><ix:nonnumeric contextref="id879b497a407453985551e83dbee75f8_D20220101-20220331" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80L2ZyYWc6MmIxZjZhOGFjNmJlNGZlZGFjOTU1Y2NjN2NlZjQ5NDYvdGFibGU6Nzk3MjM5YTg4YzljNDQxOGFkMWY2MjU5YzcwZTkyMDQvdGFibGVyYW5nZTo3OTcyMzlhODhjOWM0NDE4YWQxZjYyNTljNzBlOTIwNF80LTEtMS0xLTEwMTE5MA_5eb402e7-ea3a-478a-a057-950e16531429">2022</ix:nonnumeric><ix:nonnumeric contextref="id879b497a407453985551e83dbee75f8_D20220101-20220331" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80L2ZyYWc6MmIxZjZhOGFjNmJlNGZlZGFjOTU1Y2NjN2NlZjQ5NDYvdGFibGU6Nzk3MjM5YTg4YzljNDQxOGFkMWY2MjU5YzcwZTkyMDQvdGFibGVyYW5nZTo3OTcyMzlhODhjOWM0NDE4YWQxZjYyNTljNzBlOTIwNF81LTEtMS0xLTEwMTE5MA_90d74860-d4bc-4b63-847d-09a281f6e32c">Q1</ix:nonnumeric><ix:nonnumeric contextref="id879b497a407453985551e83dbee75f8_D20220101-20220331" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80L2ZyYWc6MmIxZjZhOGFjNmJlNGZlZGFjOTU1Y2NjN2NlZjQ5NDYvdGFibGU6Nzk3MjM5YTg4YzljNDQxOGFkMWY2MjU5YzcwZTkyMDQvdGFibGVyYW5nZTo3OTcyMzlhODhjOWM0NDE4YWQxZjYyNTljNzBlOTIwNF82LTEtMS0xLTEwMTE5MA_dc3c734c-6b62-49d4-b48c-bd2c2a058d1a">0000059478</ix:nonnumeric><ix:nonnumeric contextref="id879b497a407453985551e83dbee75f8_D20220101-20220331" name="dei:CurrentFiscalYearEndDate" format="ixt:date-month-day" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80L2ZyYWc6MmIxZjZhOGFjNmJlNGZlZGFjOTU1Y2NjN2NlZjQ5NDYvdGFibGU6Nzk3MjM5YTg4YzljNDQxOGFkMWY2MjU5YzcwZTkyMDQvdGFibGVyYW5nZTo3OTcyMzlhODhjOWM0NDE4YWQxZjYyNTljNzBlOTIwNF83LTEtMS0xLTEwMTE5MA_687f019d-18e4-4ac1-9710-608da47195b5">12/31</ix:nonnumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaref xlink:type="simple" xlink:href="lly-20220331.xsd"></link:schemaref></ix:references><ix:resources><xbrli:context id="id879b497a407453985551e83dbee75f8_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i7d49ccbde7cb4a2cb9cf5f389b03a176_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ia75e83bb4f4e4a3c9c62b191a82971b4_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">lly:A718NotesDueJune12025Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="if80e85dc929b414d9df688db7009bb76_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">lly:A1.625NotesDueJune22026Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i1e397965855b4e77bc5c57367dccd50b_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">lly:A2.125NotesDueJune32030Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i4cbc773e04594310b473287fc3d0e917_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">lly:A625Notesdue2031Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="id4aa1d7ba2764224acafc2173c662da1_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">lly:A5000NotesDue2033Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ie4719f471a1a494d8fa1a7731209c4b1_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">lly:A6.77NotesDueJanuary12036Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ia3287ec0a7f54b078a72ddf72d91d0e9_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">lly:A1625NotesDue2043Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i6759be204354404a9f0432da662a942a_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">lly:A1.700Notesdue2049Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="id376b4be939542b8aef77d2268f41c97_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">lly:A1125NotesDue2051Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i8205c2d7409c4decb9efb0638f264b89_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">lly:A1375NotesDue2061Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i62be53ac21bd4b0b8aa6e62ecf72737c_I20220426"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i010e4c0d9c6246be91d37e31d569fa6f_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitnumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitnumerator><xbrli:unitdenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitdenominator></xbrli:divide></xbrli:unit><xbrli:context id="ib1053442369e460291956c51ab7e5179_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iffa7a62ea976465eb0977d320e638511_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i534904bdfd54461a96c8246d9ecc70a8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia0c7ddea27a44153823f015b89b454d2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8c89a157b3794bb4a87d54334813d68c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i772d16d39bc747f3b52c1924fa4b03f4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TrustForBenefitOfEmployeesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibc022718ed034b20a63b39dfdbaab09e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4f2f3e9efb184f4f98baa286d8701507_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id798b7917b9b4678a259c1039255b282_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i420cdd7778cf4462a35b8db230d54b8c_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="icc3c1daa2c764c54a41ee942bc243ab1_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i041885a980a34f59af3596c66d307967_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i407fee31623f400291c46f875a97958b_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ib3b7204e3e6b45bc9b035264afbac130_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i8b5503f2535d42608e7025a646f79443_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ia9a1b635649a4926ae3309c4ec3d6d3e_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i35667239b18f436bab294df329c038eb_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i25fe75417da64029ba77ae08f2d45d8a_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i07fd33c4c9cb41beacedf6f5d24cee4c_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TrustForBenefitOfEmployeesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i43c105aca7e240178d0e89d09a70ed9b_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i73779719d6ac41d18122c2bfb22f722b_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i55bb63e488ea4862b4eeacafc3d16d3a_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2f171c9c0764435596b9addbf3a3c7b8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i763e2843c67f427eb4dbedd59fd94c83_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iddd8001ab87f416891d32f32378a1ff8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6752266e758d4a55b13ba7aa88a4106d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TrustForBenefitOfEmployeesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1ff16206b6b0437e95e85f0c0dc79f0b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i44a742d79dc140ca9d6192f1c85ec4f6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic69cdb1eadab4640aaa5db80dc9e4f66_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia86f7488e69747879c270d95f97b2fd8_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ie181c9175c2e4e0e97580f859f4cb4aa_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i5d8c885250cf41859fc49a31213d750a_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i19e48a9fdfbe4e0bb926fcc624ff1c1c_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="if01eafd1c5de4be8977529edda964bdc_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i5d450c033ae8486e83663df6458e4763_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i3b8b2bd42197422ab034e2f2cb925c9e_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id701cd4a84884cbebc65d833f9b29be8_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0264ef1afcf043d1b3dc10d561f1ad86_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3f96d2e5358847db9e2027a612b3be4c_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TrustForBenefitOfEmployeesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i43aa66474f114885b0ce1578e4c4c5ea_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5362064a415b4ef1bf7669d31f2d681f_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i98a419d099994feba11744c6093efaed_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic2d5056a8d9b48feb23cc7f8b96df053_I20210531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i00275dd8facd4dcbb0ad10126a1977c1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i67e838f8a66a44b2b504c4b1f3b10525_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic1149e00eba94a9eab47f56d4cf9e9bf_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i0c908ece78834e1094d6092d93b040f8_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i908a311d8eb54eeaae2a8faabb1c5148_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:CollaborationandOtherRevenueMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i5c360f700df74f2ab393fcbc7f1d0c86_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:CollaborationandOtherRevenueMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="id551c0dd4f8142988996d40dff58f235_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ib1cb3f43e3f14fb19a81e30a469be70e_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i057edaf4edfb4ff488df655e1ddbb15d_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ChangeInAccountingEstimateByTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="ic341dbad348840e68a9a109777641f35_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ChangeInAccountingEstimateByTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i1d928ff934414f339d711ba91de66c6c_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:TrulicityMemberMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i3d4129b004644544827c79d8fe7d7553_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:TrulicityMemberMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i43c847a6bcc2436fb9611d9c5224292e_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:TrulicityMemberMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i1a537253917d47f79d2a63b89c2047f4_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:TrulicityMemberMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i8eb2e6c4e79e4c84bbe2495e225c9ace_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:TrulicityMemberMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i7ca35c03fa5043b591914a4a7dcc003c_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:TrulicityMemberMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i2f5a660bdd654492984092e74d834aff_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:HumalogMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i66c645d6113e47d0955176d2c29149ca_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:HumalogMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i360dec42bd9f475198d2a27568c8a2d1_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:HumalogMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i1e804ce611484db3805881c6a06fe4f6_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:HumalogMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i6b49581ac9414e90b623279b08df901e_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:HumalogMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="id458828d048e4e17835286479b42ad54_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:HumalogMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ie62f212b84b84441a9d590c22ca7e076_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:JardianceMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i50e7f3e230d74d469d6374c85d49ec18_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:JardianceMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i4cb6aa62dbd343b890ba09e927b3cd93_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:JardianceMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ia7c4529116bc4c849565b039663b3620_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:JardianceMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="if5144d4906484c5c8da6a103252b001c_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:JardianceMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i777b66c425e44ef281a1ea05038a2e33_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:JardianceMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="icdaa6c5d7460426aa41e467d0a5d1a1c_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:HumulinMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i8685f0545a4e4f659ada216a354b06fc_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:HumulinMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="if28a514fbb6d452aa6354a426d371b87_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:HumulinMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="iba46f63d62554503b9b65f40f4657fe3_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:HumulinMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="if2590ae4b40c44f08b7057982d176fc6_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:HumulinMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i00b3c21da768430aabd3e36a06dc1aab_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:HumulinMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i02ca14f5a0414a43a7631e15dbc8c83e_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:BasaglarMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i45c518485c864258b8570772e23e7f3d_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:BasaglarMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ie964fd385686493399055f5b20bfe25e_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:BasaglarMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i2857f2babcfd4084bc21205f8b62d6b9_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:BasaglarMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="id40da84c657f43a3a76ff109504f757f_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:BasaglarMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ie7ec39e69cee464db36f6873b2d073f8_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:BasaglarMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="icdd881559f7c49ca9f53555b5e263c09_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:OtherDiabetesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i67f170f144f94c999ce01aabde1f4e76_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:OtherDiabetesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ib3d22ba4cfe042149bf38612aeda8005_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:OtherDiabetesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ic1f7e0c6d913421c9e9fff2c4fe23be5_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:OtherDiabetesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i0a4d94c6004843f687879c5db8de8712_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:OtherDiabetesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="if20fa24c94f54c0c8da9136e05e4b5ef_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:OtherDiabetesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i862ddf7fe37f487f90b216e79873b421_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:DiabetesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i2782631369e043a2a1043644a76a6a28_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:DiabetesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="id9014f48514443a0be11ead727a2799b_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:DiabetesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i82fdfc09ca2d405c92da72d6de7688b8_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:DiabetesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i8d70fcb627cf43bfbaa643572e0531bd_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:DiabetesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i1d14eefd28f54bd7a3bb20e633acefcd_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:DiabetesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i82b25f95ac834d7db3cc009ee7887ec4_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:VerzenioMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="id53b2f021056477b9bce0c0afd760de4_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:VerzenioMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i883a9b3ff28f4e8f823b628c6f50c431_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:VerzenioMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i8956a1fedf96422c909b9746f1cc0150_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:VerzenioMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ic89987fa855943749c0e97aafa7e34cc_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:VerzenioMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i1b0e11b6e59645e2b6a994394790b4b4_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:VerzenioMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i05f6aa31973749ae8330b8a4f6956a45_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:AlimtaMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i566d301eeea54ba6ad2547388d94347e_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:AlimtaMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i50347a0f753a4ea98550ed4615b568a8_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:AlimtaMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i4aa80bbe80b745cca4b9dd6801370e25_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:AlimtaMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="if5cb8092b8ae4df982372f0f9c88c089_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:AlimtaMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i30fc27f2b4b045abb067a4222037b8ff_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:AlimtaMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ie477ac10d2fc47b1b19b05139e80176b_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:CyramzaMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i986dec26366448bf9b38b31b125f8a99_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:CyramzaMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ia0f55d27eb544bc482fe1337e5bfa093_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:CyramzaMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i7c3481645c06471e81e99feeca522f8f_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:CyramzaMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i26107852279a4dafb2499591586a6581_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:CyramzaMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ibe2a3fa428ac4c8da1c9f47966e07f27_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:CyramzaMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i006eabb915c840708df1a30e82ac5956_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:ErbituxMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i1a89bfe808c94e1cb367a6b76d7e6d69_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:ErbituxMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="iad2987d4931049708f169b45766cd49d_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:ErbituxMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ia24a5ef3b72b4516a8337ee873113aa2_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:ErbituxMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ia63e46cfe6894ba5a869233e10eb3605_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:ErbituxMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i808e8f1fbb114baaa2cd112190e66e74_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:ErbituxMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ib865f576197b402f8c1562bbb1c788a2_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:TYVYTMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ie5736ce4bc58475884d3c62d4240640d_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:TYVYTMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ifdfcf0a8c9f24795965b4204e3e96f0c_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:TYVYTMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i4ce61e5571e745679da4dbfb0f0b623d_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:TYVYTMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="id22e362347fe4427980338d8e9198e75_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:TYVYTMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i8313e66c84c44e68889b0fac3ee0fe61_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:TYVYTMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ifdabefbad9c84ef18d4c3e3761dd59ca_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:OtherOncologyMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i335b1508eb2a4f52854281dece929b66_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:OtherOncologyMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ifb7872db7d714dbb9e985d86230c1a48_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:OtherOncologyMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i4b6302e7bb6f41c387d17e2319e42cd7_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:OtherOncologyMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i05eaa0a7bff94f2896500aa8e6f875f3_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:OtherOncologyMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ic7b40503ad284a9fb556801598af5fde_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:OtherOncologyMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i025555e7e37b45d5b61da966238aa289_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:OncologyMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ia6bab3fb55e7472081dd584fa4e83cf8_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:OncologyMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i919429aec0024d68b7f5581ce24bde7c_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:OncologyMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i1f48dd5b9b0a4cd3b6d5d597f3f5736d_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:OncologyMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i6f9475eee5284cd987d3115e0b2a2a0a_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:OncologyMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i121bf8cbd5a047aeb0b9ad229bb008df_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:OncologyMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i0eff5238e7bb4c4096828b4d242281e4_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:TaltzMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ie465cf8d77274a5ea5f74a71366c20c8_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:TaltzMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i423c701c975348e49c1a3311b4b4da45_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:TaltzMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i05f6dda03fc84150b8fd52134744ee59_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:TaltzMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i4007424e82884343bdb9de5264d7f943_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:TaltzMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ib3fd1b62c68b43a1bf7d9d8845af2eaa_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:TaltzMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i349b98309b3f4fceb73ea6c5169cec65_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i450a7aff3e13449b83a284c9335dfa6f_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i5aed712fed4f4f1a85becddb3dd53a89_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ibc3e795dd0b54a2eb1625e755da0679c_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ib48e54fe6fa34e8db597de3eb89b6323_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i4b177d421c0842769bd4a1abbec6790a_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i63babd305ab043289099f66bd0422222_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:OtherImmunologyMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ie7a881001a6d4e239e4bb857f7aacd68_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:OtherImmunologyMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="iede0ea448f234d8dbc396cf9bf12d41d_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:OtherImmunologyMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ic02b29952579470e802f2b31fa282318_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:OtherImmunologyMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="id934acb069604725bbf1ff85c1250aae_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:OtherImmunologyMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ic73028cbe9ad4854b5a0ef90d745e161_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:OtherImmunologyMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i54f9f3ff29d94a3883ca8f1dfac03410_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:ImmunologyMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ib120d1e63b764e38ace68bbdc5c6571f_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:ImmunologyMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ifae8b458d0fd4b63951c828b2311b935_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:ImmunologyMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i612c356232294c40ada63de685860055_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:ImmunologyMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i665713c1455545b4a35ef93c20f0e843_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:ImmunologyMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ifa67bf60feae4907a400c8047645aca3_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:ImmunologyMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i69cb0ee5c26a44b89452b40491cf77d8_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:EmgalityMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i102a640e3a59438ab0c9b2388c052507_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:EmgalityMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="iaf182007f4da4607982cb81017b22723_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:EmgalityMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ie57df423d0014859a70f85d67113934c_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:EmgalityMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ib8c63dcc2e9e42abbc7b004719fd4010_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:EmgalityMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="iaffe90aa2cfa40efa53b2cecdb1cac5e_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:EmgalityMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ic7c30620116044c58a77814c02f88816_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:ZyprexaMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ib7ec2785c2cb482c9e74d19b4f3df22d_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:ZyprexaMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i3862837754b545f89af624c24fc949fa_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:ZyprexaMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i4ee42647ea3d4f4f99858c5251fe6d61_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:ZyprexaMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i903bf3e6989848fa8b8d6e798c7715cf_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:ZyprexaMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i9d2829a0249840fe8b1a0a533ea49b1e_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:ZyprexaMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i010310e142234f25bd8a4d4e166bf8cf_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:CymbaltaMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ia099bc43c3844b2cbc376926ab0d35a7_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:CymbaltaMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ic3af176623c4461591be1bbd29ffa355_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:CymbaltaMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i7094597407854e0085b748e6549bf213_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:CymbaltaMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="if55a0d1991854d74ae41b7b1a1b7b3fc_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:CymbaltaMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i5ff6bfafde62400b9aee7ada39f9e0ab_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:CymbaltaMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i83891bd7e6f24c4bae27161c1f576568_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:OtherNeuroscienceMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i5909280157414ecb8aac29a09390cfa4_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:OtherNeuroscienceMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="if2df22f3724d42a1a690c948012b785c_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:OtherNeuroscienceMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i3f40ed22835f41598b5a6699ce170796_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:OtherNeuroscienceMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ie50d918e323f427bbe2c10edc5c51418_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:OtherNeuroscienceMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i8e4ceefd208946af8cbd2b75219ab5f7_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:OtherNeuroscienceMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i464c50123283492aa9a36cb55224e76b_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:NeuroscienceMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i20ce527d5a8c4d9aba1876c2ef10e2ce_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:NeuroscienceMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i1ade4bb026ae48d1a195fd513963324c_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:NeuroscienceMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i1201cced44674063b807b48adfc086a3_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:NeuroscienceMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="id372fab86b38457e9f3cfc8f2314739c_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:NeuroscienceMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i4e76f1b0acec49ac95c82ac4fa5f9d5e_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:NeuroscienceMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i3e704b348f2a4704b75dbbe76f3b0b82_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:COVID19AntibodiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ia1b8e03165714ac39995f9d5e3ebe8eb_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:COVID19AntibodiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="if68e51aede3b457a9c66472600e5be13_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:COVID19AntibodiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i6b5c557c21d042eea9ed670b81ed3082_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:COVID19AntibodiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i6a0c438a51724ed98e09d1721ebea46f_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:COVID19AntibodiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i774cde30abd54325b3366e0ebcd76a96_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:COVID19AntibodiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ia3f989fa3f944cf2a1d81465a2f97532_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:CialisMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i999eac96817140af8121825ff12657e2_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:CialisMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i30f6a635614f4ff6aa9a7e983dd085fd_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:CialisMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i14a1dc5d218a4c5c9cdc20b862af3166_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:CialisMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i642827c9c169487d97277bb0b32699c7_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:CialisMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="icaddba0b7fad48828e46f831a67face2_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:CialisMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i1e252df9f1624f35be1172875296c5db_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:ForteoMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i882f726603ae4711b25fab11cb228b17_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:ForteoMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="icb8a07c17728496094396b91d46b3ecf_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:ForteoMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i3adf8edd7f11475fb574fa64f90fae30_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:ForteoMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ic909a21213e44f578c3411734a2d5d16_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:ForteoMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i8efcfbd60405419c93c35743f971c918_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:ForteoMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i22855bd5b0ca4ab4b334d88c8b6d1320_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:OtherProductMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i11d63fdd02034efea4b8c2cd455ca44d_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:OtherProductMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ia99bdeeec6d04756a789b133fd5d2381_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:OtherProductMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i79554e9080fe4cc486cc5f315f68d8b4_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:OtherProductMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i3494051841434bfa8865df9cd8fd26d5_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:OtherProductMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i430f45f98d9848a997b95b2869d06ada_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:OtherProductMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i3fc88ef00879439fa8e6d523b66da009_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:OtherProductTotalMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ifb4f7baea94c477995a0cac6856c7459_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:OtherProductTotalMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ia68ee8ebffa5444c99f8c0702521aacc_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:OtherProductTotalMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i5458d92918464797982a6591f5fdb5e7_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:OtherProductTotalMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i4de53bc690524560aac90d45a546dee7_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:OtherProductTotalMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i5cabdee801da421dad16fee3cdab03ff_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:OtherProductTotalMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i48e724dd68594a77a1940fbb84e01c0a_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i483a0602a4a4449985dca64f9a709f68_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="if888f743065d48f8ab36d2d72ab25478_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i21afabc730b3442a955bb1adab4b07d1_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i24b5090b374b4b789cdf22d60ea81a9a_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i1d3e66fcb0fd404e807859513f037628_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ibf27df75ec7f42c496c3fe02033e090d_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ifa836704ac1c4d70887d5d8096845ffa_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ia46a6c731c5f4eccb4090c399ee2426d_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i68141633070d499096dd1177ee8e769c_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i119b94d6afc84f039c904f8e6fae6786_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">lly:OtherForeignCountriesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i20ef3d78a81d4ea7910213c99cd43f59_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">lly:OtherForeignCountriesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i1b4752c6b2ac44cd9be4af1f69afff5d_I20210131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BusinessAcquisitionAxis">lly:PrevailTherapeuticsIncMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i63b55aa2b0524f0ca0efeed454b37bbe_D20210101-20210131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BusinessAcquisitionAxis">lly:PrevailTherapeuticsIncMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-01-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:unit id="right"><xbrli:measure>lly:right</xbrli:measure></xbrli:unit><xbrli:context id="iee7f27c40fbd4c098dcae8edbea11cf9_I20210122"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BusinessAcquisitionAxis">lly:PrevailTherapeuticsIncMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iae68d981b70540feb7cdc176ba370211_D20210122-20210122"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BusinessAcquisitionAxis">lly:PrevailTherapeuticsIncMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-22</xbrli:startdate><xbrli:enddate>2021-01-22</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i284cb546a16b4766ab7fdbe181505a91_D20220201-20220228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:AssetAcquisitionAxis">lly:BioMarinPharmaceuticalIncMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-02-01</xbrli:startdate><xbrli:enddate>2022-02-28</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="icde97e5eb6884813ae3f6fc674e3ee2f_D20210301-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:AssetAcquisitionAxis">lly:RigelPharmaceuticalsIncMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-03-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i7a1bf6e57f0a49d492f68743b77ff855_D20210101-20210131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:AssetAcquisitionAxis">lly:PrecisionBiosciencesIncMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-01-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="iefbd2b2e9a6c4f708caad531a19e7008_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:JardianceMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic0abbc83b5524cf1aa65875e5b5d496f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:JardianceMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia6bcd0412da04b32a92ef790c3fad97a_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:TrajentaBIMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0cf155dc699c4bd88b23ba88d945d46a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:TrajentaBIMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i738922cd7ac64248bcd12d2d74241b20_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:BasaglarMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i82d67a39def44b099ed71b9ee99c46cc_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:BasaglarMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib10eae977de34fb2bcb6d32b86e1e00b_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:TrajentaBIMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i3692c8ddf38d41e2aaa1db31ff5ef2e7_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:TrajentaBIMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="if4ed44df0538499fb8e6d148cc9e0996_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:RoyaltyAgreementTermsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ib71be47e87cf45e09ed8b30e689ae006_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsCapitalizedAsIntangibleAssetsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i342528da2bb5408fae069b71ce902752_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsCapitalizedAsIntangibleAssetsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1b8e4440b5134d4fb2a40c2a8aa16a91_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsDevelopmentAndRegulatoryMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i08ec473bc23b4cc98e6f598c61e4a81e_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsSalesBasedMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i08b540e36f754b9185cff7340cdc0aac_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:TYVYTMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsCapitalizedAsIntangibleAssetsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i54fd35218a5349289dfb44cc0657c959_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsSuccessBasedRegulatoryAndSalesBasedMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">lly:NonCHINAMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="dei:LegalEntityAxis">lly:InnoventBiologicsIncMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:TYVYTMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4c4fc5f7f1aa45d089c061b7bb0af2cc_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsSuccessBasedRegulatoryAndSalesBasedMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="dei:LegalEntityAxis">lly:InnoventBiologicsIncMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:TYVYTMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ice5cf718015640c1b082abef326c20f3_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="dei:LegalEntityAxis">lly:RocheMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsDevelopmentAndRegulatoryMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:LebrikizumabMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i17a8e5b7cdad48e3ba35be583e59224b_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="dei:LegalEntityAxis">lly:RocheMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:LebrikizumabMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsSalesBasedMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7ba2c213d6174f03ad66d676edf41010_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsDevelopmentAndRegulatoryMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:LebrikizumabMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3fb85ae7275a4ab5b2dd5347ad84f3d7_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:LebrikizumabMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsSalesBasedMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib89d32abca5f4ef09217da80647ddbb5_D20220401-20220430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:AssetAcquisitionAxis">lly:PetraPharmaCorporationMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-04-01</xbrli:startdate><xbrli:enddate>2022-04-30</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i5828b97906464e3b820454b6eb85b325_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">lly:BuyUsDollarSellEuroMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="eur"><xbrli:measure>iso4217:EUR</xbrli:measure></xbrli:unit><xbrli:context id="i6a6c9940843c4feab2e1a0c99a63a96f_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">lly:BuyEuroSellUsDollarMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i09dde07b68a745fe82096156d8b7e181_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">lly:BuyUSDollarSellChineseYuanMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="cny"><xbrli:measure>iso4217:CNY</xbrli:measure></xbrli:unit><xbrli:context id="ia6422416ea2241a2a43437b14235b97f_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">lly:BuyUSdollarSellJapaneseYenMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="jpy"><xbrli:measure>iso4217:JPY</xbrli:measure></xbrli:unit><xbrli:context id="ib07c94a6d4af4835996d8e78d31945e5_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">lly:BuyBritishPoundandSellUSDollarsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="gbp"><xbrli:measure>iso4217:GBP</xbrli:measure></xbrli:unit><xbrli:context id="i3f3de4a6248f461e859551ca2163b789_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:LongtermDebtTypeAxis">lly:ForeignCurrencyDenominatedDebtMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i54b4e850f27d4938aca07b03f8b7cc97_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:LongtermDebtTypeAxis">lly:ForeignCurrencyDenominatedDebtMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i94ef07ec7f2b483db82b0258c0cdbc4a_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">lly:SwapU.S.DollarsToEuroMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i321796f5b515446aa0b53f4d8879a392_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">lly:SwapSwissFrancsToU.S.DollarsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2c75f5c810134d21a34c3a33d471efb5_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie6854cfb73f247ff811b4e8d19f31b99_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">lly:HedgedFixedRateDebtMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i19522356142f4cb3af656f204ff244f8_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">lly:HedgedFixedRateDebtMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="iff4b665b790a4814858d80742f67225e_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i4b3b515b4f00450d9af5f1a64809a127_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i338b627ba38e475f96ecfeadba1a994e_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="idd762b29ec5345db9fbb4ca26b4ba2e1_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i9873a4570e674b4e930c30b07ce403f7_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i8289fb108f294fe686a96c6c9694185c_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i735d91209e8643b7a14d9fa85c6db710_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">lly:HedgedFixedRateDebtMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i93af913c74824b1581bff5276cec1e5c_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">lly:HedgedFixedRateDebtMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i1616fc39bed44541af5f7cd7abea307a_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i9658e5d0746b443892d606c35ba501db_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i81716871f3a243ed8e61be41663de346_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ib0b61926a7d9492bb3843114c736f14e_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i73af0f98be8b48e58557bf37c81c9e74_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8297602a77c04dbe866c1671c9fc39f2_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idb4c476afbc64873b3c0511107fc85c9_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i553170707dac4ba4befbf57021e9352d_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8196778f6b68404d98e4bc74190f4322_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i67e65f1325bd4d80b077bdc7713893b6_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie3949e5521a749449cc7f2a26fbd50fa_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5e1799edb7794fc4b1f616df3dd091ab_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4287cfc6b146421aaf7054e3c2baf09a_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icad0fc1f1fc24058af62089ef5cc8d6b_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i11f55ba726a14bf6adea1a2c9a382844_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib166955c51b7404cb1f890ae69351664_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0889f4d6b8c84f4f86feb6e6b9e07416_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i539ac49f62204f449468230edab29f2e_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3206cdb8838c4f439e23fcebaa0a5db5_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9ce4f705c12c4dd0ad7577b94b195bc5_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i749f1e3ed9be40d4aaa1036cc4cd636e_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia68a57223c3e44258320c665e5e51da3_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i12313db9f4234ab399224dedbfa8e9a1_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i844bf1199784470bb85986e8705f63a0_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i52a94c856f8f4c708ecd0c78ae9d811b_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i58833b70044440ba8723539cd9771a96_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i08e23988b70349e48d0863a9a788859a_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia5572a5cd6cf4fef80fd4f18e84d4f7b_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i63b57e26f9874a59a56bc82f5b18fb11_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if1b1e3898b43456da01094b47acb1c76_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id19b58cff3f5453fa44ff476062a0a2d_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7ca7cae76ba4496d8f5abf5420f5d436_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i115b05d0aa7245918c041177cf891d75_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie54bd7fd72d544db998a875fd601fe50_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8409488ac5694b53b787f031304c92b7_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i41fdead00a9048b6b3cc9b6cb638331d_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia42e3f4576fe4f118bb64223c3c5ebab_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if4fc174bc75542229cc811bb39dffc30_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i59d42fbede984b688ce7c8a504c746c5_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i54b85febf3e54b15a32eb724bedd4db9_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9839e9c38a5d4d35b9fcf94838e28ff0_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">lly:OtherEquitySecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if1a0fe2b050d475fbf70c9eabde349b7_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">lly:OtherEquitySecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i202de245dca54b9fbaf785a8485b97a4_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">lly:OtherEquitySecuritiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie515f75228ff4f8b827aed3640b6deaf_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">lly:OtherEquitySecuritiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1a1737406225458ebdbe6cda04606244_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">lly:OtherEquitySecuritiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i13d950451b7e48fda3e1b024329a7c74_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">lly:OtherEquitySecuritiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5dcfe1b49a3348138d09e6e38fb729a9_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">lly:MarketableSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie35137a8dd7146f782d246046bdff5e9_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">lly:MarketableSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i24d0ea00c0fc4c69aac46b9bff293d2e_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">lly:MarketableSecuritiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i15b571ac551849a9b9cf92351d196e67_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">lly:MarketableSecuritiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4fbaf0c06826427fab08130c69d7c437_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">lly:MarketableSecuritiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifff0b8a0a33a465f93f294473ef71015_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">lly:MarketableSecuritiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i34e5580510394d9fb0a59cfe4cec75d2_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">lly:EquityMethodAndOtherInvestmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i057515f5782941809af8fac0ad822ddf_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3b22d12321a742eba88cdd7b94472599_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic769458ef1cb403f8d92df4e02a545c7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2ada8ba658a948af9bb22996a9eab24d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iccf68abee8b64588b494d4d0bcd59e25_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i298284fbe5094d049bf7ed6517060de9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6ae57b6acf9a480e815a2255a0a47172_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i97ca45854b924b6aaa19c533a897fb4b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1e316c5cad3845a991ac64bee258b844_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i04515a46362744d49cdd523efd4006f6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i844e6c2a216e4a669a4a913b04f32762_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icd7c2d39ad064e6d84ac3562cf8025df_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1bed7fb2284146bd8643e9b39f9ac451_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7faea4de0e74408b81231bf3f5e63e60_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9ab5bace01434c65b51abaee9f1db274_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia66a2eb56db04d659e7b08afb8e00b97_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i25a9ef4798f34b4c848e20f373f45fee_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6d116456bb6a4610aa2017fb9072aea1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i182112e9aeee4d92b6fca93686a55631_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i519c10d83d004381af697acde770b07c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9338f22ba6094fc282c2830f4f065887_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7223c12010024dc1bcba7a6fef6e53d7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iac5e6284cc114a9d83ce2d830c3a671f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7cdc75cf167f4e67a1ea672190673af0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i75424eb967c54c37a5493947a35db25a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieed236aec1e044be88d61bd1569b734f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icfabd5ccb95f48b0afdb0c81fc76f924_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i66c179e929fa4af99c373a63da5215e8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib4c92f85e01b446fa56db5a85f60835f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7992f3445fcf455d857370bd494fa269_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8f79fb34343e4bcbbe559d8c60857663_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifc17920e7173460596ad72a021856b63_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic685367f56cc4339adb4935065562054_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iae543a32b13146378424ca5b6f44b0c2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i76e0df9851e54717892c8f5a46e24893_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idd6696a4fa6d40ccbeeeab7cfb286206_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifd76ddec7a144856a43e75f9082488fa_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">lly:OtherEquitySecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia468c5f1389340e08b88c98938991507_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">lly:OtherEquitySecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6e745874edfb4e99917c89bf5aaa5a7a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">lly:OtherEquitySecuritiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibe91c67265284e73b644361c4e2b0b8f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">lly:OtherEquitySecuritiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icfdb865651304950a4161c0ccc0adb09_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">lly:OtherEquitySecuritiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0a064c1e1f674a109ea67b5d14516124_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">lly:OtherEquitySecuritiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7716b5d37f7b484c8545e840917541a1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">lly:MarketableSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie40648037ee1408c8682678930a548ed_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">lly:MarketableSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idbaca5a56d864677bba3c62605a8494a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">lly:MarketableSecuritiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icadd24c3d6034be18cbb14120a6e4ea2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">lly:MarketableSecuritiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia4bba9c6f0c8418d9fb7a7fb432f8e56_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">lly:MarketableSecuritiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6cd06b32d25d48e49f7e8a09e4e969ae_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">lly:MarketableSecuritiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8fe1e55b66654f16829171e30fa216cb_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">lly:EquityMethodAndOtherInvestmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1b0c53cf3bbc4ce2b0088d9820106967_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie705288cb01f4eac942cb814cdcc8539_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i90b3eb87ed804a729b780c80c325ec95_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idd019a06b4c246fd957d269e918d1c7f_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i61c30e51f61b42949ba7a628fc52c012_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i15a338b1d8b64c4b8581fc06ed807e1c_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib73c403636a344838add9dbff41764e7_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i67e720cdb81c49559e3089ce9bddce7e_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i15d8bcd7898c47f38b255daee09bcfbd_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if5ce482ee1594c5caf8b63533ab11103_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id5ceec0aa6af470ba4febd83bd9351b7_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i46c6c88db3ef42f9999f1b565a7c250c_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1153bf52ace34cca9d9d545c86b62d46_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i752afdfbea6f4b03a309d6ab352210de_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib932b535148a40099e28d14ab0c631f2_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9fedeeac6f904c69bb591eebcd4811df_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9484841943ff40d49074806914ce2416_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i33291f87ff0141a998a8e9d60c5c0adf_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5f336fc6bdf04952b388d9114a3b5bf6_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8e60daf646254f67ba1bd098098518ad_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id8b3dab6b2854200b31c2377ae5286e7_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie5416f90269c42ceb77812d86a4e39d1_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id3f0ecbad4e644b8b6314ec64ac294e0_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idae3bc9852d245869375a32c18c7262f_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i35c9b2107aa9480faa03f8d9a9dc6f2c_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8f358a15c5374d8b9337b6d1bda3a0e2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib063d25db70a4bb5b2ef696367833f00_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iee84f80dd4fc4d8281169e60c43c5a54_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8169a9d6879d467b997551d79352b58b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idd4227079f864f90a4b351adbc448ca3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieaa23265a66a4df78c59df1973ab2cee_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2e94417f504d46f6bba5032802f9b4c8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibc03d36e65aa438d82422c7c99d33275_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifa1749e8dfab4045a30fa5aba1fdaa8b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icb157ecfd611468fbdf0a25b1b443709_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib9f55f34e7464cbf99b53e10ca29e690_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i83b45056f8d64c44b68eb6b178ffd19e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ica34877b024d402f9950cd7d89e1f8fc_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i993d0e5455db4d1caaa238631c27b402_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i059a5554f48641c19638a78710ad6041_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifa73eac40d6e41218971b531ff4c7c06_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i635cffe5cb0a488aae4370830bbf2b7f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i06befc950b3d460380094acd10fef0ea_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ida06c794ac1f401ca313cd702ce80350_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i28e231c95c1548ae9f732a3057e2aa34_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i41d7aecaba42417c9eaf6014e9de28d4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i06a5c9f5caaf42bda6efa2553d69242d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if05a6befb26d44c8b18173cbe6bfebe4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i60d888d2d36d4cfe8406ddf920c43cc6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieb838166e0e24a87b90113adf849abf5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia742d0e6fff948789bf96eee343be514_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i460ddb35283849b69e71055fc598219d_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i690cde1d59fa4dab835605519a1be00d_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i07ff1b3fd36041fcb815472f33a8b2d5_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="id157979fcb794bf2a4984ef11112b041_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i053f6ca8167a4dbf90ed11b7de9780e3_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="iba71b0f04ef044648f840fc039a69113_I20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:LitigationCaseAxis">lly:EmgalityPatentLitigationMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="patent"><xbrli:measure>lly:patent</xbrli:measure></xbrli:unit><xbrli:context id="ibf856295860d4cc583a42d2f153fa1ad_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:LitigationCaseAxis">lly:EmgalityPatentLitigationMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if986aeb2b74c45c4886b5ccf762b0845_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:ByettaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">lly:ProductLiabilityMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="lawsuit"><xbrli:measure>lly:lawsuit</xbrli:measure></xbrli:unit><xbrli:context id="iccf29e7a5ff447be878fbe483ab1b640_D20090301-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:ByettaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">lly:ProductLiabilityMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2009-03-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:unit id="plaintiff"><xbrli:measure>lly:plaintiff</xbrli:measure></xbrli:unit><xbrli:context id="i0fa13f1e4f5b4989a43ad6584340167f_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:ByettaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="lly:DomicileOfLitigationAxis">lly:LosAngelesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">lly:ProductLiabilityMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i732141cbc8674e028f44ffa7b20f3f3b_D20090301-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:ByettaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="lly:DomicileOfLitigationAxis">lly:LosAngelesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">lly:ProductLiabilityMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2009-03-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="id5f7c7a0250845febe4b827e80fa3743_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:ByettaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="lly:DomicileOfLitigationAxis">lly:SouthernDistrictOfCaliforniaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">lly:ProductLiabilityMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6e5057fbcebb42e8848798cc7ca7092d_D20090301-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:ByettaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="lly:DomicileOfLitigationAxis">lly:SouthernDistrictOfCaliforniaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">lly:ProductLiabilityMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2009-03-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ib5924adeba7a47f39c0acb7d02286c6b_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:ByettaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="lly:DomicileOfLitigationAxis">lly:VariousStateDomicilesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">lly:ProductLiabilityMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2234785e0f1143e1af55c3bb337d4907_D20090301-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:ByettaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="lly:DomicileOfLitigationAxis">lly:VariousStateDomicilesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">lly:ProductLiabilityMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2009-03-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i582b4e89a2ee429da84a89ba6f1b1619_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:ByettaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="lly:PlaintiffAllegationsAxis">lly:PancreaticCancerOrThyroidCancerMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">lly:ProductLiabilityMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i35724922961344358bebddecb678393a_D20090301-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:ByettaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="lly:PlaintiffAllegationsAxis">lly:PancreaticCancerOrThyroidCancerMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">lly:ProductLiabilityMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2009-03-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i89bf4f944d24415e9da71601563d4852_D20090301-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:ByettaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">lly:ProductLiabilityMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="lly:PlaintiffAllegationsAxis">lly:PancreatitisMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2009-03-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ieb4140c6e4cf4105a3cdf1f8253fae2c_D20090301-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:ByettaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="lly:PlaintiffAllegationsAxis">lly:AmpullaryCancerMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">lly:ProductLiabilityMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2009-03-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ie2562c1a1b5740f5b312d946a2d2f727_D20220401-20220430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:ByettaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">lly:ProductLiabilityMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-04-01</xbrli:startdate><xbrli:enddate>2022-04-30</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i41b0a98c5e054d3987afeeba397fa41d_D20220401-20220430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:ByettaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="lly:DomicileOfLitigationAxis">lly:VariousStateDomicilesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">lly:ProductLiabilityMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-04-01</xbrli:startdate><xbrli:enddate>2022-04-30</xbrli:enddate></xbrli:period></xbrli:context><xbrli:unit id="claimant"><xbrli:measure>lly:claimant</xbrli:measure></xbrli:unit><xbrli:context id="ib6d3474862f44a24b3440036451e55ce_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">lly:ProductLiabilityMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:CialisMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if0b4f0a651694b5593648d55c4eafddb_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:JardianceMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">lly:ProductLiabilityMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if918188055b9499994107e688f363786_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:UnfavorableRegulatoryActionMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="site"><xbrli:measure>lly:site</xbrli:measure></xbrli:unit><xbrli:context id="i6e96d3ed596840c3888477bfb76cac53_D20180701-20180731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:BR</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:LitigationCaseAxis">lly:EmployeeLitigationMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2018-07-01</xbrli:startdate><xbrli:enddate>2018-07-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:unit id="brl"><xbrli:measure>iso4217:BRL</xbrli:measure></xbrli:unit><xbrli:context id="ie4f81fbc2bdd4384b1a0e69b7b581f32_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:BR</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:LitigationCaseAxis">lly:EmployeeLitigationMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="idd3225fae7784a42ad47ca0c8eeb43b7_D20190701-20190731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:BR</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:LitigationCaseAxis">lly:EmployeeLitigationMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2019-07-01</xbrli:startdate><xbrli:enddate>2019-07-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i2a50fb0ce395452f949119ed0d6d50eb_D20210601-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:BR</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:LitigationCaseAxis">lly:EmployeeLitigationMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-06-01</xbrli:startdate><xbrli:enddate>2021-06-30</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i70905cd2917f4e9ea9656f7b89cde516_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:BR</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:LitigationCaseAxis">lly:EmployeeLitigationMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie73ca8ee0e6e4d9daed3c9d94a4e6c83_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:HumalogHumulinAndForteoMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i95fbc04e0e8d45eb8a79226c271ed1a7_D20210701-20210731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">lly:InsulinMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-07-01</xbrli:startdate><xbrli:enddate>2021-07-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:unit id="claim"><xbrli:measure>lly:claim</xbrli:measure></xbrli:unit><xbrli:context id="i3406df20fd464dd9b628ff7336f0147b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i087fe911320144b2b4f1ba2c3e5095fd_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4e984bf7c681488f894796459d18d344_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i63f3aeca8ebc4fc48c149e0dc34d9e03_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i87e3fc7b2721478cade3b06e9ff2cf9d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7e3cba541d0a4e009649fa4e6541f00f_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ica0cd664995e4709a85c79d4a83025b5_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i1264e1c80a3841eba0ebd86ccd829da3_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i96a2b7a2a70a4e939b41906248dbfaa2_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i97559604e1bd4db9b3a4c3b5006db686_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i781dc404e04b4f40b1f028a37448086a_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i965f5355532246c29d1f56782a835356_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i97068b2af2e444778875e9cd92100ab1_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie4b77a20953648e5bd4cea2cbbad1bd0_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5bb4023f758742fbb1aba4311f25f8fa_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifd62b433d8224c8b9d454c6c10a97c2c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5e3de19f839441f285e2a284f1990c7e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idcd9436eeb374ea5be496e207dcf7514_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i819715854c1c4107a53610bac955ae0c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia38dbf3e877a4be7a3da76e0f940e927_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i3d2a23c7f59f40c9828167248f215f5d_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="if118f56641f64a2783ec07ba485ec5f8_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="id0d0a8013d5b45319209e6933a127c1c_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i083ecc10d5164ab28404da958792b18f_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia481a10d7f32410db9634bf240a6574e_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if38e7cc6dbba4458bfffe7e0d66df16d_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5cbb42d3f9894842aab21bf9721eaa2c_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6464afacc8e940d697ec8edde39803c6_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0769a82ce7f744048e07bef5e5d4900b_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ie45ab80780a84f17a66e8cee97272295_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i59b8fb8550c44df497df03d0dcdcd523_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i2b42435d81c54f5ab5d2bf7fbc0d6514_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i97cd8e395ba344aa8ecdf1bee3d8ab2f_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ib5f018cc2e8d4c5488325d1415dccb28_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i0175f8e4ed51442f9ceaf3db05b287b9_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i0d4cbe26b0d34206806f12f1fa74cd57_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i9a717408ad30404fb5e8cc3eab2ced92_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">lly:AccumulatedGainLossNetCashFlowHedgeAndForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ibed94e094d144d5aa0ca779c30eeef3e_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">lly:AccumulatedGainLossNetCashFlowHedgeAndForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i0711989944104688887390c9f0ba9c34_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i03800b22db6d45479225575f3b7b2136_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8yOC9mcmFnOjJmNjA5MWNkMjk1MzQwMDg5MGIyYTY3MWE1M2EwYzFkL3RhYmxlOjkyZmUwNzRlYjY2YjQzZDk5ZWEwYjQ1NDE4ZTJlNWMzL3RhYmxlcmFuZ2U6OTJmZTA3NGViNjZiNDNkOTllYTBiNDU0MThlMmU1YzNfMTYtMTUtMS0xLTEwMTE5MA_82a22bcc-1fff-4640-bd3b-defa6505adbf id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8yOC9mcmFnOjJmNjA5MWNkMjk1MzQwMDg5MGIyYTY3MWE1M2EwYzFkL3RhYmxlOjkyZmUwNzRlYjY2YjQzZDk5ZWEwYjQ1NDE4ZTJlNWMzL3RhYmxlcmFuZ2U6OTJmZTA3NGViNjZiNDNkOTllYTBiNDU0MThlMmU1YzNfMTQtMTUtMS0xLTEwMTE5MA_6ad9bcf5-93b3-47b3-a3f9-8431e3942604 id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8yOC9mcmFnOjJmNjA5MWNkMjk1MzQwMDg5MGIyYTY3MWE1M2EwYzFkL3RhYmxlOjkyZmUwNzRlYjY2YjQzZDk5ZWEwYjQ1NDE4ZTJlNWMzL3RhYmxlcmFuZ2U6OTJmZTA3NGViNjZiNDNkOTllYTBiNDU0MThlMmU1YzNfMy0xNS0xLTEtMTAxMTkw_1eab1afb-d765-4ee4-9e0a-107525537674 id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8yOC9mcmFnOjJmNjA5MWNkMjk1MzQwMDg5MGIyYTY3MWE1M2EwYzFkL3RhYmxlOjkyZmUwNzRlYjY2YjQzZDk5ZWEwYjQ1NDE4ZTJlNWMzL3RhYmxlcmFuZ2U6OTJmZTA3NGViNjZiNDNkOTllYTBiNDU0MThlMmU1YzNfMjItMTUtMS0xLTEwMTE5MA_f960dc5f-87c2-4907-aade-c2ac7917e5a0 id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8yOC9mcmFnOjJmNjA5MWNkMjk1MzQwMDg5MGIyYTY3MWE1M2EwYzFkL3RhYmxlOjkyZmUwNzRlYjY2YjQzZDk5ZWEwYjQ1NDE4ZTJlNWMzL3RhYmxlcmFuZ2U6OTJmZTA3NGViNjZiNDNkOTllYTBiNDU0MThlMmU1YzNfOS0xNS0xLTEtMTAxMTkw_f9c72662-4ccf-4468-9557-47b2c8adf885 id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8yOC9mcmFnOjJmNjA5MWNkMjk1MzQwMDg5MGIyYTY3MWE1M2EwYzFkL3RhYmxlOjkyZmUwNzRlYjY2YjQzZDk5ZWEwYjQ1NDE4ZTJlNWMzL3RhYmxlcmFuZ2U6OTJmZTA3NGViNjZiNDNkOTllYTBiNDU0MThlMmU1YzNfMy0xMy0xLTEtMTAxMTkw_9ca0db70-78ce-487e-82a1-58feb5efbd73 id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8yOC9mcmFnOjJmNjA5MWNkMjk1MzQwMDg5MGIyYTY3MWE1M2EwYzFkL3RhYmxlOjkyZmUwNzRlYjY2YjQzZDk5ZWEwYjQ1NDE4ZTJlNWMzL3RhYmxlcmFuZ2U6OTJmZTA3NGViNjZiNDNkOTllYTBiNDU0MThlMmU1YzNfMTQtMTMtMS0xLTEwMTE5MA_ef14de08-088f-4d7f-8d80-eafe6e77ab98 id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8yOC9mcmFnOjJmNjA5MWNkMjk1MzQwMDg5MGIyYTY3MWE1M2EwYzFkL3RhYmxlOjkyZmUwNzRlYjY2YjQzZDk5ZWEwYjQ1NDE4ZTJlNWMzL3RhYmxlcmFuZ2U6OTJmZTA3NGViNjZiNDNkOTllYTBiNDU0MThlMmU1YzNfMjItMTMtMS0xLTEwMTE5MA_142d7341-2d11-469f-986b-0c069e76c517 id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8yOC9mcmFnOjJmNjA5MWNkMjk1MzQwMDg5MGIyYTY3MWE1M2EwYzFkL3RhYmxlOjkyZmUwNzRlYjY2YjQzZDk5ZWEwYjQ1NDE4ZTJlNWMzL3RhYmxlcmFuZ2U6OTJmZTA3NGViNjZiNDNkOTllYTBiNDU0MThlMmU1YzNfMjUtMTMtMS0xLTEwMTE5MA_f7defa90-a2c1-4cd9-89eb-edcd2801fc32 id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8yOC9mcmFnOjJmNjA5MWNkMjk1MzQwMDg5MGIyYTY3MWE1M2EwYzFkL3RhYmxlOjkyZmUwNzRlYjY2YjQzZDk5ZWEwYjQ1NDE4ZTJlNWMzL3RhYmxlcmFuZ2U6OTJmZTA3NGViNjZiNDNkOTllYTBiNDU0MThlMmU1YzNfMTYtMTMtMS0xLTEwMTE5MA_914312d4-bc12-4d93-b403-e20b8cff77b4 id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8yOC9mcmFnOjJmNjA5MWNkMjk1MzQwMDg5MGIyYTY3MWE1M2EwYzFkL3RhYmxlOjkyZmUwNzRlYjY2YjQzZDk5ZWEwYjQ1NDE4ZTJlNWMzL3RhYmxlcmFuZ2U6OTJmZTA3NGViNjZiNDNkOTllYTBiNDU0MThlMmU1YzNfOS0xMy0xLTEtMTAxMTkw_37052af5-732c-44cb-b715-8ad2eed79aea id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8yOC9mcmFnOjJmNjA5MWNkMjk1MzQwMDg5MGIyYTY3MWE1M2EwYzFkL3RhYmxlOjkyZmUwNzRlYjY2YjQzZDk5ZWEwYjQ1NDE4ZTJlNWMzL3RhYmxlcmFuZ2U6OTJmZTA3NGViNjZiNDNkOTllYTBiNDU0MThlMmU1YzNfMjUtMTUtMS0xLTEwMTE5MA_581734eb-c797-48cb-8257-2a8b103b22ce" linkrole="http://www.xbrl.org/2003/role/link" torefs="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8yOC9mcmFnOjJmNjA5MWNkMjk1MzQwMDg5MGIyYTY3MWE1M2EwYzFkL3RleHRyZWdpb246MmY2MDkxY2QyOTUzNDAwODkwYjJhNjcxYTUzYTBjMWRfMTA0NDUzNjA0NjQyNTQ_a0f9b4ad-e1cf-4c01-9b88-254201374b45" order="1"></ix:relationship></ix:resources></ix:header></div><div id="ie8dc61f8e15b44db82ba16050d5b7b44_1"></div><div style="min-height:42.75pt;width:100%"><div><span><br></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tbody><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td></tr></tbody></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:120%">UNITED STATES </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:18pt;font-weight:700;line-height:120%">Form <ix:nonnumeric contextref="id879b497a407453985551e83dbee75f8_D20220101-20220331" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8xL2ZyYWc6YTYxYmRkNzc5OTQxNGIwMmI5MTA2MWExMTZjNGY0ZjEvdGV4dHJlZ2lvbjphNjFiZGQ3Nzk5NDE0YjAyYjkxMDYxYTExNmM0ZjRmMV8yMDM1_f8d0deba-5f42-419d-b7e2-46bdf9c39e61">10-Q</ix:nonnumeric> </span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%"><ix:nonnumeric contextref="id879b497a407453985551e83dbee75f8_D20220101-20220331" name="dei:DocumentQuarterlyReport" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8xL2ZyYWc6YTYxYmRkNzc5OTQxNGIwMmI5MTA2MWExMTZjNGY0ZjEvdGV4dHJlZ2lvbjphNjFiZGQ3Nzk5NDE0YjAyYjkxMDYxYTExNmM0ZjRmMV8yMDM2_96cb813b-d4b5-4f1f-8509-348d88576c64"><ix:nonnumeric contextref="id879b497a407453985551e83dbee75f8_D20220101-20220331" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8xL2ZyYWc6YTYxYmRkNzc5OTQxNGIwMmI5MTA2MWExMTZjNGY0ZjEvdGV4dHJlZ2lvbjphNjFiZGQ3Nzk5NDE0YjAyYjkxMDYxYTExNmM0ZjRmMV8yMDM2_f3ddf89e-1b39-47ad-884f-f855f88fadab">Quarterly</ix:nonnumeric></ix:nonnumeric> Report Pursuant to Section&nbsp;13 or 15(d) of the</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Securities Exchange Act of 1934</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the quarterly period ended <ix:nonnumeric contextref="id879b497a407453985551e83dbee75f8_D20220101-20220331" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8xL2ZyYWc6YTYxYmRkNzc5OTQxNGIwMmI5MTA2MWExMTZjNGY0ZjEvdGV4dHJlZ2lvbjphNjFiZGQ3Nzk5NDE0YjAyYjkxMDYxYTExNmM0ZjRmMV8yMTA_4a3d5025-d32e-4554-ae6f-9039830933a0">March&nbsp;31, 2022</ix:nonnumeric></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">COMMISSION FILE NUMBER <ix:nonnumeric contextref="id879b497a407453985551e83dbee75f8_D20220101-20220331" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8xL2ZyYWc6YTYxYmRkNzc5OTQxNGIwMmI5MTA2MWExMTZjNGY0ZjEvdGV4dHJlZ2lvbjphNjFiZGQ3Nzk5NDE0YjAyYjkxMDYxYTExNmM0ZjRmMV8yMDQ0_0b7f9e89-1de3-4627-b3f0-f6760c3845ca">001-6351</ix:nonnumeric> </span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:22pt;font-weight:700;line-height:120%"><ix:nonnumeric contextref="id879b497a407453985551e83dbee75f8_D20220101-20220331" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8xL2ZyYWc6YTYxYmRkNzc5OTQxNGIwMmI5MTA2MWExMTZjNGY0ZjEvdGV4dHJlZ2lvbjphNjFiZGQ3Nzk5NDE0YjAyYjkxMDYxYTExNmM0ZjRmMV8yMDM3_587c1ba2-4bef-4ed2-ab38-b261f826e844">ELI LILLY AND COMPANY</ix:nonnumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Exact name of Registrant as specified in its charter)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tbody><tr><td style="width:1.0%"></td><td style="width:47.948%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.560%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.192%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonnumeric contextref="id879b497a407453985551e83dbee75f8_D20220101-20220331" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8xL2ZyYWc6YTYxYmRkNzc5OTQxNGIwMmI5MTA2MWExMTZjNGY0ZjEvdGFibGU6NWI0NDAwNjRkMGRmNDJmMjkxZTY2Zjc1NjE4ZTEwOWQvdGFibGVyYW5nZTo1YjQ0MDA2NGQwZGY0MmYyOTFlNjZmNzU2MThlMTA5ZF8wLTAtMS0xLTEwMTE5MA_9860aaa2-a998-4377-b445-3b1af84fcb66">Indiana</ix:nonnumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonnumeric contextref="id879b497a407453985551e83dbee75f8_D20220101-20220331" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8xL2ZyYWc6YTYxYmRkNzc5OTQxNGIwMmI5MTA2MWExMTZjNGY0ZjEvdGFibGU6NWI0NDAwNjRkMGRmNDJmMjkxZTY2Zjc1NjE4ZTEwOWQvdGFibGVyYW5nZTo1YjQ0MDA2NGQwZGY0MmYyOTFlNjZmNzU2MThlMTA5ZF8wLTItMS0xLTEwMTE5MA_31db8352-ef24-4b68-afbf-764d1cee7ed3">35-0470950</ix:nonnumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(State or other jurisdiction of</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(I.R.S. Employer</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">incorporation or organization)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Identification No.)</span></td></tr></tbody></table></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonnumeric contextref="id879b497a407453985551e83dbee75f8_D20220101-20220331" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8xL2ZyYWc6YTYxYmRkNzc5OTQxNGIwMmI5MTA2MWExMTZjNGY0ZjEvdGV4dHJlZ2lvbjphNjFiZGQ3Nzk5NDE0YjAyYjkxMDYxYTExNmM0ZjRmMV8yMDM5_56077e23-01ea-4860-9b6b-2e60f5e0ac04">Lilly Corporate Center</ix:nonnumeric>, <ix:nonnumeric contextref="id879b497a407453985551e83dbee75f8_D20220101-20220331" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8xL2ZyYWc6YTYxYmRkNzc5OTQxNGIwMmI5MTA2MWExMTZjNGY0ZjEvdGV4dHJlZ2lvbjphNjFiZGQ3Nzk5NDE0YjAyYjkxMDYxYTExNmM0ZjRmMV8yMDM4_4f310efe-9177-4780-b45a-67b7dbac72ea">Indianapolis</ix:nonnumeric>, <ix:nonnumeric contextref="id879b497a407453985551e83dbee75f8_D20220101-20220331" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8xL2ZyYWc6YTYxYmRkNzc5OTQxNGIwMmI5MTA2MWExMTZjNGY0ZjEvdGV4dHJlZ2lvbjphNjFiZGQ3Nzk5NDE0YjAyYjkxMDYxYTExNmM0ZjRmMV8yMDQy_7e117857-6b06-4dae-958a-84fc0924eb5b">Indiana</ix:nonnumeric> <ix:nonnumeric contextref="id879b497a407453985551e83dbee75f8_D20220101-20220331" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8xL2ZyYWc6YTYxYmRkNzc5OTQxNGIwMmI5MTA2MWExMTZjNGY0ZjEvdGV4dHJlZ2lvbjphNjFiZGQ3Nzk5NDE0YjAyYjkxMDYxYTExNmM0ZjRmMV8yMDM0_29ff75d2-37ef-4b20-b323-a920fa5e77d9">46285</ix:nonnumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Address and zip code of principal executive offices)</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Registrant's telephone number, including area code (<ix:nonnumeric contextref="id879b497a407453985551e83dbee75f8_D20220101-20220331" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8xL2ZyYWc6YTYxYmRkNzc5OTQxNGIwMmI5MTA2MWExMTZjNGY0ZjEvdGV4dHJlZ2lvbjphNjFiZGQ3Nzk5NDE0YjAyYjkxMDYxYTExNmM0ZjRmMV8yMDQw_7d1c4474-6b08-41e4-b09e-c939cf3dde34">317</ix:nonnumeric>)&nbsp;<ix:nonnumeric contextref="id879b497a407453985551e83dbee75f8_D20220101-20220331" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8xL2ZyYWc6YTYxYmRkNzc5OTQxNGIwMmI5MTA2MWExMTZjNGY0ZjEvdGV4dHJlZ2lvbjphNjFiZGQ3Nzk5NDE0YjAyYjkxMDYxYTExNmM0ZjRmMV8yMDQ1_02d65215-adcd-4107-9652-7e9d505f8860">276-2000</ix:nonnumeric> </span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Securities registered pursuant to Section&nbsp;12(b) of the Exchange Act:</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tbody><tr><td style="width:1.0%"></td><td style="width:32.282%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.105%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.313%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%;text-decoration:underline">Title of Each Class</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%;text-decoration:underline">Trading Symbols</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%;text-decoration:underline">Name of Each Exchange On Which Registered</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonnumeric contextref="i7d49ccbde7cb4a2cb9cf5f389b03a176_D20220101-20220331" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8xL2ZyYWc6YTYxYmRkNzc5OTQxNGIwMmI5MTA2MWExMTZjNGY0ZjEvdGFibGU6OWNkODUzNGQ2NjQ4NDgwZGIwNjgyNWE0NGI5MmNhZGUvdGFibGVyYW5nZTo5Y2Q4NTM0ZDY2NDg0ODBkYjA2ODI1YTQ0YjkyY2FkZV8xLTAtMS0xLTEwMTE5MA_f2f57c27-2a72-4316-8b4f-022d1276387e">Common Stock (no par value)</ix:nonnumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonnumeric contextref="i7d49ccbde7cb4a2cb9cf5f389b03a176_D20220101-20220331" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8xL2ZyYWc6YTYxYmRkNzc5OTQxNGIwMmI5MTA2MWExMTZjNGY0ZjEvdGFibGU6OWNkODUzNGQ2NjQ4NDgwZGIwNjgyNWE0NGI5MmNhZGUvdGFibGVyYW5nZTo5Y2Q4NTM0ZDY2NDg0ODBkYjA2ODI1YTQ0YjkyY2FkZV8xLTEtMS0xLTEwMTE5MA_88d233d7-bf48-406d-8b53-3ff8a2f0b829">LLY</ix:nonnumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonnumeric contextref="i7d49ccbde7cb4a2cb9cf5f389b03a176_D20220101-20220331" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8xL2ZyYWc6YTYxYmRkNzc5OTQxNGIwMmI5MTA2MWExMTZjNGY0ZjEvdGFibGU6OWNkODUzNGQ2NjQ4NDgwZGIwNjgyNWE0NGI5MmNhZGUvdGFibGVyYW5nZTo5Y2Q4NTM0ZDY2NDg0ODBkYjA2ODI1YTQ0YjkyY2FkZV8xLTItMS0xLTEwMTE5MA_5759c739-8c46-425b-9f1b-01ce38a39f34">New York Stock Exchange</ix:nonnumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonnumeric contextref="ia75e83bb4f4e4a3c9c62b191a82971b4_D20220101-20220331" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8xL2ZyYWc6YTYxYmRkNzc5OTQxNGIwMmI5MTA2MWExMTZjNGY0ZjEvdGFibGU6OWNkODUzNGQ2NjQ4NDgwZGIwNjgyNWE0NGI5MmNhZGUvdGFibGVyYW5nZTo5Y2Q4NTM0ZDY2NDg0ODBkYjA2ODI1YTQ0YjkyY2FkZV8zLTAtMS0xLTEwMTE5MA_5f7172c9-094f-432b-b933-d67d00d79e4b">7 1/8% Notes due 2025</ix:nonnumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonnumeric contextref="ia75e83bb4f4e4a3c9c62b191a82971b4_D20220101-20220331" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8xL2ZyYWc6YTYxYmRkNzc5OTQxNGIwMmI5MTA2MWExMTZjNGY0ZjEvdGFibGU6OWNkODUzNGQ2NjQ4NDgwZGIwNjgyNWE0NGI5MmNhZGUvdGFibGVyYW5nZTo5Y2Q4NTM0ZDY2NDg0ODBkYjA2ODI1YTQ0YjkyY2FkZV8zLTEtMS0xLTEwMTE5MA_0e2afb03-2518-46cf-9092-43737196cb0d">LLY25</ix:nonnumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonnumeric contextref="ia75e83bb4f4e4a3c9c62b191a82971b4_D20220101-20220331" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8xL2ZyYWc6YTYxYmRkNzc5OTQxNGIwMmI5MTA2MWExMTZjNGY0ZjEvdGFibGU6OWNkODUzNGQ2NjQ4NDgwZGIwNjgyNWE0NGI5MmNhZGUvdGFibGVyYW5nZTo5Y2Q4NTM0ZDY2NDg0ODBkYjA2ODI1YTQ0YjkyY2FkZV8zLTItMS0xLTEwMTE5MA_2c76dda8-4f94-41f8-b74f-bcd59c638b42">New York Stock Exchange</ix:nonnumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonnumeric contextref="if80e85dc929b414d9df688db7009bb76_D20220101-20220331" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8xL2ZyYWc6YTYxYmRkNzc5OTQxNGIwMmI5MTA2MWExMTZjNGY0ZjEvdGFibGU6OWNkODUzNGQ2NjQ4NDgwZGIwNjgyNWE0NGI5MmNhZGUvdGFibGVyYW5nZTo5Y2Q4NTM0ZDY2NDg0ODBkYjA2ODI1YTQ0YjkyY2FkZV80LTAtMS0xLTEwMTE5MA_e6e366bb-5afb-4271-bafb-d4ec39e0f558">1.625% Notes due 2026</ix:nonnumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonnumeric contextref="if80e85dc929b414d9df688db7009bb76_D20220101-20220331" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8xL2ZyYWc6YTYxYmRkNzc5OTQxNGIwMmI5MTA2MWExMTZjNGY0ZjEvdGFibGU6OWNkODUzNGQ2NjQ4NDgwZGIwNjgyNWE0NGI5MmNhZGUvdGFibGVyYW5nZTo5Y2Q4NTM0ZDY2NDg0ODBkYjA2ODI1YTQ0YjkyY2FkZV80LTEtMS0xLTEwMTE5MA_f9dd4106-514d-48b9-8b9a-32eb5856628c">LLY26</ix:nonnumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonnumeric contextref="if80e85dc929b414d9df688db7009bb76_D20220101-20220331" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8xL2ZyYWc6YTYxYmRkNzc5OTQxNGIwMmI5MTA2MWExMTZjNGY0ZjEvdGFibGU6OWNkODUzNGQ2NjQ4NDgwZGIwNjgyNWE0NGI5MmNhZGUvdGFibGVyYW5nZTo5Y2Q4NTM0ZDY2NDg0ODBkYjA2ODI1YTQ0YjkyY2FkZV80LTItMS0xLTEwMTE5MA_494bbe1d-ec0a-4f6b-b2e6-8d6946cbc17d">New York Stock Exchange</ix:nonnumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonnumeric contextref="i1e397965855b4e77bc5c57367dccd50b_D20220101-20220331" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8xL2ZyYWc6YTYxYmRkNzc5OTQxNGIwMmI5MTA2MWExMTZjNGY0ZjEvdGFibGU6OWNkODUzNGQ2NjQ4NDgwZGIwNjgyNWE0NGI5MmNhZGUvdGFibGVyYW5nZTo5Y2Q4NTM0ZDY2NDg0ODBkYjA2ODI1YTQ0YjkyY2FkZV81LTAtMS0xLTEwMTE5MA_ac4d6104-86cd-41b3-8d85-f674e560788e">2.125% Notes due 2030</ix:nonnumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonnumeric contextref="i1e397965855b4e77bc5c57367dccd50b_D20220101-20220331" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8xL2ZyYWc6YTYxYmRkNzc5OTQxNGIwMmI5MTA2MWExMTZjNGY0ZjEvdGFibGU6OWNkODUzNGQ2NjQ4NDgwZGIwNjgyNWE0NGI5MmNhZGUvdGFibGVyYW5nZTo5Y2Q4NTM0ZDY2NDg0ODBkYjA2ODI1YTQ0YjkyY2FkZV81LTEtMS0xLTEwMTE5MA_41019243-6b0a-41da-908c-c51a0d9d51bd">LLY30</ix:nonnumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonnumeric contextref="i1e397965855b4e77bc5c57367dccd50b_D20220101-20220331" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8xL2ZyYWc6YTYxYmRkNzc5OTQxNGIwMmI5MTA2MWExMTZjNGY0ZjEvdGFibGU6OWNkODUzNGQ2NjQ4NDgwZGIwNjgyNWE0NGI5MmNhZGUvdGFibGVyYW5nZTo5Y2Q4NTM0ZDY2NDg0ODBkYjA2ODI1YTQ0YjkyY2FkZV81LTItMS0xLTEwMTE5MA_e744519d-7d91-4c16-96c1-a08b9611e48b">New York Stock Exchange</ix:nonnumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonnumeric contextref="i4cbc773e04594310b473287fc3d0e917_D20220101-20220331" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8xL2ZyYWc6YTYxYmRkNzc5OTQxNGIwMmI5MTA2MWExMTZjNGY0ZjEvdGFibGU6OWNkODUzNGQ2NjQ4NDgwZGIwNjgyNWE0NGI5MmNhZGUvdGFibGVyYW5nZTo5Y2Q4NTM0ZDY2NDg0ODBkYjA2ODI1YTQ0YjkyY2FkZV82LTAtMS0xLTEwMTE5MA_c2961687-2ff1-48c4-88aa-16722f108cf7">0.625% Notes due 2031</ix:nonnumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonnumeric contextref="i4cbc773e04594310b473287fc3d0e917_D20220101-20220331" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8xL2ZyYWc6YTYxYmRkNzc5OTQxNGIwMmI5MTA2MWExMTZjNGY0ZjEvdGFibGU6OWNkODUzNGQ2NjQ4NDgwZGIwNjgyNWE0NGI5MmNhZGUvdGFibGVyYW5nZTo5Y2Q4NTM0ZDY2NDg0ODBkYjA2ODI1YTQ0YjkyY2FkZV82LTEtMS0xLTEwMTE5MA_6fb82920-5a35-4ade-bfd5-5908ffb2460a">LLY31</ix:nonnumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonnumeric contextref="i4cbc773e04594310b473287fc3d0e917_D20220101-20220331" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8xL2ZyYWc6YTYxYmRkNzc5OTQxNGIwMmI5MTA2MWExMTZjNGY0ZjEvdGFibGU6OWNkODUzNGQ2NjQ4NDgwZGIwNjgyNWE0NGI5MmNhZGUvdGFibGVyYW5nZTo5Y2Q4NTM0ZDY2NDg0ODBkYjA2ODI1YTQ0YjkyY2FkZV82LTItMS0xLTEwMTE5MA_7c4f49a6-4b36-4a98-8ca9-a18b919b264f">New York Stock Exchange</ix:nonnumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonnumeric contextref="id4aa1d7ba2764224acafc2173c662da1_D20220101-20220331" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8xL2ZyYWc6YTYxYmRkNzc5OTQxNGIwMmI5MTA2MWExMTZjNGY0ZjEvdGFibGU6OWNkODUzNGQ2NjQ4NDgwZGIwNjgyNWE0NGI5MmNhZGUvdGFibGVyYW5nZTo5Y2Q4NTM0ZDY2NDg0ODBkYjA2ODI1YTQ0YjkyY2FkZV83LTAtMS0xLTEwMTE5MA_303295f9-71fe-417c-81d5-43780b7eed88">0.500% Notes due 2033</ix:nonnumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonnumeric contextref="id4aa1d7ba2764224acafc2173c662da1_D20220101-20220331" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8xL2ZyYWc6YTYxYmRkNzc5OTQxNGIwMmI5MTA2MWExMTZjNGY0ZjEvdGFibGU6OWNkODUzNGQ2NjQ4NDgwZGIwNjgyNWE0NGI5MmNhZGUvdGFibGVyYW5nZTo5Y2Q4NTM0ZDY2NDg0ODBkYjA2ODI1YTQ0YjkyY2FkZV83LTEtMS0xLTEwMTE5MA_3f8b9d7b-d36b-4a03-8e1a-ebf1bcace553">LLY33</ix:nonnumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonnumeric contextref="id4aa1d7ba2764224acafc2173c662da1_D20220101-20220331" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8xL2ZyYWc6YTYxYmRkNzc5OTQxNGIwMmI5MTA2MWExMTZjNGY0ZjEvdGFibGU6OWNkODUzNGQ2NjQ4NDgwZGIwNjgyNWE0NGI5MmNhZGUvdGFibGVyYW5nZTo5Y2Q4NTM0ZDY2NDg0ODBkYjA2ODI1YTQ0YjkyY2FkZV83LTItMS0xLTEwMTE5MA_eba108f8-11d4-4998-baf7-82a56ba0f3b2">New York Stock Exchange</ix:nonnumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonnumeric contextref="ie4719f471a1a494d8fa1a7731209c4b1_D20220101-20220331" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8xL2ZyYWc6YTYxYmRkNzc5OTQxNGIwMmI5MTA2MWExMTZjNGY0ZjEvdGFibGU6OWNkODUzNGQ2NjQ4NDgwZGIwNjgyNWE0NGI5MmNhZGUvdGFibGVyYW5nZTo5Y2Q4NTM0ZDY2NDg0ODBkYjA2ODI1YTQ0YjkyY2FkZV84LTAtMS0xLTEwMTE5MA_73b5d766-5ba9-41a7-95ec-4f012dbcdf27">6.77%&nbsp;Notes due 2036</ix:nonnumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonnumeric contextref="ie4719f471a1a494d8fa1a7731209c4b1_D20220101-20220331" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8xL2ZyYWc6YTYxYmRkNzc5OTQxNGIwMmI5MTA2MWExMTZjNGY0ZjEvdGFibGU6OWNkODUzNGQ2NjQ4NDgwZGIwNjgyNWE0NGI5MmNhZGUvdGFibGVyYW5nZTo5Y2Q4NTM0ZDY2NDg0ODBkYjA2ODI1YTQ0YjkyY2FkZV84LTEtMS0xLTEwMTE5MA_f997259a-ba77-4a58-a11f-cd8b63be298d">LLY36</ix:nonnumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonnumeric contextref="ie4719f471a1a494d8fa1a7731209c4b1_D20220101-20220331" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8xL2ZyYWc6YTYxYmRkNzc5OTQxNGIwMmI5MTA2MWExMTZjNGY0ZjEvdGFibGU6OWNkODUzNGQ2NjQ4NDgwZGIwNjgyNWE0NGI5MmNhZGUvdGFibGVyYW5nZTo5Y2Q4NTM0ZDY2NDg0ODBkYjA2ODI1YTQ0YjkyY2FkZV84LTItMS0xLTEwMTE5MA_4c3c7573-c275-4ab9-b16d-11abd6b67a0d">New York Stock Exchange</ix:nonnumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonnumeric contextref="ia3287ec0a7f54b078a72ddf72d91d0e9_D20220101-20220331" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8xL2ZyYWc6YTYxYmRkNzc5OTQxNGIwMmI5MTA2MWExMTZjNGY0ZjEvdGFibGU6OWNkODUzNGQ2NjQ4NDgwZGIwNjgyNWE0NGI5MmNhZGUvdGFibGVyYW5nZTo5Y2Q4NTM0ZDY2NDg0ODBkYjA2ODI1YTQ0YjkyY2FkZV85LTAtMS0xLTEwMTE5MA_a1bddc33-058d-4030-8d6c-60b63bc2f6da">1.625% Notes due 2043</ix:nonnumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonnumeric contextref="ia3287ec0a7f54b078a72ddf72d91d0e9_D20220101-20220331" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8xL2ZyYWc6YTYxYmRkNzc5OTQxNGIwMmI5MTA2MWExMTZjNGY0ZjEvdGFibGU6OWNkODUzNGQ2NjQ4NDgwZGIwNjgyNWE0NGI5MmNhZGUvdGFibGVyYW5nZTo5Y2Q4NTM0ZDY2NDg0ODBkYjA2ODI1YTQ0YjkyY2FkZV85LTEtMS0xLTEwMTE5MA_65da0f4e-63ba-40dd-bb0e-01d0027c8fcb">LLY43</ix:nonnumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonnumeric contextref="ia3287ec0a7f54b078a72ddf72d91d0e9_D20220101-20220331" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8xL2ZyYWc6YTYxYmRkNzc5OTQxNGIwMmI5MTA2MWExMTZjNGY0ZjEvdGFibGU6OWNkODUzNGQ2NjQ4NDgwZGIwNjgyNWE0NGI5MmNhZGUvdGFibGVyYW5nZTo5Y2Q4NTM0ZDY2NDg0ODBkYjA2ODI1YTQ0YjkyY2FkZV85LTItMS0xLTEwMTE5MA_06aec703-0149-4365-8134-90b1bbda5124">New York Stock Exchange</ix:nonnumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonnumeric contextref="i6759be204354404a9f0432da662a942a_D20220101-20220331" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8xL2ZyYWc6YTYxYmRkNzc5OTQxNGIwMmI5MTA2MWExMTZjNGY0ZjEvdGFibGU6OWNkODUzNGQ2NjQ4NDgwZGIwNjgyNWE0NGI5MmNhZGUvdGFibGVyYW5nZTo5Y2Q4NTM0ZDY2NDg0ODBkYjA2ODI1YTQ0YjkyY2FkZV8xMC0wLTEtMS0xMDExOTA_4e1886dc-6e68-40d6-a1e8-a3062d2af8a9">1.700% Notes due 2049</ix:nonnumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonnumeric contextref="i6759be204354404a9f0432da662a942a_D20220101-20220331" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8xL2ZyYWc6YTYxYmRkNzc5OTQxNGIwMmI5MTA2MWExMTZjNGY0ZjEvdGFibGU6OWNkODUzNGQ2NjQ4NDgwZGIwNjgyNWE0NGI5MmNhZGUvdGFibGVyYW5nZTo5Y2Q4NTM0ZDY2NDg0ODBkYjA2ODI1YTQ0YjkyY2FkZV8xMC0xLTEtMS0xMDExOTA_614f3416-66a3-405e-be91-1f6018e41d9f">LLY49A</ix:nonnumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonnumeric contextref="i6759be204354404a9f0432da662a942a_D20220101-20220331" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8xL2ZyYWc6YTYxYmRkNzc5OTQxNGIwMmI5MTA2MWExMTZjNGY0ZjEvdGFibGU6OWNkODUzNGQ2NjQ4NDgwZGIwNjgyNWE0NGI5MmNhZGUvdGFibGVyYW5nZTo5Y2Q4NTM0ZDY2NDg0ODBkYjA2ODI1YTQ0YjkyY2FkZV8xMC0yLTEtMS0xMDExOTA_9d7aec7d-943c-4fd8-b8a3-7c963c9673cc">New York Stock Exchange</ix:nonnumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonnumeric contextref="id376b4be939542b8aef77d2268f41c97_D20220101-20220331" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8xL2ZyYWc6YTYxYmRkNzc5OTQxNGIwMmI5MTA2MWExMTZjNGY0ZjEvdGFibGU6OWNkODUzNGQ2NjQ4NDgwZGIwNjgyNWE0NGI5MmNhZGUvdGFibGVyYW5nZTo5Y2Q4NTM0ZDY2NDg0ODBkYjA2ODI1YTQ0YjkyY2FkZV8xMS0wLTEtMS0xMDExOTA_51d8d41f-e049-48c9-9789-07c7d07d8507">1.125% Notes due 2051</ix:nonnumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonnumeric contextref="id376b4be939542b8aef77d2268f41c97_D20220101-20220331" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8xL2ZyYWc6YTYxYmRkNzc5OTQxNGIwMmI5MTA2MWExMTZjNGY0ZjEvdGFibGU6OWNkODUzNGQ2NjQ4NDgwZGIwNjgyNWE0NGI5MmNhZGUvdGFibGVyYW5nZTo5Y2Q4NTM0ZDY2NDg0ODBkYjA2ODI1YTQ0YjkyY2FkZV8xMS0xLTEtMS0xMDExOTA_132c9831-6102-44d6-9583-49494a67ec3f">LLY51</ix:nonnumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonnumeric contextref="id376b4be939542b8aef77d2268f41c97_D20220101-20220331" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8xL2ZyYWc6YTYxYmRkNzc5OTQxNGIwMmI5MTA2MWExMTZjNGY0ZjEvdGFibGU6OWNkODUzNGQ2NjQ4NDgwZGIwNjgyNWE0NGI5MmNhZGUvdGFibGVyYW5nZTo5Y2Q4NTM0ZDY2NDg0ODBkYjA2ODI1YTQ0YjkyY2FkZV8xMS0yLTEtMS0xMDExOTA_8781b604-08fa-4916-ba06-fad28b31ccf0">New York Stock Exchange</ix:nonnumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonnumeric contextref="i8205c2d7409c4decb9efb0638f264b89_D20220101-20220331" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8xL2ZyYWc6YTYxYmRkNzc5OTQxNGIwMmI5MTA2MWExMTZjNGY0ZjEvdGFibGU6OWNkODUzNGQ2NjQ4NDgwZGIwNjgyNWE0NGI5MmNhZGUvdGFibGVyYW5nZTo5Y2Q4NTM0ZDY2NDg0ODBkYjA2ODI1YTQ0YjkyY2FkZV8xMi0wLTEtMS0xMDExOTA_348b3548-102f-488a-94af-48812f3ae72b">1.375% Notes due 2061</ix:nonnumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonnumeric contextref="i8205c2d7409c4decb9efb0638f264b89_D20220101-20220331" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8xL2ZyYWc6YTYxYmRkNzc5OTQxNGIwMmI5MTA2MWExMTZjNGY0ZjEvdGFibGU6OWNkODUzNGQ2NjQ4NDgwZGIwNjgyNWE0NGI5MmNhZGUvdGFibGVyYW5nZTo5Y2Q4NTM0ZDY2NDg0ODBkYjA2ODI1YTQ0YjkyY2FkZV8xMi0xLTEtMS0xMDExOTA_cfd192da-eda8-42d7-afd8-1b4557fb1140">LLY61</ix:nonnumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonnumeric contextref="i8205c2d7409c4decb9efb0638f264b89_D20220101-20220331" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8xL2ZyYWc6YTYxYmRkNzc5OTQxNGIwMmI5MTA2MWExMTZjNGY0ZjEvdGFibGU6OWNkODUzNGQ2NjQ4NDgwZGIwNjgyNWE0NGI5MmNhZGUvdGFibGVyYW5nZTo5Y2Q4NTM0ZDY2NDg0ODBkYjA2ODI1YTQ0YjkyY2FkZV8xMi0yLTEtMS0xMDExOTA_76c1a284-7baa-4ed3-a203-4c06ae42d7b3">New York Stock Exchange</ix:nonnumeric></span></td></tr></tbody></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the Registrant (1)&nbsp;has filed all reports required to be filed by Section&nbsp;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports) and (2)&nbsp;has been subject to such filing requirements for the past 90 days.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonnumeric contextref="id879b497a407453985551e83dbee75f8_D20220101-20220331" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8xL2ZyYWc6YTYxYmRkNzc5OTQxNGIwMmI5MTA2MWExMTZjNGY0ZjEvdGV4dHJlZ2lvbjphNjFiZGQ3Nzk5NDE0YjAyYjkxMDYxYTExNmM0ZjRmMV8yMDQ2_2ea88553-bf78-4019-87a0-d4d4175e24d5">Yes</ix:nonnumeric> </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:120%">☒</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> No </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:120%">☐</span></div><div style="margin-top:2pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Registrant was required to submit such files).</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonnumeric contextref="id879b497a407453985551e83dbee75f8_D20220101-20220331" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8xL2ZyYWc6YTYxYmRkNzc5OTQxNGIwMmI5MTA2MWExMTZjNGY0ZjEvdGV4dHJlZ2lvbjphNjFiZGQ3Nzk5NDE0YjAyYjkxMDYxYTExNmM0ZjRmMV8yMDQ3_0c27fdf6-ebfe-4c0b-bde7-b5251ca2e728">Yes</ix:nonnumeric> </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:120%">☒</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> No </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:120%">☐</span></div><div style="margin-top:2pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:19.514%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.285%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.250%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.582%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonnumeric contextref="id879b497a407453985551e83dbee75f8_D20220101-20220331" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8xL2ZyYWc6YTYxYmRkNzc5OTQxNGIwMmI5MTA2MWExMTZjNGY0ZjEvdGFibGU6YTY1N2E5NGIzYzY4NDE2ODhmMWYxZGMyMjIwOTFlMGQvdGFibGVyYW5nZTphNjU3YTk0YjNjNjg0MTY4OGYxZjFkYzIyMjA5MWUwZF8wLTAtMS0xLTEwMTE5MA_3c40e09d-24de-4a99-bc3f-525ef6f5ab13">Large accelerated filer</ix:nonnumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:100%">☒</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accelerated&nbsp;filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:100%">☐</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:100%">☐</span></td><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Smaller reporting company</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonnumeric contextref="id879b497a407453985551e83dbee75f8_D20220101-20220331" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8xL2ZyYWc6YTYxYmRkNzc5OTQxNGIwMmI5MTA2MWExMTZjNGY0ZjEvdGFibGU6YTY1N2E5NGIzYzY4NDE2ODhmMWYxZGMyMjIwOTFlMGQvdGFibGVyYW5nZTphNjU3YTk0YjNjNjg0MTY4OGYxZjFkYzIyMjA5MWUwZF8xLTctMS0xLTEwMTE5MA_75d199c9-01ab-4b9a-832a-8ff0b905e753">☐</ix:nonnumeric></span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;&nbsp;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonnumeric contextref="id879b497a407453985551e83dbee75f8_D20220101-20220331" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8xL2ZyYWc6YTYxYmRkNzc5OTQxNGIwMmI5MTA2MWExMTZjNGY0ZjEvdGFibGU6YTY1N2E5NGIzYzY4NDE2ODhmMWYxZGMyMjIwOTFlMGQvdGFibGVyYW5nZTphNjU3YTk0YjNjNjg0MTY4OGYxZjFkYzIyMjA5MWUwZF8yLTctMS0xLTEwMTE5MA_ace82f10-260d-42ed-afd9-b242b9933e29">☐</ix:nonnumeric></span></td></tr></tbody></table></div><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the Registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:120%">☐</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Yes </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonnumeric contextref="id879b497a407453985551e83dbee75f8_D20220101-20220331" name="dei:EntityShellCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8xL2ZyYWc6YTYxYmRkNzc5OTQxNGIwMmI5MTA2MWExMTZjNGY0ZjEvdGV4dHJlZ2lvbjphNjFiZGQ3Nzk5NDE0YjAyYjkxMDYxYTExNmM0ZjRmMV8yMDQz_2b3f7eed-a1a6-4534-a55f-756e877e22ac">☐</ix:nonnumeric></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> No </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:120%">☒</span></div><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The number of shares of common stock outstanding as of April&nbsp;26, 2022:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tbody><tr><td style="width:1.0%"></td><td style="width:47.948%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.560%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.192%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Class</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Number of Shares Outstanding</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="shares" contextref="i62be53ac21bd4b0b8aa6e62ecf72737c_I20220426" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8xL2ZyYWc6YTYxYmRkNzc5OTQxNGIwMmI5MTA2MWExMTZjNGY0ZjEvdGFibGU6NDk2M2I5YmZmMmYxNGFmOTg0ZWIzNTRjNDM4NjJkZmEvdGFibGVyYW5nZTo0OTYzYjliZmYyZjE0YWY5ODRlYjM1NGM0Mzg2MmRmYV8xLTItMS0xLTEwMTE5MA_56227911-a9c7-4b8c-b651-7612d5df527a">950,159,559</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tbody><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr></tbody></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br></span></div></div></div><div id="ie8dc61f8e15b44db82ba16050d5b7b44_7"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span><br></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Eli Lilly and Company</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Form 10-Q</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the Quarter Ended March&nbsp;31, 2022 </span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Table of Contents</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:25.654%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:63.666%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.334%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Page</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie8dc61f8e15b44db82ba16050d5b7b44_13">PART I. Financial Information</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie8dc61f8e15b44db82ba16050d5b7b44_13">5</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie8dc61f8e15b44db82ba16050d5b7b44_16">Item 1.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie8dc61f8e15b44db82ba16050d5b7b44_16">Financial Statements</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie8dc61f8e15b44db82ba16050d5b7b44_16">5</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie8dc61f8e15b44db82ba16050d5b7b44_19">Consolidated Condensed Statements of Operations</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie8dc61f8e15b44db82ba16050d5b7b44_19">5</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie8dc61f8e15b44db82ba16050d5b7b44_22">Consolidated Condensed Statements of Comprehensive Income</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie8dc61f8e15b44db82ba16050d5b7b44_22">6</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie8dc61f8e15b44db82ba16050d5b7b44_25">Consolidated Condensed Balance Sheets</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie8dc61f8e15b44db82ba16050d5b7b44_25">7</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie8dc61f8e15b44db82ba16050d5b7b44_28">Consolidated Condensed Statements of Equity</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie8dc61f8e15b44db82ba16050d5b7b44_28">8</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie8dc61f8e15b44db82ba16050d5b7b44_34">Consolidated Condensed Statements of Cash Flows</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie8dc61f8e15b44db82ba16050d5b7b44_34">9</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie8dc61f8e15b44db82ba16050d5b7b44_37">Notes to Consolidated Condensed Financial Statements</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie8dc61f8e15b44db82ba16050d5b7b44_37">10</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie8dc61f8e15b44db82ba16050d5b7b44_88">Item 2.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie8dc61f8e15b44db82ba16050d5b7b44_88">Management's Discussion and Analysis of Results of Operations and Financial Condition</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie8dc61f8e15b44db82ba16050d5b7b44_88">35</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie8dc61f8e15b44db82ba16050d5b7b44_91">Executive Overview</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie8dc61f8e15b44db82ba16050d5b7b44_91">35</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie8dc61f8e15b44db82ba16050d5b7b44_94">Revenue</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie8dc61f8e15b44db82ba16050d5b7b44_94">41</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie8dc61f8e15b44db82ba16050d5b7b44_100">Gross Margin, Costs, and Expenses</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie8dc61f8e15b44db82ba16050d5b7b44_100">44</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie8dc61f8e15b44db82ba16050d5b7b44_106">Financial Condition and Liquidity</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie8dc61f8e15b44db82ba16050d5b7b44_106">45</a></span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie8dc61f8e15b44db82ba16050d5b7b44_1179">Critical Accounting Estimates</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie8dc61f8e15b44db82ba16050d5b7b44_1179">45</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie8dc61f8e15b44db82ba16050d5b7b44_112">Available Information on our Website</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie8dc61f8e15b44db82ba16050d5b7b44_112">45</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie8dc61f8e15b44db82ba16050d5b7b44_115">Item 4.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie8dc61f8e15b44db82ba16050d5b7b44_115">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie8dc61f8e15b44db82ba16050d5b7b44_115">46</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie8dc61f8e15b44db82ba16050d5b7b44_118">PART II. Other Information</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie8dc61f8e15b44db82ba16050d5b7b44_118">47</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie8dc61f8e15b44db82ba16050d5b7b44_121">Item 1.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie8dc61f8e15b44db82ba16050d5b7b44_121">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie8dc61f8e15b44db82ba16050d5b7b44_121">47</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie8dc61f8e15b44db82ba16050d5b7b44_124">Item 1A.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie8dc61f8e15b44db82ba16050d5b7b44_124">Risk Factors</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie8dc61f8e15b44db82ba16050d5b7b44_124">47</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie8dc61f8e15b44db82ba16050d5b7b44_127">Item 2.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie8dc61f8e15b44db82ba16050d5b7b44_127">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie8dc61f8e15b44db82ba16050d5b7b44_127">47</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie8dc61f8e15b44db82ba16050d5b7b44_133">Item 6.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie8dc61f8e15b44db82ba16050d5b7b44_133">Exhibits</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie8dc61f8e15b44db82ba16050d5b7b44_133">48</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie8dc61f8e15b44db82ba16050d5b7b44_139">Signatures</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie8dc61f8e15b44db82ba16050d5b7b44_139">48</a></span></div></td></tr></tbody></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="ie8dc61f8e15b44db82ba16050d5b7b44_10"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span><br></span></div></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-style:italic;font-weight:400;line-height:120%">Forward-Looking Statements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.9pt;font-weight:400;line-height:120%">This Quarterly Report on Form 10-Q </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and our other publicly available documents include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 (Exchange Act), and are subject to the safe harbor created thereby under the Private Securities Litigation Reform Act of 1995. In particular, information appearing under "Management's Discussion and Analysis of Results of Operations and Financial Condition" includes forward-looking statements. Forward-looking statements include all statements that do not relate solely to historical or current facts, and generally can be identified by the use of words such as "may," "believe," "will," "expect," "project," "estimate," "intend," "anticipate," "plan," "continue," or similar expressions or future or conditional verbs. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forward-looking statements inherently involve many risks and uncertainties that could cause actual results to differ materially from those expressed in forward-looking statements. Where, in any forward-looking statement, we express an expectation or belief as to future results or events, it is based on management's current plans and expectations, expressed in good faith and believed to have a reasonable basis. However, we can give no assurance that any such expectation or belief will result or will be achieved or accomplished. Investors therefore should not place undue reliance on forward-looking statements. The following include some but not all of the factors that could cause actual results or events to differ materially from those anticipated:</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impact of the evolving COVID-19 pandemic or any future pandemic, epidemic, or similar public health threat and the global response thereto;</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">uncertainties related to our efforts to develop, manufacture, and distribute potential treatments for COVID-19;</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the significant costs and uncertainties in the pharmaceutical research and development process, including with respect to the timing and process of obtaining regulatory approvals;</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impact and outcome of acquisitions and business development transactions and related integration costs;</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the expiration of intellectual property protection for certain of our products and competition from generic and/or biosimilar products;</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to protect and enforce patents and other intellectual property;</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in patent law or regulations related to data package exclusivity;</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">competitive developments affecting current products and our pipeline;</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">market uptake of recently launched products;</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">information technology system inadequacies, breaches, or operating failures;</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">unauthorized access, disclosure, misappropriation, or compromise of confidential information or other data stored in our information technology systems, networks, and facilities, or those of third parties with whom we share our data;</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">unexpected safety or efficacy concerns associated with our products;</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">litigation, investigations, or other similar proceedings involving past, current, or future products or commercial activities as we are largely self-insured;</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">issues with product supply and regulatory approvals stemming from manufacturing difficulties, disruptions, or shortages, including as a result of demand, labor shortages, third-party performance, or regulatory actions relating to our facilities;</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reliance on third-party relationships and outsourcing arrangements;</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory changes or other developments;</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory actions regarding currently marketed products; </span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">continued pricing pressures and the impact of actions of governmental and private payers affecting pricing of, reimbursement for, and access to pharmaceuticals;</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">devaluations in foreign currency exchange rates, changes in interest rates, and inflation;</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in tax law, tax rates, or events that differ from our assumptions related to tax positions; </span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">asset impairments and restructuring charges;</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impact of global macroeconomic conditions, trade disruptions, global disputes, unrest, war, or other costs, uncertainties and risks related to engaging in business in foreign jurisdictions; </span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in accounting and reporting standards promulgated by the Financial Accounting Standards Board and the Securities and Exchange Commission (SEC); and</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory compliance problems or government investigations.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span><br></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.9pt;font-weight:400;line-height:120%">More information on factors that could cause actual results or events to differ materially from those anticipated is included from time to time in our reports filed with the SEC, including in our Annual Report on </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.9pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0000059478/000005947822000068/lly-20211231.htm">Form 10-K</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.9pt;font-weight:400;line-height:120%"> for the year ended December&nbsp;31, 2021, particularly under the caption "Risk Factors." Investors should understand that it is not possible to predict or identify all such factors and should not consider the risks described above and under Part I, Item 1A, "Risk Factors" of our Annual Report on </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.9pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0000059478/000005947822000068/lly-20211231.htm">Form 10-K</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.9pt;font-weight:400;line-height:120%"> to be a complete statement of all potential risks and uncertainties.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.9pt;font-weight:400;line-height:120%">All forward-looking statements speak only as of the date of this Quarterly Report on Form 10-Q and are expressly qualified in their entirety by the cautionary statements included in or incorporated by reference into this Quarterly Report on Form 10-Q. Except as is required by law, we expressly disclaim any obligation to publicly release any revisions to forward-looking statements to reflect events after the date of this Quarterly Report on Form 10-Q. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="ie8dc61f8e15b44db82ba16050d5b7b44_13"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span><br></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:16pt;font-weight:400;line-height:120%;text-decoration:underline">PART I. Financial Information</span></div><div id="ie8dc61f8e15b44db82ba16050d5b7b44_16"></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Item&nbsp;1. Financial Statements</span></div><div id="ie8dc61f8e15b44db82ba16050d5b7b44_19"></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Condensed Statements of Operations</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ELI LILLY AND COMPANY AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars and shares in millions, except per-share data)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&nbsp;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:65.128%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.422%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue (Note 2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="id879b497a407453985551e83dbee75f8_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8xOS9mcmFnOjljNTQzY2IwZGI1ZTRlMzVhZWU0ZWVhMWMyN2Y3YTE2L3RhYmxlOmNhMGVhZjI1OGE4ZjQzYmM4M2E3NWFjYTlhZjkyZTVmL3RhYmxlcmFuZ2U6Y2EwZWFmMjU4YThmNDNiYzgzYTc1YWNhOWFmOTJlNWZfMi0xLTEtMS0xMDExOTA_58720749-8735-45e5-8b41-23288afb5c95">7,810.0</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i010e4c0d9c6246be91d37e31d569fa6f_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8xOS9mcmFnOjljNTQzY2IwZGI1ZTRlMzVhZWU0ZWVhMWMyN2Y3YTE2L3RhYmxlOmNhMGVhZjI1OGE4ZjQzYmM4M2E3NWFjYTlhZjkyZTVmL3RhYmxlcmFuZ2U6Y2EwZWFmMjU4YThmNDNiYzgzYTc1YWNhOWFmOTJlNWZfMi0zLTEtMS0xMDExOTA_b18aa7c0-1640-46c7-b119-ab839bb3d752">6,805.6</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costs, expenses, and other:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="id879b497a407453985551e83dbee75f8_D20220101-20220331" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8xOS9mcmFnOjljNTQzY2IwZGI1ZTRlMzVhZWU0ZWVhMWMyN2Y3YTE2L3RhYmxlOmNhMGVhZjI1OGE4ZjQzYmM4M2E3NWFjYTlhZjkyZTVmL3RhYmxlcmFuZ2U6Y2EwZWFmMjU4YThmNDNiYzgzYTc1YWNhOWFmOTJlNWZfNC0xLTEtMS0xMDExOTA_dcac734f-ee64-4a17-bd98-e1d35bc80f5b">2,072.1</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i010e4c0d9c6246be91d37e31d569fa6f_D20210101-20210331" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8xOS9mcmFnOjljNTQzY2IwZGI1ZTRlMzVhZWU0ZWVhMWMyN2Y3YTE2L3RhYmxlOmNhMGVhZjI1OGE4ZjQzYmM4M2E3NWFjYTlhZjkyZTVmL3RhYmxlcmFuZ2U6Y2EwZWFmMjU4YThmNDNiYzgzYTc1YWNhOWFmOTJlNWZfNC0zLTEtMS0xMDExOTA_43a49544-106d-47de-a2ee-05bfa44f8f04">1,878.6</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="id879b497a407453985551e83dbee75f8_D20220101-20220331" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8xOS9mcmFnOjljNTQzY2IwZGI1ZTRlMzVhZWU0ZWVhMWMyN2Y3YTE2L3RhYmxlOmNhMGVhZjI1OGE4ZjQzYmM4M2E3NWFjYTlhZjkyZTVmL3RhYmxlcmFuZ2U6Y2EwZWFmMjU4YThmNDNiYzgzYTc1YWNhOWFmOTJlNWZfNS0xLTEtMS0xMDExOTA_7e53babe-0881-456a-9f6d-2b3d8a315039">1,610.1</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i010e4c0d9c6246be91d37e31d569fa6f_D20210101-20210331" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8xOS9mcmFnOjljNTQzY2IwZGI1ZTRlMzVhZWU0ZWVhMWMyN2Y3YTE2L3RhYmxlOmNhMGVhZjI1OGE4ZjQzYmM4M2E3NWFjYTlhZjkyZTVmL3RhYmxlcmFuZ2U6Y2EwZWFmMjU4YThmNDNiYzgzYTc1YWNhOWFmOTJlNWZfNS0zLTEtMS0xMDExOTA_4f479e1f-b431-4498-9dbd-5e86e4d208a7">1,672.1</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketing, selling, and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="id879b497a407453985551e83dbee75f8_D20220101-20220331" decimals="-5" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8xOS9mcmFnOjljNTQzY2IwZGI1ZTRlMzVhZWU0ZWVhMWMyN2Y3YTE2L3RhYmxlOmNhMGVhZjI1OGE4ZjQzYmM4M2E3NWFjYTlhZjkyZTVmL3RhYmxlcmFuZ2U6Y2EwZWFmMjU4YThmNDNiYzgzYTc1YWNhOWFmOTJlNWZfNi0xLTEtMS0xMDExOTA_85385a14-c430-44ff-8f8a-7179e7a3cd84">1,557.9</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i010e4c0d9c6246be91d37e31d569fa6f_D20210101-20210331" decimals="-5" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8xOS9mcmFnOjljNTQzY2IwZGI1ZTRlMzVhZWU0ZWVhMWMyN2Y3YTE2L3RhYmxlOmNhMGVhZjI1OGE4ZjQzYmM4M2E3NWFjYTlhZjkyZTVmL3RhYmxlcmFuZ2U6Y2EwZWFmMjU4YThmNDNiYzgzYTc1YWNhOWFmOTJlNWZfNi0zLTEtMS0xMDExOTA_87cbe48c-74b7-46cb-9f68-90d6549d6237">1,576.0</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired in-process research and development and development milestones (Note 3)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="id879b497a407453985551e83dbee75f8_D20220101-20220331" decimals="-5" name="lly:AcquiredInProcessResearchAndDevelopmentAndDevelopmentMilestones" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8xOS9mcmFnOjljNTQzY2IwZGI1ZTRlMzVhZWU0ZWVhMWMyN2Y3YTE2L3RhYmxlOmNhMGVhZjI1OGE4ZjQzYmM4M2E3NWFjYTlhZjkyZTVmL3RhYmxlcmFuZ2U6Y2EwZWFmMjU4YThmNDNiYzgzYTc1YWNhOWFmOTJlNWZfNy0xLTEtMS0xMDExOTA_05b58226-7c52-465d-a89e-9a5aa7f2b193">165.6</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i010e4c0d9c6246be91d37e31d569fa6f_D20210101-20210331" decimals="-5" name="lly:AcquiredInProcessResearchAndDevelopmentAndDevelopmentMilestones" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8xOS9mcmFnOjljNTQzY2IwZGI1ZTRlMzVhZWU0ZWVhMWMyN2Y3YTE2L3RhYmxlOmNhMGVhZjI1OGE4ZjQzYmM4M2E3NWFjYTlhZjkyZTVmL3RhYmxlcmFuZ2U6Y2EwZWFmMjU4YThmNDNiYzgzYTc1YWNhOWFmOTJlNWZfNy0zLTEtMS0xMDExOTA_57e5f5c4-6b08-4862-95d2-136aa74357ac">312.0</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset impairment, restructuring, and other special charges (Note 5)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="id879b497a407453985551e83dbee75f8_D20220101-20220331" decimals="-5" name="us-gaap:RestructuringSettlementAndImpairmentProvisions" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8xOS9mcmFnOjljNTQzY2IwZGI1ZTRlMzVhZWU0ZWVhMWMyN2Y3YTE2L3RhYmxlOmNhMGVhZjI1OGE4ZjQzYmM4M2E3NWFjYTlhZjkyZTVmL3RhYmxlcmFuZ2U6Y2EwZWFmMjU4YThmNDNiYzgzYTc1YWNhOWFmOTJlNWZfOC0xLTEtMS0xMDExOTA_d1d0db18-3c80-490a-a909-ab1cc4a9b2b0">—</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i010e4c0d9c6246be91d37e31d569fa6f_D20210101-20210331" decimals="-5" name="us-gaap:RestructuringSettlementAndImpairmentProvisions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8xOS9mcmFnOjljNTQzY2IwZGI1ZTRlMzVhZWU0ZWVhMWMyN2Y3YTE2L3RhYmxlOmNhMGVhZjI1OGE4ZjQzYmM4M2E3NWFjYTlhZjkyZTVmL3RhYmxlcmFuZ2U6Y2EwZWFmMjU4YThmNDNiYzgzYTc1YWNhOWFmOTJlNWZfOC0zLTEtMS0xMDExOTA_0831ca4a-589a-4054-be63-c99930563eed">211.6</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other–net, (income) expense (Note 11)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="id879b497a407453985551e83dbee75f8_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8xOS9mcmFnOjljNTQzY2IwZGI1ZTRlMzVhZWU0ZWVhMWMyN2Y3YTE2L3RhYmxlOmNhMGVhZjI1OGE4ZjQzYmM4M2E3NWFjYTlhZjkyZTVmL3RhYmxlcmFuZ2U6Y2EwZWFmMjU4YThmNDNiYzgzYTc1YWNhOWFmOTJlNWZfOS0xLTEtMS0xMDExOTA_64819288-7699-4e94-8ff1-4f90b17c61d4">350.7</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i010e4c0d9c6246be91d37e31d569fa6f_D20210101-20210331" decimals="-5" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8xOS9mcmFnOjljNTQzY2IwZGI1ZTRlMzVhZWU0ZWVhMWMyN2Y3YTE2L3RhYmxlOmNhMGVhZjI1OGE4ZjQzYmM4M2E3NWFjYTlhZjkyZTVmL3RhYmxlcmFuZ2U6Y2EwZWFmMjU4YThmNDNiYzgzYTc1YWNhOWFmOTJlNWZfOS0zLTEtMS0xMDExOTA_80ba2352-ce65-46cc-b5e6-a4d84c406ce5">321.1</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="id879b497a407453985551e83dbee75f8_D20220101-20220331" decimals="-5" name="lly:CostOfSalesOperatingExpensesAndOtherNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8xOS9mcmFnOjljNTQzY2IwZGI1ZTRlMzVhZWU0ZWVhMWMyN2Y3YTE2L3RhYmxlOmNhMGVhZjI1OGE4ZjQzYmM4M2E3NWFjYTlhZjkyZTVmL3RhYmxlcmFuZ2U6Y2EwZWFmMjU4YThmNDNiYzgzYTc1YWNhOWFmOTJlNWZfMTAtMS0xLTEtMTAxMTkw_6f12de57-fc8f-451c-9a4e-e5db76c35ae5">5,756.4</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i010e4c0d9c6246be91d37e31d569fa6f_D20210101-20210331" decimals="-5" name="lly:CostOfSalesOperatingExpensesAndOtherNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8xOS9mcmFnOjljNTQzY2IwZGI1ZTRlMzVhZWU0ZWVhMWMyN2Y3YTE2L3RhYmxlOmNhMGVhZjI1OGE4ZjQzYmM4M2E3NWFjYTlhZjkyZTVmL3RhYmxlcmFuZ2U6Y2EwZWFmMjU4YThmNDNiYzgzYTc1YWNhOWFmOTJlNWZfMTAtMy0xLTEtMTAxMTkw_72af02b2-92e5-4939-8de3-421f2b2f1492">5,329.2</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income before income taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="id879b497a407453985551e83dbee75f8_D20220101-20220331" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8xOS9mcmFnOjljNTQzY2IwZGI1ZTRlMzVhZWU0ZWVhMWMyN2Y3YTE2L3RhYmxlOmNhMGVhZjI1OGE4ZjQzYmM4M2E3NWFjYTlhZjkyZTVmL3RhYmxlcmFuZ2U6Y2EwZWFmMjU4YThmNDNiYzgzYTc1YWNhOWFmOTJlNWZfMTEtMS0xLTEtMTAxMTkw_1d2d30e1-64e0-4b9d-bcd2-8149ed1e98cb">2,053.6</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i010e4c0d9c6246be91d37e31d569fa6f_D20210101-20210331" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8xOS9mcmFnOjljNTQzY2IwZGI1ZTRlMzVhZWU0ZWVhMWMyN2Y3YTE2L3RhYmxlOmNhMGVhZjI1OGE4ZjQzYmM4M2E3NWFjYTlhZjkyZTVmL3RhYmxlcmFuZ2U6Y2EwZWFmMjU4YThmNDNiYzgzYTc1YWNhOWFmOTJlNWZfMTEtMy0xLTEtMTAxMTkw_ee532aea-bf27-4819-ba3b-2842b3657cf9">1,476.4</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes (Note 7)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="id879b497a407453985551e83dbee75f8_D20220101-20220331" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8xOS9mcmFnOjljNTQzY2IwZGI1ZTRlMzVhZWU0ZWVhMWMyN2Y3YTE2L3RhYmxlOmNhMGVhZjI1OGE4ZjQzYmM4M2E3NWFjYTlhZjkyZTVmL3RhYmxlcmFuZ2U6Y2EwZWFmMjU4YThmNDNiYzgzYTc1YWNhOWFmOTJlNWZfMTItMS0xLTEtMTAxMTkw_e04ab0bb-f4eb-48a5-ad6a-b988d169d57f">150.7</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i010e4c0d9c6246be91d37e31d569fa6f_D20210101-20210331" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8xOS9mcmFnOjljNTQzY2IwZGI1ZTRlMzVhZWU0ZWVhMWMyN2Y3YTE2L3RhYmxlOmNhMGVhZjI1OGE4ZjQzYmM4M2E3NWFjYTlhZjkyZTVmL3RhYmxlcmFuZ2U6Y2EwZWFmMjU4YThmNDNiYzgzYTc1YWNhOWFmOTJlNWZfMTItMy0xLTEtMTAxMTkw_b44c9961-199d-483f-8695-49aa5c64ba6a">121.1</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="id879b497a407453985551e83dbee75f8_D20220101-20220331" decimals="-5" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8xOS9mcmFnOjljNTQzY2IwZGI1ZTRlMzVhZWU0ZWVhMWMyN2Y3YTE2L3RhYmxlOmNhMGVhZjI1OGE4ZjQzYmM4M2E3NWFjYTlhZjkyZTVmL3RhYmxlcmFuZ2U6Y2EwZWFmMjU4YThmNDNiYzgzYTc1YWNhOWFmOTJlNWZfMTMtMS0xLTEtMTAxMTkw_c1acb29d-effa-440a-8365-201130dd1e52">1,902.9</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i010e4c0d9c6246be91d37e31d569fa6f_D20210101-20210331" decimals="-5" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8xOS9mcmFnOjljNTQzY2IwZGI1ZTRlMzVhZWU0ZWVhMWMyN2Y3YTE2L3RhYmxlOmNhMGVhZjI1OGE4ZjQzYmM4M2E3NWFjYTlhZjkyZTVmL3RhYmxlcmFuZ2U6Y2EwZWFmMjU4YThmNDNiYzgzYTc1YWNhOWFmOTJlNWZfMTMtMy0xLTEtMTAxMTkw_de2195c4-b059-48f3-a125-09376423d02c">1,355.3</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings per share:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usdPerShare" contextref="id879b497a407453985551e83dbee75f8_D20220101-20220331" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8xOS9mcmFnOjljNTQzY2IwZGI1ZTRlMzVhZWU0ZWVhMWMyN2Y3YTE2L3RhYmxlOmNhMGVhZjI1OGE4ZjQzYmM4M2E3NWFjYTlhZjkyZTVmL3RhYmxlcmFuZ2U6Y2EwZWFmMjU4YThmNDNiYzgzYTc1YWNhOWFmOTJlNWZfMTgtMS0xLTEtMTAxMTkw_f4612fb1-4ccd-4621-a271-29a1e26c40da">2.11</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usdPerShare" contextref="i010e4c0d9c6246be91d37e31d569fa6f_D20210101-20210331" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8xOS9mcmFnOjljNTQzY2IwZGI1ZTRlMzVhZWU0ZWVhMWMyN2Y3YTE2L3RhYmxlOmNhMGVhZjI1OGE4ZjQzYmM4M2E3NWFjYTlhZjkyZTVmL3RhYmxlcmFuZ2U6Y2EwZWFmMjU4YThmNDNiYzgzYTc1YWNhOWFmOTJlNWZfMTgtMy0xLTEtMTAxMTkw_cc1eb0cf-49a6-4926-b1c1-8fe731628a79">1.49</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usdPerShare" contextref="id879b497a407453985551e83dbee75f8_D20220101-20220331" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8xOS9mcmFnOjljNTQzY2IwZGI1ZTRlMzVhZWU0ZWVhMWMyN2Y3YTE2L3RhYmxlOmNhMGVhZjI1OGE4ZjQzYmM4M2E3NWFjYTlhZjkyZTVmL3RhYmxlcmFuZ2U6Y2EwZWFmMjU4YThmNDNiYzgzYTc1YWNhOWFmOTJlNWZfMjAtMS0xLTEtMTAxMTkw_6603691a-eed0-42bc-838a-830b41b5d626">2.10</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usdPerShare" contextref="i010e4c0d9c6246be91d37e31d569fa6f_D20210101-20210331" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8xOS9mcmFnOjljNTQzY2IwZGI1ZTRlMzVhZWU0ZWVhMWMyN2Y3YTE2L3RhYmxlOmNhMGVhZjI1OGE4ZjQzYmM4M2E3NWFjYTlhZjkyZTVmL3RhYmxlcmFuZ2U6Y2EwZWFmMjU4YThmNDNiYzgzYTc1YWNhOWFmOTJlNWZfMjAtMy0xLTEtMTAxMTkw_a1742b85-74ab-4a0d-a741-134b56fb7392">1.49</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares used in calculation of earnings per share:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="shares" contextref="id879b497a407453985551e83dbee75f8_D20220101-20220331" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8xOS9mcmFnOjljNTQzY2IwZGI1ZTRlMzVhZWU0ZWVhMWMyN2Y3YTE2L3RhYmxlOmNhMGVhZjI1OGE4ZjQzYmM4M2E3NWFjYTlhZjkyZTVmL3RhYmxlcmFuZ2U6Y2EwZWFmMjU4YThmNDNiYzgzYTc1YWNhOWFmOTJlNWZfMjQtMS0xLTEtMTAxMTkw_20208de4-baff-4aaf-a21d-1e9224e0abd9">903.7</ix:nonfraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="shares" contextref="i010e4c0d9c6246be91d37e31d569fa6f_D20210101-20210331" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8xOS9mcmFnOjljNTQzY2IwZGI1ZTRlMzVhZWU0ZWVhMWMyN2Y3YTE2L3RhYmxlOmNhMGVhZjI1OGE4ZjQzYmM4M2E3NWFjYTlhZjkyZTVmL3RhYmxlcmFuZ2U6Y2EwZWFmMjU4YThmNDNiYzgzYTc1YWNhOWFmOTJlNWZfMjQtMy0xLTEtMTAxMTkw_2bb5f39b-08f0-48dd-a870-a464ed1af84f">908.8</ix:nonfraction></span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="shares" contextref="id879b497a407453985551e83dbee75f8_D20220101-20220331" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8xOS9mcmFnOjljNTQzY2IwZGI1ZTRlMzVhZWU0ZWVhMWMyN2Y3YTE2L3RhYmxlOmNhMGVhZjI1OGE4ZjQzYmM4M2E3NWFjYTlhZjkyZTVmL3RhYmxlcmFuZ2U6Y2EwZWFmMjU4YThmNDNiYzgzYTc1YWNhOWFmOTJlNWZfMjUtMS0xLTEtMTAxMTkw_581a70f9-589a-41b7-8c2c-a25849608f21">906.4</ix:nonfraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="shares" contextref="i010e4c0d9c6246be91d37e31d569fa6f_D20210101-20210331" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8xOS9mcmFnOjljNTQzY2IwZGI1ZTRlMzVhZWU0ZWVhMWMyN2Y3YTE2L3RhYmxlOmNhMGVhZjI1OGE4ZjQzYmM4M2E3NWFjYTlhZjkyZTVmL3RhYmxlcmFuZ2U6Y2EwZWFmMjU4YThmNDNiYzgzYTc1YWNhOWFmOTJlNWZfMjUtMy0xLTEtMTAxMTkw_891a245e-94b2-43fa-b719-285158f1ba9d">912.4</ix:nonfraction></span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></tbody></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&nbsp;&nbsp;&nbsp;&nbsp;</span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See notes to consolidated condensed financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="ie8dc61f8e15b44db82ba16050d5b7b44_22"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span><br></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Condensed Statements of Comprehensive Income</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ELI LILLY AND COMPANY AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in millions)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&nbsp;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:65.128%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.422%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="id879b497a407453985551e83dbee75f8_D20220101-20220331" decimals="-5" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8yMi9mcmFnOjQwYzU1MTM0ZjY3ODQwMWRiOTAwMjQ2MzdhY2I3M2JkL3RhYmxlOjczNmE5MWNiODI4YzQxZTQ4YjA5NjdjZGJhZmY4MWQzL3RhYmxlcmFuZ2U6NzM2YTkxY2I4MjhjNDFlNDhiMDk2N2NkYmFmZjgxZDNfMi0xLTEtMS0xMDExOTA_c1acb29d-effa-440a-8365-201130dd1e52">1,902.9</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i010e4c0d9c6246be91d37e31d569fa6f_D20210101-20210331" decimals="-5" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8yMi9mcmFnOjQwYzU1MTM0ZjY3ODQwMWRiOTAwMjQ2MzdhY2I3M2JkL3RhYmxlOjczNmE5MWNiODI4YzQxZTQ4YjA5NjdjZGJhZmY4MWQzL3RhYmxlcmFuZ2U6NzM2YTkxY2I4MjhjNDFlNDhiMDk2N2NkYmFmZjgxZDNfMi0zLTEtMS0xMDExOTA_de2195c4-b059-48f3-a125-09376423d02c">1,355.3</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income, net of tax (Note 10)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="id879b497a407453985551e83dbee75f8_D20220101-20220331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8yMi9mcmFnOjQwYzU1MTM0ZjY3ODQwMWRiOTAwMjQ2MzdhY2I3M2JkL3RhYmxlOjczNmE5MWNiODI4YzQxZTQ4YjA5NjdjZGJhZmY4MWQzL3RhYmxlcmFuZ2U6NzM2YTkxY2I4MjhjNDFlNDhiMDk2N2NkYmFmZjgxZDNfMy0xLTEtMS0xMDExOTA_fc87e3fa-d9e9-4872-a8d2-ca43d30a34e9">117.8</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i010e4c0d9c6246be91d37e31d569fa6f_D20210101-20210331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8yMi9mcmFnOjQwYzU1MTM0ZjY3ODQwMWRiOTAwMjQ2MzdhY2I3M2JkL3RhYmxlOjczNmE5MWNiODI4YzQxZTQ4YjA5NjdjZGJhZmY4MWQzL3RhYmxlcmFuZ2U6NzM2YTkxY2I4MjhjNDFlNDhiMDk2N2NkYmFmZjgxZDNfMy0zLTEtMS0xMDExOTA_cdbf9e5d-3cf9-4baf-8832-1ecf5c3d6666">100.8</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive income</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="id879b497a407453985551e83dbee75f8_D20220101-20220331" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8yMi9mcmFnOjQwYzU1MTM0ZjY3ODQwMWRiOTAwMjQ2MzdhY2I3M2JkL3RhYmxlOjczNmE5MWNiODI4YzQxZTQ4YjA5NjdjZGJhZmY4MWQzL3RhYmxlcmFuZ2U6NzM2YTkxY2I4MjhjNDFlNDhiMDk2N2NkYmFmZjgxZDNfNC0xLTEtMS0xMDExOTA_d1e3584e-8a36-4d99-929d-02ef0840433b">2,020.7</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i010e4c0d9c6246be91d37e31d569fa6f_D20210101-20210331" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8yMi9mcmFnOjQwYzU1MTM0ZjY3ODQwMWRiOTAwMjQ2MzdhY2I3M2JkL3RhYmxlOjczNmE5MWNiODI4YzQxZTQ4YjA5NjdjZGJhZmY4MWQzL3RhYmxlcmFuZ2U6NzM2YTkxY2I4MjhjNDFlNDhiMDk2N2NkYmFmZjgxZDNfNC0zLTEtMS0xMDExOTA_51bde540-a258-43b0-a36b-7f8f64e9ac03">1,456.1</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></tbody></table></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See notes to consolidated condensed financial statements.</span></div><div style="margin-top:9pt"><span><br></span></div><div style="margin-top:9pt"><span><br></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><div id="ie8dc61f8e15b44db82ba16050d5b7b44_25"></div><hr style="page-break-after:always"><div style="min-height:27pt;width:100%"><div><span><br></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Condensed Balance Sheets</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ELI LILLY AND COMPANY AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in millions)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:65.424%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.281%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.512%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.283%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Unaudited)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&nbsp;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Current Assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents (Note 6)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib1053442369e460291956c51ab7e5179_I20220331" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8yNS9mcmFnOjVkYTMzMTkwMzcyOTRmYzJiNWY1NDMwYzdkZjViNGIzL3RhYmxlOjYzNTU1YzMxNWQ3ODQ2NzA4ZDE2ODhlYjZmNjRiNmE2L3RhYmxlcmFuZ2U6NjM1NTVjMzE1ZDc4NDY3MDhkMTY4OGViNmY2NGI2YTZfMy0xLTEtMS0xMDExOTA_679c9097-9cf9-4146-852e-3a6552e8ce1e">2,459.2</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iffa7a62ea976465eb0977d320e638511_I20211231" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8yNS9mcmFnOjVkYTMzMTkwMzcyOTRmYzJiNWY1NDMwYzdkZjViNGIzL3RhYmxlOjYzNTU1YzMxNWQ3ODQ2NzA4ZDE2ODhlYjZmNjRiNmE2L3RhYmxlcmFuZ2U6NjM1NTVjMzE1ZDc4NDY3MDhkMTY4OGViNmY2NGI2YTZfMy0zLTEtMS0xMDExOTA_8a150335-b407-46e7-b56c-456572c236f5">3,818.5</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments (Note 6)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib1053442369e460291956c51ab7e5179_I20220331" decimals="-5" name="us-gaap:ShortTermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8yNS9mcmFnOjVkYTMzMTkwMzcyOTRmYzJiNWY1NDMwYzdkZjViNGIzL3RhYmxlOjYzNTU1YzMxNWQ3ODQ2NzA4ZDE2ODhlYjZmNjRiNmE2L3RhYmxlcmFuZ2U6NjM1NTVjMzE1ZDc4NDY3MDhkMTY4OGViNmY2NGI2YTZfNC0xLTEtMS0xMDExOTA_3d0ea82e-8ad6-442f-8eaf-4ac2d8de3d52">109.1</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iffa7a62ea976465eb0977d320e638511_I20211231" decimals="-5" name="us-gaap:ShortTermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8yNS9mcmFnOjVkYTMzMTkwMzcyOTRmYzJiNWY1NDMwYzdkZjViNGIzL3RhYmxlOjYzNTU1YzMxNWQ3ODQ2NzA4ZDE2ODhlYjZmNjRiNmE2L3RhYmxlcmFuZ2U6NjM1NTVjMzE1ZDc4NDY3MDhkMTY4OGViNmY2NGI2YTZfNC0zLTEtMS0xMDExOTA_91aeb97e-2439-4421-93b5-98aba46224f1">90.1</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net of allowances of</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> $<ix:nonfraction unitref="usd" contextref="ib1053442369e460291956c51ab7e5179_I20220331" decimals="-5" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8yNS9mcmFnOjVkYTMzMTkwMzcyOTRmYzJiNWY1NDMwYzdkZjViNGIzL3RhYmxlOjYzNTU1YzMxNWQ3ODQ2NzA4ZDE2ODhlYjZmNjRiNmE2L3RhYmxlcmFuZ2U6NjM1NTVjMzE1ZDc4NDY3MDhkMTY4OGViNmY2NGI2YTZfNS0wLTEtMS0xMDExOTAvdGV4dHJlZ2lvbjo1YTkzN2JjNDdmOTQ0ZDRmOTlmYmQyNmM1ZTI4Y2Y5OV80Ng_7629009e-c529-4634-9d60-64905fb0eb00">22.0</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2022)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> and $<ix:nonfraction unitref="usd" contextref="iffa7a62ea976465eb0977d320e638511_I20211231" decimals="-5" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8yNS9mcmFnOjVkYTMzMTkwMzcyOTRmYzJiNWY1NDMwYzdkZjViNGIzL3RhYmxlOjYzNTU1YzMxNWQ3ODQ2NzA4ZDE2ODhlYjZmNjRiNmE2L3RhYmxlcmFuZ2U6NjM1NTVjMzE1ZDc4NDY3MDhkMTY4OGViNmY2NGI2YTZfNS0wLTEtMS0xMDExOTAvdGV4dHJlZ2lvbjo1YTkzN2JjNDdmOTQ0ZDRmOTlmYmQyNmM1ZTI4Y2Y5OV82MA_f378e8ee-00e6-4c49-9cff-50340620e689">22.5</ix:nonfraction> (2021)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib1053442369e460291956c51ab7e5179_I20220331" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8yNS9mcmFnOjVkYTMzMTkwMzcyOTRmYzJiNWY1NDMwYzdkZjViNGIzL3RhYmxlOjYzNTU1YzMxNWQ3ODQ2NzA4ZDE2ODhlYjZmNjRiNmE2L3RhYmxlcmFuZ2U6NjM1NTVjMzE1ZDc4NDY3MDhkMTY4OGViNmY2NGI2YTZfNS0xLTEtMS0xMDExOTA_92ac9664-60e6-4208-a17e-9b2deab8a24e">6,322.5</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iffa7a62ea976465eb0977d320e638511_I20211231" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8yNS9mcmFnOjVkYTMzMTkwMzcyOTRmYzJiNWY1NDMwYzdkZjViNGIzL3RhYmxlOjYzNTU1YzMxNWQ3ODQ2NzA4ZDE2ODhlYjZmNjRiNmE2L3RhYmxlcmFuZ2U6NjM1NTVjMzE1ZDc4NDY3MDhkMTY4OGViNmY2NGI2YTZfNS0zLTEtMS0xMDExOTA_e13af7bb-896d-4dc6-981b-d57543674cbd">6,672.8</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib1053442369e460291956c51ab7e5179_I20220331" decimals="-5" name="us-gaap:OtherReceivablesNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8yNS9mcmFnOjVkYTMzMTkwMzcyOTRmYzJiNWY1NDMwYzdkZjViNGIzL3RhYmxlOjYzNTU1YzMxNWQ3ODQ2NzA4ZDE2ODhlYjZmNjRiNmE2L3RhYmxlcmFuZ2U6NjM1NTVjMzE1ZDc4NDY3MDhkMTY4OGViNmY2NGI2YTZfNi0xLTEtMS0xMDExOTA_d4ae79f5-c099-4830-8916-0bc27c9ee5a8">1,483.2</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iffa7a62ea976465eb0977d320e638511_I20211231" decimals="-5" name="us-gaap:OtherReceivablesNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8yNS9mcmFnOjVkYTMzMTkwMzcyOTRmYzJiNWY1NDMwYzdkZjViNGIzL3RhYmxlOjYzNTU1YzMxNWQ3ODQ2NzA4ZDE2ODhlYjZmNjRiNmE2L3RhYmxlcmFuZ2U6NjM1NTVjMzE1ZDc4NDY3MDhkMTY4OGViNmY2NGI2YTZfNi0zLTEtMS0xMDExOTA_9161a2c6-a6a9-465e-9d72-d34fdc39100f">1,454.4</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib1053442369e460291956c51ab7e5179_I20220331" decimals="-5" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8yNS9mcmFnOjVkYTMzMTkwMzcyOTRmYzJiNWY1NDMwYzdkZjViNGIzL3RhYmxlOjYzNTU1YzMxNWQ3ODQ2NzA4ZDE2ODhlYjZmNjRiNmE2L3RhYmxlcmFuZ2U6NjM1NTVjMzE1ZDc4NDY3MDhkMTY4OGViNmY2NGI2YTZfNy0xLTEtMS0xMDExOTA_f897858c-212c-4b33-86d8-c8371f88d75b">3,893.0</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iffa7a62ea976465eb0977d320e638511_I20211231" decimals="-5" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8yNS9mcmFnOjVkYTMzMTkwMzcyOTRmYzJiNWY1NDMwYzdkZjViNGIzL3RhYmxlOjYzNTU1YzMxNWQ3ODQ2NzA4ZDE2ODhlYjZmNjRiNmE2L3RhYmxlcmFuZ2U6NjM1NTVjMzE1ZDc4NDY3MDhkMTY4OGViNmY2NGI2YTZfNy0zLTEtMS0xMDExOTA_727e653a-22f3-49be-8dc4-b2d2cdc960fc">3,886.0</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib1053442369e460291956c51ab7e5179_I20220331" decimals="-5" name="us-gaap:PrepaidExpenseCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8yNS9mcmFnOjVkYTMzMTkwMzcyOTRmYzJiNWY1NDMwYzdkZjViNGIzL3RhYmxlOjYzNTU1YzMxNWQ3ODQ2NzA4ZDE2ODhlYjZmNjRiNmE2L3RhYmxlcmFuZ2U6NjM1NTVjMzE1ZDc4NDY3MDhkMTY4OGViNmY2NGI2YTZfOC0xLTEtMS0xMDExOTA_03abeb46-3c62-4196-8c6b-6fd3fa41dcf1">2,697.7</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iffa7a62ea976465eb0977d320e638511_I20211231" decimals="-5" name="us-gaap:PrepaidExpenseCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8yNS9mcmFnOjVkYTMzMTkwMzcyOTRmYzJiNWY1NDMwYzdkZjViNGIzL3RhYmxlOjYzNTU1YzMxNWQ3ODQ2NzA4ZDE2ODhlYjZmNjRiNmE2L3RhYmxlcmFuZ2U6NjM1NTVjMzE1ZDc4NDY3MDhkMTY4OGViNmY2NGI2YTZfOC0zLTEtMS0xMDExOTA_dd51affb-e6cb-48af-a4a5-25eebc99ee95">2,530.6</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib1053442369e460291956c51ab7e5179_I20220331" decimals="-5" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8yNS9mcmFnOjVkYTMzMTkwMzcyOTRmYzJiNWY1NDMwYzdkZjViNGIzL3RhYmxlOjYzNTU1YzMxNWQ3ODQ2NzA4ZDE2ODhlYjZmNjRiNmE2L3RhYmxlcmFuZ2U6NjM1NTVjMzE1ZDc4NDY3MDhkMTY4OGViNmY2NGI2YTZfOS0xLTEtMS0xMDExOTA_1e593de3-a335-4dc7-9d8a-9bba75ef018f">16,964.7</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iffa7a62ea976465eb0977d320e638511_I20211231" decimals="-5" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8yNS9mcmFnOjVkYTMzMTkwMzcyOTRmYzJiNWY1NDMwYzdkZjViNGIzL3RhYmxlOjYzNTU1YzMxNWQ3ODQ2NzA4ZDE2ODhlYjZmNjRiNmE2L3RhYmxlcmFuZ2U6NjM1NTVjMzE1ZDc4NDY3MDhkMTY4OGViNmY2NGI2YTZfOS0zLTEtMS0xMDExOTA_6e9ab023-971a-447c-b2af-e8d062fc72ba">18,452.4</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments (Note 6)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib1053442369e460291956c51ab7e5179_I20220331" decimals="-5" name="us-gaap:LongTermInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8yNS9mcmFnOjVkYTMzMTkwMzcyOTRmYzJiNWY1NDMwYzdkZjViNGIzL3RhYmxlOjYzNTU1YzMxNWQ3ODQ2NzA4ZDE2ODhlYjZmNjRiNmE2L3RhYmxlcmFuZ2U6NjM1NTVjMzE1ZDc4NDY3MDhkMTY4OGViNmY2NGI2YTZfMTAtMS0xLTEtMTAxMTkw_a9535546-1415-40ad-b2a4-9eb2f95e7b80">2,727.3</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iffa7a62ea976465eb0977d320e638511_I20211231" decimals="-5" name="us-gaap:LongTermInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8yNS9mcmFnOjVkYTMzMTkwMzcyOTRmYzJiNWY1NDMwYzdkZjViNGIzL3RhYmxlOjYzNTU1YzMxNWQ3ODQ2NzA4ZDE2ODhlYjZmNjRiNmE2L3RhYmxlcmFuZ2U6NjM1NTVjMzE1ZDc4NDY3MDhkMTY4OGViNmY2NGI2YTZfMTAtMy0xLTEtMTAxMTkw_946e68fc-8f03-4973-a3ee-57a30c058631">3,212.6</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib1053442369e460291956c51ab7e5179_I20220331" decimals="-5" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8yNS9mcmFnOjVkYTMzMTkwMzcyOTRmYzJiNWY1NDMwYzdkZjViNGIzL3RhYmxlOjYzNTU1YzMxNWQ3ODQ2NzA4ZDE2ODhlYjZmNjRiNmE2L3RhYmxlcmFuZ2U6NjM1NTVjMzE1ZDc4NDY3MDhkMTY4OGViNmY2NGI2YTZfMTEtMS0xLTEtMTAxMTkw_adc027ab-abac-468e-804a-c4574ee7c554">3,892.0</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iffa7a62ea976465eb0977d320e638511_I20211231" decimals="-5" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8yNS9mcmFnOjVkYTMzMTkwMzcyOTRmYzJiNWY1NDMwYzdkZjViNGIzL3RhYmxlOjYzNTU1YzMxNWQ3ODQ2NzA4ZDE2ODhlYjZmNjRiNmE2L3RhYmxlcmFuZ2U6NjM1NTVjMzE1ZDc4NDY3MDhkMTY4OGViNmY2NGI2YTZfMTEtMy0xLTEtMTAxMTkw_0e160c1a-cf08-4c6b-8ae9-009480b58d69">3,892.0</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other intangibles, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib1053442369e460291956c51ab7e5179_I20220331" decimals="-5" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8yNS9mcmFnOjVkYTMzMTkwMzcyOTRmYzJiNWY1NDMwYzdkZjViNGIzL3RhYmxlOjYzNTU1YzMxNWQ3ODQ2NzA4ZDE2ODhlYjZmNjRiNmE2L3RhYmxlcmFuZ2U6NjM1NTVjMzE1ZDc4NDY3MDhkMTY4OGViNmY2NGI2YTZfMTItMS0xLTEtMTAxMTkw_ba823ea2-caa3-4e48-929c-e479b0a32a2e">7,482.4</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iffa7a62ea976465eb0977d320e638511_I20211231" decimals="-5" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8yNS9mcmFnOjVkYTMzMTkwMzcyOTRmYzJiNWY1NDMwYzdkZjViNGIzL3RhYmxlOjYzNTU1YzMxNWQ3ODQ2NzA4ZDE2ODhlYjZmNjRiNmE2L3RhYmxlcmFuZ2U6NjM1NTVjMzE1ZDc4NDY3MDhkMTY4OGViNmY2NGI2YTZfMTItMy0xLTEtMTAxMTkw_68db827b-cffb-4011-8f23-9771683dda32">7,691.9</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib1053442369e460291956c51ab7e5179_I20220331" decimals="-5" name="us-gaap:DeferredIncomeTaxAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8yNS9mcmFnOjVkYTMzMTkwMzcyOTRmYzJiNWY1NDMwYzdkZjViNGIzL3RhYmxlOjYzNTU1YzMxNWQ3ODQ2NzA4ZDE2ODhlYjZmNjRiNmE2L3RhYmxlcmFuZ2U6NjM1NTVjMzE1ZDc4NDY3MDhkMTY4OGViNmY2NGI2YTZfMTMtMS0xLTEtMTAxMTkw_0bafe680-bfe4-445b-9d8b-b5862458e498">2,464.9</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iffa7a62ea976465eb0977d320e638511_I20211231" decimals="-5" name="us-gaap:DeferredIncomeTaxAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8yNS9mcmFnOjVkYTMzMTkwMzcyOTRmYzJiNWY1NDMwYzdkZjViNGIzL3RhYmxlOjYzNTU1YzMxNWQ3ODQ2NzA4ZDE2ODhlYjZmNjRiNmE2L3RhYmxlcmFuZ2U6NjM1NTVjMzE1ZDc4NDY3MDhkMTY4OGViNmY2NGI2YTZfMTMtMy0xLTEtMTAxMTkw_213b81bd-d3d8-467e-81ff-1f51da786b04">2,489.3</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net of accumulated depreciation of</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> $<ix:nonfraction unitref="usd" contextref="ib1053442369e460291956c51ab7e5179_I20220331" decimals="-5" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8yNS9mcmFnOjVkYTMzMTkwMzcyOTRmYzJiNWY1NDMwYzdkZjViNGIzL3RhYmxlOjYzNTU1YzMxNWQ3ODQ2NzA4ZDE2ODhlYjZmNjRiNmE2L3RhYmxlcmFuZ2U6NjM1NTVjMzE1ZDc4NDY3MDhkMTY4OGViNmY2NGI2YTZfMTQtMC0xLTEtMTAxMTkwL3RleHRyZWdpb246YTM0NWE4OTdlNTY3NGNiMmEwZTIxMmM3NTYwMTFiYzRfNjM_a5509082-57f3-4bdd-b274-1ff1bcfd324f">10,138.3</ix:nonfraction> (2022) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">and $<ix:nonfraction unitref="usd" contextref="iffa7a62ea976465eb0977d320e638511_I20211231" decimals="-5" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8yNS9mcmFnOjVkYTMzMTkwMzcyOTRmYzJiNWY1NDMwYzdkZjViNGIzL3RhYmxlOjYzNTU1YzMxNWQ3ODQ2NzA4ZDE2ODhlYjZmNjRiNmE2L3RhYmxlcmFuZ2U6NjM1NTVjMzE1ZDc4NDY3MDhkMTY4OGViNmY2NGI2YTZfMTQtMC0xLTEtMTAxMTkwL3RleHRyZWdpb246YTM0NWE4OTdlNTY3NGNiMmEwZTIxMmM3NTYwMTFiYzRfNzc_e305ef21-ed91-454a-9024-9cf34e9ace9e">9,976.7</ix:nonfraction> (2021)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib1053442369e460291956c51ab7e5179_I20220331" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8yNS9mcmFnOjVkYTMzMTkwMzcyOTRmYzJiNWY1NDMwYzdkZjViNGIzL3RhYmxlOjYzNTU1YzMxNWQ3ODQ2NzA4ZDE2ODhlYjZmNjRiNmE2L3RhYmxlcmFuZ2U6NjM1NTVjMzE1ZDc4NDY3MDhkMTY4OGViNmY2NGI2YTZfMTQtMS0xLTEtMTAxMTkw_17846fb1-6516-4cdb-b590-8fe7016c6118">9,102.7</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iffa7a62ea976465eb0977d320e638511_I20211231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8yNS9mcmFnOjVkYTMzMTkwMzcyOTRmYzJiNWY1NDMwYzdkZjViNGIzL3RhYmxlOjYzNTU1YzMxNWQ3ODQ2NzA4ZDE2ODhlYjZmNjRiNmE2L3RhYmxlcmFuZ2U6NjM1NTVjMzE1ZDc4NDY3MDhkMTY4OGViNmY2NGI2YTZfMTQtMy0xLTEtMTAxMTkw_480ff2e6-8b34-4b79-98e7-0be2deb03c82">8,985.1</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib1053442369e460291956c51ab7e5179_I20220331" decimals="-5" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8yNS9mcmFnOjVkYTMzMTkwMzcyOTRmYzJiNWY1NDMwYzdkZjViNGIzL3RhYmxlOjYzNTU1YzMxNWQ3ODQ2NzA4ZDE2ODhlYjZmNjRiNmE2L3RhYmxlcmFuZ2U6NjM1NTVjMzE1ZDc4NDY3MDhkMTY4OGViNmY2NGI2YTZfMTUtMS0xLTEtMTAxMTkw_af28a652-2755-471b-bc0b-e045b3ea1408">4,285.3</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iffa7a62ea976465eb0977d320e638511_I20211231" decimals="-5" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8yNS9mcmFnOjVkYTMzMTkwMzcyOTRmYzJiNWY1NDMwYzdkZjViNGIzL3RhYmxlOjYzNTU1YzMxNWQ3ODQ2NzA4ZDE2ODhlYjZmNjRiNmE2L3RhYmxlcmFuZ2U6NjM1NTVjMzE1ZDc4NDY3MDhkMTY4OGViNmY2NGI2YTZfMTUtMy0xLTEtMTAxMTkw_4ae9a703-e021-45d3-a882-5fbce33aff6e">4,082.7</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib1053442369e460291956c51ab7e5179_I20220331" decimals="-5" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8yNS9mcmFnOjVkYTMzMTkwMzcyOTRmYzJiNWY1NDMwYzdkZjViNGIzL3RhYmxlOjYzNTU1YzMxNWQ3ODQ2NzA4ZDE2ODhlYjZmNjRiNmE2L3RhYmxlcmFuZ2U6NjM1NTVjMzE1ZDc4NDY3MDhkMTY4OGViNmY2NGI2YTZfMTYtMS0xLTEtMTAxMTkw_a44ffb2a-fc5a-44e5-9f27-d062b4328836">46,919.3</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iffa7a62ea976465eb0977d320e638511_I20211231" decimals="-5" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8yNS9mcmFnOjVkYTMzMTkwMzcyOTRmYzJiNWY1NDMwYzdkZjViNGIzL3RhYmxlOjYzNTU1YzMxNWQ3ODQ2NzA4ZDE2ODhlYjZmNjRiNmE2L3RhYmxlcmFuZ2U6NjM1NTVjMzE1ZDc4NDY3MDhkMTY4OGViNmY2NGI2YTZfMTYtMy0xLTEtMTAxMTkw_de97e392-9676-4fcf-ab24-36f876b4063e">48,806.0</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities and Equity</span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Current Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term borrowings and current maturities of long-term debt</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib1053442369e460291956c51ab7e5179_I20220331" decimals="-5" name="us-gaap:DebtCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8yNS9mcmFnOjVkYTMzMTkwMzcyOTRmYzJiNWY1NDMwYzdkZjViNGIzL3RhYmxlOjYzNTU1YzMxNWQ3ODQ2NzA4ZDE2ODhlYjZmNjRiNmE2L3RhYmxlcmFuZ2U6NjM1NTVjMzE1ZDc4NDY3MDhkMTY4OGViNmY2NGI2YTZfMTktMS0xLTEtMTAxMTkw_424f6b7e-c97e-4981-bc58-fc57f515a59d">1,355.9</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iffa7a62ea976465eb0977d320e638511_I20211231" decimals="-5" name="us-gaap:DebtCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8yNS9mcmFnOjVkYTMzMTkwMzcyOTRmYzJiNWY1NDMwYzdkZjViNGIzL3RhYmxlOjYzNTU1YzMxNWQ3ODQ2NzA4ZDE2ODhlYjZmNjRiNmE2L3RhYmxlcmFuZ2U6NjM1NTVjMzE1ZDc4NDY3MDhkMTY4OGViNmY2NGI2YTZfMTktMy0xLTEtMTAxMTkw_87e4f7d5-c7af-4cc2-b1eb-08ad1d42cd3f">1,538.3</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib1053442369e460291956c51ab7e5179_I20220331" decimals="-5" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8yNS9mcmFnOjVkYTMzMTkwMzcyOTRmYzJiNWY1NDMwYzdkZjViNGIzL3RhYmxlOjYzNTU1YzMxNWQ3ODQ2NzA4ZDE2ODhlYjZmNjRiNmE2L3RhYmxlcmFuZ2U6NjM1NTVjMzE1ZDc4NDY3MDhkMTY4OGViNmY2NGI2YTZfMjAtMS0xLTEtMTAxMTkw_92b494eb-c035-4ddd-b2a3-df87a5f28cdd">1,433.3</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iffa7a62ea976465eb0977d320e638511_I20211231" decimals="-5" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8yNS9mcmFnOjVkYTMzMTkwMzcyOTRmYzJiNWY1NDMwYzdkZjViNGIzL3RhYmxlOjYzNTU1YzMxNWQ3ODQ2NzA4ZDE2ODhlYjZmNjRiNmE2L3RhYmxlcmFuZ2U6NjM1NTVjMzE1ZDc4NDY3MDhkMTY4OGViNmY2NGI2YTZfMjAtMy0xLTEtMTAxMTkw_5c79b64c-7390-4a87-b7a2-cc41bc98c442">1,670.6</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib1053442369e460291956c51ab7e5179_I20220331" decimals="-5" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8yNS9mcmFnOjVkYTMzMTkwMzcyOTRmYzJiNWY1NDMwYzdkZjViNGIzL3RhYmxlOjYzNTU1YzMxNWQ3ODQ2NzA4ZDE2ODhlYjZmNjRiNmE2L3RhYmxlcmFuZ2U6NjM1NTVjMzE1ZDc4NDY3MDhkMTY4OGViNmY2NGI2YTZfMjEtMS0xLTEtMTAxMTkw_c37ddbf6-dcf6-46bb-8cec-482597d5a1ba">693.1</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iffa7a62ea976465eb0977d320e638511_I20211231" decimals="-5" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8yNS9mcmFnOjVkYTMzMTkwMzcyOTRmYzJiNWY1NDMwYzdkZjViNGIzL3RhYmxlOjYzNTU1YzMxNWQ3ODQ2NzA4ZDE2ODhlYjZmNjRiNmE2L3RhYmxlcmFuZ2U6NjM1NTVjMzE1ZDc4NDY3MDhkMTY4OGViNmY2NGI2YTZfMjEtMy0xLTEtMTAxMTkw_7cc46de1-fd8e-4646-8519-d0d8605e75d6">958.1</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales rebates and discounts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib1053442369e460291956c51ab7e5179_I20220331" decimals="-5" name="lly:SalesRebatesAndDiscounts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8yNS9mcmFnOjVkYTMzMTkwMzcyOTRmYzJiNWY1NDMwYzdkZjViNGIzL3RhYmxlOjYzNTU1YzMxNWQ3ODQ2NzA4ZDE2ODhlYjZmNjRiNmE2L3RhYmxlcmFuZ2U6NjM1NTVjMzE1ZDc4NDY3MDhkMTY4OGViNmY2NGI2YTZfMjItMS0xLTEtMTAxMTkw_6a978d91-fe1b-4462-9779-ba8bb1c4a1a1">6,768.7</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iffa7a62ea976465eb0977d320e638511_I20211231" decimals="-5" name="lly:SalesRebatesAndDiscounts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8yNS9mcmFnOjVkYTMzMTkwMzcyOTRmYzJiNWY1NDMwYzdkZjViNGIzL3RhYmxlOjYzNTU1YzMxNWQ3ODQ2NzA4ZDE2ODhlYjZmNjRiNmE2L3RhYmxlcmFuZ2U6NjM1NTVjMzE1ZDc4NDY3MDhkMTY4OGViNmY2NGI2YTZfMjItMy0xLTEtMTAxMTkw_8911368e-b104-4078-acc4-8de2810a2119">6,845.8</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib1053442369e460291956c51ab7e5179_I20220331" decimals="-5" name="us-gaap:DividendsPayableCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8yNS9mcmFnOjVkYTMzMTkwMzcyOTRmYzJiNWY1NDMwYzdkZjViNGIzL3RhYmxlOjYzNTU1YzMxNWQ3ODQ2NzA4ZDE2ODhlYjZmNjRiNmE2L3RhYmxlcmFuZ2U6NjM1NTVjMzE1ZDc4NDY3MDhkMTY4OGViNmY2NGI2YTZfMjMtMS0xLTEtMTAxMTkw_6708ee29-a59c-4f28-b849-f82ddc7da36f">—</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iffa7a62ea976465eb0977d320e638511_I20211231" decimals="-5" name="us-gaap:DividendsPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8yNS9mcmFnOjVkYTMzMTkwMzcyOTRmYzJiNWY1NDMwYzdkZjViNGIzL3RhYmxlOjYzNTU1YzMxNWQ3ODQ2NzA4ZDE2ODhlYjZmNjRiNmE2L3RhYmxlcmFuZ2U6NjM1NTVjMzE1ZDc4NDY3MDhkMTY4OGViNmY2NGI2YTZfMjMtMy0xLTEtMTAxMTkw_1f65d9eb-f778-4231-a2bc-08774959dd69">885.5</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib1053442369e460291956c51ab7e5179_I20220331" decimals="-5" name="us-gaap:TaxesPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8yNS9mcmFnOjVkYTMzMTkwMzcyOTRmYzJiNWY1NDMwYzdkZjViNGIzL3RhYmxlOjYzNTU1YzMxNWQ3ODQ2NzA4ZDE2ODhlYjZmNjRiNmE2L3RhYmxlcmFuZ2U6NjM1NTVjMzE1ZDc4NDY3MDhkMTY4OGViNmY2NGI2YTZfMjQtMS0xLTEtMTAxMTkw_2a8ad124-1c45-4963-ae49-6e510a89ec1e">598.3</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iffa7a62ea976465eb0977d320e638511_I20211231" decimals="-5" name="us-gaap:TaxesPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8yNS9mcmFnOjVkYTMzMTkwMzcyOTRmYzJiNWY1NDMwYzdkZjViNGIzL3RhYmxlOjYzNTU1YzMxNWQ3ODQ2NzA4ZDE2ODhlYjZmNjRiNmE2L3RhYmxlcmFuZ2U6NjM1NTVjMzE1ZDc4NDY3MDhkMTY4OGViNmY2NGI2YTZfMjQtMy0xLTEtMTAxMTkw_592a24a9-bfc3-4fc3-a455-27935a0dd7f5">126.9</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib1053442369e460291956c51ab7e5179_I20220331" decimals="-5" name="us-gaap:OtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8yNS9mcmFnOjVkYTMzMTkwMzcyOTRmYzJiNWY1NDMwYzdkZjViNGIzL3RhYmxlOjYzNTU1YzMxNWQ3ODQ2NzA4ZDE2ODhlYjZmNjRiNmE2L3RhYmxlcmFuZ2U6NjM1NTVjMzE1ZDc4NDY3MDhkMTY4OGViNmY2NGI2YTZfMjUtMS0xLTEtMTAxMTkw_34f273fc-a6d7-421c-b09a-6d5f2957c40f">2,536.7</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iffa7a62ea976465eb0977d320e638511_I20211231" decimals="-5" name="us-gaap:OtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8yNS9mcmFnOjVkYTMzMTkwMzcyOTRmYzJiNWY1NDMwYzdkZjViNGIzL3RhYmxlOjYzNTU1YzMxNWQ3ODQ2NzA4ZDE2ODhlYjZmNjRiNmE2L3RhYmxlcmFuZ2U6NjM1NTVjMzE1ZDc4NDY3MDhkMTY4OGViNmY2NGI2YTZfMjUtMy0xLTEtMTAxMTkw_99d63a1a-93e5-4f21-b46a-7adb57b563df">3,027.5</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib1053442369e460291956c51ab7e5179_I20220331" decimals="-5" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8yNS9mcmFnOjVkYTMzMTkwMzcyOTRmYzJiNWY1NDMwYzdkZjViNGIzL3RhYmxlOjYzNTU1YzMxNWQ3ODQ2NzA4ZDE2ODhlYjZmNjRiNmE2L3RhYmxlcmFuZ2U6NjM1NTVjMzE1ZDc4NDY3MDhkMTY4OGViNmY2NGI2YTZfMjYtMS0xLTEtMTAxMTkw_24429443-92d4-4fe5-8b7f-12647fcf478a">13,386.0</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iffa7a62ea976465eb0977d320e638511_I20211231" decimals="-5" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8yNS9mcmFnOjVkYTMzMTkwMzcyOTRmYzJiNWY1NDMwYzdkZjViNGIzL3RhYmxlOjYzNTU1YzMxNWQ3ODQ2NzA4ZDE2ODhlYjZmNjRiNmE2L3RhYmxlcmFuZ2U6NjM1NTVjMzE1ZDc4NDY3MDhkMTY4OGViNmY2NGI2YTZfMjYtMy0xLTEtMTAxMTkw_a4c8ad03-d3f6-444b-a3f7-69a0866b09e7">15,052.7</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib1053442369e460291956c51ab7e5179_I20220331" decimals="-5" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8yNS9mcmFnOjVkYTMzMTkwMzcyOTRmYzJiNWY1NDMwYzdkZjViNGIzL3RhYmxlOjYzNTU1YzMxNWQ3ODQ2NzA4ZDE2ODhlYjZmNjRiNmE2L3RhYmxlcmFuZ2U6NjM1NTVjMzE1ZDc4NDY3MDhkMTY4OGViNmY2NGI2YTZfMjgtMS0xLTEtMTAxMTkw_24598767-5cba-4bc9-9941-8f87e7a689be">15,152.9</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iffa7a62ea976465eb0977d320e638511_I20211231" decimals="-5" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8yNS9mcmFnOjVkYTMzMTkwMzcyOTRmYzJiNWY1NDMwYzdkZjViNGIzL3RhYmxlOjYzNTU1YzMxNWQ3ODQ2NzA4ZDE2ODhlYjZmNjRiNmE2L3RhYmxlcmFuZ2U6NjM1NTVjMzE1ZDc4NDY3MDhkMTY4OGViNmY2NGI2YTZfMjgtMy0xLTEtMTAxMTkw_a13323a9-9a03-4861-ac7f-1e74ec7989c1">15,346.4</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued retirement benefits (Note 8)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib1053442369e460291956c51ab7e5179_I20220331" decimals="-5" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8yNS9mcmFnOjVkYTMzMTkwMzcyOTRmYzJiNWY1NDMwYzdkZjViNGIzL3RhYmxlOjYzNTU1YzMxNWQ3ODQ2NzA4ZDE2ODhlYjZmNjRiNmE2L3RhYmxlcmFuZ2U6NjM1NTVjMzE1ZDc4NDY3MDhkMTY4OGViNmY2NGI2YTZfMjktMS0xLTEtMTAxMTkw_32181d17-e803-4f4d-ade6-e0bd89c80e61">1,940.3</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iffa7a62ea976465eb0977d320e638511_I20211231" decimals="-5" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8yNS9mcmFnOjVkYTMzMTkwMzcyOTRmYzJiNWY1NDMwYzdkZjViNGIzL3RhYmxlOjYzNTU1YzMxNWQ3ODQ2NzA4ZDE2ODhlYjZmNjRiNmE2L3RhYmxlcmFuZ2U6NjM1NTVjMzE1ZDc4NDY3MDhkMTY4OGViNmY2NGI2YTZfMjktMy0xLTEtMTAxMTkw_bf916cf0-38ed-4d56-92e2-54484487a3b1">1,954.1</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term income taxes payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib1053442369e460291956c51ab7e5179_I20220331" decimals="-5" name="us-gaap:AccruedIncomeTaxesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8yNS9mcmFnOjVkYTMzMTkwMzcyOTRmYzJiNWY1NDMwYzdkZjViNGIzL3RhYmxlOjYzNTU1YzMxNWQ3ODQ2NzA4ZDE2ODhlYjZmNjRiNmE2L3RhYmxlcmFuZ2U6NjM1NTVjMzE1ZDc4NDY3MDhkMTY4OGViNmY2NGI2YTZfMzAtMS0xLTEtMTAxMTkw_67cec310-7062-4009-9aed-6583529c45ae">3,978.1</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iffa7a62ea976465eb0977d320e638511_I20211231" decimals="-5" name="us-gaap:AccruedIncomeTaxesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8yNS9mcmFnOjVkYTMzMTkwMzcyOTRmYzJiNWY1NDMwYzdkZjViNGIzL3RhYmxlOjYzNTU1YzMxNWQ3ODQ2NzA4ZDE2ODhlYjZmNjRiNmE2L3RhYmxlcmFuZ2U6NjM1NTVjMzE1ZDc4NDY3MDhkMTY4OGViNmY2NGI2YTZfMzAtMy0xLTEtMTAxMTkw_ec8d9008-b1f6-4d68-b60d-d3cbabbfedf9">3,920.0</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib1053442369e460291956c51ab7e5179_I20220331" decimals="-5" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8yNS9mcmFnOjVkYTMzMTkwMzcyOTRmYzJiNWY1NDMwYzdkZjViNGIzL3RhYmxlOjYzNTU1YzMxNWQ3ODQ2NzA4ZDE2ODhlYjZmNjRiNmE2L3RhYmxlcmFuZ2U6NjM1NTVjMzE1ZDc4NDY3MDhkMTY4OGViNmY2NGI2YTZfMzEtMS0xLTEtMTAxMTkw_eb0b84bd-0d53-44e1-9471-ea6ef7221927">1,286.1</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iffa7a62ea976465eb0977d320e638511_I20211231" decimals="-5" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8yNS9mcmFnOjVkYTMzMTkwMzcyOTRmYzJiNWY1NDMwYzdkZjViNGIzL3RhYmxlOjYzNTU1YzMxNWQ3ODQ2NzA4ZDE2ODhlYjZmNjRiNmE2L3RhYmxlcmFuZ2U6NjM1NTVjMzE1ZDc4NDY3MDhkMTY4OGViNmY2NGI2YTZfMzEtMy0xLTEtMTAxMTkw_4b60fd8b-3f51-4d07-9697-b1faed51b663">1,733.7</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib1053442369e460291956c51ab7e5179_I20220331" decimals="-5" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8yNS9mcmFnOjVkYTMzMTkwMzcyOTRmYzJiNWY1NDMwYzdkZjViNGIzL3RhYmxlOjYzNTU1YzMxNWQ3ODQ2NzA4ZDE2ODhlYjZmNjRiNmE2L3RhYmxlcmFuZ2U6NjM1NTVjMzE1ZDc4NDY3MDhkMTY4OGViNmY2NGI2YTZfMzItMS0xLTEtMTAxMTkw_87f9cf1d-1841-4f31-8ea7-e8db42f4f76a">1,713.9</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iffa7a62ea976465eb0977d320e638511_I20211231" decimals="-5" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8yNS9mcmFnOjVkYTMzMTkwMzcyOTRmYzJiNWY1NDMwYzdkZjViNGIzL3RhYmxlOjYzNTU1YzMxNWQ3ODQ2NzA4ZDE2ODhlYjZmNjRiNmE2L3RhYmxlcmFuZ2U6NjM1NTVjMzE1ZDc4NDY3MDhkMTY4OGViNmY2NGI2YTZfMzItMy0xLTEtMTAxMTkw_4e87efb5-610f-41dc-bba2-a4ba881b88a9">1,644.3</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib1053442369e460291956c51ab7e5179_I20220331" decimals="-5" name="us-gaap:LiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8yNS9mcmFnOjVkYTMzMTkwMzcyOTRmYzJiNWY1NDMwYzdkZjViNGIzL3RhYmxlOjYzNTU1YzMxNWQ3ODQ2NzA4ZDE2ODhlYjZmNjRiNmE2L3RhYmxlcmFuZ2U6NjM1NTVjMzE1ZDc4NDY3MDhkMTY4OGViNmY2NGI2YTZfMzMtMS0xLTEtMTAxMTkw_d8e974bb-e59c-459a-8e71-ac7154203e49">24,071.3</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iffa7a62ea976465eb0977d320e638511_I20211231" decimals="-5" name="us-gaap:LiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8yNS9mcmFnOjVkYTMzMTkwMzcyOTRmYzJiNWY1NDMwYzdkZjViNGIzL3RhYmxlOjYzNTU1YzMxNWQ3ODQ2NzA4ZDE2ODhlYjZmNjRiNmE2L3RhYmxlcmFuZ2U6NjM1NTVjMzE1ZDc4NDY3MDhkMTY4OGViNmY2NGI2YTZfMzMtMy0xLTEtMTAxMTkw_7f035b54-acc7-4f43-9ccc-afc959fd9cc5">24,598.5</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Commitments and Contingencies (Note 9)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonfraction unitref="usd" contextref="ib1053442369e460291956c51ab7e5179_I20220331" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8yNS9mcmFnOjVkYTMzMTkwMzcyOTRmYzJiNWY1NDMwYzdkZjViNGIzL3RhYmxlOjYzNTU1YzMxNWQ3ODQ2NzA4ZDE2ODhlYjZmNjRiNmE2L3RhYmxlcmFuZ2U6NjM1NTVjMzE1ZDc4NDY3MDhkMTY4OGViNmY2NGI2YTZfMzQtMS0xLTEtMTAxMTkw_9e42e8b7-9983-4c60-9e1b-f6e267a49148"></ix:nonfraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonfraction unitref="usd" contextref="iffa7a62ea976465eb0977d320e638511_I20211231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8yNS9mcmFnOjVkYTMzMTkwMzcyOTRmYzJiNWY1NDMwYzdkZjViNGIzL3RhYmxlOjYzNTU1YzMxNWQ3ODQ2NzA4ZDE2ODhlYjZmNjRiNmE2L3RhYmxlcmFuZ2U6NjM1NTVjMzE1ZDc4NDY3MDhkMTY4OGViNmY2NGI2YTZfMzQtMy0xLTEtMTAxMTkw_46835a9d-0909-447c-9e56-32b3cefb629d"></ix:nonfraction></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Eli Lilly and Company Shareholders' Equity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib1053442369e460291956c51ab7e5179_I20220331" decimals="-5" name="us-gaap:CommonStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8yNS9mcmFnOjVkYTMzMTkwMzcyOTRmYzJiNWY1NDMwYzdkZjViNGIzL3RhYmxlOjYzNTU1YzMxNWQ3ODQ2NzA4ZDE2ODhlYjZmNjRiNmE2L3RhYmxlcmFuZ2U6NjM1NTVjMzE1ZDc4NDY3MDhkMTY4OGViNmY2NGI2YTZfMzYtMS0xLTEtMTAxMTkw_627ae05c-1485-404e-9dd9-dfd5c195b17b">594.1</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iffa7a62ea976465eb0977d320e638511_I20211231" decimals="-5" name="us-gaap:CommonStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8yNS9mcmFnOjVkYTMzMTkwMzcyOTRmYzJiNWY1NDMwYzdkZjViNGIzL3RhYmxlOjYzNTU1YzMxNWQ3ODQ2NzA4ZDE2ODhlYjZmNjRiNmE2L3RhYmxlcmFuZ2U6NjM1NTVjMzE1ZDc4NDY3MDhkMTY4OGViNmY2NGI2YTZfMzYtMy0xLTEtMTAxMTkw_4800a823-1d5e-4928-9d8b-6a604420a32f">596.3</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib1053442369e460291956c51ab7e5179_I20220331" decimals="-5" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8yNS9mcmFnOjVkYTMzMTkwMzcyOTRmYzJiNWY1NDMwYzdkZjViNGIzL3RhYmxlOjYzNTU1YzMxNWQ3ODQ2NzA4ZDE2ODhlYjZmNjRiNmE2L3RhYmxlcmFuZ2U6NjM1NTVjMzE1ZDc4NDY3MDhkMTY4OGViNmY2NGI2YTZfMzctMS0xLTEtMTAxMTkw_262fdabb-4ef7-4152-84a5-27f5f91fd762">6,656.3</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iffa7a62ea976465eb0977d320e638511_I20211231" decimals="-5" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8yNS9mcmFnOjVkYTMzMTkwMzcyOTRmYzJiNWY1NDMwYzdkZjViNGIzL3RhYmxlOjYzNTU1YzMxNWQ3ODQ2NzA4ZDE2ODhlYjZmNjRiNmE2L3RhYmxlcmFuZ2U6NjM1NTVjMzE1ZDc4NDY3MDhkMTY4OGViNmY2NGI2YTZfMzctMy0xLTEtMTAxMTkw_b0fdb0f0-f22c-4f85-9b47-a87643db620f">6,833.4</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retained earnings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib1053442369e460291956c51ab7e5179_I20220331" decimals="-5" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8yNS9mcmFnOjVkYTMzMTkwMzcyOTRmYzJiNWY1NDMwYzdkZjViNGIzL3RhYmxlOjYzNTU1YzMxNWQ3ODQ2NzA4ZDE2ODhlYjZmNjRiNmE2L3RhYmxlcmFuZ2U6NjM1NTVjMzE1ZDc4NDY3MDhkMTY4OGViNmY2NGI2YTZfMzgtMS0xLTEtMTAxMTkw_59778728-aeae-47fc-826b-750abdd76f72">9,369.4</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iffa7a62ea976465eb0977d320e638511_I20211231" decimals="-5" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8yNS9mcmFnOjVkYTMzMTkwMzcyOTRmYzJiNWY1NDMwYzdkZjViNGIzL3RhYmxlOjYzNTU1YzMxNWQ3ODQ2NzA4ZDE2ODhlYjZmNjRiNmE2L3RhYmxlcmFuZ2U6NjM1NTVjMzE1ZDc4NDY3MDhkMTY4OGViNmY2NGI2YTZfMzgtMy0xLTEtMTAxMTkw_fa97b5af-a8ac-42c5-b259-fdf1e1b8c9e3">8,958.5</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee benefit trust</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ib1053442369e460291956c51ab7e5179_I20220331" decimals="-5" name="us-gaap:CommonStockSharesHeldInEmployeeTrust" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8yNS9mcmFnOjVkYTMzMTkwMzcyOTRmYzJiNWY1NDMwYzdkZjViNGIzL3RhYmxlOjYzNTU1YzMxNWQ3ODQ2NzA4ZDE2ODhlYjZmNjRiNmE2L3RhYmxlcmFuZ2U6NjM1NTVjMzE1ZDc4NDY3MDhkMTY4OGViNmY2NGI2YTZfMzktMS0xLTEtMTAxMTkw_1cda4ee2-f643-419d-b2d4-e50919e554ea">3,013.2</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="iffa7a62ea976465eb0977d320e638511_I20211231" decimals="-5" name="us-gaap:CommonStockSharesHeldInEmployeeTrust" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8yNS9mcmFnOjVkYTMzMTkwMzcyOTRmYzJiNWY1NDMwYzdkZjViNGIzL3RhYmxlOjYzNTU1YzMxNWQ3ODQ2NzA4ZDE2ODhlYjZmNjRiNmE2L3RhYmxlcmFuZ2U6NjM1NTVjMzE1ZDc4NDY3MDhkMTY4OGViNmY2NGI2YTZfMzktMy0xLTEtMTAxMTkw_3ff6c991-ec76-4a58-81b5-5c734d83477c">3,013.2</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss (Note 10)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ib1053442369e460291956c51ab7e5179_I20220331" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8yNS9mcmFnOjVkYTMzMTkwMzcyOTRmYzJiNWY1NDMwYzdkZjViNGIzL3RhYmxlOjYzNTU1YzMxNWQ3ODQ2NzA4ZDE2ODhlYjZmNjRiNmE2L3RhYmxlcmFuZ2U6NjM1NTVjMzE1ZDc4NDY3MDhkMTY4OGViNmY2NGI2YTZfNDAtMS0xLTEtMTAxMTkw_f1621007-a38e-4b35-a888-700870d7e536">4,225.3</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="iffa7a62ea976465eb0977d320e638511_I20211231" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8yNS9mcmFnOjVkYTMzMTkwMzcyOTRmYzJiNWY1NDMwYzdkZjViNGIzL3RhYmxlOjYzNTU1YzMxNWQ3ODQ2NzA4ZDE2ODhlYjZmNjRiNmE2L3RhYmxlcmFuZ2U6NjM1NTVjMzE1ZDc4NDY3MDhkMTY4OGViNmY2NGI2YTZfNDAtMy0xLTEtMTAxMTkw_b2316cd7-787d-483c-b640-631fbdb92d94">4,343.1</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of common stock in treasury</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ib1053442369e460291956c51ab7e5179_I20220331" decimals="-5" name="us-gaap:TreasuryStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8yNS9mcmFnOjVkYTMzMTkwMzcyOTRmYzJiNWY1NDMwYzdkZjViNGIzL3RhYmxlOjYzNTU1YzMxNWQ3ODQ2NzA4ZDE2ODhlYjZmNjRiNmE2L3RhYmxlcmFuZ2U6NjM1NTVjMzE1ZDc4NDY3MDhkMTY4OGViNmY2NGI2YTZfNDEtMS0xLTEtMTAxMTkw_5b51ee6b-629d-4ab7-bdff-775e40e50280">50.5</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="iffa7a62ea976465eb0977d320e638511_I20211231" decimals="-5" name="us-gaap:TreasuryStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8yNS9mcmFnOjVkYTMzMTkwMzcyOTRmYzJiNWY1NDMwYzdkZjViNGIzL3RhYmxlOjYzNTU1YzMxNWQ3ODQ2NzA4ZDE2ODhlYjZmNjRiNmE2L3RhYmxlcmFuZ2U6NjM1NTVjMzE1ZDc4NDY3MDhkMTY4OGViNmY2NGI2YTZfNDEtMy0xLTEtMTAxMTkw_2cfe07d0-ec91-444e-ab1f-17d5d7463c8d">52.7</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Eli Lilly and Company shareholders' equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib1053442369e460291956c51ab7e5179_I20220331" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8yNS9mcmFnOjVkYTMzMTkwMzcyOTRmYzJiNWY1NDMwYzdkZjViNGIzL3RhYmxlOjYzNTU1YzMxNWQ3ODQ2NzA4ZDE2ODhlYjZmNjRiNmE2L3RhYmxlcmFuZ2U6NjM1NTVjMzE1ZDc4NDY3MDhkMTY4OGViNmY2NGI2YTZfNDItMS0xLTEtMTAxMTkw_e842ddaa-6f45-4acb-8950-5a1784bec140">9,330.8</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iffa7a62ea976465eb0977d320e638511_I20211231" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8yNS9mcmFnOjVkYTMzMTkwMzcyOTRmYzJiNWY1NDMwYzdkZjViNGIzL3RhYmxlOjYzNTU1YzMxNWQ3ODQ2NzA4ZDE2ODhlYjZmNjRiNmE2L3RhYmxlcmFuZ2U6NjM1NTVjMzE1ZDc4NDY3MDhkMTY4OGViNmY2NGI2YTZfNDItMy0xLTEtMTAxMTkw_ff8e62d5-9e2f-402b-b68f-96c5fa02a4b2">8,979.2</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib1053442369e460291956c51ab7e5179_I20220331" decimals="-5" name="us-gaap:MinorityInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8yNS9mcmFnOjVkYTMzMTkwMzcyOTRmYzJiNWY1NDMwYzdkZjViNGIzL3RhYmxlOjYzNTU1YzMxNWQ3ODQ2NzA4ZDE2ODhlYjZmNjRiNmE2L3RhYmxlcmFuZ2U6NjM1NTVjMzE1ZDc4NDY3MDhkMTY4OGViNmY2NGI2YTZfNDMtMS0xLTEtMTAxMTkw_b7346e33-6f2b-47b2-ad2b-83460424955e">131.2</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iffa7a62ea976465eb0977d320e638511_I20211231" decimals="-5" name="us-gaap:MinorityInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8yNS9mcmFnOjVkYTMzMTkwMzcyOTRmYzJiNWY1NDMwYzdkZjViNGIzL3RhYmxlOjYzNTU1YzMxNWQ3ODQ2NzA4ZDE2ODhlYjZmNjRiNmE2L3RhYmxlcmFuZ2U6NjM1NTVjMzE1ZDc4NDY3MDhkMTY4OGViNmY2NGI2YTZfNDMtMy0xLTEtMTAxMTkw_6a184cf4-0639-4543-864e-240395a099ce">175.6</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib1053442369e460291956c51ab7e5179_I20220331" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8yNS9mcmFnOjVkYTMzMTkwMzcyOTRmYzJiNWY1NDMwYzdkZjViNGIzL3RhYmxlOjYzNTU1YzMxNWQ3ODQ2NzA4ZDE2ODhlYjZmNjRiNmE2L3RhYmxlcmFuZ2U6NjM1NTVjMzE1ZDc4NDY3MDhkMTY4OGViNmY2NGI2YTZfNDQtMS0xLTEtMTAxMTkw_527f6cee-9758-4d8e-be7d-9bb81f1241a8">9,462.0</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iffa7a62ea976465eb0977d320e638511_I20211231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8yNS9mcmFnOjVkYTMzMTkwMzcyOTRmYzJiNWY1NDMwYzdkZjViNGIzL3RhYmxlOjYzNTU1YzMxNWQ3ODQ2NzA4ZDE2ODhlYjZmNjRiNmE2L3RhYmxlcmFuZ2U6NjM1NTVjMzE1ZDc4NDY3MDhkMTY4OGViNmY2NGI2YTZfNDQtMy0xLTEtMTAxMTkw_73384969-adb1-45b4-9f36-b566d6a23188">9,154.8</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and equity</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib1053442369e460291956c51ab7e5179_I20220331" decimals="-5" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8yNS9mcmFnOjVkYTMzMTkwMzcyOTRmYzJiNWY1NDMwYzdkZjViNGIzL3RhYmxlOjYzNTU1YzMxNWQ3ODQ2NzA4ZDE2ODhlYjZmNjRiNmE2L3RhYmxlcmFuZ2U6NjM1NTVjMzE1ZDc4NDY3MDhkMTY4OGViNmY2NGI2YTZfNDUtMS0xLTEtMTAxMTkw_1b519416-6d38-426b-9cd9-b7f0090ec735">46,919.3</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iffa7a62ea976465eb0977d320e638511_I20211231" decimals="-5" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8yNS9mcmFnOjVkYTMzMTkwMzcyOTRmYzJiNWY1NDMwYzdkZjViNGIzL3RhYmxlOjYzNTU1YzMxNWQ3ODQ2NzA4ZDE2ODhlYjZmNjRiNmE2L3RhYmxlcmFuZ2U6NjM1NTVjMzE1ZDc4NDY3MDhkMTY4OGViNmY2NGI2YTZfNDUtMy0xLTEtMTAxMTkw_871d20da-3db1-44ee-ace8-a114125da63c">48,806.0</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See notes to consolidated condensed financial statements.</span></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><div id="ie8dc61f8e15b44db82ba16050d5b7b44_28"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span><br></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Condensed Statements of Equity</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ELI LILLY AND COMPANY AND SUBSIDIARIES</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:24.630%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.917%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.917%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.917%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.917%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.917%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.917%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.917%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.270%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="45" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Equity of Eli Lilly and Company Shareholders</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:18pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%"><br></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">(Dollars in millions and shares in thousands)</span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Additional<br>Paid-in<br>Capital</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Retained<br>Earnings</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Employee Benefit Trust</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Loss</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Common Stock in Treasury</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Noncontrolling Interests</span></td></tr><tr style="height:11pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Balance at January 1, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="shares" contextref="i534904bdfd54461a96c8246d9ecc70a8_I20201231" decimals="-3" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8yOC9mcmFnOjJmNjA5MWNkMjk1MzQwMDg5MGIyYTY3MWE1M2EwYzFkL3RhYmxlOjkyZmUwNzRlYjY2YjQzZDk5ZWEwYjQ1NDE4ZTJlNWMzL3RhYmxlcmFuZ2U6OTJmZTA3NGViNjZiNDNkOTllYTBiNDU0MThlMmU1YzNfMy0xLTEtMS0xMDExOTA_9e8d9794-be26-44c8-b916-1fc6f1dcc2f2">957,077</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i534904bdfd54461a96c8246d9ecc70a8_I20201231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8yOC9mcmFnOjJmNjA5MWNkMjk1MzQwMDg5MGIyYTY3MWE1M2EwYzFkL3RhYmxlOjkyZmUwNzRlYjY2YjQzZDk5ZWEwYjQ1NDE4ZTJlNWMzL3RhYmxlcmFuZ2U6OTJmZTA3NGViNjZiNDNkOTllYTBiNDU0MThlMmU1YzNfMy0zLTEtMS0xMDExOTA_dc3ddb8a-f0a2-4eed-be48-dbbb872f8799">598.2</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ia0c7ddea27a44153823f015b89b454d2_I20201231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8yOC9mcmFnOjJmNjA5MWNkMjk1MzQwMDg5MGIyYTY3MWE1M2EwYzFkL3RhYmxlOjkyZmUwNzRlYjY2YjQzZDk5ZWEwYjQ1NDE4ZTJlNWMzL3RhYmxlcmFuZ2U6OTJmZTA3NGViNjZiNDNkOTllYTBiNDU0MThlMmU1YzNfMy01LTEtMS0xMDExOTA_504676dd-e349-41e1-8086-2482901eee5f">6,778.5</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i8c89a157b3794bb4a87d54334813d68c_I20201231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8yOC9mcmFnOjJmNjA5MWNkMjk1MzQwMDg5MGIyYTY3MWE1M2EwYzFkL3RhYmxlOjkyZmUwNzRlYjY2YjQzZDk5ZWEwYjQ1NDE4ZTJlNWMzL3RhYmxlcmFuZ2U6OTJmZTA3NGViNjZiNDNkOTllYTBiNDU0MThlMmU1YzNfMy03LTEtMS0xMDExOTA_19847f7f-c718-4847-98f1-6e7b11a941c7">7,830.2</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i772d16d39bc747f3b52c1924fa4b03f4_I20201231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8yOC9mcmFnOjJmNjA5MWNkMjk1MzQwMDg5MGIyYTY3MWE1M2EwYzFkL3RhYmxlOjkyZmUwNzRlYjY2YjQzZDk5ZWEwYjQ1NDE4ZTJlNWMzL3RhYmxlcmFuZ2U6OTJmZTA3NGViNjZiNDNkOTllYTBiNDU0MThlMmU1YzNfMy05LTEtMS0xMDExOTA_dd4752fa-fe95-4871-aa94-9a6c28d9e695">3,013.2</ix:nonfraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ibc022718ed034b20a63b39dfdbaab09e_I20201231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8yOC9mcmFnOjJmNjA5MWNkMjk1MzQwMDg5MGIyYTY3MWE1M2EwYzFkL3RhYmxlOjkyZmUwNzRlYjY2YjQzZDk5ZWEwYjQ1NDE4ZTJlNWMzL3RhYmxlcmFuZ2U6OTJmZTA3NGViNjZiNDNkOTllYTBiNDU0MThlMmU1YzNfMy0xMS0xLTEtMTAxMTkw_94635678-8b31-44f5-a778-bab86e38b156">6,496.4</ix:nonfraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="shares" contextref="i4f2f3e9efb184f4f98baa286d8701507_I20201231" decimals="-3" name="us-gaap:SharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8yOC9mcmFnOjJmNjA5MWNkMjk1MzQwMDg5MGIyYTY3MWE1M2EwYzFkL3RhYmxlOjkyZmUwNzRlYjY2YjQzZDk5ZWEwYjQ1NDE4ZTJlNWMzL3RhYmxlcmFuZ2U6OTJmZTA3NGViNjZiNDNkOTllYTBiNDU0MThlMmU1YzNfMy0xMy0xLTEtMTAxMTkw_9ca0db70-78ce-487e-82a1-58feb5efbd73">487</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i4f2f3e9efb184f4f98baa286d8701507_I20201231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8yOC9mcmFnOjJmNjA5MWNkMjk1MzQwMDg5MGIyYTY3MWE1M2EwYzFkL3RhYmxlOjkyZmUwNzRlYjY2YjQzZDk5ZWEwYjQ1NDE4ZTJlNWMzL3RhYmxlcmFuZ2U6OTJmZTA3NGViNjZiNDNkOTllYTBiNDU0MThlMmU1YzNfMy0xNS0xLTEtMTAxMTkw_1eab1afb-d765-4ee4-9e0a-107525537674">55.7</ix:nonfraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="id798b7917b9b4678a259c1039255b282_I20201231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8yOC9mcmFnOjJmNjA5MWNkMjk1MzQwMDg5MGIyYTY3MWE1M2EwYzFkL3RhYmxlOjkyZmUwNzRlYjY2YjQzZDk5ZWEwYjQ1NDE4ZTJlNWMzL3RhYmxlcmFuZ2U6OTJmZTA3NGViNjZiNDNkOTllYTBiNDU0MThlMmU1YzNfMy0xNy0xLTEtMTAxMTkw_380b28e1-d782-44e5-9441-16cbf81d2a67">183.6</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net income </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i420cdd7778cf4462a35b8db230d54b8c_D20210101-20210331" decimals="-5" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8yOC9mcmFnOjJmNjA5MWNkMjk1MzQwMDg5MGIyYTY3MWE1M2EwYzFkL3RhYmxlOjkyZmUwNzRlYjY2YjQzZDk5ZWEwYjQ1NDE4ZTJlNWMzL3RhYmxlcmFuZ2U6OTJmZTA3NGViNjZiNDNkOTllYTBiNDU0MThlMmU1YzNfNC03LTEtMS0xMDExOTA_3f275eac-1f4c-4db0-868e-4d2a18988d5a">1,355.3</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="icc3c1daa2c764c54a41ee942bc243ab1_D20210101-20210331" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8yOC9mcmFnOjJmNjA5MWNkMjk1MzQwMDg5MGIyYTY3MWE1M2EwYzFkL3RhYmxlOjkyZmUwNzRlYjY2YjQzZDk5ZWEwYjQ1NDE4ZTJlNWMzL3RhYmxlcmFuZ2U6OTJmZTA3NGViNjZiNDNkOTllYTBiNDU0MThlMmU1YzNfNC0xNy0xLTEtMTAxMTkw_5ecd38ae-9c19-4a54-88f5-7e3f778ac86e">16.4</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other comprehensive income, net of tax</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i041885a980a34f59af3596c66d307967_D20210101-20210331" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8yOC9mcmFnOjJmNjA5MWNkMjk1MzQwMDg5MGIyYTY3MWE1M2EwYzFkL3RhYmxlOjkyZmUwNzRlYjY2YjQzZDk5ZWEwYjQ1NDE4ZTJlNWMzL3RhYmxlcmFuZ2U6OTJmZTA3NGViNjZiNDNkOTllYTBiNDU0MThlMmU1YzNfNS0xMS0xLTEtMTAxMTkw_1e1b1690-a783-4a44-92d1-36c2bf06520d">100.8</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Issuance of stock under employee stock plans, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="shares" contextref="i407fee31623f400291c46f875a97958b_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8yOC9mcmFnOjJmNjA5MWNkMjk1MzQwMDg5MGIyYTY3MWE1M2EwYzFkL3RhYmxlOjkyZmUwNzRlYjY2YjQzZDk5ZWEwYjQ1NDE4ZTJlNWMzL3RhYmxlcmFuZ2U6OTJmZTA3NGViNjZiNDNkOTllYTBiNDU0MThlMmU1YzNfOS0xLTEtMS0xMDExOTA_9afc3923-55d6-49bb-9268-f11d9f7f66b9">2,405</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i407fee31623f400291c46f875a97958b_D20210101-20210331" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8yOC9mcmFnOjJmNjA5MWNkMjk1MzQwMDg5MGIyYTY3MWE1M2EwYzFkL3RhYmxlOjkyZmUwNzRlYjY2YjQzZDk5ZWEwYjQ1NDE4ZTJlNWMzL3RhYmxlcmFuZ2U6OTJmZTA3NGViNjZiNDNkOTllYTBiNDU0MThlMmU1YzNfOS0zLTEtMS0xMDExOTA_41800342-dfab-44bc-8b41-84704ce86d72">1.5</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ib3b7204e3e6b45bc9b035264afbac130_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8yOC9mcmFnOjJmNjA5MWNkMjk1MzQwMDg5MGIyYTY3MWE1M2EwYzFkL3RhYmxlOjkyZmUwNzRlYjY2YjQzZDk5ZWEwYjQ1NDE4ZTJlNWMzL3RhYmxlcmFuZ2U6OTJmZTA3NGViNjZiNDNkOTllYTBiNDU0MThlMmU1YzNfOS01LTEtMS0xMDExOTA_960e0b2b-3d83-4822-8587-d9e02e3208a1">283.9</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="shares" contextref="i8b5503f2535d42608e7025a646f79443_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8yOC9mcmFnOjJmNjA5MWNkMjk1MzQwMDg5MGIyYTY3MWE1M2EwYzFkL3RhYmxlOjkyZmUwNzRlYjY2YjQzZDk5ZWEwYjQ1NDE4ZTJlNWMzL3RhYmxlcmFuZ2U6OTJmZTA3NGViNjZiNDNkOTllYTBiNDU0MThlMmU1YzNfOS0xMy0xLTEtMTAxMTkw_37052af5-732c-44cb-b715-8ad2eed79aea">24</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i8b5503f2535d42608e7025a646f79443_D20210101-20210331" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8yOC9mcmFnOjJmNjA5MWNkMjk1MzQwMDg5MGIyYTY3MWE1M2EwYzFkL3RhYmxlOjkyZmUwNzRlYjY2YjQzZDk5ZWEwYjQ1NDE4ZTJlNWMzL3RhYmxlcmFuZ2U6OTJmZTA3NGViNjZiNDNkOTllYTBiNDU0MThlMmU1YzNfOS0xNS0xLTEtMTAxMTkw_f9c72662-4ccf-4468-9557-47b2c8adf885">3.0</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib3b7204e3e6b45bc9b035264afbac130_D20210101-20210331" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8yOC9mcmFnOjJmNjA5MWNkMjk1MzQwMDg5MGIyYTY3MWE1M2EwYzFkL3RhYmxlOjkyZmUwNzRlYjY2YjQzZDk5ZWEwYjQ1NDE4ZTJlNWMzL3RhYmxlcmFuZ2U6OTJmZTA3NGViNjZiNDNkOTllYTBiNDU0MThlMmU1YzNfMTAtNS0xLTEtMTAxMTkw_b5a4e8fe-25fa-46dc-9129-101f58fa21a9">85.5</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ib3b7204e3e6b45bc9b035264afbac130_D20210101-20210331" decimals="-5" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8yOC9mcmFnOjJmNjA5MWNkMjk1MzQwMDg5MGIyYTY3MWE1M2EwYzFkL3RhYmxlOjkyZmUwNzRlYjY2YjQzZDk5ZWEwYjQ1NDE4ZTJlNWMzL3RhYmxlcmFuZ2U6OTJmZTA3NGViNjZiNDNkOTllYTBiNDU0MThlMmU1YzNfMTMtNS0xLTEtMTAxMTkw_ec571844-1596-480b-b60a-8748d75d2ee5">0.9</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i420cdd7778cf4462a35b8db230d54b8c_D20210101-20210331" decimals="-5" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8yOC9mcmFnOjJmNjA5MWNkMjk1MzQwMDg5MGIyYTY3MWE1M2EwYzFkL3RhYmxlOjkyZmUwNzRlYjY2YjQzZDk5ZWEwYjQ1NDE4ZTJlNWMzL3RhYmxlcmFuZ2U6OTJmZTA3NGViNjZiNDNkOTllYTBiNDU0MThlMmU1YzNfMTMtNy0xLTEtMTAxMTkw_80ec48f2-cb81-45b0-892b-b492a3f5ddcd">4.2</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="icc3c1daa2c764c54a41ee942bc243ab1_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8yOC9mcmFnOjJmNjA5MWNkMjk1MzQwMDg5MGIyYTY3MWE1M2EwYzFkL3RhYmxlOjkyZmUwNzRlYjY2YjQzZDk5ZWEwYjQ1NDE4ZTJlNWMzL3RhYmxlcmFuZ2U6OTJmZTA3NGViNjZiNDNkOTllYTBiNDU0MThlMmU1YzNfMTMtMTctMS0xLTEwMTE5MA_5b686475-d280-4ec7-b2af-85ece34435d0">0.6</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Balance at March 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="shares" contextref="ia9a1b635649a4926ae3309c4ec3d6d3e_I20210331" decimals="-3" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8yOC9mcmFnOjJmNjA5MWNkMjk1MzQwMDg5MGIyYTY3MWE1M2EwYzFkL3RhYmxlOjkyZmUwNzRlYjY2YjQzZDk5ZWEwYjQ1NDE4ZTJlNWMzL3RhYmxlcmFuZ2U6OTJmZTA3NGViNjZiNDNkOTllYTBiNDU0MThlMmU1YzNfMTQtMS0xLTEtMTAxMTkw_0d0cd7ff-63bf-410f-9459-9541879c4e3d">959,482</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ia9a1b635649a4926ae3309c4ec3d6d3e_I20210331" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8yOC9mcmFnOjJmNjA5MWNkMjk1MzQwMDg5MGIyYTY3MWE1M2EwYzFkL3RhYmxlOjkyZmUwNzRlYjY2YjQzZDk5ZWEwYjQ1NDE4ZTJlNWMzL3RhYmxlcmFuZ2U6OTJmZTA3NGViNjZiNDNkOTllYTBiNDU0MThlMmU1YzNfMTQtMy0xLTEtMTAxMTkw_9723ba2c-6605-4401-b7fd-0c4f0fb9a906">599.7</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i35667239b18f436bab294df329c038eb_I20210331" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8yOC9mcmFnOjJmNjA5MWNkMjk1MzQwMDg5MGIyYTY3MWE1M2EwYzFkL3RhYmxlOjkyZmUwNzRlYjY2YjQzZDk5ZWEwYjQ1NDE4ZTJlNWMzL3RhYmxlcmFuZ2U6OTJmZTA3NGViNjZiNDNkOTllYTBiNDU0MThlMmU1YzNfMTQtNS0xLTEtMTAxMTkw_4630d981-af75-491d-9a96-d308f488f583">6,579.2</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i25fe75417da64029ba77ae08f2d45d8a_I20210331" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8yOC9mcmFnOjJmNjA5MWNkMjk1MzQwMDg5MGIyYTY3MWE1M2EwYzFkL3RhYmxlOjkyZmUwNzRlYjY2YjQzZDk5ZWEwYjQ1NDE4ZTJlNWMzL3RhYmxlcmFuZ2U6OTJmZTA3NGViNjZiNDNkOTllYTBiNDU0MThlMmU1YzNfMTQtNy0xLTEtMTAxMTkw_c35365a5-a80d-40dc-9330-c2f013759a4f">9,181.3</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i07fd33c4c9cb41beacedf6f5d24cee4c_I20210331" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8yOC9mcmFnOjJmNjA5MWNkMjk1MzQwMDg5MGIyYTY3MWE1M2EwYzFkL3RhYmxlOjkyZmUwNzRlYjY2YjQzZDk5ZWEwYjQ1NDE4ZTJlNWMzL3RhYmxlcmFuZ2U6OTJmZTA3NGViNjZiNDNkOTllYTBiNDU0MThlMmU1YzNfMTQtOS0xLTEtMTAxMTkw_ad7edc47-7f3e-47f2-a19e-e2600ed64093">3,013.2</ix:nonfraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i43c105aca7e240178d0e89d09a70ed9b_I20210331" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8yOC9mcmFnOjJmNjA5MWNkMjk1MzQwMDg5MGIyYTY3MWE1M2EwYzFkL3RhYmxlOjkyZmUwNzRlYjY2YjQzZDk5ZWEwYjQ1NDE4ZTJlNWMzL3RhYmxlcmFuZ2U6OTJmZTA3NGViNjZiNDNkOTllYTBiNDU0MThlMmU1YzNfMTQtMTEtMS0xLTEwMTE5MA_5ef1f213-405e-40db-a522-025e02d77773">6,395.6</ix:nonfraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="shares" contextref="i73779719d6ac41d18122c2bfb22f722b_I20210331" decimals="-3" name="us-gaap:SharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8yOC9mcmFnOjJmNjA5MWNkMjk1MzQwMDg5MGIyYTY3MWE1M2EwYzFkL3RhYmxlOjkyZmUwNzRlYjY2YjQzZDk5ZWEwYjQ1NDE4ZTJlNWMzL3RhYmxlcmFuZ2U6OTJmZTA3NGViNjZiNDNkOTllYTBiNDU0MThlMmU1YzNfMTQtMTMtMS0xLTEwMTE5MA_ef14de08-088f-4d7f-8d80-eafe6e77ab98">463</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i73779719d6ac41d18122c2bfb22f722b_I20210331" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8yOC9mcmFnOjJmNjA5MWNkMjk1MzQwMDg5MGIyYTY3MWE1M2EwYzFkL3RhYmxlOjkyZmUwNzRlYjY2YjQzZDk5ZWEwYjQ1NDE4ZTJlNWMzL3RhYmxlcmFuZ2U6OTJmZTA3NGViNjZiNDNkOTllYTBiNDU0MThlMmU1YzNfMTQtMTUtMS0xLTEwMTE5MA_6ad9bcf5-93b3-47b3-a3f9-8431e3942604">52.7</ix:nonfraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i55bb63e488ea4862b4eeacafc3d16d3a_I20210331" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8yOC9mcmFnOjJmNjA5MWNkMjk1MzQwMDg5MGIyYTY3MWE1M2EwYzFkL3RhYmxlOjkyZmUwNzRlYjY2YjQzZDk5ZWEwYjQ1NDE4ZTJlNWMzL3RhYmxlcmFuZ2U6OTJmZTA3NGViNjZiNDNkOTllYTBiNDU0MThlMmU1YzNfMTQtMTctMS0xLTEwMTE5MA_cb92b8b3-b14f-4d4f-8604-b6cbfd77f978">200.6</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Balance at January 1, 2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="shares" contextref="i2f171c9c0764435596b9addbf3a3c7b8_I20211231" decimals="-3" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8yOC9mcmFnOjJmNjA5MWNkMjk1MzQwMDg5MGIyYTY3MWE1M2EwYzFkL3RhYmxlOjkyZmUwNzRlYjY2YjQzZDk5ZWEwYjQ1NDE4ZTJlNWMzL3RhYmxlcmFuZ2U6OTJmZTA3NGViNjZiNDNkOTllYTBiNDU0MThlMmU1YzNfMTYtMS0xLTEtMTAxMTkw_9190108e-27fb-48af-b6b2-66a2cc4ae214">954,116</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i2f171c9c0764435596b9addbf3a3c7b8_I20211231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8yOC9mcmFnOjJmNjA5MWNkMjk1MzQwMDg5MGIyYTY3MWE1M2EwYzFkL3RhYmxlOjkyZmUwNzRlYjY2YjQzZDk5ZWEwYjQ1NDE4ZTJlNWMzL3RhYmxlcmFuZ2U6OTJmZTA3NGViNjZiNDNkOTllYTBiNDU0MThlMmU1YzNfMTYtMy0xLTEtMTAxMTkw_929d2c02-0440-4e05-ae86-12fc8fb8dc04">596.3</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i763e2843c67f427eb4dbedd59fd94c83_I20211231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8yOC9mcmFnOjJmNjA5MWNkMjk1MzQwMDg5MGIyYTY3MWE1M2EwYzFkL3RhYmxlOjkyZmUwNzRlYjY2YjQzZDk5ZWEwYjQ1NDE4ZTJlNWMzL3RhYmxlcmFuZ2U6OTJmZTA3NGViNjZiNDNkOTllYTBiNDU0MThlMmU1YzNfMTYtNS0xLTEtMTAxMTkw_2490bcc4-469b-4360-83c9-db068ae47a99">6,833.4</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="iddd8001ab87f416891d32f32378a1ff8_I20211231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8yOC9mcmFnOjJmNjA5MWNkMjk1MzQwMDg5MGIyYTY3MWE1M2EwYzFkL3RhYmxlOjkyZmUwNzRlYjY2YjQzZDk5ZWEwYjQ1NDE4ZTJlNWMzL3RhYmxlcmFuZ2U6OTJmZTA3NGViNjZiNDNkOTllYTBiNDU0MThlMmU1YzNfMTYtNy0xLTEtMTAxMTkw_4158bbfe-09a6-4911-a6bc-570680e12723">8,958.5</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i6752266e758d4a55b13ba7aa88a4106d_I20211231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8yOC9mcmFnOjJmNjA5MWNkMjk1MzQwMDg5MGIyYTY3MWE1M2EwYzFkL3RhYmxlOjkyZmUwNzRlYjY2YjQzZDk5ZWEwYjQ1NDE4ZTJlNWMzL3RhYmxlcmFuZ2U6OTJmZTA3NGViNjZiNDNkOTllYTBiNDU0MThlMmU1YzNfMTYtOS0xLTEtMTAxMTkw_1d1505c2-a60a-4bdf-9e68-dec885ee4c60">3,013.2</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i1ff16206b6b0437e95e85f0c0dc79f0b_I20211231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8yOC9mcmFnOjJmNjA5MWNkMjk1MzQwMDg5MGIyYTY3MWE1M2EwYzFkL3RhYmxlOjkyZmUwNzRlYjY2YjQzZDk5ZWEwYjQ1NDE4ZTJlNWMzL3RhYmxlcmFuZ2U6OTJmZTA3NGViNjZiNDNkOTllYTBiNDU0MThlMmU1YzNfMTYtMTEtMS0xLTEwMTE5MA_1da3a50c-0423-4865-84ce-977dfab72186">4,343.1</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="shares" contextref="i44a742d79dc140ca9d6192f1c85ec4f6_I20211231" decimals="-3" name="us-gaap:SharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8yOC9mcmFnOjJmNjA5MWNkMjk1MzQwMDg5MGIyYTY3MWE1M2EwYzFkL3RhYmxlOjkyZmUwNzRlYjY2YjQzZDk5ZWEwYjQ1NDE4ZTJlNWMzL3RhYmxlcmFuZ2U6OTJmZTA3NGViNjZiNDNkOTllYTBiNDU0MThlMmU1YzNfMTYtMTMtMS0xLTEwMTE5MA_914312d4-bc12-4d93-b403-e20b8cff77b4">463</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i44a742d79dc140ca9d6192f1c85ec4f6_I20211231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8yOC9mcmFnOjJmNjA5MWNkMjk1MzQwMDg5MGIyYTY3MWE1M2EwYzFkL3RhYmxlOjkyZmUwNzRlYjY2YjQzZDk5ZWEwYjQ1NDE4ZTJlNWMzL3RhYmxlcmFuZ2U6OTJmZTA3NGViNjZiNDNkOTllYTBiNDU0MThlMmU1YzNfMTYtMTUtMS0xLTEwMTE5MA_82a22bcc-1fff-4640-bd3b-defa6505adbf">52.7</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="ic69cdb1eadab4640aaa5db80dc9e4f66_I20211231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8yOC9mcmFnOjJmNjA5MWNkMjk1MzQwMDg5MGIyYTY3MWE1M2EwYzFkL3RhYmxlOjkyZmUwNzRlYjY2YjQzZDk5ZWEwYjQ1NDE4ZTJlNWMzL3RhYmxlcmFuZ2U6OTJmZTA3NGViNjZiNDNkOTllYTBiNDU0MThlMmU1YzNfMTYtMTctMS0xLTEwMTE5MA_25fff6ef-b95e-4d60-b9c7-8137fb8cac18">175.6</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="ia86f7488e69747879c270d95f97b2fd8_D20220101-20220331" decimals="-5" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8yOC9mcmFnOjJmNjA5MWNkMjk1MzQwMDg5MGIyYTY3MWE1M2EwYzFkL3RhYmxlOjkyZmUwNzRlYjY2YjQzZDk5ZWEwYjQ1NDE4ZTJlNWMzL3RhYmxlcmFuZ2U6OTJmZTA3NGViNjZiNDNkOTllYTBiNDU0MThlMmU1YzNfMTctNy0xLTEtMTAxMTkw_985f4f93-34b7-4e50-965b-7448cd072102">1,902.9</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ie181c9175c2e4e0e97580f859f4cb4aa_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8yOC9mcmFnOjJmNjA5MWNkMjk1MzQwMDg5MGIyYTY3MWE1M2EwYzFkL3RhYmxlOjkyZmUwNzRlYjY2YjQzZDk5ZWEwYjQ1NDE4ZTJlNWMzL3RhYmxlcmFuZ2U6OTJmZTA3NGViNjZiNDNkOTllYTBiNDU0MThlMmU1YzNfMTctMTctMS0xLTEwMTE5MA_5df9b94f-9f94-4dc9-8f7c-8cecf280743b">36.6</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other comprehensive income, net of tax</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i5d8c885250cf41859fc49a31213d750a_D20220101-20220331" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8yOC9mcmFnOjJmNjA5MWNkMjk1MzQwMDg5MGIyYTY3MWE1M2EwYzFkL3RhYmxlOjkyZmUwNzRlYjY2YjQzZDk5ZWEwYjQ1NDE4ZTJlNWMzL3RhYmxlcmFuZ2U6OTJmZTA3NGViNjZiNDNkOTllYTBiNDU0MThlMmU1YzNfMTgtMTEtMS0xLTEwMTE5MA_72a866d3-bf8a-4fe6-ab1e-adfe7b047a2c">117.8</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Retirement of treasury shares</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonfraction unitref="shares" contextref="i19e48a9fdfbe4e0bb926fcc624ff1c1c_D20220101-20220331" decimals="-3" name="us-gaap:TreasuryStockSharesRetired" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8yOC9mcmFnOjJmNjA5MWNkMjk1MzQwMDg5MGIyYTY3MWE1M2EwYzFkL3RhYmxlOjkyZmUwNzRlYjY2YjQzZDk5ZWEwYjQ1NDE4ZTJlNWMzL3RhYmxlcmFuZ2U6OTJmZTA3NGViNjZiNDNkOTllYTBiNDU0MThlMmU1YzNfMjAtMS0xLTEtMTAxMTkw_baadb4f6-0015-48f1-bacc-4a8dfe16deb8">5,607</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i19e48a9fdfbe4e0bb926fcc624ff1c1c_D20220101-20220331" decimals="-5" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8yOC9mcmFnOjJmNjA5MWNkMjk1MzQwMDg5MGIyYTY3MWE1M2EwYzFkL3RhYmxlOjkyZmUwNzRlYjY2YjQzZDk5ZWEwYjQ1NDE4ZTJlNWMzL3RhYmxlcmFuZ2U6OTJmZTA3NGViNjZiNDNkOTllYTBiNDU0MThlMmU1YzNfMjAtMy0xLTEtMTAxMTkw_042bc3fd-c7d6-4b56-a1f9-26507597f22f">3.5</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ia86f7488e69747879c270d95f97b2fd8_D20220101-20220331" decimals="-5" name="us-gaap:TreasuryStockRetiredCostMethodAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8yOC9mcmFnOjJmNjA5MWNkMjk1MzQwMDg5MGIyYTY3MWE1M2EwYzFkL3RhYmxlOjkyZmUwNzRlYjY2YjQzZDk5ZWEwYjQ1NDE4ZTJlNWMzL3RhYmxlcmFuZ2U6OTJmZTA3NGViNjZiNDNkOTllYTBiNDU0MThlMmU1YzNfMjAtNy0xLTEtMTAxMTkw_07678408-9e01-414b-b20d-c2d0a39ad19f">1,496.5</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonfraction unitref="shares" contextref="if01eafd1c5de4be8977529edda964bdc_D20220101-20220331" decimals="-3" name="us-gaap:TreasuryStockSharesRetired" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8yOC9mcmFnOjJmNjA5MWNkMjk1MzQwMDg5MGIyYTY3MWE1M2EwYzFkL3RhYmxlOjkyZmUwNzRlYjY2YjQzZDk5ZWEwYjQ1NDE4ZTJlNWMzL3RhYmxlcmFuZ2U6OTJmZTA3NGViNjZiNDNkOTllYTBiNDU0MThlMmU1YzNfMjAtMTMtMS0xLTEwMTE5MA_2d60b084-7d30-41fc-8cda-2967a72957ff">5,607</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="if01eafd1c5de4be8977529edda964bdc_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:TreasuryStockRetiredCostMethodAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8yOC9mcmFnOjJmNjA5MWNkMjk1MzQwMDg5MGIyYTY3MWE1M2EwYzFkL3RhYmxlOjkyZmUwNzRlYjY2YjQzZDk5ZWEwYjQ1NDE4ZTJlNWMzL3RhYmxlcmFuZ2U6OTJmZTA3NGViNjZiNDNkOTllYTBiNDU0MThlMmU1YzNfMjAtMTUtMS0xLTEwMTE5MA_e28af63d-2b7a-49f3-9f1d-7c9375380998">1,500.0</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Purchase of treasury shares</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="shares" contextref="if01eafd1c5de4be8977529edda964bdc_D20220101-20220331" decimals="-3" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8yOC9mcmFnOjJmNjA5MWNkMjk1MzQwMDg5MGIyYTY3MWE1M2EwYzFkL3RhYmxlOjkyZmUwNzRlYjY2YjQzZDk5ZWEwYjQ1NDE4ZTJlNWMzL3RhYmxlcmFuZ2U6OTJmZTA3NGViNjZiNDNkOTllYTBiNDU0MThlMmU1YzNfMjEtMTMtMS0xLTEwMTE5MA_8f73b80e-df6e-4f82-9709-2def0aa389fe">5,607</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonfraction unitref="usd" contextref="if01eafd1c5de4be8977529edda964bdc_D20220101-20220331" decimals="-5" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8yOC9mcmFnOjJmNjA5MWNkMjk1MzQwMDg5MGIyYTY3MWE1M2EwYzFkL3RhYmxlOjkyZmUwNzRlYjY2YjQzZDk5ZWEwYjQ1NDE4ZTJlNWMzL3RhYmxlcmFuZ2U6OTJmZTA3NGViNjZiNDNkOTllYTBiNDU0MThlMmU1YzNfMjEtMTUtMS0xLTEwMTE5MA_ec923f75-2949-4d2b-9532-22abd3481061">1,500.0</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Issuance of stock under employee stock plans, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="shares" contextref="i19e48a9fdfbe4e0bb926fcc624ff1c1c_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8yOC9mcmFnOjJmNjA5MWNkMjk1MzQwMDg5MGIyYTY3MWE1M2EwYzFkL3RhYmxlOjkyZmUwNzRlYjY2YjQzZDk5ZWEwYjQ1NDE4ZTJlNWMzL3RhYmxlcmFuZ2U6OTJmZTA3NGViNjZiNDNkOTllYTBiNDU0MThlMmU1YzNfMjItMS0xLTEtMTAxMTkw_5f9d41b9-4443-4fdf-881e-5ba8d54d8962">2,096</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i19e48a9fdfbe4e0bb926fcc624ff1c1c_D20220101-20220331" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8yOC9mcmFnOjJmNjA5MWNkMjk1MzQwMDg5MGIyYTY3MWE1M2EwYzFkL3RhYmxlOjkyZmUwNzRlYjY2YjQzZDk5ZWEwYjQ1NDE4ZTJlNWMzL3RhYmxlcmFuZ2U6OTJmZTA3NGViNjZiNDNkOTllYTBiNDU0MThlMmU1YzNfMjItMy0xLTEtMTAxMTkw_24d8f0e7-1330-4a04-a77b-d6afcf9c6296">1.3</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i5d450c033ae8486e83663df6458e4763_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8yOC9mcmFnOjJmNjA5MWNkMjk1MzQwMDg5MGIyYTY3MWE1M2EwYzFkL3RhYmxlOjkyZmUwNzRlYjY2YjQzZDk5ZWEwYjQ1NDE4ZTJlNWMzL3RhYmxlcmFuZ2U6OTJmZTA3NGViNjZiNDNkOTllYTBiNDU0MThlMmU1YzNfMjItNS0xLTEtMTAxMTkw_a83b760c-0405-43e5-8a8a-7a6415429a0f">278.1</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonfraction unitref="shares" contextref="if01eafd1c5de4be8977529edda964bdc_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8yOC9mcmFnOjJmNjA5MWNkMjk1MzQwMDg5MGIyYTY3MWE1M2EwYzFkL3RhYmxlOjkyZmUwNzRlYjY2YjQzZDk5ZWEwYjQ1NDE4ZTJlNWMzL3RhYmxlcmFuZ2U6OTJmZTA3NGViNjZiNDNkOTllYTBiNDU0MThlMmU1YzNfMjItMTMtMS0xLTEwMTE5MA_142d7341-2d11-469f-986b-0c069e76c517">13</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="if01eafd1c5de4be8977529edda964bdc_D20220101-20220331" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8yOC9mcmFnOjJmNjA5MWNkMjk1MzQwMDg5MGIyYTY3MWE1M2EwYzFkL3RhYmxlOjkyZmUwNzRlYjY2YjQzZDk5ZWEwYjQ1NDE4ZTJlNWMzL3RhYmxlcmFuZ2U6OTJmZTA3NGViNjZiNDNkOTllYTBiNDU0MThlMmU1YzNfMjItMTUtMS0xLTEwMTE5MA_f960dc5f-87c2-4907-aade-c2ac7917e5a0">2.2</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i5d450c033ae8486e83663df6458e4763_D20220101-20220331" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8yOC9mcmFnOjJmNjA5MWNkMjk1MzQwMDg5MGIyYTY3MWE1M2EwYzFkL3RhYmxlOjkyZmUwNzRlYjY2YjQzZDk5ZWEwYjQ1NDE4ZTJlNWMzL3RhYmxlcmFuZ2U6OTJmZTA3NGViNjZiNDNkOTllYTBiNDU0MThlMmU1YzNfMjMtNS0xLTEtMTAxMTkw_ae537d34-9d7c-497f-8354-2b97b31dfed9">101.0</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonfraction unitref="usd" contextref="i5d450c033ae8486e83663df6458e4763_D20220101-20220331" sign="-" xsi:nil="true" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8yOC9mcmFnOjJmNjA5MWNkMjk1MzQwMDg5MGIyYTY3MWE1M2EwYzFkL3RhYmxlOjkyZmUwNzRlYjY2YjQzZDk5ZWEwYjQ1NDE4ZTJlNWMzL3RhYmxlcmFuZ2U6OTJmZTA3NGViNjZiNDNkOTllYTBiNDU0MThlMmU1YzNfMjQtNS0xLTEtMTAxMTkw_a2a73e9c-296a-4b1e-bd1e-68f414ff3212"></ix:nonfraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="ia86f7488e69747879c270d95f97b2fd8_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8yOC9mcmFnOjJmNjA5MWNkMjk1MzQwMDg5MGIyYTY3MWE1M2EwYzFkL3RhYmxlOjkyZmUwNzRlYjY2YjQzZDk5ZWEwYjQ1NDE4ZTJlNWMzL3RhYmxlcmFuZ2U6OTJmZTA3NGViNjZiNDNkOTllYTBiNDU0MThlMmU1YzNfMjQtNy0xLTEtMTAxMTkw_3f94bd0d-4a3e-46d5-93bd-12a53d6e8766">4.5</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ie181c9175c2e4e0e97580f859f4cb4aa_D20220101-20220331" decimals="-5" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8yOC9mcmFnOjJmNjA5MWNkMjk1MzQwMDg5MGIyYTY3MWE1M2EwYzFkL3RhYmxlOjkyZmUwNzRlYjY2YjQzZDk5ZWEwYjQ1NDE4ZTJlNWMzL3RhYmxlcmFuZ2U6OTJmZTA3NGViNjZiNDNkOTllYTBiNDU0MThlMmU1YzNfMjQtMTctMS0xLTEwMTE5MA_667d1bb3-2574-49c3-9a80-67b57eb0d365">7.8</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Balance at March 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="shares" contextref="i3b8b2bd42197422ab034e2f2cb925c9e_I20220331" decimals="-3" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8yOC9mcmFnOjJmNjA5MWNkMjk1MzQwMDg5MGIyYTY3MWE1M2EwYzFkL3RhYmxlOjkyZmUwNzRlYjY2YjQzZDk5ZWEwYjQ1NDE4ZTJlNWMzL3RhYmxlcmFuZ2U6OTJmZTA3NGViNjZiNDNkOTllYTBiNDU0MThlMmU1YzNfMjUtMS0xLTEtMTAxMTkw_af3cf650-651f-4361-b7d8-618b95f685ee">950,605</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i3b8b2bd42197422ab034e2f2cb925c9e_I20220331" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8yOC9mcmFnOjJmNjA5MWNkMjk1MzQwMDg5MGIyYTY3MWE1M2EwYzFkL3RhYmxlOjkyZmUwNzRlYjY2YjQzZDk5ZWEwYjQ1NDE4ZTJlNWMzL3RhYmxlcmFuZ2U6OTJmZTA3NGViNjZiNDNkOTllYTBiNDU0MThlMmU1YzNfMjUtMy0xLTEtMTAxMTkw_d7b6c91f-34c7-4c18-b004-63a9d333bfd8">594.1</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="id701cd4a84884cbebc65d833f9b29be8_I20220331" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8yOC9mcmFnOjJmNjA5MWNkMjk1MzQwMDg5MGIyYTY3MWE1M2EwYzFkL3RhYmxlOjkyZmUwNzRlYjY2YjQzZDk5ZWEwYjQ1NDE4ZTJlNWMzL3RhYmxlcmFuZ2U6OTJmZTA3NGViNjZiNDNkOTllYTBiNDU0MThlMmU1YzNfMjUtNS0xLTEtMTAxMTkw_6c287d6e-6cca-4325-9fe5-b1ba2f6b30a3">6,656.3</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i0264ef1afcf043d1b3dc10d561f1ad86_I20220331" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8yOC9mcmFnOjJmNjA5MWNkMjk1MzQwMDg5MGIyYTY3MWE1M2EwYzFkL3RhYmxlOjkyZmUwNzRlYjY2YjQzZDk5ZWEwYjQ1NDE4ZTJlNWMzL3RhYmxlcmFuZ2U6OTJmZTA3NGViNjZiNDNkOTllYTBiNDU0MThlMmU1YzNfMjUtNy0xLTEtMTAxMTkw_3f797db3-9727-4f37-8816-e76f22c3c11a">9,369.4</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i3f96d2e5358847db9e2027a612b3be4c_I20220331" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8yOC9mcmFnOjJmNjA5MWNkMjk1MzQwMDg5MGIyYTY3MWE1M2EwYzFkL3RhYmxlOjkyZmUwNzRlYjY2YjQzZDk5ZWEwYjQ1NDE4ZTJlNWMzL3RhYmxlcmFuZ2U6OTJmZTA3NGViNjZiNDNkOTllYTBiNDU0MThlMmU1YzNfMjUtOS0xLTEtMTAxMTkw_e9a3262d-922e-49c7-88c5-bf972118247d">3,013.2</ix:nonfraction>)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i43aa66474f114885b0ce1578e4c4c5ea_I20220331" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8yOC9mcmFnOjJmNjA5MWNkMjk1MzQwMDg5MGIyYTY3MWE1M2EwYzFkL3RhYmxlOjkyZmUwNzRlYjY2YjQzZDk5ZWEwYjQ1NDE4ZTJlNWMzL3RhYmxlcmFuZ2U6OTJmZTA3NGViNjZiNDNkOTllYTBiNDU0MThlMmU1YzNfMjUtMTEtMS0xLTEwMTE5MA_dcfdad1c-341d-4c04-b28f-e78a637eb537">4,225.3</ix:nonfraction>)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="shares" contextref="i5362064a415b4ef1bf7669d31f2d681f_I20220331" decimals="-3" name="us-gaap:SharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8yOC9mcmFnOjJmNjA5MWNkMjk1MzQwMDg5MGIyYTY3MWE1M2EwYzFkL3RhYmxlOjkyZmUwNzRlYjY2YjQzZDk5ZWEwYjQ1NDE4ZTJlNWMzL3RhYmxlcmFuZ2U6OTJmZTA3NGViNjZiNDNkOTllYTBiNDU0MThlMmU1YzNfMjUtMTMtMS0xLTEwMTE5MA_f7defa90-a2c1-4cd9-89eb-edcd2801fc32">450</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i5362064a415b4ef1bf7669d31f2d681f_I20220331" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8yOC9mcmFnOjJmNjA5MWNkMjk1MzQwMDg5MGIyYTY3MWE1M2EwYzFkL3RhYmxlOjkyZmUwNzRlYjY2YjQzZDk5ZWEwYjQ1NDE4ZTJlNWMzL3RhYmxlcmFuZ2U6OTJmZTA3NGViNjZiNDNkOTllYTBiNDU0MThlMmU1YzNfMjUtMTUtMS0xLTEwMTE5MA_581734eb-c797-48cb-8257-2a8b103b22ce">50.5</ix:nonfraction>)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i98a419d099994feba11744c6093efaed_I20220331" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8yOC9mcmFnOjJmNjA5MWNkMjk1MzQwMDg5MGIyYTY3MWE1M2EwYzFkL3RhYmxlOjkyZmUwNzRlYjY2YjQzZDk5ZWEwYjQ1NDE4ZTJlNWMzL3RhYmxlcmFuZ2U6OTJmZTA3NGViNjZiNDNkOTllYTBiNDU0MThlMmU1YzNfMjUtMTctMS0xLTEwMTE5MA_d3abedb5-a893-47bf-a0e3-34857d70b043">131.2</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></div><div style="margin-bottom:12pt;margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> <ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8yOC9mcmFnOjJmNjA5MWNkMjk1MzQwMDg5MGIyYTY3MWE1M2EwYzFkL3RleHRyZWdpb246MmY2MDkxY2QyOTUzNDAwODkwYjJhNjcxYTUzYTBjMWRfMTA0NDUzNjA0NjQyNTQ_a0f9b4ad-e1cf-4c01-9b88-254201374b45" footnoterole="http://www.xbrl.org/2003/role/footnote">As of March&nbsp;31, 2022, there was $<ix:nonfraction unitref="usd" contextref="ib1053442369e460291956c51ab7e5179_I20220331" decimals="-7" name="us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8yOC9mcmFnOjJmNjA5MWNkMjk1MzQwMDg5MGIyYTY3MWE1M2EwYzFkL3RleHRyZWdpb246MmY2MDkxY2QyOTUzNDAwODkwYjJhNjcxYTUzYTBjMWRfMTQ4NDM0MDY5NzUzODc_dfea8d80-44aa-46df-89de-e55ca218e63f">3.25</ix:nonfraction> billion remaining under our $<ix:nonfraction unitref="usd" contextref="ic2d5056a8d9b48feb23cc7f8b96df053_I20210531" decimals="INF" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8yOC9mcmFnOjJmNjA5MWNkMjk1MzQwMDg5MGIyYTY3MWE1M2EwYzFkL3RleHRyZWdpb246MmY2MDkxY2QyOTUzNDAwODkwYjJhNjcxYTUzYTBjMWRfMTY0OTI2NzQ0MjA0MA_a9b9de21-24a0-433f-94a6-af2b10e321ce">5.00</ix:nonfraction> billion share repurchase program authorized in May 2021.</ix:footnote> </span></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See notes to consolidated condensed financial statements.</span></div><div><span><br></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><div id="ie8dc61f8e15b44db82ba16050d5b7b44_34"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span><br></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Condensed Statements of Cash Flows</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ELI LILLY AND COMPANY AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in millions)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&nbsp;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:73.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.036%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash Flows from Operating Activities</span></td><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="id879b497a407453985551e83dbee75f8_D20220101-20220331" decimals="-5" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8zNC9mcmFnOjgwYzUwOTEwZjgwNjQ3NzhiOTZmY2RmN2JjN2FhZTUzL3RhYmxlOjQxZDllZDFiMWQ5NjRkM2ZhOGFlYmQwNDJhZWU3N2QyL3RhYmxlcmFuZ2U6NDFkOWVkMWIxZDk2NGQzZmE4YWViZDA0MmFlZTc3ZDJfMy0xLTEtMS0xMDExOTA_be6358c6-a54c-43a4-a3a2-7985ff0c8690">1,902.9</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i010e4c0d9c6246be91d37e31d569fa6f_D20210101-20210331" decimals="-5" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8zNC9mcmFnOjgwYzUwOTEwZjgwNjQ3NzhiOTZmY2RmN2JjN2FhZTUzL3RhYmxlOjQxZDllZDFiMWQ5NjRkM2ZhOGFlYmQwNDJhZWU3N2QyL3RhYmxlcmFuZ2U6NDFkOWVkMWIxZDk2NGQzZmE4YWViZDA0MmFlZTc3ZDJfMy0zLTEtMS0xMDExOTA_5880a328-8b04-4253-ae52-58813feab509">1,355.3</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Adjustments to Reconcile Net Income to Cash Flows from Operating Activities:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="id879b497a407453985551e83dbee75f8_D20220101-20220331" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8zNC9mcmFnOjgwYzUwOTEwZjgwNjQ3NzhiOTZmY2RmN2JjN2FhZTUzL3RhYmxlOjQxZDllZDFiMWQ5NjRkM2ZhOGFlYmQwNDJhZWU3N2QyL3RhYmxlcmFuZ2U6NDFkOWVkMWIxZDk2NGQzZmE4YWViZDA0MmFlZTc3ZDJfNi0xLTEtMS0xMDExOTA_c8727aa5-1d12-409a-9ef2-8990639bfa60">435.7</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i010e4c0d9c6246be91d37e31d569fa6f_D20210101-20210331" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8zNC9mcmFnOjgwYzUwOTEwZjgwNjQ3NzhiOTZmY2RmN2JjN2FhZTUzL3RhYmxlOjQxZDllZDFiMWQ5NjRkM2ZhOGFlYmQwNDJhZWU3N2QyL3RhYmxlcmFuZ2U6NDFkOWVkMWIxZDk2NGQzZmE4YWViZDA0MmFlZTc3ZDJfNi0zLTEtMS0xMDExOTA_201ddc49-c456-4d36-a3f2-2cc43bc24076">350.3</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in deferred income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonfraction unitref="usd" contextref="id879b497a407453985551e83dbee75f8_D20220101-20220331" decimals="-5" name="us-gaap:IncreaseDecreaseInDeferredIncomeTaxes" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8zNC9mcmFnOjgwYzUwOTEwZjgwNjQ3NzhiOTZmY2RmN2JjN2FhZTUzL3RhYmxlOjQxZDllZDFiMWQ5NjRkM2ZhOGFlYmQwNDJhZWU3N2QyL3RhYmxlcmFuZ2U6NDFkOWVkMWIxZDk2NGQzZmE4YWViZDA0MmFlZTc3ZDJfNy0xLTEtMS0xMDExOTA_62c06819-e2dc-4f70-86b5-a9edd1b09046">506.6</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i010e4c0d9c6246be91d37e31d569fa6f_D20210101-20210331" decimals="-5" name="us-gaap:IncreaseDecreaseInDeferredIncomeTaxes" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8zNC9mcmFnOjgwYzUwOTEwZjgwNjQ3NzhiOTZmY2RmN2JjN2FhZTUzL3RhYmxlOjQxZDllZDFiMWQ5NjRkM2ZhOGFlYmQwNDJhZWU3N2QyL3RhYmxlcmFuZ2U6NDFkOWVkMWIxZDk2NGQzZmE4YWViZDA0MmFlZTc3ZDJfNy0zLTEtMS0xMDExOTA_2ad44197-8661-419c-b028-cf6a77dbf8d3">119.1</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="id879b497a407453985551e83dbee75f8_D20220101-20220331" decimals="-5" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8zNC9mcmFnOjgwYzUwOTEwZjgwNjQ3NzhiOTZmY2RmN2JjN2FhZTUzL3RhYmxlOjQxZDllZDFiMWQ5NjRkM2ZhOGFlYmQwNDJhZWU3N2QyL3RhYmxlcmFuZ2U6NDFkOWVkMWIxZDk2NGQzZmE4YWViZDA0MmFlZTc3ZDJfOS0xLTEtMS0xMDExOTA_45e76f4c-e9b0-4e2c-9371-0a272b7b3033">101.0</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i010e4c0d9c6246be91d37e31d569fa6f_D20210101-20210331" decimals="-5" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8zNC9mcmFnOjgwYzUwOTEwZjgwNjQ3NzhiOTZmY2RmN2JjN2FhZTUzL3RhYmxlOjQxZDllZDFiMWQ5NjRkM2ZhOGFlYmQwNDJhZWU3N2QyL3RhYmxlcmFuZ2U6NDFkOWVkMWIxZDk2NGQzZmE4YWViZDA0MmFlZTc3ZDJfOS0zLTEtMS0xMDExOTA_26db6b2c-c6ab-4ab0-9c82-a6385a529352">85.5</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment (gains) losses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="id879b497a407453985551e83dbee75f8_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:GainLossOnInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8zNC9mcmFnOjgwYzUwOTEwZjgwNjQ3NzhiOTZmY2RmN2JjN2FhZTUzL3RhYmxlOjQxZDllZDFiMWQ5NjRkM2ZhOGFlYmQwNDJhZWU3N2QyL3RhYmxlcmFuZ2U6NDFkOWVkMWIxZDk2NGQzZmE4YWViZDA0MmFlZTc3ZDJfMTEtMS0xLTEtMTAxMTkw_764578c5-c771-477a-9d77-c9f438061193">426.1</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i010e4c0d9c6246be91d37e31d569fa6f_D20210101-20210331" decimals="-5" name="us-gaap:GainLossOnInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8zNC9mcmFnOjgwYzUwOTEwZjgwNjQ3NzhiOTZmY2RmN2JjN2FhZTUzL3RhYmxlOjQxZDllZDFiMWQ5NjRkM2ZhOGFlYmQwNDJhZWU3N2QyL3RhYmxlcmFuZ2U6NDFkOWVkMWIxZDk2NGQzZmE4YWViZDA0MmFlZTc3ZDJfMTEtMy0xLTEtMTAxMTkw_d8f07f3e-63e9-425d-97cb-fb91de7cd54c">302.2</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired in-process research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="id879b497a407453985551e83dbee75f8_D20220101-20220331" decimals="-5" name="lly:AcquiredInProcessResearchAndDevelopment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8zNC9mcmFnOjgwYzUwOTEwZjgwNjQ3NzhiOTZmY2RmN2JjN2FhZTUzL3RhYmxlOjQxZDllZDFiMWQ5NjRkM2ZhOGFlYmQwNDJhZWU3N2QyL3RhYmxlcmFuZ2U6NDFkOWVkMWIxZDk2NGQzZmE4YWViZDA0MmFlZTc3ZDJfMTItMS0xLTEtMTAxMTkw_94b78ab0-eced-4bfa-88b8-0eaefd823d69">153.0</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i010e4c0d9c6246be91d37e31d569fa6f_D20210101-20210331" decimals="-5" name="lly:AcquiredInProcessResearchAndDevelopment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8zNC9mcmFnOjgwYzUwOTEwZjgwNjQ3NzhiOTZmY2RmN2JjN2FhZTUzL3RhYmxlOjQxZDllZDFiMWQ5NjRkM2ZhOGFlYmQwNDJhZWU3N2QyL3RhYmxlcmFuZ2U6NDFkOWVkMWIxZDk2NGQzZmE4YWViZDA0MmFlZTc3ZDJfMTItMy0xLTEtMTAxMTkw_4cb9c3be-a21f-4aa3-ade6-da806346cb98">299.3</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other changes in operating assets and liabilities, net of acquisitions and divestitures</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonfraction unitref="usd" contextref="id879b497a407453985551e83dbee75f8_D20220101-20220331" decimals="-5" name="us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8zNC9mcmFnOjgwYzUwOTEwZjgwNjQ3NzhiOTZmY2RmN2JjN2FhZTUzL3RhYmxlOjQxZDllZDFiMWQ5NjRkM2ZhOGFlYmQwNDJhZWU3N2QyL3RhYmxlcmFuZ2U6NDFkOWVkMWIxZDk2NGQzZmE4YWViZDA0MmFlZTc3ZDJfMTMtMS0xLTEtMTAxMTkw_b878556d-67d8-430d-b0e7-a5a89373c453">45.5</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i010e4c0d9c6246be91d37e31d569fa6f_D20210101-20210331" decimals="-5" name="us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8zNC9mcmFnOjgwYzUwOTEwZjgwNjQ3NzhiOTZmY2RmN2JjN2FhZTUzL3RhYmxlOjQxZDllZDFiMWQ5NjRkM2ZhOGFlYmQwNDJhZWU3N2QyL3RhYmxlcmFuZ2U6NDFkOWVkMWIxZDk2NGQzZmE4YWViZDA0MmFlZTc3ZDJfMTMtMy0xLTEtMTAxMTkw_3e0ffcab-3b60-4043-b5aa-f9a04e0d1e37">102.8</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-cash operating activities, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="id879b497a407453985551e83dbee75f8_D20220101-20220331" decimals="-5" name="us-gaap:OtherOperatingActivitiesCashFlowStatement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8zNC9mcmFnOjgwYzUwOTEwZjgwNjQ3NzhiOTZmY2RmN2JjN2FhZTUzL3RhYmxlOjQxZDllZDFiMWQ5NjRkM2ZhOGFlYmQwNDJhZWU3N2QyL3RhYmxlcmFuZ2U6NDFkOWVkMWIxZDk2NGQzZmE4YWViZDA0MmFlZTc3ZDJfMTQtMS0xLTEtMTAxMTkw_651f6e20-9be8-4a8c-be0d-b63c3aa26e2d">32.6</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i010e4c0d9c6246be91d37e31d569fa6f_D20210101-20210331" decimals="-5" name="us-gaap:OtherOperatingActivitiesCashFlowStatement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8zNC9mcmFnOjgwYzUwOTEwZjgwNjQ3NzhiOTZmY2RmN2JjN2FhZTUzL3RhYmxlOjQxZDllZDFiMWQ5NjRkM2ZhOGFlYmQwNDJhZWU3N2QyL3RhYmxlcmFuZ2U6NDFkOWVkMWIxZDk2NGQzZmE4YWViZDA0MmFlZTc3ZDJfMTQtMy0xLTEtMTAxMTkw_70160b0e-1c9f-4ad2-9acd-b06fce60ae47">131.1</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Cash Provided by Operating Activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="id879b497a407453985551e83dbee75f8_D20220101-20220331" decimals="-5" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8zNC9mcmFnOjgwYzUwOTEwZjgwNjQ3NzhiOTZmY2RmN2JjN2FhZTUzL3RhYmxlOjQxZDllZDFiMWQ5NjRkM2ZhOGFlYmQwNDJhZWU3N2QyL3RhYmxlcmFuZ2U6NDFkOWVkMWIxZDk2NGQzZmE4YWViZDA0MmFlZTc3ZDJfMTUtMS0xLTEtMTAxMTkw_860ae36d-a75b-4474-952d-9e8705a1bf92">2,499.2</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i010e4c0d9c6246be91d37e31d569fa6f_D20210101-20210331" decimals="-5" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8zNC9mcmFnOjgwYzUwOTEwZjgwNjQ3NzhiOTZmY2RmN2JjN2FhZTUzL3RhYmxlOjQxZDllZDFiMWQ5NjRkM2ZhOGFlYmQwNDJhZWU3N2QyL3RhYmxlcmFuZ2U6NDFkOWVkMWIxZDk2NGQzZmE4YWViZDA0MmFlZTc3ZDJfMTUtMy0xLTEtMTAxMTkw_73dcd449-81d8-4530-b0bf-6b3aa629dca0">1,697.4</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash Flows from Investing Activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net purchases of property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonfraction unitref="usd" contextref="id879b497a407453985551e83dbee75f8_D20220101-20220331" decimals="-5" name="us-gaap:PaymentsToAcquireProductiveAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8zNC9mcmFnOjgwYzUwOTEwZjgwNjQ3NzhiOTZmY2RmN2JjN2FhZTUzL3RhYmxlOjQxZDllZDFiMWQ5NjRkM2ZhOGFlYmQwNDJhZWU3N2QyL3RhYmxlcmFuZ2U6NDFkOWVkMWIxZDk2NGQzZmE4YWViZDA0MmFlZTc3ZDJfMTctMS0xLTEtMTAxMTkw_7c3e41ad-47da-4d4d-9d4b-ed6446957027">365.4</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i010e4c0d9c6246be91d37e31d569fa6f_D20210101-20210331" decimals="-5" name="us-gaap:PaymentsToAcquireProductiveAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8zNC9mcmFnOjgwYzUwOTEwZjgwNjQ3NzhiOTZmY2RmN2JjN2FhZTUzL3RhYmxlOjQxZDllZDFiMWQ5NjRkM2ZhOGFlYmQwNDJhZWU3N2QyL3RhYmxlcmFuZ2U6NDFkOWVkMWIxZDk2NGQzZmE4YWViZDA0MmFlZTc3ZDJfMTctMy0xLTEtMTAxMTkw_fbd3da87-6aa5-4f2b-8a9a-5db5d577b806">300.3</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from sales and maturities of short-term investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="id879b497a407453985551e83dbee75f8_D20220101-20220331" decimals="-5" name="us-gaap:ProceedsFromSaleOfShortTermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8zNC9mcmFnOjgwYzUwOTEwZjgwNjQ3NzhiOTZmY2RmN2JjN2FhZTUzL3RhYmxlOjQxZDllZDFiMWQ5NjRkM2ZhOGFlYmQwNDJhZWU3N2QyL3RhYmxlcmFuZ2U6NDFkOWVkMWIxZDk2NGQzZmE4YWViZDA0MmFlZTc3ZDJfMTgtMS0xLTEtMTAxMTkw_dc40a2c2-2ca4-44ea-b4dc-4a4233daff42">26.7</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i010e4c0d9c6246be91d37e31d569fa6f_D20210101-20210331" decimals="-5" name="us-gaap:ProceedsFromSaleOfShortTermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8zNC9mcmFnOjgwYzUwOTEwZjgwNjQ3NzhiOTZmY2RmN2JjN2FhZTUzL3RhYmxlOjQxZDllZDFiMWQ5NjRkM2ZhOGFlYmQwNDJhZWU3N2QyL3RhYmxlcmFuZ2U6NDFkOWVkMWIxZDk2NGQzZmE4YWViZDA0MmFlZTc3ZDJfMTgtMy0xLTEtMTAxMTkw_6cb25885-58a0-47e3-958b-53ce90bc9311">4.0</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of short-term investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonfraction unitref="usd" contextref="id879b497a407453985551e83dbee75f8_D20220101-20220331" decimals="-5" name="us-gaap:PaymentsToAcquireShortTermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8zNC9mcmFnOjgwYzUwOTEwZjgwNjQ3NzhiOTZmY2RmN2JjN2FhZTUzL3RhYmxlOjQxZDllZDFiMWQ5NjRkM2ZhOGFlYmQwNDJhZWU3N2QyL3RhYmxlcmFuZ2U6NDFkOWVkMWIxZDk2NGQzZmE4YWViZDA0MmFlZTc3ZDJfMTktMS0xLTEtMTAxMTkw_0e5eb6b3-ae56-411e-858e-fbb7e9683a65">14.6</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i010e4c0d9c6246be91d37e31d569fa6f_D20210101-20210331" decimals="-5" name="us-gaap:PaymentsToAcquireShortTermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8zNC9mcmFnOjgwYzUwOTEwZjgwNjQ3NzhiOTZmY2RmN2JjN2FhZTUzL3RhYmxlOjQxZDllZDFiMWQ5NjRkM2ZhOGFlYmQwNDJhZWU3N2QyL3RhYmxlcmFuZ2U6NDFkOWVkMWIxZDk2NGQzZmE4YWViZDA0MmFlZTc3ZDJfMTktMy0xLTEtMTAxMTkw_54612c8e-047a-4c29-bc47-48be98b561c7">19.4</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from sales of noncurrent investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="id879b497a407453985551e83dbee75f8_D20220101-20220331" decimals="-5" name="us-gaap:ProceedsFromSaleOfLongtermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8zNC9mcmFnOjgwYzUwOTEwZjgwNjQ3NzhiOTZmY2RmN2JjN2FhZTUzL3RhYmxlOjQxZDllZDFiMWQ5NjRkM2ZhOGFlYmQwNDJhZWU3N2QyL3RhYmxlcmFuZ2U6NDFkOWVkMWIxZDk2NGQzZmE4YWViZDA0MmFlZTc3ZDJfMjAtMS0xLTEtMTAxMTkw_b0a39bb5-7770-4567-962f-92d2236c9b6d">81.4</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i010e4c0d9c6246be91d37e31d569fa6f_D20210101-20210331" decimals="-5" name="us-gaap:ProceedsFromSaleOfLongtermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8zNC9mcmFnOjgwYzUwOTEwZjgwNjQ3NzhiOTZmY2RmN2JjN2FhZTUzL3RhYmxlOjQxZDllZDFiMWQ5NjRkM2ZhOGFlYmQwNDJhZWU3N2QyL3RhYmxlcmFuZ2U6NDFkOWVkMWIxZDk2NGQzZmE4YWViZDA0MmFlZTc3ZDJfMjAtMy0xLTEtMTAxMTkw_185ce89c-06a7-4ad5-9b0b-4c3a99a185f4">284.8</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of noncurrent investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonfraction unitref="usd" contextref="id879b497a407453985551e83dbee75f8_D20220101-20220331" decimals="-5" name="us-gaap:PaymentsToAcquireLongtermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8zNC9mcmFnOjgwYzUwOTEwZjgwNjQ3NzhiOTZmY2RmN2JjN2FhZTUzL3RhYmxlOjQxZDllZDFiMWQ5NjRkM2ZhOGFlYmQwNDJhZWU3N2QyL3RhYmxlcmFuZ2U6NDFkOWVkMWIxZDk2NGQzZmE4YWViZDA0MmFlZTc3ZDJfMjEtMS0xLTEtMTAxMTkw_7d72c7ff-60e4-46ad-ac1d-fe0b6b810c05">116.7</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i010e4c0d9c6246be91d37e31d569fa6f_D20210101-20210331" decimals="-5" name="us-gaap:PaymentsToAcquireLongtermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8zNC9mcmFnOjgwYzUwOTEwZjgwNjQ3NzhiOTZmY2RmN2JjN2FhZTUzL3RhYmxlOjQxZDllZDFiMWQ5NjRkM2ZhOGFlYmQwNDJhZWU3N2QyL3RhYmxlcmFuZ2U6NDFkOWVkMWIxZDk2NGQzZmE4YWViZDA0MmFlZTc3ZDJfMjEtMy0xLTEtMTAxMTkw_b16556d8-e803-4e87-b9b4-c91f55e612fa">291.5</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for acquisitions, net of cash acquired (Note 3)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="id879b497a407453985551e83dbee75f8_D20220101-20220331" decimals="-5" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8zNC9mcmFnOjgwYzUwOTEwZjgwNjQ3NzhiOTZmY2RmN2JjN2FhZTUzL3RhYmxlOjQxZDllZDFiMWQ5NjRkM2ZhOGFlYmQwNDJhZWU3N2QyL3RhYmxlcmFuZ2U6NDFkOWVkMWIxZDk2NGQzZmE4YWViZDA0MmFlZTc3ZDJfMjItMS0xLTEtMTAxMTkw_b5b2b396-1ac9-400d-ae9e-9aa3f693a3a9">—</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i010e4c0d9c6246be91d37e31d569fa6f_D20210101-20210331" decimals="-5" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8zNC9mcmFnOjgwYzUwOTEwZjgwNjQ3NzhiOTZmY2RmN2JjN2FhZTUzL3RhYmxlOjQxZDllZDFiMWQ5NjRkM2ZhOGFlYmQwNDJhZWU3N2QyL3RhYmxlcmFuZ2U6NDFkOWVkMWIxZDk2NGQzZmE4YWViZDA0MmFlZTc3ZDJfMjItMy0xLTEtMTAxMTkw_62e33431-2e6d-44eb-acf2-81d5c625da92">747.4</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of in-process research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonfraction unitref="usd" contextref="id879b497a407453985551e83dbee75f8_D20220101-20220331" decimals="-5" name="lly:PurchasedInProcessResearchAndDevelopment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8zNC9mcmFnOjgwYzUwOTEwZjgwNjQ3NzhiOTZmY2RmN2JjN2FhZTUzL3RhYmxlOjQxZDllZDFiMWQ5NjRkM2ZhOGFlYmQwNDJhZWU3N2QyL3RhYmxlcmFuZ2U6NDFkOWVkMWIxZDk2NGQzZmE4YWViZDA0MmFlZTc3ZDJfMjQtMS0xLTEtMTAxMTkw_62eaeedc-f60a-4bea-8ab5-77b1a4c224e1">491.8</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i010e4c0d9c6246be91d37e31d569fa6f_D20210101-20210331" decimals="-5" name="lly:PurchasedInProcessResearchAndDevelopment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8zNC9mcmFnOjgwYzUwOTEwZjgwNjQ3NzhiOTZmY2RmN2JjN2FhZTUzL3RhYmxlOjQxZDllZDFiMWQ5NjRkM2ZhOGFlYmQwNDJhZWU3N2QyL3RhYmxlcmFuZ2U6NDFkOWVkMWIxZDk2NGQzZmE4YWViZDA0MmFlZTc3ZDJfMjQtMy0xLTEtMTAxMTkw_191ba4de-8a96-460f-b2cb-81d77a0f2396">191.8</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other investing activities, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonfraction unitref="usd" contextref="id879b497a407453985551e83dbee75f8_D20220101-20220331" decimals="-5" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8zNC9mcmFnOjgwYzUwOTEwZjgwNjQ3NzhiOTZmY2RmN2JjN2FhZTUzL3RhYmxlOjQxZDllZDFiMWQ5NjRkM2ZhOGFlYmQwNDJhZWU3N2QyL3RhYmxlcmFuZ2U6NDFkOWVkMWIxZDk2NGQzZmE4YWViZDA0MmFlZTc3ZDJfMjUtMS0xLTEtMTAxMTkw_225e9fc2-23b0-4ccc-a936-1ae39b981e16">133.4</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i010e4c0d9c6246be91d37e31d569fa6f_D20210101-20210331" decimals="-5" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8zNC9mcmFnOjgwYzUwOTEwZjgwNjQ3NzhiOTZmY2RmN2JjN2FhZTUzL3RhYmxlOjQxZDllZDFiMWQ5NjRkM2ZhOGFlYmQwNDJhZWU3N2QyL3RhYmxlcmFuZ2U6NDFkOWVkMWIxZDk2NGQzZmE4YWViZDA0MmFlZTc3ZDJfMjUtMy0xLTEtMTAxMTkw_1a9477d8-7032-4c71-b0c9-fc9d3a141336">21.9</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Cash Used for Investing Activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonfraction unitref="usd" contextref="id879b497a407453985551e83dbee75f8_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8zNC9mcmFnOjgwYzUwOTEwZjgwNjQ3NzhiOTZmY2RmN2JjN2FhZTUzL3RhYmxlOjQxZDllZDFiMWQ5NjRkM2ZhOGFlYmQwNDJhZWU3N2QyL3RhYmxlcmFuZ2U6NDFkOWVkMWIxZDk2NGQzZmE4YWViZDA0MmFlZTc3ZDJfMjYtMS0xLTEtMTAxMTkw_c45ead32-510c-499d-a5fd-0f87f4abe68a">1,013.8</ix:nonfraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i010e4c0d9c6246be91d37e31d569fa6f_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8zNC9mcmFnOjgwYzUwOTEwZjgwNjQ3NzhiOTZmY2RmN2JjN2FhZTUzL3RhYmxlOjQxZDllZDFiMWQ5NjRkM2ZhOGFlYmQwNDJhZWU3N2QyL3RhYmxlcmFuZ2U6NDFkOWVkMWIxZDk2NGQzZmE4YWViZDA0MmFlZTc3ZDJfMjYtMy0xLTEtMTAxMTkw_91bbcbf2-7b8c-4799-93e2-04ed55453bd6">1,283.5</ix:nonfraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash Flows from Financing Activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends paid</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonfraction unitref="usd" contextref="id879b497a407453985551e83dbee75f8_D20220101-20220331" decimals="-5" name="us-gaap:PaymentsOfDividends" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8zNC9mcmFnOjgwYzUwOTEwZjgwNjQ3NzhiOTZmY2RmN2JjN2FhZTUzL3RhYmxlOjQxZDllZDFiMWQ5NjRkM2ZhOGFlYmQwNDJhZWU3N2QyL3RhYmxlcmFuZ2U6NDFkOWVkMWIxZDk2NGQzZmE4YWViZDA0MmFlZTc3ZDJfMjgtMS0xLTEtMTAxMTkw_0841c1ec-798f-4a74-b9f7-6ca75014af89">885.5</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i010e4c0d9c6246be91d37e31d569fa6f_D20210101-20210331" decimals="-5" name="us-gaap:PaymentsOfDividends" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8zNC9mcmFnOjgwYzUwOTEwZjgwNjQ3NzhiOTZmY2RmN2JjN2FhZTUzL3RhYmxlOjQxZDllZDFiMWQ5NjRkM2ZhOGFlYmQwNDJhZWU3N2QyL3RhYmxlcmFuZ2U6NDFkOWVkMWIxZDk2NGQzZmE4YWViZDA0MmFlZTc3ZDJfMjgtMy0xLTEtMTAxMTkw_439e714d-cc61-4bfd-a502-0629d857fda6">774.8</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net change in short-term borrowings</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="id879b497a407453985551e83dbee75f8_D20220101-20220331" decimals="-5" name="us-gaap:ProceedsFromShortTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8zNC9mcmFnOjgwYzUwOTEwZjgwNjQ3NzhiOTZmY2RmN2JjN2FhZTUzL3RhYmxlOjQxZDllZDFiMWQ5NjRkM2ZhOGFlYmQwNDJhZWU3N2QyL3RhYmxlcmFuZ2U6NDFkOWVkMWIxZDk2NGQzZmE4YWViZDA0MmFlZTc3ZDJfMjktMS0xLTEtMTAxMTkw_8d522373-7ee2-4554-907a-f654009f2077">499.7</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i010e4c0d9c6246be91d37e31d569fa6f_D20210101-20210331" decimals="-5" name="us-gaap:RepaymentsOfShortTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8zNC9mcmFnOjgwYzUwOTEwZjgwNjQ3NzhiOTZmY2RmN2JjN2FhZTUzL3RhYmxlOjQxZDllZDFiMWQ5NjRkM2ZhOGFlYmQwNDJhZWU3N2QyL3RhYmxlcmFuZ2U6NDFkOWVkMWIxZDk2NGQzZmE4YWViZDA0MmFlZTc3ZDJfMjktMy0xLTEtMTAxMTkw_c237151d-c842-4a4c-ad24-c5caff8a7ac1">3.7</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repayments of long-term debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonfraction unitref="usd" contextref="id879b497a407453985551e83dbee75f8_D20220101-20220331" decimals="-5" name="us-gaap:RepaymentsOfLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8zNC9mcmFnOjgwYzUwOTEwZjgwNjQ3NzhiOTZmY2RmN2JjN2FhZTUzL3RhYmxlOjQxZDllZDFiMWQ5NjRkM2ZhOGFlYmQwNDJhZWU3N2QyL3RhYmxlcmFuZ2U6NDFkOWVkMWIxZDk2NGQzZmE4YWViZDA0MmFlZTc3ZDJfMzEtMS0xLTEtMTAxMTkw_7a3f5681-3daf-45fc-8fe5-f4cf9b48b466">710.1</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i010e4c0d9c6246be91d37e31d569fa6f_D20210101-20210331" decimals="-5" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8zNC9mcmFnOjgwYzUwOTEwZjgwNjQ3NzhiOTZmY2RmN2JjN2FhZTUzL3RhYmxlOjQxZDllZDFiMWQ5NjRkM2ZhOGFlYmQwNDJhZWU3N2QyL3RhYmxlcmFuZ2U6NDFkOWVkMWIxZDk2NGQzZmE4YWViZDA0MmFlZTc3ZDJfMzEtMy0xLTEtMTAxMTkw_bdff8d31-babb-4036-a524-f628efbcdc0a">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonfraction unitref="usd" contextref="id879b497a407453985551e83dbee75f8_D20220101-20220331" decimals="-5" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8zNC9mcmFnOjgwYzUwOTEwZjgwNjQ3NzhiOTZmY2RmN2JjN2FhZTUzL3RhYmxlOjQxZDllZDFiMWQ5NjRkM2ZhOGFlYmQwNDJhZWU3N2QyL3RhYmxlcmFuZ2U6NDFkOWVkMWIxZDk2NGQzZmE4YWViZDA0MmFlZTc3ZDJfMzItMS0xLTEtMTAxMTkw_9aec3749-cb5c-449d-87c0-6f6ea44e6cb0">1,500.0</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i010e4c0d9c6246be91d37e31d569fa6f_D20210101-20210331" decimals="-5" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8zNC9mcmFnOjgwYzUwOTEwZjgwNjQ3NzhiOTZmY2RmN2JjN2FhZTUzL3RhYmxlOjQxZDllZDFiMWQ5NjRkM2ZhOGFlYmQwNDJhZWU3N2QyL3RhYmxlcmFuZ2U6NDFkOWVkMWIxZDk2NGQzZmE4YWViZDA0MmFlZTc3ZDJfMzItMy0xLTEtMTAxMTkw_ba36f047-ae99-42d5-9bc0-84dfb3280a96">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other financing activities, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonfraction unitref="usd" contextref="id879b497a407453985551e83dbee75f8_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8zNC9mcmFnOjgwYzUwOTEwZjgwNjQ3NzhiOTZmY2RmN2JjN2FhZTUzL3RhYmxlOjQxZDllZDFiMWQ5NjRkM2ZhOGFlYmQwNDJhZWU3N2QyL3RhYmxlcmFuZ2U6NDFkOWVkMWIxZDk2NGQzZmE4YWViZDA0MmFlZTc3ZDJfMzQtMS0xLTEtMTAxMTkw_c4feab08-32c2-428e-ad8c-7e97debb098d">282.4</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i010e4c0d9c6246be91d37e31d569fa6f_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8zNC9mcmFnOjgwYzUwOTEwZjgwNjQ3NzhiOTZmY2RmN2JjN2FhZTUzL3RhYmxlOjQxZDllZDFiMWQ5NjRkM2ZhOGFlYmQwNDJhZWU3N2QyL3RhYmxlcmFuZ2U6NDFkOWVkMWIxZDk2NGQzZmE4YWViZDA0MmFlZTc3ZDJfMzQtMy0xLTEtMTAxMTkw_12f12942-e6ab-4343-944c-288986a2536b">279.9</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Cash Used for Financing Activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonfraction unitref="usd" contextref="id879b497a407453985551e83dbee75f8_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8zNC9mcmFnOjgwYzUwOTEwZjgwNjQ3NzhiOTZmY2RmN2JjN2FhZTUzL3RhYmxlOjQxZDllZDFiMWQ5NjRkM2ZhOGFlYmQwNDJhZWU3N2QyL3RhYmxlcmFuZ2U6NDFkOWVkMWIxZDk2NGQzZmE4YWViZDA0MmFlZTc3ZDJfMzUtMS0xLTEtMTAxMTkw_b25fbb29-4a73-4324-9c28-f4e969ed45eb">2,878.3</ix:nonfraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i010e4c0d9c6246be91d37e31d569fa6f_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8zNC9mcmFnOjgwYzUwOTEwZjgwNjQ3NzhiOTZmY2RmN2JjN2FhZTUzL3RhYmxlOjQxZDllZDFiMWQ5NjRkM2ZhOGFlYmQwNDJhZWU3N2QyL3RhYmxlcmFuZ2U6NDFkOWVkMWIxZDk2NGQzZmE4YWViZDA0MmFlZTc3ZDJfMzUtMy0xLTEtMTAxMTkw_72a9a1fb-1468-430b-b473-a5470dbe066b">1,058.4</ix:nonfraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of exchange rate changes on cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="id879b497a407453985551e83dbee75f8_D20220101-20220331" decimals="-5" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8zNC9mcmFnOjgwYzUwOTEwZjgwNjQ3NzhiOTZmY2RmN2JjN2FhZTUzL3RhYmxlOjQxZDllZDFiMWQ5NjRkM2ZhOGFlYmQwNDJhZWU3N2QyL3RhYmxlcmFuZ2U6NDFkOWVkMWIxZDk2NGQzZmE4YWViZDA0MmFlZTc3ZDJfMzYtMS0xLTEtMTAxMTkw_98b54fc0-e122-4160-9235-436e5913380f">33.6</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i010e4c0d9c6246be91d37e31d569fa6f_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8zNC9mcmFnOjgwYzUwOTEwZjgwNjQ3NzhiOTZmY2RmN2JjN2FhZTUzL3RhYmxlOjQxZDllZDFiMWQ5NjRkM2ZhOGFlYmQwNDJhZWU3N2QyL3RhYmxlcmFuZ2U6NDFkOWVkMWIxZDk2NGQzZmE4YWViZDA0MmFlZTc3ZDJfMzYtMy0xLTEtMTAxMTkw_70003f2c-2c32-427d-ae47-078dde416003">10.2</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net decrease in cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonfraction unitref="usd" contextref="id879b497a407453985551e83dbee75f8_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8zNC9mcmFnOjgwYzUwOTEwZjgwNjQ3NzhiOTZmY2RmN2JjN2FhZTUzL3RhYmxlOjQxZDllZDFiMWQ5NjRkM2ZhOGFlYmQwNDJhZWU3N2QyL3RhYmxlcmFuZ2U6NDFkOWVkMWIxZDk2NGQzZmE4YWViZDA0MmFlZTc3ZDJfMzgtMS0xLTEtMTAxMTkw_859b11bb-aef3-4c4e-b81e-27f5e8ac2bd0">1,359.3</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i010e4c0d9c6246be91d37e31d569fa6f_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8zNC9mcmFnOjgwYzUwOTEwZjgwNjQ3NzhiOTZmY2RmN2JjN2FhZTUzL3RhYmxlOjQxZDllZDFiMWQ5NjRkM2ZhOGFlYmQwNDJhZWU3N2QyL3RhYmxlcmFuZ2U6NDFkOWVkMWIxZDk2NGQzZmE4YWViZDA0MmFlZTc3ZDJfMzgtMy0xLTEtMTAxMTkw_168b8ee4-e3ad-4f5c-86e1-80c9dc8a2b6b">654.7</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents at January&nbsp;1</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="iffa7a62ea976465eb0977d320e638511_I20211231" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8zNC9mcmFnOjgwYzUwOTEwZjgwNjQ3NzhiOTZmY2RmN2JjN2FhZTUzL3RhYmxlOjQxZDllZDFiMWQ5NjRkM2ZhOGFlYmQwNDJhZWU3N2QyL3RhYmxlcmFuZ2U6NDFkOWVkMWIxZDk2NGQzZmE4YWViZDA0MmFlZTc3ZDJfMzktMS0xLTEtMTAxMTkw_cb14a263-21e4-4e34-a5a4-5018d4e31d63">3,818.5</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i00275dd8facd4dcbb0ad10126a1977c1_I20201231" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8zNC9mcmFnOjgwYzUwOTEwZjgwNjQ3NzhiOTZmY2RmN2JjN2FhZTUzL3RhYmxlOjQxZDllZDFiMWQ5NjRkM2ZhOGFlYmQwNDJhZWU3N2QyL3RhYmxlcmFuZ2U6NDFkOWVkMWIxZDk2NGQzZmE4YWViZDA0MmFlZTc3ZDJfMzktMy0xLTEtMTAxMTkw_a25f7a08-9552-4c2c-8521-c3854e4fa7a6">3,657.1</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash and Cash Equivalents at March 31</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib1053442369e460291956c51ab7e5179_I20220331" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8zNC9mcmFnOjgwYzUwOTEwZjgwNjQ3NzhiOTZmY2RmN2JjN2FhZTUzL3RhYmxlOjQxZDllZDFiMWQ5NjRkM2ZhOGFlYmQwNDJhZWU3N2QyL3RhYmxlcmFuZ2U6NDFkOWVkMWIxZDk2NGQzZmE4YWViZDA0MmFlZTc3ZDJfNDAtMS0xLTEtMTAxMTkw_3e3fc181-3073-4120-8a18-3d21183fb499">2,459.2</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i67e838f8a66a44b2b504c4b1f3b10525_I20210331" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF8zNC9mcmFnOjgwYzUwOTEwZjgwNjQ3NzhiOTZmY2RmN2JjN2FhZTUzL3RhYmxlOjQxZDllZDFiMWQ5NjRkM2ZhOGFlYmQwNDJhZWU3N2QyL3RhYmxlcmFuZ2U6NDFkOWVkMWIxZDk2NGQzZmE4YWViZDA0MmFlZTc3ZDJfNDAtMy0xLTEtMTAxMTkw_76dc4bdf-bb06-49a0-b99f-b23fbfa716ee">3,002.4</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See notes to consolidated condensed financial statements.</span></div><div style="margin-top:9pt"><span><br></span></div><div style="margin-top:9pt"><span><br></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><div id="ie8dc61f8e15b44db82ba16050d5b7b44_37"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span><br></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Condensed Financial Statements</span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(Tables present dollars in millions, except per-share data)</span></div><div id="ie8dc61f8e15b44db82ba16050d5b7b44_40"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 1: <ix:nonnumeric contextref="id879b497a407453985551e83dbee75f8_D20220101-20220331" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80MC9mcmFnOmM2MWJlYjBhMDJlYzRlM2ZhYjcxNDczNTM4ZDcxNWFkL3RleHRyZWdpb246YzYxYmViMGEwMmVjNGUzZmFiNzE0NzM1MzhkNzE1YWRfMjQzMg_a74d4651-6455-4420-85a5-a1f99dfdcdb1" continuedat="i5fccf63033354ac981952a1ecd84a60b" escape="true">Basis of Presentation and Implementation of New Financial Accounting Standard </ix:nonnumeric></span></div><ix:continuation id="i5fccf63033354ac981952a1ecd84a60b"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have prepared the accompanying unaudited consolidated condensed financial statements in accordance with the requirements of Form 10-Q and, therefore, they do not include all information and footnotes necessary for a fair presentation of financial position, results of operations, and cash flows in conformity with accounting principles generally accepted in the United States (GAAP). In our opinion, the consolidated condensed financial statements reflect all adjustments (including those that are normal and recurring) that are necessary for a fair presentation of the results of operations for the periods shown. In preparing financial statements in conformity with GAAP, we must make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, expenses, and related disclosures at the date of the financial statements and during the reporting period. Actual results could differ from those estimates.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information included in this Quarterly Report on Form 10-Q should be read in conjunction with our consolidated financial statements and accompanying notes included in our Annual Report on </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0000059478/000005947822000068/lly-20211231.htm">Form 10-K</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the year ended December&nbsp;31, 2021. We issue our financial statements by filing them with the Securities and Exchange Commission and have evaluated subsequent events up to the time of the filing of this Quarterly Report on Form 10-Q.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain reclassifications have been made to prior periods in the consolidated condensed financial statements and accompanying notes to conform with the current presentation.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All per-share amounts, unless otherwise noted in the footnotes, are presented on a diluted basis; that is, based on the weighted-average number of common shares outstanding plus the effect of incremental shares from our stock-based compensation programs.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate as a single operating segment engaged in the discovery, development, manufacturing, marketing, and sales of pharmaceutical products worldwide. A global research and development organization and a supply chain organization are responsible for the discovery, development, manufacturing, and supply of our products. Regional commercial organizations market, distribute, and sell the products. The business is also supported by global corporate staff functions. Our determination that we operate as a single segment is consistent with the financial information regularly reviewed by the chief operating decision maker for purposes of evaluating performance, allocating resources, setting incentive compensation targets, and planning and forecasting for future periods.</span></div><ix:nonnumeric contextref="id879b497a407453985551e83dbee75f8_D20220101-20220331" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80MC9mcmFnOmM2MWJlYjBhMDJlYzRlM2ZhYjcxNDczNTM4ZDcxNWFkL3RleHRyZWdpb246YzYxYmViMGEwMmVjNGUzZmFiNzE0NzM1MzhkNzE1YWRfMTA0NDUzNjA0NjkyMjA_be27afe6-e182-46e0-aadf-22afa17bd45e" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development Expenses and Acquired In-Process Research and Development (IPR&amp;D) and Development Milestones</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are expensed as incurred. Research and development costs consist of expenses incurred in performing research and development activities, including but not limited to, compensation and benefits, facilities and overhead expense, clinical trial expense and fees paid to contract research organizations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquired IPR&amp;D and development milestones include the initial costs of externally developed IPR&amp;D projects, acquired directly in a transaction other than a business combination, that do not have an alternative future use. Additionally, milestone payment obligations related to these transactions that are incurred prior to regulatory approval of the compound are expensed when the event triggering an obligation to pay the milestone occurs.</span></div></ix:nonnumeric><ix:nonnumeric contextref="id879b497a407453985551e83dbee75f8_D20220101-20220331" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80MC9mcmFnOmM2MWJlYjBhMDJlYzRlM2ZhYjcxNDczNTM4ZDcxNWFkL3RleHRyZWdpb246YzYxYmViMGEwMmVjNGUzZmFiNzE0NzM1MzhkNzE1YWRfMTA0NDUzNjA0NzQ5MzM_03785f01-c518-49ee-ac9e-d55079318fae" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Implementation of New Financial Accounting Standard</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounting Standards Update 2021-01, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reference Rate Reform</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, provides for temporary optional expedients and exceptions in applying current GAAP to contracts, hedging relationships, and other transactions affected by the transition from the use of the London Interbank Offered Rate (LIBOR) to an alternative reference rate. The standard is currently applicable to contracts entered into before January 1, 2023. We adopted the standard in the first quarter of 2022. The adoption did not have a material impact on our consolidated condensed financial statements.</span></div></ix:nonnumeric></ix:continuation><div style="margin-bottom:3pt"><span><br></span></div><div style="margin-bottom:3pt"><span><br></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><div id="ie8dc61f8e15b44db82ba16050d5b7b44_43"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span><br></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 2: <ix:nonnumeric contextref="id879b497a407453985551e83dbee75f8_D20220101-20220331" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80My9mcmFnOjJjMTE4OWYzNzE4OTQxYTRhMDU4MjhhODVlNDA1MmJjL3RleHRyZWdpb246MmMxMTg5ZjM3MTg5NDFhNGEwNTgyOGE4NWU0MDUyYmNfMzgwMA_03edab12-e2cb-46fd-aea7-bcbcfb5fa371" continuedat="if8e076bd61994a91adc579c655fe96b7" escape="true">Revenue</ix:nonnumeric></span></div><ix:continuation id="if8e076bd61994a91adc579c655fe96b7" continuedat="id779f2132c074942b790ef0d64262626"><ix:nonnumeric contextref="id879b497a407453985551e83dbee75f8_D20220101-20220331" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80My9mcmFnOjJjMTE4OWYzNzE4OTQxYTRhMDU4MjhhODVlNDA1MmJjL3RleHRyZWdpb246MmMxMTg5ZjM3MTg5NDFhNGEwNTgyOGE4NWU0MDUyYmNfMzgxMg_3a54d408-b71c-486c-8595-27bf3536175b" continuedat="ib28123e4cc34453ea123c30df7ebce21" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our revenue recognized in our consolidated condensed statements of operations:</span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:65.128%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.422%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net product revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="ic1149e00eba94a9eab47f56d4cf9e9bf_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80My9mcmFnOjJjMTE4OWYzNzE4OTQxYTRhMDU4MjhhODVlNDA1MmJjL3RhYmxlOmZjNzUxOGQ4MzI3ZTQ5YWFhNjA3YTM5NjZlYjUyMWVkL3RhYmxlcmFuZ2U6ZmM3NTE4ZDgzMjdlNDlhYWE2MDdhMzk2NmViNTIxZWRfMi0xLTEtMS0xMDExOTA_a3c6b446-987f-4ec3-9925-bb06c2640c2b">7,132.9</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i0c908ece78834e1094d6092d93b040f8_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80My9mcmFnOjJjMTE4OWYzNzE4OTQxYTRhMDU4MjhhODVlNDA1MmJjL3RhYmxlOmZjNzUxOGQ4MzI3ZTQ5YWFhNjA3YTM5NjZlYjUyMWVkL3RhYmxlcmFuZ2U6ZmM3NTE4ZDgzMjdlNDlhYWE2MDdhMzk2NmViNTIxZWRfMi0zLTEtMS0xMDExOTA_d5b4c571-8bb6-465b-bba3-b335a3b476ae">6,320.0</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration and other revenue</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i908a311d8eb54eeaae2a8faabb1c5148_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80My9mcmFnOjJjMTE4OWYzNzE4OTQxYTRhMDU4MjhhODVlNDA1MmJjL3RhYmxlOmZjNzUxOGQ4MzI3ZTQ5YWFhNjA3YTM5NjZlYjUyMWVkL3RhYmxlcmFuZ2U6ZmM3NTE4ZDgzMjdlNDlhYWE2MDdhMzk2NmViNTIxZWRfMy0xLTEtMS0xMDExOTA_c6eef8f9-248c-4fe3-b7ce-661e944cf1ac">677.1</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i5c360f700df74f2ab393fcbc7f1d0c86_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80My9mcmFnOjJjMTE4OWYzNzE4OTQxYTRhMDU4MjhhODVlNDA1MmJjL3RhYmxlOmZjNzUxOGQ4MzI3ZTQ5YWFhNjA3YTM5NjZlYjUyMWVkL3RhYmxlcmFuZ2U6ZmM3NTE4ZDgzMjdlNDlhYWE2MDdhMzk2NmViNTIxZWRfMy0zLTEtMS0xMDExOTA_54ce9299-97ee-4266-9377-a174321e20ad">485.6</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="id879b497a407453985551e83dbee75f8_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80My9mcmFnOjJjMTE4OWYzNzE4OTQxYTRhMDU4MjhhODVlNDA1MmJjL3RhYmxlOmZjNzUxOGQ4MzI3ZTQ5YWFhNjA3YTM5NjZlYjUyMWVkL3RhYmxlcmFuZ2U6ZmM3NTE4ZDgzMjdlNDlhYWE2MDdhMzk2NmViNTIxZWRfNC0xLTEtMS0xMDExOTA_5a33052e-d1ca-48ac-83e2-e66e3cf4978c">7,810.0</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i010e4c0d9c6246be91d37e31d569fa6f_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80My9mcmFnOjJjMTE4OWYzNzE4OTQxYTRhMDU4MjhhODVlNDA1MmJjL3RhYmxlOmZjNzUxOGQ4MzI3ZTQ5YWFhNjA3YTM5NjZlYjUyMWVkL3RhYmxlcmFuZ2U6ZmM3NTE4ZDgzMjdlNDlhYWE2MDdhMzk2NmViNTIxZWRfNC0zLTEtMS0xMDExOTA_49a602a4-a536-44ab-abe4-8f45ea30b333">6,805.6</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></tbody></table></div><div style="margin-top:1pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Collaboration and other revenue associated with prior period transfers of intellectual property was $<ix:nonfraction unitref="usd" contextref="id551c0dd4f8142988996d40dff58f235_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80My9mcmFnOjJjMTE4OWYzNzE4OTQxYTRhMDU4MjhhODVlNDA1MmJjL3RleHRyZWdpb246MmMxMTg5ZjM3MTg5NDFhNGEwNTgyOGE4NWU0MDUyYmNfMjM4_7ac5121a-6704-4caf-bce5-152bc9f381d2">53.2</ix:nonfraction> million and $<ix:nonfraction unitref="usd" contextref="ib1cb3f43e3f14fb19a81e30a469be70e_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80My9mcmFnOjJjMTE4OWYzNzE4OTQxYTRhMDU4MjhhODVlNDA1MmJjL3RleHRyZWdpb246MmMxMTg5ZjM3MTg5NDFhNGEwNTgyOGE4NWU0MDUyYmNfMTA5OTUxMTYzMTYxMg_6eb31ad2-b9d0-4d7a-8cfe-ff646ae6371e">43.0</ix:nonfraction> million during the three months ended March&nbsp;31, 2022 and 2021, respectively.</span></div></ix:nonnumeric><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize revenue primarily from two different types of contracts, product sales to customers (net product revenue) and collaborations and other arrangements. Revenue recognized from collaborations and other arrangements includes our share of profits from the collaboration, as well as royalties, upfront and milestone payments we receive under these types of contracts. See Note 4 for additional information related to our collaborations and other arrangements. Collaboration and other revenue disclosed above includes the revenue from the Jardiance</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">® </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trajenta</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> families of products resulting from our collaboration with Boehringer Ingelheim discussed in Note 4. Substantially all of the remainder of collaboration and other revenue is related to contracts accounted for as contracts with customers.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Adjustments to Revenue</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adjustments to increase revenue recognized as a result of changes in estimates for our most significant United States (U.S.) sales returns, rebates, and discounts liability balances for products shipped in previous periods were less than <ix:nonfraction unitref="number" contextref="i057edaf4edfb4ff488df655e1ddbb15d_D20220101-20220331" decimals="2" name="lly:RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80My9mcmFnOjJjMTE4OWYzNzE4OTQxYTRhMDU4MjhhODVlNDA1MmJjL3RleHRyZWdpb246MmMxMTg5ZjM3MTg5NDFhNGEwNTgyOGE4NWU0MDUyYmNfMTQ4MA_6871798d-6389-4e4b-8f36-3274e03550ca"><ix:nonfraction unitref="number" contextref="ic341dbad348840e68a9a109777641f35_D20210101-20210331" decimals="2" name="lly:RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80My9mcmFnOjJjMTE4OWYzNzE4OTQxYTRhMDU4MjhhODVlNDA1MmJjL3RleHRyZWdpb246MmMxMTg5ZjM3MTg5NDFhNGEwNTgyOGE4NWU0MDUyYmNfMTQ4MA_b1c2b5b6-e7ad-4c40-8c14-3925f16c706c">1</ix:nonfraction></ix:nonfraction> percent of U.S. revenue during each of the three months ended March&nbsp;31, 2022 and 2021. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Contract Liabilities</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our contract liabilities result from arrangements where we have received payment in advance of performance under the contract and do not include sales returns, rebates, and discounts. Changes in contract liabilities are generally due to either receipt of additional advance payments or our performance under the contract. </span></div><ix:nonnumeric contextref="id879b497a407453985551e83dbee75f8_D20220101-20220331" name="us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80My9mcmFnOjJjMTE4OWYzNzE4OTQxYTRhMDU4MjhhODVlNDA1MmJjL3RleHRyZWdpb246MmMxMTg5ZjM3MTg5NDFhNGEwNTgyOGE4NWU0MDUyYmNfMzgxNA_b9102d26-bcb2-4989-866b-21012ce4bd36" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes contract liability balances:</span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:65.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.274%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.276%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib1053442369e460291956c51ab7e5179_I20220331" decimals="-5" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80My9mcmFnOjJjMTE4OWYzNzE4OTQxYTRhMDU4MjhhODVlNDA1MmJjL3RhYmxlOjNiMjc3NDYyNjdiZDRkM2NiNTBiYzgyNTA3YTI2MDMwL3RhYmxlcmFuZ2U6M2IyNzc0NjI2N2JkNGQzY2I1MGJjODI1MDdhMjYwMzBfMS0xLTEtMS0xMDExOTA_059c494c-7369-4fb8-b126-3450c16b4863">251.6</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iffa7a62ea976465eb0977d320e638511_I20211231" decimals="-5" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80My9mcmFnOjJjMTE4OWYzNzE4OTQxYTRhMDU4MjhhODVlNDA1MmJjL3RhYmxlOjNiMjc3NDYyNjdiZDRkM2NiNTBiYzgyNTA3YTI2MDMwL3RhYmxlcmFuZ2U6M2IyNzc0NjI2N2JkNGQzY2I1MGJjODI1MDdhMjYwMzBfMS0zLTEtMS0xMDExOTA_efe7753c-1847-4d81-a3f2-efea01e4091f">262.6</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></div></ix:nonnumeric><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&nbsp;31, 2022 and 2021, revenue recognized from contract liabilities as of the beginning of the respective year was not material. Revenue expected to be recognized in the future from contract liabilities as the related performance obligations are satisfied is not expected to be material in any one year.</span></div></ix:continuation><div style="margin-bottom:12pt;margin-top:12pt"><span><br></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span><br></span></div></div><ix:continuation id="id779f2132c074942b790ef0d64262626" continuedat="i6237fd296fa949df9b552c0f87991822"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Disaggregation of Revenue</span></div><ix:continuation id="ib28123e4cc34453ea123c30df7ebce21" continuedat="ide1fa61f68b647a39ed17a868a8f8f7f"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes revenue by product for the three months ended March&nbsp;31, 2022 and 2021:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:37.642%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.699%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="9" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Outside U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Outside U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue—to unaffiliated customers:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diabetes:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Trulicity</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">®</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i1d928ff934414f339d711ba91de66c6c_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80My9mcmFnOjJjMTE4OWYzNzE4OTQxYTRhMDU4MjhhODVlNDA1MmJjL3RhYmxlOmJmZWEyNTEwYTk4YTRkN2E4MWViNjllODhiYzM4OTk3L3RhYmxlcmFuZ2U6YmZlYTI1MTBhOThhNGQ3YTgxZWI2OWU4OGJjMzg5OTdfNS0xLTEtMS0xMDExOTA_ee50733b-8621-4e39-9809-29159aa0c95a">1,313.9</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i3d4129b004644544827c79d8fe7d7553_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80My9mcmFnOjJjMTE4OWYzNzE4OTQxYTRhMDU4MjhhODVlNDA1MmJjL3RhYmxlOmJmZWEyNTEwYTk4YTRkN2E4MWViNjllODhiYzM4OTk3L3RhYmxlcmFuZ2U6YmZlYTI1MTBhOThhNGQ3YTgxZWI2OWU4OGJjMzg5OTdfNS0yLTEtMS0xMDExOTA_a61fd2d3-b6bd-4341-bb28-d207993a2c80">427.4</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i43c847a6bcc2436fb9611d9c5224292e_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80My9mcmFnOjJjMTE4OWYzNzE4OTQxYTRhMDU4MjhhODVlNDA1MmJjL3RhYmxlOmJmZWEyNTEwYTk4YTRkN2E4MWViNjllODhiYzM4OTk3L3RhYmxlcmFuZ2U6YmZlYTI1MTBhOThhNGQ3YTgxZWI2OWU4OGJjMzg5OTdfNS0zLTEtMS0xMDExOTA_557b0da9-2aa3-4bdf-9965-b88be2237abc">1,741.3</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i1a537253917d47f79d2a63b89c2047f4_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80My9mcmFnOjJjMTE4OWYzNzE4OTQxYTRhMDU4MjhhODVlNDA1MmJjL3RhYmxlOmJmZWEyNTEwYTk4YTRkN2E4MWViNjllODhiYzM4OTk3L3RhYmxlcmFuZ2U6YmZlYTI1MTBhOThhNGQ3YTgxZWI2OWU4OGJjMzg5OTdfNS01LTEtMS0xMDExOTA_f1cf044b-c3fe-4d92-bf78-e908a7cd1a5e">1,116.8</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i8eb2e6c4e79e4c84bbe2495e225c9ace_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80My9mcmFnOjJjMTE4OWYzNzE4OTQxYTRhMDU4MjhhODVlNDA1MmJjL3RhYmxlOmJmZWEyNTEwYTk4YTRkN2E4MWViNjllODhiYzM4OTk3L3RhYmxlcmFuZ2U6YmZlYTI1MTBhOThhNGQ3YTgxZWI2OWU4OGJjMzg5OTdfNS02LTEtMS0xMDExOTA_2c317459-178b-4cca-9196-2f61e193039f">335.7</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i7ca35c03fa5043b591914a4a7dcc003c_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80My9mcmFnOjJjMTE4OWYzNzE4OTQxYTRhMDU4MjhhODVlNDA1MmJjL3RhYmxlOmJmZWEyNTEwYTk4YTRkN2E4MWViNjllODhiYzM4OTk3L3RhYmxlcmFuZ2U6YmZlYTI1MTBhOThhNGQ3YTgxZWI2OWU4OGJjMzg5OTdfNS03LTEtMS0xMDExOTA_f0296796-9aef-4c71-b694-e1f417dfe03a">1,452.4</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Humalog</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">® (1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i2f5a660bdd654492984092e74d834aff_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80My9mcmFnOjJjMTE4OWYzNzE4OTQxYTRhMDU4MjhhODVlNDA1MmJjL3RhYmxlOmJmZWEyNTEwYTk4YTRkN2E4MWViNjllODhiYzM4OTk3L3RhYmxlcmFuZ2U6YmZlYTI1MTBhOThhNGQ3YTgxZWI2OWU4OGJjMzg5OTdfNi0xLTEtMS0xMDExOTA_40160c9d-f60f-4a5e-b0f9-4afc97c0fd4f">368.9</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i66c645d6113e47d0955176d2c29149ca_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80My9mcmFnOjJjMTE4OWYzNzE4OTQxYTRhMDU4MjhhODVlNDA1MmJjL3RhYmxlOmJmZWEyNTEwYTk4YTRkN2E4MWViNjllODhiYzM4OTk3L3RhYmxlcmFuZ2U6YmZlYTI1MTBhOThhNGQ3YTgxZWI2OWU4OGJjMzg5OTdfNi0yLTEtMS0xMDExOTA_bd7dd1a4-33e8-4466-91be-c550cfe7e659">249.3</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i360dec42bd9f475198d2a27568c8a2d1_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80My9mcmFnOjJjMTE4OWYzNzE4OTQxYTRhMDU4MjhhODVlNDA1MmJjL3RhYmxlOmJmZWEyNTEwYTk4YTRkN2E4MWViNjllODhiYzM4OTk3L3RhYmxlcmFuZ2U6YmZlYTI1MTBhOThhNGQ3YTgxZWI2OWU4OGJjMzg5OTdfNi0zLTEtMS0xMDExOTA_abafad38-b784-4e01-b81b-5e0e718ad9c8">618.2</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i1e804ce611484db3805881c6a06fe4f6_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80My9mcmFnOjJjMTE4OWYzNzE4OTQxYTRhMDU4MjhhODVlNDA1MmJjL3RhYmxlOmJmZWEyNTEwYTk4YTRkN2E4MWViNjllODhiYzM4OTk3L3RhYmxlcmFuZ2U6YmZlYTI1MTBhOThhNGQ3YTgxZWI2OWU4OGJjMzg5OTdfNi01LTEtMS0xMDExOTA_7d70af2a-ce23-4d8c-bd38-7b42f258c0ac">332.7</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i6b49581ac9414e90b623279b08df901e_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80My9mcmFnOjJjMTE4OWYzNzE4OTQxYTRhMDU4MjhhODVlNDA1MmJjL3RhYmxlOmJmZWEyNTEwYTk4YTRkN2E4MWViNjllODhiYzM4OTk3L3RhYmxlcmFuZ2U6YmZlYTI1MTBhOThhNGQ3YTgxZWI2OWU4OGJjMzg5OTdfNi02LTEtMS0xMDExOTA_3011c753-9791-4d1b-b996-a7b1022654ac">284.4</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="id458828d048e4e17835286479b42ad54_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80My9mcmFnOjJjMTE4OWYzNzE4OTQxYTRhMDU4MjhhODVlNDA1MmJjL3RhYmxlOmJmZWEyNTEwYTk4YTRkN2E4MWViNjllODhiYzM4OTk3L3RhYmxlcmFuZ2U6YmZlYTI1MTBhOThhNGQ3YTgxZWI2OWU4OGJjMzg5OTdfNi03LTEtMS0xMDExOTA_a895a34e-d754-457c-985c-1d1bc580464e">617.0</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Jardiance</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="ie62f212b84b84441a9d590c22ca7e076_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80My9mcmFnOjJjMTE4OWYzNzE4OTQxYTRhMDU4MjhhODVlNDA1MmJjL3RhYmxlOmJmZWEyNTEwYTk4YTRkN2E4MWViNjllODhiYzM4OTk3L3RhYmxlcmFuZ2U6YmZlYTI1MTBhOThhNGQ3YTgxZWI2OWU4OGJjMzg5OTdfNy0xLTEtMS0xMDExOTA_f99cbb91-36ac-4cb5-9732-954f39d83570">229.8</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i50e7f3e230d74d469d6374c85d49ec18_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80My9mcmFnOjJjMTE4OWYzNzE4OTQxYTRhMDU4MjhhODVlNDA1MmJjL3RhYmxlOmJmZWEyNTEwYTk4YTRkN2E4MWViNjllODhiYzM4OTk3L3RhYmxlcmFuZ2U6YmZlYTI1MTBhOThhNGQ3YTgxZWI2OWU4OGJjMzg5OTdfNy0yLTEtMS0xMDExOTA_979f16be-8e9f-4d52-a0fe-82ed1972da17">189.7</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i4cb6aa62dbd343b890ba09e927b3cd93_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80My9mcmFnOjJjMTE4OWYzNzE4OTQxYTRhMDU4MjhhODVlNDA1MmJjL3RhYmxlOmJmZWEyNTEwYTk4YTRkN2E4MWViNjllODhiYzM4OTk3L3RhYmxlcmFuZ2U6YmZlYTI1MTBhOThhNGQ3YTgxZWI2OWU4OGJjMzg5OTdfNy0zLTEtMS0xMDExOTA_1ed55943-902d-4429-96a6-0a4623ec2a2d">419.4</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ia7c4529116bc4c849565b039663b3620_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80My9mcmFnOjJjMTE4OWYzNzE4OTQxYTRhMDU4MjhhODVlNDA1MmJjL3RhYmxlOmJmZWEyNTEwYTk4YTRkN2E4MWViNjllODhiYzM4OTk3L3RhYmxlcmFuZ2U6YmZlYTI1MTBhOThhNGQ3YTgxZWI2OWU4OGJjMzg5OTdfNy01LTEtMS0xMDExOTA_00b8dc18-c0a5-4a3b-a22f-1c7667e76211">151.2</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if5144d4906484c5c8da6a103252b001c_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80My9mcmFnOjJjMTE4OWYzNzE4OTQxYTRhMDU4MjhhODVlNDA1MmJjL3RhYmxlOmJmZWEyNTEwYTk4YTRkN2E4MWViNjllODhiYzM4OTk3L3RhYmxlcmFuZ2U6YmZlYTI1MTBhOThhNGQ3YTgxZWI2OWU4OGJjMzg5OTdfNy02LTEtMS0xMDExOTA_531f6975-4a3d-4bcb-a219-e1ead1bb5c10">160.8</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i777b66c425e44ef281a1ea05038a2e33_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80My9mcmFnOjJjMTE4OWYzNzE4OTQxYTRhMDU4MjhhODVlNDA1MmJjL3RhYmxlOmJmZWEyNTEwYTk4YTRkN2E4MWViNjllODhiYzM4OTk3L3RhYmxlcmFuZ2U6YmZlYTI1MTBhOThhNGQ3YTgxZWI2OWU4OGJjMzg5OTdfNy03LTEtMS0xMDExOTA_823f3b10-17f9-4ba9-934f-d18b5b0cb046">312.0</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Humulin</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">®</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="icdaa6c5d7460426aa41e467d0a5d1a1c_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80My9mcmFnOjJjMTE4OWYzNzE4OTQxYTRhMDU4MjhhODVlNDA1MmJjL3RhYmxlOmJmZWEyNTEwYTk4YTRkN2E4MWViNjllODhiYzM4OTk3L3RhYmxlcmFuZ2U6YmZlYTI1MTBhOThhNGQ3YTgxZWI2OWU4OGJjMzg5OTdfOC0xLTEtMS0xMDExOTA_8a9b2def-b92d-4ae8-81b7-d998b2060afa">190.4</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i8685f0545a4e4f659ada216a354b06fc_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80My9mcmFnOjJjMTE4OWYzNzE4OTQxYTRhMDU4MjhhODVlNDA1MmJjL3RhYmxlOmJmZWEyNTEwYTk4YTRkN2E4MWViNjllODhiYzM4OTk3L3RhYmxlcmFuZ2U6YmZlYTI1MTBhOThhNGQ3YTgxZWI2OWU4OGJjMzg5OTdfOC0yLTEtMS0xMDExOTA_bce51ad4-dd58-4bd7-9cf4-189215ba9a15">82.8</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="if28a514fbb6d452aa6354a426d371b87_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80My9mcmFnOjJjMTE4OWYzNzE4OTQxYTRhMDU4MjhhODVlNDA1MmJjL3RhYmxlOmJmZWEyNTEwYTk4YTRkN2E4MWViNjllODhiYzM4OTk3L3RhYmxlcmFuZ2U6YmZlYTI1MTBhOThhNGQ3YTgxZWI2OWU4OGJjMzg5OTdfOC0zLTEtMS0xMDExOTA_c15b9aea-5a30-4b03-84ae-3eb522600fba">273.2</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iba46f63d62554503b9b65f40f4657fe3_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80My9mcmFnOjJjMTE4OWYzNzE4OTQxYTRhMDU4MjhhODVlNDA1MmJjL3RhYmxlOmJmZWEyNTEwYTk4YTRkN2E4MWViNjllODhiYzM4OTk3L3RhYmxlcmFuZ2U6YmZlYTI1MTBhOThhNGQ3YTgxZWI2OWU4OGJjMzg5OTdfOC01LTEtMS0xMDExOTA_c1f45e95-6d16-4ac3-8233-2999f4227039">219.0</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if2590ae4b40c44f08b7057982d176fc6_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80My9mcmFnOjJjMTE4OWYzNzE4OTQxYTRhMDU4MjhhODVlNDA1MmJjL3RhYmxlOmJmZWEyNTEwYTk4YTRkN2E4MWViNjllODhiYzM4OTk3L3RhYmxlcmFuZ2U6YmZlYTI1MTBhOThhNGQ3YTgxZWI2OWU4OGJjMzg5OTdfOC02LTEtMS0xMDExOTA_18cfe021-8ae9-4e44-b7a3-c9cd6a4ce8e6">102.7</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i00b3c21da768430aabd3e36a06dc1aab_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80My9mcmFnOjJjMTE4OWYzNzE4OTQxYTRhMDU4MjhhODVlNDA1MmJjL3RhYmxlOmJmZWEyNTEwYTk4YTRkN2E4MWViNjllODhiYzM4OTk3L3RhYmxlcmFuZ2U6YmZlYTI1MTBhOThhNGQ3YTgxZWI2OWU4OGJjMzg5OTdfOC03LTEtMS0xMDExOTA_707cec79-38f0-4c83-a5e8-b416a53c82e4">321.7</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Basaglar</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">®</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i02ca14f5a0414a43a7631e15dbc8c83e_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80My9mcmFnOjJjMTE4OWYzNzE4OTQxYTRhMDU4MjhhODVlNDA1MmJjL3RhYmxlOmJmZWEyNTEwYTk4YTRkN2E4MWViNjllODhiYzM4OTk3L3RhYmxlcmFuZ2U6YmZlYTI1MTBhOThhNGQ3YTgxZWI2OWU4OGJjMzg5OTdfOS0xLTEtMS0xMDExOTA_f6597b5c-2852-417a-96ef-e2b3714b2be0">119.3</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i45c518485c864258b8570772e23e7f3d_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80My9mcmFnOjJjMTE4OWYzNzE4OTQxYTRhMDU4MjhhODVlNDA1MmJjL3RhYmxlOmJmZWEyNTEwYTk4YTRkN2E4MWViNjllODhiYzM4OTk3L3RhYmxlcmFuZ2U6YmZlYTI1MTBhOThhNGQ3YTgxZWI2OWU4OGJjMzg5OTdfOS0yLTEtMS0xMDExOTA_4b84d4cc-4ccd-4a6f-9d2c-cd79b701b557">72.2</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="ie964fd385686493399055f5b20bfe25e_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80My9mcmFnOjJjMTE4OWYzNzE4OTQxYTRhMDU4MjhhODVlNDA1MmJjL3RhYmxlOmJmZWEyNTEwYTk4YTRkN2E4MWViNjllODhiYzM4OTk3L3RhYmxlcmFuZ2U6YmZlYTI1MTBhOThhNGQ3YTgxZWI2OWU4OGJjMzg5OTdfOS0zLTEtMS0xMDExOTA_ff68e865-5250-411f-a731-99254a7e256c">191.5</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i2857f2babcfd4084bc21205f8b62d6b9_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80My9mcmFnOjJjMTE4OWYzNzE4OTQxYTRhMDU4MjhhODVlNDA1MmJjL3RhYmxlOmJmZWEyNTEwYTk4YTRkN2E4MWViNjllODhiYzM4OTk3L3RhYmxlcmFuZ2U6YmZlYTI1MTBhOThhNGQ3YTgxZWI2OWU4OGJjMzg5OTdfOS01LTEtMS0xMDExOTA_7a256a14-bab4-4775-8902-2e2cc3ab4467">175.2</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="id40da84c657f43a3a76ff109504f757f_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80My9mcmFnOjJjMTE4OWYzNzE4OTQxYTRhMDU4MjhhODVlNDA1MmJjL3RhYmxlOmJmZWEyNTEwYTk4YTRkN2E4MWViNjllODhiYzM4OTk3L3RhYmxlcmFuZ2U6YmZlYTI1MTBhOThhNGQ3YTgxZWI2OWU4OGJjMzg5OTdfOS02LTEtMS0xMDExOTA_6ee66e15-a4b7-4b24-8fa5-88f19b7ff22f">71.4</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ie7ec39e69cee464db36f6873b2d073f8_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80My9mcmFnOjJjMTE4OWYzNzE4OTQxYTRhMDU4MjhhODVlNDA1MmJjL3RhYmxlOmJmZWEyNTEwYTk4YTRkN2E4MWViNjllODhiYzM4OTk3L3RhYmxlcmFuZ2U6YmZlYTI1MTBhOThhNGQ3YTgxZWI2OWU4OGJjMzg5OTdfOS03LTEtMS0xMDExOTA_88fea232-5a6e-478b-a43c-d01cf2de3e6f">246.6</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other diabetes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="icdd881559f7c49ca9f53555b5e263c09_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80My9mcmFnOjJjMTE4OWYzNzE4OTQxYTRhMDU4MjhhODVlNDA1MmJjL3RhYmxlOmJmZWEyNTEwYTk4YTRkN2E4MWViNjllODhiYzM4OTk3L3RhYmxlcmFuZ2U6YmZlYTI1MTBhOThhNGQ3YTgxZWI2OWU4OGJjMzg5OTdfMTAtMS0xLTEtMTAxMTkw_a85fd79c-b122-42f0-a347-6b5082f88439">54.3</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i67f170f144f94c999ce01aabde1f4e76_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80My9mcmFnOjJjMTE4OWYzNzE4OTQxYTRhMDU4MjhhODVlNDA1MmJjL3RhYmxlOmJmZWEyNTEwYTk4YTRkN2E4MWViNjllODhiYzM4OTk3L3RhYmxlcmFuZ2U6YmZlYTI1MTBhOThhNGQ3YTgxZWI2OWU4OGJjMzg5OTdfMTAtMi0xLTEtMTAxMTkw_f91a3657-7b06-44b1-864e-44be27bad43b">90.2</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib3d22ba4cfe042149bf38612aeda8005_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80My9mcmFnOjJjMTE4OWYzNzE4OTQxYTRhMDU4MjhhODVlNDA1MmJjL3RhYmxlOmJmZWEyNTEwYTk4YTRkN2E4MWViNjllODhiYzM4OTk3L3RhYmxlcmFuZ2U6YmZlYTI1MTBhOThhNGQ3YTgxZWI2OWU4OGJjMzg5OTdfMTAtMy0xLTEtMTAxMTkw_c31fad34-ebcc-4947-8841-94bfb5333631">144.6</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ic1f7e0c6d913421c9e9fff2c4fe23be5_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80My9mcmFnOjJjMTE4OWYzNzE4OTQxYTRhMDU4MjhhODVlNDA1MmJjL3RhYmxlOmJmZWEyNTEwYTk4YTRkN2E4MWViNjllODhiYzM4OTk3L3RhYmxlcmFuZ2U6YmZlYTI1MTBhOThhNGQ3YTgxZWI2OWU4OGJjMzg5OTdfMTAtNS0xLTEtMTAxMTkw_52bfec1a-6d10-46c7-acf8-f8551867b794">66.3</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i0a4d94c6004843f687879c5db8de8712_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80My9mcmFnOjJjMTE4OWYzNzE4OTQxYTRhMDU4MjhhODVlNDA1MmJjL3RhYmxlOmJmZWEyNTEwYTk4YTRkN2E4MWViNjllODhiYzM4OTk3L3RhYmxlcmFuZ2U6YmZlYTI1MTBhOThhNGQ3YTgxZWI2OWU4OGJjMzg5OTdfMTAtNi0xLTEtMTAxMTkw_f11b9d4e-00a3-4ea3-815b-11ee8913b6db">94.9</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if20fa24c94f54c0c8da9136e05e4b5ef_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80My9mcmFnOjJjMTE4OWYzNzE4OTQxYTRhMDU4MjhhODVlNDA1MmJjL3RhYmxlOmJmZWEyNTEwYTk4YTRkN2E4MWViNjllODhiYzM4OTk3L3RhYmxlcmFuZ2U6YmZlYTI1MTBhOThhNGQ3YTgxZWI2OWU4OGJjMzg5OTdfMTAtNy0xLTEtMTAxMTkw_88b643c9-5371-4248-b660-5abf174e465b">161.4</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total diabetes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i862ddf7fe37f487f90b216e79873b421_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80My9mcmFnOjJjMTE4OWYzNzE4OTQxYTRhMDU4MjhhODVlNDA1MmJjL3RhYmxlOmJmZWEyNTEwYTk4YTRkN2E4MWViNjllODhiYzM4OTk3L3RhYmxlcmFuZ2U6YmZlYTI1MTBhOThhNGQ3YTgxZWI2OWU4OGJjMzg5OTdfMTEtMS0xLTEtMTAxMTkw_6f41b497-ba1e-4983-9595-045045119864">2,276.6</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i2782631369e043a2a1043644a76a6a28_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80My9mcmFnOjJjMTE4OWYzNzE4OTQxYTRhMDU4MjhhODVlNDA1MmJjL3RhYmxlOmJmZWEyNTEwYTk4YTRkN2E4MWViNjllODhiYzM4OTk3L3RhYmxlcmFuZ2U6YmZlYTI1MTBhOThhNGQ3YTgxZWI2OWU4OGJjMzg5OTdfMTEtMi0xLTEtMTAxMTkw_12c8ef43-f104-4e66-a4be-5d57fcf430da">1,111.6</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="id9014f48514443a0be11ead727a2799b_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80My9mcmFnOjJjMTE4OWYzNzE4OTQxYTRhMDU4MjhhODVlNDA1MmJjL3RhYmxlOmJmZWEyNTEwYTk4YTRkN2E4MWViNjllODhiYzM4OTk3L3RhYmxlcmFuZ2U6YmZlYTI1MTBhOThhNGQ3YTgxZWI2OWU4OGJjMzg5OTdfMTEtMy0xLTEtMTAxMTkw_f8e9a53d-864d-40c3-8951-70933f325a9e">3,388.2</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i82fdfc09ca2d405c92da72d6de7688b8_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80My9mcmFnOjJjMTE4OWYzNzE4OTQxYTRhMDU4MjhhODVlNDA1MmJjL3RhYmxlOmJmZWEyNTEwYTk4YTRkN2E4MWViNjllODhiYzM4OTk3L3RhYmxlcmFuZ2U6YmZlYTI1MTBhOThhNGQ3YTgxZWI2OWU4OGJjMzg5OTdfMTEtNS0xLTEtMTAxMTkw_cedaf2a5-e39e-49a0-87b6-7646799dfdca">2,061.2</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i8d70fcb627cf43bfbaa643572e0531bd_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80My9mcmFnOjJjMTE4OWYzNzE4OTQxYTRhMDU4MjhhODVlNDA1MmJjL3RhYmxlOmJmZWEyNTEwYTk4YTRkN2E4MWViNjllODhiYzM4OTk3L3RhYmxlcmFuZ2U6YmZlYTI1MTBhOThhNGQ3YTgxZWI2OWU4OGJjMzg5OTdfMTEtNi0xLTEtMTAxMTkw_a0ace171-d1bf-4e20-a4db-a9490c45a652">1,049.9</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i1d14eefd28f54bd7a3bb20e633acefcd_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80My9mcmFnOjJjMTE4OWYzNzE4OTQxYTRhMDU4MjhhODVlNDA1MmJjL3RhYmxlOmJmZWEyNTEwYTk4YTRkN2E4MWViNjllODhiYzM4OTk3L3RhYmxlcmFuZ2U6YmZlYTI1MTBhOThhNGQ3YTgxZWI2OWU4OGJjMzg5OTdfMTEtNy0xLTEtMTAxMTkw_cb6f2408-5169-4606-b199-60117ffc912e">3,111.1</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Oncology:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Verzenio</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">®</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i82b25f95ac834d7db3cc009ee7887ec4_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80My9mcmFnOjJjMTE4OWYzNzE4OTQxYTRhMDU4MjhhODVlNDA1MmJjL3RhYmxlOmJmZWEyNTEwYTk4YTRkN2E4MWViNjllODhiYzM4OTk3L3RhYmxlcmFuZ2U6YmZlYTI1MTBhOThhNGQ3YTgxZWI2OWU4OGJjMzg5OTdfMTQtMS0xLTEtMTIwNDc4_8c08ef62-0f7d-4da1-9a05-eb33ef838da6">301.5</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="id53b2f021056477b9bce0c0afd760de4_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80My9mcmFnOjJjMTE4OWYzNzE4OTQxYTRhMDU4MjhhODVlNDA1MmJjL3RhYmxlOmJmZWEyNTEwYTk4YTRkN2E4MWViNjllODhiYzM4OTk3L3RhYmxlcmFuZ2U6YmZlYTI1MTBhOThhNGQ3YTgxZWI2OWU4OGJjMzg5OTdfMTQtMi0xLTEtMTIwNDc4_a1abe158-3eb3-4246-bb02-14fa5b6ee59a">167.9</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i883a9b3ff28f4e8f823b628c6f50c431_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80My9mcmFnOjJjMTE4OWYzNzE4OTQxYTRhMDU4MjhhODVlNDA1MmJjL3RhYmxlOmJmZWEyNTEwYTk4YTRkN2E4MWViNjllODhiYzM4OTk3L3RhYmxlcmFuZ2U6YmZlYTI1MTBhOThhNGQ3YTgxZWI2OWU4OGJjMzg5OTdfMTQtMy0xLTEtMTIwNDc4_9a7874d3-f964-46df-a79e-521297377797">469.4</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i8956a1fedf96422c909b9746f1cc0150_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80My9mcmFnOjJjMTE4OWYzNzE4OTQxYTRhMDU4MjhhODVlNDA1MmJjL3RhYmxlOmJmZWEyNTEwYTk4YTRkN2E4MWViNjllODhiYzM4OTk3L3RhYmxlcmFuZ2U6YmZlYTI1MTBhOThhNGQ3YTgxZWI2OWU4OGJjMzg5OTdfMTQtNS0xLTEtMTIwNDc4_72fd1cb8-c34a-4f8c-b1bf-86b5e161407b">172.8</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ic89987fa855943749c0e97aafa7e34cc_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80My9mcmFnOjJjMTE4OWYzNzE4OTQxYTRhMDU4MjhhODVlNDA1MmJjL3RhYmxlOmJmZWEyNTEwYTk4YTRkN2E4MWViNjllODhiYzM4OTk3L3RhYmxlcmFuZ2U6YmZlYTI1MTBhOThhNGQ3YTgxZWI2OWU4OGJjMzg5OTdfMTQtNi0xLTEtMTIwNDc4_140e4a2e-09c4-4a59-9763-bbd2342388e5">96.2</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i1b0e11b6e59645e2b6a994394790b4b4_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80My9mcmFnOjJjMTE4OWYzNzE4OTQxYTRhMDU4MjhhODVlNDA1MmJjL3RhYmxlOmJmZWEyNTEwYTk4YTRkN2E4MWViNjllODhiYzM4OTk3L3RhYmxlcmFuZ2U6YmZlYTI1MTBhOThhNGQ3YTgxZWI2OWU4OGJjMzg5OTdfMTQtNy0xLTEtMTIwNDc4_185b102b-5eab-406c-9d92-9cf898b5eac9">269.0</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Alimta</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">®</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i05f6aa31973749ae8330b8a4f6956a45_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80My9mcmFnOjJjMTE4OWYzNzE4OTQxYTRhMDU4MjhhODVlNDA1MmJjL3RhYmxlOmJmZWEyNTEwYTk4YTRkN2E4MWViNjllODhiYzM4OTk3L3RhYmxlcmFuZ2U6YmZlYTI1MTBhOThhNGQ3YTgxZWI2OWU4OGJjMzg5OTdfMTQtMS0xLTEtMTAxMTkw_5df39178-ba3e-461d-859b-d9b278d25605">254.3</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i566d301eeea54ba6ad2547388d94347e_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80My9mcmFnOjJjMTE4OWYzNzE4OTQxYTRhMDU4MjhhODVlNDA1MmJjL3RhYmxlOmJmZWEyNTEwYTk4YTRkN2E4MWViNjllODhiYzM4OTk3L3RhYmxlcmFuZ2U6YmZlYTI1MTBhOThhNGQ3YTgxZWI2OWU4OGJjMzg5OTdfMTQtMi0xLTEtMTAxMTkw_6a82689d-607d-4d91-9f44-fce6d3912a32">89.7</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i50347a0f753a4ea98550ed4615b568a8_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80My9mcmFnOjJjMTE4OWYzNzE4OTQxYTRhMDU4MjhhODVlNDA1MmJjL3RhYmxlOmJmZWEyNTEwYTk4YTRkN2E4MWViNjllODhiYzM4OTk3L3RhYmxlcmFuZ2U6YmZlYTI1MTBhOThhNGQ3YTgxZWI2OWU4OGJjMzg5OTdfMTQtMy0xLTEtMTAxMTkw_91d8215a-393a-45f1-91b3-0b52fb6f3316">343.9</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i4aa80bbe80b745cca4b9dd6801370e25_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80My9mcmFnOjJjMTE4OWYzNzE4OTQxYTRhMDU4MjhhODVlNDA1MmJjL3RhYmxlOmJmZWEyNTEwYTk4YTRkN2E4MWViNjllODhiYzM4OTk3L3RhYmxlcmFuZ2U6YmZlYTI1MTBhOThhNGQ3YTgxZWI2OWU4OGJjMzg5OTdfMTQtNS0xLTEtMTAxMTkw_e4e07737-fc3d-424a-a7e0-bc5c99670245">261.1</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if5cb8092b8ae4df982372f0f9c88c089_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80My9mcmFnOjJjMTE4OWYzNzE4OTQxYTRhMDU4MjhhODVlNDA1MmJjL3RhYmxlOmJmZWEyNTEwYTk4YTRkN2E4MWViNjllODhiYzM4OTk3L3RhYmxlcmFuZ2U6YmZlYTI1MTBhOThhNGQ3YTgxZWI2OWU4OGJjMzg5OTdfMTQtNi0xLTEtMTAxMTkw_49967710-0ec0-4daf-bf42-57ecd56b4584">297.8</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i30fc27f2b4b045abb067a4222037b8ff_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80My9mcmFnOjJjMTE4OWYzNzE4OTQxYTRhMDU4MjhhODVlNDA1MmJjL3RhYmxlOmJmZWEyNTEwYTk4YTRkN2E4MWViNjllODhiYzM4OTk3L3RhYmxlcmFuZ2U6YmZlYTI1MTBhOThhNGQ3YTgxZWI2OWU4OGJjMzg5OTdfMTQtNy0xLTEtMTAxMTkw_075ee583-e3b0-456e-b2ef-952d5bb3cbb0">559.0</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Cyramza</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">®</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="ie477ac10d2fc47b1b19b05139e80176b_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80My9mcmFnOjJjMTE4OWYzNzE4OTQxYTRhMDU4MjhhODVlNDA1MmJjL3RhYmxlOmJmZWEyNTEwYTk4YTRkN2E4MWViNjllODhiYzM4OTk3L3RhYmxlcmFuZ2U6YmZlYTI1MTBhOThhNGQ3YTgxZWI2OWU4OGJjMzg5OTdfMTYtMS0xLTEtMTAxMTkw_26b0c30a-e522-4f0c-a6d4-bc3c50e2767f">79.2</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i986dec26366448bf9b38b31b125f8a99_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80My9mcmFnOjJjMTE4OWYzNzE4OTQxYTRhMDU4MjhhODVlNDA1MmJjL3RhYmxlOmJmZWEyNTEwYTk4YTRkN2E4MWViNjllODhiYzM4OTk3L3RhYmxlcmFuZ2U6YmZlYTI1MTBhOThhNGQ3YTgxZWI2OWU4OGJjMzg5OTdfMTYtMi0xLTEtMTAxMTkw_1429c257-db0c-49e5-8375-948d8ff4eb0c">151.1</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="ia0f55d27eb544bc482fe1337e5bfa093_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80My9mcmFnOjJjMTE4OWYzNzE4OTQxYTRhMDU4MjhhODVlNDA1MmJjL3RhYmxlOmJmZWEyNTEwYTk4YTRkN2E4MWViNjllODhiYzM4OTk3L3RhYmxlcmFuZ2U6YmZlYTI1MTBhOThhNGQ3YTgxZWI2OWU4OGJjMzg5OTdfMTYtMy0xLTEtMTAxMTkw_708b9410-bc4b-4ea8-9f37-14094f511ec2">230.3</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i7c3481645c06471e81e99feeca522f8f_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80My9mcmFnOjJjMTE4OWYzNzE4OTQxYTRhMDU4MjhhODVlNDA1MmJjL3RhYmxlOmJmZWEyNTEwYTk4YTRkN2E4MWViNjllODhiYzM4OTk3L3RhYmxlcmFuZ2U6YmZlYTI1MTBhOThhNGQ3YTgxZWI2OWU4OGJjMzg5OTdfMTYtNS0xLTEtMTAxMTkw_00586e6e-bc1b-400f-ac83-2d38ed1f097b">80.2</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i26107852279a4dafb2499591586a6581_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80My9mcmFnOjJjMTE4OWYzNzE4OTQxYTRhMDU4MjhhODVlNDA1MmJjL3RhYmxlOmJmZWEyNTEwYTk4YTRkN2E4MWViNjllODhiYzM4OTk3L3RhYmxlcmFuZ2U6YmZlYTI1MTBhOThhNGQ3YTgxZWI2OWU4OGJjMzg5OTdfMTYtNi0xLTEtMTAxMTkw_7740b650-abfe-4fce-821d-5589e0698692">160.3</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ibe2a3fa428ac4c8da1c9f47966e07f27_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80My9mcmFnOjJjMTE4OWYzNzE4OTQxYTRhMDU4MjhhODVlNDA1MmJjL3RhYmxlOmJmZWEyNTEwYTk4YTRkN2E4MWViNjllODhiYzM4OTk3L3RhYmxlcmFuZ2U6YmZlYTI1MTBhOThhNGQ3YTgxZWI2OWU4OGJjMzg5OTdfMTYtNy0xLTEtMTAxMTkw_b7d9b3fc-5282-412b-92a8-37c23a6e2c4a">240.5</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Erbitux</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">®</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i006eabb915c840708df1a30e82ac5956_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80My9mcmFnOjJjMTE4OWYzNzE4OTQxYTRhMDU4MjhhODVlNDA1MmJjL3RhYmxlOmJmZWEyNTEwYTk4YTRkN2E4MWViNjllODhiYzM4OTk3L3RhYmxlcmFuZ2U6YmZlYTI1MTBhOThhNGQ3YTgxZWI2OWU4OGJjMzg5OTdfMTctMS0xLTEtMTAxMTkw_9917eb4a-f8b4-429e-bd88-5da769f0519f">109.7</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i1a89bfe808c94e1cb367a6b76d7e6d69_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80My9mcmFnOjJjMTE4OWYzNzE4OTQxYTRhMDU4MjhhODVlNDA1MmJjL3RhYmxlOmJmZWEyNTEwYTk4YTRkN2E4MWViNjllODhiYzM4OTk3L3RhYmxlcmFuZ2U6YmZlYTI1MTBhOThhNGQ3YTgxZWI2OWU4OGJjMzg5OTdfMTctMi0xLTEtMTAxMTkw_f1cd180f-fe30-4d82-bfab-2d242566ca09">13.0</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="iad2987d4931049708f169b45766cd49d_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80My9mcmFnOjJjMTE4OWYzNzE4OTQxYTRhMDU4MjhhODVlNDA1MmJjL3RhYmxlOmJmZWEyNTEwYTk4YTRkN2E4MWViNjllODhiYzM4OTk3L3RhYmxlcmFuZ2U6YmZlYTI1MTBhOThhNGQ3YTgxZWI2OWU4OGJjMzg5OTdfMTctMy0xLTEtMTAxMTkw_a8b187c6-e510-482a-9d96-778d320c6e78">122.7</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ia24a5ef3b72b4516a8337ee873113aa2_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80My9mcmFnOjJjMTE4OWYzNzE4OTQxYTRhMDU4MjhhODVlNDA1MmJjL3RhYmxlOmJmZWEyNTEwYTk4YTRkN2E4MWViNjllODhiYzM4OTk3L3RhYmxlcmFuZ2U6YmZlYTI1MTBhOThhNGQ3YTgxZWI2OWU4OGJjMzg5OTdfMTctNS0xLTEtMTAxMTkw_8563ecd5-24f5-4072-b628-27c71645bccb">107.9</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ia63e46cfe6894ba5a869233e10eb3605_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80My9mcmFnOjJjMTE4OWYzNzE4OTQxYTRhMDU4MjhhODVlNDA1MmJjL3RhYmxlOmJmZWEyNTEwYTk4YTRkN2E4MWViNjllODhiYzM4OTk3L3RhYmxlcmFuZ2U6YmZlYTI1MTBhOThhNGQ3YTgxZWI2OWU4OGJjMzg5OTdfMTctNi0xLTEtMTAxMTkw_46ecb64a-9352-4ad7-ae69-c5eb5c913c22">14.4</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i808e8f1fbb114baaa2cd112190e66e74_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80My9mcmFnOjJjMTE4OWYzNzE4OTQxYTRhMDU4MjhhODVlNDA1MmJjL3RhYmxlOmJmZWEyNTEwYTk4YTRkN2E4MWViNjllODhiYzM4OTk3L3RhYmxlcmFuZ2U6YmZlYTI1MTBhOThhNGQ3YTgxZWI2OWU4OGJjMzg5OTdfMTctNy0xLTEtMTAxMTkw_1cfef669-04bf-415c-9ad8-1ca8b466fb82">122.4</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Tyvyt</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">®</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib865f576197b402f8c1562bbb1c788a2_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80My9mcmFnOjJjMTE4OWYzNzE4OTQxYTRhMDU4MjhhODVlNDA1MmJjL3RhYmxlOmJmZWEyNTEwYTk4YTRkN2E4MWViNjllODhiYzM4OTk3L3RhYmxlcmFuZ2U6YmZlYTI1MTBhOThhNGQ3YTgxZWI2OWU4OGJjMzg5OTdfMTgtMS0xLTEtMTAxMTkw_8389fc1b-3383-4d21-888d-3a31dff76918">—</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="ie5736ce4bc58475884d3c62d4240640d_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80My9mcmFnOjJjMTE4OWYzNzE4OTQxYTRhMDU4MjhhODVlNDA1MmJjL3RhYmxlOmJmZWEyNTEwYTk4YTRkN2E4MWViNjllODhiYzM4OTk3L3RhYmxlcmFuZ2U6YmZlYTI1MTBhOThhNGQ3YTgxZWI2OWU4OGJjMzg5OTdfMTgtMi0xLTEtMTAxMTkw_fa699e25-5ced-4494-bcd9-9c03175dcb62">85.5</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="ifdfcf0a8c9f24795965b4204e3e96f0c_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80My9mcmFnOjJjMTE4OWYzNzE4OTQxYTRhMDU4MjhhODVlNDA1MmJjL3RhYmxlOmJmZWEyNTEwYTk4YTRkN2E4MWViNjllODhiYzM4OTk3L3RhYmxlcmFuZ2U6YmZlYTI1MTBhOThhNGQ3YTgxZWI2OWU4OGJjMzg5OTdfMTgtMy0xLTEtMTAxMTkw_8e3f8cf7-6d97-4a88-8208-bf8ca0fb219d">85.5</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i4ce61e5571e745679da4dbfb0f0b623d_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80My9mcmFnOjJjMTE4OWYzNzE4OTQxYTRhMDU4MjhhODVlNDA1MmJjL3RhYmxlOmJmZWEyNTEwYTk4YTRkN2E4MWViNjllODhiYzM4OTk3L3RhYmxlcmFuZ2U6YmZlYTI1MTBhOThhNGQ3YTgxZWI2OWU4OGJjMzg5OTdfMTgtNS0xLTEtMTAxMTkw_677a9b73-6cc1-4c3c-b4fb-18f965ca72be">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="id22e362347fe4427980338d8e9198e75_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80My9mcmFnOjJjMTE4OWYzNzE4OTQxYTRhMDU4MjhhODVlNDA1MmJjL3RhYmxlOmJmZWEyNTEwYTk4YTRkN2E4MWViNjllODhiYzM4OTk3L3RhYmxlcmFuZ2U6YmZlYTI1MTBhOThhNGQ3YTgxZWI2OWU4OGJjMzg5OTdfMTgtNi0xLTEtMTAxMTkw_a01ac100-e417-466d-addc-d39c7fccf6dc">109.7</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i8313e66c84c44e68889b0fac3ee0fe61_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80My9mcmFnOjJjMTE4OWYzNzE4OTQxYTRhMDU4MjhhODVlNDA1MmJjL3RhYmxlOmJmZWEyNTEwYTk4YTRkN2E4MWViNjllODhiYzM4OTk3L3RhYmxlcmFuZ2U6YmZlYTI1MTBhOThhNGQ3YTgxZWI2OWU4OGJjMzg5OTdfMTgtNy0xLTEtMTAxMTkw_ab3c0c7b-85d0-4fd1-9ce9-c495ade43eef">109.7</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other oncology</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="ifdabefbad9c84ef18d4c3e3761dd59ca_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80My9mcmFnOjJjMTE4OWYzNzE4OTQxYTRhMDU4MjhhODVlNDA1MmJjL3RhYmxlOmJmZWEyNTEwYTk4YTRkN2E4MWViNjllODhiYzM4OTk3L3RhYmxlcmFuZ2U6YmZlYTI1MTBhOThhNGQ3YTgxZWI2OWU4OGJjMzg5OTdfMTktMS0xLTEtMTAxMTkw_0e6bbf4c-bd7f-4141-b3d7-729c3048fd7a">39.0</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i335b1508eb2a4f52854281dece929b66_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80My9mcmFnOjJjMTE4OWYzNzE4OTQxYTRhMDU4MjhhODVlNDA1MmJjL3RhYmxlOmJmZWEyNTEwYTk4YTRkN2E4MWViNjllODhiYzM4OTk3L3RhYmxlcmFuZ2U6YmZlYTI1MTBhOThhNGQ3YTgxZWI2OWU4OGJjMzg5OTdfMTktMi0xLTEtMTAxMTkw_5be4ddc5-72d7-46ea-a972-51de9b39b7b4">62.0</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="ifb7872db7d714dbb9e985d86230c1a48_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80My9mcmFnOjJjMTE4OWYzNzE4OTQxYTRhMDU4MjhhODVlNDA1MmJjL3RhYmxlOmJmZWEyNTEwYTk4YTRkN2E4MWViNjllODhiYzM4OTk3L3RhYmxlcmFuZ2U6YmZlYTI1MTBhOThhNGQ3YTgxZWI2OWU4OGJjMzg5OTdfMTktMy0xLTEtMTAxMTkw_1742a594-5b98-46d4-b8a1-0e9e495563a2">101.2</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i4b6302e7bb6f41c387d17e2319e42cd7_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80My9mcmFnOjJjMTE4OWYzNzE4OTQxYTRhMDU4MjhhODVlNDA1MmJjL3RhYmxlOmJmZWEyNTEwYTk4YTRkN2E4MWViNjllODhiYzM4OTk3L3RhYmxlcmFuZ2U6YmZlYTI1MTBhOThhNGQ3YTgxZWI2OWU4OGJjMzg5OTdfMTktNS0xLTEtMTAxMTkw_8794822e-b923-4412-a0e1-5a86328845f8">20.5</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i05eaa0a7bff94f2896500aa8e6f875f3_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80My9mcmFnOjJjMTE4OWYzNzE4OTQxYTRhMDU4MjhhODVlNDA1MmJjL3RhYmxlOmJmZWEyNTEwYTk4YTRkN2E4MWViNjllODhiYzM4OTk3L3RhYmxlcmFuZ2U6YmZlYTI1MTBhOThhNGQ3YTgxZWI2OWU4OGJjMzg5OTdfMTktNi0xLTEtMTAxMTkw_6e34c875-fb8d-4abb-8fef-93d1d5a13208">51.3</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ic7b40503ad284a9fb556801598af5fde_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80My9mcmFnOjJjMTE4OWYzNzE4OTQxYTRhMDU4MjhhODVlNDA1MmJjL3RhYmxlOmJmZWEyNTEwYTk4YTRkN2E4MWViNjllODhiYzM4OTk3L3RhYmxlcmFuZ2U6YmZlYTI1MTBhOThhNGQ3YTgxZWI2OWU4OGJjMzg5OTdfMTktNy0xLTEtMTAxMTkw_b87ab165-2741-4c11-9cf0-16c92546800b">71.6</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total oncology</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i025555e7e37b45d5b61da966238aa289_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80My9mcmFnOjJjMTE4OWYzNzE4OTQxYTRhMDU4MjhhODVlNDA1MmJjL3RhYmxlOmJmZWEyNTEwYTk4YTRkN2E4MWViNjllODhiYzM4OTk3L3RhYmxlcmFuZ2U6YmZlYTI1MTBhOThhNGQ3YTgxZWI2OWU4OGJjMzg5OTdfMjAtMS0xLTEtMTAxMTkw_5a041abd-7145-449e-ba3f-4fa49f8c6af6">783.7</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="ia6bab3fb55e7472081dd584fa4e83cf8_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80My9mcmFnOjJjMTE4OWYzNzE4OTQxYTRhMDU4MjhhODVlNDA1MmJjL3RhYmxlOmJmZWEyNTEwYTk4YTRkN2E4MWViNjllODhiYzM4OTk3L3RhYmxlcmFuZ2U6YmZlYTI1MTBhOThhNGQ3YTgxZWI2OWU4OGJjMzg5OTdfMjAtMi0xLTEtMTAxMTkw_16aec538-aef7-4a88-9e13-4a2f955cc667">569.2</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i919429aec0024d68b7f5581ce24bde7c_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80My9mcmFnOjJjMTE4OWYzNzE4OTQxYTRhMDU4MjhhODVlNDA1MmJjL3RhYmxlOmJmZWEyNTEwYTk4YTRkN2E4MWViNjllODhiYzM4OTk3L3RhYmxlcmFuZ2U6YmZlYTI1MTBhOThhNGQ3YTgxZWI2OWU4OGJjMzg5OTdfMjAtMy0xLTEtMTAxMTkw_d5bec46d-d6c7-40c0-885c-760fa5a00b59">1,353.0</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i1f48dd5b9b0a4cd3b6d5d597f3f5736d_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80My9mcmFnOjJjMTE4OWYzNzE4OTQxYTRhMDU4MjhhODVlNDA1MmJjL3RhYmxlOmJmZWEyNTEwYTk4YTRkN2E4MWViNjllODhiYzM4OTk3L3RhYmxlcmFuZ2U6YmZlYTI1MTBhOThhNGQ3YTgxZWI2OWU4OGJjMzg5OTdfMjAtNS0xLTEtMTAxMTkw_819c4fba-432d-4d1a-95af-91e1f824f64f">642.5</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i6f9475eee5284cd987d3115e0b2a2a0a_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80My9mcmFnOjJjMTE4OWYzNzE4OTQxYTRhMDU4MjhhODVlNDA1MmJjL3RhYmxlOmJmZWEyNTEwYTk4YTRkN2E4MWViNjllODhiYzM4OTk3L3RhYmxlcmFuZ2U6YmZlYTI1MTBhOThhNGQ3YTgxZWI2OWU4OGJjMzg5OTdfMjAtNi0xLTEtMTAxMTkw_9c7b0bbd-e6de-4c36-aa2f-f516b9fde667">729.7</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i121bf8cbd5a047aeb0b9ad229bb008df_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80My9mcmFnOjJjMTE4OWYzNzE4OTQxYTRhMDU4MjhhODVlNDA1MmJjL3RhYmxlOmJmZWEyNTEwYTk4YTRkN2E4MWViNjllODhiYzM4OTk3L3RhYmxlcmFuZ2U6YmZlYTI1MTBhOThhNGQ3YTgxZWI2OWU4OGJjMzg5OTdfMjAtNy0xLTEtMTAxMTkw_68c50291-7b77-48e3-bc9b-72313fc8a29b">1,372.2</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Immunology:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Taltz</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">®</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i0eff5238e7bb4c4096828b4d242281e4_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80My9mcmFnOjJjMTE4OWYzNzE4OTQxYTRhMDU4MjhhODVlNDA1MmJjL3RhYmxlOmJmZWEyNTEwYTk4YTRkN2E4MWViNjllODhiYzM4OTk3L3RhYmxlcmFuZ2U6YmZlYTI1MTBhOThhNGQ3YTgxZWI2OWU4OGJjMzg5OTdfMjMtMS0xLTEtMTAxMTkw_18df180a-8be8-4cd8-ac91-864e3acc223d">307.2</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="ie465cf8d77274a5ea5f74a71366c20c8_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80My9mcmFnOjJjMTE4OWYzNzE4OTQxYTRhMDU4MjhhODVlNDA1MmJjL3RhYmxlOmJmZWEyNTEwYTk4YTRkN2E4MWViNjllODhiYzM4OTk3L3RhYmxlcmFuZ2U6YmZlYTI1MTBhOThhNGQ3YTgxZWI2OWU4OGJjMzg5OTdfMjMtMi0xLTEtMTAxMTkw_5616f524-f888-4051-9ef6-2e7af6eee518">180.8</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i423c701c975348e49c1a3311b4b4da45_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80My9mcmFnOjJjMTE4OWYzNzE4OTQxYTRhMDU4MjhhODVlNDA1MmJjL3RhYmxlOmJmZWEyNTEwYTk4YTRkN2E4MWViNjllODhiYzM4OTk3L3RhYmxlcmFuZ2U6YmZlYTI1MTBhOThhNGQ3YTgxZWI2OWU4OGJjMzg5OTdfMjMtMy0xLTEtMTAxMTkw_5e07c56e-5775-4a3c-abc9-7da85caf21c8">488.1</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i05f6dda03fc84150b8fd52134744ee59_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80My9mcmFnOjJjMTE4OWYzNzE4OTQxYTRhMDU4MjhhODVlNDA1MmJjL3RhYmxlOmJmZWEyNTEwYTk4YTRkN2E4MWViNjllODhiYzM4OTk3L3RhYmxlcmFuZ2U6YmZlYTI1MTBhOThhNGQ3YTgxZWI2OWU4OGJjMzg5OTdfMjMtNS0xLTEtMTAxMTkw_a179fd1e-89bc-48b6-999e-8a623ced3c67">249.6</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i4007424e82884343bdb9de5264d7f943_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80My9mcmFnOjJjMTE4OWYzNzE4OTQxYTRhMDU4MjhhODVlNDA1MmJjL3RhYmxlOmJmZWEyNTEwYTk4YTRkN2E4MWViNjllODhiYzM4OTk3L3RhYmxlcmFuZ2U6YmZlYTI1MTBhOThhNGQ3YTgxZWI2OWU4OGJjMzg5OTdfMjMtNi0xLTEtMTAxMTkw_d0065f5e-7470-4f16-8f62-baed7b626fa2">153.6</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib3fd1b62c68b43a1bf7d9d8845af2eaa_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80My9mcmFnOjJjMTE4OWYzNzE4OTQxYTRhMDU4MjhhODVlNDA1MmJjL3RhYmxlOmJmZWEyNTEwYTk4YTRkN2E4MWViNjllODhiYzM4OTk3L3RhYmxlcmFuZ2U6YmZlYTI1MTBhOThhNGQ3YTgxZWI2OWU4OGJjMzg5OTdfMjMtNy0xLTEtMTAxMTkw_894a5202-fc3e-497e-9e53-8eb8f44a517a">403.2</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Olumiant</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">® (3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i349b98309b3f4fceb73ea6c5169cec65_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80My9mcmFnOjJjMTE4OWYzNzE4OTQxYTRhMDU4MjhhODVlNDA1MmJjL3RhYmxlOmJmZWEyNTEwYTk4YTRkN2E4MWViNjllODhiYzM4OTk3L3RhYmxlcmFuZ2U6YmZlYTI1MTBhOThhNGQ3YTgxZWI2OWU4OGJjMzg5OTdfMjQtMS0xLTEtMTAxMTkw_f158f55f-7fe0-44be-a1c4-7cde77c54663">71.3</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i450a7aff3e13449b83a284c9335dfa6f_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80My9mcmFnOjJjMTE4OWYzNzE4OTQxYTRhMDU4MjhhODVlNDA1MmJjL3RhYmxlOmJmZWEyNTEwYTk4YTRkN2E4MWViNjllODhiYzM4OTk3L3RhYmxlcmFuZ2U6YmZlYTI1MTBhOThhNGQ3YTgxZWI2OWU4OGJjMzg5OTdfMjQtMi0xLTEtMTAxMTkw_b8c2e81c-94fb-44f6-a87a-5d461fc1c3f2">184.3</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i5aed712fed4f4f1a85becddb3dd53a89_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80My9mcmFnOjJjMTE4OWYzNzE4OTQxYTRhMDU4MjhhODVlNDA1MmJjL3RhYmxlOmJmZWEyNTEwYTk4YTRkN2E4MWViNjllODhiYzM4OTk3L3RhYmxlcmFuZ2U6YmZlYTI1MTBhOThhNGQ3YTgxZWI2OWU4OGJjMzg5OTdfMjQtMy0xLTEtMTAxMTkw_1322bc1d-aa85-4ffd-ba40-4447bdf3fa4e">255.6</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ibc3e795dd0b54a2eb1625e755da0679c_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80My9mcmFnOjJjMTE4OWYzNzE4OTQxYTRhMDU4MjhhODVlNDA1MmJjL3RhYmxlOmJmZWEyNTEwYTk4YTRkN2E4MWViNjllODhiYzM4OTk3L3RhYmxlcmFuZ2U6YmZlYTI1MTBhOThhNGQ3YTgxZWI2OWU4OGJjMzg5OTdfMjQtNS0xLTEtMTAxMTkw_1791ccdf-23fe-42ff-abc3-ccf70c97fded">24.7</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib48e54fe6fa34e8db597de3eb89b6323_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80My9mcmFnOjJjMTE4OWYzNzE4OTQxYTRhMDU4MjhhODVlNDA1MmJjL3RhYmxlOmJmZWEyNTEwYTk4YTRkN2E4MWViNjllODhiYzM4OTk3L3RhYmxlcmFuZ2U6YmZlYTI1MTBhOThhNGQ3YTgxZWI2OWU4OGJjMzg5OTdfMjQtNi0xLTEtMTAxMTkw_e5cb47da-978d-451c-9350-28e2e0227710">169.1</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i4b177d421c0842769bd4a1abbec6790a_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80My9mcmFnOjJjMTE4OWYzNzE4OTQxYTRhMDU4MjhhODVlNDA1MmJjL3RhYmxlOmJmZWEyNTEwYTk4YTRkN2E4MWViNjllODhiYzM4OTk3L3RhYmxlcmFuZ2U6YmZlYTI1MTBhOThhNGQ3YTgxZWI2OWU4OGJjMzg5OTdfMjQtNy0xLTEtMTAxMTkw_d74dad02-b53f-48f3-9437-7ec67ebbec6d">193.8</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other immunology</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i63babd305ab043289099f66bd0422222_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80My9mcmFnOjJjMTE4OWYzNzE4OTQxYTRhMDU4MjhhODVlNDA1MmJjL3RhYmxlOmJmZWEyNTEwYTk4YTRkN2E4MWViNjllODhiYzM4OTk3L3RhYmxlcmFuZ2U6YmZlYTI1MTBhOThhNGQ3YTgxZWI2OWU4OGJjMzg5OTdfMjUtMS0xLTEtMTAxMTkw_fd86cb86-7bb5-488b-8f58-955d8ffd143c">—</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="ie7a881001a6d4e239e4bb857f7aacd68_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80My9mcmFnOjJjMTE4OWYzNzE4OTQxYTRhMDU4MjhhODVlNDA1MmJjL3RhYmxlOmJmZWEyNTEwYTk4YTRkN2E4MWViNjllODhiYzM4OTk3L3RhYmxlcmFuZ2U6YmZlYTI1MTBhOThhNGQ3YTgxZWI2OWU4OGJjMzg5OTdfMjUtMi0xLTEtMTAxMTkw_fab3f5ce-6129-44f0-8458-7d0bbd626545">4.5</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="iede0ea448f234d8dbc396cf9bf12d41d_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80My9mcmFnOjJjMTE4OWYzNzE4OTQxYTRhMDU4MjhhODVlNDA1MmJjL3RhYmxlOmJmZWEyNTEwYTk4YTRkN2E4MWViNjllODhiYzM4OTk3L3RhYmxlcmFuZ2U6YmZlYTI1MTBhOThhNGQ3YTgxZWI2OWU4OGJjMzg5OTdfMjUtMy0xLTEtMTAxMTkw_0446d414-28ae-4633-8916-d9d0624ff341">4.5</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ic02b29952579470e802f2b31fa282318_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80My9mcmFnOjJjMTE4OWYzNzE4OTQxYTRhMDU4MjhhODVlNDA1MmJjL3RhYmxlOmJmZWEyNTEwYTk4YTRkN2E4MWViNjllODhiYzM4OTk3L3RhYmxlcmFuZ2U6YmZlYTI1MTBhOThhNGQ3YTgxZWI2OWU4OGJjMzg5OTdfMjUtNS0xLTEtMTAxMTkw_af88a2e9-e0a6-40b1-b5a4-9cc3405e3e02">10.5</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="id934acb069604725bbf1ff85c1250aae_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80My9mcmFnOjJjMTE4OWYzNzE4OTQxYTRhMDU4MjhhODVlNDA1MmJjL3RhYmxlOmJmZWEyNTEwYTk4YTRkN2E4MWViNjllODhiYzM4OTk3L3RhYmxlcmFuZ2U6YmZlYTI1MTBhOThhNGQ3YTgxZWI2OWU4OGJjMzg5OTdfMjUtNi0xLTEtMTAxMTkw_7cc5ae45-7dcc-4c3c-aee8-44d60775a830">6.4</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ic73028cbe9ad4854b5a0ef90d745e161_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80My9mcmFnOjJjMTE4OWYzNzE4OTQxYTRhMDU4MjhhODVlNDA1MmJjL3RhYmxlOmJmZWEyNTEwYTk4YTRkN2E4MWViNjllODhiYzM4OTk3L3RhYmxlcmFuZ2U6YmZlYTI1MTBhOThhNGQ3YTgxZWI2OWU4OGJjMzg5OTdfMjUtNy0xLTEtMTAxMTkw_2ad2ad1e-3bb3-4d2d-9762-25bb1f2ebeed">16.9</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total immunology</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i54f9f3ff29d94a3883ca8f1dfac03410_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80My9mcmFnOjJjMTE4OWYzNzE4OTQxYTRhMDU4MjhhODVlNDA1MmJjL3RhYmxlOmJmZWEyNTEwYTk4YTRkN2E4MWViNjllODhiYzM4OTk3L3RhYmxlcmFuZ2U6YmZlYTI1MTBhOThhNGQ3YTgxZWI2OWU4OGJjMzg5OTdfMjYtMS0xLTEtMTAxMTkw_cca628c9-7f7e-4612-b9ff-631bae5739c6">378.5</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib120d1e63b764e38ace68bbdc5c6571f_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80My9mcmFnOjJjMTE4OWYzNzE4OTQxYTRhMDU4MjhhODVlNDA1MmJjL3RhYmxlOmJmZWEyNTEwYTk4YTRkN2E4MWViNjllODhiYzM4OTk3L3RhYmxlcmFuZ2U6YmZlYTI1MTBhOThhNGQ3YTgxZWI2OWU4OGJjMzg5OTdfMjYtMi0xLTEtMTAxMTkw_2b64408c-3702-469a-9740-2f07dfae71ac">369.6</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="ifae8b458d0fd4b63951c828b2311b935_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80My9mcmFnOjJjMTE4OWYzNzE4OTQxYTRhMDU4MjhhODVlNDA1MmJjL3RhYmxlOmJmZWEyNTEwYTk4YTRkN2E4MWViNjllODhiYzM4OTk3L3RhYmxlcmFuZ2U6YmZlYTI1MTBhOThhNGQ3YTgxZWI2OWU4OGJjMzg5OTdfMjYtMy0xLTEtMTAxMTkw_fd5c9a93-7f35-4286-991f-99f411422b2e">748.1</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i612c356232294c40ada63de685860055_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80My9mcmFnOjJjMTE4OWYzNzE4OTQxYTRhMDU4MjhhODVlNDA1MmJjL3RhYmxlOmJmZWEyNTEwYTk4YTRkN2E4MWViNjllODhiYzM4OTk3L3RhYmxlcmFuZ2U6YmZlYTI1MTBhOThhNGQ3YTgxZWI2OWU4OGJjMzg5OTdfMjYtNS0xLTEtMTAxMTkw_a37e050b-2a62-46e6-9418-99a7d89e38dc">284.8</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i665713c1455545b4a35ef93c20f0e843_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80My9mcmFnOjJjMTE4OWYzNzE4OTQxYTRhMDU4MjhhODVlNDA1MmJjL3RhYmxlOmJmZWEyNTEwYTk4YTRkN2E4MWViNjllODhiYzM4OTk3L3RhYmxlcmFuZ2U6YmZlYTI1MTBhOThhNGQ3YTgxZWI2OWU4OGJjMzg5OTdfMjYtNi0xLTEtMTAxMTkw_431cc982-be72-4d33-ace3-00bcadeff261">329.1</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ifa67bf60feae4907a400c8047645aca3_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80My9mcmFnOjJjMTE4OWYzNzE4OTQxYTRhMDU4MjhhODVlNDA1MmJjL3RhYmxlOmJmZWEyNTEwYTk4YTRkN2E4MWViNjllODhiYzM4OTk3L3RhYmxlcmFuZ2U6YmZlYTI1MTBhOThhNGQ3YTgxZWI2OWU4OGJjMzg5OTdfMjYtNy0xLTEtMTAxMTkw_2b25bbe7-9705-4f02-8fd0-a70ae3cb9bac">613.9</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neuroscience:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Emgality</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">®</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i69cb0ee5c26a44b89452b40491cf77d8_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80My9mcmFnOjJjMTE4OWYzNzE4OTQxYTRhMDU4MjhhODVlNDA1MmJjL3RhYmxlOmJmZWEyNTEwYTk4YTRkN2E4MWViNjllODhiYzM4OTk3L3RhYmxlcmFuZ2U6YmZlYTI1MTBhOThhNGQ3YTgxZWI2OWU4OGJjMzg5OTdfMjktMS0xLTEtMTAxMTkw_5859694c-40fa-4ac4-89f8-5bc4cc35b0ac">108.3</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i102a640e3a59438ab0c9b2388c052507_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80My9mcmFnOjJjMTE4OWYzNzE4OTQxYTRhMDU4MjhhODVlNDA1MmJjL3RhYmxlOmJmZWEyNTEwYTk4YTRkN2E4MWViNjllODhiYzM4OTk3L3RhYmxlcmFuZ2U6YmZlYTI1MTBhOThhNGQ3YTgxZWI2OWU4OGJjMzg5OTdfMjktMi0xLTEtMTAxMTkw_0741c1a9-6f43-4e1d-953f-aa8e1a9f3993">41.0</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="iaf182007f4da4607982cb81017b22723_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80My9mcmFnOjJjMTE4OWYzNzE4OTQxYTRhMDU4MjhhODVlNDA1MmJjL3RhYmxlOmJmZWEyNTEwYTk4YTRkN2E4MWViNjllODhiYzM4OTk3L3RhYmxlcmFuZ2U6YmZlYTI1MTBhOThhNGQ3YTgxZWI2OWU4OGJjMzg5OTdfMjktMy0xLTEtMTAxMTkw_3a4570c3-7324-4732-93b6-2e4804f0e0a2">149.3</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ie57df423d0014859a70f85d67113934c_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80My9mcmFnOjJjMTE4OWYzNzE4OTQxYTRhMDU4MjhhODVlNDA1MmJjL3RhYmxlOmJmZWEyNTEwYTk4YTRkN2E4MWViNjllODhiYzM4OTk3L3RhYmxlcmFuZ2U6YmZlYTI1MTBhOThhNGQ3YTgxZWI2OWU4OGJjMzg5OTdfMjktNS0xLTEtMTAxMTkw_a0db8343-837f-4bef-96df-b9511156bca0">101.5</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib8c63dcc2e9e42abbc7b004719fd4010_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80My9mcmFnOjJjMTE4OWYzNzE4OTQxYTRhMDU4MjhhODVlNDA1MmJjL3RhYmxlOmJmZWEyNTEwYTk4YTRkN2E4MWViNjllODhiYzM4OTk3L3RhYmxlcmFuZ2U6YmZlYTI1MTBhOThhNGQ3YTgxZWI2OWU4OGJjMzg5OTdfMjktNi0xLTEtMTAxMTkw_7bfa4538-5aeb-4c92-ae48-9ee881d3e71e">18.0</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iaffe90aa2cfa40efa53b2cecdb1cac5e_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80My9mcmFnOjJjMTE4OWYzNzE4OTQxYTRhMDU4MjhhODVlNDA1MmJjL3RhYmxlOmJmZWEyNTEwYTk4YTRkN2E4MWViNjllODhiYzM4OTk3L3RhYmxlcmFuZ2U6YmZlYTI1MTBhOThhNGQ3YTgxZWI2OWU4OGJjMzg5OTdfMjktNy0xLTEtMTAxMTkw_1ae1b63c-5e06-4bae-bb6e-edeeb14cf489">119.5</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Zyprexa</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">®</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="ic7c30620116044c58a77814c02f88816_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80My9mcmFnOjJjMTE4OWYzNzE4OTQxYTRhMDU4MjhhODVlNDA1MmJjL3RhYmxlOmJmZWEyNTEwYTk4YTRkN2E4MWViNjllODhiYzM4OTk3L3RhYmxlcmFuZ2U6YmZlYTI1MTBhOThhNGQ3YTgxZWI2OWU4OGJjMzg5OTdfMzAtMS0xLTEtMTIwNTUy_473f6cdc-b547-4b62-9ed1-2615c4725471">9.6</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib7ec2785c2cb482c9e74d19b4f3df22d_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80My9mcmFnOjJjMTE4OWYzNzE4OTQxYTRhMDU4MjhhODVlNDA1MmJjL3RhYmxlOmJmZWEyNTEwYTk4YTRkN2E4MWViNjllODhiYzM4OTk3L3RhYmxlcmFuZ2U6YmZlYTI1MTBhOThhNGQ3YTgxZWI2OWU4OGJjMzg5OTdfMzAtMi0xLTEtMTIwNTUy_3275b501-327b-4527-962c-0701a40a840c">83.5</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i3862837754b545f89af624c24fc949fa_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80My9mcmFnOjJjMTE4OWYzNzE4OTQxYTRhMDU4MjhhODVlNDA1MmJjL3RhYmxlOmJmZWEyNTEwYTk4YTRkN2E4MWViNjllODhiYzM4OTk3L3RhYmxlcmFuZ2U6YmZlYTI1MTBhOThhNGQ3YTgxZWI2OWU4OGJjMzg5OTdfMzAtMy0xLTEtMTIwNTUy_a8271bd4-e4af-4a91-809d-885baaf95f56">93.1</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i4ee42647ea3d4f4f99858c5251fe6d61_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80My9mcmFnOjJjMTE4OWYzNzE4OTQxYTRhMDU4MjhhODVlNDA1MmJjL3RhYmxlOmJmZWEyNTEwYTk4YTRkN2E4MWViNjllODhiYzM4OTk3L3RhYmxlcmFuZ2U6YmZlYTI1MTBhOThhNGQ3YTgxZWI2OWU4OGJjMzg5OTdfMzAtNS0xLTEtMTIwNTUy_5994899e-57d0-4679-8722-c6622e6dc444">6.9</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i903bf3e6989848fa8b8d6e798c7715cf_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80My9mcmFnOjJjMTE4OWYzNzE4OTQxYTRhMDU4MjhhODVlNDA1MmJjL3RhYmxlOmJmZWEyNTEwYTk4YTRkN2E4MWViNjllODhiYzM4OTk3L3RhYmxlcmFuZ2U6YmZlYTI1MTBhOThhNGQ3YTgxZWI2OWU4OGJjMzg5OTdfMzAtNi0xLTEtMTIwNTUy_c559349d-aa70-4425-b03e-572963a2b96b">88.9</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9d2829a0249840fe8b1a0a533ea49b1e_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80My9mcmFnOjJjMTE4OWYzNzE4OTQxYTRhMDU4MjhhODVlNDA1MmJjL3RhYmxlOmJmZWEyNTEwYTk4YTRkN2E4MWViNjllODhiYzM4OTk3L3RhYmxlcmFuZ2U6YmZlYTI1MTBhOThhNGQ3YTgxZWI2OWU4OGJjMzg5OTdfMzAtNy0xLTEtMTIwNTUy_be90b2ce-bc03-45af-a093-cae809cbdb84">95.8</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Cymbalta</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">®</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i010310e142234f25bd8a4d4e166bf8cf_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80My9mcmFnOjJjMTE4OWYzNzE4OTQxYTRhMDU4MjhhODVlNDA1MmJjL3RhYmxlOmJmZWEyNTEwYTk4YTRkN2E4MWViNjllODhiYzM4OTk3L3RhYmxlcmFuZ2U6YmZlYTI1MTBhOThhNGQ3YTgxZWI2OWU4OGJjMzg5OTdfMzAtMS0xLTEtMTAxMTkw_933b4651-59c2-409e-8bbf-a5e4a80ea9a7">9.1</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="ia099bc43c3844b2cbc376926ab0d35a7_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80My9mcmFnOjJjMTE4OWYzNzE4OTQxYTRhMDU4MjhhODVlNDA1MmJjL3RhYmxlOmJmZWEyNTEwYTk4YTRkN2E4MWViNjllODhiYzM4OTk3L3RhYmxlcmFuZ2U6YmZlYTI1MTBhOThhNGQ3YTgxZWI2OWU4OGJjMzg5OTdfMzAtMi0xLTEtMTAxMTkw_4185d940-5df3-41ca-a971-30b474ee1f16">71.9</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="ic3af176623c4461591be1bbd29ffa355_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80My9mcmFnOjJjMTE4OWYzNzE4OTQxYTRhMDU4MjhhODVlNDA1MmJjL3RhYmxlOmJmZWEyNTEwYTk4YTRkN2E4MWViNjllODhiYzM4OTk3L3RhYmxlcmFuZ2U6YmZlYTI1MTBhOThhNGQ3YTgxZWI2OWU4OGJjMzg5OTdfMzAtMy0xLTEtMTAxMTkw_32a3265f-2323-4b69-ad9c-27cf8f79dae5">81.1</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i7094597407854e0085b748e6549bf213_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80My9mcmFnOjJjMTE4OWYzNzE4OTQxYTRhMDU4MjhhODVlNDA1MmJjL3RhYmxlOmJmZWEyNTEwYTk4YTRkN2E4MWViNjllODhiYzM4OTk3L3RhYmxlcmFuZ2U6YmZlYTI1MTBhOThhNGQ3YTgxZWI2OWU4OGJjMzg5OTdfMzAtNS0xLTEtMTAxMTkw_778bd3d2-b0c2-49c9-a88b-bf1fc337d079">11.0</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if55a0d1991854d74ae41b7b1a1b7b3fc_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80My9mcmFnOjJjMTE4OWYzNzE4OTQxYTRhMDU4MjhhODVlNDA1MmJjL3RhYmxlOmJmZWEyNTEwYTk4YTRkN2E4MWViNjllODhiYzM4OTk3L3RhYmxlcmFuZ2U6YmZlYTI1MTBhOThhNGQ3YTgxZWI2OWU4OGJjMzg5OTdfMzAtNi0xLTEtMTAxMTkw_70e54ea4-9b2c-4806-9f8f-f02a14f66f75">165.7</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i5ff6bfafde62400b9aee7ada39f9e0ab_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80My9mcmFnOjJjMTE4OWYzNzE4OTQxYTRhMDU4MjhhODVlNDA1MmJjL3RhYmxlOmJmZWEyNTEwYTk4YTRkN2E4MWViNjllODhiYzM4OTk3L3RhYmxlcmFuZ2U6YmZlYTI1MTBhOThhNGQ3YTgxZWI2OWU4OGJjMzg5OTdfMzAtNy0xLTEtMTAxMTkw_d8ed0125-b4a9-4218-bb07-c09e98af6dfd">176.6</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other neuroscience</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i83891bd7e6f24c4bae27161c1f576568_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80My9mcmFnOjJjMTE4OWYzNzE4OTQxYTRhMDU4MjhhODVlNDA1MmJjL3RhYmxlOmJmZWEyNTEwYTk4YTRkN2E4MWViNjllODhiYzM4OTk3L3RhYmxlcmFuZ2U6YmZlYTI1MTBhOThhNGQ3YTgxZWI2OWU4OGJjMzg5OTdfMzMtMS0xLTEtMTAxMTkw_203a8063-5a1c-47ef-98b7-e1cbbb317fda">26.4</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i5909280157414ecb8aac29a09390cfa4_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80My9mcmFnOjJjMTE4OWYzNzE4OTQxYTRhMDU4MjhhODVlNDA1MmJjL3RhYmxlOmJmZWEyNTEwYTk4YTRkN2E4MWViNjllODhiYzM4OTk3L3RhYmxlcmFuZ2U6YmZlYTI1MTBhOThhNGQ3YTgxZWI2OWU4OGJjMzg5OTdfMzMtMi0xLTEtMTAxMTkw_e88dd7c0-169b-42b0-9cbc-a7d800f49607">48.0</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="if2df22f3724d42a1a690c948012b785c_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80My9mcmFnOjJjMTE4OWYzNzE4OTQxYTRhMDU4MjhhODVlNDA1MmJjL3RhYmxlOmJmZWEyNTEwYTk4YTRkN2E4MWViNjllODhiYzM4OTk3L3RhYmxlcmFuZ2U6YmZlYTI1MTBhOThhNGQ3YTgxZWI2OWU4OGJjMzg5OTdfMzMtMy0xLTEtMTAxMTkw_d93ea464-db48-4d01-8642-03197996be67">74.2</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i3f40ed22835f41598b5a6699ce170796_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80My9mcmFnOjJjMTE4OWYzNzE4OTQxYTRhMDU4MjhhODVlNDA1MmJjL3RhYmxlOmJmZWEyNTEwYTk4YTRkN2E4MWViNjllODhiYzM4OTk3L3RhYmxlcmFuZ2U6YmZlYTI1MTBhOThhNGQ3YTgxZWI2OWU4OGJjMzg5OTdfMzMtNS0xLTEtMTAxMTkw_c0470b90-53f4-41d4-8611-c35c412064d3">22.3</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ie50d918e323f427bbe2c10edc5c51418_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80My9mcmFnOjJjMTE4OWYzNzE4OTQxYTRhMDU4MjhhODVlNDA1MmJjL3RhYmxlOmJmZWEyNTEwYTk4YTRkN2E4MWViNjllODhiYzM4OTk3L3RhYmxlcmFuZ2U6YmZlYTI1MTBhOThhNGQ3YTgxZWI2OWU4OGJjMzg5OTdfMzMtNi0xLTEtMTAxMTkw_9d1e0001-a9a8-430c-853f-65a77618a467">51.1</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i8e4ceefd208946af8cbd2b75219ab5f7_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80My9mcmFnOjJjMTE4OWYzNzE4OTQxYTRhMDU4MjhhODVlNDA1MmJjL3RhYmxlOmJmZWEyNTEwYTk4YTRkN2E4MWViNjllODhiYzM4OTk3L3RhYmxlcmFuZ2U6YmZlYTI1MTBhOThhNGQ3YTgxZWI2OWU4OGJjMzg5OTdfMzMtNy0xLTEtMTAxMTkw_93726e35-c03a-4f84-98d8-389dc1651337">73.5</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total neuroscience</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i464c50123283492aa9a36cb55224e76b_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80My9mcmFnOjJjMTE4OWYzNzE4OTQxYTRhMDU4MjhhODVlNDA1MmJjL3RhYmxlOmJmZWEyNTEwYTk4YTRkN2E4MWViNjllODhiYzM4OTk3L3RhYmxlcmFuZ2U6YmZlYTI1MTBhOThhNGQ3YTgxZWI2OWU4OGJjMzg5OTdfMzQtMS0xLTEtMTAxMTkw_3e8cccbb-2523-455b-83d8-8e996aed0bfc">153.4</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i20ce527d5a8c4d9aba1876c2ef10e2ce_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80My9mcmFnOjJjMTE4OWYzNzE4OTQxYTRhMDU4MjhhODVlNDA1MmJjL3RhYmxlOmJmZWEyNTEwYTk4YTRkN2E4MWViNjllODhiYzM4OTk3L3RhYmxlcmFuZ2U6YmZlYTI1MTBhOThhNGQ3YTgxZWI2OWU4OGJjMzg5OTdfMzQtMi0xLTEtMTAxMTkw_0010ec58-3270-4901-b048-659fa8ff6cfd">244.4</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i1ade4bb026ae48d1a195fd513963324c_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80My9mcmFnOjJjMTE4OWYzNzE4OTQxYTRhMDU4MjhhODVlNDA1MmJjL3RhYmxlOmJmZWEyNTEwYTk4YTRkN2E4MWViNjllODhiYzM4OTk3L3RhYmxlcmFuZ2U6YmZlYTI1MTBhOThhNGQ3YTgxZWI2OWU4OGJjMzg5OTdfMzQtMy0xLTEtMTAxMTkw_04bfc4ea-2493-4bd3-be1a-17799ed21d15">397.7</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i1201cced44674063b807b48adfc086a3_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80My9mcmFnOjJjMTE4OWYzNzE4OTQxYTRhMDU4MjhhODVlNDA1MmJjL3RhYmxlOmJmZWEyNTEwYTk4YTRkN2E4MWViNjllODhiYzM4OTk3L3RhYmxlcmFuZ2U6YmZlYTI1MTBhOThhNGQ3YTgxZWI2OWU4OGJjMzg5OTdfMzQtNS0xLTEtMTAxMTkw_255f761b-8997-4460-9d57-81e37bfe0975">141.7</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="id372fab86b38457e9f3cfc8f2314739c_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80My9mcmFnOjJjMTE4OWYzNzE4OTQxYTRhMDU4MjhhODVlNDA1MmJjL3RhYmxlOmJmZWEyNTEwYTk4YTRkN2E4MWViNjllODhiYzM4OTk3L3RhYmxlcmFuZ2U6YmZlYTI1MTBhOThhNGQ3YTgxZWI2OWU4OGJjMzg5OTdfMzQtNi0xLTEtMTAxMTkw_54174403-bfab-43b4-adce-4c52ff6a2feb">323.7</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i4e76f1b0acec49ac95c82ac4fa5f9d5e_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80My9mcmFnOjJjMTE4OWYzNzE4OTQxYTRhMDU4MjhhODVlNDA1MmJjL3RhYmxlOmJmZWEyNTEwYTk4YTRkN2E4MWViNjllODhiYzM4OTk3L3RhYmxlcmFuZ2U6YmZlYTI1MTBhOThhNGQ3YTgxZWI2OWU4OGJjMzg5OTdfMzQtNy0xLTEtMTAxMTkw_8b5016d2-16c0-4a8a-b06e-8df6fab9892a">465.4</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">COVID-19 antibodies</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i3e704b348f2a4704b75dbbe76f3b0b82_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80My9mcmFnOjJjMTE4OWYzNzE4OTQxYTRhMDU4MjhhODVlNDA1MmJjL3RhYmxlOmJmZWEyNTEwYTk4YTRkN2E4MWViNjllODhiYzM4OTk3L3RhYmxlcmFuZ2U6YmZlYTI1MTBhOThhNGQ3YTgxZWI2OWU4OGJjMzg5OTdfMzgtMS0xLTEtMTAxMTkw_c3322ef0-185c-48d2-ae2c-e1905014fdbe">1,455.2</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="ia1b8e03165714ac39995f9d5e3ebe8eb_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80My9mcmFnOjJjMTE4OWYzNzE4OTQxYTRhMDU4MjhhODVlNDA1MmJjL3RhYmxlOmJmZWEyNTEwYTk4YTRkN2E4MWViNjllODhiYzM4OTk3L3RhYmxlcmFuZ2U6YmZlYTI1MTBhOThhNGQ3YTgxZWI2OWU4OGJjMzg5OTdfMzgtMi0xLTEtMTAxMTkw_a299cbc2-06df-4bb2-99de-eb0c57760147">14.7</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="if68e51aede3b457a9c66472600e5be13_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80My9mcmFnOjJjMTE4OWYzNzE4OTQxYTRhMDU4MjhhODVlNDA1MmJjL3RhYmxlOmJmZWEyNTEwYTk4YTRkN2E4MWViNjllODhiYzM4OTk3L3RhYmxlcmFuZ2U6YmZlYTI1MTBhOThhNGQ3YTgxZWI2OWU4OGJjMzg5OTdfMzgtMy0xLTEtMTAxMTkw_82437126-bdff-44bc-8ed5-dbc023b29424">1,469.8</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i6b5c557c21d042eea9ed670b81ed3082_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80My9mcmFnOjJjMTE4OWYzNzE4OTQxYTRhMDU4MjhhODVlNDA1MmJjL3RhYmxlOmJmZWEyNTEwYTk4YTRkN2E4MWViNjllODhiYzM4OTk3L3RhYmxlcmFuZ2U6YmZlYTI1MTBhOThhNGQ3YTgxZWI2OWU4OGJjMzg5OTdfMzgtNS0xLTEtMTAxMTkw_4a17dd85-58e2-4017-891f-d63858044474">650.6</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i6a0c438a51724ed98e09d1721ebea46f_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80My9mcmFnOjJjMTE4OWYzNzE4OTQxYTRhMDU4MjhhODVlNDA1MmJjL3RhYmxlOmJmZWEyNTEwYTk4YTRkN2E4MWViNjllODhiYzM4OTk3L3RhYmxlcmFuZ2U6YmZlYTI1MTBhOThhNGQ3YTgxZWI2OWU4OGJjMzg5OTdfMzgtNi0xLTEtMTAxMTkw_7cc5f233-4b0c-45d9-b1c3-8fe53f500c5f">159.5</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i774cde30abd54325b3366e0ebcd76a96_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80My9mcmFnOjJjMTE4OWYzNzE4OTQxYTRhMDU4MjhhODVlNDA1MmJjL3RhYmxlOmJmZWEyNTEwYTk4YTRkN2E4MWViNjllODhiYzM4OTk3L3RhYmxlcmFuZ2U6YmZlYTI1MTBhOThhNGQ3YTgxZWI2OWU4OGJjMzg5OTdfMzgtNy0xLTEtMTAxMTkw_cdb3dc0b-92a9-4277-91e6-15e650bfbf9b">810.1</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Cialis</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">®</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="ia3f989fa3f944cf2a1d81465a2f97532_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80My9mcmFnOjJjMTE4OWYzNzE4OTQxYTRhMDU4MjhhODVlNDA1MmJjL3RhYmxlOmJmZWEyNTEwYTk4YTRkN2E4MWViNjllODhiYzM4OTk3L3RhYmxlcmFuZ2U6YmZlYTI1MTBhOThhNGQ3YTgxZWI2OWU4OGJjMzg5OTdfNDAtMS0xLTEtMTIwNTE4_b8d80e18-1c8a-4c94-8265-0bcf6e1c1b01">6.9</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i999eac96817140af8121825ff12657e2_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80My9mcmFnOjJjMTE4OWYzNzE4OTQxYTRhMDU4MjhhODVlNDA1MmJjL3RhYmxlOmJmZWEyNTEwYTk4YTRkN2E4MWViNjllODhiYzM4OTk3L3RhYmxlcmFuZ2U6YmZlYTI1MTBhOThhNGQ3YTgxZWI2OWU4OGJjMzg5OTdfNDAtMi0xLTEtMTIwNTE4_a142e2b7-7451-4d93-822e-ef4a22aaef63">210.8</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i30f6a635614f4ff6aa9a7e983dd085fd_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80My9mcmFnOjJjMTE4OWYzNzE4OTQxYTRhMDU4MjhhODVlNDA1MmJjL3RhYmxlOmJmZWEyNTEwYTk4YTRkN2E4MWViNjllODhiYzM4OTk3L3RhYmxlcmFuZ2U6YmZlYTI1MTBhOThhNGQ3YTgxZWI2OWU4OGJjMzg5OTdfNDAtMy0xLTEtMTIwNTE4_d7a8f18b-7dd2-4c5e-b84a-cd5e0d7d3994">217.7</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i14a1dc5d218a4c5c9cdc20b862af3166_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80My9mcmFnOjJjMTE4OWYzNzE4OTQxYTRhMDU4MjhhODVlNDA1MmJjL3RhYmxlOmJmZWEyNTEwYTk4YTRkN2E4MWViNjllODhiYzM4OTk3L3RhYmxlcmFuZ2U6YmZlYTI1MTBhOThhNGQ3YTgxZWI2OWU4OGJjMzg5OTdfNDAtNS0xLTEtMTIwNTE4_77de4ef4-b953-48c4-b2d0-a4dd4d58f524">8.6</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i642827c9c169487d97277bb0b32699c7_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80My9mcmFnOjJjMTE4OWYzNzE4OTQxYTRhMDU4MjhhODVlNDA1MmJjL3RhYmxlOmJmZWEyNTEwYTk4YTRkN2E4MWViNjllODhiYzM4OTk3L3RhYmxlcmFuZ2U6YmZlYTI1MTBhOThhNGQ3YTgxZWI2OWU4OGJjMzg5OTdfNDAtNi0xLTEtMTIwNTE4_75d2c1c1-5aa5-4344-a14f-0982ac2e3a91">118.1</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="icaddba0b7fad48828e46f831a67face2_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80My9mcmFnOjJjMTE4OWYzNzE4OTQxYTRhMDU4MjhhODVlNDA1MmJjL3RhYmxlOmJmZWEyNTEwYTk4YTRkN2E4MWViNjllODhiYzM4OTk3L3RhYmxlcmFuZ2U6YmZlYTI1MTBhOThhNGQ3YTgxZWI2OWU4OGJjMzg5OTdfNDAtNy0xLTEtMTIwNTE4_fd9eabc2-63bf-4631-8977-074ca4d5f78f">126.8</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Forteo</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">®</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i1e252df9f1624f35be1172875296c5db_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80My9mcmFnOjJjMTE4OWYzNzE4OTQxYTRhMDU4MjhhODVlNDA1MmJjL3RhYmxlOmJmZWEyNTEwYTk4YTRkN2E4MWViNjllODhiYzM4OTk3L3RhYmxlcmFuZ2U6YmZlYTI1MTBhOThhNGQ3YTgxZWI2OWU4OGJjMzg5OTdfMzktMS0xLTEtMTAxMTkw_e4580265-d811-49c8-90b2-f24f8e89230c">70.2</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i882f726603ae4711b25fab11cb228b17_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80My9mcmFnOjJjMTE4OWYzNzE4OTQxYTRhMDU4MjhhODVlNDA1MmJjL3RhYmxlOmJmZWEyNTEwYTk4YTRkN2E4MWViNjllODhiYzM4OTk3L3RhYmxlcmFuZ2U6YmZlYTI1MTBhOThhNGQ3YTgxZWI2OWU4OGJjMzg5OTdfMzktMi0xLTEtMTAxMTkw_1f1ce8c3-f8a1-45dd-bff7-be2f82b10b74">67.3</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="icb8a07c17728496094396b91d46b3ecf_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80My9mcmFnOjJjMTE4OWYzNzE4OTQxYTRhMDU4MjhhODVlNDA1MmJjL3RhYmxlOmJmZWEyNTEwYTk4YTRkN2E4MWViNjllODhiYzM4OTk3L3RhYmxlcmFuZ2U6YmZlYTI1MTBhOThhNGQ3YTgxZWI2OWU4OGJjMzg5OTdfMzktMy0xLTEtMTAxMTkw_ab57eb1e-d3d6-4377-acd3-16bbd69c203a">137.4</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i3adf8edd7f11475fb574fa64f90fae30_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80My9mcmFnOjJjMTE4OWYzNzE4OTQxYTRhMDU4MjhhODVlNDA1MmJjL3RhYmxlOmJmZWEyNTEwYTk4YTRkN2E4MWViNjllODhiYzM4OTk3L3RhYmxlcmFuZ2U6YmZlYTI1MTBhOThhNGQ3YTgxZWI2OWU4OGJjMzg5OTdfMzktNS0xLTEtMTAxMTkw_18692cdf-8999-4489-85e7-cff34762f428">97.7</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ic909a21213e44f578c3411734a2d5d16_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80My9mcmFnOjJjMTE4OWYzNzE4OTQxYTRhMDU4MjhhODVlNDA1MmJjL3RhYmxlOmJmZWEyNTEwYTk4YTRkN2E4MWViNjllODhiYzM4OTk3L3RhYmxlcmFuZ2U6YmZlYTI1MTBhOThhNGQ3YTgxZWI2OWU4OGJjMzg5OTdfMzktNi0xLTEtMTAxMTkw_3e0d59bd-10f7-4b71-843c-b4968b975229">100.8</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i8efcfbd60405419c93c35743f971c918_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80My9mcmFnOjJjMTE4OWYzNzE4OTQxYTRhMDU4MjhhODVlNDA1MmJjL3RhYmxlOmJmZWEyNTEwYTk4YTRkN2E4MWViNjllODhiYzM4OTk3L3RhYmxlcmFuZ2U6YmZlYTI1MTBhOThhNGQ3YTgxZWI2OWU4OGJjMzg5OTdfMzktNy0xLTEtMTAxMTkw_5708f419-24f8-41c9-b463-1a1f541eeba6">198.5</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i22855bd5b0ca4ab4b334d88c8b6d1320_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80My9mcmFnOjJjMTE4OWYzNzE4OTQxYTRhMDU4MjhhODVlNDA1MmJjL3RhYmxlOmJmZWEyNTEwYTk4YTRkN2E4MWViNjllODhiYzM4OTk3L3RhYmxlcmFuZ2U6YmZlYTI1MTBhOThhNGQ3YTgxZWI2OWU4OGJjMzg5OTdfNDEtMS0xLTEtMTAxMTkw_be6482ff-24f5-4f7b-92cd-36e75e162ecd">50.1</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i11d63fdd02034efea4b8c2cd455ca44d_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80My9mcmFnOjJjMTE4OWYzNzE4OTQxYTRhMDU4MjhhODVlNDA1MmJjL3RhYmxlOmJmZWEyNTEwYTk4YTRkN2E4MWViNjllODhiYzM4OTk3L3RhYmxlcmFuZ2U6YmZlYTI1MTBhOThhNGQ3YTgxZWI2OWU4OGJjMzg5OTdfNDEtMi0xLTEtMTAxMTkw_cc67af33-c9f8-4fa3-8fcf-7b5b744dcb6c">47.8</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="ia99bdeeec6d04756a789b133fd5d2381_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80My9mcmFnOjJjMTE4OWYzNzE4OTQxYTRhMDU4MjhhODVlNDA1MmJjL3RhYmxlOmJmZWEyNTEwYTk4YTRkN2E4MWViNjllODhiYzM4OTk3L3RhYmxlcmFuZ2U6YmZlYTI1MTBhOThhNGQ3YTgxZWI2OWU4OGJjMzg5OTdfNDEtMy0xLTEtMTAxMTkw_fc3a6790-32a5-4888-aae6-1c07e62d8f2f">98.1</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i79554e9080fe4cc486cc5f315f68d8b4_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80My9mcmFnOjJjMTE4OWYzNzE4OTQxYTRhMDU4MjhhODVlNDA1MmJjL3RhYmxlOmJmZWEyNTEwYTk4YTRkN2E4MWViNjllODhiYzM4OTk3L3RhYmxlcmFuZ2U6YmZlYTI1MTBhOThhNGQ3YTgxZWI2OWU4OGJjMzg5OTdfNDEtNS0xLTEtMTAxMTkw_3e456f29-c7f7-4c9e-96df-908a639f019c">54.2</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i3494051841434bfa8865df9cd8fd26d5_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80My9mcmFnOjJjMTE4OWYzNzE4OTQxYTRhMDU4MjhhODVlNDA1MmJjL3RhYmxlOmJmZWEyNTEwYTk4YTRkN2E4MWViNjllODhiYzM4OTk3L3RhYmxlcmFuZ2U6YmZlYTI1MTBhOThhNGQ3YTgxZWI2OWU4OGJjMzg5OTdfNDEtNi0xLTEtMTAxMTkw_3000ae24-d8a9-4357-8272-a6f3a4ef0095">53.4</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i430f45f98d9848a997b95b2869d06ada_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80My9mcmFnOjJjMTE4OWYzNzE4OTQxYTRhMDU4MjhhODVlNDA1MmJjL3RhYmxlOmJmZWEyNTEwYTk4YTRkN2E4MWViNjllODhiYzM4OTk3L3RhYmxlcmFuZ2U6YmZlYTI1MTBhOThhNGQ3YTgxZWI2OWU4OGJjMzg5OTdfNDEtNy0xLTEtMTAxMTkw_4129cdbd-c120-4f82-abef-85f6c6089ff4">107.5</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i3fc88ef00879439fa8e6d523b66da009_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80My9mcmFnOjJjMTE4OWYzNzE4OTQxYTRhMDU4MjhhODVlNDA1MmJjL3RhYmxlOmJmZWEyNTEwYTk4YTRkN2E4MWViNjllODhiYzM4OTk3L3RhYmxlcmFuZ2U6YmZlYTI1MTBhOThhNGQ3YTgxZWI2OWU4OGJjMzg5OTdfNDItMS0xLTEtMTAxMTkw_0368d140-963f-40fd-9b63-4d7a165f5107">1,582.4</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="ifb4f7baea94c477995a0cac6856c7459_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80My9mcmFnOjJjMTE4OWYzNzE4OTQxYTRhMDU4MjhhODVlNDA1MmJjL3RhYmxlOmJmZWEyNTEwYTk4YTRkN2E4MWViNjllODhiYzM4OTk3L3RhYmxlcmFuZ2U6YmZlYTI1MTBhOThhNGQ3YTgxZWI2OWU4OGJjMzg5OTdfNDItMi0xLTEtMTAxMTkw_5667b744-161a-4436-ae40-5e006e1ec477">340.6</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="ia68ee8ebffa5444c99f8c0702521aacc_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80My9mcmFnOjJjMTE4OWYzNzE4OTQxYTRhMDU4MjhhODVlNDA1MmJjL3RhYmxlOmJmZWEyNTEwYTk4YTRkN2E4MWViNjllODhiYzM4OTk3L3RhYmxlcmFuZ2U6YmZlYTI1MTBhOThhNGQ3YTgxZWI2OWU4OGJjMzg5OTdfNDItMy0xLTEtMTAxMTkw_9fd38163-cfc7-4049-9b86-fbdedc361388">1,923.0</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i5458d92918464797982a6591f5fdb5e7_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80My9mcmFnOjJjMTE4OWYzNzE4OTQxYTRhMDU4MjhhODVlNDA1MmJjL3RhYmxlOmJmZWEyNTEwYTk4YTRkN2E4MWViNjllODhiYzM4OTk3L3RhYmxlcmFuZ2U6YmZlYTI1MTBhOThhNGQ3YTgxZWI2OWU4OGJjMzg5OTdfNDItNS0xLTEtMTAxMTkw_b9241d0c-4e11-4a2f-9ff6-7f79e0312bc0">811.1</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i4de53bc690524560aac90d45a546dee7_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80My9mcmFnOjJjMTE4OWYzNzE4OTQxYTRhMDU4MjhhODVlNDA1MmJjL3RhYmxlOmJmZWEyNTEwYTk4YTRkN2E4MWViNjllODhiYzM4OTk3L3RhYmxlcmFuZ2U6YmZlYTI1MTBhOThhNGQ3YTgxZWI2OWU4OGJjMzg5OTdfNDItNi0xLTEtMTAxMTkw_d3d1cce5-a358-4dae-b45e-0ab24a4f523f">431.8</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i5cabdee801da421dad16fee3cdab03ff_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80My9mcmFnOjJjMTE4OWYzNzE4OTQxYTRhMDU4MjhhODVlNDA1MmJjL3RhYmxlOmJmZWEyNTEwYTk4YTRkN2E4MWViNjllODhiYzM4OTk3L3RhYmxlcmFuZ2U6YmZlYTI1MTBhOThhNGQ3YTgxZWI2OWU4OGJjMzg5OTdfNDItNy0xLTEtMTAxMTkw_a03f6db9-3a1b-45ee-b76b-c2aad5d86ee4">1,242.9</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i48e724dd68594a77a1940fbb84e01c0a_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80My9mcmFnOjJjMTE4OWYzNzE4OTQxYTRhMDU4MjhhODVlNDA1MmJjL3RhYmxlOmJmZWEyNTEwYTk4YTRkN2E4MWViNjllODhiYzM4OTk3L3RhYmxlcmFuZ2U6YmZlYTI1MTBhOThhNGQ3YTgxZWI2OWU4OGJjMzg5OTdfNDMtMS0xLTEtMTAxMTkw_7831cbeb-0d79-4162-998f-ce6d3f366b8f">5,174.6</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i483a0602a4a4449985dca64f9a709f68_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80My9mcmFnOjJjMTE4OWYzNzE4OTQxYTRhMDU4MjhhODVlNDA1MmJjL3RhYmxlOmJmZWEyNTEwYTk4YTRkN2E4MWViNjllODhiYzM4OTk3L3RhYmxlcmFuZ2U6YmZlYTI1MTBhOThhNGQ3YTgxZWI2OWU4OGJjMzg5OTdfNDMtMi0xLTEtMTAxMTkw_c6280584-e123-45d8-b6df-90486752fc96">2,635.4</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="id879b497a407453985551e83dbee75f8_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80My9mcmFnOjJjMTE4OWYzNzE4OTQxYTRhMDU4MjhhODVlNDA1MmJjL3RhYmxlOmJmZWEyNTEwYTk4YTRkN2E4MWViNjllODhiYzM4OTk3L3RhYmxlcmFuZ2U6YmZlYTI1MTBhOThhNGQ3YTgxZWI2OWU4OGJjMzg5OTdfNDMtMy0xLTEtMTAxMTkw_c199e943-fae2-4042-81f9-fd71d427c65c">7,810.0</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if888f743065d48f8ab36d2d72ab25478_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80My9mcmFnOjJjMTE4OWYzNzE4OTQxYTRhMDU4MjhhODVlNDA1MmJjL3RhYmxlOmJmZWEyNTEwYTk4YTRkN2E4MWViNjllODhiYzM4OTk3L3RhYmxlcmFuZ2U6YmZlYTI1MTBhOThhNGQ3YTgxZWI2OWU4OGJjMzg5OTdfNDMtNS0xLTEtMTAxMTkw_33db1a7f-c68d-415a-9182-fd3bf5e01381">3,941.3</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i21afabc730b3442a955bb1adab4b07d1_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80My9mcmFnOjJjMTE4OWYzNzE4OTQxYTRhMDU4MjhhODVlNDA1MmJjL3RhYmxlOmJmZWEyNTEwYTk4YTRkN2E4MWViNjllODhiYzM4OTk3L3RhYmxlcmFuZ2U6YmZlYTI1MTBhOThhNGQ3YTgxZWI2OWU4OGJjMzg5OTdfNDMtNi0xLTEtMTAxMTkw_7d4f7c57-24ad-453b-98ed-af26e4e54c01">2,864.3</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i010e4c0d9c6246be91d37e31d569fa6f_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80My9mcmFnOjJjMTE4OWYzNzE4OTQxYTRhMDU4MjhhODVlNDA1MmJjL3RhYmxlOmJmZWEyNTEwYTk4YTRkN2E4MWViNjllODhiYzM4OTk3L3RhYmxlcmFuZ2U6YmZlYTI1MTBhOThhNGQ3YTgxZWI2OWU4OGJjMzg5OTdfNDMtNy0xLTEtMTAxMTkw_94f08449-6bd5-4398-a8c5-158ccc4850ca">6,805.6</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></tbody></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Numbers may not add due to rounding.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Humalog revenue includes insulin lispro.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Jardiance revenue includes Glyxambi</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Synjardy</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">and Trijardy</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> XR.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Olumiant revenue includes sales for baricitinib, for treatment in hospitalized COVID-19 patients, that were made pursuant to Emergency Use Authorization (EUA) or similar regulatory authorizations.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(4) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">COVID-19 antibodies include sales for bamlanivimab administered alone, for bamlanivimab and etesevimab administered together, and for bebtelovimab and were made pursuant to EUAs or similar regulatory authorizations.</span></div></ix:continuation></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span><br></span></div></div><ix:continuation id="i6237fd296fa949df9b552c0f87991822"><ix:continuation id="ide1fa61f68b647a39ed17a868a8f8f7f"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes revenue by geographical area:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:65.128%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.422%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue—to unaffiliated customers</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i48e724dd68594a77a1940fbb84e01c0a_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80My9mcmFnOjJjMTE4OWYzNzE4OTQxYTRhMDU4MjhhODVlNDA1MmJjL3RhYmxlOmY1MDE1ZTViMTBjMTRlNDZhN2NlN2ExNGU5YmE1OGU3L3RhYmxlcmFuZ2U6ZjUwMTVlNWIxMGMxNGU0NmE3Y2U3YTE0ZTliYTU4ZTdfMy0xLTEtMS0xMDExOTA_aaac5839-a82c-4dac-94ce-1636b2f77bbc">5,174.6</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if888f743065d48f8ab36d2d72ab25478_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80My9mcmFnOjJjMTE4OWYzNzE4OTQxYTRhMDU4MjhhODVlNDA1MmJjL3RhYmxlOmY1MDE1ZTViMTBjMTRlNDZhN2NlN2ExNGU5YmE1OGU3L3RhYmxlcmFuZ2U6ZjUwMTVlNWIxMGMxNGU0NmE3Y2U3YTE0ZTliYTU4ZTdfMy0zLTEtMS0xMDExOTA_0df16bb7-2ad7-4aa7-8adf-9524463546b9">3,941.3</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i24b5090b374b4b789cdf22d60ea81a9a_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80My9mcmFnOjJjMTE4OWYzNzE4OTQxYTRhMDU4MjhhODVlNDA1MmJjL3RhYmxlOmY1MDE1ZTViMTBjMTRlNDZhN2NlN2ExNGU5YmE1OGU3L3RhYmxlcmFuZ2U6ZjUwMTVlNWIxMGMxNGU0NmE3Y2U3YTE0ZTliYTU4ZTdfNC0xLTEtMS0xMDExOTA_8086c6a5-e39c-4438-b64c-8a7e8c17f484">1,067.3</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i1d3e66fcb0fd404e807859513f037628_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80My9mcmFnOjJjMTE4OWYzNzE4OTQxYTRhMDU4MjhhODVlNDA1MmJjL3RhYmxlOmY1MDE1ZTViMTBjMTRlNDZhN2NlN2ExNGU5YmE1OGU3L3RhYmxlcmFuZ2U6ZjUwMTVlNWIxMGMxNGU0NmE3Y2U3YTE0ZTliYTU4ZTdfNC0zLTEtMS0xMDExOTA_cf2ea24f-d66c-447d-81a5-56d506298e4a">1,321.2</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="ibf27df75ec7f42c496c3fe02033e090d_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80My9mcmFnOjJjMTE4OWYzNzE4OTQxYTRhMDU4MjhhODVlNDA1MmJjL3RhYmxlOmY1MDE1ZTViMTBjMTRlNDZhN2NlN2ExNGU5YmE1OGU3L3RhYmxlcmFuZ2U6ZjUwMTVlNWIxMGMxNGU0NmE3Y2U3YTE0ZTliYTU4ZTdfNS0xLTEtMS0xMDExOTA_064fad90-90a8-42a5-86ff-ab32356fa03d">410.2</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ifa836704ac1c4d70887d5d8096845ffa_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80My9mcmFnOjJjMTE4OWYzNzE4OTQxYTRhMDU4MjhhODVlNDA1MmJjL3RhYmxlOmY1MDE1ZTViMTBjMTRlNDZhN2NlN2ExNGU5YmE1OGU3L3RhYmxlcmFuZ2U6ZjUwMTVlNWIxMGMxNGU0NmE3Y2U3YTE0ZTliYTU4ZTdfNS0zLTEtMS0xMDExOTA_36fc9349-3f9e-4929-a593-1d580b4c586f">571.8</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="ia46a6c731c5f4eccb4090c399ee2426d_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80My9mcmFnOjJjMTE4OWYzNzE4OTQxYTRhMDU4MjhhODVlNDA1MmJjL3RhYmxlOmY1MDE1ZTViMTBjMTRlNDZhN2NlN2ExNGU5YmE1OGU3L3RhYmxlcmFuZ2U6ZjUwMTVlNWIxMGMxNGU0NmE3Y2U3YTE0ZTliYTU4ZTdfNi0xLTEtMS0xMDExOTA_a5f12a57-bae6-4ccf-b042-304080442981">406.5</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i68141633070d499096dd1177ee8e769c_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80My9mcmFnOjJjMTE4OWYzNzE4OTQxYTRhMDU4MjhhODVlNDA1MmJjL3RhYmxlOmY1MDE1ZTViMTBjMTRlNDZhN2NlN2ExNGU5YmE1OGU3L3RhYmxlcmFuZ2U6ZjUwMTVlNWIxMGMxNGU0NmE3Y2U3YTE0ZTliYTU4ZTdfNi0zLTEtMS0xMDExOTA_fdf05ca4-b5c2-433e-a31a-91a6b49f53f5">362.2</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other foreign countries</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i119b94d6afc84f039c904f8e6fae6786_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80My9mcmFnOjJjMTE4OWYzNzE4OTQxYTRhMDU4MjhhODVlNDA1MmJjL3RhYmxlOmY1MDE1ZTViMTBjMTRlNDZhN2NlN2ExNGU5YmE1OGU3L3RhYmxlcmFuZ2U6ZjUwMTVlNWIxMGMxNGU0NmE3Y2U3YTE0ZTliYTU4ZTdfNy0xLTEtMS0xMDExOTA_17239344-43cf-48a6-b94d-bcdd57d1c59d">751.5</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i20ef3d78a81d4ea7910213c99cd43f59_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80My9mcmFnOjJjMTE4OWYzNzE4OTQxYTRhMDU4MjhhODVlNDA1MmJjL3RhYmxlOmY1MDE1ZTViMTBjMTRlNDZhN2NlN2ExNGU5YmE1OGU3L3RhYmxlcmFuZ2U6ZjUwMTVlNWIxMGMxNGU0NmE3Y2U3YTE0ZTliYTU4ZTdfNy0zLTEtMS0xMDExOTA_396f5f8c-ff62-48dd-a881-e8afc1d0b16d">609.1</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="id879b497a407453985551e83dbee75f8_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80My9mcmFnOjJjMTE4OWYzNzE4OTQxYTRhMDU4MjhhODVlNDA1MmJjL3RhYmxlOmY1MDE1ZTViMTBjMTRlNDZhN2NlN2ExNGU5YmE1OGU3L3RhYmxlcmFuZ2U6ZjUwMTVlNWIxMGMxNGU0NmE3Y2U3YTE0ZTliYTU4ZTdfOC0xLTEtMS0xMDExOTA_b337e4a0-2791-414a-9359-a68446717538">7,810.0</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i010e4c0d9c6246be91d37e31d569fa6f_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80My9mcmFnOjJjMTE4OWYzNzE4OTQxYTRhMDU4MjhhODVlNDA1MmJjL3RhYmxlOmY1MDE1ZTViMTBjMTRlNDZhN2NlN2ExNGU5YmE1OGU3L3RhYmxlcmFuZ2U6ZjUwMTVlNWIxMGMxNGU0NmE3Y2U3YTE0ZTliYTU4ZTdfOC0zLTEtMS0xMDExOTA_a3ec605e-61ed-4e7f-a38a-16200e057140">6,805.6</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></tbody></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Numbers may not add due to rounding.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Revenue is attributed to the countries based on the location of the customer.</span></div></ix:continuation></ix:continuation><div style="margin-bottom:12pt;margin-top:3pt"><span><br></span></div><div id="ie8dc61f8e15b44db82ba16050d5b7b44_49"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note&nbsp;3:&nbsp;<ix:nonnumeric contextref="id879b497a407453985551e83dbee75f8_D20220101-20220331" name="us-gaap:AssetAcquisitionTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80OS9mcmFnOjI4N2IyM2IzZGMxNzQ0YmVhOWI0OGNiMTUwMjljZjZlL3RleHRyZWdpb246Mjg3YjIzYjNkYzE3NDRiZWE5YjQ4Y2IxNTAyOWNmNmVfNjA3Mw_653746e1-1ccb-4295-9cfe-c6806a64ec9c" continuedat="i288e12d0f7e74ff5ab224ddb1b72f761" escape="true"><ix:nonnumeric contextref="id879b497a407453985551e83dbee75f8_D20220101-20220331" name="us-gaap:BusinessCombinationDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80OS9mcmFnOjI4N2IyM2IzZGMxNzQ0YmVhOWI0OGNiMTUwMjljZjZlL3RleHRyZWdpb246Mjg3YjIzYjNkYzE3NDRiZWE5YjQ4Y2IxNTAyOWNmNmVfNjA3Mw_fad20493-64b5-4e5c-bffd-7bbf4fc1e80f" continuedat="ia43ce7b9c866453f85ddc5b64bc4807a" escape="true">Acquisitions</ix:nonnumeric></ix:nonnumeric></span></div><ix:continuation id="i288e12d0f7e74ff5ab224ddb1b72f761" continuedat="ibd055c6d45534fa9a03b223c17333b7b"><ix:continuation id="ia43ce7b9c866453f85ddc5b64bc4807a" continuedat="i81770b199ff440a39f918b51bd888935"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, we completed the acquisition of Prevail Therapeutics Inc. (Prevail). This transaction, as further discussed in this note below in Acquisition of a Business, was accounted for as a business combination under the acquisition method of accounting. <ix:nonnumeric contextref="id879b497a407453985551e83dbee75f8_D20220101-20220331" name="us-gaap:BusinessCombinationsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80OS9mcmFnOjI4N2IyM2IzZGMxNzQ0YmVhOWI0OGNiMTUwMjljZjZlL3RleHRyZWdpb246Mjg3YjIzYjNkYzE3NDRiZWE5YjQ4Y2IxNTAyOWNmNmVfNjA2OQ_301faa17-cbfe-4b3e-a82c-bd8494b7dc5a" continuedat="icaf19356a9794804ac9806a08b261451" escape="true">Under this method, the assets acquired and liabilities assumed were recorded at their respective fair values as of the acquisition date in our consolidated condensed financial statements. The determination of estimated fair value required management to make significant estimates and assumptions. The excess of the purchase price over the fair value of the acquired net assets, where applicable, has been recorded as goodwill. The results of operations of this acquisition is included in our consolidated condensed financial statements from the date of acquisition.</ix:nonnumeric></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also acquired assets in development which are further discussed in this note below in Asset Acquisitions. <ix:continuation id="icaf19356a9794804ac9806a08b261451">Upon each acquisition, the cost allocated to acquired IPR&amp;D is immediately expensed if the compound has no alternative future use. Milestone payment obligations incurred prior to regulatory approval of the compound are expensed when the event triggering an obligation to pay the milestone occurs. W</ix:continuation>e recognized $<ix:nonfraction unitref="usd" contextref="id879b497a407453985551e83dbee75f8_D20220101-20220331" decimals="-5" name="us-gaap:PaymentsToAcquireIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80OS9mcmFnOjI4N2IyM2IzZGMxNzQ0YmVhOWI0OGNiMTUwMjljZjZlL3RleHRyZWdpb246Mjg3YjIzYjNkYzE3NDRiZWE5YjQ4Y2IxNTAyOWNmNmVfMTA5OTUxMTYzOTQxNA_b3818eb0-24d7-4a92-8de7-b22609581c7e">165.6</ix:nonfraction> million and $<ix:nonfraction unitref="usd" contextref="i010e4c0d9c6246be91d37e31d569fa6f_D20210101-20210331" decimals="-5" name="us-gaap:PaymentsToAcquireIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80OS9mcmFnOjI4N2IyM2IzZGMxNzQ0YmVhOWI0OGNiMTUwMjljZjZlL3RleHRyZWdpb246Mjg3YjIzYjNkYzE3NDRiZWE5YjQ4Y2IxNTAyOWNmNmVfMTA5OTUxMTYzOTQyMg_3bbec6d3-6e34-49f4-8aee-e8a337831c93">312.0</ix:nonfraction>&nbsp;million of acquired IPR&amp;D and development milestones during the three months ended March&nbsp;31, 2022 and 2021, respectively. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Acquisition of a Business</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Prevail Acquisition</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Overview of Transaction</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, we acquired all shares of Prevail for a purchase price that included $<ix:nonfraction unitref="usdPerShare" contextref="i1b4752c6b2ac44cd9be4af1f69afff5d_I20210131" decimals="INF" name="us-gaap:BusinessAcquisitionSharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80OS9mcmFnOjI4N2IyM2IzZGMxNzQ0YmVhOWI0OGNiMTUwMjljZjZlL3RleHRyZWdpb246Mjg3YjIzYjNkYzE3NDRiZWE5YjQ4Y2IxNTAyOWNmNmVfMTYwOQ_81da76b3-b53d-4a5d-83f5-b481bd2e0a6a">22.50</ix:nonfraction> per share in cash (or an aggregate of $<ix:nonfraction unitref="usd" contextref="i63b55aa2b0524f0ca0efeed454b37bbe_D20210101-20210131" decimals="-5" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80OS9mcmFnOjI4N2IyM2IzZGMxNzQ0YmVhOWI0OGNiMTUwMjljZjZlL3RleHRyZWdpb246Mjg3YjIzYjNkYzE3NDRiZWE5YjQ4Y2IxNTAyOWNmNmVfMTA5OTUxMTYzMzg4Nw_c6b923d1-b2e5-48e9-a3ef-508f9ee419f0">747.4</ix:nonfraction>&nbsp;million, net of cash acquired) plus <ix:nonfraction unitref="right" contextref="i63b55aa2b0524f0ca0efeed454b37bbe_D20210101-20210131" decimals="INF" name="lly:BusinessCombinationConsiderationTransferredNumberOfContingentValueRights" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80OS9mcmFnOjI4N2IyM2IzZGMxNzQ0YmVhOWI0OGNiMTUwMjljZjZlL3RleHRyZWdpb246Mjg3YjIzYjNkYzE3NDRiZWE5YjQ4Y2IxNTAyOWNmNmVfMTY4OQ_ee6eb69c-2064-4282-9560-9c9b3db96188">one</ix:nonfraction> non-tradable contingent value right (CVR) per share. The CVR entitles Prevail stockholders up to an additional $<ix:nonfraction unitref="usdPerShare" contextref="i1b4752c6b2ac44cd9be4af1f69afff5d_I20210131" decimals="INF" name="lly:BusinessAcquisitionContingentValueRightAdditionalPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80OS9mcmFnOjI4N2IyM2IzZGMxNzQ0YmVhOWI0OGNiMTUwMjljZjZlL3RleHRyZWdpb246Mjg3YjIzYjNkYzE3NDRiZWE5YjQ4Y2IxNTAyOWNmNmVfMTgwMw_279e67dc-8dca-4a4c-833e-540e89b60923">4.00</ix:nonfraction> per share in cash (or an aggregate of approximately $<ix:nonfraction unitref="usd" contextref="i1b4752c6b2ac44cd9be4af1f69afff5d_I20210131" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80OS9mcmFnOjI4N2IyM2IzZGMxNzQ0YmVhOWI0OGNiMTUwMjljZjZlL3RleHRyZWdpb246Mjg3YjIzYjNkYzE3NDRiZWE5YjQ4Y2IxNTAyOWNmNmVfMTg1OA_ab026f25-c853-4216-b990-1743951ca576">160</ix:nonfraction>&nbsp;million) payable, subject to certain terms and conditions, upon the first regulatory approval of a Prevail product in one of the following countries: U.S., Japan, United Kingdom, Germany, France, Italy or Spain. To achieve the full value of the CVR, such regulatory approval must occur by December 31, 2024. If such regulatory approval occurs after December 31, 2024, the value of the CVR will be reduced by approximately <ix:nonfraction unitref="usdPerShare" contextref="i1b4752c6b2ac44cd9be4af1f69afff5d_I20210131" decimals="3" name="lly:BusinessAcquisitionContingentValueRightRegulatoryApprovalDelayMonthlyReduction" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80OS9mcmFnOjI4N2IyM2IzZGMxNzQ0YmVhOWI0OGNiMTUwMjljZjZlL3RleHRyZWdpb246Mjg3YjIzYjNkYzE3NDRiZWE5YjQ4Y2IxNTAyOWNmNmVfMjI3NQ_b6c7c53d-566a-45a2-b46b-aae889977fec">8.3</ix:nonfraction> cents per month until December 1, 2028, at which point the CVR will expire without payment.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the agreement, we acquired potentially disease-modifying AAV9-based gene therapies for patients with neurodegenerative diseases. The acquisition establishes a new modality for drug discovery and development, extending our research efforts through the creation of a gene therapy program that is being anchored by Prevail's portfolio of assets. The lead gene therapies in clinical development that we acquired were PR001 for patients with Parkinson's disease with GBA1 mutations and neuronopathic Gaucher disease and PR006 for patients with frontotemporal dementia with GRN mutations. Both PR001 and PR006 were granted Fast Track designation from the U.S. Food and Drug Administration (FDA). </span></div></ix:continuation></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span><br></span></div></div><ix:continuation id="ibd055c6d45534fa9a03b223c17333b7b"><ix:continuation id="i81770b199ff440a39f918b51bd888935"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Assets Acquired and Liabilities Assumed</span></div><ix:nonnumeric contextref="id879b497a407453985551e83dbee75f8_D20220101-20220331" name="us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80OS9mcmFnOjI4N2IyM2IzZGMxNzQ0YmVhOWI0OGNiMTUwMjljZjZlL3RleHRyZWdpb246Mjg3YjIzYjNkYzE3NDRiZWE5YjQ4Y2IxNTAyOWNmNmVfNjA5Ng_a58e4eca-c698-468b-994b-00a76980b5b1" continuedat="iaad52d292ee44e348501656cdea080e2" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the preliminary amounts recognized for assets acquired and liabilities assumed as of the acquisition date:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:79.016%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.784%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value at January 22, 2021</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iee7f27c40fbd4c098dcae8edbea11cf9_I20210122" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80OS9mcmFnOjI4N2IyM2IzZGMxNzQ0YmVhOWI0OGNiMTUwMjljZjZlL3RhYmxlOjM5NmYzNDI3YTRkNDQzZGJiMDFjZjMzMWZmZjlmNGFhL3RhYmxlcmFuZ2U6Mzk2ZjM0MjdhNGQ0NDNkYmIwMWNmMzMxZmZmOWY0YWFfMS0xLTEtMS0xMTY5ODQ_97ec996c-7840-415c-b4f9-d8ad0985e5d2">90.5</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired IPR&amp;D</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iee7f27c40fbd4c098dcae8edbea11cf9_I20210122" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80OS9mcmFnOjI4N2IyM2IzZGMxNzQ0YmVhOWI0OGNiMTUwMjljZjZlL3RhYmxlOjM5NmYzNDI3YTRkNDQzZGJiMDFjZjMzMWZmZjlmNGFhL3RhYmxlcmFuZ2U6Mzk2ZjM0MjdhNGQ0NDNkYmIwMWNmMzMxZmZmOWY0YWFfMi0xLTEtMS0xMTY5ODQ_25042495-79d8-46bd-840d-eed7192cd0fd">824.0</ix:nonfraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iee7f27c40fbd4c098dcae8edbea11cf9_I20210122" decimals="-5" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80OS9mcmFnOjI4N2IyM2IzZGMxNzQ0YmVhOWI0OGNiMTUwMjljZjZlL3RhYmxlOjM5NmYzNDI3YTRkNDQzZGJiMDFjZjMzMWZmZjlmNGFhL3RhYmxlcmFuZ2U6Mzk2ZjM0MjdhNGQ0NDNkYmIwMWNmMzMxZmZmOWY0YWFfMy0xLTEtMS0xMTY5ODQ_1dadafa3-5537-48b9-8c3b-04833c499cb1">126.8</ix:nonfraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="iee7f27c40fbd4c098dcae8edbea11cf9_I20210122" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80OS9mcmFnOjI4N2IyM2IzZGMxNzQ0YmVhOWI0OGNiMTUwMjljZjZlL3RhYmxlOjM5NmYzNDI3YTRkNDQzZGJiMDFjZjMzMWZmZjlmNGFhL3RhYmxlcmFuZ2U6Mzk2ZjM0MjdhNGQ0NDNkYmIwMWNmMzMxZmZmOWY0YWFfNC0xLTEtMS0xMTY5ODQ_895efe99-7a5c-4a41-a7dc-659a16179748">106.0</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets and liabilities, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="iee7f27c40fbd4c098dcae8edbea11cf9_I20210122" decimals="-5" sign="-" name="lly:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssetsLiabilitiesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80OS9mcmFnOjI4N2IyM2IzZGMxNzQ0YmVhOWI0OGNiMTUwMjljZjZlL3RhYmxlOjM5NmYzNDI3YTRkNDQzZGJiMDFjZjMzMWZmZjlmNGFhL3RhYmxlcmFuZ2U6Mzk2ZjM0MjdhNGQ0NDNkYmIwMWNmMzMxZmZmOWY0YWFfNS0xLTEtMS0xMTY5ODQ_b24f25ee-16a4-46c6-939c-9ef6aef28024">31.5</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition date fair value of consideration transferred </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iee7f27c40fbd4c098dcae8edbea11cf9_I20210122" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80OS9mcmFnOjI4N2IyM2IzZGMxNzQ0YmVhOWI0OGNiMTUwMjljZjZlL3RhYmxlOjM5NmYzNDI3YTRkNDQzZGJiMDFjZjMzMWZmZjlmNGFhL3RhYmxlcmFuZ2U6Mzk2ZjM0MjdhNGQ0NDNkYmIwMWNmMzMxZmZmOWY0YWFfNi0xLTEtMS0xMTY5ODQ_52a5a560-193c-4fc3-9884-1301ca1c5750">903.8</ix:nonfraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash acquired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="iae68d981b70540feb7cdc176ba370211_D20210122-20210122" decimals="-5" name="us-gaap:CashAcquiredFromAcquisition" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80OS9mcmFnOjI4N2IyM2IzZGMxNzQ0YmVhOWI0OGNiMTUwMjljZjZlL3RhYmxlOjM5NmYzNDI3YTRkNDQzZGJiMDFjZjMzMWZmZjlmNGFhL3RhYmxlcmFuZ2U6Mzk2ZjM0MjdhNGQ0NDNkYmIwMWNmMzMxZmZmOWY0YWFfOC0xLTEtMS0xMTY5ODQ_04272877-0dc5-4137-b36f-6a0f35703fb1">90.5</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of CVR liability</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="iee7f27c40fbd4c098dcae8edbea11cf9_I20210122" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80OS9mcmFnOjI4N2IyM2IzZGMxNzQ0YmVhOWI0OGNiMTUwMjljZjZlL3RhYmxlOjM5NmYzNDI3YTRkNDQzZGJiMDFjZjMzMWZmZjlmNGFhL3RhYmxlcmFuZ2U6Mzk2ZjM0MjdhNGQ0NDNkYmIwMWNmMzMxZmZmOWY0YWFfOS0xLTEtMS0xMTY5ODQ_6c7ac4bf-0cf1-4138-8e35-6a420f762c0b">65.9</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid, net of cash acquired</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i63b55aa2b0524f0ca0efeed454b37bbe_D20210101-20210131" decimals="-5" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80OS9mcmFnOjI4N2IyM2IzZGMxNzQ0YmVhOWI0OGNiMTUwMjljZjZlL3RhYmxlOjM5NmYzNDI3YTRkNDQzZGJiMDFjZjMzMWZmZjlmNGFhL3RhYmxlcmFuZ2U6Mzk2ZjM0MjdhNGQ0NDNkYmIwMWNmMzMxZmZmOWY0YWFfMTAtMS0xLTEtMTAxMTkw_c6b923d1-b2e5-48e9-a3ef-508f9ee419f0">747.4</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Acquired IPR&amp;D intangibles primarily relate to PR001.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The goodwill recognized from this acquisition is not deductible for tax purposes. </span></div></ix:nonnumeric><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"><ix:continuation id="iaad52d292ee44e348501656cdea080e2" continuedat="id8c6f8e12dbd483e84789dd92d477e51">(3) </ix:continuation></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:continuation id="id8c6f8e12dbd483e84789dd92d477e51">See Note 6 for a discussion on the estimation of the CVR liability.</ix:continuation> </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are unable to provide the results of operations for the three months ended March&nbsp;31, 2022 and 2021 attributable to Prevail as those operations were substantially integrated into our legacy business.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pro forma information has not been included as this acquisition did not have a material impact on our consolidated condensed statements of operations for the three months ended March 31, 2021.</span></div><div style="margin-top:6pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Asset Acquisitions</span></div><ix:nonnumeric contextref="id879b497a407453985551e83dbee75f8_D20220101-20220331" name="us-gaap:ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80OS9mcmFnOjI4N2IyM2IzZGMxNzQ0YmVhOWI0OGNiMTUwMjljZjZlL3RleHRyZWdpb246Mjg3YjIzYjNkYzE3NDRiZWE5YjQ4Y2IxNTAyOWNmNmVfNjA3Mg_599b5f21-1911-45e5-bd88-9986814a77b3" continuedat="i849d250d754145dabcf288a83fbff7e0" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our significant asset acquisitions during the three months ended March&nbsp;31, 2022 and 2021:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:26.531%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.104%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.916%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Counterparty</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Compound(s), Therapy or Asset</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Acquisition Month</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Phase of Development</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Acquired IPR&amp;D Expense</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BioMarin Pharmaceutical Inc.</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Priority Review Voucher</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Not applicable</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i284cb546a16b4766ab7fdbe181505a91_D20220201-20220228" decimals="-5" name="lly:PaymentsForAssetAcquisitions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80OS9mcmFnOjI4N2IyM2IzZGMxNzQ0YmVhOWI0OGNiMTUwMjljZjZlL3RhYmxlOmZhY2M2ZmMzMjAzNjQ1OWRhOGE2NTZkNmJhMWEyNWFjL3RhYmxlcmFuZ2U6ZmFjYzZmYzMyMDM2NDU5ZGE4YTY1NmQ2YmExYTI1YWNfMS02LTEtMS0xMTY5ODc_09539884-f04c-4625-a5f3-56e1228068f0">110.0</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rigel Pharmaceuticals, Inc.</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R552, a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor, for the potential treatment of autoimmune and inflammatory diseases</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase I</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="icde97e5eb6884813ae3f6fc674e3ee2f_D20210301-20210331" decimals="-5" name="lly:PaymentsForAssetAcquisitions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80OS9mcmFnOjI4N2IyM2IzZGMxNzQ0YmVhOWI0OGNiMTUwMjljZjZlL3RhYmxlOmZhY2M2ZmMzMjAzNjQ1OWRhOGE2NTZkNmJhMWEyNWFjL3RhYmxlcmFuZ2U6ZmFjYzZmYzMyMDM2NDU5ZGE4YTY1NmQ2YmExYTI1YWNfMy02LTEtMS0xMjM3Mjk_bf9effc1-4d4f-4929-b9a2-2aaf9989eedb">125.0</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Precision Biosciences, Inc. </span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Potential in vivo therapies for genetic disorders</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 2021</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i7a1bf6e57f0a49d492f68743b77ff855_D20210101-20210131" decimals="-5" name="lly:PaymentsForAssetAcquisitions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF80OS9mcmFnOjI4N2IyM2IzZGMxNzQ0YmVhOWI0OGNiMTUwMjljZjZlL3RhYmxlOmZhY2M2ZmMzMjAzNjQ1OWRhOGE2NTZkNmJhMWEyNWFjL3RhYmxlcmFuZ2U6ZmFjYzZmYzMyMDM2NDU5ZGE4YTY1NmQ2YmExYTI1YWNfMS02LTEtMS0xMDExOTA_e7796d15-0f0a-415f-be77-15e9e7362a3c">107.8</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></tbody></table></div></ix:nonnumeric><div style="padding-left:9pt;text-indent:-9pt"><ix:continuation id="i849d250d754145dabcf288a83fbff7e0" continuedat="i75ab212844a240f2bd616dd6e14f0fa1"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span></ix:continuation><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:continuation id="i75ab212844a240f2bd616dd6e14f0fa1">The phase of development presented is as of the date of the arrangement and represents the phase of development of the most advanced asset acquired, where applicable.</ix:continuation> </span></div><div style="padding-left:9pt;text-indent:-9pt"><span><br></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized no significant development milestones during each of the three months ended March 31, 2022 and 2021.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with asset acquisitions, our partners may be entitled to future royalties and/or commercial milestones based on sales should products be approved for commercialization and/or milestones based on the successful progress of compounds through the development process.</span></div></ix:continuation></ix:continuation><div style="margin-top:6pt"><span><br></span></div><div><span><br></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><div id="ie8dc61f8e15b44db82ba16050d5b7b44_52"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span><br></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 4: <ix:nonnumeric contextref="id879b497a407453985551e83dbee75f8_D20220101-20220331" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF81Mi9mcmFnOjI1ZmE4YmZlYjZiZTQ1MDVhYWNjOWY3ZWY3OWMyNTY0L3RleHRyZWdpb246MjVmYThiZmViNmJlNDUwNWFhY2M5ZjdlZjc5YzI1NjRfMTIzMzc_d8bc44bf-5fc8-4a37-87c4-d3a8a06880be" continuedat="i7e81159bdf7b4fd0b7594f31f20ebb7d" escape="true">Collaborations and Other Arrangements</ix:nonnumeric></span></div><ix:continuation id="i7e81159bdf7b4fd0b7594f31f20ebb7d" continuedat="idcd7324a51de476084446882d8dfa431"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We often enter into collaborative and other similar arrangements to develop and commercialize drug candidates. Collaborative activities may include research and development, marketing and selling (including promotional activities and physician detailing), manufacturing, and distribution. These arrangements often require milestone as well as royalty or profit-share payments, contingent upon the occurrence of certain future events linked to the success of the asset in development, as well as expense reimbursements from or payments to the collaboration partner. See Note 2 for amounts of collaboration and other revenue recognized from these types of arrangements. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating expenses for costs incurred pursuant to these arrangements are reported in their respective expense line item, net of any payments due to or reimbursements due from our collaboration partners, with such reimbursements being recognized at the time the party becomes obligated to pay. Each collaboration is unique in nature, and our more significant arrangements are discussed below. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Boehringer Ingelheim Diabetes Collaboration</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and Boehringer Ingelheim have a global agreement to jointly develop and commercialize a portfolio of diabetes compounds. Currently included in the collaboration are Boehringer Ingelheim's oral diabetes products: Jardiance, Glyxambi, Synjardy, Trijardy XR, Trajenta, and Jentadueto</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as well as our basal insulin, Basaglar. Glyxambi, Synjardy, and Trijardy XR are included in the Jardiance product family. Jentadueto is included in the Trajenta product family. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the regulatory approvals of Jardiance, Trajenta, and Basaglar in the U.S., Europe, and Japan, milestone payments made for Jardiance and Trajenta were capitalized as intangible assets and are being amortized to cost of sales, and milestone payments received for Basaglar were recorded as contract liabilities and are being amortized to collaboration and other revenue. The milestones pertaining to Jardiance and Trajenta are being amortized through their respective term under the collaboration which, depending on country or region, is determined based on the latest to occur of (a) a defined number of years following launch date, (b) the expiration of the compound patent, or (c) the expiration of marketing authorization exclusivity. The milestones pertaining to Basaglar are being amortized through 2029. <ix:nonnumeric contextref="id879b497a407453985551e83dbee75f8_D20220101-20220331" name="us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF81Mi9mcmFnOjI1ZmE4YmZlYjZiZTQ1MDVhYWNjOWY3ZWY3OWMyNTY0L3RleHRyZWdpb246MjVmYThiZmViNmJlNDUwNWFhY2M5ZjdlZjc5YzI1NjRfMTIzNDk_15d76097-f95a-4e27-9233-abc1e76c0cb9" continuedat="i249c414f75184a0e8d5e87a58246d0d8" escape="true">The table below summarizes the net milestones capitalized with respect to the Jardiance and Trajenta families of products and the net milestones deferred with respect to Basaglar at March&nbsp;31, 2022 and December&nbsp;31, 2021: </ix:nonnumeric></span></div><ix:continuation id="i249c414f75184a0e8d5e87a58246d0d8" continuedat="ic34772ed6f3b45d8a0b67759e6cc9035"><div style="margin-top:6pt;padding-left:9pt;text-indent:-9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:63.812%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.443%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.445%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Milestones Capitalized (Deferred)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">as of:</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jardiance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="iefbd2b2e9a6c4f708caad531a19e7008_I20220331" decimals="-5" name="lly:CollaborativeArrangementRightsAndObligationsRightsObligations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF81Mi9mcmFnOjI1ZmE4YmZlYjZiZTQ1MDVhYWNjOWY3ZWY3OWMyNTY0L3RhYmxlOmE4ZTAzMDc0ODU3NjQxNjhhZDg5NTZkOGM2ZGRmODFkL3RhYmxlcmFuZ2U6YThlMDMwNzQ4NTc2NDE2OGFkODk1NmQ4YzZkZGY4MWRfMi0xLTEtMS0xMDExOTA_7580d7ee-a4c1-4a44-aeec-f5a4fcea0b9d">131.1</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ic0abbc83b5524cf1aa65875e5b5d496f_I20211231" decimals="-5" name="lly:CollaborativeArrangementRightsAndObligationsRightsObligations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF81Mi9mcmFnOjI1ZmE4YmZlYjZiZTQ1MDVhYWNjOWY3ZWY3OWMyNTY0L3RhYmxlOmE4ZTAzMDc0ODU3NjQxNjhhZDg5NTZkOGM2ZGRmODFkL3RhYmxlcmFuZ2U6YThlMDMwNzQ4NTc2NDE2OGFkODk1NmQ4YzZkZGY4MWRfMi0yLTEtMS0xMDExOTA_9c682323-5488-46a0-a992-247d2d73c546">136.1</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trajenta</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="ia6bcd0412da04b32a92ef790c3fad97a_I20220331" decimals="-5" name="lly:CollaborativeArrangementRightsAndObligationsRightsObligations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF81Mi9mcmFnOjI1ZmE4YmZlYjZiZTQ1MDVhYWNjOWY3ZWY3OWMyNTY0L3RhYmxlOmE4ZTAzMDc0ODU3NjQxNjhhZDg5NTZkOGM2ZGRmODFkL3RhYmxlcmFuZ2U6YThlMDMwNzQ4NTc2NDE2OGFkODk1NmQ4YzZkZGY4MWRfMy0xLTEtMS0xMDExOTA_8348932d-5fb7-406b-a974-b25e0d6057b5">82.0</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i0cf155dc699c4bd88b23ba88d945d46a_I20211231" decimals="-5" name="lly:CollaborativeArrangementRightsAndObligationsRightsObligations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF81Mi9mcmFnOjI1ZmE4YmZlYjZiZTQ1MDVhYWNjOWY3ZWY3OWMyNTY0L3RhYmxlOmE4ZTAzMDc0ODU3NjQxNjhhZDg5NTZkOGM2ZGRmODFkL3RhYmxlcmFuZ2U6YThlMDMwNzQ4NTc2NDE2OGFkODk1NmQ4YzZkZGY4MWRfMy0yLTEtMS0xMDExOTA_9abf831e-bcb7-4bb8-b489-3137ed39bcce">88.5</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basaglar</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i738922cd7ac64248bcd12d2d74241b20_I20220331" decimals="-5" sign="-" name="lly:CollaborativeArrangementRightsAndObligationsRightsObligations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF81Mi9mcmFnOjI1ZmE4YmZlYjZiZTQ1MDVhYWNjOWY3ZWY3OWMyNTY0L3RhYmxlOmE4ZTAzMDc0ODU3NjQxNjhhZDg5NTZkOGM2ZGRmODFkL3RhYmxlcmFuZ2U6YThlMDMwNzQ4NTc2NDE2OGFkODk1NmQ4YzZkZGY4MWRfNC0xLTEtMS0xMDExOTA_5fb69ac4-0a9d-41d6-ac71-d3ce7d8cb7f2">144.6</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i82d67a39def44b099ed71b9ee99c46cc_I20211231" decimals="-5" sign="-" name="lly:CollaborativeArrangementRightsAndObligationsRightsObligations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF81Mi9mcmFnOjI1ZmE4YmZlYjZiZTQ1MDVhYWNjOWY3ZWY3OWMyNTY0L3RhYmxlOmE4ZTAzMDc0ODU3NjQxNjhhZDg5NTZkOGM2ZGRmODFkL3RhYmxlcmFuZ2U6YThlMDMwNzQ4NTc2NDE2OGFkODk1NmQ4YzZkZGY4MWRfNC0yLTEtMS0xMDExOTA_fc31ba50-473c-4fdc-9df6-b3182a6ed218">149.3</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></tbody></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">This represents the amounts that have been capitalized (deferred) from the start of this collaboration through the end of the reporting period, net of amount amortized. </span></div></ix:continuation><div style="padding-left:9pt;text-indent:-9pt"><span><br></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the Jardiance product family, we and Boehringer Ingelheim share equally the ongoing development and commercialization costs in the most significant markets, and we record our portion of the development and commercialization costs as research and development expense and marketing, selling, and administrative expense, respectively. We receive a royalty on net sales of Boehringer Ingelheim's products in the most significant markets and recognize the royalty as collaboration and other revenue. Boehringer Ingelheim is entitled to potential performance payments depending on the net sales of the Jardiance product family; therefore, our reported revenue for Jardiance may be reduced by any potential performance payments we make related to this product family. The royalty received by us related to the Jardiance product family may also be increased or decreased depending on whether net sales for this product family exceed or fall below certain thresholds. We pay to Boehringer Ingelheim a royalty on net sales for Basaglar in the U.S. We record our sales of Basaglar to third parties as net product revenue with the royalty payments made to Boehringer Ingelheim recorded as cost of sales.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span><br></span></div></div><ix:continuation id="idcd7324a51de476084446882d8dfa431" continuedat="i895f1d61e1204187a3fc33c7a3bed07c"><ix:continuation id="ic34772ed6f3b45d8a0b67759e6cc9035" continuedat="if77f8002c9ef444aafd658eda66dcefe"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our collaboration and other revenue recognized with respect to the Jardiance and Trajenta families of products and net product revenue recognized with respect to Basaglar:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:65.128%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.422%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jardiance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i4cb6aa62dbd343b890ba09e927b3cd93_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF81Mi9mcmFnOjI1ZmE4YmZlYjZiZTQ1MDVhYWNjOWY3ZWY3OWMyNTY0L3RhYmxlOjhlODFlM2UzZDhmNzRjODM4Yzk1ZDU3OTkwNWQ1YmFhL3RhYmxlcmFuZ2U6OGU4MWUzZTNkOGY3NGM4MzhjOTVkNTc5OTA1ZDViYWFfMi0xLTEtMS0xMDExOTA_1ed55943-902d-4429-96a6-0a4623ec2a2d">419.4</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i777b66c425e44ef281a1ea05038a2e33_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF81Mi9mcmFnOjI1ZmE4YmZlYjZiZTQ1MDVhYWNjOWY3ZWY3OWMyNTY0L3RhYmxlOjhlODFlM2UzZDhmNzRjODM4Yzk1ZDU3OTkwNWQ1YmFhL3RhYmxlcmFuZ2U6OGU4MWUzZTNkOGY3NGM4MzhjOTVkNTc5OTA1ZDViYWFfMi0zLTEtMS0xMDExOTA_823f3b10-17f9-4ba9-934f-d18b5b0cb046">312.0</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basaglar</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="ie964fd385686493399055f5b20bfe25e_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF81Mi9mcmFnOjI1ZmE4YmZlYjZiZTQ1MDVhYWNjOWY3ZWY3OWMyNTY0L3RhYmxlOjhlODFlM2UzZDhmNzRjODM4Yzk1ZDU3OTkwNWQ1YmFhL3RhYmxlcmFuZ2U6OGU4MWUzZTNkOGY3NGM4MzhjOTVkNTc5OTA1ZDViYWFfMy0xLTEtMS0xMDExOTA_ff68e865-5250-411f-a731-99254a7e256c">191.5</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ie7ec39e69cee464db36f6873b2d073f8_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF81Mi9mcmFnOjI1ZmE4YmZlYjZiZTQ1MDVhYWNjOWY3ZWY3OWMyNTY0L3RhYmxlOjhlODFlM2UzZDhmNzRjODM4Yzk1ZDU3OTkwNWQ1YmFhL3RhYmxlcmFuZ2U6OGU4MWUzZTNkOGY3NGM4MzhjOTVkNTc5OTA1ZDViYWFfMy0zLTEtMS0xMDExOTA_88fea232-5a6e-478b-a43c-d01cf2de3e6f">246.6</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trajenta</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib10eae977de34fb2bcb6d32b86e1e00b_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF81Mi9mcmFnOjI1ZmE4YmZlYjZiZTQ1MDVhYWNjOWY3ZWY3OWMyNTY0L3RhYmxlOjhlODFlM2UzZDhmNzRjODM4Yzk1ZDU3OTkwNWQ1YmFhL3RhYmxlcmFuZ2U6OGU4MWUzZTNkOGY3NGM4MzhjOTVkNTc5OTA1ZDViYWFfNC0xLTEtMS0xMDExOTA_057a66d8-87f3-4647-9464-72b2aa19d709">92.0</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i3692c8ddf38d41e2aaa1db31ff5ef2e7_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF81Mi9mcmFnOjI1ZmE4YmZlYjZiZTQ1MDVhYWNjOWY3ZWY3OWMyNTY0L3RhYmxlOjhlODFlM2UzZDhmNzRjODM4Yzk1ZDU3OTkwNWQ1YmFhL3RhYmxlcmFuZ2U6OGU4MWUzZTNkOGY3NGM4MzhjOTVkNTc5OTA1ZDViYWFfNC0zLTEtMS0xMDExOTA_9211faf6-811b-4fd0-a4dc-a5886f88f662">94.6</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></tbody></table></div></ix:continuation><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Olumiant</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a worldwide license and collaboration agreement with Incyte Corporation (Incyte), which provides us the development and commercialization rights to its Janus tyrosine kinase (JAK) inhibitor compound, now known as Olumiant (baricitinib), and certain follow-on compounds, for the treatment of inflammatory and autoimmune diseases. Incyte has the right to receive tiered, double digit royalty payments on worldwide net sales with rates ranging up to <ix:nonfraction unitref="number" contextref="if4ed44df0538499fb8e6d148cc9e0996_D20220101-20220331" decimals="2" name="lly:CollaborativeArrangementRightsAndObligationsPercent" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF81Mi9mcmFnOjI1ZmE4YmZlYjZiZTQ1MDVhYWNjOWY3ZWY3OWMyNTY0L3RleHRyZWdpb246MjVmYThiZmViNmJlNDUwNWFhY2M5ZjdlZjc5YzI1NjRfNDY5MA_af1092e4-95d2-412b-8ec5-19ff89096805">20</ix:nonfraction> percent. Incyte has the right to receive an additional royalty ranging up to the low teens on worldwide net sales for the treatment of COVID-19 that exceed a specified aggregate worldwide net sales threshold. The agreement calls for payments by us to Incyte associated with certain development, success-based regulatory, and sales-based milestones. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the regulatory approvals of Olumiant in the U.S., Europe, and Japan, as well as achievement of a sales-based milestone, milestone payments of $<ix:nonfraction unitref="usd" contextref="ib71be47e87cf45e09ed8b30e689ae006_I20220331" decimals="-5" name="lly:CollaborativeArrangementRightsAndObligationsRightsObligations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF81Mi9mcmFnOjI1ZmE4YmZlYjZiZTQ1MDVhYWNjOWY3ZWY3OWMyNTY0L3RleHRyZWdpb246MjVmYThiZmViNmJlNDUwNWFhY2M5ZjdlZjc5YzI1NjRfNTIyMw_0d7d0ee9-fdc9-4eb1-94d2-2da374825a46"><ix:nonfraction unitref="usd" contextref="i342528da2bb5408fae069b71ce902752_I20211231" decimals="-5" name="lly:CollaborativeArrangementRightsAndObligationsRightsObligations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF81Mi9mcmFnOjI1ZmE4YmZlYjZiZTQ1MDVhYWNjOWY3ZWY3OWMyNTY0L3RleHRyZWdpb246MjVmYThiZmViNmJlNDUwNWFhY2M5ZjdlZjc5YzI1NjRfNTIyMw_b3d68606-6172-4848-9967-09d188ebd9a4">260.0</ix:nonfraction></ix:nonfraction> million were capitalized as intangible assets as of March&nbsp;31, 2022 and December&nbsp;31, 2021 and are being amortized to cost of sales through the term of the collaboration. This represents the cumulative amounts that have been capitalized from the start of this collaboration through the end of each reporting period.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&nbsp;31, 2022, Incyte is eligible to receive up to $<ix:nonfraction unitref="usd" contextref="i1b8e4440b5134d4fb2a40c2a8aa16a91_I20220331" decimals="-5" name="lly:CollaborativeArrangementRightsAndObligationsRightsObligations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF81Mi9mcmFnOjI1ZmE4YmZlYjZiZTQ1MDVhYWNjOWY3ZWY3OWMyNTY0L3RleHRyZWdpb246MjVmYThiZmViNmJlNDUwNWFhY2M5ZjdlZjc5YzI1NjRfNTU4Mg_0cce44d3-0d9b-4c67-8048-140e4ecdcd48">70.0</ix:nonfraction> million of additional payments from us contingent upon certain success-based regulatory milestones based on current development plans. Incyte is also eligible to receive up to $<ix:nonfraction unitref="usd" contextref="i08ec473bc23b4cc98e6f598c61e4a81e_I20220331" decimals="-5" name="lly:CollaborativeArrangementRightsAndObligationsRightsObligations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF81Mi9mcmFnOjI1ZmE4YmZlYjZiZTQ1MDVhYWNjOWY3ZWY3OWMyNTY0L3RleHRyZWdpb246MjVmYThiZmViNmJlNDUwNWFhY2M5ZjdlZjc5YzI1NjRfNTcxOA_22f89977-34ca-4e90-8aab-3aab10ec4c68">100.0</ix:nonfraction>&nbsp;million of potential sales-based milestones.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record our sales of Olumiant, including sales of baricitinib that were made pursuant to EUA or similar regulatory authorizations, to third parties as net product revenue with the royalty payments made to Incyte recorded as cost of sales. <ix:continuation id="if77f8002c9ef444aafd658eda66dcefe" continuedat="i032532333b40432fb91802b528706838">The following table summarizes our net product revenue recognized with respect to Olumiant:</ix:continuation></span></div><div style="margin-top:6pt;text-align:center"><ix:continuation id="i032532333b40432fb91802b528706838" continuedat="i905d26aefcaf44eeba942d6779071c61"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:65.128%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.422%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Olumiant</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i5aed712fed4f4f1a85becddb3dd53a89_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF81Mi9mcmFnOjI1ZmE4YmZlYjZiZTQ1MDVhYWNjOWY3ZWY3OWMyNTY0L3RhYmxlOmM4MzQ1ZWZhODdiMDQwZmU4ZjllZjg5ZjU5Nzk3NTllL3RhYmxlcmFuZ2U6YzgzNDVlZmE4N2IwNDBmZThmOWVmODlmNTk3OTc1OWVfMi0xLTEtMS0xMDExOTA_1322bc1d-aa85-4ffd-ba40-4447bdf3fa4e">255.6</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i4b177d421c0842769bd4a1abbec6790a_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF81Mi9mcmFnOjI1ZmE4YmZlYjZiZTQ1MDVhYWNjOWY3ZWY3OWMyNTY0L3RhYmxlOmM4MzQ1ZWZhODdiMDQwZmU4ZjllZjg5ZjU5Nzk3NTllL3RhYmxlcmFuZ2U6YzgzNDVlZmE4N2IwNDBmZThmOWVmODlmNTk3OTc1OWVfMi0zLTEtMS0xMDExOTA_d74dad02-b53f-48f3-9437-7ec67ebbec6d">193.8</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></tbody></table></ix:continuation></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">COVID-19 Antibodies</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a worldwide license and collaboration agreement with AbCellera Biologics Inc. (AbCellera) to co-develop therapeutic antibodies for the potential prevention and treatment of COVID-19, including bamlanivimab and bebtelovimab, for which we hold development and commercialization rights. AbCellera has the right to receive tiered royalty payments on worldwide net sales of bamlanivimab and bebtelovimab with percentages ranging in the mid-teens to mid-twenties. Royalty payments made to AbCellera are recorded as cost of sales.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a license and collaboration agreement with Shanghai Junshi Biosciences Co., Ltd. (Junshi Biosciences) to co-develop therapeutic antibodies for the potential prevention and treatment of COVID-19, including etesevimab, for which we hold development and commercialization rights outside of mainland China and the Special Administrative Regions of Hong Kong and Macau, and for which Junshi Biosciences currently maintains all rights in mainland China and the Special Administrative Regions of Hong Kong and Macau. Junshi Biosciences has the right to receive royalty payments in the mid-teens on our net sales of etesevimab. Junshi Biosciences received certain development, success-based regulatory and sales-based milestones. Capitalized regulatory and sales-based milestones were fully amortized to cost of sales as of March&nbsp;31, 2022. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to EUAs or similar regulatory authorizations, we recognized $<ix:nonfraction unitref="usd" contextref="if68e51aede3b457a9c66472600e5be13_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF81Mi9mcmFnOjI1ZmE4YmZlYjZiZTQ1MDVhYWNjOWY3ZWY3OWMyNTY0L3RleHRyZWdpb246MjVmYThiZmViNmJlNDUwNWFhY2M5ZjdlZjc5YzI1NjRfMTY0OTI2NzQ3NjgyMg_64137162-f6ad-4c16-9ff6-fa5a565cc656">1.47</ix:nonfraction>&nbsp;billion and $<ix:nonfraction unitref="usd" contextref="i774cde30abd54325b3366e0ebcd76a96_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF81Mi9mcmFnOjI1ZmE4YmZlYjZiZTQ1MDVhYWNjOWY3ZWY3OWMyNTY0L3RleHRyZWdpb246MjVmYThiZmViNmJlNDUwNWFhY2M5ZjdlZjc5YzI1NjRfMTA5OTUxMTY0MDIyNQ_cdb3dc0b-92a9-4277-91e6-15e650bfbf9b">810.1</ix:nonfraction>&nbsp;million of net product revenue associated with our sales of our COVID-19 antibodies during the three months ended March&nbsp;31, 2022 and 2021, respectively. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span><br></span></div></div><ix:continuation id="i895f1d61e1204187a3fc33c7a3bed07c"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Sintilimab Injection</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a collaboration agreement with Innovent to jointly develop and commercialize sintilimab injection in China, where it is branded and trademarked as Tyvyt. In 2019, we and Innovent began co-commercializing Tyvyt in China. In 2020, we obtained an exclusive license for sintilimab injection from Innovent for geographies outside of China. Innovent, with collaboration from us, filed the initial registration of sintilimab injection in the U.S. that the FDA did not approve in its current form and recommended an additional multiregional clinical study be performed. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with a regulatory approval for Tyvyt in China in 2021, we capitalized a milestone payment of $<ix:nonfraction unitref="usd" contextref="i08b540e36f754b9185cff7340cdc0aac_I20211231" decimals="-5" name="lly:CollaborativeArrangementRightsAndObligationsRightsObligations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF81Mi9mcmFnOjI1ZmE4YmZlYjZiZTQ1MDVhYWNjOWY3ZWY3OWMyNTY0L3RleHRyZWdpb246MjVmYThiZmViNmJlNDUwNWFhY2M5ZjdlZjc5YzI1NjRfODcxMg_1dcd313c-e124-49f7-98de-378072c447db">40.0</ix:nonfraction>&nbsp;million as an intangible asset which is being amortized to cost of sales through the term of the collaboration.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&nbsp;31, 2022, Innovent is eligible to receive up to $<ix:nonfraction unitref="usd" contextref="i54fd35218a5349289dfb44cc0657c959_I20220331" decimals="-5" name="lly:CollaborativeArrangementRightsAndObligationsRightsObligations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF81Mi9mcmFnOjI1ZmE4YmZlYjZiZTQ1MDVhYWNjOWY3ZWY3OWMyNTY0L3RleHRyZWdpb246MjVmYThiZmViNmJlNDUwNWFhY2M5ZjdlZjc5YzI1NjRfODg2Nw_33f11c75-e287-43a4-89a7-0b024d48014d">825.0</ix:nonfraction> million for geographies outside of China and up to $<ix:nonfraction unitref="usd" contextref="i4c4fc5f7f1aa45d089c061b7bb0af2cc_I20220331" decimals="-5" name="lly:CollaborativeArrangementRightsAndObligationsRightsObligations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF81Mi9mcmFnOjI1ZmE4YmZlYjZiZTQ1MDVhYWNjOWY3ZWY3OWMyNTY0L3RleHRyZWdpb246MjVmYThiZmViNmJlNDUwNWFhY2M5ZjdlZjc5YzI1NjRfODkxMw_4a407827-1743-4c96-b8ff-98418b717794">195.0</ix:nonfraction>&nbsp;million in China in success-based regulatory and sales-based milestones. Innovent is also eligible to receive tiered double digit royalties on net sales for geographies outside of China. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record our sales of Tyvyt to third parties as net product revenue, with payments made to Innovent for its portion of the gross margin reported as cost of sales. We report as collaboration and other revenue our portion of the gross margin for Tyvyt sales made by Innovent to third parties. <ix:continuation id="i905d26aefcaf44eeba942d6779071c61" continuedat="ic3b295f0cca540a59367255f822b6b56">The following table summarizes our revenue recognized in China with respect to Tyvyt:</ix:continuation></span></div><div style="margin-top:6pt;text-align:center"><ix:continuation id="ic3b295f0cca540a59367255f822b6b56"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:65.128%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.422%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tyvyt</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="ifdfcf0a8c9f24795965b4204e3e96f0c_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF81Mi9mcmFnOjI1ZmE4YmZlYjZiZTQ1MDVhYWNjOWY3ZWY3OWMyNTY0L3RhYmxlOjk4Nzk3NjVhNzkyNzRlY2ZiNTNlODZlYTY5YzUzMDUxL3RhYmxlcmFuZ2U6OTg3OTc2NWE3OTI3NGVjZmI1M2U4NmVhNjljNTMwNTFfMi0xLTEtMS0xMDExOTA_8e3f8cf7-6d97-4a88-8208-bf8ca0fb219d">85.5</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i8313e66c84c44e68889b0fac3ee0fe61_D20210101-20210331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF81Mi9mcmFnOjI1ZmE4YmZlYjZiZTQ1MDVhYWNjOWY3ZWY3OWMyNTY0L3RhYmxlOjk4Nzk3NjVhNzkyNzRlY2ZiNTNlODZlYTY5YzUzMDUxL3RhYmxlcmFuZ2U6OTg3OTc2NWE3OTI3NGVjZmI1M2U4NmVhNjljNTMwNTFfMi0zLTEtMS0xMDExOTA_ab3c0c7b-85d0-4fd1-9ce9-c495ade43eef">109.7</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></tbody></table></ix:continuation></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Lebrikizumab</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of our acquisition of Dermira, Inc. (Dermira), we have a worldwide license agreement with F. Hoffmann-La Roche Ltd and Genentech, Inc. (collectively Roche), which provides us the worldwide development and commercialization rights to lebrikizumab. Roche has the right to receive tiered royalty payments on future worldwide net sales ranging in percentages from high single digits to high teens if the product is successfully commercialized. As of March&nbsp;31, 2022, Roche is eligible to receive up to $<ix:nonfraction unitref="usd" contextref="ice5cf718015640c1b082abef326c20f3_I20220331" decimals="-5" name="lly:CollaborativeArrangementRightsAndObligationsRightsObligations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF81Mi9mcmFnOjI1ZmE4YmZlYjZiZTQ1MDVhYWNjOWY3ZWY3OWMyNTY0L3RleHRyZWdpb246MjVmYThiZmViNmJlNDUwNWFhY2M5ZjdlZjc5YzI1NjRfMTA0Nzc_d5e2c9f5-f319-4940-bace-ba4d75f29788">180.0</ix:nonfraction> million of payments from us contingent upon the achievement of success-based regulatory milestones and up to $<ix:nonfraction unitref="usd" contextref="i17a8e5b7cdad48e3ba35be583e59224b_I20220331" decimals="-7" name="lly:CollaborativeArrangementRightsAndObligationsRightsObligations" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF81Mi9mcmFnOjI1ZmE4YmZlYjZiZTQ1MDVhYWNjOWY3ZWY3OWMyNTY0L3RleHRyZWdpb246MjVmYThiZmViNmJlNDUwNWFhY2M5ZjdlZjc5YzI1NjRfMTA1ODE_9aaa08e2-ec51-4b2b-a18a-a8162934bb0f">1.03</ix:nonfraction> billion in a series of sales-based milestones, contingent upon the commercial success of lebrikizumab.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of our acquisition of Dermira, we have a license agreement with Almirall, S.A. (Almirall), under which Almirall licensed the rights to develop and commercialize lebrikizumab for the treatment or prevention of dermatology indications, including, but not limited to, atopic dermatitis in Europe. We have the right to receive tiered royalty payments on future net sales in Europe ranging in percentages from low double digits to low twenties if the product is successfully commercialized. As of March&nbsp;31, 2022, we are eligible to receive additional payments of $<ix:nonfraction unitref="usd" contextref="i7ba2c213d6174f03ad66d676edf41010_I20220331" decimals="-5" name="lly:CollaborativeArrangementRightsAndObligationsRightsObligations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF81Mi9mcmFnOjI1ZmE4YmZlYjZiZTQ1MDVhYWNjOWY3ZWY3OWMyNTY0L3RleHRyZWdpb246MjVmYThiZmViNmJlNDUwNWFhY2M5ZjdlZjc5YzI1NjRfMTEyMzc_c7d532e8-c8e1-48df-9148-885fa96f4a63">85.0</ix:nonfraction>&nbsp;million from Almirall contingent upon the achievement of success-based regulatory milestones and up to $<ix:nonfraction unitref="usd" contextref="i3fb85ae7275a4ab5b2dd5347ad84f3d7_I20220331" decimals="-7" name="lly:CollaborativeArrangementRightsAndObligationsRightsObligations" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF81Mi9mcmFnOjI1ZmE4YmZlYjZiZTQ1MDVhYWNjOWY3ZWY3OWMyNTY0L3RleHRyZWdpb246MjVmYThiZmViNmJlNDUwNWFhY2M5ZjdlZjc5YzI1NjRfMTEzMzU_a4e9697b-9da7-4355-a50a-5fce689039e7">1.25</ix:nonfraction>&nbsp;billion in a series of sales-based milestones, contingent upon the commercial success of lebrikizumab. As of March&nbsp;31, 2022 and December&nbsp;31, 2021, contract liabilities were not material. During the three months ended March&nbsp;31, 2022 and 2021, collaboration and other revenue recognized was not material. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Petra Pharma Corporation (Petra)</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of our acquisition of Petra, we are required to make milestone payments to Petra shareholders contingent upon the occurrence of certain future events linked to the success of the mutant-selective PI3K</span><span style="color:#000000;font-family:'Book Antiqua',sans-serif;font-size:10pt;font-weight:400;line-height:120%">α</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> inhibitor. In April 2022, we entered into agreements with substantially all Petra shareholders to acquire their rights to receive any future milestone payments in exchange for a one-time payment. As a result of these agreements, we will record a charge of approximately $<ix:nonfraction unitref="usd" contextref="ib89d32abca5f4ef09217da80647ddbb5_D20220401-20220430" decimals="-6" name="lly:PaymentsForAssetAcquisitions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF81Mi9mcmFnOjI1ZmE4YmZlYjZiZTQ1MDVhYWNjOWY3ZWY3OWMyNTY0L3RleHRyZWdpb246MjVmYThiZmViNmJlNDUwNWFhY2M5ZjdlZjc5YzI1NjRfMTA0NDUzNjA0OTg5OTQ_829abff8-af42-48a8-af14-dbfc121bba01">335</ix:nonfraction>&nbsp;million to acquired IPR&amp;D and development milestones in the second quarter of 2022. Any remaining contingent milestones payments linked to the success of the mutant-selective PI3Kα are not expected to be material.</span></div></ix:continuation><div style="margin-top:6pt"><span><br></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><div id="ie8dc61f8e15b44db82ba16050d5b7b44_61"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span><br></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 5: <ix:nonnumeric contextref="id879b497a407453985551e83dbee75f8_D20220101-20220331" name="us-gaap:RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82MS9mcmFnOmJkYTI1MWM1ODBiOTQ5MGE4MTJlYTlmYTRmM2FkMzI5L3RleHRyZWdpb246YmRhMjUxYzU4MGI5NDkwYTgxMmVhOWZhNGYzYWQzMjlfMTYyNA_aaaf724b-295c-4a57-bc25-de9a06d7597a" continuedat="i28e493cdf31a4f5d86f08945020e5415" escape="true">Asset Impairment, Restructuring, and Other Special Charges</ix:nonnumeric></span></div><ix:continuation id="i28e493cdf31a4f5d86f08945020e5415" continuedat="id39fd4776fe4445f8632d0c239bdb722"><ix:nonnumeric contextref="id879b497a407453985551e83dbee75f8_D20220101-20220331" name="us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82MS9mcmFnOmJkYTI1MWM1ODBiOTQ5MGE4MTJlYTlmYTRmM2FkMzI5L3RleHRyZWdpb246YmRhMjUxYzU4MGI5NDkwYTgxMmVhOWZhNGYzYWQzMjlfMTYxOA_8580145f-aca9-4385-b5cc-d91eb235920b" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of the charges included in asset impairment, restructuring, and other special charges in our consolidated condensed statements of operations are described below. </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:65.128%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.422%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Severance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="id879b497a407453985551e83dbee75f8_D20220101-20220331" decimals="-5" name="us-gaap:SeveranceCosts1" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82MS9mcmFnOmJkYTI1MWM1ODBiOTQ5MGE4MTJlYTlmYTRmM2FkMzI5L3RhYmxlOjI1MzE0MTViY2NjZjRiNTFhM2U5NzM0MDIyZWRiYjE1L3RhYmxlcmFuZ2U6MjUzMTQxNWJjY2NmNGI1MWEzZTk3MzQwMjJlZGJiMTVfMi0xLTEtMS0xMDExOTA_d1687bb7-5c6e-41b9-8778-d887d15f19aa">—</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i010e4c0d9c6246be91d37e31d569fa6f_D20210101-20210331" decimals="-5" name="us-gaap:SeveranceCosts1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82MS9mcmFnOmJkYTI1MWM1ODBiOTQ5MGE4MTJlYTlmYTRmM2FkMzI5L3RhYmxlOjI1MzE0MTViY2NjZjRiNTFhM2U5NzM0MDIyZWRiYjE1L3RhYmxlcmFuZ2U6MjUzMTQxNWJjY2NmNGI1MWEzZTk3MzQwMjJlZGJiMTVfMi0zLTEtMS0xMDExOTA_30a99547-2320-461d-9190-2d3ea5eafd35">11.5</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset impairment and other special charges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="id879b497a407453985551e83dbee75f8_D20220101-20220331" decimals="-5" name="lly:AssetImpairmentChargesRecoveriesAndOtherSpecialCharges" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82MS9mcmFnOmJkYTI1MWM1ODBiOTQ5MGE4MTJlYTlmYTRmM2FkMzI5L3RhYmxlOjI1MzE0MTViY2NjZjRiNTFhM2U5NzM0MDIyZWRiYjE1L3RhYmxlcmFuZ2U6MjUzMTQxNWJjY2NmNGI1MWEzZTk3MzQwMjJlZGJiMTVfMy0xLTEtMS0xMDExOTA_7522276e-32d2-4395-9f95-b6713365d709">—</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i010e4c0d9c6246be91d37e31d569fa6f_D20210101-20210331" decimals="-5" name="lly:AssetImpairmentChargesRecoveriesAndOtherSpecialCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82MS9mcmFnOmJkYTI1MWM1ODBiOTQ5MGE4MTJlYTlmYTRmM2FkMzI5L3RhYmxlOjI1MzE0MTViY2NjZjRiNTFhM2U5NzM0MDIyZWRiYjE1L3RhYmxlcmFuZ2U6MjUzMTQxNWJjY2NmNGI1MWEzZTk3MzQwMjJlZGJiMTVfMy0zLTEtMS0xMDExOTA_e9bc3072-43ad-47c6-be2c-25b6a192e85e">200.1</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total asset impairment, restructuring, and other special charges</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="id879b497a407453985551e83dbee75f8_D20220101-20220331" decimals="-5" name="us-gaap:RestructuringSettlementAndImpairmentProvisions" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82MS9mcmFnOmJkYTI1MWM1ODBiOTQ5MGE4MTJlYTlmYTRmM2FkMzI5L3RhYmxlOjI1MzE0MTViY2NjZjRiNTFhM2U5NzM0MDIyZWRiYjE1L3RhYmxlcmFuZ2U6MjUzMTQxNWJjY2NmNGI1MWEzZTk3MzQwMjJlZGJiMTVfNC0xLTEtMS0xMDExOTA_d1d0db18-3c80-490a-a909-ab1cc4a9b2b0">—</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i010e4c0d9c6246be91d37e31d569fa6f_D20210101-20210331" decimals="-5" name="us-gaap:RestructuringSettlementAndImpairmentProvisions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82MS9mcmFnOmJkYTI1MWM1ODBiOTQ5MGE4MTJlYTlmYTRmM2FkMzI5L3RhYmxlOjI1MzE0MTViY2NjZjRiNTFhM2U5NzM0MDIyZWRiYjE1L3RhYmxlcmFuZ2U6MjUzMTQxNWJjY2NmNGI1MWEzZTk3MzQwMjJlZGJiMTVfNC0zLTEtMS0xMDExOTA_0831ca4a-589a-4054-be63-c99930563eed">211.6</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></tbody></table></div></ix:nonnumeric></ix:continuation><div style="margin-top:6pt"><ix:continuation id="id39fd4776fe4445f8632d0c239bdb722" continuedat="ic729da67c3884806ad54cda11ff05923"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Asset impairment, restructuring, and other special charges recognized during the three months ended March&nbsp;31, 2021 were primarily related to an intangible asset impairment of $<ix:nonfraction unitref="usd" contextref="id879b497a407453985551e83dbee75f8_D20220101-20220331" decimals="-5" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82MS9mcmFnOmJkYTI1MWM1ODBiOTQ5MGE4MTJlYTlmYTRmM2FkMzI5L3RleHRyZWdpb246YmRhMjUxYzU4MGI5NDkwYTgxMmVhOWZhNGYzYWQzMjlfNDE0_e423e8c7-7143-4a27-a9e3-087c6be77b72">108.1</ix:nonfraction>&nbsp;million resulting from the sale of the rights to Qbrexza</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span></ix:continuation><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ic729da67c3884806ad54cda11ff05923">, as well as acquisition and integration costs associated with the acquisition of Prevail.</ix:continuation> </span></div><div style="margin-top:6pt"><span><br></span></div><div id="ie8dc61f8e15b44db82ba16050d5b7b44_64"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 6: <ix:nonnumeric contextref="id879b497a407453985551e83dbee75f8_D20220101-20220331" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RleHRyZWdpb246NWNkZmEwZDVmNzVlNGY2N2E1ZTQ0NjAxMTQ3MmJlNWZfMTYyNzA_d2a4d2a8-4204-43ea-b669-1ac5f187c7b1" continuedat="idfedf180a0c6422db51d3313f7e0d170" escape="true">Financial Instruments</ix:nonnumeric></span></div><ix:continuation id="idfedf180a0c6422db51d3313f7e0d170" continuedat="icf365f90cccd48f587d31ee59e36419e"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject us to credit risk consist principally of trade receivables and interest-bearing investments. Wholesale distributors of life science products account for a substantial portion of our trade receivables; collateral is generally not required. We seek to mitigate the risk associated with this concentration through our ongoing credit-review procedures and insurance. A large portion of our cash is held by a few major financial institutions. We monitor our exposures with these institutions and do not expect any of these institutions to fail to meet their obligations. In accordance with documented corporate risk-management policies, we monitor the amount of credit exposure to any one financial institution or corporate issuer. We are exposed to credit-related losses in the event of nonperformance by counterparties to risk-management instruments but do not expect any counterparties to fail to meet their obligations given their high credit ratings.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consider all highly liquid investments with a maturity of three months or less from the date of purchase to be cash equivalents. The cost of these investments approximates fair value.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our equity investments are accounted for using three different methods depending on the type of equity investment:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Investments in companies over which we have significant influence but not a controlling interest are accounted for using the equity method, with our share of earnings or losses reported in other-net, (income) expense. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">For equity investments that do not have readily determinable fair values, we measure these investments at cost, less any impairment, plus or minus changes resulting from observable price changes in orderly transactions for the identical or similar investment of the same issuer. Any change in recorded value is recorded in other-net, (income) expense. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our public equity investments are measured and carried at fair value. Any change in fair value is recognized in other-net, (income) expense. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We review equity investments other than public equity investments for indications of impairment and observable price changes on a regular basis.</span></div><ix:nonnumeric contextref="id879b497a407453985551e83dbee75f8_D20220101-20220331" name="us-gaap:DerivativesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RleHRyZWdpb246NWNkZmEwZDVmNzVlNGY2N2E1ZTQ0NjAxMTQ3MmJlNWZfMTYyNjQ_0ed77d6e-992c-4d18-8440-31174156b0f9" continuedat="i0195e4d411c84ee8bc9156a95fd72e2e" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our derivative activities are initiated within the guidelines of documented corporate risk-management policies and are intended to offset losses and gains on the assets, liabilities, and transactions being hedged. Management reviews the correlation and effectiveness of our derivatives on a quarterly basis.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For derivative instruments that are designated and qualify as fair value hedges, the derivative instrument is marked to market, with gains and losses recognized currently in income to offset the respective losses and gains recognized on the underlying exposure. For derivative instruments that are designated and qualify as cash flow hedges, gains and losses are reported as a component of accumulated other comprehensive loss and reclassified into earnings in the same period the hedged transaction affects earnings. For derivative and non-derivative instruments that are designated and qualify as net investment hedges, the foreign currency translation gains or losses due to spot rate fluctuations are reported as a component of accumulated other comprehensive loss. Derivative contracts that are not designated as hedging instruments are recorded at fair value with the gain or loss recognized in earnings during the period of change.</span></div></ix:nonnumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span><br></span></div></div><ix:continuation id="icf365f90cccd48f587d31ee59e36419e" continuedat="ie4d56fa3ce1b42bc90763b7b2a5aa395"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i0195e4d411c84ee8bc9156a95fd72e2e">We may enter into foreign currency forward or option contracts to reduce the effect of fluctuating currency exchange rates (principally the euro, British pound, and Japanese yen). Foreign currency derivatives used for hedging are put in place using the same or like currencies and duration as the underlying exposures. Forward and option contracts are principally used to manage exposures arising from subsidiary trade and loan payables and receivables denominated in foreign currencies. These contracts are recorded at fair value with the gain or loss recognized in other–net, (income) expense. We may enter into foreign currency forward and option contracts and currency swaps as fair value hedges of firm commitments. Forward contracts generally have maturities not exceeding 12 months.</ix:continuation> At March&nbsp;31, 2022, we had outstanding foreign currency forward commitments to purchase <ix:nonfraction unitref="usd" contextref="i5828b97906464e3b820454b6eb85b325_I20220331" decimals="-5" name="us-gaap:DerivativeLiabilityNotionalAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RleHRyZWdpb246NWNkZmEwZDVmNzVlNGY2N2E1ZTQ0NjAxMTQ3MmJlNWZfNDMwNw_c22704c8-bd93-41c3-a1cb-2080a7c0dbd7">3.47</ix:nonfraction> billion U.S. dollars and sell <ix:nonfraction unitref="eur" contextref="i5828b97906464e3b820454b6eb85b325_I20220331" decimals="-5" name="us-gaap:DerivativeAssetNotionalAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RleHRyZWdpb246NWNkZmEwZDVmNzVlNGY2N2E1ZTQ0NjAxMTQ3MmJlNWZfNDMzMg_94bf4e8a-53ea-40c2-b741-fb4db8974104">3.13</ix:nonfraction> billion euro; commitments to purchase <ix:nonfraction unitref="eur" contextref="i6a6c9940843c4feab2e1a0c99a63a96f_I20220331" decimals="-7" name="us-gaap:DerivativeLiabilityNotionalAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RleHRyZWdpb246NWNkZmEwZDVmNzVlNGY2N2E1ZTQ0NjAxMTQ3MmJlNWZfNDM2NQ_c7b5c45d-548c-4921-ae6c-59eab94eea45">5.05</ix:nonfraction> billion euro and sell <ix:nonfraction unitref="usd" contextref="i6a6c9940843c4feab2e1a0c99a63a96f_I20220331" decimals="-7" name="us-gaap:DerivativeAssetNotionalAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RleHRyZWdpb246NWNkZmEwZDVmNzVlNGY2N2E1ZTQ0NjAxMTQ3MmJlNWZfNDM4Mg_5b286744-7f9e-4418-9b56-a6ba38f490b9">5.61</ix:nonfraction> billion U.S. dollars; commitments to purchase <ix:nonfraction unitref="usd" contextref="i09dde07b68a745fe82096156d8b7e181_I20220331" decimals="-5" name="us-gaap:DerivativeLiabilityNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RleHRyZWdpb246NWNkZmEwZDVmNzVlNGY2N2E1ZTQ0NjAxMTQ3MmJlNWZfNDQyMw_da8f963a-15c3-41b1-9bfa-178acc435aa9">195.6</ix:nonfraction> million U.S. dollars and sell <ix:nonfraction unitref="cny" contextref="i09dde07b68a745fe82096156d8b7e181_I20220331" decimals="-5" name="us-gaap:DerivativeAssetNotionalAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RleHRyZWdpb246NWNkZmEwZDVmNzVlNGY2N2E1ZTQ0NjAxMTQ3MmJlNWZfNDQ0OA_cf2fde52-ce20-4e37-b08e-d195d43ed333">1.25</ix:nonfraction> billion Chinese yuan; commitments to purchase <ix:nonfraction unitref="usd" contextref="ia6422416ea2241a2a43437b14235b97f_I20220331" decimals="-5" name="us-gaap:DerivativeLiabilityNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RleHRyZWdpb246NWNkZmEwZDVmNzVlNGY2N2E1ZTQ0NjAxMTQ3MmJlNWZfNDQ4OQ_70988b24-e67d-4d9d-95c8-374cfab849d9">89.4</ix:nonfraction>&nbsp;million U.S. dollars and sell <ix:nonfraction unitref="jpy" contextref="ia6422416ea2241a2a43437b14235b97f_I20220331" decimals="-7" name="us-gaap:DerivativeAssetNotionalAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RleHRyZWdpb246NWNkZmEwZDVmNzVlNGY2N2E1ZTQ0NjAxMTQ3MmJlNWZfNDUxNA_821fcd4a-5a04-4f98-b46e-d8dd0915ca8e">10.85</ix:nonfraction> billion Japanese yen; and commitments to purchase <ix:nonfraction unitref="gbp" contextref="ib07c94a6d4af4835996d8e78d31945e5_I20220331" decimals="-5" name="us-gaap:DerivativeLiabilityNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RleHRyZWdpb246NWNkZmEwZDVmNzVlNGY2N2E1ZTQ0NjAxMTQ3MmJlNWZfNDU1OQ_d079ee3f-926b-4765-8b19-1579a534a921">191.6</ix:nonfraction> million British pounds and sell <ix:nonfraction unitref="usd" contextref="ib07c94a6d4af4835996d8e78d31945e5_I20220331" decimals="-5" name="us-gaap:DerivativeAssetNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RleHRyZWdpb246NWNkZmEwZDVmNzVlNGY2N2E1ZTQ0NjAxMTQ3MmJlNWZfNDU4Ng_c0f70719-9f3c-4b2b-aef9-e01ce6e0aee0">252.4</ix:nonfraction>&nbsp;million U.S. dollars, which all have settlement dates within <ix:nonnumeric contextref="id879b497a407453985551e83dbee75f8_D20220101-20220331" name="us-gaap:MaximumRemainingMaturityOfForeignCurrencyDerivatives1" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RleHRyZWdpb246NWNkZmEwZDVmNzVlNGY2N2E1ZTQ0NjAxMTQ3MmJlNWZfNDY0Mg_cd354309-4a3e-422f-a59c-55a948f606c5">180</ix:nonnumeric> days.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign currency exchange risk is also managed through the use of foreign currency debt and cross-currency interest rate swaps. Our foreign currency-denominated notes had carrying amounts of $<ix:nonfraction unitref="usd" contextref="i3f3de4a6248f461e859551ca2163b789_I20220331" decimals="-7" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RleHRyZWdpb246NWNkZmEwZDVmNzVlNGY2N2E1ZTQ0NjAxMTQ3MmJlNWZfNDgzNw_6bb09bc6-c345-4403-bf41-19c5bf44661d">7.12</ix:nonfraction> billion and $<ix:nonfraction unitref="usd" contextref="i54b4e850f27d4938aca07b03f8b7cc97_I20211231" decimals="-7" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RleHRyZWdpb246NWNkZmEwZDVmNzVlNGY2N2E1ZTQ0NjAxMTQ3MmJlNWZfNDg0NA_88c78fe7-f68b-4636-b1ba-35a3dcbcbb58">7.90</ix:nonfraction>&nbsp;billion as of March&nbsp;31, 2022 and December&nbsp;31, 2021, respectively, of which $<ix:nonfraction unitref="usd" contextref="ib1053442369e460291956c51ab7e5179_I20220331" decimals="-7" name="us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTax" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RleHRyZWdpb246NWNkZmEwZDVmNzVlNGY2N2E1ZTQ0NjAxMTQ3MmJlNWZfNDg4Nw_f7570035-575e-4912-b215-e62f0acda67b">4.90</ix:nonfraction> billion and $<ix:nonfraction unitref="usd" contextref="iffa7a62ea976465eb0977d320e638511_I20211231" decimals="-7" name="us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTax" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RleHRyZWdpb246NWNkZmEwZDVmNzVlNGY2N2E1ZTQ0NjAxMTQ3MmJlNWZfNDg5NA_dbbe880a-d317-49c9-b76c-6094d49c1964">5.79</ix:nonfraction> billion have been designated as, and are effective as, economic hedges of net investments in certain of our foreign operations as of March&nbsp;31, 2022 and December&nbsp;31, 2021, respectively. At March&nbsp;31, 2022, we had outstanding cross-currency swaps with notional amounts of $<ix:nonfraction unitref="usd" contextref="i94ef07ec7f2b483db82b0258c0cdbc4a_I20220331" decimals="-7" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RleHRyZWdpb246NWNkZmEwZDVmNzVlNGY2N2E1ZTQ0NjAxMTQ3MmJlNWZfNTExOQ_a1c8905a-2283-42b4-ad03-2b0000dcedd6">1.02</ix:nonfraction> billion swapping U.S. dollars to euro and $<ix:nonfraction unitref="usd" contextref="i321796f5b515446aa0b53f4d8879a392_I20220331" decimals="-7" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RleHRyZWdpb246NWNkZmEwZDVmNzVlNGY2N2E1ZTQ0NjAxMTQ3MmJlNWZfNTE1Ng_f4252504-50bd-4b4b-914f-b5948b87ba68">1.00</ix:nonfraction> billion swapping Swiss francs to U.S. dollars which have settlement dates ranging through 2028. Our cross-currency interest rate swaps, for which a majority convert a portion of our U.S. dollar-denominated fixed-rate debt to foreign-denominated fixed-rate debt, have also been designated as, and are effective as, economic hedges of net investments.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, our operations are exposed to fluctuations in interest rates which can vary the costs of financing, investing, and operating. We seek to address a portion of these risks through a controlled program of risk management that includes the use of derivative financial instruments. The objective of controlling these risks is to limit the impact of fluctuations in interest rates on earnings. Our primary interest-rate risk exposure results from changes in short-term U.S. dollar interest rates. In an effort to manage interest-rate exposures, we strive to achieve an acceptable balance between fixed- and floating-rate debt and investment positions and may enter into interest rate swaps or collars to help maintain that balance.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest rate swaps or collars that convert our fixed-rate debt to a floating rate are designated as fair value hedges of the underlying instruments. Interest rate swaps or collars that convert floating-rate debt to a fixed rate are designated as cash flow hedges. Interest expense on the debt is adjusted to include the payments made or received under the swap agreements. Cash proceeds from or payments to counterparties resulting from the termination of interest rate swaps are classified as operating activities in our consolidated condensed statements of cash flows. At March&nbsp;31, 2022, substantially all of our total long-term debt is at a fixed rate. We have converted approximately <ix:nonfraction unitref="number" contextref="ib1053442369e460291956c51ab7e5179_I20220331" decimals="2" name="lly:DescriptionOfDerivativeActivityVolumePercent" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RleHRyZWdpb246NWNkZmEwZDVmNzVlNGY2N2E1ZTQ0NjAxMTQ3MmJlNWZfNjkzOA_75d57b4d-dbe0-4cfd-ba16-a7e45901cd24">14</ix:nonfraction> percent of our long-term fixed-rate notes to floating rates through the use of interest rate swaps.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also may enter into forward-starting interest rate swaps, which we designate as cash flow hedges, as part of any anticipated future debt issuances in order to reduce the risk of cash flow volatility from future changes in interest rates. The change in fair value of these instruments is recorded as part of other comprehensive income, and upon completion of a debt issuance and termination of the swap, is amortized to interest expense over the life of the underlying debt. As of March&nbsp;31, 2022, the total notional amounts of forward-starting interest rate contracts in designated cash flow hedging instruments were $<ix:nonfraction unitref="usd" contextref="i2c75f5c810134d21a34c3a33d471efb5_I20220331" decimals="-7" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RleHRyZWdpb246NWNkZmEwZDVmNzVlNGY2N2E1ZTQ0NjAxMTQ3MmJlNWZfNzY0Nw_fcf13ea5-2314-4e61-838a-ca4d7a25afe1">1.75</ix:nonfraction> billion, which have settlement dates ranging between 2023 and 2025.</span></div></ix:continuation><div style="margin-top:6pt"><span><br></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span><br></span></div></div><ix:continuation id="ie4d56fa3ce1b42bc90763b7b2a5aa395" continuedat="id2a0110f0b514870bfd58677aa6771b3"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The Effect of Risk-Management Instruments on the Consolidated Condensed Statements of Operations</span></div><ix:nonnumeric contextref="id879b497a407453985551e83dbee75f8_D20220101-20220331" name="us-gaap:ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RleHRyZWdpb246NWNkZmEwZDVmNzVlNGY2N2E1ZTQ0NjAxMTQ3MmJlNWZfMTYzMzc_bd7c9eb7-1c2c-4105-bd87-c9840c55426f" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following effects of risk-management instruments were recognized in other–net, (income) expense:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:65.128%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.422%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value hedges:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect from hedged fixed-rate debt</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ie6854cfb73f247ff811b4e8d19f31b99_D20220101-20220331" decimals="-5" name="us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOmYwOThmMThlMzEyNzRhYTNiNDFlMTc0ODE0MjdlN2M4L3RhYmxlcmFuZ2U6ZjA5OGYxOGUzMTI3NGFhM2I0MWUxNzQ4MTQyN2U3YzhfMy0xLTEtMS0xMDExOTA_8494367d-a4c9-499d-9d51-fadba5aff9ef">94.6</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i19522356142f4cb3af656f204ff244f8_D20210101-20210331" decimals="-5" name="us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOmYwOThmMThlMzEyNzRhYTNiNDFlMTc0ODE0MjdlN2M4L3RhYmxlcmFuZ2U6ZjA5OGYxOGUzMTI3NGFhM2I0MWUxNzQ4MTQyN2U3YzhfMy0zLTEtMS0xMDExOTA_cfcb063b-dda2-4311-b2b2-3aee75846b47">81.5</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect from interest rate contracts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="iff4b665b790a4814858d80742f67225e_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOmYwOThmMThlMzEyNzRhYTNiNDFlMTc0ODE0MjdlN2M4L3RhYmxlcmFuZ2U6ZjA5OGYxOGUzMTI3NGFhM2I0MWUxNzQ4MTQyN2U3YzhfNC0xLTEtMS0xMDExOTA_00edafba-ba3b-4b31-a674-6bc11f2cc2b6">94.6</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i4b3b515b4f00450d9af5f1a64809a127_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOmYwOThmMThlMzEyNzRhYTNiNDFlMTc0ODE0MjdlN2M4L3RhYmxlcmFuZ2U6ZjA5OGYxOGUzMTI3NGFhM2I0MWUxNzQ4MTQyN2U3YzhfNC0zLTEtMS0xMDExOTA_f5716f5e-000b-4b3e-b21d-0ed0fe2c9e14">81.5</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flow hedges:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective portion of losses on interest rate contracts reclassified from accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="iff4b665b790a4814858d80742f67225e_D20220101-20220331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOmYwOThmMThlMzEyNzRhYTNiNDFlMTc0ODE0MjdlN2M4L3RhYmxlcmFuZ2U6ZjA5OGYxOGUzMTI3NGFhM2I0MWUxNzQ4MTQyN2U3YzhfNi0xLTEtMS0xMDExOTA_8805df41-b468-4ee9-a4a2-fb3d0711a95a">4.1</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i4b3b515b4f00450d9af5f1a64809a127_D20210101-20210331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOmYwOThmMThlMzEyNzRhYTNiNDFlMTc0ODE0MjdlN2M4L3RhYmxlcmFuZ2U6ZjA5OGYxOGUzMTI3NGFhM2I0MWUxNzQ4MTQyN2U3YzhfNi0zLTEtMS0xMDExOTA_ea53593e-9eb8-4f14-b957-066494164fed">4.1</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency interest rate swaps</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i338b627ba38e475f96ecfeadba1a994e_D20220101-20220331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOmYwOThmMThlMzEyNzRhYTNiNDFlMTc0ODE0MjdlN2M4L3RhYmxlcmFuZ2U6ZjA5OGYxOGUzMTI3NGFhM2I0MWUxNzQ4MTQyN2U3YzhfNy0xLTEtMS0xMDExOTA_0c38e3db-7a03-4062-ae60-ef2b285179f0">8.3</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="idd762b29ec5345db9fbb4ca26b4ba2e1_D20210101-20210331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOmYwOThmMThlMzEyNzRhYTNiNDFlMTc0ODE0MjdlN2M4L3RhYmxlcmFuZ2U6ZjA5OGYxOGUzMTI3NGFhM2I0MWUxNzQ4MTQyN2U3YzhfNy0zLTEtMS0xMDExOTA_41dc75a6-93ea-4a1a-903c-d957e2f7ab15">71.5</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (gains) losses on foreign currency exchange contracts not designated as hedging instruments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i9873a4570e674b4e930c30b07ce403f7_D20220101-20220331" decimals="-5" name="us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOmYwOThmMThlMzEyNzRhYTNiNDFlMTc0ODE0MjdlN2M4L3RhYmxlcmFuZ2U6ZjA5OGYxOGUzMTI3NGFhM2I0MWUxNzQ4MTQyN2U3YzhfOC0xLTEtMS0xMDExOTA_9a4c2051-2d17-4a06-a6aa-fdf1bd620de8">6.1</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i8289fb108f294fe686a96c6c9694185c_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOmYwOThmMThlMzEyNzRhYTNiNDFlMTc0ODE0MjdlN2M4L3RhYmxlcmFuZ2U6ZjA5OGYxOGUzMTI3NGFhM2I0MWUxNzQ4MTQyN2U3YzhfOC0zLTEtMS0xMDExOTA_2c4b149f-fff2-4a8a-a9b6-b4c1512a1072">133.0</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="id879b497a407453985551e83dbee75f8_D20220101-20220331" decimals="-5" sign="-" name="lly:DerivativeInstrumentsGainLossRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOmYwOThmMThlMzEyNzRhYTNiNDFlMTc0ODE0MjdlN2M4L3RhYmxlcmFuZ2U6ZjA5OGYxOGUzMTI3NGFhM2I0MWUxNzQ4MTQyN2U3YzhfOS0xLTEtMS0xMDExOTA_9ce5739f-1fff-49b5-bfed-19d1caaa17a5">6.3</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i010e4c0d9c6246be91d37e31d569fa6f_D20210101-20210331" decimals="-5" sign="-" name="lly:DerivativeInstrumentsGainLossRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOmYwOThmMThlMzEyNzRhYTNiNDFlMTc0ODE0MjdlN2M4L3RhYmxlcmFuZ2U6ZjA5OGYxOGUzMTI3NGFhM2I0MWUxNzQ4MTQyN2U3YzhfOS0zLTEtMS0xMDExOTA_eb61309b-2e6c-4dcc-af44-ffb59141711e">208.6</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></tbody></table></div></ix:nonnumeric><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&nbsp;31, 2022 and 2021, the amortization of losses related to the portion of our risk management hedging instruments, fair value hedges, and cash flow hedges that was excluded from the assessment of effectiveness was not material.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The Effect of Risk-Management Instruments on Other Comprehensive Income (Loss)</span></div><ix:nonnumeric contextref="id879b497a407453985551e83dbee75f8_D20220101-20220331" name="us-gaap:ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RleHRyZWdpb246NWNkZmEwZDVmNzVlNGY2N2E1ZTQ0NjAxMTQ3MmJlNWZfMTYyNjU_fa0bed56-cf61-4a36-99d4-4c2769e49224" escape="true"><ix:nonnumeric contextref="id879b497a407453985551e83dbee75f8_D20220101-20220331" name="us-gaap:ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RleHRyZWdpb246NWNkZmEwZDVmNzVlNGY2N2E1ZTQ0NjAxMTQ3MmJlNWZfMTYyOTI_1b97c710-c797-45cd-9f2a-a65cf10fa320" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effective portion of risk-management instruments that was recognized in other comprehensive income (loss) is as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:65.128%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.422%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment hedges:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency-denominated notes</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i735d91209e8643b7a14d9fa85c6db710_D20220101-20220331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOjIxZWQ5YzMxY2I5NjQ1Yjc5ODcwMGMzZDk1Mzc2NjE2L3RhYmxlcmFuZ2U6MjFlZDljMzFjYjk2NDViNzk4NzAwYzNkOTUzNzY2MTZfMy0xLTEtMS0xMDExOTA_84e92fe3-0c3b-4f5b-bedf-d49c0839286f">54.4</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i93af913c74824b1581bff5276cec1e5c_D20210101-20210331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOjIxZWQ5YzMxY2I5NjQ1Yjc5ODcwMGMzZDk1Mzc2NjE2L3RhYmxlcmFuZ2U6MjFlZDljMzFjYjk2NDViNzk4NzAwYzNkOTUzNzY2MTZfMy0zLTEtMS0xMDExOTA_82b6aa3e-253b-4898-98db-3ea8ea4000c9">207.7</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency interest rate swaps</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i1616fc39bed44541af5f7cd7abea307a_D20220101-20220331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOjIxZWQ5YzMxY2I5NjQ1Yjc5ODcwMGMzZDk1Mzc2NjE2L3RhYmxlcmFuZ2U6MjFlZDljMzFjYjk2NDViNzk4NzAwYzNkOTUzNzY2MTZfNC0xLTEtMS0xMDExOTA_23ec0fa3-2600-41bb-a81e-328ed51b42bf">10.8</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9658e5d0746b443892d606c35ba501db_D20210101-20210331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOjIxZWQ5YzMxY2I5NjQ1Yjc5ODcwMGMzZDk1Mzc2NjE2L3RhYmxlcmFuZ2U6MjFlZDljMzFjYjk2NDViNzk4NzAwYzNkOTUzNzY2MTZfNC0zLTEtMS0xMDExOTA_2fc4656a-4a0d-4ce7-96ae-d465a3530e69">150.6</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flow hedges:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward-starting interest rate swaps</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i81716871f3a243ed8e61be41663de346_D20220101-20220331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOjIxZWQ5YzMxY2I5NjQ1Yjc5ODcwMGMzZDk1Mzc2NjE2L3RhYmxlcmFuZ2U6MjFlZDljMzFjYjk2NDViNzk4NzAwYzNkOTUzNzY2MTZfNy0xLTEtMS0xMDExOTA_258996c7-915a-4738-b572-0c03c806a995">122.5</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib0b61926a7d9492bb3843114c736f14e_D20210101-20210331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOjIxZWQ5YzMxY2I5NjQ1Yjc5ODcwMGMzZDk1Mzc2NjE2L3RhYmxlcmFuZ2U6MjFlZDljMzFjYjk2NDViNzk4NzAwYzNkOTUzNzY2MTZfNy0zLTEtMS0xMDExOTA_993e9b7f-dba5-460a-bcb8-dbafada8f6c6">295.1</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency interest rate swaps</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i1616fc39bed44541af5f7cd7abea307a_D20220101-20220331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOjIxZWQ5YzMxY2I5NjQ1Yjc5ODcwMGMzZDk1Mzc2NjE2L3RhYmxlcmFuZ2U6MjFlZDljMzFjYjk2NDViNzk4NzAwYzNkOTUzNzY2MTZfOC0xLTEtMS0xMDExOTA_deef6396-4bf5-4a03-b32c-71e1ec20f665">17.1</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9658e5d0746b443892d606c35ba501db_D20210101-20210331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOjIxZWQ5YzMxY2I5NjQ1Yjc5ODcwMGMzZDk1Mzc2NjE2L3RhYmxlcmFuZ2U6MjFlZDljMzFjYjk2NDViNzk4NzAwYzNkOTUzNzY2MTZfOC0zLTEtMS0xMDExOTA_4b3bb6fa-401c-432c-b42b-4ff5de804b50">26.3</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></tbody></table></div></ix:nonnumeric></ix:nonnumeric><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the next 12&nbsp;months, we expect to reclassify $<ix:nonfraction unitref="usd" contextref="ib1053442369e460291956c51ab7e5179_I20220331" decimals="-5" sign="-" name="us-gaap:InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RleHRyZWdpb246NWNkZmEwZDVmNzVlNGY2N2E1ZTQ0NjAxMTQ3MmJlNWZfOTc5MQ_8b24ed11-8136-43b0-8ccb-1412b33a532f">16.5</ix:nonfraction>&nbsp;million of pretax net losses on cash flow hedges from accumulated other comprehensive loss to other–net, (income) expense. During the three months ended March&nbsp;31, 2022 and 2021, the amounts excluded from the assessment of hedge effectiveness recognized in other comprehensive income (loss) were not material.</span></div></ix:continuation><div style="margin-top:9pt"><span><br></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span><br></span></div></div><ix:continuation id="id2a0110f0b514870bfd58677aa6771b3" continuedat="iaa1751e5f0a041f880bf3c8bbebd2bc1"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value of Financial Instruments</span></div><ix:nonnumeric contextref="id879b497a407453985551e83dbee75f8_D20220101-20220331" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RleHRyZWdpb246NWNkZmEwZDVmNzVlNGY2N2E1ZTQ0NjAxMTQ3MmJlNWZfMTYzMjM_2c86ab03-4cb9-470d-9e48-4ff3a2234513" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize certain fair value information at March&nbsp;31, 2022 and December&nbsp;31, 2021 for assets and liabilities measured at fair value on a recurring basis, as well as the carrying amount and amortized cost of certain other investments:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&nbsp;</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tbody><tr><td style="width:1.0%"></td><td style="width:34.624%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.466%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.714%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements Using</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&nbsp;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br>Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices in Active Markets for Identical Assets<br>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant Other<br>Observable Inputs<br>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br>Unobservable<br>Inputs<br>(Level 3)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i73af0f98be8b48e58557bf37c81c9e74_I20220331" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOmZjMTVkNGYwODMzMjQ1ZDI4ZGY3ODUwYjkyM2EzNDE3L3RhYmxlcmFuZ2U6ZmMxNWQ0ZjA4MzMyNDVkMjhkZjc4NTBiOTIzYTM0MTdfMy0xLTEtMS0xMDExOTA_c9a11693-da88-4a59-a0d3-2cb0ef9b5fbb">1,104.1</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i8297602a77c04dbe866c1671c9fc39f2_I20220331" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOmZjMTVkNGYwODMzMjQ1ZDI4ZGY3ODUwYjkyM2EzNDE3L3RhYmxlcmFuZ2U6ZmMxNWQ0ZjA4MzMyNDVkMjhkZjc4NTBiOTIzYTM0MTdfMy0zLTEtMS0xMDExOTA_2ccc90ed-a0dd-4557-85ca-b0553bd0be5e">1,104.1</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="idb4c476afbc64873b3c0511107fc85c9_I20220331" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOmZjMTVkNGYwODMzMjQ1ZDI4ZGY3ODUwYjkyM2EzNDE3L3RhYmxlcmFuZ2U6ZmMxNWQ0ZjA4MzMyNDVkMjhkZjc4NTBiOTIzYTM0MTdfMy01LTEtMS0xMDExOTA_b5471b0b-365c-43f0-86af-19c047e1dcf1">1,095.0</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i553170707dac4ba4befbf57021e9352d_I20220331" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOmZjMTVkNGYwODMzMjQ1ZDI4ZGY3ODUwYjkyM2EzNDE3L3RhYmxlcmFuZ2U6ZmMxNWQ0ZjA4MzMyNDVkMjhkZjc4NTBiOTIzYTM0MTdfMy03LTEtMS0xMDExOTA_6100c88b-425a-4cb1-bd96-b1d104597e02">9.1</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i8196778f6b68404d98e4bc74190f4322_I20220331" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOmZjMTVkNGYwODMzMjQ1ZDI4ZGY3ODUwYjkyM2EzNDE3L3RhYmxlcmFuZ2U6ZmMxNWQ0ZjA4MzMyNDVkMjhkZjc4NTBiOTIzYTM0MTdfMy05LTEtMS0xMDExOTA_f8cd5928-5527-401d-ad85-d4d967792678">—</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i67e65f1325bd4d80b077bdc7713893b6_I20220331" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOmZjMTVkNGYwODMzMjQ1ZDI4ZGY3ODUwYjkyM2EzNDE3L3RhYmxlcmFuZ2U6ZmMxNWQ0ZjA4MzMyNDVkMjhkZjc4NTBiOTIzYTM0MTdfMy0xMS0xLTEtMTAxMTkw_f3858dbf-ba1e-4edf-bbb8-b2bd06691078">1,104.1</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-term investments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="ie3949e5521a749449cc7f2a26fbd50fa_I20220331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOmZjMTVkNGYwODMzMjQ1ZDI4ZGY3ODUwYjkyM2EzNDE3L3RhYmxlcmFuZ2U6ZmMxNWQ0ZjA4MzMyNDVkMjhkZjc4NTBiOTIzYTM0MTdfNi0xLTEtMS0xMDExOTA_11ad939a-8179-460c-94d0-a41b44459463">45.1</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i5e1799edb7794fc4b1f616df3dd091ab_I20220331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOmZjMTVkNGYwODMzMjQ1ZDI4ZGY3ODUwYjkyM2EzNDE3L3RhYmxlcmFuZ2U6ZmMxNWQ0ZjA4MzMyNDVkMjhkZjc4NTBiOTIzYTM0MTdfNi0zLTEtMS0xMDExOTA_2ae25a63-3f32-48ec-be2a-86e71954c008">45.4</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i4287cfc6b146421aaf7054e3c2baf09a_I20220331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOmZjMTVkNGYwODMzMjQ1ZDI4ZGY3ODUwYjkyM2EzNDE3L3RhYmxlcmFuZ2U6ZmMxNWQ0ZjA4MzMyNDVkMjhkZjc4NTBiOTIzYTM0MTdfNi01LTEtMS0xMDExOTA_0f4c66ce-7f99-424f-bc69-c84bee90887a">45.1</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="icad0fc1f1fc24058af62089ef5cc8d6b_I20220331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOmZjMTVkNGYwODMzMjQ1ZDI4ZGY3ODUwYjkyM2EzNDE3L3RhYmxlcmFuZ2U6ZmMxNWQ0ZjA4MzMyNDVkMjhkZjc4NTBiOTIzYTM0MTdfNi03LTEtMS0xMDExOTA_df354d2e-19a3-41b4-ae52-46d2ba988202">—</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i11f55ba726a14bf6adea1a2c9a382844_I20220331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOmZjMTVkNGYwODMzMjQ1ZDI4ZGY3ODUwYjkyM2EzNDE3L3RhYmxlcmFuZ2U6ZmMxNWQ0ZjA4MzMyNDVkMjhkZjc4NTBiOTIzYTM0MTdfNi05LTEtMS0xMDExOTA_a0fe6d23-026c-4e38-b64f-6d456a84b6b2">—</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib166955c51b7404cb1f890ae69351664_I20220331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOmZjMTVkNGYwODMzMjQ1ZDI4ZGY3ODUwYjkyM2EzNDE3L3RhYmxlcmFuZ2U6ZmMxNWQ0ZjA4MzMyNDVkMjhkZjc4NTBiOTIzYTM0MTdfNi0xMS0xLTEtMTAxMTkw_2d76eece-08d5-427d-8d58-91c53909afed">45.1</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i0889f4d6b8c84f4f86feb6e6b9e07416_I20220331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOmZjMTVkNGYwODMzMjQ1ZDI4ZGY3ODUwYjkyM2EzNDE3L3RhYmxlcmFuZ2U6ZmMxNWQ0ZjA4MzMyNDVkMjhkZjc4NTBiOTIzYTM0MTdfNy0xLTEtMS0xMDExOTA_a076e7d2-460e-4284-80b9-141854ae1900">50.6</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i539ac49f62204f449468230edab29f2e_I20220331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOmZjMTVkNGYwODMzMjQ1ZDI4ZGY3ODUwYjkyM2EzNDE3L3RhYmxlcmFuZ2U6ZmMxNWQ0ZjA4MzMyNDVkMjhkZjc4NTBiOTIzYTM0MTdfNy0zLTEtMS0xMDExOTA_458c44ee-3416-42ec-a130-083af4d8ea44">50.7</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i3206cdb8838c4f439e23fcebaa0a5db5_I20220331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOmZjMTVkNGYwODMzMjQ1ZDI4ZGY3ODUwYjkyM2EzNDE3L3RhYmxlcmFuZ2U6ZmMxNWQ0ZjA4MzMyNDVkMjhkZjc4NTBiOTIzYTM0MTdfNy01LTEtMS0xMDExOTA_8e861d95-fe32-4662-b01e-2429404664d0">—</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9ce4f705c12c4dd0ad7577b94b195bc5_I20220331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOmZjMTVkNGYwODMzMjQ1ZDI4ZGY3ODUwYjkyM2EzNDE3L3RhYmxlcmFuZ2U6ZmMxNWQ0ZjA4MzMyNDVkMjhkZjc4NTBiOTIzYTM0MTdfNy03LTEtMS0xMDExOTA_1f943e43-676e-4871-8199-3fb6bd0d929c">50.6</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i749f1e3ed9be40d4aaa1036cc4cd636e_I20220331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOmZjMTVkNGYwODMzMjQ1ZDI4ZGY3ODUwYjkyM2EzNDE3L3RhYmxlcmFuZ2U6ZmMxNWQ0ZjA4MzMyNDVkMjhkZjc4NTBiOTIzYTM0MTdfNy05LTEtMS0xMDExOTA_cb0c6d8e-f289-46e5-99b7-a8b9be9be661">—</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="ia68a57223c3e44258320c665e5e51da3_I20220331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOmZjMTVkNGYwODMzMjQ1ZDI4ZGY3ODUwYjkyM2EzNDE3L3RhYmxlcmFuZ2U6ZmMxNWQ0ZjA4MzMyNDVkMjhkZjc4NTBiOTIzYTM0MTdfNy0xMS0xLTEtMTAxMTkw_9bd9ccce-8dcb-4b39-856d-bb8b3dcab423">50.6</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i12313db9f4234ab399224dedbfa8e9a1_I20220331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOmZjMTVkNGYwODMzMjQ1ZDI4ZGY3ODUwYjkyM2EzNDE3L3RhYmxlcmFuZ2U6ZmMxNWQ0ZjA4MzMyNDVkMjhkZjc4NTBiOTIzYTM0MTdfOC0xLTEtMS0xMDExOTA_2f43e30b-2837-4bc5-a8c9-1713f913c285">0.2</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i844bf1199784470bb85986e8705f63a0_I20220331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOmZjMTVkNGYwODMzMjQ1ZDI4ZGY3ODUwYjkyM2EzNDE3L3RhYmxlcmFuZ2U6ZmMxNWQ0ZjA4MzMyNDVkMjhkZjc4NTBiOTIzYTM0MTdfOC0zLTEtMS0xMDExOTA_94c7d53f-e1ae-4965-a2d9-adf9f7911c2c">0.2</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i52a94c856f8f4c708ecd0c78ae9d811b_I20220331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOmZjMTVkNGYwODMzMjQ1ZDI4ZGY3ODUwYjkyM2EzNDE3L3RhYmxlcmFuZ2U6ZmMxNWQ0ZjA4MzMyNDVkMjhkZjc4NTBiOTIzYTM0MTdfOC01LTEtMS0xMDExOTA_389a0cb3-8b2a-45a8-9e54-f6f0e4038273">—</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i58833b70044440ba8723539cd9771a96_I20220331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOmZjMTVkNGYwODMzMjQ1ZDI4ZGY3ODUwYjkyM2EzNDE3L3RhYmxlcmFuZ2U6ZmMxNWQ0ZjA4MzMyNDVkMjhkZjc4NTBiOTIzYTM0MTdfOC03LTEtMS0xMDExOTA_fe4a478e-0ccb-4f4c-b6c2-9c6c1c92d555">0.2</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i08e23988b70349e48d0863a9a788859a_I20220331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOmZjMTVkNGYwODMzMjQ1ZDI4ZGY3ODUwYjkyM2EzNDE3L3RhYmxlcmFuZ2U6ZmMxNWQ0ZjA4MzMyNDVkMjhkZjc4NTBiOTIzYTM0MTdfOC05LTEtMS0xMDExOTA_f78a28a9-fd2a-4969-a697-dc11f36af189">—</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="ia5572a5cd6cf4fef80fd4f18e84d4f7b_I20220331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOmZjMTVkNGYwODMzMjQ1ZDI4ZGY3ODUwYjkyM2EzNDE3L3RhYmxlcmFuZ2U6ZmMxNWQ0ZjA4MzMyNDVkMjhkZjc4NTBiOTIzYTM0MTdfOC0xMS0xLTEtMTAxMTkw_6943f3f4-3518-4944-8ccb-ff472720d2d1">0.2</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i63b57e26f9874a59a56bc82f5b18fb11_I20220331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOmZjMTVkNGYwODMzMjQ1ZDI4ZGY3ODUwYjkyM2EzNDE3L3RhYmxlcmFuZ2U6ZmMxNWQ0ZjA4MzMyNDVkMjhkZjc4NTBiOTIzYTM0MTdfOS0xLTEtMS0xMDExOTA_f7e538c9-05ec-4dd1-aec8-ee0453c56835">2.9</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="if1b1e3898b43456da01094b47acb1c76_I20220331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOmZjMTVkNGYwODMzMjQ1ZDI4ZGY3ODUwYjkyM2EzNDE3L3RhYmxlcmFuZ2U6ZmMxNWQ0ZjA4MzMyNDVkMjhkZjc4NTBiOTIzYTM0MTdfOS0zLTEtMS0xMDExOTA_f4666368-2fd4-45db-8a34-ce41995cd026">3.0</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="id19b58cff3f5453fa44ff476062a0a2d_I20220331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOmZjMTVkNGYwODMzMjQ1ZDI4ZGY3ODUwYjkyM2EzNDE3L3RhYmxlcmFuZ2U6ZmMxNWQ0ZjA4MzMyNDVkMjhkZjc4NTBiOTIzYTM0MTdfOS01LTEtMS0xMDExOTA_5ee43a1a-f335-4996-bb40-c82ddb729c39">—</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i7ca7cae76ba4496d8f5abf5420f5d436_I20220331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOmZjMTVkNGYwODMzMjQ1ZDI4ZGY3ODUwYjkyM2EzNDE3L3RhYmxlcmFuZ2U6ZmMxNWQ0ZjA4MzMyNDVkMjhkZjc4NTBiOTIzYTM0MTdfOS03LTEtMS0xMDExOTA_12dfd550-4951-4af5-9ba4-8e920074a058">2.9</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i115b05d0aa7245918c041177cf891d75_I20220331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOmZjMTVkNGYwODMzMjQ1ZDI4ZGY3ODUwYjkyM2EzNDE3L3RhYmxlcmFuZ2U6ZmMxNWQ0ZjA4MzMyNDVkMjhkZjc4NTBiOTIzYTM0MTdfOS05LTEtMS0xMDExOTA_76c8d806-8d97-4697-85f5-c179cdc69ca9">—</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="ie54bd7fd72d544db998a875fd601fe50_I20220331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOmZjMTVkNGYwODMzMjQ1ZDI4ZGY3ODUwYjkyM2EzNDE3L3RhYmxlcmFuZ2U6ZmMxNWQ0ZjA4MzMyNDVkMjhkZjc4NTBiOTIzYTM0MTdfOS0xMS0xLTEtMTAxMTkw_807c1ea2-4c0c-409a-820c-2f9319271365">2.9</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i8409488ac5694b53b787f031304c92b7_I20220331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOmZjMTVkNGYwODMzMjQ1ZDI4ZGY3ODUwYjkyM2EzNDE3L3RhYmxlcmFuZ2U6ZmMxNWQ0ZjA4MzMyNDVkMjhkZjc4NTBiOTIzYTM0MTdfMTAtMS0xLTEtMTAxMTkw_14192872-d6e2-4fd6-a2a3-df13291934f1">10.3</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i41fdead00a9048b6b3cc9b6cb638331d_I20220331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOmZjMTVkNGYwODMzMjQ1ZDI4ZGY3ODUwYjkyM2EzNDE3L3RhYmxlcmFuZ2U6ZmMxNWQ0ZjA4MzMyNDVkMjhkZjc4NTBiOTIzYTM0MTdfMTAtMy0xLTEtMTAxMTkw_72579188-558e-4be6-90b9-d838c847ae5b">10.3</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="ia42e3f4576fe4f118bb64223c3c5ebab_I20220331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOmZjMTVkNGYwODMzMjQ1ZDI4ZGY3ODUwYjkyM2EzNDE3L3RhYmxlcmFuZ2U6ZmMxNWQ0ZjA4MzMyNDVkMjhkZjc4NTBiOTIzYTM0MTdfMTAtNS0xLTEtMTAxMTkw_3cb5467b-323f-4a45-ba4a-69a638bcbd8a">—</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="if4fc174bc75542229cc811bb39dffc30_I20220331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOmZjMTVkNGYwODMzMjQ1ZDI4ZGY3ODUwYjkyM2EzNDE3L3RhYmxlcmFuZ2U6ZmMxNWQ0ZjA4MzMyNDVkMjhkZjc4NTBiOTIzYTM0MTdfMTAtNy0xLTEtMTAxMTkw_aa9325b7-39c5-4cd0-b585-91f924fe6ee2">—</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i59d42fbede984b688ce7c8a504c746c5_I20220331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOmZjMTVkNGYwODMzMjQ1ZDI4ZGY3ODUwYjkyM2EzNDE3L3RhYmxlcmFuZ2U6ZmMxNWQ0ZjA4MzMyNDVkMjhkZjc4NTBiOTIzYTM0MTdfMTAtOS0xLTEtMTAxMTkw_28726cd3-6e2b-4a9d-8311-2604fd50eb16">10.3</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i54b85febf3e54b15a32eb724bedd4db9_I20220331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOmZjMTVkNGYwODMzMjQ1ZDI4ZGY3ODUwYjkyM2EzNDE3L3RhYmxlcmFuZ2U6ZmMxNWQ0ZjA4MzMyNDVkMjhkZjc4NTBiOTIzYTM0MTdfMTAtMTEtMS0xLTEwMTE5MA_d9d78984-87e7-4ff9-8381-fe0154c829d5">10.3</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-term investments</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i73af0f98be8b48e58557bf37c81c9e74_I20220331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOmZjMTVkNGYwODMzMjQ1ZDI4ZGY3ODUwYjkyM2EzNDE3L3RhYmxlcmFuZ2U6ZmMxNWQ0ZjA4MzMyNDVkMjhkZjc4NTBiOTIzYTM0MTdfMTItMS0xLTEtMTAxMTkw_773ac518-c7c9-44aa-999c-472010a94a05">109.1</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncurrent investments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="ie3949e5521a749449cc7f2a26fbd50fa_I20220331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOmZjMTVkNGYwODMzMjQ1ZDI4ZGY3ODUwYjkyM2EzNDE3L3RhYmxlcmFuZ2U6ZmMxNWQ0ZjA4MzMyNDVkMjhkZjc4NTBiOTIzYTM0MTdfMTUtMS0xLTEtMTAxMTkw_83865426-14d2-48d3-96ea-4e7a53943b50">116.2</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i5e1799edb7794fc4b1f616df3dd091ab_I20220331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOmZjMTVkNGYwODMzMjQ1ZDI4ZGY3ODUwYjkyM2EzNDE3L3RhYmxlcmFuZ2U6ZmMxNWQ0ZjA4MzMyNDVkMjhkZjc4NTBiOTIzYTM0MTdfMTUtMy0xLTEtMTAxMTkw_0676f97d-53da-4dbf-bfa6-ec48f0273678">123.0</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i4287cfc6b146421aaf7054e3c2baf09a_I20220331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOmZjMTVkNGYwODMzMjQ1ZDI4ZGY3ODUwYjkyM2EzNDE3L3RhYmxlcmFuZ2U6ZmMxNWQ0ZjA4MzMyNDVkMjhkZjc4NTBiOTIzYTM0MTdfMTUtNS0xLTEtMTAxMTkw_0d6220b7-602d-485b-a7b9-67ae9e0d9918">116.2</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="icad0fc1f1fc24058af62089ef5cc8d6b_I20220331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOmZjMTVkNGYwODMzMjQ1ZDI4ZGY3ODUwYjkyM2EzNDE3L3RhYmxlcmFuZ2U6ZmMxNWQ0ZjA4MzMyNDVkMjhkZjc4NTBiOTIzYTM0MTdfMTUtNy0xLTEtMTAxMTkw_460cc63a-564c-49f2-8e5c-0dbebdd156a4">—</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i11f55ba726a14bf6adea1a2c9a382844_I20220331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOmZjMTVkNGYwODMzMjQ1ZDI4ZGY3ODUwYjkyM2EzNDE3L3RhYmxlcmFuZ2U6ZmMxNWQ0ZjA4MzMyNDVkMjhkZjc4NTBiOTIzYTM0MTdfMTUtOS0xLTEtMTAxMTkw_8b0735f3-cd26-4d59-b419-db9eee726b62">—</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib166955c51b7404cb1f890ae69351664_I20220331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOmZjMTVkNGYwODMzMjQ1ZDI4ZGY3ODUwYjkyM2EzNDE3L3RhYmxlcmFuZ2U6ZmMxNWQ0ZjA4MzMyNDVkMjhkZjc4NTBiOTIzYTM0MTdfMTUtMTEtMS0xLTEwMTE5MA_fa9edb12-68cf-49a4-92b9-874835b1815e">116.2</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i0889f4d6b8c84f4f86feb6e6b9e07416_I20220331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOmZjMTVkNGYwODMzMjQ1ZDI4ZGY3ODUwYjkyM2EzNDE3L3RhYmxlcmFuZ2U6ZmMxNWQ0ZjA4MzMyNDVkMjhkZjc4NTBiOTIzYTM0MTdfMTctMS0xLTEtMTAxMTkw_f4a1d4a2-f50f-4d31-b32b-73e86c5322b2">212.3</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i539ac49f62204f449468230edab29f2e_I20220331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOmZjMTVkNGYwODMzMjQ1ZDI4ZGY3ODUwYjkyM2EzNDE3L3RhYmxlcmFuZ2U6ZmMxNWQ0ZjA4MzMyNDVkMjhkZjc4NTBiOTIzYTM0MTdfMTctMy0xLTEtMTAxMTkw_2eb417c9-918c-4f46-8fd0-ca040749cb94">224.3</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i3206cdb8838c4f439e23fcebaa0a5db5_I20220331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOmZjMTVkNGYwODMzMjQ1ZDI4ZGY3ODUwYjkyM2EzNDE3L3RhYmxlcmFuZ2U6ZmMxNWQ0ZjA4MzMyNDVkMjhkZjc4NTBiOTIzYTM0MTdfMTctNS0xLTEtMTAxMTkw_cbf5a59e-8b88-4f11-ab29-0bb4261d5f44">—</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9ce4f705c12c4dd0ad7577b94b195bc5_I20220331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOmZjMTVkNGYwODMzMjQ1ZDI4ZGY3ODUwYjkyM2EzNDE3L3RhYmxlcmFuZ2U6ZmMxNWQ0ZjA4MzMyNDVkMjhkZjc4NTBiOTIzYTM0MTdfMTctNy0xLTEtMTAxMTkw_0889a3ad-93a5-4ac4-b512-ada11d9468ed">224.3</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i749f1e3ed9be40d4aaa1036cc4cd636e_I20220331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOmZjMTVkNGYwODMzMjQ1ZDI4ZGY3ODUwYjkyM2EzNDE3L3RhYmxlcmFuZ2U6ZmMxNWQ0ZjA4MzMyNDVkMjhkZjc4NTBiOTIzYTM0MTdfMTctOS0xLTEtMTAxMTkw_569bae73-3582-4f44-80b2-c61d88fa7950">—</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="ia68a57223c3e44258320c665e5e51da3_I20220331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOmZjMTVkNGYwODMzMjQ1ZDI4ZGY3ODUwYjkyM2EzNDE3L3RhYmxlcmFuZ2U6ZmMxNWQ0ZjA4MzMyNDVkMjhkZjc4NTBiOTIzYTM0MTdfMTctMTEtMS0xLTEwMTE5MA_e30a18bd-8e38-48d5-9a6a-0c7ab109a3aa">224.3</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i12313db9f4234ab399224dedbfa8e9a1_I20220331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOmZjMTVkNGYwODMzMjQ1ZDI4ZGY3ODUwYjkyM2EzNDE3L3RhYmxlcmFuZ2U6ZmMxNWQ0ZjA4MzMyNDVkMjhkZjc4NTBiOTIzYTM0MTdfMTgtMS0xLTEtMTAxMTkw_d32cf5b3-dd1d-454d-a686-3f3ec8b9667f">105.1</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i844bf1199784470bb85986e8705f63a0_I20220331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOmZjMTVkNGYwODMzMjQ1ZDI4ZGY3ODUwYjkyM2EzNDE3L3RhYmxlcmFuZ2U6ZmMxNWQ0ZjA4MzMyNDVkMjhkZjc4NTBiOTIzYTM0MTdfMTgtMy0xLTEtMTAxMTkw_2dc48724-ef0f-442d-9e49-c3c4bef11558">109.0</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i52a94c856f8f4c708ecd0c78ae9d811b_I20220331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOmZjMTVkNGYwODMzMjQ1ZDI4ZGY3ODUwYjkyM2EzNDE3L3RhYmxlcmFuZ2U6ZmMxNWQ0ZjA4MzMyNDVkMjhkZjc4NTBiOTIzYTM0MTdfMTgtNS0xLTEtMTAxMTkw_7b8ece85-d2d0-4287-a037-c45392b882e6">—</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i58833b70044440ba8723539cd9771a96_I20220331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOmZjMTVkNGYwODMzMjQ1ZDI4ZGY3ODUwYjkyM2EzNDE3L3RhYmxlcmFuZ2U6ZmMxNWQ0ZjA4MzMyNDVkMjhkZjc4NTBiOTIzYTM0MTdfMTgtNy0xLTEtMTAxMTkw_4e90b98a-75df-483d-ad2b-6a17f0f6ba88">105.1</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i08e23988b70349e48d0863a9a788859a_I20220331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOmZjMTVkNGYwODMzMjQ1ZDI4ZGY3ODUwYjkyM2EzNDE3L3RhYmxlcmFuZ2U6ZmMxNWQ0ZjA4MzMyNDVkMjhkZjc4NTBiOTIzYTM0MTdfMTgtOS0xLTEtMTAxMTkw_43e87015-f060-44d4-9a24-ff21f9ae0bcc">—</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="ia5572a5cd6cf4fef80fd4f18e84d4f7b_I20220331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOmZjMTVkNGYwODMzMjQ1ZDI4ZGY3ODUwYjkyM2EzNDE3L3RhYmxlcmFuZ2U6ZmMxNWQ0ZjA4MzMyNDVkMjhkZjc4NTBiOTIzYTM0MTdfMTgtMTEtMS0xLTEwMTE5MA_caac7356-8ace-464f-b141-d2574c14a0e4">105.1</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i63b57e26f9874a59a56bc82f5b18fb11_I20220331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOmZjMTVkNGYwODMzMjQ1ZDI4ZGY3ODUwYjkyM2EzNDE3L3RhYmxlcmFuZ2U6ZmMxNWQ0ZjA4MzMyNDVkMjhkZjc4NTBiOTIzYTM0MTdfMTktMS0xLTEtMTAxMTkw_ff5a52d6-e99d-43eb-9cd5-c0efb46e2cfa">34.6</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="if1b1e3898b43456da01094b47acb1c76_I20220331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOmZjMTVkNGYwODMzMjQ1ZDI4ZGY3ODUwYjkyM2EzNDE3L3RhYmxlcmFuZ2U6ZmMxNWQ0ZjA4MzMyNDVkMjhkZjc4NTBiOTIzYTM0MTdfMTktMy0xLTEtMTAxMTkw_3ab23223-683d-458a-ab31-a57d14734abc">35.4</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="id19b58cff3f5453fa44ff476062a0a2d_I20220331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOmZjMTVkNGYwODMzMjQ1ZDI4ZGY3ODUwYjkyM2EzNDE3L3RhYmxlcmFuZ2U6ZmMxNWQ0ZjA4MzMyNDVkMjhkZjc4NTBiOTIzYTM0MTdfMTktNS0xLTEtMTAxMTkw_5e89dd9d-a2ed-4de2-98df-fd43d9baef60">—</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i7ca7cae76ba4496d8f5abf5420f5d436_I20220331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOmZjMTVkNGYwODMzMjQ1ZDI4ZGY3ODUwYjkyM2EzNDE3L3RhYmxlcmFuZ2U6ZmMxNWQ0ZjA4MzMyNDVkMjhkZjc4NTBiOTIzYTM0MTdfMTktNy0xLTEtMTAxMTkw_f57e5daf-84f6-4f7b-b5f1-689f4dd6349b">34.6</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i115b05d0aa7245918c041177cf891d75_I20220331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOmZjMTVkNGYwODMzMjQ1ZDI4ZGY3ODUwYjkyM2EzNDE3L3RhYmxlcmFuZ2U6ZmMxNWQ0ZjA4MzMyNDVkMjhkZjc4NTBiOTIzYTM0MTdfMTktOS0xLTEtMTAxMTkw_d87bd795-cd04-4b43-90d0-101c298ff0cb">—</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="ie54bd7fd72d544db998a875fd601fe50_I20220331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOmZjMTVkNGYwODMzMjQ1ZDI4ZGY3ODUwYjkyM2EzNDE3L3RhYmxlcmFuZ2U6ZmMxNWQ0ZjA4MzMyNDVkMjhkZjc4NTBiOTIzYTM0MTdfMTktMTEtMS0xLTEwMTE5MA_3c3c1f64-8aaa-4927-b080-622a8197532a">34.6</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9839e9c38a5d4d35b9fcf94838e28ff0_I20220331" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOmZjMTVkNGYwODMzMjQ1ZDI4ZGY3ODUwYjkyM2EzNDE3L3RhYmxlcmFuZ2U6ZmMxNWQ0ZjA4MzMyNDVkMjhkZjc4NTBiOTIzYTM0MTdfMjAtMS0xLTEtMTAxMTkw_265196ac-32d0-4f33-a80a-78cd436484d9">112.5</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="if1a0fe2b050d475fbf70c9eabde349b7_I20220331" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOmZjMTVkNGYwODMzMjQ1ZDI4ZGY3ODUwYjkyM2EzNDE3L3RhYmxlcmFuZ2U6ZmMxNWQ0ZjA4MzMyNDVkMjhkZjc4NTBiOTIzYTM0MTdfMjAtMy0xLTEtMTAxMTkw_35a79a78-fa3a-4c04-882a-d1c7f3aa6ab4">15.3</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i202de245dca54b9fbaf785a8485b97a4_I20220331" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOmZjMTVkNGYwODMzMjQ1ZDI4ZGY3ODUwYjkyM2EzNDE3L3RhYmxlcmFuZ2U6ZmMxNWQ0ZjA4MzMyNDVkMjhkZjc4NTBiOTIzYTM0MTdfMjAtNS0xLTEtMTAxMTkw_f7c730be-bef9-48ba-a3b4-00ef4be878b9">—</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="ie515f75228ff4f8b827aed3640b6deaf_I20220331" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOmZjMTVkNGYwODMzMjQ1ZDI4ZGY3ODUwYjkyM2EzNDE3L3RhYmxlcmFuZ2U6ZmMxNWQ0ZjA4MzMyNDVkMjhkZjc4NTBiOTIzYTM0MTdfMjAtNy0xLTEtMTAxMTkw_e23d9f14-fdf9-4966-b280-840e91a79fa1">—</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i1a1737406225458ebdbe6cda04606244_I20220331" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOmZjMTVkNGYwODMzMjQ1ZDI4ZGY3ODUwYjkyM2EzNDE3L3RhYmxlcmFuZ2U6ZmMxNWQ0ZjA4MzMyNDVkMjhkZjc4NTBiOTIzYTM0MTdfMjAtOS0xLTEtMTAxMTkw_347817ce-7f8a-4b08-8d15-04f3a5b27867">112.5</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i13d950451b7e48fda3e1b024329a7c74_I20220331" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOmZjMTVkNGYwODMzMjQ1ZDI4ZGY3ODUwYjkyM2EzNDE3L3RhYmxlcmFuZ2U6ZmMxNWQ0ZjA4MzMyNDVkMjhkZjc4NTBiOTIzYTM0MTdfMjAtMTEtMS0xLTEwMTE5MA_1bcd9570-fc42-4f44-91d7-c5565fd813bc">112.5</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketable equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i5dcfe1b49a3348138d09e6e38fb729a9_I20220331" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOmZjMTVkNGYwODMzMjQ1ZDI4ZGY3ODUwYjkyM2EzNDE3L3RhYmxlcmFuZ2U6ZmMxNWQ0ZjA4MzMyNDVkMjhkZjc4NTBiOTIzYTM0MTdfMjEtMS0xLTEtMTAxMTkw_d9e0dc3a-6b43-4400-b3b5-323350c71c8a">807.9</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="ie35137a8dd7146f782d246046bdff5e9_I20220331" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOmZjMTVkNGYwODMzMjQ1ZDI4ZGY3ODUwYjkyM2EzNDE3L3RhYmxlcmFuZ2U6ZmMxNWQ0ZjA4MzMyNDVkMjhkZjc4NTBiOTIzYTM0MTdfMjEtMy0xLTEtMTAxMTkw_b810304c-ab8c-4013-8e0e-d16491c6e1f3">481.9</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i24d0ea00c0fc4c69aac46b9bff293d2e_I20220331" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOmZjMTVkNGYwODMzMjQ1ZDI4ZGY3ODUwYjkyM2EzNDE3L3RhYmxlcmFuZ2U6ZmMxNWQ0ZjA4MzMyNDVkMjhkZjc4NTBiOTIzYTM0MTdfMjEtNS0xLTEtMTAxMTkw_81c9451d-51a0-4f3b-9a34-2db166cb1458">807.9</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i15b571ac551849a9b9cf92351d196e67_I20220331" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOmZjMTVkNGYwODMzMjQ1ZDI4ZGY3ODUwYjkyM2EzNDE3L3RhYmxlcmFuZ2U6ZmMxNWQ0ZjA4MzMyNDVkMjhkZjc4NTBiOTIzYTM0MTdfMjEtNy0xLTEtMTAxMTkw_68203058-9e5b-48a7-8c87-cfc2605a68d1">—</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i4fbaf0c06826427fab08130c69d7c437_I20220331" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOmZjMTVkNGYwODMzMjQ1ZDI4ZGY3ODUwYjkyM2EzNDE3L3RhYmxlcmFuZ2U6ZmMxNWQ0ZjA4MzMyNDVkMjhkZjc4NTBiOTIzYTM0MTdfMjEtOS0xLTEtMTAxMTkw_798eea8c-0c3c-4a39-980f-ef20400cf007">—</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="ifff0b8a0a33a465f93f294473ef71015_I20220331" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOmZjMTVkNGYwODMzMjQ1ZDI4ZGY3ODUwYjkyM2EzNDE3L3RhYmxlcmFuZ2U6ZmMxNWQ0ZjA4MzMyNDVkMjhkZjc4NTBiOTIzYTM0MTdfMjEtMTEtMS0xLTEwMTE5MA_3e9e0dcc-58ba-4516-a8a7-681ea9ae1d7e">807.9</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity investments without readily determinable fair values</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i73af0f98be8b48e58557bf37c81c9e74_I20220331" decimals="-5" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOmZjMTVkNGYwODMzMjQ1ZDI4ZGY3ODUwYjkyM2EzNDE3L3RhYmxlcmFuZ2U6ZmMxNWQ0ZjA4MzMyNDVkMjhkZjc4NTBiOTIzYTM0MTdfMjItMS0xLTEtMTAxMTkw_c1bb66c8-b383-405e-893a-3e18cb2584fc">569.5</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity method investments</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i34e5580510394d9fb0a59cfe4cec75d2_I20220331" decimals="-5" name="us-gaap:OtherLongTermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOmZjMTVkNGYwODMzMjQ1ZDI4ZGY3ODUwYjkyM2EzNDE3L3RhYmxlcmFuZ2U6ZmMxNWQ0ZjA4MzMyNDVkMjhkZjc4NTBiOTIzYTM0MTdfMjMtMS0xLTEtMTAxMTkw_b2141c2d-66ff-4cce-b97a-5545b8c59b72">769.2</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncurrent investments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i73af0f98be8b48e58557bf37c81c9e74_I20220331" decimals="-5" name="us-gaap:LongTermInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOmZjMTVkNGYwODMzMjQ1ZDI4ZGY3ODUwYjkyM2EzNDE3L3RhYmxlcmFuZ2U6ZmMxNWQ0ZjA4MzMyNDVkMjhkZjc4NTBiOTIzYTM0MTdfMjQtMS0xLTEtMTAxMTkw_4dde9e36-38b5-4c54-a244-67394fbacfa0">2,727.3</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i057515f5782941809af8fac0ad822ddf_I20211231" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOmZjMTVkNGYwODMzMjQ1ZDI4ZGY3ODUwYjkyM2EzNDE3L3RhYmxlcmFuZ2U6ZmMxNWQ0ZjA4MzMyNDVkMjhkZjc4NTBiOTIzYTM0MTdfMjctMS0xLTEtMTAxMTkw_81a8027c-4d3a-47a5-92e1-b047fb7139dd">2,379.5</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i3b22d12321a742eba88cdd7b94472599_I20211231" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOmZjMTVkNGYwODMzMjQ1ZDI4ZGY3ODUwYjkyM2EzNDE3L3RhYmxlcmFuZ2U6ZmMxNWQ0ZjA4MzMyNDVkMjhkZjc4NTBiOTIzYTM0MTdfMjctMy0xLTEtMTAxMTkw_a8e0dbea-2b0e-4e41-999a-10f8e219121b">2,379.5</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ic769458ef1cb403f8d92df4e02a545c7_I20211231" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOmZjMTVkNGYwODMzMjQ1ZDI4ZGY3ODUwYjkyM2EzNDE3L3RhYmxlcmFuZ2U6ZmMxNWQ0ZjA4MzMyNDVkMjhkZjc4NTBiOTIzYTM0MTdfMjctNS0xLTEtMTAxMTkw_9dcdb8cf-409c-4edc-98ba-1e53276a27bf">2,361.0</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i2ada8ba658a948af9bb22996a9eab24d_I20211231" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOmZjMTVkNGYwODMzMjQ1ZDI4ZGY3ODUwYjkyM2EzNDE3L3RhYmxlcmFuZ2U6ZmMxNWQ0ZjA4MzMyNDVkMjhkZjc4NTBiOTIzYTM0MTdfMjctNy0xLTEtMTAxMTkw_5aca3eab-de6d-4578-9b20-1942d3058bfa">18.5</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iccf68abee8b64588b494d4d0bcd59e25_I20211231" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOmZjMTVkNGYwODMzMjQ1ZDI4ZGY3ODUwYjkyM2EzNDE3L3RhYmxlcmFuZ2U6ZmMxNWQ0ZjA4MzMyNDVkMjhkZjc4NTBiOTIzYTM0MTdfMjctOS0xLTEtMTAxMTkw_cf54489c-59e5-4e73-a63c-6aca7e54a727">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i298284fbe5094d049bf7ed6517060de9_I20211231" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOmZjMTVkNGYwODMzMjQ1ZDI4ZGY3ODUwYjkyM2EzNDE3L3RhYmxlcmFuZ2U6ZmMxNWQ0ZjA4MzMyNDVkMjhkZjc4NTBiOTIzYTM0MTdfMjctMTEtMS0xLTEwMTE5MA_c7d6bf97-3a9e-46ca-a35c-1b043adb7800">2,379.5</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-term investments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i6ae57b6acf9a480e815a2255a0a47172_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOmZjMTVkNGYwODMzMjQ1ZDI4ZGY3ODUwYjkyM2EzNDE3L3RhYmxlcmFuZ2U6ZmMxNWQ0ZjA4MzMyNDVkMjhkZjc4NTBiOTIzYTM0MTdfMzAtMS0xLTEtMTAxMTkw_d569bfcb-fd7b-45b4-9f84-a5f32ef6b6ef">25.7</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i97ca45854b924b6aaa19c533a897fb4b_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOmZjMTVkNGYwODMzMjQ1ZDI4ZGY3ODUwYjkyM2EzNDE3L3RhYmxlcmFuZ2U6ZmMxNWQ0ZjA4MzMyNDVkMjhkZjc4NTBiOTIzYTM0MTdfMzAtMy0xLTEtMTAxMTkw_c2f803fc-4f37-45dc-b38a-f57a0cfa712e">25.6</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i1e316c5cad3845a991ac64bee258b844_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOmZjMTVkNGYwODMzMjQ1ZDI4ZGY3ODUwYjkyM2EzNDE3L3RhYmxlcmFuZ2U6ZmMxNWQ0ZjA4MzMyNDVkMjhkZjc4NTBiOTIzYTM0MTdfMzAtNS0xLTEtMTAxMTkw_2f407746-928d-4fb9-b45e-ad1c81f1d630">25.7</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i04515a46362744d49cdd523efd4006f6_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOmZjMTVkNGYwODMzMjQ1ZDI4ZGY3ODUwYjkyM2EzNDE3L3RhYmxlcmFuZ2U6ZmMxNWQ0ZjA4MzMyNDVkMjhkZjc4NTBiOTIzYTM0MTdfMzAtNy0xLTEtMTAxMTkw_d8f2d25d-306c-4f14-8086-d718b3b03d21">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i844e6c2a216e4a669a4a913b04f32762_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOmZjMTVkNGYwODMzMjQ1ZDI4ZGY3ODUwYjkyM2EzNDE3L3RhYmxlcmFuZ2U6ZmMxNWQ0ZjA4MzMyNDVkMjhkZjc4NTBiOTIzYTM0MTdfMzAtOS0xLTEtMTAxMTkw_7a8ebc27-d067-4a9f-9a51-59d33cf20e07">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="icd7c2d39ad064e6d84ac3562cf8025df_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOmZjMTVkNGYwODMzMjQ1ZDI4ZGY3ODUwYjkyM2EzNDE3L3RhYmxlcmFuZ2U6ZmMxNWQ0ZjA4MzMyNDVkMjhkZjc4NTBiOTIzYTM0MTdfMzAtMTEtMS0xLTEwMTE5MA_d37539b2-5677-43f1-afd1-574349b22c92">25.7</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i1bed7fb2284146bd8643e9b39f9ac451_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOmZjMTVkNGYwODMzMjQ1ZDI4ZGY3ODUwYjkyM2EzNDE3L3RhYmxlcmFuZ2U6ZmMxNWQ0ZjA4MzMyNDVkMjhkZjc4NTBiOTIzYTM0MTdfMzEtMS0xLTEtMTAxMTkw_1ab697b1-58aa-4dcf-ac85-1820f0850fcd">43.7</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i7faea4de0e74408b81231bf3f5e63e60_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOmZjMTVkNGYwODMzMjQ1ZDI4ZGY3ODUwYjkyM2EzNDE3L3RhYmxlcmFuZ2U6ZmMxNWQ0ZjA4MzMyNDVkMjhkZjc4NTBiOTIzYTM0MTdfMzEtMy0xLTEtMTAxMTkw_0c8b57a2-9cbe-47ec-8274-95d6825c9ba7">43.7</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9ab5bace01434c65b51abaee9f1db274_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOmZjMTVkNGYwODMzMjQ1ZDI4ZGY3ODUwYjkyM2EzNDE3L3RhYmxlcmFuZ2U6ZmMxNWQ0ZjA4MzMyNDVkMjhkZjc4NTBiOTIzYTM0MTdfMzEtNS0xLTEtMTAxMTkw_50d227af-e22e-4c8d-a326-7401b717b87b">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ia66a2eb56db04d659e7b08afb8e00b97_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOmZjMTVkNGYwODMzMjQ1ZDI4ZGY3ODUwYjkyM2EzNDE3L3RhYmxlcmFuZ2U6ZmMxNWQ0ZjA4MzMyNDVkMjhkZjc4NTBiOTIzYTM0MTdfMzEtNy0xLTEtMTAxMTkw_528ab03e-edb2-4ef3-ba1c-a9611a105820">43.7</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i25a9ef4798f34b4c848e20f373f45fee_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOmZjMTVkNGYwODMzMjQ1ZDI4ZGY3ODUwYjkyM2EzNDE3L3RhYmxlcmFuZ2U6ZmMxNWQ0ZjA4MzMyNDVkMjhkZjc4NTBiOTIzYTM0MTdfMzEtOS0xLTEtMTAxMTkw_af92d6ee-7458-46cd-97f7-3cf08f40fbb8">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i6d116456bb6a4610aa2017fb9072aea1_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOmZjMTVkNGYwODMzMjQ1ZDI4ZGY3ODUwYjkyM2EzNDE3L3RhYmxlcmFuZ2U6ZmMxNWQ0ZjA4MzMyNDVkMjhkZjc4NTBiOTIzYTM0MTdfMzEtMTEtMS0xLTEwMTE5MA_0eeb7919-5c53-4b52-9dfb-76684de08b83">43.7</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i182112e9aeee4d92b6fca93686a55631_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOmZjMTVkNGYwODMzMjQ1ZDI4ZGY3ODUwYjkyM2EzNDE3L3RhYmxlcmFuZ2U6ZmMxNWQ0ZjA4MzMyNDVkMjhkZjc4NTBiOTIzYTM0MTdfMzItMS0xLTEtMTA0NzQy_228cf9cb-d48d-47f5-bf8a-fd09497f2677">0.2</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i519c10d83d004381af697acde770b07c_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOmZjMTVkNGYwODMzMjQ1ZDI4ZGY3ODUwYjkyM2EzNDE3L3RhYmxlcmFuZ2U6ZmMxNWQ0ZjA4MzMyNDVkMjhkZjc4NTBiOTIzYTM0MTdfMzItMy0xLTEtMTA0NzQy_95c65bff-5ca2-4440-9eef-066327ca49d9">0.2</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9338f22ba6094fc282c2830f4f065887_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOmZjMTVkNGYwODMzMjQ1ZDI4ZGY3ODUwYjkyM2EzNDE3L3RhYmxlcmFuZ2U6ZmMxNWQ0ZjA4MzMyNDVkMjhkZjc4NTBiOTIzYTM0MTdfMzItNS0xLTEtMTA0NzQy_66391942-6512-4526-9598-f83727456c5f">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i7223c12010024dc1bcba7a6fef6e53d7_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOmZjMTVkNGYwODMzMjQ1ZDI4ZGY3ODUwYjkyM2EzNDE3L3RhYmxlcmFuZ2U6ZmMxNWQ0ZjA4MzMyNDVkMjhkZjc4NTBiOTIzYTM0MTdfMzItNy0xLTEtMTA0NzQy_dd8a22fb-52fc-4e2b-8f7f-506bc6a4e26c">0.2</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iac5e6284cc114a9d83ce2d830c3a671f_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOmZjMTVkNGYwODMzMjQ1ZDI4ZGY3ODUwYjkyM2EzNDE3L3RhYmxlcmFuZ2U6ZmMxNWQ0ZjA4MzMyNDVkMjhkZjc4NTBiOTIzYTM0MTdfMzItOS0xLTEtMTA0NzQy_241d5eca-1974-4d9a-819a-dfdec4932774">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i7cdc75cf167f4e67a1ea672190673af0_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOmZjMTVkNGYwODMzMjQ1ZDI4ZGY3ODUwYjkyM2EzNDE3L3RhYmxlcmFuZ2U6ZmMxNWQ0ZjA4MzMyNDVkMjhkZjc4NTBiOTIzYTM0MTdfMzItMTEtMS0xLTEwNDc0Mg_e60aca37-e29c-4cd9-8d8e-a3c21eb7d148">0.2</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i75424eb967c54c37a5493947a35db25a_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOmZjMTVkNGYwODMzMjQ1ZDI4ZGY3ODUwYjkyM2EzNDE3L3RhYmxlcmFuZ2U6ZmMxNWQ0ZjA4MzMyNDVkMjhkZjc4NTBiOTIzYTM0MTdfMzItMS0xLTEtMTAxMTkw_61aedd1c-b8d5-48e5-b887-98c54d297d5d">6.2</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ieed236aec1e044be88d61bd1569b734f_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOmZjMTVkNGYwODMzMjQ1ZDI4ZGY3ODUwYjkyM2EzNDE3L3RhYmxlcmFuZ2U6ZmMxNWQ0ZjA4MzMyNDVkMjhkZjc4NTBiOTIzYTM0MTdfMzItMy0xLTEtMTAxMTkw_910782bf-428d-4276-a6b8-083a95aff95d">6.2</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="icfabd5ccb95f48b0afdb0c81fc76f924_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOmZjMTVkNGYwODMzMjQ1ZDI4ZGY3ODUwYjkyM2EzNDE3L3RhYmxlcmFuZ2U6ZmMxNWQ0ZjA4MzMyNDVkMjhkZjc4NTBiOTIzYTM0MTdfMzItNS0xLTEtMTAxMTkw_de3a6ee9-2b71-4293-8de2-cf7ce12e005b">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i66c179e929fa4af99c373a63da5215e8_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOmZjMTVkNGYwODMzMjQ1ZDI4ZGY3ODUwYjkyM2EzNDE3L3RhYmxlcmFuZ2U6ZmMxNWQ0ZjA4MzMyNDVkMjhkZjc4NTBiOTIzYTM0MTdfMzItNy0xLTEtMTAxMTkw_86599c20-51de-49b6-827d-b1638290ffff">6.2</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib4c92f85e01b446fa56db5a85f60835f_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOmZjMTVkNGYwODMzMjQ1ZDI4ZGY3ODUwYjkyM2EzNDE3L3RhYmxlcmFuZ2U6ZmMxNWQ0ZjA4MzMyNDVkMjhkZjc4NTBiOTIzYTM0MTdfMzItOS0xLTEtMTAxMTkw_ea5600ef-bdd5-4269-a937-60d6d34ed0ab">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i7992f3445fcf455d857370bd494fa269_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOmZjMTVkNGYwODMzMjQ1ZDI4ZGY3ODUwYjkyM2EzNDE3L3RhYmxlcmFuZ2U6ZmMxNWQ0ZjA4MzMyNDVkMjhkZjc4NTBiOTIzYTM0MTdfMzItMTEtMS0xLTEwMTE5MA_e4969649-1b10-4998-9ffb-f6a472abb919">6.2</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i8f79fb34343e4bcbbe559d8c60857663_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOmZjMTVkNGYwODMzMjQ1ZDI4ZGY3ODUwYjkyM2EzNDE3L3RhYmxlcmFuZ2U6ZmMxNWQ0ZjA4MzMyNDVkMjhkZjc4NTBiOTIzYTM0MTdfMzMtMS0xLTEtMTAxMTkw_4ba7f885-e9a3-4cc2-a626-8eee1f922eb6">14.3</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ifc17920e7173460596ad72a021856b63_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOmZjMTVkNGYwODMzMjQ1ZDI4ZGY3ODUwYjkyM2EzNDE3L3RhYmxlcmFuZ2U6ZmMxNWQ0ZjA4MzMyNDVkMjhkZjc4NTBiOTIzYTM0MTdfMzMtMy0xLTEtMTAxMTkw_a312c57d-db2e-423a-88f1-7bb86a2c8135">14.3</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ic685367f56cc4339adb4935065562054_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOmZjMTVkNGYwODMzMjQ1ZDI4ZGY3ODUwYjkyM2EzNDE3L3RhYmxlcmFuZ2U6ZmMxNWQ0ZjA4MzMyNDVkMjhkZjc4NTBiOTIzYTM0MTdfMzMtNS0xLTEtMTAxMTkw_196a7e08-b919-4344-879f-2a76bc9406f2">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iae543a32b13146378424ca5b6f44b0c2_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOmZjMTVkNGYwODMzMjQ1ZDI4ZGY3ODUwYjkyM2EzNDE3L3RhYmxlcmFuZ2U6ZmMxNWQ0ZjA4MzMyNDVkMjhkZjc4NTBiOTIzYTM0MTdfMzMtNy0xLTEtMTAxMTkw_9e307a49-3dc8-4f1e-bebd-fe4af2ee0aa3">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i76e0df9851e54717892c8f5a46e24893_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOmZjMTVkNGYwODMzMjQ1ZDI4ZGY3ODUwYjkyM2EzNDE3L3RhYmxlcmFuZ2U6ZmMxNWQ0ZjA4MzMyNDVkMjhkZjc4NTBiOTIzYTM0MTdfMzMtOS0xLTEtMTAxMTkw_0f54da74-a47e-4bd6-8cf4-6a10ab372280">14.3</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="idd6696a4fa6d40ccbeeeab7cfb286206_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOmZjMTVkNGYwODMzMjQ1ZDI4ZGY3ODUwYjkyM2EzNDE3L3RhYmxlcmFuZ2U6ZmMxNWQ0ZjA4MzMyNDVkMjhkZjc4NTBiOTIzYTM0MTdfMzMtMTEtMS0xLTEwMTE5MA_678146db-46a2-4ebc-8615-fe35df1edc9f">14.3</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-term investments</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i057515f5782941809af8fac0ad822ddf_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOmZjMTVkNGYwODMzMjQ1ZDI4ZGY3ODUwYjkyM2EzNDE3L3RhYmxlcmFuZ2U6ZmMxNWQ0ZjA4MzMyNDVkMjhkZjc4NTBiOTIzYTM0MTdfMzUtMS0xLTEtMTAxMTkw_fd041434-bfdd-42e5-94f4-cdcfe9366c03">90.1</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncurrent investments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i6ae57b6acf9a480e815a2255a0a47172_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOmZjMTVkNGYwODMzMjQ1ZDI4ZGY3ODUwYjkyM2EzNDE3L3RhYmxlcmFuZ2U6ZmMxNWQ0ZjA4MzMyNDVkMjhkZjc4NTBiOTIzYTM0MTdfMzgtMS0xLTEtMTAxMTkw_ac0c0dd4-e477-4d91-90f4-8edb6e1241ec">137.0</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i97ca45854b924b6aaa19c533a897fb4b_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOmZjMTVkNGYwODMzMjQ1ZDI4ZGY3ODUwYjkyM2EzNDE3L3RhYmxlcmFuZ2U6ZmMxNWQ0ZjA4MzMyNDVkMjhkZjc4NTBiOTIzYTM0MTdfMzgtMy0xLTEtMTAxMTkw_b491755a-867a-4941-9d52-5c9bf03d9f44">136.8</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i1e316c5cad3845a991ac64bee258b844_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOmZjMTVkNGYwODMzMjQ1ZDI4ZGY3ODUwYjkyM2EzNDE3L3RhYmxlcmFuZ2U6ZmMxNWQ0ZjA4MzMyNDVkMjhkZjc4NTBiOTIzYTM0MTdfMzgtNS0xLTEtMTAxMTkw_51c9a192-1135-409e-aa68-9d362c5ca7c0">137.0</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i04515a46362744d49cdd523efd4006f6_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOmZjMTVkNGYwODMzMjQ1ZDI4ZGY3ODUwYjkyM2EzNDE3L3RhYmxlcmFuZ2U6ZmMxNWQ0ZjA4MzMyNDVkMjhkZjc4NTBiOTIzYTM0MTdfMzgtNy0xLTEtMTAxMTkw_f93552bc-ad88-440c-a3ef-77ae9aeca3c4">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i844e6c2a216e4a669a4a913b04f32762_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOmZjMTVkNGYwODMzMjQ1ZDI4ZGY3ODUwYjkyM2EzNDE3L3RhYmxlcmFuZ2U6ZmMxNWQ0ZjA4MzMyNDVkMjhkZjc4NTBiOTIzYTM0MTdfMzgtOS0xLTEtMTAxMTkw_a72bfa92-99c6-43a3-bc2e-117427184ec2">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="icd7c2d39ad064e6d84ac3562cf8025df_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOmZjMTVkNGYwODMzMjQ1ZDI4ZGY3ODUwYjkyM2EzNDE3L3RhYmxlcmFuZ2U6ZmMxNWQ0ZjA4MzMyNDVkMjhkZjc4NTBiOTIzYTM0MTdfMzgtMTEtMS0xLTEwMTE5MA_ec0a965d-bad1-4729-bbe6-8b946fa2c710">137.0</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i1bed7fb2284146bd8643e9b39f9ac451_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOmZjMTVkNGYwODMzMjQ1ZDI4ZGY3ODUwYjkyM2EzNDE3L3RhYmxlcmFuZ2U6ZmMxNWQ0ZjA4MzMyNDVkMjhkZjc4NTBiOTIzYTM0MTdfMzktMS0xLTEtMTAxMTkw_15b99568-6ad6-4f9f-8c2b-d39071f06acc">235.3</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i7faea4de0e74408b81231bf3f5e63e60_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOmZjMTVkNGYwODMzMjQ1ZDI4ZGY3ODUwYjkyM2EzNDE3L3RhYmxlcmFuZ2U6ZmMxNWQ0ZjA4MzMyNDVkMjhkZjc4NTBiOTIzYTM0MTdfMzktMy0xLTEtMTAxMTkw_96975bcf-6c8c-4d96-b0e0-881b718a6fbd">232.7</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9ab5bace01434c65b51abaee9f1db274_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOmZjMTVkNGYwODMzMjQ1ZDI4ZGY3ODUwYjkyM2EzNDE3L3RhYmxlcmFuZ2U6ZmMxNWQ0ZjA4MzMyNDVkMjhkZjc4NTBiOTIzYTM0MTdfMzktNS0xLTEtMTAxMTkw_82477493-f42f-4b03-b121-c648e4f2178c">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ia66a2eb56db04d659e7b08afb8e00b97_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOmZjMTVkNGYwODMzMjQ1ZDI4ZGY3ODUwYjkyM2EzNDE3L3RhYmxlcmFuZ2U6ZmMxNWQ0ZjA4MzMyNDVkMjhkZjc4NTBiOTIzYTM0MTdfMzktNy0xLTEtMTAxMTkw_a2dc6a4c-ab85-469e-8473-00b1a69fb928">235.3</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i25a9ef4798f34b4c848e20f373f45fee_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOmZjMTVkNGYwODMzMjQ1ZDI4ZGY3ODUwYjkyM2EzNDE3L3RhYmxlcmFuZ2U6ZmMxNWQ0ZjA4MzMyNDVkMjhkZjc4NTBiOTIzYTM0MTdfMzktOS0xLTEtMTAxMTkw_f2d765b9-0272-4b85-bb67-3de7cce349a8">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i6d116456bb6a4610aa2017fb9072aea1_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOmZjMTVkNGYwODMzMjQ1ZDI4ZGY3ODUwYjkyM2EzNDE3L3RhYmxlcmFuZ2U6ZmMxNWQ0ZjA4MzMyNDVkMjhkZjc4NTBiOTIzYTM0MTdfMzktMTEtMS0xLTEwMTE5MA_eae2ec54-ba56-42cc-b2c7-31b39091ad61">235.3</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i182112e9aeee4d92b6fca93686a55631_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOmZjMTVkNGYwODMzMjQ1ZDI4ZGY3ODUwYjkyM2EzNDE3L3RhYmxlcmFuZ2U6ZmMxNWQ0ZjA4MzMyNDVkMjhkZjc4NTBiOTIzYTM0MTdfNDAtMS0xLTEtMTAxMTkw_4edf7e00-e1f7-4757-9e1a-90f8bd8ec7c3">109.8</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i519c10d83d004381af697acde770b07c_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOmZjMTVkNGYwODMzMjQ1ZDI4ZGY3ODUwYjkyM2EzNDE3L3RhYmxlcmFuZ2U6ZmMxNWQ0ZjA4MzMyNDVkMjhkZjc4NTBiOTIzYTM0MTdfNDAtMy0xLTEtMTAxMTkw_876f5332-009f-40f6-aa92-bbb8e957673b">108.1</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9338f22ba6094fc282c2830f4f065887_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOmZjMTVkNGYwODMzMjQ1ZDI4ZGY3ODUwYjkyM2EzNDE3L3RhYmxlcmFuZ2U6ZmMxNWQ0ZjA4MzMyNDVkMjhkZjc4NTBiOTIzYTM0MTdfNDAtNS0xLTEtMTAxMTkw_6f36f0ab-8494-42f6-8084-fb9afb801c88">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i7223c12010024dc1bcba7a6fef6e53d7_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOmZjMTVkNGYwODMzMjQ1ZDI4ZGY3ODUwYjkyM2EzNDE3L3RhYmxlcmFuZ2U6ZmMxNWQ0ZjA4MzMyNDVkMjhkZjc4NTBiOTIzYTM0MTdfNDAtNy0xLTEtMTAxMTkw_756fc4a3-adda-4c64-9e66-bc8a13bc00aa">109.8</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iac5e6284cc114a9d83ce2d830c3a671f_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOmZjMTVkNGYwODMzMjQ1ZDI4ZGY3ODUwYjkyM2EzNDE3L3RhYmxlcmFuZ2U6ZmMxNWQ0ZjA4MzMyNDVkMjhkZjc4NTBiOTIzYTM0MTdfNDAtOS0xLTEtMTAxMTkw_1e0cc868-e88d-4852-bea0-f9ef6c08a505">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i7cdc75cf167f4e67a1ea672190673af0_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOmZjMTVkNGYwODMzMjQ1ZDI4ZGY3ODUwYjkyM2EzNDE3L3RhYmxlcmFuZ2U6ZmMxNWQ0ZjA4MzMyNDVkMjhkZjc4NTBiOTIzYTM0MTdfNDAtMTEtMS0xLTEwMTE5MA_7c988694-ec10-4aca-b5b2-9e7ef1e6134d">109.8</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i75424eb967c54c37a5493947a35db25a_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOmZjMTVkNGYwODMzMjQ1ZDI4ZGY3ODUwYjkyM2EzNDE3L3RhYmxlcmFuZ2U6ZmMxNWQ0ZjA4MzMyNDVkMjhkZjc4NTBiOTIzYTM0MTdfNDEtMS0xLTEtMTAxMTkw_cf5e86ed-0258-4797-ac97-55c77e154958">23.1</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ieed236aec1e044be88d61bd1569b734f_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOmZjMTVkNGYwODMzMjQ1ZDI4ZGY3ODUwYjkyM2EzNDE3L3RhYmxlcmFuZ2U6ZmMxNWQ0ZjA4MzMyNDVkMjhkZjc4NTBiOTIzYTM0MTdfNDEtMy0xLTEtMTAxMTkw_e9e29631-8002-4d87-a8b7-186e056aacd5">23.1</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="icfabd5ccb95f48b0afdb0c81fc76f924_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOmZjMTVkNGYwODMzMjQ1ZDI4ZGY3ODUwYjkyM2EzNDE3L3RhYmxlcmFuZ2U6ZmMxNWQ0ZjA4MzMyNDVkMjhkZjc4NTBiOTIzYTM0MTdfNDEtNS0xLTEtMTAxMTkw_ef7f6797-d554-465d-acd2-aa24da11d3c4">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i66c179e929fa4af99c373a63da5215e8_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOmZjMTVkNGYwODMzMjQ1ZDI4ZGY3ODUwYjkyM2EzNDE3L3RhYmxlcmFuZ2U6ZmMxNWQ0ZjA4MzMyNDVkMjhkZjc4NTBiOTIzYTM0MTdfNDEtNy0xLTEtMTAxMTkw_7aae383f-9b99-4d11-805f-a013820da721">23.1</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib4c92f85e01b446fa56db5a85f60835f_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOmZjMTVkNGYwODMzMjQ1ZDI4ZGY3ODUwYjkyM2EzNDE3L3RhYmxlcmFuZ2U6ZmMxNWQ0ZjA4MzMyNDVkMjhkZjc4NTBiOTIzYTM0MTdfNDEtOS0xLTEtMTAxMTkw_c4a68a94-c892-456c-a0bf-4f4380ea11cd">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i7992f3445fcf455d857370bd494fa269_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOmZjMTVkNGYwODMzMjQ1ZDI4ZGY3ODUwYjkyM2EzNDE3L3RhYmxlcmFuZ2U6ZmMxNWQ0ZjA4MzMyNDVkMjhkZjc4NTBiOTIzYTM0MTdfNDEtMTEtMS0xLTEwMTE5MA_dceb7172-df6b-41fc-9a10-14c56f97d6eb">23.1</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ifd76ddec7a144856a43e75f9082488fa_I20211231" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOmZjMTVkNGYwODMzMjQ1ZDI4ZGY3ODUwYjkyM2EzNDE3L3RhYmxlcmFuZ2U6ZmMxNWQ0ZjA4MzMyNDVkMjhkZjc4NTBiOTIzYTM0MTdfNDItMS0xLTEtMTAxMTkw_b3965e5f-1674-4494-9a7f-13286f7c6228">108.1</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ia468c5f1389340e08b88c98938991507_I20211231" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOmZjMTVkNGYwODMzMjQ1ZDI4ZGY3ODUwYjkyM2EzNDE3L3RhYmxlcmFuZ2U6ZmMxNWQ0ZjA4MzMyNDVkMjhkZjc4NTBiOTIzYTM0MTdfNDItMy0xLTEtMTAxMTkw_d4be4e4f-1fed-4481-b096-4ae481c4d6c8">22.2</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i6e745874edfb4e99917c89bf5aaa5a7a_I20211231" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOmZjMTVkNGYwODMzMjQ1ZDI4ZGY3ODUwYjkyM2EzNDE3L3RhYmxlcmFuZ2U6ZmMxNWQ0ZjA4MzMyNDVkMjhkZjc4NTBiOTIzYTM0MTdfNDItNS0xLTEtMTAxMTkw_9f7fad42-c2ac-4d03-a332-8d50676fb2b8">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ibe91c67265284e73b644361c4e2b0b8f_I20211231" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOmZjMTVkNGYwODMzMjQ1ZDI4ZGY3ODUwYjkyM2EzNDE3L3RhYmxlcmFuZ2U6ZmMxNWQ0ZjA4MzMyNDVkMjhkZjc4NTBiOTIzYTM0MTdfNDItNy0xLTEtMTAxMTkw_a8c177ac-763a-4c1d-820e-252e4cb58e62">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="icfdb865651304950a4161c0ccc0adb09_I20211231" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOmZjMTVkNGYwODMzMjQ1ZDI4ZGY3ODUwYjkyM2EzNDE3L3RhYmxlcmFuZ2U6ZmMxNWQ0ZjA4MzMyNDVkMjhkZjc4NTBiOTIzYTM0MTdfNDItOS0xLTEtMTAxMTkw_352690b6-b1fb-460c-a648-82b4733c96ff">108.1</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i0a064c1e1f674a109ea67b5d14516124_I20211231" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOmZjMTVkNGYwODMzMjQ1ZDI4ZGY3ODUwYjkyM2EzNDE3L3RhYmxlcmFuZ2U6ZmMxNWQ0ZjA4MzMyNDVkMjhkZjc4NTBiOTIzYTM0MTdfNDItMTEtMS0xLTEwMTE5MA_2c6ec0b8-baef-4eba-9393-9edb2fafdfbc">108.1</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketable equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i7716b5d37f7b484c8545e840917541a1_I20211231" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOmZjMTVkNGYwODMzMjQ1ZDI4ZGY3ODUwYjkyM2EzNDE3L3RhYmxlcmFuZ2U6ZmMxNWQ0ZjA4MzMyNDVkMjhkZjc4NTBiOTIzYTM0MTdfNDMtMS0xLTEtMTAxMTkw_c0e60750-2e99-44f1-8f76-9b6ebdf8cd6a">1,279.7</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ie40648037ee1408c8682678930a548ed_I20211231" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOmZjMTVkNGYwODMzMjQ1ZDI4ZGY3ODUwYjkyM2EzNDE3L3RhYmxlcmFuZ2U6ZmMxNWQ0ZjA4MzMyNDVkMjhkZjc4NTBiOTIzYTM0MTdfNDMtMy0xLTEtMTAxMTkw_9c4b824b-bb04-47a7-854b-1801b3cb540b">487.0</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="idbaca5a56d864677bba3c62605a8494a_I20211231" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOmZjMTVkNGYwODMzMjQ1ZDI4ZGY3ODUwYjkyM2EzNDE3L3RhYmxlcmFuZ2U6ZmMxNWQ0ZjA4MzMyNDVkMjhkZjc4NTBiOTIzYTM0MTdfNDMtNS0xLTEtMTAxMTkw_38fc3573-463c-46d8-8f62-dd20e3b84be1">1,279.7</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="icadd24c3d6034be18cbb14120a6e4ea2_I20211231" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOmZjMTVkNGYwODMzMjQ1ZDI4ZGY3ODUwYjkyM2EzNDE3L3RhYmxlcmFuZ2U6ZmMxNWQ0ZjA4MzMyNDVkMjhkZjc4NTBiOTIzYTM0MTdfNDMtNy0xLTEtMTAxMTkw_3406e16e-a084-44ea-8bc9-544d85955c74">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ia4bba9c6f0c8418d9fb7a7fb432f8e56_I20211231" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOmZjMTVkNGYwODMzMjQ1ZDI4ZGY3ODUwYjkyM2EzNDE3L3RhYmxlcmFuZ2U6ZmMxNWQ0ZjA4MzMyNDVkMjhkZjc4NTBiOTIzYTM0MTdfNDMtOS0xLTEtMTAxMTkw_d69004a1-bb1b-470d-bae4-16c4f2ccb4ec">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i6cd06b32d25d48e49f7e8a09e4e969ae_I20211231" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOmZjMTVkNGYwODMzMjQ1ZDI4ZGY3ODUwYjkyM2EzNDE3L3RhYmxlcmFuZ2U6ZmMxNWQ0ZjA4MzMyNDVkMjhkZjc4NTBiOTIzYTM0MTdfNDMtMTEtMS0xLTEwMTE5MA_8cc949d9-37f4-481a-88dd-a7e0c6472618">1,279.7</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity investments without readily determinable fair values</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i057515f5782941809af8fac0ad822ddf_I20211231" decimals="-5" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOmZjMTVkNGYwODMzMjQ1ZDI4ZGY3ODUwYjkyM2EzNDE3L3RhYmxlcmFuZ2U6ZmMxNWQ0ZjA4MzMyNDVkMjhkZjc4NTBiOTIzYTM0MTdfNDQtMS0xLTEtMTAxMTkw_54efc92f-a9fc-414d-948f-4a83ea0843bb">548.1</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity method investments</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i8fe1e55b66654f16829171e30fa216cb_I20211231" decimals="-5" name="us-gaap:OtherLongTermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOmZjMTVkNGYwODMzMjQ1ZDI4ZGY3ODUwYjkyM2EzNDE3L3RhYmxlcmFuZ2U6ZmMxNWQ0ZjA4MzMyNDVkMjhkZjc4NTBiOTIzYTM0MTdfNDUtMS0xLTEtMTAxMTkw_82f392b5-98a8-470c-987f-7d26ebcdd925">771.5</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncurrent investments</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i057515f5782941809af8fac0ad822ddf_I20211231" decimals="-5" name="us-gaap:LongTermInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOmZjMTVkNGYwODMzMjQ1ZDI4ZGY3ODUwYjkyM2EzNDE3L3RhYmxlcmFuZ2U6ZmMxNWQ0ZjA4MzMyNDVkMjhkZjc4NTBiOTIzYTM0MTdfNDYtMS0xLTEtMTAxMTkw_a9ad4798-9c5c-494d-ac69-03ce5785ce7b">3,212.6</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></tbody></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">For available-for-sale debt securities, amounts disclosed represent the securities' amortized cost.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Fair value disclosures are not applicable for equity method investments and investments accounted for under the measurement alternative for equity investments.</span></div></ix:nonnumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span><br></span></div></div><div style="margin-top:11pt"><ix:continuation id="iaa1751e5f0a041f880bf3c8bbebd2bc1" continuedat="icd5bb79e49c7416b89940d8613604545"><ix:nonnumeric contextref="id879b497a407453985551e83dbee75f8_D20220101-20220331" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RleHRyZWdpb246NWNkZmEwZDVmNzVlNGY2N2E1ZTQ0NjAxMTQ3MmJlNWZfMTYyNzI_e40bfcb3-3af4-414b-9b47-92196a37482f" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tbody><tr><td style="width:1.0%"></td><td style="width:38.870%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.320%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.320%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.320%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.320%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.322%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements Using</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&nbsp;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br>Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices in Active Markets for Identical Assets<br>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br>Other Observable Inputs<br>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br>Unobservable<br>Inputs<br>(Level 3)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Short-term commercial paper borrowings</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 31, 2022</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i73af0f98be8b48e58557bf37c81c9e74_I20220331" decimals="-5" name="us-gaap:CommercialPaper" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOjkxY2NlMWRmNWQ1YTRiOGNiNzhhYjQ4YzAwMzEzYmJjL3RhYmxlcmFuZ2U6OTFjY2UxZGY1ZDVhNGI4Y2I3OGFiNDhjMDAzMTNiYmNfMy0xLTEtMS0xMDExOTA_f6bff518-b283-4f77-91f0-60ac5e8d0be4">499.7</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="idb4c476afbc64873b3c0511107fc85c9_I20220331" decimals="-5" name="us-gaap:CommercialPaper" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOjkxY2NlMWRmNWQ1YTRiOGNiNzhhYjQ4YzAwMzEzYmJjL3RhYmxlcmFuZ2U6OTFjY2UxZGY1ZDVhNGI4Y2I3OGFiNDhjMDAzMTNiYmNfMy0zLTEtMS0xMDExOTA_318b7a3c-812a-4743-9521-b64816f7bea2">—</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i553170707dac4ba4befbf57021e9352d_I20220331" decimals="-5" name="us-gaap:CommercialPaper" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOjkxY2NlMWRmNWQ1YTRiOGNiNzhhYjQ4YzAwMzEzYmJjL3RhYmxlcmFuZ2U6OTFjY2UxZGY1ZDVhNGI4Y2I3OGFiNDhjMDAzMTNiYmNfMy01LTEtMS0xMDExOTA_7f994208-ec03-4d78-a138-58d557e947b8">499.7</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i8196778f6b68404d98e4bc74190f4322_I20220331" decimals="-5" name="us-gaap:CommercialPaper" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOjkxY2NlMWRmNWQ1YTRiOGNiNzhhYjQ4YzAwMzEzYmJjL3RhYmxlcmFuZ2U6OTFjY2UxZGY1ZDVhNGI4Y2I3OGFiNDhjMDAzMTNiYmNfMy03LTEtMS0xMDExOTA_68663fdb-0708-4964-ae98-a42f8ae5534b">—</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i67e65f1325bd4d80b077bdc7713893b6_I20220331" decimals="-5" name="us-gaap:CommercialPaper" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOjkxY2NlMWRmNWQ1YTRiOGNiNzhhYjQ4YzAwMzEzYmJjL3RhYmxlcmFuZ2U6OTFjY2UxZGY1ZDVhNGI4Y2I3OGFiNDhjMDAzMTNiYmNfMy05LTEtMS0xMDExOTA_6bb149c8-ed68-4d81-aa33-beca78ed07b4">499.7</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i057515f5782941809af8fac0ad822ddf_I20211231" decimals="-5" name="us-gaap:CommercialPaper" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOjkxY2NlMWRmNWQ1YTRiOGNiNzhhYjQ4YzAwMzEzYmJjL3RhYmxlcmFuZ2U6OTFjY2UxZGY1ZDVhNGI4Y2I3OGFiNDhjMDAzMTNiYmNfNC0xLTEtMS0xMDExOTA_fff40396-a58b-43ac-a464-86c1e64a96bc">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ic769458ef1cb403f8d92df4e02a545c7_I20211231" decimals="-5" name="us-gaap:CommercialPaper" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOjkxY2NlMWRmNWQ1YTRiOGNiNzhhYjQ4YzAwMzEzYmJjL3RhYmxlcmFuZ2U6OTFjY2UxZGY1ZDVhNGI4Y2I3OGFiNDhjMDAzMTNiYmNfNC0zLTEtMS0xMDExOTA_390f3048-31fe-46f9-b877-c59b08683f6b">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i2ada8ba658a948af9bb22996a9eab24d_I20211231" decimals="-5" name="us-gaap:CommercialPaper" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOjkxY2NlMWRmNWQ1YTRiOGNiNzhhYjQ4YzAwMzEzYmJjL3RhYmxlcmFuZ2U6OTFjY2UxZGY1ZDVhNGI4Y2I3OGFiNDhjMDAzMTNiYmNfNC01LTEtMS0xMDExOTA_4530677b-bbb4-40eb-859b-c1f9082379f0">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iccf68abee8b64588b494d4d0bcd59e25_I20211231" decimals="-5" name="us-gaap:CommercialPaper" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOjkxY2NlMWRmNWQ1YTRiOGNiNzhhYjQ4YzAwMzEzYmJjL3RhYmxlcmFuZ2U6OTFjY2UxZGY1ZDVhNGI4Y2I3OGFiNDhjMDAzMTNiYmNfNC03LTEtMS0xMDExOTA_3eed9f3c-292e-470e-8e0b-072276a7c8eb">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i298284fbe5094d049bf7ed6517060de9_I20211231" decimals="-5" name="us-gaap:CommercialPaper" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOjkxY2NlMWRmNWQ1YTRiOGNiNzhhYjQ4YzAwMzEzYmJjL3RhYmxlcmFuZ2U6OTFjY2UxZGY1ZDVhNGI4Y2I3OGFiNDhjMDAzMTNiYmNfNC05LTEtMS0xMDExOTA_eaaa2fed-57f1-4b15-8ee1-36f2585b605b">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Long-term debt, including current portion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 31, 2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i73af0f98be8b48e58557bf37c81c9e74_I20220331" decimals="-5" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOjkxY2NlMWRmNWQ1YTRiOGNiNzhhYjQ4YzAwMzEzYmJjL3RhYmxlcmFuZ2U6OTFjY2UxZGY1ZDVhNGI4Y2I3OGFiNDhjMDAzMTNiYmNfNi0xLTEtMS0xMDExOTA_3262db25-8ea5-4704-b3fb-11f9f8014607">16,009.1</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="idb4c476afbc64873b3c0511107fc85c9_I20220331" decimals="-5" name="us-gaap:LongTermDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOjkxY2NlMWRmNWQ1YTRiOGNiNzhhYjQ4YzAwMzEzYmJjL3RhYmxlcmFuZ2U6OTFjY2UxZGY1ZDVhNGI4Y2I3OGFiNDhjMDAzMTNiYmNfNi0zLTEtMS0xMDExOTA_fb301f05-fc08-4d9c-adb8-cc7eaa259598">—</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i553170707dac4ba4befbf57021e9352d_I20220331" decimals="-5" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOjkxY2NlMWRmNWQ1YTRiOGNiNzhhYjQ4YzAwMzEzYmJjL3RhYmxlcmFuZ2U6OTFjY2UxZGY1ZDVhNGI4Y2I3OGFiNDhjMDAzMTNiYmNfNi01LTEtMS0xMDExOTA_8b687cdd-eba5-44c7-aebb-7c4aae610ea5">15,798.9</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i8196778f6b68404d98e4bc74190f4322_I20220331" decimals="-5" name="us-gaap:LongTermDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOjkxY2NlMWRmNWQ1YTRiOGNiNzhhYjQ4YzAwMzEzYmJjL3RhYmxlcmFuZ2U6OTFjY2UxZGY1ZDVhNGI4Y2I3OGFiNDhjMDAzMTNiYmNfNi03LTEtMS0xMDExOTA_5315e05c-6c6f-4833-97f8-585b2cc4e52a">—</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i67e65f1325bd4d80b077bdc7713893b6_I20220331" decimals="-5" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOjkxY2NlMWRmNWQ1YTRiOGNiNzhhYjQ4YzAwMzEzYmJjL3RhYmxlcmFuZ2U6OTFjY2UxZGY1ZDVhNGI4Y2I3OGFiNDhjMDAzMTNiYmNfNi05LTEtMS0xMDExOTA_24b36d31-ab8a-484a-ae28-9c51250d3854">15,798.9</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i057515f5782941809af8fac0ad822ddf_I20211231" decimals="-5" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOjkxY2NlMWRmNWQ1YTRiOGNiNzhhYjQ4YzAwMzEzYmJjL3RhYmxlcmFuZ2U6OTFjY2UxZGY1ZDVhNGI4Y2I3OGFiNDhjMDAzMTNiYmNfNy0xLTEtMS0xMDExOTA_e5f9cce3-be75-414a-b9ab-7f998c8865c9">16,884.7</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ic769458ef1cb403f8d92df4e02a545c7_I20211231" decimals="-5" name="us-gaap:LongTermDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOjkxY2NlMWRmNWQ1YTRiOGNiNzhhYjQ4YzAwMzEzYmJjL3RhYmxlcmFuZ2U6OTFjY2UxZGY1ZDVhNGI4Y2I3OGFiNDhjMDAzMTNiYmNfNy0zLTEtMS0xMDExOTA_722a4ef0-78fa-4250-b09e-8dd68c5d8f58">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i2ada8ba658a948af9bb22996a9eab24d_I20211231" decimals="-5" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOjkxY2NlMWRmNWQ1YTRiOGNiNzhhYjQ4YzAwMzEzYmJjL3RhYmxlcmFuZ2U6OTFjY2UxZGY1ZDVhNGI4Y2I3OGFiNDhjMDAzMTNiYmNfNy01LTEtMS0xMDExOTA_667a71b7-4f48-4225-b274-32fadb203512">18,157.7</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iccf68abee8b64588b494d4d0bcd59e25_I20211231" decimals="-5" name="us-gaap:LongTermDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOjkxY2NlMWRmNWQ1YTRiOGNiNzhhYjQ4YzAwMzEzYmJjL3RhYmxlcmFuZ2U6OTFjY2UxZGY1ZDVhNGI4Y2I3OGFiNDhjMDAzMTNiYmNfNy03LTEtMS0xMDExOTA_8bafa61f-2a2a-4066-b848-12974b828abd">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i298284fbe5094d049bf7ed6517060de9_I20211231" decimals="-5" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOjkxY2NlMWRmNWQ1YTRiOGNiNzhhYjQ4YzAwMzEzYmJjL3RhYmxlcmFuZ2U6OTFjY2UxZGY1ZDVhNGI4Y2I3OGFiNDhjMDAzMTNiYmNfNy05LTEtMS0xMDExOTA_93701aa6-e635-418d-9f88-2d8cb7b6f512">18,157.7</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></ix:nonnumeric></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span><br></span></div></div><div style="margin-top:5pt"><span><br></span></div><div><ix:continuation id="icd5bb79e49c7416b89940d8613604545" continuedat="i9d4e2c16aa094337b03faa0cd6470bdc"><ix:nonnumeric contextref="id879b497a407453985551e83dbee75f8_D20220101-20220331" name="us-gaap:FairValueByBalanceSheetGroupingTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RleHRyZWdpb246NWNkZmEwZDVmNzVlNGY2N2E1ZTQ0NjAxMTQ3MmJlNWZfMTYzMzA_6c051007-22c3-430f-ba11-8a7a95381e47" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tbody><tr><td style="width:1.0%"></td><td style="width:37.870%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.517%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.517%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.517%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.517%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.522%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements Using</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&nbsp;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br>Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices in Active Markets for Identical Assets<br>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br>Other Observable Inputs<br>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br>Unobservable<br>Inputs<br>(Level 3)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br>Value</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Risk-management instruments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest rate contracts designated as fair value hedges:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other receivables</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i1b0c53cf3bbc4ce2b0088d9820106967_I20220331" decimals="-5" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOjQ0YjQ3MWExMTZjYzRjM2E5M2RlYjcxNzdhMTkzM2Y5L3RhYmxlcmFuZ2U6NDRiNDcxYTExNmNjNGMzYTkzZGViNzE3N2ExOTMzZjlfNS0xLTEtMS0xMDExOTA_e3a023b8-675a-4dea-b072-84e5203a8bb0">1.3</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="ie705288cb01f4eac942cb814cdcc8539_I20220331" decimals="-5" name="us-gaap:DerivativeAssetsCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOjQ0YjQ3MWExMTZjYzRjM2E5M2RlYjcxNzdhMTkzM2Y5L3RhYmxlcmFuZ2U6NDRiNDcxYTExNmNjNGMzYTkzZGViNzE3N2ExOTMzZjlfNS0zLTEtMS0xMDExOTA_08935f00-3cad-43c3-87ac-9a074c1f9cd9">—</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i90b3eb87ed804a729b780c80c325ec95_I20220331" decimals="-5" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOjQ0YjQ3MWExMTZjYzRjM2E5M2RlYjcxNzdhMTkzM2Y5L3RhYmxlcmFuZ2U6NDRiNDcxYTExNmNjNGMzYTkzZGViNzE3N2ExOTMzZjlfNS01LTEtMS0xMDExOTA_0ed5b773-c512-40dc-b914-0bd28b3ab08d">1.3</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="idd019a06b4c246fd957d269e918d1c7f_I20220331" decimals="-5" name="us-gaap:DerivativeAssetsCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOjQ0YjQ3MWExMTZjYzRjM2E5M2RlYjcxNzdhMTkzM2Y5L3RhYmxlcmFuZ2U6NDRiNDcxYTExNmNjNGMzYTkzZGViNzE3N2ExOTMzZjlfNS03LTEtMS0xMDExOTA_2d170b86-f944-4d56-bf65-93b81ba4a743">—</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i61c30e51f61b42949ba7a628fc52c012_I20220331" decimals="-5" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOjQ0YjQ3MWExMTZjYzRjM2E5M2RlYjcxNzdhMTkzM2Y5L3RhYmxlcmFuZ2U6NDRiNDcxYTExNmNjNGMzYTkzZGViNzE3N2ExOTMzZjlfNS05LTEtMS0xMDExOTA_4510dfa3-cc0d-4c23-8b85-c0371b03d4ed">1.3</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i1b0c53cf3bbc4ce2b0088d9820106967_I20220331" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOjQ0YjQ3MWExMTZjYzRjM2E5M2RlYjcxNzdhMTkzM2Y5L3RhYmxlcmFuZ2U6NDRiNDcxYTExNmNjNGMzYTkzZGViNzE3N2ExOTMzZjlfNi0xLTEtMS0xMDExOTA_578a4c2f-99ff-4855-967d-9d74eb1c0614">22.8</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="ie705288cb01f4eac942cb814cdcc8539_I20220331" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOjQ0YjQ3MWExMTZjYzRjM2E5M2RlYjcxNzdhMTkzM2Y5L3RhYmxlcmFuZ2U6NDRiNDcxYTExNmNjNGMzYTkzZGViNzE3N2ExOTMzZjlfNi0zLTEtMS0xMDExOTA_436e3d61-01fa-4519-b2d3-82e699a076b6">—</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i90b3eb87ed804a729b780c80c325ec95_I20220331" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOjQ0YjQ3MWExMTZjYzRjM2E5M2RlYjcxNzdhMTkzM2Y5L3RhYmxlcmFuZ2U6NDRiNDcxYTExNmNjNGMzYTkzZGViNzE3N2ExOTMzZjlfNi01LTEtMS0xMDExOTA_30dc6a81-ccd3-4a6f-b279-dfd1134025fd">22.8</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="idd019a06b4c246fd957d269e918d1c7f_I20220331" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOjQ0YjQ3MWExMTZjYzRjM2E5M2RlYjcxNzdhMTkzM2Y5L3RhYmxlcmFuZ2U6NDRiNDcxYTExNmNjNGMzYTkzZGViNzE3N2ExOTMzZjlfNi03LTEtMS0xMDExOTA_a15f8571-5dae-4c0d-a1a8-685e268d8a57">—</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i61c30e51f61b42949ba7a628fc52c012_I20220331" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOjQ0YjQ3MWExMTZjYzRjM2E5M2RlYjcxNzdhMTkzM2Y5L3RhYmxlcmFuZ2U6NDRiNDcxYTExNmNjNGMzYTkzZGViNzE3N2ExOTMzZjlfNi05LTEtMS0xMDExOTA_e5c0735b-b7b2-49b2-9f47-203d70cf80c1">22.8</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i1b0c53cf3bbc4ce2b0088d9820106967_I20220331" decimals="-5" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOjQ0YjQ3MWExMTZjYzRjM2E5M2RlYjcxNzdhMTkzM2Y5L3RhYmxlcmFuZ2U6NDRiNDcxYTExNmNjNGMzYTkzZGViNzE3N2ExOTMzZjlfOC0xLTEtMS0xMDExOTA_9111179e-9090-488b-a568-c7b909f3a064">43.2</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="ie705288cb01f4eac942cb814cdcc8539_I20220331" decimals="-5" name="us-gaap:DerivativeLiabilitiesNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOjQ0YjQ3MWExMTZjYzRjM2E5M2RlYjcxNzdhMTkzM2Y5L3RhYmxlcmFuZ2U6NDRiNDcxYTExNmNjNGMzYTkzZGViNzE3N2ExOTMzZjlfOC0zLTEtMS0xMDExOTA_58d269dc-4d90-4255-82c5-5c24c8c2a32f">—</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i90b3eb87ed804a729b780c80c325ec95_I20220331" decimals="-5" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOjQ0YjQ3MWExMTZjYzRjM2E5M2RlYjcxNzdhMTkzM2Y5L3RhYmxlcmFuZ2U6NDRiNDcxYTExNmNjNGMzYTkzZGViNzE3N2ExOTMzZjlfOC01LTEtMS0xMDExOTA_662196b0-fca8-4db2-b3ac-26c751c01229">43.2</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="idd019a06b4c246fd957d269e918d1c7f_I20220331" decimals="-5" name="us-gaap:DerivativeLiabilitiesNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOjQ0YjQ3MWExMTZjYzRjM2E5M2RlYjcxNzdhMTkzM2Y5L3RhYmxlcmFuZ2U6NDRiNDcxYTExNmNjNGMzYTkzZGViNzE3N2ExOTMzZjlfOC03LTEtMS0xMDExOTA_755c5f27-4448-4800-9163-730549a39a60">—</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i61c30e51f61b42949ba7a628fc52c012_I20220331" decimals="-5" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOjQ0YjQ3MWExMTZjYzRjM2E5M2RlYjcxNzdhMTkzM2Y5L3RhYmxlcmFuZ2U6NDRiNDcxYTExNmNjNGMzYTkzZGViNzE3N2ExOTMzZjlfOC05LTEtMS0xMDExOTA_fe7b9b90-d4e9-487d-88a8-f8dd93b92784">43.2</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest rate contracts designated as cash flow hedges:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i15a338b1d8b64c4b8581fc06ed807e1c_I20220331" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOjQ0YjQ3MWExMTZjYzRjM2E5M2RlYjcxNzdhMTkzM2Y5L3RhYmxlcmFuZ2U6NDRiNDcxYTExNmNjNGMzYTkzZGViNzE3N2ExOTMzZjlfMTItMS0xLTEtMTAxMTkw_de433479-9bec-49b5-9189-26bc31c35e42">140.0</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib73c403636a344838add9dbff41764e7_I20220331" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOjQ0YjQ3MWExMTZjYzRjM2E5M2RlYjcxNzdhMTkzM2Y5L3RhYmxlcmFuZ2U6NDRiNDcxYTExNmNjNGMzYTkzZGViNzE3N2ExOTMzZjlfMTItMy0xLTEtMTAxMTkw_5e056507-7799-49ca-8f1b-acc1f3a53e13">—</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i67e720cdb81c49559e3089ce9bddce7e_I20220331" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOjQ0YjQ3MWExMTZjYzRjM2E5M2RlYjcxNzdhMTkzM2Y5L3RhYmxlcmFuZ2U6NDRiNDcxYTExNmNjNGMzYTkzZGViNzE3N2ExOTMzZjlfMTItNS0xLTEtMTAxMTkw_4678cf0b-36fe-41fd-a7ea-22b8ec156c21">140.0</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i15d8bcd7898c47f38b255daee09bcfbd_I20220331" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOjQ0YjQ3MWExMTZjYzRjM2E5M2RlYjcxNzdhMTkzM2Y5L3RhYmxlcmFuZ2U6NDRiNDcxYTExNmNjNGMzYTkzZGViNzE3N2ExOTMzZjlfMTItNy0xLTEtMTAxMTkw_01321dd6-ddee-4b59-ac9c-39301daa0bb3">—</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="if5ce482ee1594c5caf8b63533ab11103_I20220331" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOjQ0YjQ3MWExMTZjYzRjM2E5M2RlYjcxNzdhMTkzM2Y5L3RhYmxlcmFuZ2U6NDRiNDcxYTExNmNjNGMzYTkzZGViNzE3N2ExOTMzZjlfMTItOS0xLTEtMTAxMTkw_86f64570-4ebb-4de7-a277-557bec35b94c">140.0</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cross-currency interest rate contracts designated as net investment hedges:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="id5ceec0aa6af470ba4febd83bd9351b7_I20220331" decimals="-5" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOjQ0YjQ3MWExMTZjYzRjM2E5M2RlYjcxNzdhMTkzM2Y5L3RhYmxlcmFuZ2U6NDRiNDcxYTExNmNjNGMzYTkzZGViNzE3N2ExOTMzZjlfMTUtMS0xLTEtMTAxMTkw_951e8792-f845-4b66-9a90-d62d3c8fc012">2.0</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i46c6c88db3ef42f9999f1b565a7c250c_I20220331" decimals="-5" name="us-gaap:DerivativeAssetsCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOjQ0YjQ3MWExMTZjYzRjM2E5M2RlYjcxNzdhMTkzM2Y5L3RhYmxlcmFuZ2U6NDRiNDcxYTExNmNjNGMzYTkzZGViNzE3N2ExOTMzZjlfMTUtMy0xLTEtMTAxMTkw_623822b0-d7db-490a-a464-fe83a0e7693f">—</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i1153bf52ace34cca9d9d545c86b62d46_I20220331" decimals="-5" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOjQ0YjQ3MWExMTZjYzRjM2E5M2RlYjcxNzdhMTkzM2Y5L3RhYmxlcmFuZ2U6NDRiNDcxYTExNmNjNGMzYTkzZGViNzE3N2ExOTMzZjlfMTUtNS0xLTEtMTAxMTkw_37697bfe-6978-4d8f-8685-3840172f9116">2.0</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i752afdfbea6f4b03a309d6ab352210de_I20220331" decimals="-5" name="us-gaap:DerivativeAssetsCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOjQ0YjQ3MWExMTZjYzRjM2E5M2RlYjcxNzdhMTkzM2Y5L3RhYmxlcmFuZ2U6NDRiNDcxYTExNmNjNGMzYTkzZGViNzE3N2ExOTMzZjlfMTUtNy0xLTEtMTAxMTkw_37b700aa-6708-4fb9-9ec4-2bc3d7581f97">—</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib932b535148a40099e28d14ab0c631f2_I20220331" decimals="-5" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOjQ0YjQ3MWExMTZjYzRjM2E5M2RlYjcxNzdhMTkzM2Y5L3RhYmxlcmFuZ2U6NDRiNDcxYTExNmNjNGMzYTkzZGViNzE3N2ExOTMzZjlfMTUtOS0xLTEtMTAxMTkw_16d31a32-5f1c-465c-85e8-1abd6a8af679">2.0</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="id5ceec0aa6af470ba4febd83bd9351b7_I20220331" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOjQ0YjQ3MWExMTZjYzRjM2E5M2RlYjcxNzdhMTkzM2Y5L3RhYmxlcmFuZ2U6NDRiNDcxYTExNmNjNGMzYTkzZGViNzE3N2ExOTMzZjlfMTYtMS0xLTEtMTAxMTkw_734f1a7b-e454-4dd9-ab0c-a127fe6dc11b">40.0</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i46c6c88db3ef42f9999f1b565a7c250c_I20220331" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOjQ0YjQ3MWExMTZjYzRjM2E5M2RlYjcxNzdhMTkzM2Y5L3RhYmxlcmFuZ2U6NDRiNDcxYTExNmNjNGMzYTkzZGViNzE3N2ExOTMzZjlfMTYtMy0xLTEtMTAxMTkw_4d9300b4-e016-4868-b425-ec1781ca02dd">—</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i1153bf52ace34cca9d9d545c86b62d46_I20220331" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOjQ0YjQ3MWExMTZjYzRjM2E5M2RlYjcxNzdhMTkzM2Y5L3RhYmxlcmFuZ2U6NDRiNDcxYTExNmNjNGMzYTkzZGViNzE3N2ExOTMzZjlfMTYtNS0xLTEtMTAxMTkw_dc961048-1ed0-4c5d-8e0a-586f1aa97755">40.0</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i752afdfbea6f4b03a309d6ab352210de_I20220331" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOjQ0YjQ3MWExMTZjYzRjM2E5M2RlYjcxNzdhMTkzM2Y5L3RhYmxlcmFuZ2U6NDRiNDcxYTExNmNjNGMzYTkzZGViNzE3N2ExOTMzZjlfMTYtNy0xLTEtMTAxMTkw_69a8fb4e-53cd-475d-a1e5-46865da6e161">—</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib932b535148a40099e28d14ab0c631f2_I20220331" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOjQ0YjQ3MWExMTZjYzRjM2E5M2RlYjcxNzdhMTkzM2Y5L3RhYmxlcmFuZ2U6NDRiNDcxYTExNmNjNGMzYTkzZGViNzE3N2ExOTMzZjlfMTYtOS0xLTEtMTAxMTkw_3b43b678-99d6-4467-9e11-216f8dbbc905">40.0</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cross-currency interest rate contracts designated as cash flow hedges:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9fedeeac6f904c69bb591eebcd4811df_I20220331" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOjQ0YjQ3MWExMTZjYzRjM2E5M2RlYjcxNzdhMTkzM2Y5L3RhYmxlcmFuZ2U6NDRiNDcxYTExNmNjNGMzYTkzZGViNzE3N2ExOTMzZjlfMjAtMS0xLTEtMTAxMTkw_d05c116a-ae0d-4e1b-a7e5-638f00696bff">40.8</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9484841943ff40d49074806914ce2416_I20220331" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOjQ0YjQ3MWExMTZjYzRjM2E5M2RlYjcxNzdhMTkzM2Y5L3RhYmxlcmFuZ2U6NDRiNDcxYTExNmNjNGMzYTkzZGViNzE3N2ExOTMzZjlfMjAtMy0xLTEtMTAxMTkw_af788594-367f-4726-af6e-edf8b115c0e4">—</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i33291f87ff0141a998a8e9d60c5c0adf_I20220331" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOjQ0YjQ3MWExMTZjYzRjM2E5M2RlYjcxNzdhMTkzM2Y5L3RhYmxlcmFuZ2U6NDRiNDcxYTExNmNjNGMzYTkzZGViNzE3N2ExOTMzZjlfMjAtNS0xLTEtMTAxMTkw_f8edbe9a-be52-43ab-9be7-f1b96d6b238f">40.8</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i5f336fc6bdf04952b388d9114a3b5bf6_I20220331" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOjQ0YjQ3MWExMTZjYzRjM2E5M2RlYjcxNzdhMTkzM2Y5L3RhYmxlcmFuZ2U6NDRiNDcxYTExNmNjNGMzYTkzZGViNzE3N2ExOTMzZjlfMjAtNy0xLTEtMTAxMTkw_16a7e384-cd37-4da3-8da2-7616b9ddacc6">—</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i8e60daf646254f67ba1bd098098518ad_I20220331" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOjQ0YjQ3MWExMTZjYzRjM2E5M2RlYjcxNzdhMTkzM2Y5L3RhYmxlcmFuZ2U6NDRiNDcxYTExNmNjNGMzYTkzZGViNzE3N2ExOTMzZjlfMjAtOS0xLTEtMTAxMTkw_756b6f7b-cd1f-4c6e-a097-3f89875457e8">40.8</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign exchange contracts not designated as hedging instruments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="id8b3dab6b2854200b31c2377ae5286e7_I20220331" decimals="-5" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOjQ0YjQ3MWExMTZjYzRjM2E5M2RlYjcxNzdhMTkzM2Y5L3RhYmxlcmFuZ2U6NDRiNDcxYTExNmNjNGMzYTkzZGViNzE3N2ExOTMzZjlfMjMtMS0xLTEtMTAxMTkw_e29600e2-1f5b-4a84-b302-3750c04c6190">38.8</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="ie5416f90269c42ceb77812d86a4e39d1_I20220331" decimals="-5" name="us-gaap:DerivativeAssetsCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOjQ0YjQ3MWExMTZjYzRjM2E5M2RlYjcxNzdhMTkzM2Y5L3RhYmxlcmFuZ2U6NDRiNDcxYTExNmNjNGMzYTkzZGViNzE3N2ExOTMzZjlfMjMtMy0xLTEtMTAxMTkw_36f7ce51-78dc-43a2-b7b1-c05224daff58">—</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="id3f0ecbad4e644b8b6314ec64ac294e0_I20220331" decimals="-5" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOjQ0YjQ3MWExMTZjYzRjM2E5M2RlYjcxNzdhMTkzM2Y5L3RhYmxlcmFuZ2U6NDRiNDcxYTExNmNjNGMzYTkzZGViNzE3N2ExOTMzZjlfMjMtNS0xLTEtMTAxMTkw_ec49112d-e689-47c1-921c-56fd55b94183">38.8</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="idae3bc9852d245869375a32c18c7262f_I20220331" decimals="-5" name="us-gaap:DerivativeAssetsCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOjQ0YjQ3MWExMTZjYzRjM2E5M2RlYjcxNzdhMTkzM2Y5L3RhYmxlcmFuZ2U6NDRiNDcxYTExNmNjNGMzYTkzZGViNzE3N2ExOTMzZjlfMjMtNy0xLTEtMTAxMTkw_771d8d9e-6c2b-4487-b5c7-3434a74e450c">—</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i35c9b2107aa9480faa03f8d9a9dc6f2c_I20220331" decimals="-5" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOjQ0YjQ3MWExMTZjYzRjM2E5M2RlYjcxNzdhMTkzM2Y5L3RhYmxlcmFuZ2U6NDRiNDcxYTExNmNjNGMzYTkzZGViNzE3N2ExOTMzZjlfMjMtOS0xLTEtMTAxMTkw_2e180937-021a-4afc-8fef-f03ee80e0e7a">38.8</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonfraction unitref="usd" contextref="id8b3dab6b2854200b31c2377ae5286e7_I20220331" decimals="-5" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOjQ0YjQ3MWExMTZjYzRjM2E5M2RlYjcxNzdhMTkzM2Y5L3RhYmxlcmFuZ2U6NDRiNDcxYTExNmNjNGMzYTkzZGViNzE3N2ExOTMzZjlfMjQtMS0xLTEtMTAxMTkw_55383c24-5756-4d18-a12c-d01b9bc80f94">45.8</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="ie5416f90269c42ceb77812d86a4e39d1_I20220331" decimals="-5" name="us-gaap:DerivativeLiabilitiesCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOjQ0YjQ3MWExMTZjYzRjM2E5M2RlYjcxNzdhMTkzM2Y5L3RhYmxlcmFuZ2U6NDRiNDcxYTExNmNjNGMzYTkzZGViNzE3N2ExOTMzZjlfMjQtMy0xLTEtMTAxMTkw_b2c236b4-d437-4b90-8137-64e66f79de3d">—</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonfraction unitref="usd" contextref="id3f0ecbad4e644b8b6314ec64ac294e0_I20220331" decimals="-5" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOjQ0YjQ3MWExMTZjYzRjM2E5M2RlYjcxNzdhMTkzM2Y5L3RhYmxlcmFuZ2U6NDRiNDcxYTExNmNjNGMzYTkzZGViNzE3N2ExOTMzZjlfMjQtNS0xLTEtMTAxMTkw_ae19e048-9890-4f6b-99a7-e55e70e75caf">45.8</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="idae3bc9852d245869375a32c18c7262f_I20220331" decimals="-5" name="us-gaap:DerivativeLiabilitiesCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOjQ0YjQ3MWExMTZjYzRjM2E5M2RlYjcxNzdhMTkzM2Y5L3RhYmxlcmFuZ2U6NDRiNDcxYTExNmNjNGMzYTkzZGViNzE3N2ExOTMzZjlfMjQtNy0xLTEtMTAxMTkw_abf7cbbc-c3d3-40c2-b44e-75a7ef48822e">—</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i35c9b2107aa9480faa03f8d9a9dc6f2c_I20220331" decimals="-5" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOjQ0YjQ3MWExMTZjYzRjM2E5M2RlYjcxNzdhMTkzM2Y5L3RhYmxlcmFuZ2U6NDRiNDcxYTExNmNjNGMzYTkzZGViNzE3N2ExOTMzZjlfMjQtOS0xLTEtMTAxMTkw_db2645c8-3950-4895-b706-81ba90414b35">45.8</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingent consideration liability:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i73af0f98be8b48e58557bf37c81c9e74_I20220331" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOjQ0YjQ3MWExMTZjYzRjM2E5M2RlYjcxNzdhMTkzM2Y5L3RhYmxlcmFuZ2U6NDRiNDcxYTExNmNjNGMzYTkzZGViNzE3N2ExOTMzZjlfMjktMS0xLTEtMTAxMTkw_df793fa0-613f-4a34-86cb-bd52b9192d2a">70.0</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="idb4c476afbc64873b3c0511107fc85c9_I20220331" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOjQ0YjQ3MWExMTZjYzRjM2E5M2RlYjcxNzdhMTkzM2Y5L3RhYmxlcmFuZ2U6NDRiNDcxYTExNmNjNGMzYTkzZGViNzE3N2ExOTMzZjlfMjktMy0xLTEtMTAxMTkw_0c2b1c21-6101-4072-aa62-ba8a2eed8a95">—</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i553170707dac4ba4befbf57021e9352d_I20220331" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOjQ0YjQ3MWExMTZjYzRjM2E5M2RlYjcxNzdhMTkzM2Y5L3RhYmxlcmFuZ2U6NDRiNDcxYTExNmNjNGMzYTkzZGViNzE3N2ExOTMzZjlfMjktNS0xLTEtMTAxMTkw_017f2960-2b5a-443f-994d-87690907e2a2">—</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i8196778f6b68404d98e4bc74190f4322_I20220331" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOjQ0YjQ3MWExMTZjYzRjM2E5M2RlYjcxNzdhMTkzM2Y5L3RhYmxlcmFuZ2U6NDRiNDcxYTExNmNjNGMzYTkzZGViNzE3N2ExOTMzZjlfMjktNy0xLTEtMTAxMTkw_d60b6681-e96a-4a09-9a28-c5e7a7bf9a8b">70.0</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i67e65f1325bd4d80b077bdc7713893b6_I20220331" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOjQ0YjQ3MWExMTZjYzRjM2E5M2RlYjcxNzdhMTkzM2Y5L3RhYmxlcmFuZ2U6NDRiNDcxYTExNmNjNGMzYTkzZGViNzE3N2ExOTMzZjlfMjktOS0xLTEtMTAxMTkw_48e6633c-5c64-4804-a32c-58aba206e28d">70.0</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Risk-management instruments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest rate contracts designated as fair value hedges:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other receivables</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i8f358a15c5374d8b9337b6d1bda3a0e2_I20211231" decimals="-5" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOjQ0YjQ3MWExMTZjYzRjM2E5M2RlYjcxNzdhMTkzM2Y5L3RhYmxlcmFuZ2U6NDRiNDcxYTExNmNjNGMzYTkzZGViNzE3N2ExOTMzZjlfMzQtMS0xLTEtMTAxMTkw_a3eb9a7a-650b-4f03-8e95-eb18c3e16b9b">4.8</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib063d25db70a4bb5b2ef696367833f00_I20211231" decimals="-5" name="us-gaap:DerivativeAssetsCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOjQ0YjQ3MWExMTZjYzRjM2E5M2RlYjcxNzdhMTkzM2Y5L3RhYmxlcmFuZ2U6NDRiNDcxYTExNmNjNGMzYTkzZGViNzE3N2ExOTMzZjlfMzQtMy0xLTEtMTAxMTkw_393d2d0c-15f2-49e8-be18-368890591ff6">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iee84f80dd4fc4d8281169e60c43c5a54_I20211231" decimals="-5" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOjQ0YjQ3MWExMTZjYzRjM2E5M2RlYjcxNzdhMTkzM2Y5L3RhYmxlcmFuZ2U6NDRiNDcxYTExNmNjNGMzYTkzZGViNzE3N2ExOTMzZjlfMzQtNS0xLTEtMTAxMTkw_d5d16ad0-893e-4f01-b5a6-1a0a4757d451">4.8</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i8169a9d6879d467b997551d79352b58b_I20211231" decimals="-5" name="us-gaap:DerivativeAssetsCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOjQ0YjQ3MWExMTZjYzRjM2E5M2RlYjcxNzdhMTkzM2Y5L3RhYmxlcmFuZ2U6NDRiNDcxYTExNmNjNGMzYTkzZGViNzE3N2ExOTMzZjlfMzQtNy0xLTEtMTAxMTkw_7ccc7995-23f7-483a-8717-120caeca4797">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="idd4227079f864f90a4b351adbc448ca3_I20211231" decimals="-5" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOjQ0YjQ3MWExMTZjYzRjM2E5M2RlYjcxNzdhMTkzM2Y5L3RhYmxlcmFuZ2U6NDRiNDcxYTExNmNjNGMzYTkzZGViNzE3N2ExOTMzZjlfMzQtOS0xLTEtMTAxMTkw_0632d032-5e37-45a5-bbfa-6482dee01838">4.8</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i8f358a15c5374d8b9337b6d1bda3a0e2_I20211231" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOjQ0YjQ3MWExMTZjYzRjM2E5M2RlYjcxNzdhMTkzM2Y5L3RhYmxlcmFuZ2U6NDRiNDcxYTExNmNjNGMzYTkzZGViNzE3N2ExOTMzZjlfMzUtMS0xLTEtMTAxMTkw_d398ac8c-a070-4718-911d-c9b7168cd497">78.3</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib063d25db70a4bb5b2ef696367833f00_I20211231" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOjQ0YjQ3MWExMTZjYzRjM2E5M2RlYjcxNzdhMTkzM2Y5L3RhYmxlcmFuZ2U6NDRiNDcxYTExNmNjNGMzYTkzZGViNzE3N2ExOTMzZjlfMzUtMy0xLTEtMTAxMTkw_f77dfb75-e7cf-4427-9dec-45efe5d7c34b">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iee84f80dd4fc4d8281169e60c43c5a54_I20211231" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOjQ0YjQ3MWExMTZjYzRjM2E5M2RlYjcxNzdhMTkzM2Y5L3RhYmxlcmFuZ2U6NDRiNDcxYTExNmNjNGMzYTkzZGViNzE3N2ExOTMzZjlfMzUtNS0xLTEtMTAxMTkw_d8af619b-5b18-4824-988e-1472198e174f">78.3</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i8169a9d6879d467b997551d79352b58b_I20211231" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOjQ0YjQ3MWExMTZjYzRjM2E5M2RlYjcxNzdhMTkzM2Y5L3RhYmxlcmFuZ2U6NDRiNDcxYTExNmNjNGMzYTkzZGViNzE3N2ExOTMzZjlfMzUtNy0xLTEtMTAxMTkw_e3579215-3967-4c9f-a6b6-39acd4013573">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="idd4227079f864f90a4b351adbc448ca3_I20211231" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOjQ0YjQ3MWExMTZjYzRjM2E5M2RlYjcxNzdhMTkzM2Y5L3RhYmxlcmFuZ2U6NDRiNDcxYTExNmNjNGMzYTkzZGViNzE3N2ExOTMzZjlfMzUtOS0xLTEtMTAxMTkw_a57ae3dc-72ec-4487-a97d-24197a8d444b">78.3</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i8f358a15c5374d8b9337b6d1bda3a0e2_I20211231" decimals="-5" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOjQ0YjQ3MWExMTZjYzRjM2E5M2RlYjcxNzdhMTkzM2Y5L3RhYmxlcmFuZ2U6NDRiNDcxYTExNmNjNGMzYTkzZGViNzE3N2ExOTMzZjlfMzctMS0xLTEtMTAxMTkw_a70bca90-d9e0-4365-b6a5-926775e10e94">7.6</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib063d25db70a4bb5b2ef696367833f00_I20211231" decimals="-5" name="us-gaap:DerivativeLiabilitiesNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOjQ0YjQ3MWExMTZjYzRjM2E5M2RlYjcxNzdhMTkzM2Y5L3RhYmxlcmFuZ2U6NDRiNDcxYTExNmNjNGMzYTkzZGViNzE3N2ExOTMzZjlfMzctMy0xLTEtMTAxMTkw_8f4abf89-fc0e-46f6-ac29-d42a620c4017">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="iee84f80dd4fc4d8281169e60c43c5a54_I20211231" decimals="-5" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOjQ0YjQ3MWExMTZjYzRjM2E5M2RlYjcxNzdhMTkzM2Y5L3RhYmxlcmFuZ2U6NDRiNDcxYTExNmNjNGMzYTkzZGViNzE3N2ExOTMzZjlfMzctNS0xLTEtMTAxMTkw_67bfb542-e0ec-4331-a295-794307c5e178">7.6</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i8169a9d6879d467b997551d79352b58b_I20211231" decimals="-5" name="us-gaap:DerivativeLiabilitiesNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOjQ0YjQ3MWExMTZjYzRjM2E5M2RlYjcxNzdhMTkzM2Y5L3RhYmxlcmFuZ2U6NDRiNDcxYTExNmNjNGMzYTkzZGViNzE3N2ExOTMzZjlfMzctNy0xLTEtMTAxMTkw_41aa1153-9ac6-4554-b8af-91f0e550c1cf">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="idd4227079f864f90a4b351adbc448ca3_I20211231" decimals="-5" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOjQ0YjQ3MWExMTZjYzRjM2E5M2RlYjcxNzdhMTkzM2Y5L3RhYmxlcmFuZ2U6NDRiNDcxYTExNmNjNGMzYTkzZGViNzE3N2ExOTMzZjlfMzctOS0xLTEtMTAxMTkw_e1b5f942-7d8f-49cb-816b-6b2d6dc93ffb">7.6</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest rate contracts designated as cash flow hedges:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ieaa23265a66a4df78c59df1973ab2cee_I20211231" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOjQ0YjQ3MWExMTZjYzRjM2E5M2RlYjcxNzdhMTkzM2Y5L3RhYmxlcmFuZ2U6NDRiNDcxYTExNmNjNGMzYTkzZGViNzE3N2ExOTMzZjlfMzktMS0xLTEtMTAxMTkw_f6e708b8-38f7-4764-b979-0d6942814091">49.2</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i2e94417f504d46f6bba5032802f9b4c8_I20211231" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOjQ0YjQ3MWExMTZjYzRjM2E5M2RlYjcxNzdhMTkzM2Y5L3RhYmxlcmFuZ2U6NDRiNDcxYTExNmNjNGMzYTkzZGViNzE3N2ExOTMzZjlfMzktMy0xLTEtMTAxMTkw_6538d08f-7fff-4b15-b4f9-353968e9d7fe">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ibc03d36e65aa438d82422c7c99d33275_I20211231" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOjQ0YjQ3MWExMTZjYzRjM2E5M2RlYjcxNzdhMTkzM2Y5L3RhYmxlcmFuZ2U6NDRiNDcxYTExNmNjNGMzYTkzZGViNzE3N2ExOTMzZjlfMzktNS0xLTEtMTAxMTkw_15d75017-53fd-4f5f-89db-db79d3f167b5">49.2</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ifa1749e8dfab4045a30fa5aba1fdaa8b_I20211231" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOjQ0YjQ3MWExMTZjYzRjM2E5M2RlYjcxNzdhMTkzM2Y5L3RhYmxlcmFuZ2U6NDRiNDcxYTExNmNjNGMzYTkzZGViNzE3N2ExOTMzZjlfMzktNy0xLTEtMTAxMTkw_651251ed-6311-4e9c-ae2f-18d648b06f21">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="icb157ecfd611468fbdf0a25b1b443709_I20211231" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOjQ0YjQ3MWExMTZjYzRjM2E5M2RlYjcxNzdhMTkzM2Y5L3RhYmxlcmFuZ2U6NDRiNDcxYTExNmNjNGMzYTkzZGViNzE3N2ExOTMzZjlfMzktOS0xLTEtMTAxMTkw_3aa37ca5-1028-487b-ba0e-80baf012c251">49.2</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ieaa23265a66a4df78c59df1973ab2cee_I20211231" decimals="-5" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOjQ0YjQ3MWExMTZjYzRjM2E5M2RlYjcxNzdhMTkzM2Y5L3RhYmxlcmFuZ2U6NDRiNDcxYTExNmNjNGMzYTkzZGViNzE3N2ExOTMzZjlfNDAtMS0xLTEtMTAxMTkw_58ca2391-8e26-4cc2-9ec7-6355b3fca63e">31.7</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i2e94417f504d46f6bba5032802f9b4c8_I20211231" decimals="-5" name="us-gaap:DerivativeLiabilitiesNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOjQ0YjQ3MWExMTZjYzRjM2E5M2RlYjcxNzdhMTkzM2Y5L3RhYmxlcmFuZ2U6NDRiNDcxYTExNmNjNGMzYTkzZGViNzE3N2ExOTMzZjlfNDAtMy0xLTEtMTAxMTkw_19791520-035f-4b04-a70c-a292b6e51eba">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ibc03d36e65aa438d82422c7c99d33275_I20211231" decimals="-5" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOjQ0YjQ3MWExMTZjYzRjM2E5M2RlYjcxNzdhMTkzM2Y5L3RhYmxlcmFuZ2U6NDRiNDcxYTExNmNjNGMzYTkzZGViNzE3N2ExOTMzZjlfNDAtNS0xLTEtMTAxMTkw_2a8cae6e-586a-4294-a162-96f354e92dfe">31.7</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ifa1749e8dfab4045a30fa5aba1fdaa8b_I20211231" decimals="-5" name="us-gaap:DerivativeLiabilitiesNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOjQ0YjQ3MWExMTZjYzRjM2E5M2RlYjcxNzdhMTkzM2Y5L3RhYmxlcmFuZ2U6NDRiNDcxYTExNmNjNGMzYTkzZGViNzE3N2ExOTMzZjlfNDAtNy0xLTEtMTAxMTkw_dd0814cf-4821-463f-9da8-0058619cac8e">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="icb157ecfd611468fbdf0a25b1b443709_I20211231" decimals="-5" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOjQ0YjQ3MWExMTZjYzRjM2E5M2RlYjcxNzdhMTkzM2Y5L3RhYmxlcmFuZ2U6NDRiNDcxYTExNmNjNGMzYTkzZGViNzE3N2ExOTMzZjlfNDAtOS0xLTEtMTAxMTkw_6e1ee33c-f223-4d55-8dd0-356030b88a1b">31.7</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cross-currency interest rate contracts designated as net investment hedges:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib9f55f34e7464cbf99b53e10ca29e690_I20211231" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOjQ0YjQ3MWExMTZjYzRjM2E5M2RlYjcxNzdhMTkzM2Y5L3RhYmxlcmFuZ2U6NDRiNDcxYTExNmNjNGMzYTkzZGViNzE3N2ExOTMzZjlfNDMtMS0xLTEtMTA0ODQ4_6aae6822-8317-467d-9c73-ee0f46f674d3">31.3</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i83b45056f8d64c44b68eb6b178ffd19e_I20211231" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOjQ0YjQ3MWExMTZjYzRjM2E5M2RlYjcxNzdhMTkzM2Y5L3RhYmxlcmFuZ2U6NDRiNDcxYTExNmNjNGMzYTkzZGViNzE3N2ExOTMzZjlfNDMtMy0xLTEtMTA0ODUw_e63102fb-a7c6-4bd8-a2f8-dad604804b7b">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ica34877b024d402f9950cd7d89e1f8fc_I20211231" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOjQ0YjQ3MWExMTZjYzRjM2E5M2RlYjcxNzdhMTkzM2Y5L3RhYmxlcmFuZ2U6NDRiNDcxYTExNmNjNGMzYTkzZGViNzE3N2ExOTMzZjlfNDMtNS0xLTEtMTA0ODUw_bfe4b006-8299-445b-b7ba-a5e84c32c922">31.3</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i993d0e5455db4d1caaa238631c27b402_I20211231" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOjQ0YjQ3MWExMTZjYzRjM2E5M2RlYjcxNzdhMTkzM2Y5L3RhYmxlcmFuZ2U6NDRiNDcxYTExNmNjNGMzYTkzZGViNzE3N2ExOTMzZjlfNDMtNy0xLTEtMTA0ODUw_002a7a58-9f84-4f5d-8458-65f0888dde51">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i059a5554f48641c19638a78710ad6041_I20211231" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOjQ0YjQ3MWExMTZjYzRjM2E5M2RlYjcxNzdhMTkzM2Y5L3RhYmxlcmFuZ2U6NDRiNDcxYTExNmNjNGMzYTkzZGViNzE3N2ExOTMzZjlfNDMtOS0xLTEtMTA0ODUw_595460f3-11f4-4559-9a7d-11d4fca78fc6">31.3</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ib9f55f34e7464cbf99b53e10ca29e690_I20211231" decimals="-5" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOjQ0YjQ3MWExMTZjYzRjM2E5M2RlYjcxNzdhMTkzM2Y5L3RhYmxlcmFuZ2U6NDRiNDcxYTExNmNjNGMzYTkzZGViNzE3N2ExOTMzZjlfNDMtMS0xLTEtMTAxMTkw_c025bde6-fff8-4724-9d05-05bdf9be8037">1.2</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i83b45056f8d64c44b68eb6b178ffd19e_I20211231" decimals="-5" name="us-gaap:DerivativeLiabilitiesCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOjQ0YjQ3MWExMTZjYzRjM2E5M2RlYjcxNzdhMTkzM2Y5L3RhYmxlcmFuZ2U6NDRiNDcxYTExNmNjNGMzYTkzZGViNzE3N2ExOTMzZjlfNDMtMy0xLTEtMTAxMTkw_8ee0380e-b80d-4538-ae7c-3c8bdbbbebeb">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ica34877b024d402f9950cd7d89e1f8fc_I20211231" decimals="-5" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOjQ0YjQ3MWExMTZjYzRjM2E5M2RlYjcxNzdhMTkzM2Y5L3RhYmxlcmFuZ2U6NDRiNDcxYTExNmNjNGMzYTkzZGViNzE3N2ExOTMzZjlfNDMtNS0xLTEtMTAxMTkw_67761d8f-007b-4292-8570-6711b17cbd06">1.2</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i993d0e5455db4d1caaa238631c27b402_I20211231" decimals="-5" name="us-gaap:DerivativeLiabilitiesCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOjQ0YjQ3MWExMTZjYzRjM2E5M2RlYjcxNzdhMTkzM2Y5L3RhYmxlcmFuZ2U6NDRiNDcxYTExNmNjNGMzYTkzZGViNzE3N2ExOTMzZjlfNDMtNy0xLTEtMTAxMTkw_742e5cf2-9314-4dda-b37f-e55fe73666bd">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i059a5554f48641c19638a78710ad6041_I20211231" decimals="-5" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOjQ0YjQ3MWExMTZjYzRjM2E5M2RlYjcxNzdhMTkzM2Y5L3RhYmxlcmFuZ2U6NDRiNDcxYTExNmNjNGMzYTkzZGViNzE3N2ExOTMzZjlfNDMtOS0xLTEtMTAxMTkw_e77706e2-867e-49e5-ae84-b3203da1ab5b">1.2</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cross-currency interest rate contracts designated as cash flow hedges:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ifa73eac40d6e41218971b531ff4c7c06_I20211231" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOjQ0YjQ3MWExMTZjYzRjM2E5M2RlYjcxNzdhMTkzM2Y5L3RhYmxlcmFuZ2U6NDRiNDcxYTExNmNjNGMzYTkzZGViNzE3N2ExOTMzZjlfNDYtMS0xLTEtMTAxMTkw_c0e644d0-38ad-46d1-9a92-24d75db51bdd">33.2</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i635cffe5cb0a488aae4370830bbf2b7f_I20211231" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOjQ0YjQ3MWExMTZjYzRjM2E5M2RlYjcxNzdhMTkzM2Y5L3RhYmxlcmFuZ2U6NDRiNDcxYTExNmNjNGMzYTkzZGViNzE3N2ExOTMzZjlfNDYtMy0xLTEtMTAxMTkw_a9ad6e12-ab58-41f1-804d-28d7ba7e3813">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i06befc950b3d460380094acd10fef0ea_I20211231" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOjQ0YjQ3MWExMTZjYzRjM2E5M2RlYjcxNzdhMTkzM2Y5L3RhYmxlcmFuZ2U6NDRiNDcxYTExNmNjNGMzYTkzZGViNzE3N2ExOTMzZjlfNDYtNS0xLTEtMTAxMTkw_1622211c-52b6-4b04-a95e-af05abffdd61">33.2</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ida06c794ac1f401ca313cd702ce80350_I20211231" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOjQ0YjQ3MWExMTZjYzRjM2E5M2RlYjcxNzdhMTkzM2Y5L3RhYmxlcmFuZ2U6NDRiNDcxYTExNmNjNGMzYTkzZGViNzE3N2ExOTMzZjlfNDYtNy0xLTEtMTAxMTkw_6f15f917-4fd5-48bc-ae90-2e6533722275">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i28e231c95c1548ae9f732a3057e2aa34_I20211231" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOjQ0YjQ3MWExMTZjYzRjM2E5M2RlYjcxNzdhMTkzM2Y5L3RhYmxlcmFuZ2U6NDRiNDcxYTExNmNjNGMzYTkzZGViNzE3N2ExOTMzZjlfNDYtOS0xLTEtMTAxMTkw_ea548ac4-da6d-4f20-8f83-6932f817b731">33.2</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ifa73eac40d6e41218971b531ff4c7c06_I20211231" decimals="-5" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOjQ0YjQ3MWExMTZjYzRjM2E5M2RlYjcxNzdhMTkzM2Y5L3RhYmxlcmFuZ2U6NDRiNDcxYTExNmNjNGMzYTkzZGViNzE3N2ExOTMzZjlfNDctMS0xLTEtMTAxMTkw_d0971a81-6df9-456b-a95d-e801b3587dfd">1.3</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i635cffe5cb0a488aae4370830bbf2b7f_I20211231" decimals="-5" name="us-gaap:DerivativeLiabilitiesNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOjQ0YjQ3MWExMTZjYzRjM2E5M2RlYjcxNzdhMTkzM2Y5L3RhYmxlcmFuZ2U6NDRiNDcxYTExNmNjNGMzYTkzZGViNzE3N2ExOTMzZjlfNDctMy0xLTEtMTAxMTkw_6f985c64-e504-4a59-9f1c-c887519cbb87">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i06befc950b3d460380094acd10fef0ea_I20211231" decimals="-5" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOjQ0YjQ3MWExMTZjYzRjM2E5M2RlYjcxNzdhMTkzM2Y5L3RhYmxlcmFuZ2U6NDRiNDcxYTExNmNjNGMzYTkzZGViNzE3N2ExOTMzZjlfNDctNS0xLTEtMTAxMTkw_9007adab-edd2-4fe3-b40a-3abdb5c12c47">1.3</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ida06c794ac1f401ca313cd702ce80350_I20211231" decimals="-5" name="us-gaap:DerivativeLiabilitiesNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOjQ0YjQ3MWExMTZjYzRjM2E5M2RlYjcxNzdhMTkzM2Y5L3RhYmxlcmFuZ2U6NDRiNDcxYTExNmNjNGMzYTkzZGViNzE3N2ExOTMzZjlfNDctNy0xLTEtMTAxMTkw_b92dac9f-0ceb-4e89-8bba-4ae5bec38a94">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i28e231c95c1548ae9f732a3057e2aa34_I20211231" decimals="-5" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOjQ0YjQ3MWExMTZjYzRjM2E5M2RlYjcxNzdhMTkzM2Y5L3RhYmxlcmFuZ2U6NDRiNDcxYTExNmNjNGMzYTkzZGViNzE3N2ExOTMzZjlfNDctOS0xLTEtMTAxMTkw_af0d34e6-5acc-44ee-96d1-fb289d094a32">1.3</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign exchange contracts not designated as hedging instruments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i41d7aecaba42417c9eaf6014e9de28d4_I20211231" decimals="-5" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOjQ0YjQ3MWExMTZjYzRjM2E5M2RlYjcxNzdhMTkzM2Y5L3RhYmxlcmFuZ2U6NDRiNDcxYTExNmNjNGMzYTkzZGViNzE3N2ExOTMzZjlfNDktMS0xLTEtMTAxMTkw_d238f7cb-f395-4eca-9497-b4862ee5d847">9.9</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i06a5c9f5caaf42bda6efa2553d69242d_I20211231" decimals="-5" name="us-gaap:DerivativeAssetsCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOjQ0YjQ3MWExMTZjYzRjM2E5M2RlYjcxNzdhMTkzM2Y5L3RhYmxlcmFuZ2U6NDRiNDcxYTExNmNjNGMzYTkzZGViNzE3N2ExOTMzZjlfNDktMy0xLTEtMTAxMTkw_3e3d719d-6f73-48c5-b2d6-aaa206c9ab99">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if05a6befb26d44c8b18173cbe6bfebe4_I20211231" decimals="-5" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOjQ0YjQ3MWExMTZjYzRjM2E5M2RlYjcxNzdhMTkzM2Y5L3RhYmxlcmFuZ2U6NDRiNDcxYTExNmNjNGMzYTkzZGViNzE3N2ExOTMzZjlfNDktNS0xLTEtMTAxMTkw_846ca637-c119-494f-9cde-c08a611ab92f">9.9</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i60d888d2d36d4cfe8406ddf920c43cc6_I20211231" decimals="-5" name="us-gaap:DerivativeAssetsCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOjQ0YjQ3MWExMTZjYzRjM2E5M2RlYjcxNzdhMTkzM2Y5L3RhYmxlcmFuZ2U6NDRiNDcxYTExNmNjNGMzYTkzZGViNzE3N2ExOTMzZjlfNDktNy0xLTEtMTAxMTkw_ae3abe65-0db0-4152-9e23-bbafc24b8d6a">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ieb838166e0e24a87b90113adf849abf5_I20211231" decimals="-5" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOjQ0YjQ3MWExMTZjYzRjM2E5M2RlYjcxNzdhMTkzM2Y5L3RhYmxlcmFuZ2U6NDRiNDcxYTExNmNjNGMzYTkzZGViNzE3N2ExOTMzZjlfNDktOS0xLTEtMTAxMTkw_5cbdb44a-cc91-4952-8076-055657222492">9.9</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i41d7aecaba42417c9eaf6014e9de28d4_I20211231" decimals="-5" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOjQ0YjQ3MWExMTZjYzRjM2E5M2RlYjcxNzdhMTkzM2Y5L3RhYmxlcmFuZ2U6NDRiNDcxYTExNmNjNGMzYTkzZGViNzE3N2ExOTMzZjlfNTAtMS0xLTEtMTAxMTkw_36232fd6-418a-435b-8a8f-0821d2cc89f8">35.3</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i06a5c9f5caaf42bda6efa2553d69242d_I20211231" decimals="-5" name="us-gaap:DerivativeLiabilitiesCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOjQ0YjQ3MWExMTZjYzRjM2E5M2RlYjcxNzdhMTkzM2Y5L3RhYmxlcmFuZ2U6NDRiNDcxYTExNmNjNGMzYTkzZGViNzE3N2ExOTMzZjlfNTAtMy0xLTEtMTAxMTkw_5570bfb5-7a36-4352-ba48-9b5b6a2587fb">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="if05a6befb26d44c8b18173cbe6bfebe4_I20211231" decimals="-5" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOjQ0YjQ3MWExMTZjYzRjM2E5M2RlYjcxNzdhMTkzM2Y5L3RhYmxlcmFuZ2U6NDRiNDcxYTExNmNjNGMzYTkzZGViNzE3N2ExOTMzZjlfNTAtNS0xLTEtMTAxMTkw_24560dab-feda-46bf-b824-5a07373bc47a">35.3</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i60d888d2d36d4cfe8406ddf920c43cc6_I20211231" decimals="-5" name="us-gaap:DerivativeLiabilitiesCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOjQ0YjQ3MWExMTZjYzRjM2E5M2RlYjcxNzdhMTkzM2Y5L3RhYmxlcmFuZ2U6NDRiNDcxYTExNmNjNGMzYTkzZGViNzE3N2ExOTMzZjlfNTAtNy0xLTEtMTAxMTkw_ceb8f0d6-312b-4d74-b2e8-2befb00b62d3">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ieb838166e0e24a87b90113adf849abf5_I20211231" decimals="-5" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOjQ0YjQ3MWExMTZjYzRjM2E5M2RlYjcxNzdhMTkzM2Y5L3RhYmxlcmFuZ2U6NDRiNDcxYTExNmNjNGMzYTkzZGViNzE3N2ExOTMzZjlfNTAtOS0xLTEtMTAxMTkw_6a374079-13e5-41b9-8434-db77b9ce541d">35.3</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingent consideration liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i057515f5782941809af8fac0ad822ddf_I20211231" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOjQ0YjQ3MWExMTZjYzRjM2E5M2RlYjcxNzdhMTkzM2Y5L3RhYmxlcmFuZ2U6NDRiNDcxYTExNmNjNGMzYTkzZGViNzE3N2ExOTMzZjlfNTMtMS0xLTEtMTAxMTkw_976c226b-e2ba-4306-9449-8f2e876f7f7e">70.5</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ic769458ef1cb403f8d92df4e02a545c7_I20211231" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOjQ0YjQ3MWExMTZjYzRjM2E5M2RlYjcxNzdhMTkzM2Y5L3RhYmxlcmFuZ2U6NDRiNDcxYTExNmNjNGMzYTkzZGViNzE3N2ExOTMzZjlfNTMtMy0xLTEtMTAxMTkw_484b3f92-8a7c-47dc-b2f2-8e241b535342">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i2ada8ba658a948af9bb22996a9eab24d_I20211231" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOjQ0YjQ3MWExMTZjYzRjM2E5M2RlYjcxNzdhMTkzM2Y5L3RhYmxlcmFuZ2U6NDRiNDcxYTExNmNjNGMzYTkzZGViNzE3N2ExOTMzZjlfNTMtNS0xLTEtMTAxMTkw_64256fa7-e4a2-49c2-867f-5878b9ff9bbd">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="iccf68abee8b64588b494d4d0bcd59e25_I20211231" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOjQ0YjQ3MWExMTZjYzRjM2E5M2RlYjcxNzdhMTkzM2Y5L3RhYmxlcmFuZ2U6NDRiNDcxYTExNmNjNGMzYTkzZGViNzE3N2ExOTMzZjlfNTMtNy0xLTEtMTAxMTkw_5bbe2663-6276-40bc-b0ba-20147d14899c">70.5</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i298284fbe5094d049bf7ed6517060de9_I20211231" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOjQ0YjQ3MWExMTZjYzRjM2E5M2RlYjcxNzdhMTkzM2Y5L3RhYmxlcmFuZ2U6NDRiNDcxYTExNmNjNGMzYTkzZGViNzE3N2ExOTMzZjlfNTMtOS0xLTEtMTAxMTkw_716de8a9-8009-4817-a7ef-57eb7bfb542e">70.5</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></tbody></table></ix:nonnumeric></ix:continuation></div><div><span><br></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span><br></span></div></div><ix:continuation id="i9d4e2c16aa094337b03faa0cd6470bdc" continuedat="i22c74d160e2c41fb9c2222f9e59613e4"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk-management instruments above are disclosed on a gross basis. There are various rights of setoff associated with certain of the risk-management instruments above that are subject to enforceable master netting arrangements or similar agreements. Although various rights of setoff and master netting arrangements or similar agreements may exist with the individual counterparties to the risk-management instruments above, individually, these financial rights are not material.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine our Level 1 and Level 2 fair value measurements based on a market approach using quoted market values, significant other observable inputs for identical or comparable assets or liabilities, or discounted cash flow analyses. Level 3 fair value measurements for other investment securities are determined using unobservable inputs, including the investments' cost adjusted for impairments and price changes from orderly transactions. Fair values are not readily available for certain equity investments measured under the measurement alternative. As of March&nbsp;31, 2022, we had approximately $<ix:nonfraction unitref="usd" contextref="ib1053442369e460291956c51ab7e5179_I20220331" decimals="-6" name="us-gaap:FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RleHRyZWdpb246NWNkZmEwZDVmNzVlNGY2N2E1ZTQ0NjAxMTQ3MmJlNWZfMTE3MTk_5a85840d-9e01-4f77-a7d4-cecef9cc653f">843</ix:nonfraction> million of unfunded commitments to invest in venture capital funds, which we anticipate will be paid over a period of up to <ix:nonnumeric contextref="id879b497a407453985551e83dbee75f8_D20220101-20220331" name="lly:FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommitmentsPaymentPeriod" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RleHRyZWdpb246NWNkZmEwZDVmNzVlNGY2N2E1ZTQ0NjAxMTQ3MmJlNWZfMTE4Mzg_9722cdce-b6ee-4bc2-ac35-46c9c442b4dc">10</ix:nonnumeric> years. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contingent consideration liability relates to our liability arising in connection with the CVR issued as a result of the Prevail acquisition. The fair value of the CVR liability was estimated using a discounted cash flow analysis and Level 3 inputs, including projections representative of a market participant's view of the expected cash payment associated with the first potential regulatory approval of a Prevail compound in the applicable countries based on probabilities of technical success, timing of the potential approval events for the compounds, and an estimated discount rate. See Note 3 for additional information related to the CVR arrangement. </span></div><ix:nonnumeric contextref="id879b497a407453985551e83dbee75f8_D20220101-20220331" name="us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RleHRyZWdpb246NWNkZmEwZDVmNzVlNGY2N2E1ZTQ0NjAxMTQ3MmJlNWZfMTYzMDQ_1758c336-8f7b-41a1-afe8-7c3f9f63c9aa" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes the contractual maturities of our investments in debt securities measured at fair value as of March&nbsp;31, 2022:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tbody><tr><td style="width:1.0%"></td><td style="width:40.162%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.060%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.060%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.060%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.060%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.062%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maturities by Period</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Less&nbsp;Than<br>1 Year</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1-5<br>Years</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">6-10<br>Years</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">More&nbsp;Than<br>10 Years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of debt securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib1053442369e460291956c51ab7e5179_I20220331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOmEwMDBmODg5MzJkMDQwN2Y5ZWRhMWExOTZmYTBjNmJhL3RhYmxlcmFuZ2U6YTAwMGY4ODkzMmQwNDA3ZjllZGExYTE5NmZhMGM2YmFfMi0xLTEtMS0xMDExOTA_0931a88e-e0f1-4de3-a080-18ec298cc603">567.1</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib1053442369e460291956c51ab7e5179_I20220331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOmEwMDBmODg5MzJkMDQwN2Y5ZWRhMWExOTZmYTBjNmJhL3RhYmxlcmFuZ2U6YTAwMGY4ODkzMmQwNDA3ZjllZGExYTE5NmZhMGM2YmFfMi0zLTEtMS0xMDExOTA_584d7fc8-0a52-4f69-b284-27e9945d23c8">98.9</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib1053442369e460291956c51ab7e5179_I20220331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOmEwMDBmODg5MzJkMDQwN2Y5ZWRhMWExOTZmYTBjNmJhL3RhYmxlcmFuZ2U6YTAwMGY4ODkzMmQwNDA3ZjllZGExYTE5NmZhMGM2YmFfMi01LTEtMS0xMDExOTA_216161ff-fbe9-49e9-b641-cda8465c04cf">197.7</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib1053442369e460291956c51ab7e5179_I20220331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOmEwMDBmODg5MzJkMDQwN2Y5ZWRhMWExOTZmYTBjNmJhL3RhYmxlcmFuZ2U6YTAwMGY4ODkzMmQwNDA3ZjllZGExYTE5NmZhMGM2YmFfMi03LTEtMS0xMDExOTA_fc42d58b-bac9-4849-9ee4-4317b5932e8f">110.7</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib1053442369e460291956c51ab7e5179_I20220331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOmEwMDBmODg5MzJkMDQwN2Y5ZWRhMWExOTZmYTBjNmJhL3RhYmxlcmFuZ2U6YTAwMGY4ODkzMmQwNDA3ZjllZGExYTE5NmZhMGM2YmFfMi05LTEtMS0xMDExOTA_b8496094-612c-48e9-95dc-80e4a32f57d9">159.8</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></tbody></table></div></ix:nonnumeric><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net gains (losses) recognized in our consolidated condensed statements of operations for equity securities were $(<ix:nonfraction unitref="usd" contextref="id879b497a407453985551e83dbee75f8_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:EquitySecuritiesFvNiGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RleHRyZWdpb246NWNkZmEwZDVmNzVlNGY2N2E1ZTQ0NjAxMTQ3MmJlNWZfMTI3NDY_169a4e76-1dc4-4181-9f6c-e3b9a54a4159">425.4</ix:nonfraction>)&nbsp;million and $<ix:nonfraction unitref="usd" contextref="i010e4c0d9c6246be91d37e31d569fa6f_D20210101-20210331" decimals="-5" name="us-gaap:EquitySecuritiesFvNiGainLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RleHRyZWdpb246NWNkZmEwZDVmNzVlNGY2N2E1ZTQ0NjAxMTQ3MmJlNWZfMTY0OTI2NzQ1ODE0Nw_f7a33344-5f67-48e8-889e-12b7f74cf0c1">301.5</ix:nonfraction> million for the three months ended March&nbsp;31, 2022 and 2021, respectively. The net gains/losses recognized for the three months ended March&nbsp;31, 2022 and 2021 on equity securities sold during the respective periods were not material.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We adjust our equity investments without readily determinable fair values based upon changes in the equity instruments' values resulting from observable price changes in orderly transactions for an identical or similar investment of the same issuer. Downward adjustments resulting from an impairment are recorded based upon impairment considerations, including the financial condition and near term prospects of the issuer, general market conditions, and industry specific factors. Adjustments recorded for the three months ended March&nbsp;31, 2022 and 2021 were not material.</span></div><ix:nonnumeric contextref="id879b497a407453985551e83dbee75f8_D20220101-20220331" name="us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RleHRyZWdpb246NWNkZmEwZDVmNzVlNGY2N2E1ZTQ0NjAxMTQ3MmJlNWZfMTYyNzQ_971c1690-6866-4786-8a61-6e798d70ae3a" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the amount of unrealized gains and losses in accumulated other comprehensive loss and the fair value of available-for-sale securities in an unrealized gain or loss position follows:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&nbsp;</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tbody><tr><td style="width:1.0%"></td><td style="width:66.249%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.859%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.860%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gross gains</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib1053442369e460291956c51ab7e5179_I20220331" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOjlmNTIwMDFhYWIwNjQyNDY4MDFlNjJjMTAxNDNlODFhL3RhYmxlcmFuZ2U6OWY1MjAwMWFhYjA2NDI0NjgwMWU2MmMxMDE0M2U4MWFfMS0xLTEtMS0xMDExOTA_d6c1363f-9954-4355-95fc-c92ab36d2db3">1.3</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iffa7a62ea976465eb0977d320e638511_I20211231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOjlmNTIwMDFhYWIwNjQyNDY4MDFlNjJjMTAxNDNlODFhL3RhYmxlcmFuZ2U6OWY1MjAwMWFhYjA2NDI0NjgwMWU2MmMxMDE0M2U4MWFfMS0zLTEtMS0xMDExOTA_0f11fb13-bcba-4c90-9ed5-af12a3e40284">9.7</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gross losses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib1053442369e460291956c51ab7e5179_I20220331" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOjlmNTIwMDFhYWIwNjQyNDY4MDFlNjJjMTAxNDNlODFhL3RhYmxlcmFuZ2U6OWY1MjAwMWFhYjA2NDI0NjgwMWU2MmMxMDE0M2U4MWFfMi0xLTEtMS0xMDExOTA_1bf57558-671a-43ed-a7d0-e1243b0cd504">25.2</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iffa7a62ea976465eb0977d320e638511_I20211231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOjlmNTIwMDFhYWIwNjQyNDY4MDFlNjJjMTAxNDNlODFhL3RhYmxlcmFuZ2U6OWY1MjAwMWFhYjA2NDI0NjgwMWU2MmMxMDE0M2U4MWFfMi0zLTEtMS0xMDExOTA_7e3677c5-3d2a-4888-a6c7-815d930134b5">5.2</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of securities in an unrealized gain position</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib1053442369e460291956c51ab7e5179_I20220331" decimals="-5" name="lly:DebtSecuritiesAvailableforsaleUnrealizedGainPosition" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOjlmNTIwMDFhYWIwNjQyNDY4MDFlNjJjMTAxNDNlODFhL3RhYmxlcmFuZ2U6OWY1MjAwMWFhYjA2NDI0NjgwMWU2MmMxMDE0M2U4MWFfMy0xLTEtMS0xMDExOTA_2d0fdda2-75c1-48b9-b184-12ffbd6ab00f">89.5</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iffa7a62ea976465eb0977d320e638511_I20211231" decimals="-5" name="lly:DebtSecuritiesAvailableforsaleUnrealizedGainPosition" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOjlmNTIwMDFhYWIwNjQyNDY4MDFlNjJjMTAxNDNlODFhL3RhYmxlcmFuZ2U6OWY1MjAwMWFhYjA2NDI0NjgwMWU2MmMxMDE0M2U4MWFfMy0zLTEtMS0xMDExOTA_12999127-16a8-4a90-a54b-680510e1dc3f">250.7</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of securities in an unrealized loss position</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib1053442369e460291956c51ab7e5179_I20220331" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOjlmNTIwMDFhYWIwNjQyNDY4MDFlNjJjMTAxNDNlODFhL3RhYmxlcmFuZ2U6OWY1MjAwMWFhYjA2NDI0NjgwMWU2MmMxMDE0M2U4MWFfNC0xLTEtMS0xMDExOTA_92c96fb7-fb9d-4384-825c-0712893b41a5">440.6</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iffa7a62ea976465eb0977d320e638511_I20211231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOjlmNTIwMDFhYWIwNjQyNDY4MDFlNjJjMTAxNDNlODFhL3RhYmxlcmFuZ2U6OWY1MjAwMWFhYjA2NDI0NjgwMWU2MmMxMDE0M2U4MWFfNC0zLTEtMS0xMDExOTA_31bd570f-da1e-47be-892e-806f5c5dff47">290.2</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></tbody></table></div></ix:nonnumeric><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We periodically assess our investment in available-for-sale securities for impairment losses and credit losses. The amount of credit losses are determined by comparing the difference between the present value of future cash flows expected to be collected on these securities and the amortized cost. Factors considered in assessing credit losses include the position in the capital structure, vintage and amount of collateral, delinquency rates, current credit support, and geographic concentration. Impairment and credit losses related to available-for-sale securities were not material for the three months ended March&nbsp;31, 2022 and 2021.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span><br></span></div></div><ix:continuation id="i22c74d160e2c41fb9c2222f9e59613e4"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&nbsp;31, 2022, the available-for-sale securities in an unrealized loss position include primarily fixed-rate debt securities of varying maturities, which are sensitive to changes in the yield curve and other market conditions. Approximately <ix:nonfraction unitref="number" contextref="id879b497a407453985551e83dbee75f8_D20220101-20220331" decimals="2" name="us-gaap:AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureOtherPercentageOfNonperformingAssets" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RleHRyZWdpb246NWNkZmEwZDVmNzVlNGY2N2E1ZTQ0NjAxMTQ3MmJlNWZfMTQ2OTM_106c1d9d-2ba7-4653-9b7c-94f6e54566b1">97</ix:nonfraction> percent&nbsp;of the fixed-rate debt securities in a loss position are investment-grade debt securities. As of March&nbsp;31, 2022, we do not intend to sell, and it is not more likely than not that we will be required to sell, the securities in a loss position before the market values recover or the underlying cash flows have been received, and there is no indication of default on interest or principal payments for any of our debt securities.</span></div><ix:nonnumeric contextref="id879b497a407453985551e83dbee75f8_D20220101-20220331" name="us-gaap:GainLossOnInvestmentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RleHRyZWdpb246NWNkZmEwZDVmNzVlNGY2N2E1ZTQ0NjAxMTQ3MmJlNWZfMTYyNjk_d40936bc-d4ba-4288-8bc3-6b895354e131" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Activity related to our available-for-sale securities was as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:65.128%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.422%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="id879b497a407453985551e83dbee75f8_D20220101-20220331" decimals="-5" name="lly:ProceedsfromSaleofEquityandAvailableforSaleSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOjAwZGYxZTk5ZjYxNTRhYmE5N2E2ZGEwM2QzNzM5NTNhL3RhYmxlcmFuZ2U6MDBkZjFlOTlmNjE1NGFiYTk3YTZkYTAzZDM3Mzk1M2FfMi0xLTEtMS0xMDExOTA_a9ded376-8110-4492-aac7-b08327ce5394">35.2</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i010e4c0d9c6246be91d37e31d569fa6f_D20210101-20210331" decimals="-5" name="lly:ProceedsfromSaleofEquityandAvailableforSaleSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOjAwZGYxZTk5ZjYxNTRhYmE5N2E2ZGEwM2QzNzM5NTNhL3RhYmxlcmFuZ2U6MDBkZjFlOTlmNjE1NGFiYTk3YTZkYTAzZDM3Mzk1M2FfMi0zLTEtMS0xMDExOTA_5c7973b2-dc93-4d5b-aeea-ebd6dce8bf76">43.3</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Realized gross gains on sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="id879b497a407453985551e83dbee75f8_D20220101-20220331" decimals="-5" name="lly:AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOjAwZGYxZTk5ZjYxNTRhYmE5N2E2ZGEwM2QzNzM5NTNhL3RhYmxlcmFuZ2U6MDBkZjFlOTlmNjE1NGFiYTk3YTZkYTAzZDM3Mzk1M2FfMy0xLTEtMS0xMDExOTA_106ef5e7-e367-44d4-a3c2-8c54ace4ed84">0.1</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i010e4c0d9c6246be91d37e31d569fa6f_D20210101-20210331" decimals="-5" name="lly:AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOjAwZGYxZTk5ZjYxNTRhYmE5N2E2ZGEwM2QzNzM5NTNhL3RhYmxlcmFuZ2U6MDBkZjFlOTlmNjE1NGFiYTk3YTZkYTAzZDM3Mzk1M2FfMy0zLTEtMS0xMDExOTA_447e39f2-4839-440d-9dc2-46a0c9a66b41">1.1</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Realized gross losses on sales</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="id879b497a407453985551e83dbee75f8_D20220101-20220331" decimals="-5" name="lly:AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOjAwZGYxZTk5ZjYxNTRhYmE5N2E2ZGEwM2QzNzM5NTNhL3RhYmxlcmFuZ2U6MDBkZjFlOTlmNjE1NGFiYTk3YTZkYTAzZDM3Mzk1M2FfNC0xLTEtMS0xMDExOTA_50f99dbe-54ad-4aee-bded-e50114e53409">0.8</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i010e4c0d9c6246be91d37e31d569fa6f_D20210101-20210331" decimals="-5" name="lly:AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RhYmxlOjAwZGYxZTk5ZjYxNTRhYmE5N2E2ZGEwM2QzNzM5NTNhL3RhYmxlcmFuZ2U6MDBkZjFlOTlmNjE1NGFiYTk3YTZkYTAzZDM3Mzk1M2FfNC0zLTEtMS0xMDExOTA_c282099e-1da4-494a-af28-106fbed5423d">0.4</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></tbody></table></div></ix:nonnumeric><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Realized gains and losses on sales of available-for-sale investments are computed based upon specific identification of the initial cost adjusted for any other-than-temporary declines in fair value that were recorded in earnings.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounts Receivable Factoring Arrangements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into accounts receivable factoring agreements with financial institutions to sell certain of our non-U.S. accounts receivable. These transactions are accounted for as sales and result in a reduction in accounts receivable because the agreements transfer effective control over and, risk related to, the receivables to the buyers. Our factoring agreements do not allow for recourse in the event of uncollectibility, and we do not retain any interest in the underlying accounts receivable once sold. We derecognized $<ix:nonfraction unitref="usd" contextref="ib1053442369e460291956c51ab7e5179_I20220331" decimals="-5" name="us-gaap:TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RleHRyZWdpb246NWNkZmEwZDVmNzVlNGY2N2E1ZTQ0NjAxMTQ3MmJlNWZfMTU5ODc_8bb3135c-ec67-40c6-a2ca-e515ddb08595">449.5</ix:nonfraction> million and $<ix:nonfraction unitref="usd" contextref="iffa7a62ea976465eb0977d320e638511_I20211231" decimals="-5" name="us-gaap:TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82NC9mcmFnOjVjZGZhMGQ1Zjc1ZTRmNjdhNWU0NDYwMTE0NzJiZTVmL3RleHRyZWdpb246NWNkZmEwZDVmNzVlNGY2N2E1ZTQ0NjAxMTQ3MmJlNWZfMTU5OTQ_1c04eac1-d44b-42cd-a559-1d84a6d4f3b3">550.5</ix:nonfraction> million&nbsp;of accounts receivable as of March&nbsp;31, 2022 and December 31, 2021, respectively, under these factoring arrangements. The costs of factoring such accounts receivable on our consolidated condensed results of operations for the three months ended March&nbsp;31, 2022 and 2021&nbsp;were&nbsp;not material.</span></div></ix:continuation><div style="margin-top:6pt"><span><br></span></div><div id="ie8dc61f8e15b44db82ba16050d5b7b44_67"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 7: <ix:nonnumeric contextref="id879b497a407453985551e83dbee75f8_D20220101-20220331" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82Ny9mcmFnOjNkODk2MmViNjJkNjQ2N2RhMGE1M2RhNGY3NTRjODc3L3RleHRyZWdpb246M2Q4OTYyZWI2MmQ2NDY3ZGEwYTUzZGE0Zjc1NGM4NzdfMTMwMg_f79085be-b78b-4ec4-9ac1-9b6acff83195" continuedat="i11f3bbc7c00f4cbc88d61991bb6600a9" escape="true">Income Taxes </ix:nonnumeric></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i11f3bbc7c00f4cbc88d61991bb6600a9" continuedat="i05277141ce85460892638c9793b7c570">The effective tax rate was <ix:nonfraction unitref="number" contextref="id879b497a407453985551e83dbee75f8_D20220101-20220331" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82Ny9mcmFnOjNkODk2MmViNjJkNjQ2N2RhMGE1M2RhNGY3NTRjODc3L3RleHRyZWdpb246M2Q4OTYyZWI2MmQ2NDY3ZGEwYTUzZGE0Zjc1NGM4NzdfNTQ_8bc06f7a-d2e1-46fa-a4d1-1a38c0386200">7.3</ix:nonfraction> percent for the three months ended March&nbsp;31, 2022, compared with <ix:nonfraction unitref="number" contextref="i010e4c0d9c6246be91d37e31d569fa6f_D20210101-20210331" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82Ny9mcmFnOjNkODk2MmViNjJkNjQ2N2RhMGE1M2RhNGY3NTRjODc3L3RleHRyZWdpb246M2Q4OTYyZWI2MmQ2NDY3ZGEwYTUzZGE0Zjc1NGM4NzdfMTAy_cfe16272-6930-4b9b-ba88-d67161be7e6d">8.2</ix:nonfraction> percent for the three months ended March&nbsp;31, 2021. The lower effective tax rate for the three months ended March&nbsp;31, 2022 was largely driven by decreased tax expense related to net investment losses on equity securities compared to net investment gains on equity securities for the three months ended March&nbsp;31, 2021 and decreased tax expense related to the implementation of the provision in the Tax Cuts and Jobs Act (the 2017 Tax Act) that requires capitalization and amortization of research and development expenses for tax purposes starting in 2022, partially offset by a lower net discrete tax benefit compared to the three months ended March&nbsp;31, 2021. If this provision of the 2017 Tax Act is deferred or repealed by Congress effective for 2022, we expect our effective tax rate to be approximately <ix:nonfraction unitref="number" contextref="ia742d0e6fff948789bf96eee343be514_D20220101-20221231" decimals="2" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82Ny9mcmFnOjNkODk2MmViNjJkNjQ2N2RhMGE1M2RhNGY3NTRjODc3L3RleHRyZWdpb246M2Q4OTYyZWI2MmQ2NDY3ZGEwYTUzZGE0Zjc1NGM4NzdfMTA0NDUzNjA0Njg2NzE_b7c90293-57af-45a7-be51-169a2145d1e6">13</ix:nonfraction> percent to <ix:nonfraction unitref="number" contextref="i460ddb35283849b69e71055fc598219d_D20220101-20221231" decimals="2" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF82Ny9mcmFnOjNkODk2MmViNjJkNjQ2N2RhMGE1M2RhNGY3NTRjODc3L3RleHRyZWdpb246M2Q4OTYyZWI2MmQ2NDY3ZGEwYTUzZGE0Zjc1NGM4NzdfMTA0NDUzNjA0Njg0ODc_84b1a6b4-358b-43fe-877a-3e119980656c">14</ix:nonfraction> percent for 2022.</ix:continuation></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i05277141ce85460892638c9793b7c570">The U.S. examination of tax years 2016-2018 began in the fourth quarter of 2019 and remains ongoing. The resolution of this audit period will likely extend beyond the next 12 months.</ix:continuation> </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><div id="ie8dc61f8e15b44db82ba16050d5b7b44_70"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span><br></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 8: <ix:nonnumeric contextref="id879b497a407453985551e83dbee75f8_D20220101-20220331" name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF83MC9mcmFnOjYwNzQ4NmVhMWRmYzRiNzBiYTkyMmQyNDA3OGM2OTE4L3RleHRyZWdpb246NjA3NDg2ZWExZGZjNGI3MGJhOTIyZDI0MDc4YzY5MThfMTI1_dabdb7b7-d4ee-4b77-98e5-33053600883c" continuedat="i693be14bc9db4233a9d99b6a8a4ca789" escape="true">Retirement Benefits</ix:nonnumeric></span></div><ix:continuation id="i693be14bc9db4233a9d99b6a8a4ca789"><ix:nonnumeric contextref="id879b497a407453985551e83dbee75f8_D20220101-20220331" name="us-gaap:ScheduleOfNetBenefitCostsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF83MC9mcmFnOjYwNzQ4NmVhMWRmYzRiNzBiYTkyMmQyNDA3OGM2OTE4L3RleHRyZWdpb246NjA3NDg2ZWExZGZjNGI3MGJhOTIyZDI0MDc4YzY5MThfMTM2_68d8656a-188e-481b-9a0c-9025bbbf49c4" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net pension and retiree health benefit (income) cost included the following components:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:65.128%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.422%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Defined Benefit Pension Plans</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Components of net periodic benefit cost:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i690cde1d59fa4dab835605519a1be00d_D20220101-20220331" decimals="-5" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF83MC9mcmFnOjYwNzQ4NmVhMWRmYzRiNzBiYTkyMmQyNDA3OGM2OTE4L3RhYmxlOmZiZGYwMDM2ZmI0MjQzYWU4M2YzOGMyZTA0ODBmNzNiL3RhYmxlcmFuZ2U6ZmJkZjAwMzZmYjQyNDNhZTgzZjM4YzJlMDQ4MGY3M2JfNC0xLTEtMS0xMDExOTA_89b99dfa-bfd5-470d-abe3-fb6299a97649">89.1</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i07ff1b3fd36041fcb815472f33a8b2d5_D20210101-20210331" decimals="-5" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF83MC9mcmFnOjYwNzQ4NmVhMWRmYzRiNzBiYTkyMmQyNDA3OGM2OTE4L3RhYmxlOmZiZGYwMDM2ZmI0MjQzYWU4M2YzOGMyZTA0ODBmNzNiL3RhYmxlcmFuZ2U6ZmJkZjAwMzZmYjQyNDNhZTgzZjM4YzJlMDQ4MGY3M2JfNC0zLTEtMS0xMDExOTA_ea5c211f-8317-4d92-94e3-e2d523af9569">92.0</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i690cde1d59fa4dab835605519a1be00d_D20220101-20220331" decimals="-5" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF83MC9mcmFnOjYwNzQ4NmVhMWRmYzRiNzBiYTkyMmQyNDA3OGM2OTE4L3RhYmxlOmZiZGYwMDM2ZmI0MjQzYWU4M2YzOGMyZTA0ODBmNzNiL3RhYmxlcmFuZ2U6ZmJkZjAwMzZmYjQyNDNhZTgzZjM4YzJlMDQ4MGY3M2JfNS0xLTEtMS0xMDExOTA_1111ce2c-2740-4130-a318-96b686f89052">100.5</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i07ff1b3fd36041fcb815472f33a8b2d5_D20210101-20210331" decimals="-5" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF83MC9mcmFnOjYwNzQ4NmVhMWRmYzRiNzBiYTkyMmQyNDA3OGM2OTE4L3RhYmxlOmZiZGYwMDM2ZmI0MjQzYWU4M2YzOGMyZTA0ODBmNzNiL3RhYmxlcmFuZ2U6ZmJkZjAwMzZmYjQyNDNhZTgzZjM4YzJlMDQ4MGY3M2JfNS0zLTEtMS0xMDExOTA_7d960010-ad12-4d5f-b4f1-70ce1f923685">84.3</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i690cde1d59fa4dab835605519a1be00d_D20220101-20220331" decimals="-5" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF83MC9mcmFnOjYwNzQ4NmVhMWRmYzRiNzBiYTkyMmQyNDA3OGM2OTE4L3RhYmxlOmZiZGYwMDM2ZmI0MjQzYWU4M2YzOGMyZTA0ODBmNzNiL3RhYmxlcmFuZ2U6ZmJkZjAwMzZmYjQyNDNhZTgzZjM4YzJlMDQ4MGY3M2JfNi0xLTEtMS0xMDExOTA_d660e0b2-0293-44f9-bd78-df8fe1b220f7">239.5</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i07ff1b3fd36041fcb815472f33a8b2d5_D20210101-20210331" decimals="-5" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF83MC9mcmFnOjYwNzQ4NmVhMWRmYzRiNzBiYTkyMmQyNDA3OGM2OTE4L3RhYmxlOmZiZGYwMDM2ZmI0MjQzYWU4M2YzOGMyZTA0ODBmNzNiL3RhYmxlcmFuZ2U6ZmJkZjAwMzZmYjQyNDNhZTgzZjM4YzJlMDQ4MGY3M2JfNi0zLTEtMS0xMDExOTA_9c6043d8-ccc3-4787-9f09-1cc0efc7f6fe">238.0</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of prior service cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i690cde1d59fa4dab835605519a1be00d_D20220101-20220331" decimals="-5" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF83MC9mcmFnOjYwNzQ4NmVhMWRmYzRiNzBiYTkyMmQyNDA3OGM2OTE4L3RhYmxlOmZiZGYwMDM2ZmI0MjQzYWU4M2YzOGMyZTA0ODBmNzNiL3RhYmxlcmFuZ2U6ZmJkZjAwMzZmYjQyNDNhZTgzZjM4YzJlMDQ4MGY3M2JfNy0xLTEtMS0xMDExOTA_44b88ef9-3230-4d84-9b91-414be2cbad72">0.7</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i07ff1b3fd36041fcb815472f33a8b2d5_D20210101-20210331" decimals="-5" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF83MC9mcmFnOjYwNzQ4NmVhMWRmYzRiNzBiYTkyMmQyNDA3OGM2OTE4L3RhYmxlOmZiZGYwMDM2ZmI0MjQzYWU4M2YzOGMyZTA0ODBmNzNiL3RhYmxlcmFuZ2U6ZmJkZjAwMzZmYjQyNDNhZTgzZjM4YzJlMDQ4MGY3M2JfNy0zLTEtMS0xMDExOTA_e1eed408-32a9-4319-adb1-5710206d09d8">1.1</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognized actuarial loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i690cde1d59fa4dab835605519a1be00d_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF83MC9mcmFnOjYwNzQ4NmVhMWRmYzRiNzBiYTkyMmQyNDA3OGM2OTE4L3RhYmxlOmZiZGYwMDM2ZmI0MjQzYWU4M2YzOGMyZTA0ODBmNzNiL3RhYmxlcmFuZ2U6ZmJkZjAwMzZmYjQyNDNhZTgzZjM4YzJlMDQ4MGY3M2JfOC0xLTEtMS0xMDExOTA_22fd765a-7828-4ee2-8cb5-9e108efb20f1">87.0</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i07ff1b3fd36041fcb815472f33a8b2d5_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF83MC9mcmFnOjYwNzQ4NmVhMWRmYzRiNzBiYTkyMmQyNDA3OGM2OTE4L3RhYmxlOmZiZGYwMDM2ZmI0MjQzYWU4M2YzOGMyZTA0ODBmNzNiL3RhYmxlcmFuZ2U6ZmJkZjAwMzZmYjQyNDNhZTgzZjM4YzJlMDQ4MGY3M2JfOC0zLTEtMS0xMDExOTA_0f44972e-cb04-42bf-b064-1898c415d462">121.8</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net periodic benefit cost</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i690cde1d59fa4dab835605519a1be00d_D20220101-20220331" decimals="-5" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF83MC9mcmFnOjYwNzQ4NmVhMWRmYzRiNzBiYTkyMmQyNDA3OGM2OTE4L3RhYmxlOmZiZGYwMDM2ZmI0MjQzYWU4M2YzOGMyZTA0ODBmNzNiL3RhYmxlcmFuZ2U6ZmJkZjAwMzZmYjQyNDNhZTgzZjM4YzJlMDQ4MGY3M2JfMTAtMS0xLTEtMTAxMTkw_0a61728d-6abd-47a0-ba29-4445836b20ff">37.8</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i07ff1b3fd36041fcb815472f33a8b2d5_D20210101-20210331" decimals="-5" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF83MC9mcmFnOjYwNzQ4NmVhMWRmYzRiNzBiYTkyMmQyNDA3OGM2OTE4L3RhYmxlOmZiZGYwMDM2ZmI0MjQzYWU4M2YzOGMyZTA0ODBmNzNiL3RhYmxlcmFuZ2U6ZmJkZjAwMzZmYjQyNDNhZTgzZjM4YzJlMDQ4MGY3M2JfMTAtMy0xLTEtMTAxMTkw_2709d4bc-f31c-4a21-8527-f1a7bc859541">61.2</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></tbody></table></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:65.128%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.422%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Retiree Health Benefit Plans</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Components of net periodic benefit income:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="id157979fcb794bf2a4984ef11112b041_D20220101-20220331" decimals="-5" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF83MC9mcmFnOjYwNzQ4NmVhMWRmYzRiNzBiYTkyMmQyNDA3OGM2OTE4L3RhYmxlOmVmODJmYWZhMWI2MTQxMzY5YzBhOTIwNzE1Mzc1ZDg3L3RhYmxlcmFuZ2U6ZWY4MmZhZmExYjYxNDEzNjljMGE5MjA3MTUzNzVkODdfNC0xLTEtMS0xMDExOTA_e3a3887c-bf76-4266-b11f-02853517e528">11.2</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i053f6ca8167a4dbf90ed11b7de9780e3_D20210101-20210331" decimals="-5" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF83MC9mcmFnOjYwNzQ4NmVhMWRmYzRiNzBiYTkyMmQyNDA3OGM2OTE4L3RhYmxlOmVmODJmYWZhMWI2MTQxMzY5YzBhOTIwNzE1Mzc1ZDg3L3RhYmxlcmFuZ2U6ZWY4MmZhZmExYjYxNDEzNjljMGE5MjA3MTUzNzVkODdfNC0zLTEtMS0xMDExOTA_9a5de7e8-f3ad-4d3a-b253-ac8ab80a486e">11.7</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="id157979fcb794bf2a4984ef11112b041_D20220101-20220331" decimals="-5" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF83MC9mcmFnOjYwNzQ4NmVhMWRmYzRiNzBiYTkyMmQyNDA3OGM2OTE4L3RhYmxlOmVmODJmYWZhMWI2MTQxMzY5YzBhOTIwNzE1Mzc1ZDg3L3RhYmxlcmFuZ2U6ZWY4MmZhZmExYjYxNDEzNjljMGE5MjA3MTUzNzVkODdfNS0xLTEtMS0xMDExOTA_322b4187-7a3c-4eab-a017-4e9689c1ad9a">9.4</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i053f6ca8167a4dbf90ed11b7de9780e3_D20210101-20210331" decimals="-5" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF83MC9mcmFnOjYwNzQ4NmVhMWRmYzRiNzBiYTkyMmQyNDA3OGM2OTE4L3RhYmxlOmVmODJmYWZhMWI2MTQxMzY5YzBhOTIwNzE1Mzc1ZDg3L3RhYmxlcmFuZ2U6ZWY4MmZhZmExYjYxNDEzNjljMGE5MjA3MTUzNzVkODdfNS0zLTEtMS0xMDExOTA_b0b5c0f0-0789-465d-b7d4-19ab4268320a">8.1</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonfraction unitref="usd" contextref="id157979fcb794bf2a4984ef11112b041_D20220101-20220331" decimals="-5" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF83MC9mcmFnOjYwNzQ4NmVhMWRmYzRiNzBiYTkyMmQyNDA3OGM2OTE4L3RhYmxlOmVmODJmYWZhMWI2MTQxMzY5YzBhOTIwNzE1Mzc1ZDg3L3RhYmxlcmFuZ2U6ZWY4MmZhZmExYjYxNDEzNjljMGE5MjA3MTUzNzVkODdfNi0xLTEtMS0xMDExOTA_e1687623-eb95-49c7-ad01-6bb2a86dadbb">37.9</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i053f6ca8167a4dbf90ed11b7de9780e3_D20210101-20210331" decimals="-5" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF83MC9mcmFnOjYwNzQ4NmVhMWRmYzRiNzBiYTkyMmQyNDA3OGM2OTE4L3RhYmxlOmVmODJmYWZhMWI2MTQxMzY5YzBhOTIwNzE1Mzc1ZDg3L3RhYmxlcmFuZ2U6ZWY4MmZhZmExYjYxNDEzNjljMGE5MjA3MTUzNzVkODdfNi0zLTEtMS0xMDExOTA_36c13fcf-3408-4397-8f24-511198c969ca">36.6</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of prior service benefit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonfraction unitref="usd" contextref="id157979fcb794bf2a4984ef11112b041_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF83MC9mcmFnOjYwNzQ4NmVhMWRmYzRiNzBiYTkyMmQyNDA3OGM2OTE4L3RhYmxlOmVmODJmYWZhMWI2MTQxMzY5YzBhOTIwNzE1Mzc1ZDg3L3RhYmxlcmFuZ2U6ZWY4MmZhZmExYjYxNDEzNjljMGE5MjA3MTUzNzVkODdfNy0xLTEtMS0xMDExOTA_aaf5aa0e-8d5a-42a6-9015-581422ef5348">13.7</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i053f6ca8167a4dbf90ed11b7de9780e3_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF83MC9mcmFnOjYwNzQ4NmVhMWRmYzRiNzBiYTkyMmQyNDA3OGM2OTE4L3RhYmxlOmVmODJmYWZhMWI2MTQxMzY5YzBhOTIwNzE1Mzc1ZDg3L3RhYmxlcmFuZ2U6ZWY4MmZhZmExYjYxNDEzNjljMGE5MjA3MTUzNzVkODdfNy0zLTEtMS0xMDExOTA_220edb98-ade7-4c2c-a7b3-17a742a34263">14.9</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognized actuarial loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="id157979fcb794bf2a4984ef11112b041_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF83MC9mcmFnOjYwNzQ4NmVhMWRmYzRiNzBiYTkyMmQyNDA3OGM2OTE4L3RhYmxlOmVmODJmYWZhMWI2MTQxMzY5YzBhOTIwNzE1Mzc1ZDg3L3RhYmxlcmFuZ2U6ZWY4MmZhZmExYjYxNDEzNjljMGE5MjA3MTUzNzVkODdfOC0xLTEtMS0xMDExOTA_4c45f0e8-c079-4c77-9e1f-f8560ae1408f">0.2</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i053f6ca8167a4dbf90ed11b7de9780e3_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF83MC9mcmFnOjYwNzQ4NmVhMWRmYzRiNzBiYTkyMmQyNDA3OGM2OTE4L3RhYmxlOmVmODJmYWZhMWI2MTQxMzY5YzBhOTIwNzE1Mzc1ZDg3L3RhYmxlcmFuZ2U6ZWY4MmZhZmExYjYxNDEzNjljMGE5MjA3MTUzNzVkODdfOC0zLTEtMS0xMDExOTA_23e90b2f-8b96-486f-b63a-24082b6be153">0.8</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net periodic benefit income</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonfraction unitref="usd" contextref="id157979fcb794bf2a4984ef11112b041_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF83MC9mcmFnOjYwNzQ4NmVhMWRmYzRiNzBiYTkyMmQyNDA3OGM2OTE4L3RhYmxlOmVmODJmYWZhMWI2MTQxMzY5YzBhOTIwNzE1Mzc1ZDg3L3RhYmxlcmFuZ2U6ZWY4MmZhZmExYjYxNDEzNjljMGE5MjA3MTUzNzVkODdfMTAtMS0xLTEtMTAxMTkw_6322aa0b-020e-4170-9460-12cec9da21d9">30.8</ix:nonfraction>)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i053f6ca8167a4dbf90ed11b7de9780e3_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF83MC9mcmFnOjYwNzQ4NmVhMWRmYzRiNzBiYTkyMmQyNDA3OGM2OTE4L3RhYmxlOmVmODJmYWZhMWI2MTQxMzY5YzBhOTIwNzE1Mzc1ZDg3L3RhYmxlcmFuZ2U6ZWY4MmZhZmExYjYxNDEzNjljMGE5MjA3MTUzNzVkODdfMTAtMy0xLTEtMTAxMTkw_f4eb3669-d023-4522-9bd8-ffc74119e1e5">30.9</ix:nonfraction>)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></tbody></table></div></ix:nonnumeric></ix:continuation><div style="margin-top:6pt"><span><br></span></div><div id="ie8dc61f8e15b44db82ba16050d5b7b44_73"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 9: <ix:nonnumeric contextref="id879b497a407453985551e83dbee75f8_D20220101-20220331" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF83My9mcmFnOjNlOTY2M2IzZWI2MjQ1ZTA4OTE2MmFkODI2ZDc4MDAxL3RleHRyZWdpb246M2U5NjYzYjNlYjYyNDVlMDg5MTYyYWQ4MjZkNzgwMDFfMTA0NDUzNjA1NTY2ODI_951f7ee5-0e0d-4ebf-99f6-7544ddf13184" continuedat="ib963fb5b4ebd4d30b1c589ba5160c0d1" escape="true">Contingencies</ix:nonnumeric></span></div><ix:continuation id="ib963fb5b4ebd4d30b1c589ba5160c0d1" continuedat="i103b673fdd384fd2b4526d5999133665"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are involved in various lawsuits, claims, government investigations and other legal proceedings that arise in the ordinary course of business. These claims or proceedings can involve various types of parties, including governments, competitors, customers, suppliers, service providers, licensees, employees, or shareholders, among others. These matters may involve patent infringement, antitrust, securities, pricing, sales and marketing practices, environmental, commercial, contractual rights, licensing obligations, health and safety matters, consumer fraud, employment matters, product liability and insurance coverage, among others. The resolution of these matters often develops over a long period of time and expectations can change as a result of new findings, rulings, appeals or settlement arrangements. Legal proceedings that are significant or that we believe could become significant or material are described below. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe the legal proceedings in which we are named as defendants are without merit and we are defending against them vigorously. It is not possible to determine the final outcome of these matters, and we cannot reasonably estimate the maximum potential exposure or the range of possible loss in excess of amounts accrued for any of these matters; however, we believe that the resolution of all such matters will not have a material adverse effect on our consolidated financial position or liquidity, but could possibly be material to our consolidated results of operations in any one accounting period.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonnumeric contextref="id879b497a407453985551e83dbee75f8_D20220101-20220331" name="us-gaap:CommitmentsAndContingenciesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF83My9mcmFnOjNlOTY2M2IzZWI2MjQ1ZTA4OTE2MmFkODI2ZDc4MDAxL3RleHRyZWdpb246M2U5NjYzYjNlYjYyNDVlMDg5MTYyYWQ4MjZkNzgwMDFfMTA0NDUzNjA1NTY2ODM_cbc69913-9244-4608-8216-e7082b0d60fb" continuedat="i7e9627988c0a4a159c3a425b1b740eee" escape="true">Litigation accruals, environmental liabilities, and the related estimated insurance recoverables are reflected on a gross basis as liabilities and assets, respectively, on our consolidated condensed balance sheets. With respect to the product liability claims currently asserted against us, we have accrued for our estimated exposures to the extent they are both probable and reasonably estimable based on the information available to us. We accrue for certain product liability claims incurred but not filed to the extent we can formulate a reasonable estimate of their costs. We estimate these expenses based primarily on historical claims experience and data regarding product usage. Legal defense costs expected to be incurred in connection with significant product liability loss contingencies are accrued when both probable and reasonably estimable.</ix:nonnumeric></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i7e9627988c0a4a159c3a425b1b740eee">Because of the nature of pharmaceutical products, it is possible that we could become subject to large numbers of additional product liability and related claims in the future. Due to a very restrictive market for litigation liability insurance, we are self-insured for litigation liability losses for all our currently and previously marketed products.</ix:continuation> </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span><br></span></div></div><ix:continuation id="i103b673fdd384fd2b4526d5999133665" continuedat="i7345881896664eb29b4b6d43882b0eba"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Patent Litigation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Alimta Patent Litigation </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">U.S. Patent Litigation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Alimta (pemetrexed) was protected by a vitamin regimen patent until November 2021, and since then has been protected by pediatric exclusivity through May 2022.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, we settled a lawsuit we filed against Eagle Pharmaceuticals, Inc. (Eagle) in response to its application to market a product using an alternative form of pemetrexed. Per the settlement agreement, Eagle has a limited initial entry into the market with its product starting February 2022 (up to an approximate three-week supply) and subsequent unlimited entry starting April 2022. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">European Patent Litigation</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In Europe, Alimta</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was protected by the vitamin regimen patent through June 2021. Despite the recent patent expiration, a number of legal proceedings that were initiated prior to expiration are ongoing</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Emgality Patent Litigation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2018, we were</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> named as a defendant in litigation filed by Teva Pharmaceuticals International GMBH and Teva Pharmaceuticals USA, Inc. (collectively, Teva) in the U.S. District Court for the District of Massa</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">chusetts seeking a ruling that various claims in <ix:nonfraction unitref="patent" contextref="iba71b0f04ef044648f840fc039a69113_I20180930" decimals="INF" name="lly:LossContingencyNumberOfPatents" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF83My9mcmFnOjNlOTY2M2IzZWI2MjQ1ZTA4OTE2MmFkODI2ZDc4MDAxL3RleHRyZWdpb246M2U5NjYzYjNlYjYyNDVlMDg5MTYyYWQ4MjZkNzgwMDFfMTA5OTUxMTcyMDI3OQ_8c91dd9a-d0dd-4aff-b39a-681e91c7138d">nine</ix:nonfraction> different Teva patents would be infringed by our launch and continued sales of Emgality for the prevention of migraine in adults. Trial is currently scheduled to begin in October 2022. In June 2021, we were named as a defendant in a second litigation filed by Teva in the U.S. District Court for the District of Massachusetts seeking a ruling that <ix:nonfraction unitref="patent" contextref="ibf856295860d4cc583a42d2f153fa1ad_I20210630" decimals="INF" name="lly:LossContingencyNumberOfPatents" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF83My9mcmFnOjNlOTY2M2IzZWI2MjQ1ZTA4OTE2MmFkODI2ZDc4MDAxL3RleHRyZWdpb246M2U5NjYzYjNlYjYyNDVlMDg5MTYyYWQ4MjZkNzgwMDFfMTA5OTUxMTcyMDI4Nw_840b7d8c-ec8c-4da9-b832-b04bffd11ea0">two</ix:nonfraction> of Teva's patents, which are directed toward use of the active ingredient in Emgality to treat migraine, would be infringed by our continued sales of Emgality. This matter is ongoing.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Jardiance Patent Litigation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2018, Boehringer Ingelheim (BI), our partner in marketing and development of Jardiance, initiated U.S. patent litigation in the U.S. District Court of Delaware alleging infringement arising from submissions of Abbreviated New Drug Applications (ANDA) by a number of generic companies seeking approval to market generic versions of Jardiance, Glyxambi, and Synjardy in accordance with the procedures set out in the Drug Price Competition and Patent Term Restoration Act of 1984 (the Hatch-Waxman Act). Particularly with respect to Jardiance, the generic companies' ANDAs seek approval to market generic versions of Jardiance prior to the expiration of the relevant patents, and allege that certain patents, including in some allegations the compound patent, are invalid or would not be infringed. We are not a party to this litigation. This litigation has been stayed. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Taltz Patent Litigation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2021, we petitioned the High Court of Ireland to declare invalid the patent that Novartis Pharma AG (Novartis) purchased from Genentech, Inc. in 2020. Novartis responded by filing a claim against us alleging patent infringement related to our commercialization of Taltz and seeking damages for past infringement and an injunction against future infringement. This matter is ongoing. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2021 and November 2021, Novartis petitioned the Court of Rome Intellectual Property Division and the Swiss Federal Patent Court, respectively, in preliminary injunction (PI) and main infringement proceedings against us related to our commercialization of Taltz. In June 2021, the Court of Rome Intellectual Property Division dismissed Novartis' PI action. Novartis appealed the ruling and, in October 2021, the panel hearing Novartis' appeal appointed a technical expert to assess the merits of the case. In April 2022, Novartis withdrew its PI request in Switzerland, but the main infringement proceedings continue. A hearing on the Italian PI request is scheduled for May 2022.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span><br></span></div></div><ix:continuation id="i7345881896664eb29b4b6d43882b0eba" continuedat="i64f714563b114c6c85deb26a4f537eec"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Zyprexa Canada Patent Litigation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in the mid-2000s, several generic companies in Canada challenged the validity of our Zyprexa compound patent. In 2012, the Canadian Federal Court of Appeals denied our appeal of a lower court's decision that certain patent claims were invalid for lack of utility. In 2013, Apotex Inc. and Apotex Pharmachem Inc. (collectively, Apotex) brought claims against us in the Ontario Superior Court of Justice at Toronto for damages related to our enforcement of the Zyprexa compound patent under Canadian regulations governing patented drugs. Apotex seeks compensation based on novel legal theories under the Statute of Monopolies, Trade-Mark Act, and common law. In March 2021, the Ontario Superior Court granted our motion for summary judgment, thereby dismissing Apotex's case. Apotex appealed that ruling to the Court of Appeal for Ontario in April 2021 and a hearing occurred February 2022. We await a decision.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Product Liability Litigation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Byetta® Product Liability</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are named as a defendant in approximately <ix:nonfraction unitref="lawsuit" contextref="if986aeb2b74c45c4886b5ccf762b0845_I20220331" decimals="0" name="us-gaap:LossContingencyPendingClaimsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF83My9mcmFnOjNlOTY2M2IzZWI2MjQ1ZTA4OTE2MmFkODI2ZDc4MDAxL3RleHRyZWdpb246M2U5NjYzYjNlYjYyNDVlMDg5MTYyYWQ4MjZkNzgwMDFfMTA5OTUxMTcyMDM4MQ_5a3492e0-4b68-4b40-ae51-fe9ef4401074">570</ix:nonfraction> Byetta product liability lawsuits in the U.S. which were first initiated in March 2009 and involve approximately <ix:nonfraction unitref="plaintiff" contextref="iccf29e7a5ff447be878fbe483ab1b640_D20090301-20220331" decimals="0" name="us-gaap:LossContingencyNumberOfPlaintiffs" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF83My9mcmFnOjNlOTY2M2IzZWI2MjQ1ZTA4OTE2MmFkODI2ZDc4MDAxL3RleHRyZWdpb246M2U5NjYzYjNlYjYyNDVlMDg5MTYyYWQ4MjZkNzgwMDFfMTA5OTUxMTcyMDM4NQ_10f72191-48b2-4205-bc6a-cabeeb9f9c32">805</ix:nonfraction> plaintiffs. Approximately <ix:nonfraction unitref="lawsuit" contextref="i0fa13f1e4f5b4989a43ad6584340167f_I20220331" decimals="0" name="us-gaap:LossContingencyPendingClaimsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF83My9mcmFnOjNlOTY2M2IzZWI2MjQ1ZTA4OTE2MmFkODI2ZDc4MDAxL3RleHRyZWdpb246M2U5NjYzYjNlYjYyNDVlMDg5MTYyYWQ4MjZkNzgwMDFfMTA5OTUxMTcyMDM4OQ_2313aed1-a316-4320-ab0e-f51a8eb8287c">55</ix:nonfraction> of these lawsuits, covering about <ix:nonfraction unitref="plaintiff" contextref="i732141cbc8674e028f44ffa7b20f3f3b_D20090301-20220331" decimals="0" name="us-gaap:LossContingencyNumberOfPlaintiffs" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF83My9mcmFnOjNlOTY2M2IzZWI2MjQ1ZTA4OTE2MmFkODI2ZDc4MDAxL3RleHRyZWdpb246M2U5NjYzYjNlYjYyNDVlMDg5MTYyYWQ4MjZkNzgwMDFfMTA5OTUxMTcyMDM5Mw_d430f45a-be69-4b83-9e08-e52874286c71">285</ix:nonfraction> plaintiffs, are filed in California state court and coordinated in a Los Angeles Superior Court. Approximately <ix:nonfraction unitref="lawsuit" contextref="id5f7c7a0250845febe4b827e80fa3743_I20220331" decimals="0" name="us-gaap:LossContingencyPendingClaimsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF83My9mcmFnOjNlOTY2M2IzZWI2MjQ1ZTA4OTE2MmFkODI2ZDc4MDAxL3RleHRyZWdpb246M2U5NjYzYjNlYjYyNDVlMDg5MTYyYWQ4MjZkNzgwMDFfMTA5OTUxMTcyMDM5Nw_0a9c36d4-4e1e-4526-b0df-ffffcba87ad8">515</ix:nonfraction> of the lawsuits, covering about <ix:nonfraction unitref="plaintiff" contextref="i6e5057fbcebb42e8848798cc7ca7092d_D20090301-20220331" decimals="0" name="us-gaap:LossContingencyNumberOfPlaintiffs" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF83My9mcmFnOjNlOTY2M2IzZWI2MjQ1ZTA4OTE2MmFkODI2ZDc4MDAxL3RleHRyZWdpb246M2U5NjYzYjNlYjYyNDVlMDg5MTYyYWQ4MjZkNzgwMDFfMTA5OTUxMTcyMDQwMQ_a5032ae6-c9bc-480c-a19e-6e2ea5281893">515</ix:nonfraction> plaintiffs, are filed in federal court, the majority of which are coordinated in a multi-district litigation (MDL) in the U.S. District Court for the Southern District of California. <ix:nonfraction unitref="lawsuit" contextref="ib5924adeba7a47f39c0acb7d02286c6b_I20220331" decimals="INF" name="us-gaap:LossContingencyPendingClaimsNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF83My9mcmFnOjNlOTY2M2IzZWI2MjQ1ZTA4OTE2MmFkODI2ZDc4MDAxL3RleHRyZWdpb246M2U5NjYzYjNlYjYyNDVlMDg5MTYyYWQ4MjZkNzgwMDFfMTA5OTUxMTcyMDQwNQ_9e40a8e9-f395-4453-954f-6fe24d50a06a">Two</ix:nonfraction> lawsuits, representing approximately <ix:nonfraction unitref="plaintiff" contextref="i2234785e0f1143e1af55c3bb337d4907_D20090301-20220331" decimals="INF" name="us-gaap:LossContingencyNumberOfPlaintiffs" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF83My9mcmFnOjNlOTY2M2IzZWI2MjQ1ZTA4OTE2MmFkODI2ZDc4MDAxL3RleHRyZWdpb246M2U5NjYzYjNlYjYyNDVlMDg5MTYyYWQ4MjZkNzgwMDFfMTA5OTUxMTcyMDQxOA_603b08b8-f3d3-4af2-ba6b-c72449fb9f77">two</ix:nonfraction> plaintiffs, have also been filed in various state courts. Approximately <ix:nonfraction unitref="lawsuit" contextref="i582b4e89a2ee429da84a89ba6f1b1619_I20220331" decimals="0" name="us-gaap:LossContingencyPendingClaimsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF83My9mcmFnOjNlOTY2M2IzZWI2MjQ1ZTA4OTE2MmFkODI2ZDc4MDAxL3RleHRyZWdpb246M2U5NjYzYjNlYjYyNDVlMDg5MTYyYWQ4MjZkNzgwMDFfMTA5OTUxMTcyMDQyOQ_07af55ea-3e87-47fb-aeaa-98d9b63b77d9">565</ix:nonfraction> of the lawsuits, involving approximately <ix:nonfraction unitref="plaintiff" contextref="i35724922961344358bebddecb678393a_D20090301-20220331" decimals="0" name="us-gaap:LossContingencyNumberOfPlaintiffs" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF83My9mcmFnOjNlOTY2M2IzZWI2MjQ1ZTA4OTE2MmFkODI2ZDc4MDAxL3RleHRyZWdpb246M2U5NjYzYjNlYjYyNDVlMDg5MTYyYWQ4MjZkNzgwMDFfMTA5OTUxMTcyMDQzMw_2d78ac06-ddd8-4365-96bb-bd3f73db31dc">800</ix:nonfraction> plaintiffs, contain allegations that Byetta caused or contributed to the plaintiffs' cancer (primarily pancreatic cancer or thyroid cancer); while <ix:nonfraction unitref="plaintiff" contextref="i89bf4f944d24415e9da71601563d4852_D20090301-20220331" decimals="INF" name="us-gaap:LossContingencyNumberOfPlaintiffs" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF83My9mcmFnOjNlOTY2M2IzZWI2MjQ1ZTA4OTE2MmFkODI2ZDc4MDAxL3RleHRyZWdpb246M2U5NjYzYjNlYjYyNDVlMDg5MTYyYWQ4MjZkNzgwMDFfMTA5OTUxMTcyMDQzNw_f101f6cd-3c9a-4a5e-bfff-15b21763dcb1">six</ix:nonfraction> plaintiffs allege Byetta caused or contributed to pancreatitis. In addition, <ix:nonfraction unitref="plaintiff" contextref="ieb4140c6e4cf4105a3cdf1f8253fae2c_D20090301-20220331" decimals="INF" name="us-gaap:LossContingencyNumberOfPlaintiffs" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF83My9mcmFnOjNlOTY2M2IzZWI2MjQ1ZTA4OTE2MmFkODI2ZDc4MDAxL3RleHRyZWdpb246M2U5NjYzYjNlYjYyNDVlMDg5MTYyYWQ4MjZkNzgwMDFfMTA5OTUxMTcyMDQ2Nw_cf5bbbc3-2171-41df-b2b6-5bc2350acb6f">one</ix:nonfraction> case alleges that Byetta caused or contributed to ampullary cancer. The federal and state trial courts granted summary judgment in favor of us and our co-defendants on the claims alleging pancreatic cancer. The plaintiffs appealed those rulings. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2017, the U.S. Court of Appeals for the Ninth Circuit reversed the U.S. District Court for the Southern District of California's grant of summary judgment in the MDL based on that court's discovery rulings and remanded the cases back to the U.S. District Court for further proceedings. In March 2021, the U.S. District Court granted summary judgment for the defendants. In April 2021, the plaintiffs filed a notice of appeal to the U.S. Court of Appeals for the Ninth Circuit, but we have now been dismissed from that appeal. In March 2022, the U.S. Court of Appeals for the Ninth Circuit affirmed the U.S. District Court's grant of summary judgment with respect to the remaining defendant in the appeal. Certain plaintiffs have agreed to dismiss their lawsuits in exchange for a waiver of costs, and individual plaintiffs have begun dismissing their claims based upon this agreement. Approximately <ix:nonfraction unitref="lawsuit" contextref="ie2562c1a1b5740f5b312d946a2d2f727_D20220401-20220430" decimals="INF" name="us-gaap:LossContingencyClaimsDismissedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF83My9mcmFnOjNlOTY2M2IzZWI2MjQ1ZTA4OTE2MmFkODI2ZDc4MDAxL3RleHRyZWdpb246M2U5NjYzYjNlYjYyNDVlMDg5MTYyYWQ4MjZkNzgwMDFfMTA5OTUxMTcyNTE0MQ_ae038ab3-affc-411c-b0a5-39e8803c6626">333</ix:nonfraction> of the MDL lawsuits have been dismissed as of April 2022. In the state court actions, in November 2018, the California Court of Appeal reversed the Los Angeles County Superior Court of California's grant of summary judgment based on that court's discovery rulings and remanded for further proceedings. In April 2021, the Los Angeles County Superior Court of California granted summary judgment for the defendants and the parties await entry of the order of judgment. Approximately <ix:nonfraction unitref="lawsuit" contextref="i41b0a98c5e054d3987afeeba397fa41d_D20220401-20220430" decimals="INF" name="us-gaap:LossContingencyClaimsDismissedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF83My9mcmFnOjNlOTY2M2IzZWI2MjQ1ZTA4OTE2MmFkODI2ZDc4MDAxL3RleHRyZWdpb246M2U5NjYzYjNlYjYyNDVlMDg5MTYyYWQ4MjZkNzgwMDFfMTA5OTUxMTcyNTE0Ng_ad504a86-2062-4bff-9384-8da3bc977ffe">34</ix:nonfraction> of the state court lawsuits have been dismissed as of April 2022. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are aware of approximately <ix:nonfraction unitref="claimant" contextref="if986aeb2b74c45c4886b5ccf762b0845_I20220331" decimals="0" name="lly:LossContingencyNumberOfClaimants" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF83My9mcmFnOjNlOTY2M2IzZWI2MjQ1ZTA4OTE2MmFkODI2ZDc4MDAxL3RleHRyZWdpb246M2U5NjYzYjNlYjYyNDVlMDg5MTYyYWQ4MjZkNzgwMDFfMTA5OTUxMTcyMDQ4Mw_54fb330e-1b8d-4149-bebb-ff07cfef661e">20</ix:nonfraction> additional potential claimants who have not yet filed suit. These additional possible claims allege damages for pancreatic cancer or thyroid cancer.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Cialis Product Liability</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are named as a defendant in approximately <ix:nonfraction unitref="lawsuit" contextref="ib6d3474862f44a24b3440036451e55ce_I20220331" decimals="0" name="us-gaap:LossContingencyPendingClaimsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF83My9mcmFnOjNlOTY2M2IzZWI2MjQ1ZTA4OTE2MmFkODI2ZDc4MDAxL3RleHRyZWdpb246M2U5NjYzYjNlYjYyNDVlMDg5MTYyYWQ4MjZkNzgwMDFfMTA5OTUxMTcyMDQ4Nw_fa69dc46-d2a5-47c1-9d13-64a13d8c7f0a">350</ix:nonfraction> Cialis product liability lawsuits in the U.S. which were first initiated in August 2015. These cases, many of which were originally filed in various federal courts, contain allegations that Cialis caused or contributed to the plaintiffs' cancer (melanoma). In December 2016, the Judicial Panel on Multidistrict Litigation (JPML) granted the plaintiffs' petition to have filed cases and an unspecified number of future cases coordinated into a federal MDL in the U.S. District Court for the Northern District of California, alongside an existing coordinated proceeding involving Viagra</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The JPML ordered the transfer of the existing cases to the now-renamed MDL </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re: Viagra (Sildenafil Citrate) and Cialis (Tadalafil) Products Liability Litigation</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In April 2020, the MDL court granted summary judgment to the defendants on all of the claims brought against them by the plaintiffs. In May 2020, plaintiffs filed an appeal in the U.S. Court of Appeals for the Ninth Circuit. The parties have reached agreement to resolve the majority of claims pending in the appeal and expect those claims to soon be dismissed.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span><br></span></div></div><ix:continuation id="i64f714563b114c6c85deb26a4f537eec" continuedat="i091f8446d5574053b0addea8c756797f"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Jardiance Product Liability </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">First initiated in January 2019, we and Boehringer Ingelheim Pharmaceuticals, Inc., a subsidiary of BI, have been named as a defendant in <ix:nonfraction unitref="lawsuit" contextref="if0b4f0a651694b5593648d55c4eafddb_I20220331" decimals="INF" name="us-gaap:LossContingencyPendingClaimsNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF83My9mcmFnOjNlOTY2M2IzZWI2MjQ1ZTA4OTE2MmFkODI2ZDc4MDAxL3RleHRyZWdpb246M2U5NjYzYjNlYjYyNDVlMDg5MTYyYWQ4MjZkNzgwMDFfMTA5OTUxMTcyMDU2Ng_dfe2ca6c-4ce3-4409-ab5d-1ba1a7d6712e">five</ix:nonfraction> currently pending product liability lawsuits in Stamford Superior Court in Connecticut, alleging that Jardiance caused or contributed to plaintiffs' Fournier's gangrene. Our agreement with BI calls for BI to defend and indemnify us against any damages, costs, expenses, and certain other losses with respect to product liability claims in accordance with the terms of the agreement. All pending cases have been paused to allow for settlement negotiations and dismissals. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Environmental Proceedings</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Comprehensive Environmental Response, Compensation, and Liability Act, commonly known as "Superfund," we have been designated as one of several potentially responsible parties with respect to the cleanup of fewer than <ix:nonfraction unitref="site" contextref="if918188055b9499994107e688f363786_I20220331" decimals="0" name="lly:LossContingencyNumberOfSitesJointlyAndSeverallyLiableForCleanup" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF83My9mcmFnOjNlOTY2M2IzZWI2MjQ1ZTA4OTE2MmFkODI2ZDc4MDAxL3RleHRyZWdpb246M2U5NjYzYjNlYjYyNDVlMDg5MTYyYWQ4MjZkNzgwMDFfMTA5OTUxMTcyMDQ5MQ_4690a9f5-d51f-446f-b84b-3fca8376657b">10</ix:nonfraction> sites. Under Superfund, each responsible party may be jointly and severally liable for the entire amount of the cleanup.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Matters</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">340B Litigation and Investigations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are the plaintiff in a lawsuit filed in January 2021 in the U.S. District Court for the Southern District of Indiana against the U.S. Department of Health and Human Services (HHS), the Secretary of HHS, the Health Resources and Services Administration (HRSA), and the Administrator of HRSA. The lawsuit challenges the HHS's December 30, 2020 advisory opinion stating that drug manufacturers are required to deliver discounts under the 340B program to all contract pharmacies. We seek a declaratory judgment that the defendants violated the Administrative Procedures Act and the U.S. Constitution, a preliminary injunction enjoining implementation of the administrative dispute resolution process created by defendants and, with it, their application of the advisory opinion, and other related relief. In March 2021, the court entered an order preliminarily enjoining the government's enforcement of the administrative dispute resolution process against us. In May 2021, HRSA notified us that it determined that our policy was contrary to the 340B statute. In response, in May 2021, we filed a motion for preliminary injunction and temporary restraining order requesting that the U.S. District Court for the Southern District of Indiana enjoin defendants from taking any action against us relating to the 340B drug pricing program until after the court issues a final judgment on the aforementioned litigation. In May 2021, the court denied our motion for a temporary restraining order but deferred resolution of our motion for preliminary injunction. In June 2021, the defendants withdrew the HHS December 30, 2020 advisory opinion. In July 2021, the court held oral argument on the parties' cross motions for summary judgment, the defendants' motion to dismiss, and our motion for preliminary injunction related to HRSA's May 2021 enforcement letter. In October 2021, the court denied the defendants' motion to dismiss, and granted in part and denied in part the parties' cross motions for summary judgment. Both parties have filed notices of appeal related to the court's summary judgment order. In April 2022, the U.S. Court of Appeals for the Seventh Circuit remanded the case to the U.S. District Court for the Southern District of Indiana for the limited purpose of the district court amending its partial final judgment to ensure proper jurisdiction for the appeal. The district court amended its partial final judgment in April 2022, and the appeal will proceed to briefing in the U.S. Court of Appeals for the Seventh Circuit. This matter is ongoing.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, we, along with other pharmaceutical manufacturers, were named as a defendant in a petition currently pending before the HHS Administrative Dispute Resolution Panel. Petitioner seeks declaratory and other injunctive relief related to the 340B program. As described above, the U.S. District Court for the Southern District of Indiana has entered a preliminary injunction enjoining the government's enforcement of this administrative dispute resolution process against us. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2021, we, along with Sanofi-Aventis U.S., LLC (Sanofi), Novo Nordisk Inc. (Novo Nordisk), and AstraZeneca Pharmaceuticals LP, were named as a defendant in a purported class action lawsuit filed in the U.S. District Court for the Western District of New York by Mosaic Health, Inc. alleging antitrust and unjust enrichment claims related to the defendants' 340B distribution programs. We, with Sanofi and Novo Nordisk, filed a motion to dismiss the lawsuit. This matter is ongoing.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We received a civil investigative subpoena in February 2021 from the Office of the Attorney General for the State of Vermont relating to the sale of pharmaceutical products to Vermont covered entities under the 340B program. We are cooperating with this subpoena. </span></div></ix:continuation><div style="margin-top:6pt"><span><br></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span><br></span></div></div><ix:continuation id="i091f8446d5574053b0addea8c756797f" continuedat="i566b09bf3f8e4b59977126a674deb79d"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Branchburg Manufacturing Facility </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, we received a subpoena from the United States Department of Justice requesting the production of certain documents relating to our manufacturing site in Branchburg, New Jersey. We are cooperating with the subpoena.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Brazil Litigation – Cosmopolis Facility </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Labor Attorney Litigation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">First initiated in 2008, our subsidiary in Brazil, Eli Lilly do Brasil Limitada (Lilly Brasil), is named in a Public Civil Action brought by the Labor Public Attorney (LPA) for the 15th Region in the Labor Court of Paulinia, State of Sao Paulo, Brazil, (the Labor Court) alleging possible harm to employees and former employees caused by alleged exposure to soil and groundwater contaminants at a former Lilly Brasil manufacturing facility in Cosmopolis, Brazil, operated by the company between 1977 and 2003. In May 2014, the Labor Court judge ruled against Lilly Brasil, ordering it to undertake several actions, including some with unspecified financial impact, consisting primarily of paying lifetime health coverage for the employees and contractors who worked at the Cosmopolis facility for more than six months during the affected years and their children who were born during and after this period. We appealed this decision. In July 2018, the appeals court (TRT) generally affirmed the Labor Court's ruling, which included a liquidated award of&nbsp;<ix:nonfraction unitref="brl" contextref="i6e96d3ed596840c3888477bfb76cac53_D20180701-20180731" decimals="-6" name="us-gaap:LossContingencyDamagesAwardedValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF83My9mcmFnOjNlOTY2M2IzZWI2MjQ1ZTA4OTE2MmFkODI2ZDc4MDAxL3RleHRyZWdpb246M2U5NjYzYjNlYjYyNDVlMDg5MTYyYWQ4MjZkNzgwMDFfMTA5OTUxMTcyMDQ5NQ_934fff70-9cdd-4667-af7d-9e64cdbcaed3">300</ix:nonfraction>&nbsp;million&nbsp;Brazilian real. This <ix:nonfraction unitref="brl" contextref="i6e96d3ed596840c3888477bfb76cac53_D20180701-20180731" decimals="-6" name="us-gaap:LossContingencyDamagesAwardedValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF83My9mcmFnOjNlOTY2M2IzZWI2MjQ1ZTA4OTE2MmFkODI2ZDc4MDAxL3RleHRyZWdpb246M2U5NjYzYjNlYjYyNDVlMDg5MTYyYWQ4MjZkNzgwMDFfMTA5OTUxMTcyMDQ5OQ_934fff70-9cdd-4667-af7d-9e64cdbcaed3">300</ix:nonfraction>&nbsp;million Brazilian real liquidated award, when adjusted for inflation and the addition of pre and post judgment interest using the current Central Bank of Brazil's special system of clearance and custody rate, is approximately <ix:nonfraction unitref="brl" contextref="ie4f81fbc2bdd4384b1a0e69b7b581f32_D20220101-20220331" decimals="-9" name="us-gaap:LossContingencyDamagesAwardedValue" format="ixt-sec:numwordsen" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF83My9mcmFnOjNlOTY2M2IzZWI2MjQ1ZTA4OTE2MmFkODI2ZDc4MDAxL3RleHRyZWdpb246M2U5NjYzYjNlYjYyNDVlMDg5MTYyYWQ4MjZkNzgwMDFfMTA0NDUzNjA1NjEyNzk_8a0c1120-20a5-4d1c-aa1c-635a4e54852f">one</ix:nonfraction> billion Brazilian real (approximately $<ix:nonfraction unitref="usd" contextref="ie4f81fbc2bdd4384b1a0e69b7b581f32_D20220101-20220331" decimals="-6" name="us-gaap:LossContingencyDamagesAwardedValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF83My9mcmFnOjNlOTY2M2IzZWI2MjQ1ZTA4OTE2MmFkODI2ZDc4MDAxL3RleHRyZWdpb246M2U5NjYzYjNlYjYyNDVlMDg5MTYyYWQ4MjZkNzgwMDFfMTA0NDUzNjA1NjEzMDE_ce961250-14b0-4d96-9fbb-efac29178177">210</ix:nonfraction>&nbsp;million as of March 31, 2022). The TRT also restricted the broad health coverage awarded by the Labor Court to health problems that claimants could prove in a separate evidentiary proceeding arose from exposure to the alleged contamination. In August 2019, Lilly Brasil filed an appeal to the superior labor court (TST) and in June 2021, the TRT published its decision on the admissibility of Lilly Brasil's appeal, allowing the majority of the elements of the appeal to proceed; elements not proceeding are subject to an interlocutory appeal to the TST that was filed in June 2021. In September 2019, the TRT stayed a number of elements of its trial court decision pending the determination of Lilly Brasil's appeal to the TST.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2019, the LPA filed an application in the Labor Court for enforcement of the healthcare coverage granted by the TRT in its July 2018 ruling, requested restrictions on Lilly Brasil’s assets in Brazil, and required Lilly Brasil and Antibióticos do Brasil Ltda. (ABL) to submit a list of potential beneficiaries of the Public Civil Action for the LPA to identify and contact those individuals. In July 2019, the Labor Court issued a ruling requiring a freeze of Lilly Brasil’s immovable property or, alternatively, a security deposit or lien of <ix:nonfraction unitref="brl" contextref="idd3225fae7784a42ad47ca0c8eeb43b7_D20190701-20190731" decimals="-6" name="us-gaap:LossContingencyDamagesAwardedValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF83My9mcmFnOjNlOTY2M2IzZWI2MjQ1ZTA4OTE2MmFkODI2ZDc4MDAxL3RleHRyZWdpb246M2U5NjYzYjNlYjYyNDVlMDg5MTYyYWQ4MjZkNzgwMDFfMTA5OTUxMTcyMDUyOA_27b686a2-c1db-4c5a-9911-be3c6d5a2dbd">500</ix:nonfraction>&nbsp;million Brazilian real. Lilly Brasil filed a writ of mandamus challenging this ruling. In June 2021, the court reduced the security deposit or lien to <ix:nonfraction unitref="brl" contextref="i2a50fb0ce395452f949119ed0d6d50eb_D20210601-20210630" decimals="-6" name="us-gaap:LossContingencyDamagesAwardedValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF83My9mcmFnOjNlOTY2M2IzZWI2MjQ1ZTA4OTE2MmFkODI2ZDc4MDAxL3RleHRyZWdpb246M2U5NjYzYjNlYjYyNDVlMDg5MTYyYWQ4MjZkNzgwMDFfMTA5OTUxMTcyMDUzMg_6614d344-bb91-41ec-8ce0-5c54b6264380">100</ix:nonfraction>&nbsp;million Brazilian real and limited the scope of the initial order. ABL and LPA appealed to the TST, which appeal is currently still under review. In addition, in September 2020, the LPA initiated a second preliminary enforcement of the portion of the July 2018 TRT decision in the Labor Court that prohibits the exposure of workers to the contaminated areas. The Labor Court is currently assessing the status of Lilly Brasil’s compliance with such portion of the July 2018 TRT decision and an inspection in the industrial plant should be scheduled at some point. These matters are ongoing.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Individual Former Employee Litigation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lilly Brasil is also named in approximately <ix:nonfraction unitref="lawsuit" contextref="i70905cd2917f4e9ea9656f7b89cde516_I20220331" decimals="0" name="us-gaap:LossContingencyPendingClaimsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF83My9mcmFnOjNlOTY2M2IzZWI2MjQ1ZTA4OTE2MmFkODI2ZDc4MDAxL3RleHRyZWdpb246M2U5NjYzYjNlYjYyNDVlMDg5MTYyYWQ4MjZkNzgwMDFfMTA5OTUxMTcyNTE1MQ_2f15e789-fe5a-46df-a8fd-d294fbd2162e">27</ix:nonfraction> pending&nbsp;lawsuits filed in the Labor Court by individual former employees making similar claims. These lawsuits are each at various stages in the litigation process, with judgments being handed down in more than half of the lawsuits by the trial courts, of which, approximately half of those judgments are on appeal in the labor courts.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Puerto Rico Tax Matter</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2013, the Municipality of Carolina in Puerto Rico (Municipality) filed a lawsuit against us alleging noncompliance with respect to a contract with the Municipality and seeking a declaratory judgment. In December 2020, the Puerto Rico Appellate Court (AP) reversed the summary judgment previously granted by the Court of First Instance (CFI) in our favor, dismissing the Municipality's complaint in its entirety. The AP remanded the case to the CFI for trial on the merits and trial has been scheduled to begin in May and continue in September 2022.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, the Municipality filed a motion to execute a purported judgment, and the CFI scheduled a hearing in March 2022 to consider the Municipality's motion. In April 2022, the CFI denied the Municipality's motion. This matter is ongoing. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span><br></span></div></div><ix:continuation id="i566b09bf3f8e4b59977126a674deb79d" continuedat="i386c263c2528480a85ff57c94bd501b7"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Eastern District of Pennsylvania Pricing (Average Manufacturer Price) Inquiry</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2014, we, along with another pharmaceutical manufacturer, were named as co-defendants in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">United States et al. ex rel. Streck v. Takeda Pharm. Am., Inc., et al.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which was filed in November 2014 and unsealed in the U.S. District Court for the Northern District of Illinois. The complaint alleges that the defendants should have treated certain credits from distributors as retroactive price increases and included such increases in calculating average manufacturer prices. In October 2021 the parties filed cross motions for summary judgment. In February 2022, the U.S. District Court denied our motion and partially granted the relator's motion. In March 2022, we filed a motion for interlocutory appeal and the relator filed a motion for reconsideration of the court's summary judgment rulings. Both motions were denied, and the court set trial to begin in July 2022.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Health Choice Alliance </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are named as a defendant in a lawsuit filed in June 2017 in the U.S. District Court for the Eastern District of Texas seeking damages under the federal anti-kickback statute and state and federal false claims acts for certain patient support programs related to our products Humalog, Humulin, and Forteo. In September 2019, the U.S. District Court granted the U.S. Department of Justice's motion to dismiss the relator's second amended complaint. In January 2020, the relator appealed the District Court's dismissal to the U.S. Court of Appeals for the Fifth Circuit. In July 2021, the U.S. Court of Appeals for the Fifth Circuit affirmed the dismissal of the lawsuit, and the relator did not petition the U.S. Supreme Court for certiorari.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also named as a defendant in <ix:nonfraction unitref="lawsuit" contextref="ie73ca8ee0e6e4d9daed3c9d94a4e6c83_I20220331" decimals="INF" name="us-gaap:LossContingencyPendingClaimsNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF83My9mcmFnOjNlOTY2M2IzZWI2MjQ1ZTA4OTE2MmFkODI2ZDc4MDAxL3RleHRyZWdpb246M2U5NjYzYjNlYjYyNDVlMDg5MTYyYWQ4MjZkNzgwMDFfMTA5OTUxMTcyMDU1MA_841fc9a8-49be-43a1-b8b0-94d59fb51c75">two</ix:nonfraction> similar lawsuits filed in Texas and New Jersey state courts in October 2019 seeking damages under the Texas Medicaid Fraud Prevention Act and New Jersey Medicaid False Claims Act, respectively. In November 2020, the Texas state court action was stayed pending a final determination with respect to the aforementioned federal lawsuit. In April 2021, the New Jersey state court action was dismissed with prejudice and in June 2021, the relator appealed the state court's decision to the Appellate Division of the New Jersey Superior Court. In January 2022, the relator filed its appellate brief and we filed our response in March 2022.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Pricing Litigation, Investigations, and Inquiries</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Litigation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2017, we, along with Sanofi and Novo Nordisk were named as defendants in a consolidated purported class action lawsuit,&nbsp;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re. Insulin Pricing Litigation</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in the U.S. District Court for the District of New Jersey relating to insulin pricing seeking damages under various state consumer protection laws and the Federal Racketeer Influenced and Corrupt Organization Act (federal RICO Act). Separately, in February 2018, we, along with Sanofi and Novo Nordisk, were named as defendants in&nbsp;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">MSP Recovery Claims, Series, LLC et al. v. Sanofi Aventis U.S. LLC et al.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in the same court, seeking damages under various state consumer protection laws, common law fraud, unjust enrichment, and the federal RICO Act. In both</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> In re. Insulin Pricing Litigation </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and the</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> MSP Recovery Claims</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> litigation, the court dismissed claims under the federal RICO Act and certain state laws. In April 2021, the plaintiffs in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re. Insulin Pricing Litigation</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> amended their complaint to allege additional state law claims for civil conspiracy and violations of state RICO statutes. The court has allowed the Arizona RICO statute and certain state civil conspiracy law claims to proceed.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also, we, along with Sanofi, Novo Nordisk, CVS, Express Scripts, and Optum, have been sued in a purported class action, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">FWK Holdings, LLC v. Novo Nordisk Inc., et al., </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">filed in the same court in November 2020, for alleged violations of the federal RICO Act as well as the New Jersey RICO Act and antitrust law. That same group of defendants, along with Medco Health and United Health Group, also have been sued in other purported class actions in the same court, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Rochester Drug Co-Operative Inc. v. Eli Lilly &amp; Co. et al. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Value Drug Co. v. Eli Lilly &amp; Co. et al. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">both initiated in March 2020, for alleged violations of the federal RICO Act. In September 2020, the U.S. District Court for the District of New Jersey granted plaintiffs' motion to consolidate </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">FWK Holdings, LLC v. Novo Nordisk Inc., et al.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Rochester Drug Co-Operative Inc. v. Eli Lilly &amp; Co. et al.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Value Drug Co. v. Eli Lilly &amp; Co. et al. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2021, the U.S. District Court for the District of New Jersey dismissed the <ix:nonfraction unitref="claim" contextref="i95fbc04e0e8d45eb8a79226c271ed1a7_D20210701-20210731" decimals="INF" name="lly:LitigationClaimsDismissedNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF83My9mcmFnOjNlOTY2M2IzZWI2MjQ1ZTA4OTE2MmFkODI2ZDc4MDAxL3RleHRyZWdpb246M2U5NjYzYjNlYjYyNDVlMDg5MTYyYWQ4MjZkNzgwMDFfMTA5OTUxMTcyMDU1OA_ee395999-1430-4522-bdfd-048c8354b211">three</ix:nonfraction> antitrust claims alleged by plaintiffs in the consolidated litigation and denied dismissal of the RICO claims.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span><br></span></div></div><ix:continuation id="i386c263c2528480a85ff57c94bd501b7" continuedat="i8a30df14a14a43ad978ce1ed158f9811"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018, the Minnesota Attorney General's Office initiated litigation against us, Sanofi, and Novo Nordisk,&nbsp;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">State of Minnesota v. Sanofi-Aventis U.S. LLC et al.,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&nbsp;in the U.S. District Court for the District of New Jersey, alleging unjust enrichment, violations of various Minnesota state consumer protection laws, and the federal RICO Act. In March 2021, the U.S. District Court for the District of New Jersey dismissed with prejudice the Minnesota Attorney General's federal RICO claims and false advertising claims under state law; the consumer fraud and other related state law claims remain ongoing. Additionally, in May 2019, the Kentucky Attorney General's Office filed a complaint against us, Sanofi, and Novo Nordisk,&nbsp;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Commonwealth of Kentucky v. Novo Nordisk, Inc. et al.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in Kentucky state court, alleging violations of the Kentucky consumer protection law, false advertising, and unjust enrichment. In November 2019, Harris County in Texas initiated litigation against us, Sanofi, Novo Nordisk, Express Scripts, CVS, Optum, and Aetna, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">County of</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Harris Texas v. Eli Lilly &amp; Co., et al.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in federal court in the Southern District of Texas alleging violations of the federal RICO Act, the state deceptive trade practices-consumer protection act, and common law claims such as fraud, unjust enrichment, and civil conspiracy. Harris County also alleged violations of federal and state antitrust law, but voluntarily dismissed them. This lawsuit relates to our insulin products as well as Trulicity. In March 2022, the Court entered final judgment for all defendants and dismissed all remaining claims with prejudice.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021, the City of Miami, Florida initiated litigation against us, Sanofi, Novo Nordisk, ESI, CVS/Caremark/Aetna, and Optum, asserting state law antitrust, common law fraud, money had and received, unjust enrichment, and civil conspiracy claims. After removing the case to federal court, we, along with the other defendants, filed a motion to dismiss the lawsuit. In January 2022, the court granted the motion in part but has allowed the antitrust and conspiracy claims to proceed against us, Sanofi and Novo Nordisk. We, along with Sanofi and Novo Nordisk, have moved the court to reconsider its denial of our motion to dismiss the antitrust and conspiracy claims.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021, the Mississippi Attorney General's Office initiated litigation against us, Sanofi, Novo Nordisk, Evernorth/ESI, CVS/Caremark, and United/Optum in the Hinds County, Mississippi Chancery Court, alleging state law consumer protection, unjust enrichment, and civil conspiracy claims. After the case was removed to federal court, we, along with the other defendants, filed a motion to dismiss the lawsuit. This matter is ongoing.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investigations, Subpoenas, and Inquiries</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We received subpoenas from the New York and Vermont Attorney General Offices and civil investigative demands from the Washington, New Mexico, and Colorado Attorney General Offices relating to the pricing and sale of our insulin products. The Offices of the Attorney General in Mississippi, Washington D.C., California, Florida, Hawaii, and Nevada have requested information relating to the pricing and sale of our insulin products. We also received interrogatories and a subpoena from the California Attorney General's Office regarding our competition in the long-acting insulin market, which was subsequently withdrawn in June 2021. In January 2022, the Michigan Attorney General filed against us in state court a petition seeking authorization to investigate Lilly for potential violations of the Michigan Consumer Protection Act (MCPA), and a complaint seeking a declaratory judgment that the MCPA applies to the conduct it seeks to investigate and allows it to conduct the investigation. The state court granted the State's petition to investigate, authorizing the State to issue civil investigative subpoenas. The State's complaint for declaratory judgment remains pending. In March 2022, we filed a motion for summary disposition in the State's declaratory judgment action seeking judgment in our favor. Hearing on our motion for summary disposition is scheduled for September 2022. In April 2022, the parties entered into a stipulation providing that the State will not issue any civil investigative subpoena to us under the MCPA until the declaratory judgment action is resolved.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We received a request in January 2019 from the House of Representatives' Committee on Oversight and Reform seeking commercial information and business records related to the pricing of insulin products, among other issues. We also received requests from the Senate Finance Committee and the Senate Committee on Health, Education, Labor, and Pensions, and separate requests from the House Committee on Energy and Commerce majority and minority members. Those requests sought pricing and other commercial information regarding Lilly's insulin products. In January 2021, the Senate Finance Committee released a report summarizing the findings of its investigation. In December 2021 the House of Representatives' Committee on Oversight and Reform majority and minority staffs released separate reports with findings from their investigations into drug pricing, including of insulin products.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are cooperating with all of these aforementioned investigations, subpoenas, and inquiries.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span><br></span></div></div><ix:continuation id="i8a30df14a14a43ad978ce1ed158f9811"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Research Corporation Technologies, Inc. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2016, we were named as a defendant in litigation filed by Research Corporation Technologies, Inc. (RCT) in the U.S. District Court for the District of Arizona. RCT is seeking damages for breach of contract, unjust enrichment, and conversion related to processes used to manufacture certain products, including Humalog and Humulin. Both parties moved for summary judgment and hearing on the motions took place in August 2021. In October 2021, the Court issued a summary judgment decision finding in favor of RCT on certain issues, including with respect to a disputed royalty. Both parties filed motions for reconsideration. This matter is ongoing. Potential damages payable under the litigation, if finally awarded after an appeal, could be material but are not currently reasonably estimable. A trial date has not been set.</span></div></ix:continuation><div style="margin-top:6pt"><span><br></span></div><div id="ie8dc61f8e15b44db82ba16050d5b7b44_79"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 10: <ix:nonnumeric contextref="id879b497a407453985551e83dbee75f8_D20220101-20220331" name="us-gaap:ComprehensiveIncomeNoteTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF83OS9mcmFnOmM4OTQxNTM1MDg1NTQ3ZmViMmI5ZGFjNmIwOTZmOWM2L3RleHRyZWdpb246Yzg5NDE1MzUwODU1NDdmZWIyYjlkYWM2YjA5NmY5YzZfMTI1Mw_37d1f408-cfab-42b3-aca9-970f24f0fa47" continuedat="ic9bf3cb05b70426a808d86bddffe6642" escape="true">Other Comprehensive Income (Loss)</ix:nonnumeric></span></div><ix:continuation id="ic9bf3cb05b70426a808d86bddffe6642" continuedat="if3592a2d71b44d3c9f81c3460b2ee7c9"><ix:nonnumeric contextref="id879b497a407453985551e83dbee75f8_D20220101-20220331" name="us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF83OS9mcmFnOmM4OTQxNTM1MDg1NTQ3ZmViMmI5ZGFjNmIwOTZmOWM2L3RleHRyZWdpb246Yzg5NDE1MzUwODU1NDdmZWIyYjlkYWM2YjA5NmY5YzZfMTI0OA_97ab11dd-2bc2-488d-bbef-89f5a8695be3" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the activity related to each component of other comprehensive income (loss) during the three months ended March&nbsp;31, 2022 and 2021:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:40.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.601%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Amounts presented net of taxes)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Foreign Currency Translation Gains&nbsp;(Losses)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Unrealized Net Gains (Losses) on&nbsp;Securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Defined Benefit Pension and Retiree&nbsp;Health Benefit Plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Effective Portion of Cash&nbsp;Flow Hedges</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Loss</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at January 1, 2022</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i3406df20fd464dd9b628ff7336f0147b_I20211231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF83OS9mcmFnOmM4OTQxNTM1MDg1NTQ3ZmViMmI5ZGFjNmIwOTZmOWM2L3RhYmxlOmY4MjM1YjA3MDU2ZjQ1MGQ4MzdjM2YzZjM0MGVhYTMyL3RhYmxlcmFuZ2U6ZjgyMzViMDcwNTZmNDUwZDgzN2MzZjNmMzQwZWFhMzJfMi0xLTEtMS0xMDExOTA_9ce0ac30-7fff-4bad-85b4-a8e5f61a5446">1,550.2</ix:nonfraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i087fe911320144b2b4f1ba2c3e5095fd_I20211231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF83OS9mcmFnOmM4OTQxNTM1MDg1NTQ3ZmViMmI5ZGFjNmIwOTZmOWM2L3RhYmxlOmY4MjM1YjA3MDU2ZjQ1MGQ4MzdjM2YzZjM0MGVhYTMyL3RhYmxlcmFuZ2U6ZjgyMzViMDcwNTZmNDUwZDgzN2MzZjNmMzQwZWFhMzJfMi0zLTEtMS0xMDExOTA_2896e6af-3cfa-480c-af3c-b3bb466e99d5">3.7</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i4e984bf7c681488f894796459d18d344_I20211231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF83OS9mcmFnOmM4OTQxNTM1MDg1NTQ3ZmViMmI5ZGFjNmIwOTZmOWM2L3RhYmxlOmY4MjM1YjA3MDU2ZjQ1MGQ4MzdjM2YzZjM0MGVhYTMyL3RhYmxlcmFuZ2U6ZjgyMzViMDcwNTZmNDUwZDgzN2MzZjNmMzQwZWFhMzJfMi01LTEtMS0xMDExOTA_bd7b7df3-1dc1-45cb-bb48-92e2193cb4e9">2,583.6</ix:nonfraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i63f3aeca8ebc4fc48c149e0dc34d9e03_I20211231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF83OS9mcmFnOmM4OTQxNTM1MDg1NTQ3ZmViMmI5ZGFjNmIwOTZmOWM2L3RhYmxlOmY4MjM1YjA3MDU2ZjQ1MGQ4MzdjM2YzZjM0MGVhYTMyL3RhYmxlcmFuZ2U6ZjgyMzViMDcwNTZmNDUwZDgzN2MzZjNmMzQwZWFhMzJfMi03LTEtMS0xMDExOTA_8b175a62-1170-498a-b90c-09bc2163a587">213.0</ix:nonfraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i87e3fc7b2721478cade3b06e9ff2cf9d_I20211231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF83OS9mcmFnOmM4OTQxNTM1MDg1NTQ3ZmViMmI5ZGFjNmIwOTZmOWM2L3RhYmxlOmY4MjM1YjA3MDU2ZjQ1MGQ4MzdjM2YzZjM0MGVhYTMyL3RhYmxlcmFuZ2U6ZjgyMzViMDcwNTZmNDUwZDgzN2MzZjNmMzQwZWFhMzJfMi0xMS0xLTEtMTAxMTkw_4718668f-a400-41c3-9e1a-6bb6f45138ca">4,343.1</ix:nonfraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i7e3cba541d0a4e009649fa4e6541f00f_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF83OS9mcmFnOmM4OTQxNTM1MDg1NTQ3ZmViMmI5ZGFjNmIwOTZmOWM2L3RhYmxlOmY4MjM1YjA3MDU2ZjQ1MGQ4MzdjM2YzZjM0MGVhYTMyL3RhYmxlcmFuZ2U6ZjgyMzViMDcwNTZmNDUwZDgzN2MzZjNmMzQwZWFhMzJfNC0xLTEtMS0xMDExOTA_a8ec4737-0e59-4565-ad3c-5d7d77b56aed">25.0</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ica0cd664995e4709a85c79d4a83025b5_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF83OS9mcmFnOmM4OTQxNTM1MDg1NTQ3ZmViMmI5ZGFjNmIwOTZmOWM2L3RhYmxlOmY4MjM1YjA3MDU2ZjQ1MGQ4MzdjM2YzZjM0MGVhYTMyL3RhYmxlcmFuZ2U6ZjgyMzViMDcwNTZmNDUwZDgzN2MzZjNmMzQwZWFhMzJfNC0zLTEtMS0xMDExOTA_eebba8bd-9b92-4c13-a503-b62e14ee054c">21.3</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i1264e1c80a3841eba0ebd86ccd829da3_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF83OS9mcmFnOmM4OTQxNTM1MDg1NTQ3ZmViMmI5ZGFjNmIwOTZmOWM2L3RhYmxlOmY4MjM1YjA3MDU2ZjQ1MGQ4MzdjM2YzZjM0MGVhYTMyL3RhYmxlcmFuZ2U6ZjgyMzViMDcwNTZmNDUwZDgzN2MzZjNmMzQwZWFhMzJfNC01LTEtMS0xMDExOTA_809edf1e-2630-4e25-b8ce-fd18d7bdfde7">6.6</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i96a2b7a2a70a4e939b41906248dbfaa2_D20220101-20220331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF83OS9mcmFnOmM4OTQxNTM1MDg1NTQ3ZmViMmI5ZGFjNmIwOTZmOWM2L3RhYmxlOmY4MjM1YjA3MDU2ZjQ1MGQ4MzdjM2YzZjM0MGVhYTMyL3RhYmxlcmFuZ2U6ZjgyMzViMDcwNTZmNDUwZDgzN2MzZjNmMzQwZWFhMzJfNC03LTEtMS0xMDExOTA_e3eca668-f022-4d1a-8200-68be73fb8607">109.4</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="id879b497a407453985551e83dbee75f8_D20220101-20220331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF83OS9mcmFnOmM4OTQxNTM1MDg1NTQ3ZmViMmI5ZGFjNmIwOTZmOWM2L3RhYmxlOmY4MjM1YjA3MDU2ZjQ1MGQ4MzdjM2YzZjM0MGVhYTMyL3RhYmxlcmFuZ2U6ZjgyMzViMDcwNTZmNDUwZDgzN2MzZjNmMzQwZWFhMzJfNC0xMS0xLTEtMTAxMTkw_66d930f6-efed-4032-91e9-2fc597c04545">56.5</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net amount reclassified from accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i7e3cba541d0a4e009649fa4e6541f00f_D20220101-20220331" decimals="-5" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF83OS9mcmFnOmM4OTQxNTM1MDg1NTQ3ZmViMmI5ZGFjNmIwOTZmOWM2L3RhYmxlOmY4MjM1YjA3MDU2ZjQ1MGQ4MzdjM2YzZjM0MGVhYTMyL3RhYmxlcmFuZ2U6ZjgyMzViMDcwNTZmNDUwZDgzN2MzZjNmMzQwZWFhMzJfNS0xLTEtMS0xMDExOTA_e9b98f35-3abb-4bc0-9a87-a5722ccfe6da">—</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ica0cd664995e4709a85c79d4a83025b5_D20220101-20220331" decimals="-5" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF83OS9mcmFnOmM4OTQxNTM1MDg1NTQ3ZmViMmI5ZGFjNmIwOTZmOWM2L3RhYmxlOmY4MjM1YjA3MDU2ZjQ1MGQ4MzdjM2YzZjM0MGVhYTMyL3RhYmxlcmFuZ2U6ZjgyMzViMDcwNTZmNDUwZDgzN2MzZjNmMzQwZWFhMzJfNS0zLTEtMS0xMDExOTA_9166c67c-0a82-42e8-8783-2035a90cb72a">0.5</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i1264e1c80a3841eba0ebd86ccd829da3_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF83OS9mcmFnOmM4OTQxNTM1MDg1NTQ3ZmViMmI5ZGFjNmIwOTZmOWM2L3RhYmxlOmY4MjM1YjA3MDU2ZjQ1MGQ4MzdjM2YzZjM0MGVhYTMyL3RhYmxlcmFuZ2U6ZjgyMzViMDcwNTZmNDUwZDgzN2MzZjNmMzQwZWFhMzJfNS01LTEtMS0xMDExOTA_076bd211-807d-4cce-9906-7f98e5bd8715">58.6</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i96a2b7a2a70a4e939b41906248dbfaa2_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF83OS9mcmFnOmM4OTQxNTM1MDg1NTQ3ZmViMmI5ZGFjNmIwOTZmOWM2L3RhYmxlOmY4MjM1YjA3MDU2ZjQ1MGQ4MzdjM2YzZjM0MGVhYTMyL3RhYmxlcmFuZ2U6ZjgyMzViMDcwNTZmNDUwZDgzN2MzZjNmMzQwZWFhMzJfNS03LTEtMS0xMDExOTA_73c5ead9-9d5b-442d-92a4-bb5162d612d9">3.2</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="id879b497a407453985551e83dbee75f8_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF83OS9mcmFnOmM4OTQxNTM1MDg1NTQ3ZmViMmI5ZGFjNmIwOTZmOWM2L3RhYmxlOmY4MjM1YjA3MDU2ZjQ1MGQ4MzdjM2YzZjM0MGVhYTMyL3RhYmxlcmFuZ2U6ZjgyMzViMDcwNTZmNDUwZDgzN2MzZjNmMzQwZWFhMzJfNS0xMS0xLTEtMTAxMTkw_fab826ad-0f3c-48aa-b1d8-dba5f3213380">61.3</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i7e3cba541d0a4e009649fa4e6541f00f_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF83OS9mcmFnOmM4OTQxNTM1MDg1NTQ3ZmViMmI5ZGFjNmIwOTZmOWM2L3RhYmxlOmY4MjM1YjA3MDU2ZjQ1MGQ4MzdjM2YzZjM0MGVhYTMyL3RhYmxlcmFuZ2U6ZjgyMzViMDcwNTZmNDUwZDgzN2MzZjNmMzQwZWFhMzJfNi0xLTEtMS0xMDExOTA_e5d316a8-0c3b-470f-ac5a-379d16b373d0">25.0</ix:nonfraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ica0cd664995e4709a85c79d4a83025b5_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF83OS9mcmFnOmM4OTQxNTM1MDg1NTQ3ZmViMmI5ZGFjNmIwOTZmOWM2L3RhYmxlOmY4MjM1YjA3MDU2ZjQ1MGQ4MzdjM2YzZjM0MGVhYTMyL3RhYmxlcmFuZ2U6ZjgyMzViMDcwNTZmNDUwZDgzN2MzZjNmMzQwZWFhMzJfNi0zLTEtMS0xMDExOTA_880a7ac3-a17f-42fc-b9cd-11c3abbd2605">21.8</ix:nonfraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i1264e1c80a3841eba0ebd86ccd829da3_D20220101-20220331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF83OS9mcmFnOmM4OTQxNTM1MDg1NTQ3ZmViMmI5ZGFjNmIwOTZmOWM2L3RhYmxlOmY4MjM1YjA3MDU2ZjQ1MGQ4MzdjM2YzZjM0MGVhYTMyL3RhYmxlcmFuZ2U6ZjgyMzViMDcwNTZmNDUwZDgzN2MzZjNmMzQwZWFhMzJfNi01LTEtMS0xMDExOTA_a121c377-e29d-4e66-8839-74b6c4a8c263">52.0</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i96a2b7a2a70a4e939b41906248dbfaa2_D20220101-20220331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF83OS9mcmFnOmM4OTQxNTM1MDg1NTQ3ZmViMmI5ZGFjNmIwOTZmOWM2L3RhYmxlOmY4MjM1YjA3MDU2ZjQ1MGQ4MzdjM2YzZjM0MGVhYTMyL3RhYmxlcmFuZ2U6ZjgyMzViMDcwNTZmNDUwZDgzN2MzZjNmMzQwZWFhMzJfNi03LTEtMS0xMDExOTA_6a4adae1-1fd2-46fc-aba7-086686b06028">112.6</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="id879b497a407453985551e83dbee75f8_D20220101-20220331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF83OS9mcmFnOmM4OTQxNTM1MDg1NTQ3ZmViMmI5ZGFjNmIwOTZmOWM2L3RhYmxlOmY4MjM1YjA3MDU2ZjQ1MGQ4MzdjM2YzZjM0MGVhYTMyL3RhYmxlcmFuZ2U6ZjgyMzViMDcwNTZmNDUwZDgzN2MzZjNmMzQwZWFhMzJfNi0xMS0xLTEtMTAxMTkw_c9995e20-efb5-4edc-9dd2-7883dd22c202">117.8</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31, 2022</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i97559604e1bd4db9b3a4c3b5006db686_I20220331" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF83OS9mcmFnOmM4OTQxNTM1MDg1NTQ3ZmViMmI5ZGFjNmIwOTZmOWM2L3RhYmxlOmY4MjM1YjA3MDU2ZjQ1MGQ4MzdjM2YzZjM0MGVhYTMyL3RhYmxlcmFuZ2U6ZjgyMzViMDcwNTZmNDUwZDgzN2MzZjNmMzQwZWFhMzJfOC0xLTEtMS0xMDExOTA_1bb00780-a940-420c-8e7d-fc496a645e33">1,575.2</ix:nonfraction>)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i781dc404e04b4f40b1f028a37448086a_I20220331" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF83OS9mcmFnOmM4OTQxNTM1MDg1NTQ3ZmViMmI5ZGFjNmIwOTZmOWM2L3RhYmxlOmY4MjM1YjA3MDU2ZjQ1MGQ4MzdjM2YzZjM0MGVhYTMyL3RhYmxlcmFuZ2U6ZjgyMzViMDcwNTZmNDUwZDgzN2MzZjNmMzQwZWFhMzJfOC0zLTEtMS0xMDExOTA_f2f43548-bc28-4247-807d-bee33944923e">18.1</ix:nonfraction>)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i965f5355532246c29d1f56782a835356_I20220331" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF83OS9mcmFnOmM4OTQxNTM1MDg1NTQ3ZmViMmI5ZGFjNmIwOTZmOWM2L3RhYmxlOmY4MjM1YjA3MDU2ZjQ1MGQ4MzdjM2YzZjM0MGVhYTMyL3RhYmxlcmFuZ2U6ZjgyMzViMDcwNTZmNDUwZDgzN2MzZjNmMzQwZWFhMzJfOC01LTEtMS0xMDExOTA_5c82f6fe-8520-415a-a29c-77c9916736cf">2,531.6</ix:nonfraction>)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i97068b2af2e444778875e9cd92100ab1_I20220331" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF83OS9mcmFnOmM4OTQxNTM1MDg1NTQ3ZmViMmI5ZGFjNmIwOTZmOWM2L3RhYmxlOmY4MjM1YjA3MDU2ZjQ1MGQ4MzdjM2YzZjM0MGVhYTMyL3RhYmxlcmFuZ2U6ZjgyMzViMDcwNTZmNDUwZDgzN2MzZjNmMzQwZWFhMzJfOC03LTEtMS0xMDExOTA_0b717cbc-18c1-4c37-9ddf-f8dcc66eec96">100.4</ix:nonfraction>)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ie4b77a20953648e5bd4cea2cbbad1bd0_I20220331" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF83OS9mcmFnOmM4OTQxNTM1MDg1NTQ3ZmViMmI5ZGFjNmIwOTZmOWM2L3RhYmxlOmY4MjM1YjA3MDU2ZjQ1MGQ4MzdjM2YzZjM0MGVhYTMyL3RhYmxlcmFuZ2U6ZjgyMzViMDcwNTZmNDUwZDgzN2MzZjNmMzQwZWFhMzJfOC0xMS0xLTEtMTAxMTkw_922032c1-c9b3-4a6d-854f-9b08f3253203">4,225.3</ix:nonfraction>)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:40.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.455%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Amounts presented net of taxes)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Foreign Currency Translation Gains&nbsp;(Losses)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Unrealized Net Gains (Losses) on&nbsp;Securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Defined Benefit Pension and Retiree&nbsp;Health Benefit Plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Effective Portion of Cash&nbsp;Flow Hedges</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Loss</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at January 1, 2021</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i5bb4023f758742fbb1aba4311f25f8fa_I20201231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF83OS9mcmFnOmM4OTQxNTM1MDg1NTQ3ZmViMmI5ZGFjNmIwOTZmOWM2L3RhYmxlOjkzNzllMzVmMGZlNTRkNjFhYjMxZDFlOTliNWVjODA5L3RhYmxlcmFuZ2U6OTM3OWUzNWYwZmU1NGQ2MWFiMzFkMWU5OWI1ZWM4MDlfMi0xLTEtMS0xMDExOTA_4322eb3a-468c-442b-a1af-ff685fdfd913">1,427.5</ix:nonfraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ifd62b433d8224c8b9d454c6c10a97c2c_I20201231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF83OS9mcmFnOmM4OTQxNTM1MDg1NTQ3ZmViMmI5ZGFjNmIwOTZmOWM2L3RhYmxlOjkzNzllMzVmMGZlNTRkNjFhYjMxZDFlOTliNWVjODA5L3RhYmxlcmFuZ2U6OTM3OWUzNWYwZmU1NGQ2MWFiMzFkMWU5OWI1ZWM4MDlfMi0zLTEtMS0xMDExOTA_f42b8ad9-a70d-4af0-bf00-79d93d4e1fd1">14.8</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i5e3de19f839441f285e2a284f1990c7e_I20201231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF83OS9mcmFnOmM4OTQxNTM1MDg1NTQ3ZmViMmI5ZGFjNmIwOTZmOWM2L3RhYmxlOjkzNzllMzVmMGZlNTRkNjFhYjMxZDFlOTliNWVjODA5L3RhYmxlcmFuZ2U6OTM3OWUzNWYwZmU1NGQ2MWFiMzFkMWU5OWI1ZWM4MDlfMi01LTEtMS0xMDExOTA_c94404e8-e5b9-404c-b0f6-6cae793402e4">4,751.0</ix:nonfraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="idcd9436eeb374ea5be496e207dcf7514_I20201231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF83OS9mcmFnOmM4OTQxNTM1MDg1NTQ3ZmViMmI5ZGFjNmIwOTZmOWM2L3RhYmxlOjkzNzllMzVmMGZlNTRkNjFhYjMxZDFlOTliNWVjODA5L3RhYmxlcmFuZ2U6OTM3OWUzNWYwZmU1NGQ2MWFiMzFkMWU5OWI1ZWM4MDlfMi03LTEtMS0xMDExOTA_65328b87-1e06-43e5-8b90-2acaf5b453d8">332.7</ix:nonfraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i819715854c1c4107a53610bac955ae0c_I20201231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF83OS9mcmFnOmM4OTQxNTM1MDg1NTQ3ZmViMmI5ZGFjNmIwOTZmOWM2L3RhYmxlOjkzNzllMzVmMGZlNTRkNjFhYjMxZDFlOTliNWVjODA5L3RhYmxlcmFuZ2U6OTM3OWUzNWYwZmU1NGQ2MWFiMzFkMWU5OWI1ZWM4MDlfMi0xMS0xLTEtMTAxMTkw_ff550bf2-c33f-4fd0-acc4-57662320094a">6,496.4</ix:nonfraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ia38dbf3e877a4be7a3da76e0f940e927_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF83OS9mcmFnOmM4OTQxNTM1MDg1NTQ3ZmViMmI5ZGFjNmIwOTZmOWM2L3RhYmxlOjkzNzllMzVmMGZlNTRkNjFhYjMxZDFlOTliNWVjODA5L3RhYmxlcmFuZ2U6OTM3OWUzNWYwZmU1NGQ2MWFiMzFkMWU5OWI1ZWM4MDlfNC0xLTEtMS0xMDExOTA_0be3355b-6e2a-4ac3-b7ba-aec6883f40b3">249.7</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i3d2a23c7f59f40c9828167248f215f5d_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF83OS9mcmFnOmM4OTQxNTM1MDg1NTQ3ZmViMmI5ZGFjNmIwOTZmOWM2L3RhYmxlOjkzNzllMzVmMGZlNTRkNjFhYjMxZDFlOTliNWVjODA5L3RhYmxlcmFuZ2U6OTM3OWUzNWYwZmU1NGQ2MWFiMzFkMWU5OWI1ZWM4MDlfNC0zLTEtMS0xMDExOTA_a1d44eee-d7fd-4555-afa0-7dcaa038d1c3">10.8</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if118f56641f64a2783ec07ba485ec5f8_D20210101-20210331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF83OS9mcmFnOmM4OTQxNTM1MDg1NTQ3ZmViMmI5ZGFjNmIwOTZmOWM2L3RhYmxlOjkzNzllMzVmMGZlNTRkNjFhYjMxZDFlOTliNWVjODA5L3RhYmxlcmFuZ2U6OTM3OWUzNWYwZmU1NGQ2MWFiMzFkMWU5OWI1ZWM4MDlfNC01LTEtMS0xMDExOTA_9807bbe6-a79c-491c-b1d8-9569ab1559f6">18.8</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="id0d0a8013d5b45319209e6933a127c1c_D20210101-20210331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF83OS9mcmFnOmM4OTQxNTM1MDg1NTQ3ZmViMmI5ZGFjNmIwOTZmOWM2L3RhYmxlOjkzNzllMzVmMGZlNTRkNjFhYjMxZDFlOTliNWVjODA5L3RhYmxlcmFuZ2U6OTM3OWUzNWYwZmU1NGQ2MWFiMzFkMWU5OWI1ZWM4MDlfNC03LTEtMS0xMDExOTA_74ba6b59-85c1-4137-87aa-1e6cc2e19d69">252.8</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i010e4c0d9c6246be91d37e31d569fa6f_D20210101-20210331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF83OS9mcmFnOmM4OTQxNTM1MDg1NTQ3ZmViMmI5ZGFjNmIwOTZmOWM2L3RhYmxlOjkzNzllMzVmMGZlNTRkNjFhYjMxZDFlOTliNWVjODA5L3RhYmxlcmFuZ2U6OTM3OWUzNWYwZmU1NGQ2MWFiMzFkMWU5OWI1ZWM4MDlfNC0xMS0xLTEtMTAxMTkw_55bfebfd-fa03-44ff-90ba-a8df78f82e4e">11.1</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net amount reclassified from accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ia38dbf3e877a4be7a3da76e0f940e927_D20210101-20210331" decimals="-5" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF83OS9mcmFnOmM4OTQxNTM1MDg1NTQ3ZmViMmI5ZGFjNmIwOTZmOWM2L3RhYmxlOjkzNzllMzVmMGZlNTRkNjFhYjMxZDFlOTliNWVjODA5L3RhYmxlcmFuZ2U6OTM3OWUzNWYwZmU1NGQ2MWFiMzFkMWU5OWI1ZWM4MDlfNS0xLTEtMS0xMDExOTA_f8f16c95-0ff2-49ba-b3b2-bb0249350dd7">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i3d2a23c7f59f40c9828167248f215f5d_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF83OS9mcmFnOmM4OTQxNTM1MDg1NTQ3ZmViMmI5ZGFjNmIwOTZmOWM2L3RhYmxlOjkzNzllMzVmMGZlNTRkNjFhYjMxZDFlOTliNWVjODA5L3RhYmxlcmFuZ2U6OTM3OWUzNWYwZmU1NGQ2MWFiMzFkMWU5OWI1ZWM4MDlfNS0zLTEtMS0xMDExOTA_6926e4f2-a876-46ce-a349-356dcd802f1b">0.5</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if118f56641f64a2783ec07ba485ec5f8_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF83OS9mcmFnOmM4OTQxNTM1MDg1NTQ3ZmViMmI5ZGFjNmIwOTZmOWM2L3RhYmxlOjkzNzllMzVmMGZlNTRkNjFhYjMxZDFlOTliNWVjODA5L3RhYmxlcmFuZ2U6OTM3OWUzNWYwZmU1NGQ2MWFiMzFkMWU5OWI1ZWM4MDlfNS01LTEtMS0xMDExOTA_eac83990-c26b-4402-83f7-3e9de8a68652">85.9</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="id0d0a8013d5b45319209e6933a127c1c_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF83OS9mcmFnOmM4OTQxNTM1MDg1NTQ3ZmViMmI5ZGFjNmIwOTZmOWM2L3RhYmxlOjkzNzllMzVmMGZlNTRkNjFhYjMxZDFlOTliNWVjODA5L3RhYmxlcmFuZ2U6OTM3OWUzNWYwZmU1NGQ2MWFiMzFkMWU5OWI1ZWM4MDlfNS03LTEtMS0xMDExOTA_a7a0f017-dce1-4492-bb74-73ad3a0b092f">3.3</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i010e4c0d9c6246be91d37e31d569fa6f_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF83OS9mcmFnOmM4OTQxNTM1MDg1NTQ3ZmViMmI5ZGFjNmIwOTZmOWM2L3RhYmxlOjkzNzllMzVmMGZlNTRkNjFhYjMxZDFlOTliNWVjODA5L3RhYmxlcmFuZ2U6OTM3OWUzNWYwZmU1NGQ2MWFiMzFkMWU5OWI1ZWM4MDlfNS0xMS0xLTEtMTAxMTkw_3a2d888b-b42c-4c16-9c1e-4ac67ccea36a">89.7</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ia38dbf3e877a4be7a3da76e0f940e927_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF83OS9mcmFnOmM4OTQxNTM1MDg1NTQ3ZmViMmI5ZGFjNmIwOTZmOWM2L3RhYmxlOjkzNzllMzVmMGZlNTRkNjFhYjMxZDFlOTliNWVjODA5L3RhYmxlcmFuZ2U6OTM3OWUzNWYwZmU1NGQ2MWFiMzFkMWU5OWI1ZWM4MDlfNi0xLTEtMS0xMDExOTA_04f48d49-ddca-4c29-bc84-e4ee48cafb89">249.7</ix:nonfraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i3d2a23c7f59f40c9828167248f215f5d_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF83OS9mcmFnOmM4OTQxNTM1MDg1NTQ3ZmViMmI5ZGFjNmIwOTZmOWM2L3RhYmxlOjkzNzllMzVmMGZlNTRkNjFhYjMxZDFlOTliNWVjODA5L3RhYmxlcmFuZ2U6OTM3OWUzNWYwZmU1NGQ2MWFiMzFkMWU5OWI1ZWM4MDlfNi0zLTEtMS0xMDExOTA_a992e2b3-2232-4436-a1c8-86c9b04cc19b">10.3</ix:nonfraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if118f56641f64a2783ec07ba485ec5f8_D20210101-20210331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF83OS9mcmFnOmM4OTQxNTM1MDg1NTQ3ZmViMmI5ZGFjNmIwOTZmOWM2L3RhYmxlOjkzNzllMzVmMGZlNTRkNjFhYjMxZDFlOTliNWVjODA5L3RhYmxlcmFuZ2U6OTM3OWUzNWYwZmU1NGQ2MWFiMzFkMWU5OWI1ZWM4MDlfNi01LTEtMS0xMDExOTA_04017d0d-e718-45a6-ad88-404025947af2">104.7</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="id0d0a8013d5b45319209e6933a127c1c_D20210101-20210331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF83OS9mcmFnOmM4OTQxNTM1MDg1NTQ3ZmViMmI5ZGFjNmIwOTZmOWM2L3RhYmxlOjkzNzllMzVmMGZlNTRkNjFhYjMxZDFlOTliNWVjODA5L3RhYmxlcmFuZ2U6OTM3OWUzNWYwZmU1NGQ2MWFiMzFkMWU5OWI1ZWM4MDlfNi03LTEtMS0xMDExOTA_f27f51c1-c28b-41e4-a9e1-00118e4408d4">256.1</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i010e4c0d9c6246be91d37e31d569fa6f_D20210101-20210331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF83OS9mcmFnOmM4OTQxNTM1MDg1NTQ3ZmViMmI5ZGFjNmIwOTZmOWM2L3RhYmxlOjkzNzllMzVmMGZlNTRkNjFhYjMxZDFlOTliNWVjODA5L3RhYmxlcmFuZ2U6OTM3OWUzNWYwZmU1NGQ2MWFiMzFkMWU5OWI1ZWM4MDlfNi0xMS0xLTEtMTAxMTkw_54701907-3718-4e04-a16c-5b30475f5d98">100.8</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31, 2021</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i083ecc10d5164ab28404da958792b18f_I20210331" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF83OS9mcmFnOmM4OTQxNTM1MDg1NTQ3ZmViMmI5ZGFjNmIwOTZmOWM2L3RhYmxlOjkzNzllMzVmMGZlNTRkNjFhYjMxZDFlOTliNWVjODA5L3RhYmxlcmFuZ2U6OTM3OWUzNWYwZmU1NGQ2MWFiMzFkMWU5OWI1ZWM4MDlfOC0xLTEtMS0xMDExOTA_c054a64f-a96c-4ddf-b338-eb5465498639">1,677.2</ix:nonfraction>)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ia481a10d7f32410db9634bf240a6574e_I20210331" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF83OS9mcmFnOmM4OTQxNTM1MDg1NTQ3ZmViMmI5ZGFjNmIwOTZmOWM2L3RhYmxlOjkzNzllMzVmMGZlNTRkNjFhYjMxZDFlOTliNWVjODA5L3RhYmxlcmFuZ2U6OTM3OWUzNWYwZmU1NGQ2MWFiMzFkMWU5OWI1ZWM4MDlfOC0zLTEtMS0xMDExOTA_2a60f05a-5589-4ca7-b02a-c862a184bcfe">4.5</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="if38e7cc6dbba4458bfffe7e0d66df16d_I20210331" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF83OS9mcmFnOmM4OTQxNTM1MDg1NTQ3ZmViMmI5ZGFjNmIwOTZmOWM2L3RhYmxlOjkzNzllMzVmMGZlNTRkNjFhYjMxZDFlOTliNWVjODA5L3RhYmxlcmFuZ2U6OTM3OWUzNWYwZmU1NGQ2MWFiMzFkMWU5OWI1ZWM4MDlfOC01LTEtMS0xMDExOTA_a5d8b877-a971-4881-a55b-24b6e35ba197">4,646.3</ix:nonfraction>)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i5cbb42d3f9894842aab21bf9721eaa2c_I20210331" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF83OS9mcmFnOmM4OTQxNTM1MDg1NTQ3ZmViMmI5ZGFjNmIwOTZmOWM2L3RhYmxlOjkzNzllMzVmMGZlNTRkNjFhYjMxZDFlOTliNWVjODA5L3RhYmxlcmFuZ2U6OTM3OWUzNWYwZmU1NGQ2MWFiMzFkMWU5OWI1ZWM4MDlfOC03LTEtMS0xMDExOTA_58cd6b11-b009-4b8d-91ab-49bec2e770bf">76.6</ix:nonfraction>)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i6464afacc8e940d697ec8edde39803c6_I20210331" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF83OS9mcmFnOmM4OTQxNTM1MDg1NTQ3ZmViMmI5ZGFjNmIwOTZmOWM2L3RhYmxlOjkzNzllMzVmMGZlNTRkNjFhYjMxZDFlOTliNWVjODA5L3RhYmxlcmFuZ2U6OTM3OWUzNWYwZmU1NGQ2MWFiMzFkMWU5OWI1ZWM4MDlfOC0xMS0xLTEtMTAxMTkw_fff88aff-6053-43f6-a740-b6a906e0b910">6,395.6</ix:nonfraction>)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></tbody></table></div><div style="margin-top:6pt"><span><br></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tax effects on the net activity related to each component of other comprehensive income (loss) were as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:65.128%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.422%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Tax benefit (expense) </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation gains/losses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i7e3cba541d0a4e009649fa4e6541f00f_D20220101-20220331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF83OS9mcmFnOmM4OTQxNTM1MDg1NTQ3ZmViMmI5ZGFjNmIwOTZmOWM2L3RhYmxlOjYxMmU2NjcxNjJjZDQ0YThhMWZlMzdiOWVlNWFmNzk3L3RhYmxlcmFuZ2U6NjEyZTY2NzE2MmNkNDRhOGExZmUzN2I5ZWU1YWY3OTdfMi0xLTEtMS0xMDExOTA_01f47dcc-233b-4904-9a7c-9e9174d16a9d">13.7</ix:nonfraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ia38dbf3e877a4be7a3da76e0f940e927_D20210101-20210331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF83OS9mcmFnOmM4OTQxNTM1MDg1NTQ3ZmViMmI5ZGFjNmIwOTZmOWM2L3RhYmxlOjYxMmU2NjcxNjJjZDQ0YThhMWZlMzdiOWVlNWFmNzk3L3RhYmxlcmFuZ2U6NjEyZTY2NzE2MmNkNDRhOGExZmUzN2I5ZWU1YWY3OTdfMi0zLTEtMS0xMDExOTA_166ecf58-cc94-4575-b8dc-58df71743104">75.3</ix:nonfraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized net gains/losses on securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="ica0cd664995e4709a85c79d4a83025b5_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF83OS9mcmFnOmM4OTQxNTM1MDg1NTQ3ZmViMmI5ZGFjNmIwOTZmOWM2L3RhYmxlOjYxMmU2NjcxNjJjZDQ0YThhMWZlMzdiOWVlNWFmNzk3L3RhYmxlcmFuZ2U6NjEyZTY2NzE2MmNkNDRhOGExZmUzN2I5ZWU1YWY3OTdfMy0xLTEtMS0xMDExOTA_e0162bca-5a8c-49fb-b460-ab2079cd253a">6.7</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i3d2a23c7f59f40c9828167248f215f5d_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF83OS9mcmFnOmM4OTQxNTM1MDg1NTQ3ZmViMmI5ZGFjNmIwOTZmOWM2L3RhYmxlOjYxMmU2NjcxNjJjZDQ0YThhMWZlMzdiOWVlNWFmNzk3L3RhYmxlcmFuZ2U6NjEyZTY2NzE2MmNkNDRhOGExZmUzN2I5ZWU1YWY3OTdfMy0zLTEtMS0xMDExOTA_07790cfa-5dd0-447c-a441-74995c110f1a">4.4</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Defined benefit pension and retiree health benefit plans</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i1264e1c80a3841eba0ebd86ccd829da3_D20220101-20220331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF83OS9mcmFnOmM4OTQxNTM1MDg1NTQ3ZmViMmI5ZGFjNmIwOTZmOWM2L3RhYmxlOjYxMmU2NjcxNjJjZDQ0YThhMWZlMzdiOWVlNWFmNzk3L3RhYmxlcmFuZ2U6NjEyZTY2NzE2MmNkNDRhOGExZmUzN2I5ZWU1YWY3OTdfNC0xLTEtMS0xMDExOTA_dcc73d15-f415-45b6-bdb6-bcc5338c47a1">28.4</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="if118f56641f64a2783ec07ba485ec5f8_D20210101-20210331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF83OS9mcmFnOmM4OTQxNTM1MDg1NTQ3ZmViMmI5ZGFjNmIwOTZmOWM2L3RhYmxlOjYxMmU2NjcxNjJjZDQ0YThhMWZlMzdiOWVlNWFmNzk3L3RhYmxlcmFuZ2U6NjEyZTY2NzE2MmNkNDRhOGExZmUzN2I5ZWU1YWY3OTdfNC0zLTEtMS0xMDExOTA_86d437f7-57f9-48b3-9beb-057a23e749d4">31.3</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective portion of cash flow hedges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i0769a82ce7f744048e07bef5e5d4900b_D20220101-20220331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF83OS9mcmFnOmM4OTQxNTM1MDg1NTQ3ZmViMmI5ZGFjNmIwOTZmOWM2L3RhYmxlOjYxMmU2NjcxNjJjZDQ0YThhMWZlMzdiOWVlNWFmNzk3L3RhYmxlcmFuZ2U6NjEyZTY2NzE2MmNkNDRhOGExZmUzN2I5ZWU1YWY3OTdfNS0xLTEtMS0xMDExOTA_4ae1b183-6d15-499c-a705-c951882ae516">29.9</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ie45ab80780a84f17a66e8cee97272295_D20210101-20210331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF83OS9mcmFnOmM4OTQxNTM1MDg1NTQ3ZmViMmI5ZGFjNmIwOTZmOWM2L3RhYmxlOjYxMmU2NjcxNjJjZDQ0YThhMWZlMzdiOWVlNWFmNzk3L3RhYmxlcmFuZ2U6NjEyZTY2NzE2MmNkNDRhOGExZmUzN2I5ZWU1YWY3OTdfNS0zLTEtMS0xMDExOTA_d17c8033-dab0-4367-b69c-76fddaddb37e">68.1</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit (expense) for income taxes allocated to other comprehensive income (loss) items</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonfraction unitref="usd" contextref="id879b497a407453985551e83dbee75f8_D20220101-20220331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF83OS9mcmFnOmM4OTQxNTM1MDg1NTQ3ZmViMmI5ZGFjNmIwOTZmOWM2L3RhYmxlOjYxMmU2NjcxNjJjZDQ0YThhMWZlMzdiOWVlNWFmNzk3L3RhYmxlcmFuZ2U6NjEyZTY2NzE2MmNkNDRhOGExZmUzN2I5ZWU1YWY3OTdfNi0xLTEtMS0xMDExOTA_9bea14ac-37a2-4320-860d-537acfeccf1b">65.3</ix:nonfraction>)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i010e4c0d9c6246be91d37e31d569fa6f_D20210101-20210331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF83OS9mcmFnOmM4OTQxNTM1MDg1NTQ3ZmViMmI5ZGFjNmIwOTZmOWM2L3RhYmxlOjYxMmU2NjcxNjJjZDQ0YThhMWZlMzdiOWVlNWFmNzk3L3RhYmxlcmFuZ2U6NjEyZTY2NzE2MmNkNDRhOGExZmUzN2I5ZWU1YWY3OTdfNi0zLTEtMS0xMDExOTA_489257f6-719c-4612-a4c1-8d418f326a30">170.3</ix:nonfraction>)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></tbody></table></div></ix:nonnumeric></ix:continuation><div style="margin-top:6pt"><span><br></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span><br></span></div></div><ix:continuation id="if3592a2d71b44d3c9f81c3460b2ee7c9"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except for the tax effects of foreign currency translation gains and losses related to our foreign currency-denominated notes, cross-currency interest rate swaps, and other foreign currency exchange contracts designated as net investment hedges (see Note 6), income taxes were not provided for foreign currency translation. Generally, the assets and liabilities of foreign operations are translated into U.S. dollars using the current exchange rate. For those operations, changes in exchange rates generally do not affect cash flows; therefore, resulting translation adjustments are made in shareholders' equity rather than in the consolidated condensed statements of operations.</span></div><ix:nonnumeric contextref="id879b497a407453985551e83dbee75f8_D20220101-20220331" name="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF83OS9mcmFnOmM4OTQxNTM1MDg1NTQ3ZmViMmI5ZGFjNmIwOTZmOWM2L3RleHRyZWdpb246Yzg5NDE1MzUwODU1NDdmZWIyYjlkYWM2YjA5NmY5YzZfMTI1OA_c6677a9b-a1b0-49f0-bfb1-4c065f03e4ea" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reclassifications out of accumulated other comprehensive loss were as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:35.888%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:27.412%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Details about Accumulated Other Comprehensive Loss Components</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Affected Line Item in the Consolidated Condensed Statements of Operations</span></td></tr><tr style="height:14pt"><td colspan="30" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of retirement benefit items:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior service benefits, net</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i59b8fb8550c44df497df03d0dcdcd523_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF83OS9mcmFnOmM4OTQxNTM1MDg1NTQ3ZmViMmI5ZGFjNmIwOTZmOWM2L3RhYmxlOjgwYWJjNDRmNTA3ZjRiM2JiOTJmZWU1NWE1ZWEyMmQ1L3RhYmxlcmFuZ2U6ODBhYmM0NGY1MDdmNGIzYmI5MmZlZTU1YTVlYTIyZDVfNC0yLTEtMS0xMDExOTA_b8f67d8f-7286-4577-b661-fe664e687af7">13.0</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i2b42435d81c54f5ab5d2bf7fbc0d6514_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF83OS9mcmFnOmM4OTQxNTM1MDg1NTQ3ZmViMmI5ZGFjNmIwOTZmOWM2L3RhYmxlOjgwYWJjNDRmNTA3ZjRiM2JiOTJmZWU1NWE1ZWEyMmQ1L3RhYmxlcmFuZ2U6ODBhYmM0NGY1MDdmNGIzYmI5MmZlZTU1YTVlYTIyZDVfNC00LTEtMS0xMDExOTA_721cd66f-a9f4-4d70-9c58-0d6c7d7a108c">13.8</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other–net, (income) expense</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actuarial losses, net</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i97cd8e395ba344aa8ecdf1bee3d8ab2f_D20220101-20220331" decimals="-5" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF83OS9mcmFnOmM4OTQxNTM1MDg1NTQ3ZmViMmI5ZGFjNmIwOTZmOWM2L3RhYmxlOjgwYWJjNDRmNTA3ZjRiM2JiOTJmZWU1NWE1ZWEyMmQ1L3RhYmxlcmFuZ2U6ODBhYmM0NGY1MDdmNGIzYmI5MmZlZTU1YTVlYTIyZDVfNS0yLTEtMS0xMDExOTA_affd2f7d-c988-4af3-abf9-e2bef10d9497">87.2</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib5f018cc2e8d4c5488325d1415dccb28_D20210101-20210331" decimals="-5" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF83OS9mcmFnOmM4OTQxNTM1MDg1NTQ3ZmViMmI5ZGFjNmIwOTZmOWM2L3RhYmxlOjgwYWJjNDRmNTA3ZjRiM2JiOTJmZWU1NWE1ZWEyMmQ1L3RhYmxlcmFuZ2U6ODBhYmM0NGY1MDdmNGIzYmI5MmZlZTU1YTVlYTIyZDVfNS00LTEtMS0xMDExOTA_c41d1cef-84e0-4392-bb41-5d1b4648e48c">122.6</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other–net, (income) expense</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total before tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i0175f8e4ed51442f9ceaf3db05b287b9_D20220101-20220331" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF83OS9mcmFnOmM4OTQxNTM1MDg1NTQ3ZmViMmI5ZGFjNmIwOTZmOWM2L3RhYmxlOjgwYWJjNDRmNTA3ZjRiM2JiOTJmZWU1NWE1ZWEyMmQ1L3RhYmxlcmFuZ2U6ODBhYmM0NGY1MDdmNGIzYmI5MmZlZTU1YTVlYTIyZDVfNi0yLTEtMS0xMDExOTA_100fe9d2-5755-49ec-aaf5-e51fee8d0ca6">74.2</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i0d4cbe26b0d34206806f12f1fa74cd57_D20210101-20210331" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF83OS9mcmFnOmM4OTQxNTM1MDg1NTQ3ZmViMmI5ZGFjNmIwOTZmOWM2L3RhYmxlOjgwYWJjNDRmNTA3ZjRiM2JiOTJmZWU1NWE1ZWEyMmQ1L3RhYmxlcmFuZ2U6ODBhYmM0NGY1MDdmNGIzYmI5MmZlZTU1YTVlYTIyZDVfNi00LTEtMS0xMDExOTA_7260c79f-1e3d-4085-9743-53dd6630f4f0">108.8</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax benefit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i0175f8e4ed51442f9ceaf3db05b287b9_D20220101-20220331" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF83OS9mcmFnOmM4OTQxNTM1MDg1NTQ3ZmViMmI5ZGFjNmIwOTZmOWM2L3RhYmxlOjgwYWJjNDRmNTA3ZjRiM2JiOTJmZWU1NWE1ZWEyMmQ1L3RhYmxlcmFuZ2U6ODBhYmM0NGY1MDdmNGIzYmI5MmZlZTU1YTVlYTIyZDVfNy0yLTEtMS0xMDExOTA_7a262cd0-0f09-42ed-b160-0a9b4b1dc497">15.6</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i0d4cbe26b0d34206806f12f1fa74cd57_D20210101-20210331" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF83OS9mcmFnOmM4OTQxNTM1MDg1NTQ3ZmViMmI5ZGFjNmIwOTZmOWM2L3RhYmxlOjgwYWJjNDRmNTA3ZjRiM2JiOTJmZWU1NWE1ZWEyMmQ1L3RhYmxlcmFuZ2U6ODBhYmM0NGY1MDdmNGIzYmI5MmZlZTU1YTVlYTIyZDVfNy00LTEtMS0xMDExOTA_b717bc76-a37a-4cd6-8faa-1b550b35573e">22.9</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net of tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i0175f8e4ed51442f9ceaf3db05b287b9_D20220101-20220331" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF83OS9mcmFnOmM4OTQxNTM1MDg1NTQ3ZmViMmI5ZGFjNmIwOTZmOWM2L3RhYmxlOjgwYWJjNDRmNTA3ZjRiM2JiOTJmZWU1NWE1ZWEyMmQ1L3RhYmxlcmFuZ2U6ODBhYmM0NGY1MDdmNGIzYmI5MmZlZTU1YTVlYTIyZDVfOC0yLTEtMS0xMDExOTA_98cf7fe3-a925-4d8b-ab83-0eca5455f03c">58.6</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i0d4cbe26b0d34206806f12f1fa74cd57_D20210101-20210331" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF83OS9mcmFnOmM4OTQxNTM1MDg1NTQ3ZmViMmI5ZGFjNmIwOTZmOWM2L3RhYmxlOjgwYWJjNDRmNTA3ZjRiM2JiOTJmZWU1NWE1ZWEyMmQ1L3RhYmxlcmFuZ2U6ODBhYmM0NGY1MDdmNGIzYmI5MmZlZTU1YTVlYTIyZDVfOC00LTEtMS0xMDExOTA_55712584-2835-4047-89f6-637986e0b7a7">85.9</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net of tax</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9a717408ad30404fb5e8cc3eab2ced92_D20220101-20220331" decimals="-5" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF83OS9mcmFnOmM4OTQxNTM1MDg1NTQ3ZmViMmI5ZGFjNmIwOTZmOWM2L3RhYmxlOjgwYWJjNDRmNTA3ZjRiM2JiOTJmZWU1NWE1ZWEyMmQ1L3RhYmxlcmFuZ2U6ODBhYmM0NGY1MDdmNGIzYmI5MmZlZTU1YTVlYTIyZDVfMTAtMi0xLTEtMTAxMTkw_52b117d1-6fb7-487d-9b4e-34aeab1368f7">2.7</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ibed94e094d144d5aa0ca779c30eeef3e_D20210101-20210331" decimals="-5" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF83OS9mcmFnOmM4OTQxNTM1MDg1NTQ3ZmViMmI5ZGFjNmIwOTZmOWM2L3RhYmxlOjgwYWJjNDRmNTA3ZjRiM2JiOTJmZWU1NWE1ZWEyMmQ1L3RhYmxlcmFuZ2U6ODBhYmM0NGY1MDdmNGIzYmI5MmZlZTU1YTVlYTIyZDVfMTAtNC0xLTEtMTAxMTkw_2b558099-9324-4802-b935-bcc10feb4659">3.8</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other–net, (income) expense</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total reclassifications, net of tax</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i0711989944104688887390c9f0ba9c34_D20220101-20220331" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF83OS9mcmFnOmM4OTQxNTM1MDg1NTQ3ZmViMmI5ZGFjNmIwOTZmOWM2L3RhYmxlOjgwYWJjNDRmNTA3ZjRiM2JiOTJmZWU1NWE1ZWEyMmQ1L3RhYmxlcmFuZ2U6ODBhYmM0NGY1MDdmNGIzYmI5MmZlZTU1YTVlYTIyZDVfMTItMi0xLTEtMTAxMTkw_2ad5f192-5c26-4c5c-831d-6924092515d0">61.3</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i03800b22db6d45479225575f3b7b2136_D20210101-20210331" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF83OS9mcmFnOmM4OTQxNTM1MDg1NTQ3ZmViMmI5ZGFjNmIwOTZmOWM2L3RhYmxlOjgwYWJjNDRmNTA3ZjRiM2JiOTJmZWU1NWE1ZWEyMmQ1L3RhYmxlcmFuZ2U6ODBhYmM0NGY1MDdmNGIzYmI5MmZlZTU1YTVlYTIyZDVfMTItNC0xLTEtMTAxMTkw_3459bd50-b5a6-437e-b647-475c80bc87bb">89.7</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></tbody></table></div></ix:nonnumeric></ix:continuation><div style="margin-top:6pt;text-align:justify"><span><br></span></div><div id="ie8dc61f8e15b44db82ba16050d5b7b44_85"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 11: <ix:nonnumeric contextref="id879b497a407453985551e83dbee75f8_D20220101-20220331" name="us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF84NS9mcmFnOmEwNzdkNjhmOWZlYTQwYzE4YjRkMjczMGM4NjBkZDAzL3RleHRyZWdpb246YTA3N2Q2OGY5ZmVhNDBjMThiNGQyNzMwYzg2MGRkMDNfMTA3_191dd6ac-fc52-4e47-8c7d-9a7081c8ada6" continuedat="i551128903f434b4b92ab48df681187b0" escape="true">Other–Net, (Income) Expense</ix:nonnumeric></span></div><ix:continuation id="i551128903f434b4b92ab48df681187b0"><ix:nonnumeric contextref="id879b497a407453985551e83dbee75f8_D20220101-20220331" name="us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF84NS9mcmFnOmEwNzdkNjhmOWZlYTQwYzE4YjRkMjczMGM4NjBkZDAzL3RleHRyZWdpb246YTA3N2Q2OGY5ZmVhNDBjMThiNGQyNzMwYzg2MGRkMDNfMTA5_dead0611-23c1-4a3d-85dc-05052d7564a7" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other–net, (income) expense consisted of the following:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:65.128%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.422%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="id879b497a407453985551e83dbee75f8_D20220101-20220331" decimals="-5" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF84NS9mcmFnOmEwNzdkNjhmOWZlYTQwYzE4YjRkMjczMGM4NjBkZDAzL3RhYmxlOmVmZDI2YTY1MDI1MDRlNGM4YzcwOTMyZTZhOWMyMjMyL3RhYmxlcmFuZ2U6ZWZkMjZhNjUwMjUwNGU0YzhjNzA5MzJlNmE5YzIyMzJfMi0xLTEtMS0xMDExOTA_fa5d86be-5964-421b-a599-c0b6972a330d">84.9</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i010e4c0d9c6246be91d37e31d569fa6f_D20210101-20210331" decimals="-5" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF84NS9mcmFnOmEwNzdkNjhmOWZlYTQwYzE4YjRkMjczMGM4NjBkZDAzL3RhYmxlOmVmZDI2YTY1MDI1MDRlNGM4YzcwOTMyZTZhOWMyMjMyL3RhYmxlcmFuZ2U6ZWZkMjZhNjUwMjUwNGU0YzhjNzA5MzJlNmE5YzIyMzJfMi0zLTEtMS0xMDExOTA_3c354244-ed19-4db0-a54b-964e5dae3019">87.8</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonfraction unitref="usd" contextref="id879b497a407453985551e83dbee75f8_D20220101-20220331" decimals="-5" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF84NS9mcmFnOmEwNzdkNjhmOWZlYTQwYzE4YjRkMjczMGM4NjBkZDAzL3RhYmxlOmVmZDI2YTY1MDI1MDRlNGM4YzcwOTMyZTZhOWMyMjMyL3RhYmxlcmFuZ2U6ZWZkMjZhNjUwMjUwNGU0YzhjNzA5MzJlNmE5YzIyMzJfMy0xLTEtMS0xMDExOTA_ec711eff-b8c4-4fe8-a37d-22f3d10c1734">7.0</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i010e4c0d9c6246be91d37e31d569fa6f_D20210101-20210331" decimals="-5" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF84NS9mcmFnOmEwNzdkNjhmOWZlYTQwYzE4YjRkMjczMGM4NjBkZDAzL3RhYmxlOmVmZDI2YTY1MDI1MDRlNGM4YzcwOTMyZTZhOWMyMjMyL3RhYmxlcmFuZ2U6ZWZkMjZhNjUwMjUwNGU0YzhjNzA5MzJlNmE5YzIyMzJfMy0zLTEtMS0xMDExOTA_89599431-310f-4fbd-a3a7-81c302a9059a">5.5</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment (gains) losses on equity securities (Note 6)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="id879b497a407453985551e83dbee75f8_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:EquitySecuritiesFvNiGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF84NS9mcmFnOmEwNzdkNjhmOWZlYTQwYzE4YjRkMjczMGM4NjBkZDAzL3RhYmxlOmVmZDI2YTY1MDI1MDRlNGM4YzcwOTMyZTZhOWMyMjMyL3RhYmxlcmFuZ2U6ZWZkMjZhNjUwMjUwNGU0YzhjNzA5MzJlNmE5YzIyMzJfNC0xLTEtMS0xMDExOTA_e9897d90-fc2b-4629-87e1-5c75a2105776">425.4</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i010e4c0d9c6246be91d37e31d569fa6f_D20210101-20210331" decimals="-5" name="us-gaap:EquitySecuritiesFvNiGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF84NS9mcmFnOmEwNzdkNjhmOWZlYTQwYzE4YjRkMjczMGM4NjBkZDAzL3RhYmxlOmVmZDI2YTY1MDI1MDRlNGM4YzcwOTMyZTZhOWMyMjMyL3RhYmxlcmFuZ2U6ZWZkMjZhNjUwMjUwNGU0YzhjNzA5MzJlNmE5YzIyMzJfNC0zLTEtMS0xMDExOTA_9f4c2c81-9ab3-4bf8-baab-d1cd2bd25f98">301.5</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retirement benefit plans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonfraction unitref="usd" contextref="id879b497a407453985551e83dbee75f8_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF84NS9mcmFnOmEwNzdkNjhmOWZlYTQwYzE4YjRkMjczMGM4NjBkZDAzL3RhYmxlOmVmZDI2YTY1MDI1MDRlNGM4YzcwOTMyZTZhOWMyMjMyL3RhYmxlcmFuZ2U6ZWZkMjZhNjUwMjUwNGU0YzhjNzA5MzJlNmE5YzIyMzJfNS0xLTEtMS0xMDExOTA_216b2827-17ec-441b-9899-7c38668f59f3">93.3</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i010e4c0d9c6246be91d37e31d569fa6f_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF84NS9mcmFnOmEwNzdkNjhmOWZlYTQwYzE4YjRkMjczMGM4NjBkZDAzL3RhYmxlOmVmZDI2YTY1MDI1MDRlNGM4YzcwOTMyZTZhOWMyMjMyL3RhYmxlcmFuZ2U6ZWZkMjZhNjUwMjUwNGU0YzhjNzA5MzJlNmE5YzIyMzJfNS0zLTEtMS0xMDExOTA_b568b6ad-3200-4789-bd07-3d7849d8c868">73.4</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (income) expense </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonfraction unitref="usd" contextref="id879b497a407453985551e83dbee75f8_D20220101-20220331" decimals="-5" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF84NS9mcmFnOmEwNzdkNjhmOWZlYTQwYzE4YjRkMjczMGM4NjBkZDAzL3RhYmxlOmVmZDI2YTY1MDI1MDRlNGM4YzcwOTMyZTZhOWMyMjMyL3RhYmxlcmFuZ2U6ZWZkMjZhNjUwMjUwNGU0YzhjNzA5MzJlNmE5YzIyMzJfNy0xLTEtMS0xMDExOTA_e5353c56-a3c2-4bf1-8402-a15e57d4a2f3">59.3</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i010e4c0d9c6246be91d37e31d569fa6f_D20210101-20210331" decimals="-5" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF84NS9mcmFnOmEwNzdkNjhmOWZlYTQwYzE4YjRkMjczMGM4NjBkZDAzL3RhYmxlOmVmZDI2YTY1MDI1MDRlNGM4YzcwOTMyZTZhOWMyMjMyL3RhYmxlcmFuZ2U6ZWZkMjZhNjUwMjUwNGU0YzhjNzA5MzJlNmE5YzIyMzJfNy0zLTEtMS0xMDExOTA_c1c72e24-bfad-4e9a-aa4a-46e0c9028242">28.5</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other–net, (income) expense</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="id879b497a407453985551e83dbee75f8_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF84NS9mcmFnOmEwNzdkNjhmOWZlYTQwYzE4YjRkMjczMGM4NjBkZDAzL3RhYmxlOmVmZDI2YTY1MDI1MDRlNGM4YzcwOTMyZTZhOWMyMjMyL3RhYmxlcmFuZ2U6ZWZkMjZhNjUwMjUwNGU0YzhjNzA5MzJlNmE5YzIyMzJfOC0xLTEtMS0xMDExOTA_915a7a91-06d1-4cee-a0f2-78d22c656040">350.7</ix:nonfraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i010e4c0d9c6246be91d37e31d569fa6f_D20210101-20210331" decimals="-5" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4ZGM2MWY4ZTE1YjQ0ZGI4MmJhMTYwNTBkNWI3YjQ0L3NlYzplOGRjNjFmOGUxNWI0NGRiODJiYTE2MDUwZDViN2I0NF84NS9mcmFnOmEwNzdkNjhmOWZlYTQwYzE4YjRkMjczMGM4NjBkZDAzL3RhYmxlOmVmZDI2YTY1MDI1MDRlNGM4YzcwOTMyZTZhOWMyMjMyL3RhYmxlcmFuZ2U6ZWZkMjZhNjUwMjUwNGU0YzhjNzA5MzJlNmE5YzIyMzJfOC0zLTEtMS0xMDExOTA_a90f25c4-e827-44fe-99d8-86abe2f4ba05">321.1</ix:nonfraction>)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></tbody></table></div></ix:nonnumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><div id="ie8dc61f8e15b44db82ba16050d5b7b44_88"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span><br></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Item&nbsp;2. Management's Discussion and Analysis of Results of Operations and Financial Condition</span></div><div id="ie8dc61f8e15b44db82ba16050d5b7b44_91"></div><div><span><br></span></div><div style="-sec-extract:summary"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Results of Operations</span></div><div><span><br></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Tables present dollars in millions, except per-share data)</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management's discussion and analysis of results of operations and financial condition is intended to assist the reader in understanding and assessing significant changes and trends related to the results of operations and financial position of our consolidated company. This discussion and analysis should be read in conjunction with the consolidated condensed financial statements and accompanying footnotes in Part I, Item 1 of this Quarterly Report on Form 10-Q. Certain statements in this Part I, Item 2 of this Quarterly Report on Form 10-Q constitute forward-looking statements. Various risks and uncertainties, including those discussed in "Forward-Looking Statements" in this Quarterly Report on Form 10-Q and "Risk Factors" in Part I, Item 1A of our Annual Report on </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0000059478/000005947822000068/lly-20211231.htm">Form 10-K</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the year ended December&nbsp;31, 2021, may cause our actual results, financial position, and cash generated from operations to differ materially from these forward-looking statements.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Executive Overview</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This section provides an overview of our financial results, recent product and late-stage pipeline developments, and other matters affecting our company and the pharmaceutical industry. Earnings per share (EPS) data are presented on a diluted basis.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">COVID-19 Pandemic</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In response to the COVID-19 pandemic, we have focused on maintaining a supply of our medicines; reducing the strain on the medical system; developing treatments for COVID-19; protecting the health, safety, and well-being of our employees; supporting our communities; and ensuring affordability of and access to our medicines, particularly insulin. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2022, the United States Food and Drug Administration (FDA) granted an Emergency Use Authorization (EUA) for bebtelovimab for certain high-risk patients who have been recently diagnosed with mild-to-moderate COVID-19. We have received additional EUAs for other COVID-19 therapies as described in "Business" in Part I, Item 1 of our Annual Report on </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0000059478/000005947822000068/lly-20211231.htm">Form 10-K</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the year ended December&nbsp;31, 2021. During the three months ended March 31, 2022, we supplied the United States (U.S.) government 600,000 doses of bebtelovimab. Our agreement with the U.S. government includes an option to supply up to 500,000 additional doses of bebtelovimab no later than July 31, 2022, but it is uncertain whether the option will be exercised. In general, we expect additional revenue from sales of our COVID-19 antibodies will be limited beginning with the second quarter of 2022. The FDA has revised, and may in the future revise, any EUA for our COVID-19 therapies in response to the prevalence of variants against which our therapies have varying degrees of efficacy. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic has, and may continue to, adversely impact our business and operations. Strain on global transportation, logistics, manufacturing, and labor markets, including as aggravated by the pandemic and global unrest, the focus of resources on COVID-19, widespread protective measures implemented to control the spread of COVID-19, and an increase in overall demand in our industry for certain materials resulting in changed buying patterns and constrained supply, have negatively impacted development, manufacturing, supply, distribution, and sales of our medicines. If the COVID-19 pandemic undergoes resurgent or more severe waves, its impact and the impact of any associated supply chain disruption, labor market impact, increased costs, recession, or depression on our business and results of operations could be exacerbated.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It remains difficult to reasonably assess or predict the full extent of the ongoing impact of the COVID-19 pandemic on us. The degree to which the COVID-19 pandemic continues to affect us will depend on developments that are highly uncertain and beyond our knowledge or control. We are currently unable to predict the full extent to which the COVID-19 pandemic or any future pandemic, epidemic or similar public health threat will adversely impact our business and operations in the future.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See "Risk Factors" in Part I, Item 1A of our Annual Report on </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0000059478/000005947822000068/lly-20211231.htm">Form 10-K</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the year ended December&nbsp;31, 2021 for additional information on risk factors that could impact our business and operations.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span><br></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Results</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our key operating results:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:54.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.699%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Percent Change</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,810.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,805.6&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross margin</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,737.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,927.0&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross margin as a percent of revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">73.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72.4&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,610.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,672.1&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketing, selling, and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,557.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,576.0&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired in-process research and development (IPR&amp;D) and development milestones</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">165.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">312.0&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset impairment, restructuring, and other special charges</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">211.6&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NM</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other–net, (income) expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">350.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(321.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NM</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,902.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,355.3&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EPS - diluted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2.10</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.49&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></tbody></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">NM - not meaningful</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue increased for the three months ended March&nbsp;31, 2022, driven by increased volume, partially offset by lower realized prices and the unfavorable impact of foreign exchange rates. Research and development expenses decreased for the three months ended March&nbsp;31, 2022, largely driven by lower development expenses for COVID-19 antibodies, partially offset by higher development expenses for late-stage assets. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following highlighted items also affect comparisons of our financial results for the three months ended March&nbsp;31, 2022 and 2021:</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022 </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquired IPR&amp;D and Development Milestones (See Note 3 to the consolidated condensed financial statements)</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We recognized $165.6 million of acquired IPR&amp;D and development milestones primarily related to a purchase of a Priority Review Voucher.</span></div><div style="margin-top:6pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other-Net, (Income) Expense (See Note 11 to the consolidated condensed financial statements)</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We recognized $425.4 million of net investment losses on equity securities.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021 </span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquired IPR&amp;D and Development Milestones (See Note 3 to the consolidated condensed financial statements)</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We recognized $312.0 million of acquired IPR&amp;D and development milestones primarily related to acquired IPR&amp;D charges resulting from business development transactions with Rigel Pharmaceuticals, Inc. (Rigel) and Precision Biosciences, Inc. (Precision).</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Asset Impairment, Restructuring, and Other Special Charges (See Note 5 to the consolidated condensed financial statements)</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We recognized charges of $211.6 million largely related to an intangible asset impairment resulting from the sale of the rights to Qbrexza</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, as well as acquisition and integration costs associated with the acquisition of Prevail Therapeutics Inc. (Prevail). </span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other-Net, (Income) Expense (See Note 11 to the consolidated condensed financial statements)</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We recognized $301.5 million of net investment gains on equity securities. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span><br></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Late-Stage Pipeline</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our long-term success depends on our ability to continually discover or acquire, develop, and commercialize innovative new medicines. We currently have approximately 45 new medicine candidates in clinical development or under regulatory review, and a larger number of projects in the discovery phase.</span></div><div style="margin-bottom:8pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following certain new molecular entities (NMEs) are currently in Phase II or Phase III clinical trials or have been submitted for regulatory review in the U.S., Europe, or Japan. The following table reflects the status of these NMEs, including certain other developments since our Annual Report on </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0000059478/000005947822000068/lly-20211231.htm">Form 10-K</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the year ended December&nbsp;31, 2021. </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.373%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.539%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Compound</span></td><td colspan="3" style="background-color:#d8d8d8;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Indication</span></td><td colspan="3" style="background-color:#d8d8d8;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Status </span></td><td colspan="3" style="background-color:#d8d8d8;border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Developments</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="12" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Diabetes</span></td><td colspan="3" style="display:none"></td></tr><tr style="height:24pt"><td colspan="3" rowspan="4" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tirzepatide </span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Type 2 diabetes</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Submitted</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Submitted in the U.S. using a Priority Review Voucher and in Europe and Japan in 2021. </span></td><td colspan="3" style="display:none"></td></tr><tr style="height:35pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Heart failure with preserved ejection fraction</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase III</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase III trials are ongoing.</span></td><td colspan="3" style="display:none"></td></tr><tr style="height:35pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Obesity</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase III</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Announced in April 2022 that the initial Phase III trial met co-primary and all key secondary endpoints. Phase III trials are ongoing.</span></td><td colspan="3" style="display:none"></td></tr><tr style="height:24pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonalcoholic steatohepatitis </span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II trial is ongoing. </span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basal Insulin-Fc</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Type 1 and 2 diabetes</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase III</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase III trial initiated in the first quarter of 2022. </span></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" rowspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">GGG Tri-Agonist</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Obesity</span></td><td colspan="3" rowspan="2" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II</span></td><td colspan="3" rowspan="2" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II trials are ongoing. </span></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Type 2 diabetes</span></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" rowspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">GLP-1R NPA</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Obesity</span></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II</span></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II trials are ongoing.</span></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Type 2 diabetes</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="12" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Immunology</span></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" rowspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mirikizumab</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ulcerative colitis</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Submitted</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Submitted in the U.S. in first quarter of 2022.</span></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Crohn's Disease</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase III</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase III trials are ongoing. </span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Lebrikizumab</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Atopic dermatitis</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Phase III</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted FDA Fast Track designation</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Announced in 2021 that Phase III trials met primary and all key secondary endpoints. Phase III trials are ongoing.</span></div></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CXCR1/2 Ligands Monoclonal Antibody</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hidradenitis suppurativa</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II trial is ongoing.</span></td><td colspan="3" style="display:none"></td></tr><tr style="height:24pt"><td colspan="3" rowspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IL-2 Conjugate</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Systemic lupus erythematosus</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Phase II trial is ongoing.</span></td><td colspan="3" style="display:none"></td></tr><tr style="height:35pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Ulcerative colitis</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Announced in April 2022 that we have discontinued the Phase II trial due to lack of efficacy based on interim analysis.</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Peresolimab (PD-1 MAB Agonist)</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Rheumatoid arthritis</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Phase II</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Phase II trial is ongoing.</span></td><td colspan="3" style="display:none"></td></tr></tbody></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span><br></span></div></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.373%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.539%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Compound</span></td><td colspan="3" style="background-color:#d8d8d8;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Indication</span></td><td colspan="3" style="background-color:#d8d8d8;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Status </span></td><td colspan="3" style="background-color:#d8d8d8;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Developments</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="12" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Neuroscience</span></td><td colspan="3" style="display:none"></td></tr><tr style="height:45pt"><td colspan="3" rowspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Donanemab</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Early Alzheimer's disease</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Submission initiated </span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted FDA Breakthrough Therapy designation</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Initiated a rolling submission in the U.S. for accelerated approval in 2021. Phase III trials are ongoing.</span></div></td><td colspan="3" style="display:none"></td></tr><tr style="height:24pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preclinical Alzheimer's disease</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase III</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase III trial is ongoing.</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Solanezumab</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preclinical Alzheimer's disease</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase III</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase III trial is ongoing. </span></td><td colspan="3" style="display:none"></td></tr><tr style="height:24pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">GBA1 Gene Therapy (PR001)</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Parkinson's disease </span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II</span></td><td colspan="3" rowspan="2" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted FDA Fast Track designation</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Phase II trials are ongoing. </span></div></td><td colspan="3" style="display:none"></td></tr><tr style="height:24pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">GRN Gene Therapy (PR006)</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Frontotemporal dementia</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">O-glc-NAcase</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alzheimer's disease</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II trial is ongoing.</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PACAP38 Antibody</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chronic pain</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II trial is ongoing.</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SSTR4 Agonist</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chronic pain</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II trials are ongoing.</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TRPA1 Antagonist</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pain</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II trials are ongoing.</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Epiregulin/TGFα MAB</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chronic pain</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Announced in April 2022 that we have discontinued the Phase II trial because it did not meet criteria for proceeding.</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="12" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Oncology</span></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" rowspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selpercatinib (Retevmo</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">)</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lung cancer</span></td><td colspan="3" rowspan="2" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Approved</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" rowspan="2" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase III trials are ongoing. </span></div></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thyroid cancer</span></td><td colspan="3" style="display:none"></td></tr><tr style="height:35pt"><td colspan="3" rowspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pirtobrutinib (LOXO-305)</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mantle cell lymphoma</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Submission initiated</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Initiated a rolling submission in the U.S. for accelerated approval in 2021. Phase II and Phase III trials are ongoing.</span></div></td><td colspan="3" style="display:none"></td></tr><tr style="height:24pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chronic lymphocytic leukemia</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase III</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase III trials are ongoing.</span></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">B-cell malignancies</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II trial is ongoing.</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Imlunestrant</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ER+HER2- metastatic breast cancer</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase III</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase III trial is ongoing.</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sintilimab injection</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lung cancer </span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Not approved</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In the first quarter of 2022 the FDA issued a complete response letter indicating that the FDA did not approve the application in its current form and recommended an additional multiregional clinical study be performed. In collaboration with Innovent, we are assessing next steps in the U.S.</span></td><td colspan="3" style="display:none"></td></tr></tbody></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In collaboration with Almirall, S.A. in Europe. </span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Fast Track designation is designed to expedite the development and review of new therapies to treat serious conditions and address unmet medical needs.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Breakthrough Therapy designation is designed to expedite the development and review of potential medicines that are intended to treat a serious condition where preliminary clinical evidence indicates that the treatment may demonstrate substantial improvement over available therapy on a clinically significant endpoint. </span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Continued approval may be contingent on verification and description of clinical benefit in confirmatory Phase III trials.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(5) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In collaboration with Innovent Biologics, Inc.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span><br></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span><br></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our pipeline also contains several new indication line extension (NILEX) products. The following certain NILEX products for use in the indication described are currently in Phase II or Phase III clinical trials or have been submitted for regulatory review in the U.S., Europe, or Japan. The following table reflects the status of these NILEX products, including certain other developments since our Annual Report on </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0000059478/000005947822000068/lly-20211231.htm">Form 10-K</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the year ended December&nbsp;31, 2021. </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.373%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.539%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Compound</span></td><td colspan="3" style="background-color:#d8d8d8;border-bottom:1pt solid #000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Indication</span></td><td colspan="3" style="background-color:#d8d8d8;border-bottom:1pt solid #000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Status</span></td><td colspan="3" style="background-color:#d8d8d8;border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Developments</span></td></tr><tr><td colspan="12" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Diabetes</span></td></tr><tr style="height:35pt"><td colspan="3" rowspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Empagliflozin (Jardiance</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Heart failure with preserved ejection fraction</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Approved</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Approved in the U.S. and Europe in the first quarter of 2022 and in Japan in April 2022.</span></div></td></tr><tr style="height:45pt"><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chronic kidney disease</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase III</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted FDA Fast Track designation</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. In the first quarter of 2022 the Independent Data Monitoring Committee recommended stopping the Phase III trial early due to clear positive efficacy.</span></div></td></tr><tr><td colspan="12" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Immunology</span></td></tr><tr style="height:35pt"><td colspan="3" rowspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Baricitinib (Olumiant</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">)</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">COVID-19</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emergency Use Authorization</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3) </span></div></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Submitted in the U.S. and the FDA granted priority review in the first quarter of 2022.</span></td></tr><tr style="height:45pt"><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alopecia areata</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Submitted</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted FDA Breakthrough Therapy designation</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Submitted in U.S., Europe, and Japan in 2021. In the first quarter of 2022 the FDA granted priority review in severe alopecia areata. </span></div></td></tr><tr><td colspan="12" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Oncology</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Abemaciclib (Verzenio</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">)</span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Prostate cancer</span></div></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Phase III</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase III trials are ongoing.</span></div></td></tr></tbody></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In collaboration with Boehringer Ingelheim. </span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Fast Track designation is designed to expedite the development and review of new therapies to treat serious conditions and address unmet medical needs.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> The FDA granted EUA for treatment with or without remdesivir in hospitalized COVID-19 patients.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(4) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Breakthrough Therapy designation is designed to expedite the development and review of potential medicines that are intended to treat a serious condition where preliminary clinical evidence indicates that the treatment may demonstrate substantial improvement over available therapy on a clinically significant endpoint.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Matters</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Patent Matters</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We depend on patents or other forms of intellectual property protection for most of our revenue, cash flows, and earnings. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021, our vitamin regimen patents for Alimta</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> expired worldwide. Following the loss of patent exclusivity in major European countries and Japan, we faced, and remain exposed to, generic competition which has eroded revenue and is likely to continue to rapidly and severely erode revenue from current levels. In the U.S., we expect pediatric data exclusivity to provide us with protection through May 2022. However, we and Eagle Pharmaceuticals, Inc. (Eagle) reached an agreement in December 2019 to settle all pending U.S. patent litigation, allowing Eagle a limited initial entry into the market with an alternative form of pemetrexed during the first quarter of 2022 (up to an approximate three-week supply) and subsequent unlimited entry starting April 2022. We expect that the entry of multiple generics in the U.S. following the loss of exclusivity will cause a rapid and severe decline in revenue and will have a material adverse effect on our consolidated results of operations and cash flows. See Note 9 to the consolidated condensed financial statements for a more detailed account of the legal proceedings currently pending regarding, among others, our Alimta patents.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our compound patent for Humalog</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (insulin lispro) has expired in major markets. Global regulators have different legal pathways to approve similar versions of insulin lispro. A competitor has a similar version of insulin lispro in the U.S. and in certain European markets. While it is difficult to estimate the severity of the impact of insulin lispro products entering the market, we do not expect and have not experienced a rapid and severe decline in revenue; however, we expect additional pricing pressure and some loss of market share that may continue over time.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our formulation and use patents for Forteo</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> have expired in major markets. We expect further decline in revenue as a result of the entry of generic and biosimilar competition due to the loss of patent exclusivity in major markets. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span><br></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Foreign Currency Exchange Rates</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a global company, we face foreign currency risk exposure from fluctuating currency exchange rates, primarily the U.S. dollar against the euro, Japanese yen, and Chinese yuan. While we seek to manage a portion of these exposures through hedging and other risk management techniques, significant fluctuations in currency rates can have a material impact, either positive or negative, on operating expenses. While there is uncertainty in the future movements in foreign exchange rates, fluctuations in these rates could adversely impact our future consolidated results of operations and cash flows.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Trends Affecting Pharmaceutical Pricing, Reimbursement, and Access </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Global concern over access to and affordability of pharmaceutical products continues to drive regulatory and legislative debate, as well as worldwide cost containment efforts by governmental authorities. Such measures may include the use of mandated discounts, price reporting requirements, mandated reference prices, restrictive formularies, changes to available intellectual property protections, as well as other efforts. In addition, consolidation of private payors in the U.S. has significantly impacted the market for pharmaceuticals by increasing payor leverage in negotiating manufacturer price concessions and pharmacy reimbursement rates. Furthermore, restrictive or unfavorable pricing, coverage, or reimbursement determinations for our medicines or product candidates by governments, regulatory agencies, or private payers, such as the Centers for Medicare &amp; Medicaid Services' recently released National Coverage Determination for monoclonal antibodies for the treatment of Alzheimer's Disease, may adversely impact our business and financial results. We expect that these actions may intensify and could particularly affect certain products, such as insulin, as governments manage and emerge from the COVID-19 pandemic, which could adversely affect our business. In addition, we are engaged in litigation and investigations related to our 340B program that, if resolved adversely to us, could negatively impact our business and consolidated results of operations. It is not currently possible to predict the overall potential adverse impact to us or the general pharmaceutical industry of continued cost containment efforts worldwide. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, evolving regulatory priorities have intensified governmental scrutiny of our operations and our industry, including with respect to current Good Manufacturing Practices, quality assurance, and similar regulations, and increased focus on business combinations in our industry. Any regulatory issues concerning these matters could lead to regulatory and legal actions, product recalls and seizures, fines and penalties, interruption of production leading to product shortages, import bans or denials of import certifications, delays or denials in the approvals of new products or supplemental approvals of current products pending resolution of the issues, impediments to the completion of business combinations, and reputational harm, any of which would adversely affect our business.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See "Business - Regulations and Private Payer Actions Affecting Pharmaceutical Pricing, Reimbursement, and Access" in Part I, Item 1 and "Risk Factors" in Part I, Item 1A of our Annual Report on </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0000059478/000005947822000068/lly-20211231.htm">Form 10-K</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the year ended December&nbsp;31, 2021. See also Note 9 to the consolidated condensed financial statements.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Tax Matters</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to income taxes and various other taxes in the U.S. and in many foreign jurisdictions; therefore, changes in both domestic and international tax laws or regulations have affected and may affect our effective tax rate, results of operations, and cash flows. In 2017, the U.S. enacted the Tax Cuts and Jobs Act (the 2017 Tax Act), which contains a provision that requires capitalization and amortization of research and development expenses for tax purposes starting in 2022. Previously, these expenses could be deducted in the year incurred. The implementation of this provision is expected to increase our 2022 cash payments of income taxes by up to $1.50 billion and subsequently decrease our cash payments of income taxes moderately over the five-year amortization period. For the three months ended March 31, 2022, the implementation of this provision favorably impacted other tax items that decreased our effective tax rate by approximately 4 percentage points. If this provision of the 2017 Tax Act is deferred or repealed by Congress effective for 2022, we expect our effective tax rate to be approximately 13 percent to 14 percent for 2022.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. and countries around the world are actively considering and enacting tax law changes. Tax proposals introduced by Congress and the U.S. presidential administration contain significant changes, including increases to the tax rates at which both domestic and foreign income of U.S. companies would be taxed. In addition, tax authorities in the U.S. and other jurisdictions in which we do business routinely examine our tax returns and are intensifying their scrutiny and examinations of profit allocations among jurisdictions, which could adversely impact our future consolidated results of operations and cash flows. Further, actions taken with respect to tax-related matters by associations such as the Organisation for Economic Co-operation and Development and the European Commission could influence tax laws in countries in which we operate.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span><br></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acquisitions</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We opportunistically invest in external research and technologies that we believe complement and strengthen our own efforts. These investments can take many forms, including acquisitions, collaborations, investments, and licensing arrangements. We view our business development activity as a way to enhance our pipeline and strengthen our business. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 3 to the consolidated condensed financial statements for further discussion regarding our recent acquisitions.</span></div><div id="ie8dc61f8e15b44db82ba16050d5b7b44_94"></div><div><span><br></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our revenue activity by region:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:54.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.699%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Percent Change</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,174.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,941.3&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outside U.S.</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,635.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,864.3&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,810.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,805.6&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></tbody></table></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Numbers may not add due to rounding.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following are components of the change in revenue compared with the prior year:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:49.338%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.422%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022 vs. 2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Outside U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Consolidated</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volume</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Price</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange rates</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Percent change</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></tbody></table></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Numbers may not add due to rounding.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S. for the three months ended March&nbsp;31, 2022, the increase in volume was primarily driven by COVID-19 antibodies, Trulicity</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Verzenio, and Jardiance.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outside the U.S. for the three months ended March&nbsp;31, 2022, the increase in volume was largely driven by Trulicity, Verzenio, Tyvyt</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Taltz</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and Jardiance, as well as sales of our rights to Cialis</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in Taiwan and Saudi Arabia. This increase in volume outside the U.S. for the three months ended March&nbsp;31, 2022 was partially offset by decreased volume for Alimta</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and Cymbalta</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> resulting from the entry of generic competition, as well as decreased volume for COVID-19 antibodies. Outside the U.S. for the three months ended March&nbsp;31, 2022, the decrease in realized prices was primarily driven by the impact of the National Reimbursement Drug List formulary for certain products in China, particularly Tyvyt. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br></span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span><br></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our revenue activity by product for the three months ended March&nbsp;31, 2022 and 2021: </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tbody><tr><td style="width:1.0%"></td><td style="width:37.225%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.651%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" rowspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td></tr><tr style="height:20pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Product</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S. </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Outside U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Percent Change</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trulicity</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,313.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">427.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,741.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,452.4&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">COVID-19 antibodies</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,455.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,469.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">810.1&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Humalog</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">368.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">249.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">618.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">617.0&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Taltz</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">307.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">180.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">488.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">403.2&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Verzenio</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">301.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">167.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">469.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">269.0&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jardiance</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">229.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">189.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">419.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">312.0&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alimta</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">254.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">89.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">343.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">559.0&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38)</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Humulin</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">®</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">190.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">82.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">273.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">321.7&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Olumiant</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">71.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">184.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">255.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193.8&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cyramza</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">®</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">79.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">151.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">230.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">240.5&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cialis</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">210.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">217.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126.8&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basaglar</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">®</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">119.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">72.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">191.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246.6&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emgality</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">®</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">108.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">41.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">149.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119.5&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forteo</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">70.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">67.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">137.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198.5&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31)</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Erbitux</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">®</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">109.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">13.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">122.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122.4&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Zyprexa</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">®</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">83.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">93.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95.8&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tyvyt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">85.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">85.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109.7&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cymbalta</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">71.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">81.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176.6&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54)</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other products</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">169.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">252.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">422.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">431.0&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,174.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,635.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,810.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,805.6&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15</span></td><td colspan="3" style="display:none"></td></tr></tbody></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Numbers may not add due to rounding.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">NM - not meaningful</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">COVID-19 antibodies include sales for bamlanivimab administered alone, for bamlanivimab and etesevimab administered together, and for bebtelovimab and were made pursuant to EUAs or similar regulatory authorizations.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Humalog revenue includes insulin lispro. </span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Jardiance revenue includes Glyxambi</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Synjardy</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">, and Trijardy</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> XR. </span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(4) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Olumiant revenue includes sales for baricitinib, for treatment in hospitalized COVID-19 patients, that were made pursuant to EUA or similar regulatory authorizations.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"> </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue of Trulicity, a treatment for type 2 diabetes and to reduce the risk of major adverse cardiovascular events in adult patients with type 2 diabetes and established cardiovascular disease or multiple cardiovascular risk factors, increased 18 percent in the U.S. during the three months ended March&nbsp;31, 2022, driven by increased demand, partially offset by lower realized prices as well as wholesale and retail buying patterns. Revenue outside the U.S. increased 27 percent during the three months ended March&nbsp;31, 2022, driven by increased volume, partially offset by the unfavorable impact of foreign exchange rates and, to a lesser extent, lower realized prices.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue of COVID-19 antibodies, treatments for mild to moderate COVID-19 for higher-risk patients and for post-exposure prophylaxis in certain individuals for the prevention of SARS-CoV-2 infection, was $1.46&nbsp;billion in the U.S. during the three months ended March&nbsp;31, 2022. Revenue outside the U.S. was $14.7&nbsp;million during the three months ended March&nbsp;31, 2022. The availability of superior or competitive therapies, including therapies that can be administered more easily, or preventative measures, such as vaccines, coupled with the unpredictable nature of pandemics, have and could further negatively impact or eliminate demand for these COVID-19 antibodies. The FDA has revised, and may in the future revise, any EUA for our COVID-19 antibodies in response to the prevalence of variants against which our antibodies have varying degrees of efficacy. Our agreement with the U.S. government includes an option to supply up to 500,000 doses of bebtelovimab no later than July 31, 2022, but it is uncertain whether the option will be exercised. In general, we expect additional revenue from sales of our COVID-19 antibodies will be limited beginning with the second quarter of 2022.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span><br></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue of Humalog, an injectable human insulin analog for the treatment of diabetes, increased 11 percent in the U.S. during the three months ended March&nbsp;31, 2022, primarily driven by higher realized prices due to changes to estimates for rebates and discounts in both periods and, to a lesser extent, increased demand. Revenue outside the U.S. decreased 12 percent during the three months ended March&nbsp;31, 2022, driven by decreased volume, the unfavorable impact of foreign exchange rates and, to a lesser extent, lower realized prices. While it is difficult to estimate the severity of the impact of insulin lispro products entering the market, we do not expect and have not experienced a rapid and severe decline in revenue. However, due to the impact of competition and due to pricing pressure in the U.S. and some international markets, we expect some realized price decline and loss of market share to continue over time. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue of Taltz, a treatment for moderate-to-severe plaque psoriasis, active psoriatic arthritis, ankylosing spondylitis, and active non-radiographic axial spondyloarthritis, increased 23 percent in the U.S. during the three months ended March&nbsp;31, 2022, driven by increased demand and higher realized prices due to segment mix, partially offset by specialty pharmacy buying patterns. Revenue outside the U.S. increased 18 percent during the three months ended March&nbsp;31, 2022, driven by increased volume, partially offset by lower realized prices and the unfavorable impact of foreign exchange rates.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue of Verzenio, a treatment for HR+, HER2- metastatic breast cancer and high risk early breast cancer, increased 74 percent in the U.S. during the three months ended March&nbsp;31, 2022, primarily driven by increased demand. Revenue outside the U.S. increased 74 percent during the three months ended March&nbsp;31, 2022, largely driven by increased volume, partially offset by the unfavorable impact of foreign exchange rates.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue of Jardiance, a treatment for type 2 diabetes, to reduce the risk of cardiovascular death in adult patients with type 2 diabetes and established cardiovascular disease, and to reduce the risk of cardiovascular death and hospitalization for heart failure in adults with heart failure, regardless of left ventricular ejection fraction, increased 52 percent in the U.S. during the three months ended March&nbsp;31, 2022, primarily driven by increased demand. Revenue outside the U.S. increased 18 percent during the three months ended March&nbsp;31, 2022, driven by increased volume, partially offset by the unfavorable impact of foreign exchange rates. See Note 4 to the consolidated condensed financial statements for information regarding our collaboration with Boehringer Ingelheim involving Jardiance.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue of Alimta, a treatment for various cancers, decreased 3 percent in the U.S. during the three months ended March&nbsp;31, 2022, driven by decreased volume, partially offset by higher realized prices. Revenue outside the U.S. decreased 70 percent during the three months ended March&nbsp;31, 2022, largely driven by decreased volume due to entry of generic competition in certain major markets and, to a lesser extent, lower realized prices. Following the loss of exclusivity in major European countries and Japan in June 2021, we faced, and remain exposed to, generic competition which has eroded revenue and is likely to continue to rapidly and severely erode revenue from current levels. In the U.S., an alternative form of pemetrexed launched during the first quarter of 2022, and we expect multiple generics to launch in the second quarter of 2022, causing a rapid and severe decline in revenue. See "Executive Overview - Other Matters- Patent Matters" for additional information. </span></div><div style="margin-top:6pt"><span><br></span></div><div style="margin-top:6pt"><span><br></span></div><div style="margin-top:6pt"><span><br></span></div><div style="margin-top:6pt"><span><br></span></div><div style="margin-top:6pt"><span><br></span></div><div style="margin-top:6pt"><span><br></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><div id="ie8dc61f8e15b44db82ba16050d5b7b44_100"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span><br></span></div></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Gross Margin, Costs, and Expenses</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross margin as a percent of revenue was 73.5 percent for the three months ended March&nbsp;31, 2022, an increase of 1.1 percentage points compared with the three months ended March&nbsp;31, 2021, primarily driven by an unfavorable effect in the three months ended March&nbsp;31, 2021 of foreign exchange rates on international inventories sold, partially offset by increased sales of COVID-19 antibodies and, to a lesser extent, lower realized prices. </span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Res</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">earch and development expenses decreased 4 percent to $1.61 billion for the three months ended March&nbsp;31, 2022, largely driven by lower development expenses for COVID-19 antibodies, partially offset by higher development expenses for late-stage assets. </span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketing, selling, and administrative expenses </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">decreased</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1 percent to $1.56 billion for the three months ended March&nbsp;31, 2022.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized $165.6 million of acquired IPR&amp;D and development milestones for the three months ended March&nbsp;31, 2022, primarily related to a purchase of a Priority Review Voucher. We recognized $312.0 million of acquired IPR&amp;D and development milestones for the three months ended March&nbsp;31, 2021, primarily related to acquired IPR&amp;D charges from business development transactions with Rigel and Precision. See Note 3 to the consolidated condensed financial statements for additional information.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no asset impairment, restructuring, and other special charges recognized for the three months ended March&nbsp;31, 2022. We recognized asset impairment, restructuring, and other special charges of $211.6 million for the three months ended March&nbsp;31, 2021, largely related to an intangible asset impairment resulting from the sale of the rights to Qbrexza, as well as acquisition and integration costs associated with the acquisition of Prevail.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other–net, (income) expense was expense of $350.7 million for the three months ended March&nbsp;31, 2022, primarily driven by net investment losses on equity securities. Other–net, (income) expense was income of $321.1 million for the three months ended March&nbsp;31, 2021, primarily driven by net investment gains on equity securities.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effective tax rate was 7.3 percent for the three months ended March&nbsp;31, 2022, compared with 8.2 percent for the three months ended March&nbsp;31, 2021. The lower effective tax rate for the three months ended March&nbsp;31, 2022 was largely driven by decreased tax expense related to net investment losses on equity securities compared to net investment gains on equity securities for the three months ended March&nbsp;31, 2021 and decreased tax expense related to the implementation of the provision in the 2017 Tax Act that requires capitalization and amortization of research and development expenses for tax purposes starting in 2022, partially offset by a lower net discrete tax benefit compared to the three months ended March&nbsp;31, 2021. If this provision of the 2017 Tax Act is deferred or repealed by Congress effective for 2022, we expect our effective tax rate to be approximately 13 percent to 14 percent for 2022.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><div id="ie8dc61f8e15b44db82ba16050d5b7b44_106"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span><br></span></div></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Condition and Liquidity&nbsp;&nbsp;&nbsp;&nbsp;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe our available cash and cash equivalents, together with our ability to generate operating cash flow and our access to short-term and long-term borrowings, are sufficient to fund our existing and planned capital requirements. For a discussion of our capital requirements, see "Management's Discussion and Analysis of Results of Operations and Financial Condition" in Part II, Item 7 of our Annual Report on </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0000059478/000005947822000068/lly-20211231.htm">Form 10-K</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the year ended December&nbsp;31, 2021. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents decreased to $2.46 billion as of March&nbsp;31, 2022, compared with $3.82 billion as of December&nbsp;31, 2021. Refer to the consolidated condensed statements of cash flows for additional information on the significant sources and uses of cash for the three months ended March&nbsp;31, 2022 and 2021. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to our cash and cash equivalents, we held total investments of $2.84 billion and $3.30 billion as of March&nbsp;31, 2022 and December&nbsp;31, 2021, respectively. See Note 6 to the consolidated condensed financial statements for additional information. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&nbsp;31, 2022, total debt was $16.51 billion, a decrease of $375.9&nbsp;million compared with $16.88&nbsp;billion as of December&nbsp;31, 2021. See Note 6 to the consolidated condensed financial statements for additional information. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&nbsp;31, 2022, we had a total of $5.26 billion of unused committed bank credit facilities, $5.00 billion of which is available to support our commercial paper program. We believe that amounts accessible through existing commercial paper markets should be adequate to fund short-term borrowing needs. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&nbsp;31, 2022, we repurchased $1.50&nbsp;billion of shares under our $5.00&nbsp;billion share repurchase program authorized in May 2021. As of March&nbsp;31, 2022, we had $3.25 billion remaining under this program. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&nbsp;31, 2022, we paid dividends of $885.5&nbsp;million, or $0.98 per share, to our shareholders. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See "Executive Overview - Other Matters - Patent Matters" for information regarding recent and upcoming losses of patent protection.</span></div><div style="margin-bottom:12pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Both domestically and abroad, we continue to monitor the potential impacts of the economic environment; the creditworthiness of our wholesalers and other customers, including foreign government-backed agencies and suppliers; the uncertain impact of health care legislation; various international government funding levels; and fluctuations in interest rates, foreign currency exchange rates (see "Executive Overview - Other Matters - Foreign Currency Exchange Rates"), and fair values of equity securities.</span></div><div id="ie8dc61f8e15b44db82ba16050d5b7b44_1179"></div><div><span><br></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Estimates&nbsp;&nbsp;&nbsp;&nbsp;</span></div><div style="margin-bottom:12pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a discussion of our critical accounting estimates, refer to "Management's Discussion and Analysis of Results of Operations and Financial Condition" in Part II, Item 7 and the notes to our consolidated financial statements in Part II, Item 8 of our Annual Report on </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0000059478/000005947822000068/lly-20211231.htm">Form 10-K</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the year ended December&nbsp;31, 2021. See also Note 1 to the consolidated condensed financial statements. There have been no material changes to our critical accounting estimates since our Annual Report on </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0000059478/000005947822000068/lly-20211231.htm">Form 10-K</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the year ended December&nbsp;31, 2021. </span></div><div id="ie8dc61f8e15b44db82ba16050d5b7b44_112"></div><div><span><br></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Available Information on our Website</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We make available through our company website, free of charge, our company filings with the Securities and Exchange Commission (SEC) as soon as reasonably practicable after we electronically file them with, or furnish them to, the SEC. The reports we make available include annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, proxy statements, registration statements, and any amendments to those documents.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The website link to our SEC filings is </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">investor.lilly.com/financial-information/sec-filings</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The information contained in, or that can be accessed through, our website is not a part of, or incorporated by reference in, this Quarterly Report.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><div id="ie8dc61f8e15b44db82ba16050d5b7b44_115"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span><br></span></div></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Item&nbsp;4. Controls and Procedures</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:23.78pt">Evaluation of Disclosure Controls and Procedures</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Under applicable Securities and Exchange Commission (SEC) regulations, management of a reporting company, with the participation of the principal executive officer and principal financial officer, must periodically evaluate the company's "disclosure controls and procedures," which are defined generally as controls and other procedures of a reporting company designed to ensure that information required to be disclosed by the reporting company in its periodic reports filed with the SEC (such as this Quarterly Report on Form&nbsp;10-Q) is recorded, processed, summarized, and reported on a timely basis.</span></div><div style="margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, with the participation of David A. Ricks, president and chief executive officer, and Anat Ashkenazi, senior vice president and chief financial officer, evaluated our disclosure controls and procedures (as such terms are defined in our Annual Report on </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0000059478/000005947822000068/lly-20211231.htm">Form 10-K</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the year ended December&nbsp;31, 2021) as of March&nbsp;31, 2022, and concluded that they were effective.</span></div><div style="margin-bottom:12pt;margin-top:6pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:23.78pt">Changes in Internal Controls</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. During the first quarter of 2022, there were no changes in our internal control over financial reporting that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><div id="ie8dc61f8e15b44db82ba16050d5b7b44_118"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span><br></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:16pt;font-weight:400;line-height:120%;text-decoration:underline">PART II. Other Information</span></div><div id="ie8dc61f8e15b44db82ba16050d5b7b44_121"></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Item&nbsp;1. Legal Proceedings</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a party to various currently pending legal actions, government investigations, and environmental proceedings. See Note 9 to the consolidated condensed financial statements for information on various legal proceedings. </span></div><div style="margin-bottom:9pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Item should be read in conjunction with "Legal Proceedings" in Part I, Item 3 of our Annual Report on </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0000059478/000005947822000068/lly-20211231.htm">Form 10-K</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the year ended December&nbsp;31, 2021.</span></div><div style="margin-bottom:9pt;margin-top:6pt"><span><br></span></div><div id="ie8dc61f8e15b44db82ba16050d5b7b44_124"></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Item&nbsp;1A. Risk Factors</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our material risk factors are disclosed in "Risk Factors" in Part I, Item 1A of our Annual Report on </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0000059478/000005947822000068/lly-20211231.htm">Form 10-K</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the year ended December&nbsp;31, 2021. There have been no material changes from the risk factors previously disclosed in our Annual Report on </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0000059478/000005947822000068/lly-20211231.htm">Form 10-K</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the year ended December&nbsp;31, 2021. </span></div><div style="margin-bottom:9pt;margin-top:6pt"><span><br></span></div><div id="ie8dc61f8e15b44db82ba16050d5b7b44_127"></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Item&nbsp;2. Unregistered Sales of Equity Securities and Use of Proceeds</span></div><div id="ie8dc61f8e15b44db82ba16050d5b7b44_130"></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information relating to the principal market for our common stock and related shareholder matters is described in "Management's Discussion and Analysis of Results of Operations and Financial Condition" in Part II, Item 7 and in "Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters" in Part III, Item 12 of our Annual Report on </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0000059478/000005947822000068/lly-20211231.htm">Form 10-K</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the year ended December&nbsp;31, 2021. </span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity related to repurchases of our equity securities during the three months ended March&nbsp;31, 2022:</span></div><div style="margin-bottom:6pt;margin-top:14pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tbody><tr><td style="width:1.0%"></td><td style="width:23.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.589%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.735%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.427%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.017%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Period</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Number of<br>Shares Purchased<br>(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Average&nbsp;Price Paid&nbsp;<br>per Share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total&nbsp;Number of Shares<br>Purchased&nbsp;as Part of<br>Publicly Announced<br>Plans or Programs<br>(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Approximate Dollar Value of Shares that May Yet Be Purchased Under the Plans or Programs <br>(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,750.0&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,394&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">261.69&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,394&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,861.9&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,213&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">276.52&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,213&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,250.0&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,607&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">267.54&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,607&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></tbody></table></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&nbsp;31, 2022, we repurchased $1.50&nbsp;billion of shares under our $5.00 billion share repurchase program authorized in May 2021. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><div id="ie8dc61f8e15b44db82ba16050d5b7b44_133"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span><br></span></div></div><div style="-sec-extract:summary;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Item&nbsp;6. Exhibits</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following documents are filed as a part of this Quarterly Report:</span></div><div style="margin-bottom:12pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tbody><tr><td style="width:1.0%"></td><td style="width:16.323%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.145%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:77.232%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Description</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EXHIBIT 3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/59478/000005947814000078/lly-20131231x10kexhibit31.htm">Amended Articles of Incorporation are incorporated by reference to Exhibit 3.1 to the Company's Annual Report on Form 10-K for the year ended December 31, 2013</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EXHIBIT 3.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0000059478/000119312521359144/d246572dex31.htm">Bylaws, as amended, are incorporated by reference to Exhibit 3.1 to the Company's Current Report on Form 8-K filed on December 16, 2021</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EXHIBIT&nbsp;31.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="lly-03312022x10qxexhibit311.htm">Rule&nbsp;13a-14(a) Certification of David A. Ricks, Chair</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="lly-03312022x10qxexhibit311.htm">, President, and Chief Executive Officer</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EXHIBIT 31.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="lly-03312022x10qxexhibit312.htm">Rule&nbsp;13a-14(a) Certification of Anat Ashkenazi, Senior Vice President and Chief Financial Officer</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EXHIBIT 32.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="lly-03312022x10qxexhibit32.htm">Section 1350 Certification</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EXHIBIT 101.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interactive Data Files (embedded within the Inline XBRL document)</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EXHIBIT 104.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)</span></td></tr></tbody></table></div><div style="margin-bottom:12pt;margin-top:1pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(i) Long-term debt instruments under which the total amount of securities authorized does not exceed 10 percent of our consolidated assets are not filed as exhibits to this Quarterly Report. We will furnish a copy of these agreements to the Securities and Exchange Commission upon request.</span></div><div id="ie8dc61f8e15b44db82ba16050d5b7b44_139"></div><div style="text-align:center"><span><br></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Signatures</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="margin-top:14pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tbody><tr><td style="width:1.0%"></td><td style="width:4.756%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.298%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:76.646%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">ELI LILLY AND COMPANY</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Registrant)</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 29, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Anat Ashkenazi</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anat Ashkenazi</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Vice President and Chief Financial Officer</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 29, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Donald A. Zakrowski</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Donald A. Zakrowski</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vice President, Finance, and Chief Accounting Officer</span></td></tr></tbody></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div>
</div>


	</div>

	<div id="form-information-modal" data-test="form-information-modal" class="reboot dialog-box fixed-dialog-box d-none bg-white">
		<div class="reboot dialog-header bg-sec text-white px-1 d-flex justify-content-between">
			<p id="form-information-modal-title" data-test="form-information-modal-title" class="reboot lead mb-0"></p>
			<div class="reboot dialog-header-actions">
				<i id="form-information-modal-drag" title="Click and drag to move this Dialog Box." class="reboot fas fa-arrows-alt m-1 drag-icon d-none d-sm-inline-block" tabindex="14"></i>

				<i id="dialog-box-copy-content" title="Click to Copy all Dialog Box Content." class="reboot fas fa-copy m-1 click" tabindex="14"></i>

				<i id="dialog-box-close" data-name="Form Information Modal" title="Click to Close this Dialog Box." class="reboot fas fa-times m-1 click" tabindex="14"></i>

			</div>
		</div>
		<div class="reboot dialog-content">
			<div id="form-information-copy-paste" class="reboot form-group d-none">
				<label class="reboot">Copy and Paste Below Content.</label>
				<a id="dialog-content-copy-content" class="reboot float-right click color-inherit" tabindex="14">
					<i class="reboot fas fa-times-circle mt-2"></i>
				</a>
				<textarea class="reboot form-control" rows="5" tabindex="14"></textarea>
			</div>
			<div id="form-information-modal-carousel" class="reboot carousel pointer-event" data-interval="false" data-ride="carousel">
				<div class="reboot carousel-inner">
					<div class="reboot carousel-item table-responsive active">
						<table class="reboot table table-striped table-sm">
							<tbody class="reboot" id="form-information-modal-carousel-page-1" tabindex="14">
								<!-- Below is populated dynamically VIA JS -->
								<tr class="reboot">
									<td class="reboot text-center">
										<i class="reboot fas fa-spinner fa-spin"></i>
									</td>
								</tr>
							</tbody>
						</table>
					</div>
					<div class="reboot carousel-item table-responsive">
						<table class="reboot table table-striped table-bordered table-sm">
							<tbody class="reboot" id="form-information-modal-carousel-page-2" tabindex="14">
								<!-- Below is populated dynamically VIA JS -->
								<tr class="reboot">
									<td class="reboot text-center">
										<i class="reboot fas fa-spinner fa-spin"></i>
									</td>
								</tr>
							</tbody>
						</table>
					</div>
					<div class="reboot carousel-item table-responsive">
						<table class="reboot table table-striped table-sm">
							<tbody class="reboot" id="form-information-modal-carousel-page-3" tabindex="14">
								<!-- Below is populated dynamically VIA JS -->
								<tr class="reboot">
									<td class="reboot text-center">
										<i class="reboot fas fa-spinner fa-spin"></i>
									</td>
								</tr>
							</tbody>
						</table>
					</div>
					<div class="reboot carousel-item table-responsive">
						<table class="reboot table table-striped table-sm">
							<tbody class="reboot" id="form-information-modal-carousel-page-4" tabindex="14">
								<!-- Below is populated dynamically VIA JS -->
								<tr class="reboot">
									<td class="reboot text-center">
										<i class="reboot fas fa-spinner fa-spin"></i>
									</td>
								</tr>
							</tbody>
						</table>
					</div>
				</div>
			</div>
		</div>
		<div class="reboot dialog-footer d-flex justify-content-around">
			<button id="form-information-prev" class="reboot btn btn-link text-dark" href="#form-information-modal-carousel" role="button" data-slide="prev" tabindex="14">
				<i class="reboot fas fa-chevron-left" title="Previous"></i>
				<span class="reboot sr-only">Previous</span>
			</button>
			<ol id="form-information-carousel-indicators" class="reboot carousel-indicators mx-0 my-3 p-initial">
			</ol>
			<button id="form-information-next" data-test="form-information-next" class="reboot btn btn-link text-dark" href="#form-information-modal-carousel" role="button" data-slide="next" tabindex="14">
				<i class="reboot fas fa-chevron-right" title="Next"></i>
				<span class="reboot sr-only">Next</span>
			</button>
		</div>
	</div>

	<div id="settings-modal" data-test="settings-modal" class="reboot dialog-box fixed-dialog-box d-none bg-white">
		<div class="reboot dialog-header bg-sec text-white px-1 d-flex justify-content-between">
			<p id="settings-modal-title" data-test="settings-modal-title" class="reboot lead mb-0">Settings</p>
			<div class="reboot dialog-header-actions">
				<i id="settings-modal-drag" title="Click and drag to move this Dialog Box." class="reboot fas fa-arrows-alt m-1 drag-icon d-none d-sm-inline-block" tabindex="15"></i>

				<i id="settings-modal-close" data-name="Settings Modal" title="Click to Close this Dialog Box." class="reboot fas fa-times m-1 click" tabindex="15"></i>
			</div>
		</div>
		<div class="reboot dialog-content">
			<form class="reboot">
				<div class="reboot form-group row">
					<label class="reboot col-sm-4 col-form-label" tabindex="15">Hover
						over Fact for quick information.</label>
					<select id="hover-option-select" class="reboot col-sm-8 form-control" tabindex="15">
						<option class="reboot" value="true">On</option>
						<option class="reboot" value="false">Off</option>
					</select>
				</div>
				<div class="reboot form-group row">
					<label class="reboot col-sm-4 col-form-label" tabindex="15">Auto
						Scrolling Position</label>
					<select id="scroll-position-select" class="reboot col-sm-8 form-control" tabindex="15">
						<option class="reboot" value="start">Top</option>
						<option class="reboot" value="center">Center</option>
					</select>
					<small class="reboot form-text text-muted col-sm-12" tabindex="15">Selecting
						a fact from the Sections Menu or the Fact Menu will automatically
						scroll that element to the (Top, or Middle) of the viewer window.
						This setting will have no use on IE 10, or Safari.</small>
				</div>
				<hr class="reboot">
				<div class="reboot form-group row">
					<label class="reboot col-sm-4 col-form-label" tabindex="15">
						<span class="reboot tagged-data-example-1">Tagged Data</span>
					</label>
					<div class="reboot col-sm-4">
						<div class="reboot" id="tagged-data-color-picker" tabindex="15"><div class="picker_wrapper layout_default no_alpha no_editor" tabindex="-1"><div class="picker_arrow"></div><div class="picker_hue picker_slider" style="color: rgb(255, 102, 0);"><div class="picker_selector" style="left: 6.66667%;"></div></div><div class="picker_sl" style="background-color: rgb(255, 102, 0); color: rgb(255, 102, 0);"><div class="picker_selector" style="left: 100%; top: 50%;"></div></div><div class="picker_alpha picker_slider" style="background-image: linear-gradient(rgb(255, 102, 0), rgba(255, 102, 0, 0)), url(&quot;data:image/svg+xml,%3Csvg xmlns='http://www.w3.org/2000/svg' width='2' height='2'%3E%3Cpath d='M1,0H0V1H2V2H1' fill='lightgrey'/%3E%3C/svg%3E&quot;);"><div class="picker_selector" style="top: 0%;"></div></div><div class="picker_editor"><input aria-label="Type a color name or hex value"></div><div class="picker_sample" style="color: rgb(255, 102, 0);"></div><div class="picker_done"><button>Save</button></div><div class="picker_cancel"><button>Reset</button></div></div></div>
					</div>
				</div>
				<hr>
				<div class="reboot form-group row">
					<label class="reboot col-sm-4 col-form-label" tabindex="15">
						<span class="reboot search-results-example-1">Search
							Results</span>
					</label>
					<div class="reboot col-sm-4">
						<div class="reboot" id="search-results-color-picker" tabindex="15"><div class="picker_wrapper layout_default no_alpha no_editor" tabindex="-1"><div class="picker_arrow"></div><div class="picker_hue picker_slider" style="color: rgb(255, 215, 0);"><div class="picker_selector" style="left: 14.0523%;"></div></div><div class="picker_sl" style="background-color: rgb(255, 215, 0); color: rgb(255, 215, 0);"><div class="picker_selector" style="left: 100%; top: 50%;"></div></div><div class="picker_alpha picker_slider" style="background-image: linear-gradient(rgb(255, 215, 0), rgba(255, 215, 0, 0)), url(&quot;data:image/svg+xml,%3Csvg xmlns='http://www.w3.org/2000/svg' width='2' height='2'%3E%3Cpath d='M1,0H0V1H2V2H1' fill='lightgrey'/%3E%3C/svg%3E&quot;);"><div class="picker_selector" style="top: 0%;"></div></div><div class="picker_editor"><input aria-label="Type a color name or hex value"></div><div class="picker_sample" style="color: rgb(255, 215, 0);"></div><div class="picker_done"><button>Save</button></div><div class="picker_cancel"><button>Reset</button></div></div></div>
					</div>
				</div>
				<hr>
				<div class="reboot form-group row">
					<label class="reboot col-sm-4 col-form-label" tabindex="15">
						<span class="reboot selected-fact-example-1">Selected Fact</span>
					</label>
					<div class="reboot col-sm-4">
						<div class="reboot" id="selected-fact-color-picker" tabindex="15"><div class="picker_wrapper layout_default no_alpha no_editor" tabindex="-1"><div class="picker_arrow"></div><div class="picker_hue picker_slider" style="color: rgb(0, 135, 255);"><div class="picker_selector" style="left: 57.8526%;"></div></div><div class="picker_sl" style="background-color: rgb(0, 135, 255); color: rgb(0, 55, 104);"><div class="picker_selector" style="left: 100%; top: 79.6078%;"></div></div><div class="picker_alpha picker_slider" style="background-image: linear-gradient(rgb(0, 55, 104), rgba(0, 55, 104, 0)), url(&quot;data:image/svg+xml,%3Csvg xmlns='http://www.w3.org/2000/svg' width='2' height='2'%3E%3Cpath d='M1,0H0V1H2V2H1' fill='lightgrey'/%3E%3C/svg%3E&quot;);"><div class="picker_selector" style="top: 0%;"></div></div><div class="picker_editor"><input aria-label="Type a color name or hex value"></div><div class="picker_sample" style="color: rgb(0, 55, 104);"></div><div class="picker_done"><button>Save</button></div><div class="picker_cancel"><button>Reset</button></div></div></div>
					</div>
				</div>
				<hr>
				<div class="reboot form-group row">
					<label class="reboot col-sm-4 col-form-label" tabindex="15">
						<span class="reboot tag-shading-exmple-1">Tag Shading
							(hover)</span>
					</label>
					<div class="reboot col-sm-4">
						<div class="reboot" id="tag-shading-color-picker" tabindex="15"><div class="picker_wrapper layout_default no_editor" tabindex="-1"><div class="picker_arrow"></div><div class="picker_hue picker_slider" style="color: rgb(255, 0, 0);"><div class="picker_selector" style="left: 0%;"></div></div><div class="picker_sl" style="background-color: rgb(255, 0, 0); color: rgb(255, 0, 0);"><div class="picker_selector" style="left: 100%; top: 50%;"></div></div><div class="picker_alpha picker_slider" style="background-image: linear-gradient(rgb(255, 0, 0), rgba(255, 0, 0, 0)), url(&quot;data:image/svg+xml,%3Csvg xmlns='http://www.w3.org/2000/svg' width='2' height='2'%3E%3Cpath d='M1,0H0V1H2V2H1' fill='lightgrey'/%3E%3C/svg%3E&quot;);"><div class="picker_selector" style="top: 70%;"></div></div><div class="picker_editor"><input aria-label="Type a color name or hex value"></div><div class="picker_sample" style="color: rgba(255, 0, 0, 0.3);"></div><div class="picker_done"><button>Save</button></div><div class="picker_cancel"><button>Reset</button></div></div></div>
					</div>
				</div>
				<hr>
				<div class="reboot form-group row">
					<label class="reboot col-sm-4 col-form-label" tabindex="15">
						<span class="reboot text-block-exmple-1">Text Block Indicators</span>
					</label>
					<div class="reboot col-sm-4">
						<div class="reboot" id="text-block-color-picker" tabindex="15"><div class="picker_wrapper layout_default no_alpha no_editor" tabindex="-1"><div class="picker_arrow"></div><div class="picker_hue picker_slider" style="color: rgb(0, 135, 255);"><div class="picker_selector" style="left: 57.8526%;"></div></div><div class="picker_sl" style="background-color: rgb(0, 135, 255); color: rgb(0, 55, 104);"><div class="picker_selector" style="left: 100%; top: 79.6078%;"></div></div><div class="picker_alpha picker_slider" style="background-image: linear-gradient(rgb(0, 55, 104), rgba(0, 55, 104, 0)), url(&quot;data:image/svg+xml,%3Csvg xmlns='http://www.w3.org/2000/svg' width='2' height='2'%3E%3Cpath d='M1,0H0V1H2V2H1' fill='lightgrey'/%3E%3C/svg%3E&quot;);"><div class="picker_selector" style="top: 0%;"></div></div><div class="picker_editor"><input aria-label="Type a color name or hex value"></div><div class="picker_sample" style="color: rgb(0, 55, 104);"></div><div class="picker_done"><button>Save</button></div><div class="picker_cancel"><button>Reset</button></div></div></div>
					</div>
				</div>
			</form>
		</div>
		<div class="reboot dialog-footer d-flex justify-content-around"></div>
	</div>

	<div id="taxonomy-modal" class="reboot dialog-box fixed-dialog-box d-none bg-white">
		<div class="reboot dialog-header bg-sec text-white px-1 d-flex justify-content-between">
			<p id="taxonomy-modal-title" class="reboot lead mb-0"></p>
			<div class="reboot dialog-header-actions">

				<i id="taxonomy-modal-drag" title="Click and drag to move this Dialog Box." class="reboot fas fa-arrows-alt m-1 drag-icon d-none d-sm-inline-block" tabindex="16"></i>

				<i id="taxonomy-modal-jump" title="Click to see this in the Facts sidebar." class="reboot fas fa-directions m-1 click" tabindex="16"></i>
				<i id="taxonomy-modal-copy-content" class="reboot fas fa-copy m-1 click" tabindex="16"></i>

				<i id="taxonomy-modal-compress" class="reboot fas fa-compress m-1 click d-none" tabindex="16"></i>

				<i id="taxonomy-modal-expand" class="reboot fas fa-expand m-1 click d-none" tabindex="16"></i>

				<i id="taxonomy-modal-close" class="reboot fas fa-times m-1 click" tabindex="16"></i>
			</div>
		</div>
		<div class="reboot dialog-content">
			<p id="taxonomy-modal-subtitle" class="reboot text-center font-weight-bold"></p>
			<div id="taxonomy-copy-paste" class="reboot form-group d-none">
				<label>Copy and Paste Below Content.</label>
				<a id="taxonomy-copy-content" class="reboot float-right click color-inherit" tabindex="16">
					<i class="reboot fas fa-times-circle mt-2"></i>
				</a>
				<textarea class="reboot form-control" rows="5" tabindex="16"></textarea>
			</div>
			<div id="taxonomy-modal-carousel" class="reboot carousel" data-interval="false" data-keyboard="false">
				<div class="reboot carousel-inner">
					<div class="reboot carousel-item table-responsive active">
						<table class="reboot table table-striped table-sm" id="taxonomy-modal-carousel-page-1" tabindex="16">
							<!-- Below is populated dynamically VIA JS -->
							<tbody class="reboot">
								<tr class="reboot">
									<td class="reboot text-center">
										<i class="reboot fas fa-spinner fa-spin"></i>
									</td>
								</tr>
							</tbody>
						</table>
					</div>
					<div class="reboot carousel-item table-responsive">
						<table class="reboot table table-striped table-sm" id="taxonomy-modal-carousel-page-2" tabindex="16">
							<!-- Below is populated dynamically VIA JS -->
							<tbody class="reboot">
								<tr class="reboot">
									<td class="reboot text-center">
										<i class="reboot fas fa-spinner fa-spin"></i>
									</td>
								</tr>
							</tbody>
						</table>
					</div>
					<div class="reboot carousel-item table-responsive">
						<table class="reboot table table-striped table-sm" id="taxonomy-modal-carousel-page-3" tabindex="16">
							<!-- Below is populated dynamically VIA JS -->
							<tbody class="reboot">
								<tr class="reboot">
									<td class="reboot text-center">
										<i class="reboot fas fa-spinner fa-spin"></i>
									</td>
								</tr>
							</tbody>
						</table>
					</div>
					<div class="reboot carousel-item table-responsive">
						<table class="reboot table table-striped table-sm" id="taxonomy-modal-carousel-page-4" tabindex="16">
							<!-- Below is populated dynamically VIA JS -->
							<tbody class="reboot">
								<tr class="reboot">
									<td class="reboot text-center">
										<i class="reboot fas fa-spinner fa-spin"></i>
									</td>
								</tr>
							</tbody>
						</table>
					</div>
				</div>
			</div>
		</div>
		<div class="reboot dialog-footer d-flex justify-content-around">
			<button data-test="modal-taxonomy-prev" class="reboot btn btn-link text-dark" href="#taxonomy-modal-carousel" role="button" data-slide="prev" tabindex="16">
				<i class="reboot fas fa-chevron-left" title="Previous"></i>
				<span class="reboot sr-only">Previous</span>
			</button>
			<ol id="taxonomy-modal-carousel-indicators" class="reboot carousel-indicators mx-0 my-3 p-initial">
			</ol>
			<button data-test="modal-taxonomy-next" class="reboot btn btn-link text-dark" href="#taxonomy-modal-carousel" role="button" data-slide="next" tabindex="16">
				<i class="reboot fas fa-chevron-right" title="Next"></i>
				<span class="reboot sr-only">Next</span>
			</button>
		</div>
	</div>

	<div id="taxonomy-nested-modal" class="reboot dialog-box fixed-dialog-box d-none bg-white">
		<div class="reboot dialog-header bg-sec text-white px-1 d-flex justify-content-between">
			<p class="reboot lead mb-0">
				Nested Facts
				<span class="reboot" id="nested-page"></span>
				<span class="reboot">/</span>
				<span class="reboot" id="nested-count"></span>
			</p>
			<div class="reboot dialog-header-actions">
				<i id="taxonomy-nested-modal-drag" title="Click and drag to move this Dialog Box." class="reboot fas fa-arrows-alt m-1 drag-icon d-none d-sm-inline-block" tabindex="17"></i>

				<i id="nested-taxonomy-modal-jump" title="Click to see this in the Facts sidebar." class="reboot fas fa-directions m-1 click" tabindex="17"></i>

				<i id="taxonomy-nested-modal-copy-content" class="reboot fas fa-copy m-1 click" tabindex="17"></i>

				<i id="taxonomy-nested-modal-compress" class="reboot fas fa-compress m-1 click d-none" tabindex="17"></i>

				<i id="taxonomy-nested-modal-expand" class="reboot fas fa-expand m-1 click d-none" tabindex="17"></i>

				<i id="taxonomy-nested-modal-close" class="reboot fas fa-times m-1 click" tabindex="17"></i>
			</div>
		</div>
		<div class="reboot dialog-content pt-0">
			<div id="modal-nested-fact-labels" class="reboot carousel" data-interval="false" data-keyboard="false">
				<div class="reboot d-flex">
					<button data-test="modal-taxonomy-nested-prev" class="reboot btn btn-link text-dark" href="#modal-nested-fact-labels" role="button" data-slide="prev" tabindex="17">
						<i class="reboot fas fa-chevron-left" title="Previous"></i>
						<span class="reboot sr-only">Previous</span>
					</button>
					<div id="modal-taxonomy-nested-label-carousel" class="reboot carousel-inner">
						<!-- Below is populated dynamically VIA JS -->
					</div>
					<button data-test="modal-taxonomy-nested-next" class="reboot btn btn-link text-dark" href="#modal-nested-fact-labels" role="button" data-slide="next" tabindex="17">
						<i class="reboot fas fa-chevron-right" title="Next"></i>
						<span class="reboot sr-only">Next</span>
					</button>
				</div>
			</div>
			<div id="taxonomy-nested-copy-paste" class="reboot form-group d-none">
				<label class="reboot">Copy and Paste Below Content.</label>
				<a id="taxonomy-nested-copy-content" class="reboot float-right click color-inherit" tabindex="17">
					<i class="reboot fas fa-times-circle mt-2"></i>
				</a>
				<textarea class="reboot form-control" rows="5" tabindex="17"></textarea>
			</div>
			<div id="modal-taxonomy-nested-content-carousel" class="reboot carousel" data-interval="false" data-keyboard="false">
				<div class="reboot carousel-inner">
					<div class="reboot carousel-item table-responsive active">
						<table class="reboot table table-striped table-sm">
							<tbody class="reboot" id="modal-taxonomy-nested-content-carousel-page-1" tabindex="17">
								<!-- Below is populated dynamically VIA JS -->
								<tr class="reboot">
									<td class="reboot text-center">
										<i class="reboot fas fa-spinner fa-spin"></i>
									</td>
								</tr>
							</tbody>
						</table>
					</div>
					<div class="reboot carousel-item table-responsive">
						<table class="reboot table table-striped table-bordered table-sm">
							<tbody class="reboot" id="modal-taxonomy-nested-content-carousel-page-2" tabindex="17">
								<!-- Below is populated dynamically VIA JS -->
								<tr class="reboot">
									<td class="reboot text-center">
										<i class="reboot fas fa-spinner fa-spin"></i>
									</td>
								</tr>
							</tbody>
						</table>
					</div>
					<div class="reboot carousel-item table-responsive">
						<table class="reboot table table-striped table-sm">
							<tbody class="reboot" id="modal-taxonomy-nested-content-carousel-page-3" tabindex="17">
								<!-- Below is populated dynamically VIA JS -->
								<tr class="reboot">
									<td class="reboot text-center">
										<i class="reboot fas fa-spinner fa-spin"></i>
									</td>
								</tr>
							</tbody>
						</table>
					</div>
					<div class="reboot carousel-item table-responsive">
						<table class="reboot table table-striped table-sm">
							<tbody class="reboot" id="modal-taxonomy-nested-content-carousel-page-4" tabindex="17">
								<!-- Below is populated dynamically VIA JS -->
								<tr class="reboot">
									<td class="reboot text-center">
										<i class="reboot fas fa-spinner fa-spin"></i>
									</td>
								</tr>
							</tbody>
						</table>
					</div>
				</div>
			</div>
		</div>
		<div id="taxonomy-nested-nav-controls" class="reboot dialog-footer d-flex justify-content-around">
			<button data-test="modal-taxonomy-prev" class="reboot btn btn-link text-dark" href="#modal-taxonomy-nested-content-carousel" role="button" data-slide="prev" tabindex="17">
				<i class="reboot fas fa-chevron-left" title="Previous"></i>
				<span class="reboot sr-only">Previous</span>
			</button>
			<ol id="taxonomy-nested-modal-carousel-indicators" class="reboot carousel-indicators mx-0 my-3 p-initial">
				<!-- Below is populated dynamically VIA JS -->
			</ol>
			<button data-test="modal-taxonomy-next" class="reboot btn btn-link text-dark" href="#modal-taxonomy-nested-content-carousel" role="button" data-slide="next" tabindex="17">
				<i class="reboot fas fa-chevron-right" title="Next"></i>
				<span class="reboot sr-only">Next</span>
			</button>
		</div>
	</div>



</body></html>